"Article ID","Publication Year","Reference","US$/QALY *","Ratio Description","PubMed ID","Target Population","Intervention Description","Title","Comparator Description","Impact"
"2014-01-15750","2014","Shafie 2014 Diabetes Res Clin Pract","1800","BIAsp 30 (biphasic insulin aspart 30)+oral glucose-lowering drug VERSUS Oral glucose-lowering drug IN Specific disease- Type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Indonesia.","25305133","Specific disease- Type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Indonesia.","BIAsp 30 (biphasic insulin aspart 30)+oral glucose-lowering drug","An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes.","Oral glucose-lowering drug","NE"
"2014-01-15750","2014","Shafie 2014 Diabetes Res Clin Pract","2100","BIAsp 30 (biphasic insulin aspart 30)+oral glucose-lowering drug VERSUS Oral glucose-lowering drug IN Specific disease- Type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Algeria.","25305133","Specific disease- Type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Algeria.","BIAsp 30 (biphasic insulin aspart 30)+oral glucose-lowering drug","An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes.","Oral glucose-lowering drug","NE"
"2014-01-15750","2014","Shafie 2014 Diabetes Res Clin Pract","400","BIAsp 30 (biphasic insulin aspart 30)+oral glucose-lowering drug VERSUS Oral glucose-lowering drug IN Specific disease- Type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- India.","25305133","Specific disease- Type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- India.","BIAsp 30 (biphasic insulin aspart 30)+oral glucose-lowering drug","An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes.","Oral glucose-lowering drug","NE"
"2014-01-15750","2014","Shafie 2014 Diabetes Res Clin Pract","Cost-Saving","BIAsp 30 (biphasic insulin aspart 30)+oral glucose-lowering drug VERSUS Oral glucose-lowering drug IN Specific disease- Type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Saudi Arabia.","25305133","Specific disease- Type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Saudi Arabia.","BIAsp 30 (biphasic insulin aspart 30)+oral glucose-lowering drug","An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes.","Oral glucose-lowering drug","SE"
"2014-01-15548","2014","Home 2014 J Med Econ","16000","Insulin detemir VERSUS oral glucose-lowering drugs (OGLDs) IN Specific disease- type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- South Korea; Other- insulin-naÃ¯ve.","25407031","Specific disease- type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- South Korea; Other- insulin-naÃ¯ve.","Insulin detemir","An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes.","oral glucose-lowering drugs (OGLDs)","NE"
"2014-01-15548","2014","Home 2014 J Med Econ","4.3e+006","Insulin detemir VERSUS oral glucose-lowering drugs (OGLDs) IN Specific disease- type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Indonesia; Other- insulin-naÃ¯ve.","25407031","Specific disease- type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Indonesia; Other- insulin-naÃ¯ve.","Insulin detemir","An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes.","oral glucose-lowering drugs (OGLDs)","NE"
"2014-01-15548","2014","Home 2014 J Med Econ","400000","Insulin detemir VERSUS oral glucose-lowering drugs (OGLDs) IN Specific disease- type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Algeria; Other- insulin-naÃ¯ve.","25407031","Specific disease- type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Algeria; Other- insulin-naÃ¯ve.","Insulin detemir","An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes.","oral glucose-lowering drugs (OGLDs)","NE"
"2014-01-15548","2014","Home 2014 J Med Econ","42000","Insulin detemir VERSUS oral glucose-lowering drugs (OGLDs) IN Specific disease- type 2 diabetes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- India; Other- insulin-naÃ¯ve.","25407031","Specific disease- type 2 diabetes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- India; Other- insulin-naÃ¯ve.","Insulin detemir","An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes.","oral glucose-lowering drugs (OGLDs)","NE"
"2014-01-15548","2014","Home 2014 J Med Econ","Cost-Saving","Insulin detemir VERSUS oral glucose-lowering drugs (OGLDs) IN Specific disease- type 2 diabetes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Mexico; Other- insulin-naÃ¯ve.","25407031","Specific disease- type 2 diabetes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Mexico; Other- insulin-naÃ¯ve.","Insulin detemir","An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes.","oral glucose-lowering drugs (OGLDs)","SE"
"2015-01-17789","2015","Giorgi 2015 Health Econ Rev","86000","Apixaban VERSUS Standard/Usual Care- Vitamin K antagonist warfarin IN Specific disease- Atrial fibrillation; Age- Unknown; Gender- Both; Country- Argentina; Other- Suitable for the use of oral anticoagulants.","26112219","Specific disease- Atrial fibrillation; Age- Unknown; Gender- Both; Country- Argentina; Other- Suitable for the use of oral anticoagulants.","Apixaban","Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in  the management of atrial fibrillation in Argentina.","Standard/Usual Care- Vitamin K antagonist warfarin","NE"
"2015-01-17376","2015","Marti                            2015 Vaccine","1800","Rotavirus vaccination Rotarix (RV1) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Argentina.","26303875","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Argentina.","Rotavirus vaccination Rotarix (RV1)","Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.","None","NE"
"2015-01-17376","2015","Marti                            2015 Vaccine","Cost-Saving","Rotavirus vaccination RotaTeq (RV5) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Argentina.","26303875","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Argentina.","Rotavirus vaccination RotaTeq (RV5)","Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.","None","SE"
"2013-01-14300","2013","Marti                            2013 Cost Eff Resour Alloc","3500","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru.","24004943","Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru.","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV)","A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.","None","NE"
"2013-01-14300","2013","Marti                            2013 Cost Eff Resour Alloc","3900","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Argentina.","24004943","Healthy; Age- 0 to 18 years; Gender- Both; Country- Argentina.","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV)","A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.","None","NE"
"2013-01-14300","2013","Marti                            2013 Cost Eff Resour Alloc","4700","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Colombia.","24004943","Healthy; Age- 0 to 18 years; Gender- Both; Country- Colombia.","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV)","A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.","None","NE"
"2013-01-14300","2013","Marti                            2013 Cost Eff Resour Alloc","5400","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Mexico.","24004943","Healthy; Age- 0 to 18 years; Gender- Both; Country- Mexico.","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV)","A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.","None","NE"
"2013-01-14300","2013","Marti                            2013 Cost Eff Resour Alloc","8300","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Brazil.","24004943","Healthy; Age- 0 to 18 years; Gender- Both; Country- Brazil.","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV)","A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.","None","NE"
"2013-01-14300","2013","Marti                            2013 Cost Eff Resour Alloc","Cost-Saving","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Chile.","24004943","Healthy; Age- 0 to 18 years; Gender- Both; Country- Chile.","10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV)","A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.","None","SE"
"2013-01-11271","2013","Elgart 2013 Health Econ Rev","8600","Metformin plus saxagliptin (MET + SAX) VERSUS Metformin plus sulfonylurea (MET + SU) IN Specific disease- type 2 diabetes; Age-; Gender- Both; Country- Argentina.","23621944","Specific disease- type 2 diabetes; Age-; Gender- Both; Country- Argentina.","Metformin plus saxagliptin (MET + SAX)","Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina.","Metformin plus sulfonylurea (MET + SU)","NE"
"2012-01-09801","2012","Poggio 2012 Int J Technol Assess Health Care","35000","Cardiac resynchronization therapy (CRT) + optimal medical treatment (OMT) VERSUS Optimal medical treatment (OMT) (maximum tolerated doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers, spironolactone, and beta-blockers) IN Patients with New York Heart Association (NYHA) functional class (FC) I heart failure symptoms and severe left ventricular dysfunction in Argentina","23006489","Patients with New York Heart Association (NYHA) functional class (FC) I heart failure symptoms and severe left ventricular dysfunction in Argentina","Cardiac resynchronization therapy (CRT) + optimal medical treatment (OMT)","Cost-effectiveness of cardiac resynchronization therapy: perspective from Argentina.","Optimal medical treatment (OMT) (maximum tolerated doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers, spironolactone, and beta-blockers)","NE"
"2012-01-09801","2012","Poggio 2012 Int J Technol Assess Health Care","40000","Cardiac resynchronization therapy (CRT) + optimal medical treatment (OMT) VERSUS Optimal medical treatment (OMT) (maximum tolerated doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers, spironolactone, and beta-blockers) IN Patients with New York Heart Association (NYHA) functional class (FC) I or II heart failure symptoms and severe left ventricular dysfunction in Argentina","23006489","Patients with New York Heart Association (NYHA) functional class (FC) I or II heart failure symptoms and severe left ventricular dysfunction in Argentina","Cardiac resynchronization therapy (CRT) + optimal medical treatment (OMT)","Cost-effectiveness of cardiac resynchronization therapy: perspective from Argentina.","Optimal medical treatment (OMT) (maximum tolerated doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers, spironolactone, and beta-blockers)","NE"
"2009-01-05593","2009","Colantonio 2009 Vaccine","13000","Universal vaccination of all 12 year old females VERSUS Current practice IN 12 year old females in Brazil","19616499","12 year old females in Brazil","Universal vaccination of all 12 year old females","Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.","Current practice","NE"
"2009-01-05593","2009","Colantonio 2009 Vaccine","13000","Universal vaccination of all 12 year old females VERSUS Current practice IN 12 year old females in Mexico","19616499","12 year old females in Mexico","Universal vaccination of all 12 year old females","Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.","Current practice","NE"
"2009-01-05593","2009","Colantonio 2009 Vaccine","22000","Universal vaccination of all 12 year old females VERSUS Current practice IN 12 year old females in Chile","19616499","12 year old females in Chile","Universal vaccination of all 12 year old females","Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.","Current practice","NE"
"2009-01-05593","2009","Colantonio 2009 Vaccine","5700","Universal vaccination of all 12 year old females VERSUS Current practice IN 12 year old females in Peru","19616499","12 year old females in Peru","Universal vaccination of all 12 year old females","Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.","Current practice","NE"
"2009-01-05593","2009","Colantonio 2009 Vaccine","7400","Universal vaccination of all 12 year old females VERSUS Current practice IN 12 year old females in Argentina","19616499","12 year old females in Argentina","Universal vaccination of all 12 year old females","Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.","Current practice","NE"
"2007-01-03121","2007","Ellis 2007 Rev Panam Salud Publica","1200","One dose of Hepatitis A vaccination at 12 months of age and second dose at age 72 months VERSUS One dose of Hepatitis A vaccination at 12 months of age IN 2005 Argentinian birth cohort","17761046","2005 Argentinian birth cohort","One dose of Hepatitis A vaccination at 12 months of age and second dose at age 72 months","Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted.","One dose of Hepatitis A vaccination at 12 months of age","NE"
"2007-01-03121","2007","Ellis 2007 Rev Panam Salud Publica","690","One dose of Hepatitis A vaccination at 12 months of age and second dose at age 18 months VERSUS One dose of Hepatitis A vaccination at 12 months of age IN 2005 Argentinian birth cohort","17761046","2005 Argentinian birth cohort","One dose of Hepatitis A vaccination at 12 months of age and second dose at age 18 months","Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted.","One dose of Hepatitis A vaccination at 12 months of age","NE"
"2007-01-03121","2007","Ellis 2007 Rev Panam Salud Publica","Cost-Saving","One dose of Hepatitis A vaccination at 12 months of age VERSUS No vaccination IN 2005 Argentinian birth cohort","17761046","2005 Argentinian birth cohort","One dose of Hepatitis A vaccination at 12 months of age","Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted.","No vaccination","SE"
"2014-01-16549","2014","Wong 2014 Ann Intern Med","71000","Echocardiographic screening, followed by angiotensin-converting enzyme (ACE) inhibitor and beta-blocker therapies after asymptomatic left ventriuclar dysfunction (ALVD) VERSUS None IN Specific disease- Childhood cancers survivors; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- United States.","24842414","Specific disease- Childhood cancers survivors; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- United States.","Echocardiographic screening, followed by angiotensin-converting enzyme (ACE) inhibitor and beta-blocker therapies after asymptomatic left ventriuclar dysfunction (ALVD)","Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.","None","NE"
"2018-01-28548","2018","Si 2018 PLoS One","33000","Age Specific Health Check for cardiovascular risk factors VERSUS Standard/Usual Care- No Health Check IN Healthy; Age- 41 to 64 years; Gender- Male; Country- Australia.","30412596","Healthy; Age- 41 to 64 years; Gender- Male; Country- Australia.","Age Specific Health Check for cardiovascular risk factors","Cost-effectiveness evaluation of the 45-49 year old health check versus usual care in Australian general practice: A modelling study.","Standard/Usual Care- No Health Check","NE"
"2018-01-28548","2018","Si 2018 PLoS One","89000","Age Specific Health Check for cardiovascular risk factors VERSUS Standard/Usual Care- No Health Checks IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Australia.","30412596","Healthy; Age- 41 to 64 years; Gender- Female; Country- Australia.","Age Specific Health Check for cardiovascular risk factors","Cost-effectiveness evaluation of the 45-49 year old health check versus usual care in Australian general practice: A modelling study.","Standard/Usual Care- No Health Checks","NE"
"2018-01-28296","2018","Zomer 2018 Eur J Prev Cardiol","20000","Low-dose rivaroxaban and aspirin therapy VERSUS Aspirin therapy IN Specific disease- Peripheral or carotid artery disease; Age- Adult; Gender- Both; Country- Australia.","30526023","Specific disease- Peripheral or carotid artery disease; Age- Adult; Gender- Both; Country- Australia.","Low-dose rivaroxaban and aspirin therapy","Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.","Aspirin therapy","NE"
"2018-01-27657","2018","Wales 2018 Clin Rehabil","Dominated","Enhanced occupational therapy discharge planning program VERSUS In-hospital consultation IN Healthy; Age- >=65 years; Gender- Both; Country- Australia; Other- Patients expected to return to a community dwelling at discharge, had no significant cognitive impairment (score of <5 adjusted errors on the Short Portable Mental Status Questionnaire) and were conversant in English.","29569470","Healthy; Age- >=65 years; Gender- Both; Country- Australia; Other- Patients expected to return to a community dwelling at discharge, had no significant cognitive impairment (score of <5 adjusted errors on the Short Portable Mental Status Questionnaire) and were conversant in English.","Enhanced occupational therapy discharge planning program","A trial based economic evaluation of occupational therapy discharge planning for  older adults: the HOME randomized trial.","In-hospital consultation","NW"
"2018-01-27640","2018","Sarfaty 2018 Eur Urol","100000","Pembrolizumab VERSUS Chemotherapy IN Specific disease- Metastatic bladder cancer ; Age- Adult; Gender- Both; Country- Australia.","29576265","Specific disease- Metastatic bladder cancer ; Age- Adult; Gender- Both; Country- Australia.","Pembrolizumab","Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.","Chemotherapy","NE"
"2018-01-27640","2018","Sarfaty 2018 Eur Urol","130000","Pembrolizumab VERSUS Chemotherapy IN Specific disease- Metatstatic bladder cancer ; Age- Adult; Gender- Both; Country- United States.","29576265","Specific disease- Metatstatic bladder cancer ; Age- Adult; Gender- Both; Country- United States.","Pembrolizumab","Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.","Chemotherapy","NE"
"2018-01-27640","2018","Sarfaty 2018 Eur Urol","92000","Pembrolizumab VERSUS Chemotherapy IN Specific disease- Metastatic Bladder Cancer; Age- Adult; Gender- Both; Country- Canada.","29576265","Specific disease- Metastatic Bladder Cancer; Age- Adult; Gender- Both; Country- Canada.","Pembrolizumab","Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.","Chemotherapy","NE"
"2018-01-27640","2018","Sarfaty 2018 Eur Urol","94000","Pembrolizumab VERSUS Chemotherapy IN Specific disease- Metatstatic bladder cancer  ; Age- Adult; Gender- Both; Country- United Kingdom.","29576265","Specific disease- Metatstatic bladder cancer  ; Age- Adult; Gender- Both; Country- United Kingdom.","Pembrolizumab","Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.","Chemotherapy","NE"
"2018-01-27597","2018","Shaker 2018 Allergy","Cost-Saving","Early peanut introduction without screening   VERSUS Early peanut introduction with skin test screening IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- High-risk population.","29601091","Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- High-risk population.","Early peanut introduction without screening","""To screen or not to screen"": Comparing the health and economic benefits of early peanut introduction strategies in five countries.","Early peanut introduction with skin test screening","SE"
"2018-01-27597","2018","Shaker 2018 Allergy","Cost-Saving","Early peanut introduction without screening  VERSUS Early peanut introduction with serum-specific IgE screening  IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- High-risk population.","29601091","Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- High-risk population.","Early peanut introduction without screening","""To screen or not to screen"": Comparing the health and economic benefits of early peanut introduction strategies in five countries.","Early peanut introduction with serum-specific IgE screening","SE"
"2018-01-27597","2018","Shaker 2018 Allergy","Cost-Saving","Early peanut introduction without screening  VERSUS Early peanut introduction with serum-specific IgE screening IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- Low-risk  population.","29601091","Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- Low-risk  population.","Early peanut introduction without screening","""To screen or not to screen"": Comparing the health and economic benefits of early peanut introduction strategies in five countries.","Early peanut introduction with serum-specific IgE screening","SE"
"2018-01-27597","2018","Shaker 2018 Allergy","Cost-Saving","Early peanut introduction without screening  VERSUS Early peanut introduction with skin test screening  IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- Low-risk  population.","29601091","Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- Low-risk  population.","Early peanut introduction without screening","""To screen or not to screen"": Comparing the health and economic benefits of early peanut introduction strategies in five countries.","Early peanut introduction with skin test screening","SE"
"2018-01-27597","2018","Shaker 2018 Allergy","Cost-Saving","Early peanut introduction without screening VERSUS Delayed introduction without screening IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- High-risk population.","29601091","Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- High-risk population.","Early peanut introduction without screening","""To screen or not to screen"": Comparing the health and economic benefits of early peanut introduction strategies in five countries.","Delayed introduction without screening","SE"
"2018-01-27387","2018","Wade 2018 J Thorac Oncol","1.2e+006","Low-Dose Computed Tomography screening for lung cancer VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Australia; Other- Smoking history of 30 or more pack-years and 15 years or less since quitting, past smokers.","29689434","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Australia; Other- Smoking history of 30 or more pack-years and 15 years or less since quitting, past smokers.","Low-Dose Computed Tomography screening for lung cancer","Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.","None","NE"
"2018-01-27387","2018","Wade 2018 J Thorac Oncol","190000","Low-dose computed tomography screening for lung cancer VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Australia; Other- Smoking history of 30 or more pack-years and 15 years or less since quitting.","29689434","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Australia; Other- Smoking history of 30 or more pack-years and 15 years or less since quitting.","Low-dose computed tomography screening for lung cancer","Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.","None","NE"
"2018-01-27387","2018","Wade 2018 J Thorac Oncol","98000","Low-Dose Computed Tomography screening for lung cancer VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Australia; Other- Smoking history of 30 or more pack-years and 15 years or less since quitting, current smokers.","29689434","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Australia; Other- Smoking history of 30 or more pack-years and 15 years or less since quitting, current smokers.","Low-Dose Computed Tomography screening for lung cancer","Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.","None","NE"
"2018-01-27265","2018","Kumar 2018 Int J Cardiol","240000","Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) VERSUS Placebo IN Specific disease- Evident artherosclerotic cardiovascular disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Australia; Other- Patients with elevated LDL-C and/or non-high density lipoprotein cholesterol (HDL-C) despite being on an optimized regimen of lipid-lowering therapy .","29731350","Specific disease- Evident artherosclerotic cardiovascular disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Australia; Other- Patients with elevated LDL-C and/or non-high density lipoprotein cholesterol (HDL-C) despite being on an optimized regimen of lipid-lowering therapy .","Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)","The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.","Placebo","NE"
"2018-01-27244","2018","Arora 2018 J Med Econ","10000","Mechanical Thrombectomy + Usual Care VERSUS Standard/Usual Care- Thrombolysis or medical management with anti-thrombotic therapy in patients ineligible for intravenous thrombolytic therapy IN Specific disease- Acute Ischemic Stroke; Age- Adult; Gender- Both; Country- Australia.","29741126","Specific disease- Acute Ischemic Stroke; Age- Adult; Gender- Both; Country- Australia.","Mechanical Thrombectomy + Usual Care","Cost-effectiveness of mechanical thrombectomy for acute ischemic stroke: an Australian payer perspective.","Standard/Usual Care- Thrombolysis or medical management with anti-thrombotic therapy in patients ineligible for intravenous thrombolytic therapy","NE"
"2018-01-27193","2018","Stark 2018 Genet Med","6300","Changes in Management, Cascade Testing, and Reproductive Outcomes  VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Australia.","29765138","Healthy; Age- 0 to 18 years; Gender- Both; Country- Australia.","Changes in Management, Cascade Testing, and Reproductive Outcomes","Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness.","None","NE"
"2018-01-27193","2018","Stark 2018 Genet Med","Cost-Saving","Changed Management  VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Australia.","29765138","Healthy; Age- 0 to 18 years; Gender- Both; Country- Australia.","Changed Management","Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness.","None","SE"
"2018-01-27182","2018","Van Bellinghen 2018 Hum Vaccin Immunother","25000","Pertussis vaccination of pregnant women VERSUS 2016 Pertussis vaccination strategy (excluded pregnant women) IN Healthy; Age- Adult; Gender- Female; Country- Australia; Other- Pregnant.","29771574","Healthy; Age- Adult; Gender- Female; Country- Australia; Other- Pregnant.","Pertussis vaccination of pregnant women","Is adding maternal vaccination to prevent whooping cough cost-effective in Australia?","2016 Pertussis vaccination strategy (excluded pregnant women)","NE"
"2018-01-27109","2018","Gao 2018 Breast Cancer","3100","Lipegfilgrastim for febrile neutropenia VERSUS Pegfilgrastim for febrile neutropenia IN Specific disease- Stage II breast cancer; Age- Adult; Gender- Female; Country- Australia; Other- Undergoing chemotherapy.","29802592","Specific disease- Stage II breast cancer; Age- Adult; Gender- Female; Country- Australia; Other- Undergoing chemotherapy.","Lipegfilgrastim for febrile neutropenia","Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.","Pegfilgrastim for febrile neutropenia","SW"
"2018-01-27109","2018","Gao 2018 Breast Cancer","540","Lipegfilgrastim for treatment delay cases VERSUS Pegfilgrastim for treatment delay cases IN Specific disease- Stage II breast cancer; Age- Adult; Gender- Female; Country- Australia; Other- Undergoing chemotherapy.","29802592","Specific disease- Stage II breast cancer; Age- Adult; Gender- Female; Country- Australia; Other- Undergoing chemotherapy.","Lipegfilgrastim for treatment delay cases","Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.","Pegfilgrastim for treatment delay cases","SW"
"2018-01-27109","2018","Gao 2018 Breast Cancer","5400","Lipegfilgrastim for infection cases VERSUS Pegfilgrastim for infection cases IN Specific disease- Stage II breast cancer; Age- Adult; Gender- Female; Country- Australia; Other- Undergoing chemotherapy.","29802592","Specific disease- Stage II breast cancer; Age- Adult; Gender- Female; Country- Australia; Other- Undergoing chemotherapy.","Lipegfilgrastim for infection cases","Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.","Pegfilgrastim for infection cases","SW"
"2018-01-27109","2018","Gao 2018 Breast Cancer","640","Lipegfilgrastim for severe neutropenia VERSUS Pegfilgrastim for severe neutropenia IN Specific disease- Stage II breast cancer; Age- Adult; Gender- Female; Country- Australia; Other- Undergoing chemotherapy.","29802592","Specific disease- Stage II breast cancer; Age- Adult; Gender- Female; Country- Australia; Other- Undergoing chemotherapy.","Lipegfilgrastim for severe neutropenia","Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.","Pegfilgrastim for severe neutropenia","SW"
"2018-01-27109","2018","Gao 2018 Breast Cancer","Cost-Saving","Lipegfigrastim VERSUS Pegfilgrastim IN Specific disease- Stage II breast cancer; Age- Adult; Gender- Female; Country- Australia; Other- Undergoing chemotherapy.","29802592","Specific disease- Stage II breast cancer; Age- Adult; Gender- Female; Country- Australia; Other- Undergoing chemotherapy.","Lipegfigrastim","Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.","Pegfilgrastim","SE"
"2018-01-26476","2018","Dillon 2018 PLoS Med","10000","70% participation in full National Bowel Screening Programme: risk category 1 VERSUS Standard/Usual Care- 39% participation in full National Bowel Screening Programme: risk category 1 IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","30114221","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","70% participation in full National Bowel Screening Programme: risk category 1","Family history-based colorectal cancer screening in Australia: A modelling study  of the costs, benefits, and harms of different participation scenarios.","Standard/Usual Care- 39% participation in full National Bowel Screening Programme: risk category 1","NE"
"2018-01-26476","2018","Dillon 2018 PLoS Med","110000","70% participation in full National Bowel Screening Programme: risk category 3 VERSUS Standard/Usual Care- Actual screening participation in full National Bowel Screening Programme: risk category 3 (Potentially high risk) IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","30114221","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","70% participation in full National Bowel Screening Programme: risk category 3","Family history-based colorectal cancer screening in Australia: A modelling study  of the costs, benefits, and harms of different participation scenarios.","Standard/Usual Care- Actual screening participation in full National Bowel Screening Programme: risk category 3 (Potentially high risk)","NE"
"2018-01-26476","2018","Dillon 2018 PLoS Med","13000","100% participation in screening (complete): risk category 1 (At or slightly above average risk) VERSUS Standard/Usual Care- 39% participation in full National Bowel Screening Programme: risk category 1 (At or slightly above average risk) IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","30114221","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","100% participation in screening (complete): risk category 1 (At or slightly above average risk)","Family history-based colorectal cancer screening in Australia: A modelling study  of the costs, benefits, and harms of different participation scenarios.","Standard/Usual Care- 39% participation in full National Bowel Screening Programme: risk category 1 (At or slightly above average risk)","NE"
"2018-01-26476","2018","Dillon 2018 PLoS Med","15000","70% participation in full National Bowel Screening Programme: risk category 2  VERSUS Standard/Usual Care- Actual screening participation in full National Bowel Screening Programme: risk category 2 (Moderately increased risk) IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","30114221","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","70% participation in full National Bowel Screening Programme: risk category 2","Family history-based colorectal cancer screening in Australia: A modelling study  of the costs, benefits, and harms of different participation scenarios.","Standard/Usual Care- Actual screening participation in full National Bowel Screening Programme: risk category 2 (Moderately increased risk)","NE"
"2018-01-26476","2018","Dillon 2018 PLoS Med","150000","100% participation in National Bowel Screening Programme(complete): risk category 3 VERSUS Standard/Usual Care- Actual screening participation in full National Bowel Screening Programme: risk category 3 (Potentially high risk) IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","30114221","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","100% participation in National Bowel Screening Programme(complete): risk category 3","Family history-based colorectal cancer screening in Australia: A modelling study  of the costs, benefits, and harms of different participation scenarios.","Standard/Usual Care- Actual screening participation in full National Bowel Screening Programme: risk category 3 (Potentially high risk)","NE"
"2018-01-26476","2018","Dillon 2018 PLoS Med","19000","100% participation in National Bowel Screening Programme(complete): risk category 2 VERSUS Standard/Usual Care- Actual screening participation in full National Bowel Screening Programme: risk category 2 (Moderately increased risk) IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","30114221","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","100% participation in National Bowel Screening Programme(complete): risk category 2","Family history-based colorectal cancer screening in Australia: A modelling study  of the costs, benefits, and harms of different participation scenarios.","Standard/Usual Care- Actual screening participation in full National Bowel Screening Programme: risk category 2 (Moderately increased risk)","NE"
"2018-01-26476","2018","Dillon 2018 PLoS Med","6600","Actual colorectal cancer screening (baseline): risk category 1 (At or slightly above average risk) VERSUS Standard/Usual Care- 39% participation in full National Bowel Screening Programme: risk category 1 (At or slightly above average risk) IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","30114221","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Australia.","Actual colorectal cancer screening (baseline): risk category 1 (At or slightly above average risk)","Family history-based colorectal cancer screening in Australia: A modelling study  of the costs, benefits, and harms of different participation scenarios.","Standard/Usual Care- 39% participation in full National Bowel Screening Programme: risk category 1 (At or slightly above average risk)","NE"
"2018-01-26451","2018","Weeks 2018 J Arthroplasty","Cost-Saving","Resurfacing of the patella during total knee arthroplasty  VERSUS Standard/Usual Care IN Specific disease- Primary knee osteoarthritis; Age- >=65 years; Gender- Both; Country- Canada.","30122432","Specific disease- Primary knee osteoarthritis; Age- >=65 years; Gender- Both; Country- Canada.","Resurfacing of the patella during total knee arthroplasty","Patellar Resurfacing in Total Knee Arthroplasty: A Cost-Effectiveness Analysis.","Standard/Usual Care","SE"
"2018-01-26250","2018","Chen 2018 Vaccine","180000","PPV23 immunization  VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Australia.","30213457","Healthy; Age- >=65 years; Gender- Both; Country- Australia.","PPV23 immunization","Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.","None","NE"
"2018-01-26232","2018","Ademi 2018 Int J Cardiol","25000","Rivaroxaban plus aspirin VERSUS Standard/Usual Care- Aspirin (100 mg once daily) IN Specific disease- Stable atherosclerotic vascular disease; Age- Adult; Gender- Both; Country- Australia.","30220379","Specific disease- Stable atherosclerotic vascular disease; Age- Adult; Gender- Both; Country- Australia.","Rivaroxaban plus aspirin","Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.","Standard/Usual Care- Aspirin (100 mg once daily)","NE"
"2018-01-25930","2018","Robinson 2018 J Rheumatol","5600","Annual urate monitoring VERSUS None IN Specific disease- Gout; Age- Unknown; Gender- Both; Country- Australia.","29449500","Specific disease- Gout; Age- Unknown; Gender- Both; Country- Australia.","Annual urate monitoring","The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring.","None","NE"
"2018-01-25930","2018","Robinson 2018 J Rheumatol","8400","Biannual urate monitoring VERSUS None IN Specific disease- Gout; Age- Unknown; Gender- Both; Country- Australia.","29449500","Specific disease- Gout; Age- Unknown; Gender- Both; Country- Australia.","Biannual urate monitoring","The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring.","None","NE"
"2018-01-25694","2018","Tuffaha 2018 Genet Med","12000","BRCA gene mutation screening for those with breast cancer and all female family members VERSUS None IN Specific disease- Breast cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Australia.","29300376","Specific disease- Breast cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Australia.","BRCA gene mutation screening for those with breast cancer and all female family members","Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.","None","NE"
"2018-01-25694","2018","Tuffaha 2018 Genet Med","15000","BRCA gene mutation screening for those with breast cancer only (""affected individuals"") VERSUS None IN Specific disease- Breast cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Australia.","29300376","Specific disease- Breast cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Australia.","BRCA gene mutation screening for those with breast cancer only (""affected individuals"")","Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.","None","NE"
"2017-01-24936","2017","Zhang 2017 Vaccine","5300","The boys program + 10 %  p.a. vaccine  VERSUS With boys program  IN Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","28789853","Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","The boys program + 10 %  p.a. vaccine","Targeted human papillomavirus vaccination for young men who have sex with men in  Australia yields significant population benefits and is cost-effective.","With boys program","NE"
"2017-01-24936","2017","Zhang 2017 Vaccine","5300","The boys program + 5 % p.a. vaccine  VERSUS With boys program  IN Specific disease- Human  papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","28789853","Specific disease- Human  papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","The boys program + 5 % p.a. vaccine","Targeted human papillomavirus vaccination for young men who have sex with men in  Australia yields significant population benefits and is cost-effective.","With boys program","NE"
"2017-01-24936","2017","Zhang 2017 Vaccine","5400","The boys program + 20 %  p.a. vaccine  VERSUS With boys program  IN Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","28789853","Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","The boys program + 20 %  p.a. vaccine","Targeted human papillomavirus vaccination for young men who have sex with men in  Australia yields significant population benefits and is cost-effective.","With boys program","NE"
"2017-01-24936","2017","Zhang 2017 Vaccine","58000","The boys program + 20 % p.a. vaccine (10 year delay ) VERSUS With boys program  IN Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","28789853","Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","The boys program + 20 % p.a. vaccine (10 year delay )","Targeted human papillomavirus vaccination for young men who have sex with men in  Australia yields significant population benefits and is cost-effective.","With boys program","NE"
"2017-01-24936","2017","Zhang 2017 Vaccine","9000","20% p.a. only vaccine  VERSUS No boys program IN Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","28789853","Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","20% p.a. only vaccine","Targeted human papillomavirus vaccination for young men who have sex with men in  Australia yields significant population benefits and is cost-effective.","No boys program","NE"
"2017-01-24936","2017","Zhang 2017 Vaccine","9100","10% p.a. only vaccine  VERSUS No boys program IN Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","28789853","Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","10% p.a. only vaccine","Targeted human papillomavirus vaccination for young men who have sex with men in  Australia yields significant population benefits and is cost-effective.","No boys program","NE"
"2017-01-24936","2017","Zhang 2017 Vaccine","9100","5% p.a. only vaccine  VERSUS No boys program IN Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","28789853","Specific disease- Human papillomavirus; Age- 0 to 18 years, 19 to 40 years; Gender- Male; Country- Australia; Other- Young men who have sex with men.","5% p.a. only vaccine","Targeted human papillomavirus vaccination for young men who have sex with men in  Australia yields significant population benefits and is cost-effective.","No boys program","NE"
"2017-01-24918","2017","Scott 2017 Int J Drug Policy","37","All health system interventions VERSUS Standard/Usual Care- Usual Care plus direct-acting antiviral IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Australia.","28797497","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Australia.","All health system interventions","Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.","Standard/Usual Care- Usual Care plus direct-acting antiviral","NE"
"2017-01-24918","2017","Scott 2017 Int J Drug Policy","Cost-Saving","Scaled up primary care + aspartate aminotransferase-to-platelet ratio index + annual testing of people who inject drugs on opioid substitution therapy VERSUS Standard/Usual Care- Current with direct acting antiviral  IN Specific disease- Hepatitis C virus ; Age- Adult; Gender- Both; Country- Australia.","28797497","Specific disease- Hepatitis C virus ; Age- Adult; Gender- Both; Country- Australia.","Scaled up primary care + aspartate aminotransferase-to-platelet ratio index + annual testing of people who inject drugs on opioid substitution therapy","Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.","Standard/Usual Care- Current with direct acting antiviral","SE"
"2017-01-24918","2017","Scott 2017 Int J Drug Policy","Cost-Saving","Scaled up primary care + aspartate aminotransferase-to-platelet ratio index + point of care RNA VERSUS Standard/Usual Care- Current with direct acting antiviral  IN Specific disease- Hepatitis C virus ; Age- Adult; Gender- Both; Country- Australia.","28797497","Specific disease- Hepatitis C virus ; Age- Adult; Gender- Both; Country- Australia.","Scaled up primary care + aspartate aminotransferase-to-platelet ratio index + point of care RNA","Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.","Standard/Usual Care- Current with direct acting antiviral","SE"
"2017-01-24918","2017","Scott 2017 Int J Drug Policy","Cost-Saving","Scenario 1: scaled up primary care VERSUS Standard/Usual Care- Current with direct acting antiviral  IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Australia.","28797497","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Australia.","Scenario 1: scaled up primary care","Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.","Standard/Usual Care- Current with direct acting antiviral","SE"
"2017-01-24918","2017","Scott 2017 Int J Drug Policy","Cost-Saving","Scenario 2: scaled up primary care + aspartate aminotransferase-to-platelet ratio index VERSUS Standard/Usual Care- Current with direct acting antiviral  IN Specific disease- Hepatitis C virus ; Age- Adult; Gender- Both; Country- Australia.","28797497","Specific disease- Hepatitis C virus ; Age- Adult; Gender- Both; Country- Australia.","Scenario 2: scaled up primary care + aspartate aminotransferase-to-platelet ratio index","Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.","Standard/Usual Care- Current with direct acting antiviral","SE"
"2017-01-24907","2017","Jacklin 2017 BMJ Open","33000","NICE 2015 diagnostic criteria for gestational diabetes mellitus VERSUS No treatment IN Specific disease- Gestational diabetes mellitus; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Gestational age 24â28 weeks without pre-existing diabetes..","28801424","Specific disease- Gestational diabetes mellitus; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Gestational age 24â28 weeks without pre-existing diabetes..","NICE 2015 diagnostic criteria for gestational diabetes mellitus","A cost-effectiveness comparison of the NICE 2015 and WHO 2013 diagnostic criteria for women with gestational diabetes with and without risk factors.","No treatment","NE"
"2017-01-24907","2017","Jacklin 2017 BMJ Open","50000","WHO 2013 diagnostic criteria for gestational diabetes mellitus VERSUS NICE 2015 diagnostic criteria for gestational diabetes mellitus IN Specific disease- Gestational diabetes mellitus; Age- Adult; Gender- Female; Country- United Kingdom (UK); Other- Gestational age 24â28 weeks without pre-existing diabetes..","28801424","Specific disease- Gestational diabetes mellitus; Age- Adult; Gender- Female; Country- United Kingdom (UK); Other- Gestational age 24â28 weeks without pre-existing diabetes..","WHO 2013 diagnostic criteria for gestational diabetes mellitus","A cost-effectiveness comparison of the NICE 2015 and WHO 2013 diagnostic criteria for women with gestational diabetes with and without risk factors.","NICE 2015 diagnostic criteria for gestational diabetes mellitus","NE"
"2017-01-24560","2017","Kosaner Kliess 2017 Value Health","7900","Vibrant Soundbridge Implantation VERSUS Standard/Usual Care- No intervention IN Specific disease- Sensorineural Hearing Loss; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Austria; Other- Post lingual mild to severe disease.","28964441","Specific disease- Sensorineural Hearing Loss; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Austria; Other- Post lingual mild to severe disease.","Vibrant Soundbridge Implantation","Cost-Utility of Partially Implantable Active Middle Ear Implants for Sensorineural Hearing Loss: A Decision Analysis.","Standard/Usual Care- No intervention","NE"
"2017-01-24078","2017","Watts 2017 J Clin Oncol","Cost-Saving","Specialized Skin Surveillance VERSUS Standard/Usual Care IN Specific disease- Melanoma; Age- Adult; Gender- Both; Country- Australia; Other- Patients at High Risk of Melanoma.","28034073","Specific disease- Melanoma; Age- Adult; Gender- Both; Country- Australia; Other- Patients at High Risk of Melanoma.","Specialized Skin Surveillance","Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.","Standard/Usual Care","SE"
"2017-01-23491","2017","Karnon 2017 Appl Health Econ Health Policy","6500","Physiotherapy-based intervention VERSUS Standard/Usual Care IN Healthy; Age- >=65 years; Gender- Both; Country- Australia; Other- Frailty.","28349499","Healthy; Age- >=65 years; Gender- Both; Country- Australia; Other- Frailty.","Physiotherapy-based intervention","A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention.","Standard/Usual Care","NE"
"2017-01-23353","2017","Gordon 2017 Value Health","Dominated","Cancer screening: educational DVD about self-skin examination and the importance of presenting to a doctor if there were lesions of concern, postcard reminders to watch the DVD, a body chart to note down  the location of skin lesions, and a colored brochure differentiating benign and malignant skin lesions. VERSUS colored brochure differentiating benign and malignant skin lesions IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- Australia.","28408001","Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- Australia.","Cancer screening: educational DVD about self-skin examination and the importance of presenting to a doctor if there were lesions of concern, postcard reminders to watch the DVD, a body chart to note down  the location of skin lesions, and a colored brochure differentiating benign and malignant skin lesions.","Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection  of Skin Cancer Targeting Men Older Than 50 Years.","colored brochure differentiating benign and malignant skin lesions","NW"
"2017-01-23246","2017","Wentworth 2017 J Diabetes Complications","31000","Gastric band surgery + usual care VERSUS Standard/Usual Care IN Specific disease- Overweight; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States; Other- Patients with type 2 diabetes (T2D) of less than 5 years' duration and a BMI between 25 and 30
kg/m^2.","28462893","Specific disease- Overweight; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States; Other- Patients with type 2 diabetes (T2D) of less than 5 years' duration and a BMI between 25 and 30
kg/m^2.","Gastric band surgery + usual care","Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S.","Standard/Usual Care","NE"
"2016-01-24075","2016","de Graaff 2016 Appl Health Econ Health Policy","12000","Genotype screening (buccal) VERSUS Status quo IN Healthy; Age- 19 to 40 years; Gender- Male; Country- Australia; Other- 30-year-old males of northern European ancestry.","28035629","Healthy; Age- 19 to 40 years; Gender- Male; Country- Australia; Other- 30-year-old males of northern European ancestry.","Genotype screening (buccal)","Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia.","Status quo","NE"
"2018-01-27723","2018","Broekhuizen 2018 Int J Behav Nutr Phys Act","210000","Physical activity promotion intervention during pregnancy VERSUS Standard/Usual Care- Received care as usual by their midwife or obstetrician and did not receive any of the lifestyle interventions IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United Kingdom, Ireland, Austria, Poland, Italy (Padua, Pisa), Spain, Denmark (Odense, Copenhagen), Belgium, and the Netherlands.; Other- Pregnant women with a pre-pregnancy body mass index (BMI) of >=29 kg/m2.","29540227","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United Kingdom, Ireland, Austria, Poland, Italy (Padua, Pisa), Spain, Denmark (Odense, Copenhagen), Belgium, and the Netherlands.; Other- Pregnant women with a pre-pregnancy body mass index (BMI) of >=29 kg/m2.","Physical activity promotion intervention during pregnancy","Cost-effectiveness of healthy eating and/or physical activity promotion in pregnant women at increased risk of gestational diabetes mellitus: economic evaluation alongside the DALI study, a European multicenter randomized controlled trial.","Standard/Usual Care- Received care as usual by their midwife or obstetrician and did not receive any of the lifestyle interventions","SW"
"2018-01-27723","2018","Broekhuizen 2018 Int J Behav Nutr Phys Act","Cost-Saving","Healthy eating promotion intervention+Physical activity promotion intervention during pregnancy VERSUS Standard/Usual Care- Received care as usual by their midwife or obstetrician and did not receive any of the lifestyle interventions IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United Kingdom, Ireland, Austria, Poland, Italy (Padua, Pisa), Spain, Denmark (Odense, Copenhagen), Belgium, and the Netherlands.; Other- Pregnant women with a pre-pregnancy body mass index (BMI) of >=29 kg/m2.","29540227","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United Kingdom, Ireland, Austria, Poland, Italy (Padua, Pisa), Spain, Denmark (Odense, Copenhagen), Belgium, and the Netherlands.; Other- Pregnant women with a pre-pregnancy body mass index (BMI) of >=29 kg/m2.","Healthy eating promotion intervention+Physical activity promotion intervention during pregnancy","Cost-effectiveness of healthy eating and/or physical activity promotion in pregnant women at increased risk of gestational diabetes mellitus: economic evaluation alongside the DALI study, a European multicenter randomized controlled trial.","Standard/Usual Care- Received care as usual by their midwife or obstetrician and did not receive any of the lifestyle interventions","SE"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","16000","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Intermediate (individual breast cancer specific mortality (BCMS)9%=BCMS<17%) OncotypeDX Intermediate (Recurrence risk score (RS) 18=RS<30).","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Intermediate (individual breast cancer specific mortality (BCMS)9%=BCMS<17%) OncotypeDX Intermediate (Recurrence risk score (RS) 18=RS<30).","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NE"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","17000","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: High (individual breast cancer specific mortality (BCMS)= 17%) OncotypeDX Intermediate (Recurrence risk score (RS) 18=RS<30).","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: High (individual breast cancer specific mortality (BCMS)= 17%) OncotypeDX Intermediate (Recurrence risk score (RS) 18=RS<30).","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NE"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","3600","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: High (individual breast cancer specific mortality (BCMS)= 17%) OncotypeDX Not applied.","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: High (individual breast cancer specific mortality (BCMS)= 17%) OncotypeDX Not applied.","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NE"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","4000","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Low (individual breast cancer specific mortality (BCMS)<9%) OncotypeDX High (Recurrence risk score (RS) RS= 30).","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Low (individual breast cancer specific mortality (BCMS)<9%) OncotypeDX High (Recurrence risk score (RS) RS= 30).","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NE"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","5600","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Patients with estrogen receptor (ER) and/or progesterone receptor (PR) positive, human epidermal growth factor receptor 2/neu (HER-2/neu) negative and lymph node negative early breast cancer.","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Patients with estrogen receptor (ER) and/or progesterone receptor (PR) positive, human epidermal growth factor receptor 2/neu (HER-2/neu) negative and lymph node negative early breast cancer.","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NE"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","670000","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Low (individual breast cancer specific mortality (BCMS)<9%) OncotypeDX Not applied.","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Low (individual breast cancer specific mortality (BCMS)<9%) OncotypeDX Not applied.","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NE"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","790","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: High (individual breast cancer specific mortality (BCMS)= 17%) OncotypeDX High (Recurrence risk score (RS) RS= 30).","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: High (individual breast cancer specific mortality (BCMS)= 17%) OncotypeDX High (Recurrence risk score (RS) RS= 30).","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NE"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","820","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Intermediate (individual breast cancer specific mortality (BCMS)9%=BCMS<17%) OncotypeDX High (Recurrence risk score (RS) RS= 30).","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Intermediate (individual breast cancer specific mortality (BCMS)9%=BCMS<17%) OncotypeDX High (Recurrence risk score (RS) RS= 30).","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NE"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","Dominated","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: High (individual breast cancer specific mortality (BCMS)= 17%) OncotypeDX Low (Recurrence risk score (RS) <18).","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: High (individual breast cancer specific mortality (BCMS)= 17%) OncotypeDX Low (Recurrence risk score (RS) <18).","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NW"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","Dominated","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Intermediate (individual breast cancer specific mortality (BCMS)9%=BCMS<17%) OncotypeDX Low (Recurrence risk score (RS) <18).","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Intermediate (individual breast cancer specific mortality (BCMS)9%=BCMS<17%) OncotypeDX Low (Recurrence risk score (RS) <18).","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NW"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","Dominated","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No Chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Low (individual breast cancer specific mortality (BCMS)<9%) OncotypeDX Intermediate (Recurrence risk score (RS) 18=RS<30).","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Low (individual breast cancer specific mortality (BCMS)<9%) OncotypeDX Intermediate (Recurrence risk score (RS) 18=RS<30).","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No Chemotherapy","NW"
"2017-01-24429","2017","Jahn 2017 BMC Cancer","Dominated","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor) VERSUS No chemotherapy IN Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Low (individual breast cancer specific mortality (BCMS)<9%) OncotypeDX Low (Recurrence risk score (RS) <18).","29037213","Specific disease- Early breast Cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- Risk Group: Low (individual breast cancer specific mortality (BCMS)<9%) OncotypeDX Low (Recurrence risk score (RS) <18).","Chemotherapy (5-flurorouracil,epirubicin, cyclophosphamide, docetaxel, aromatase inhibitor)","Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.","No chemotherapy","NW"
"2017-01-23778","2017","Dranitsaris 2017 Support Care Cancer","5800","Dalteparin VERSUS Standard/Usual Care- Oral anticoagulant therapy (Vitamin K antagonists) IN Specific disease- Venous thromboembolism; Age- Adult; Gender- Both; Country- Austria; Other- Cancer patients who developed an initial venous thromboembolism.","28204995","Specific disease- Venous thromboembolism; Age- Adult; Gender- Both; Country- Austria; Other- Cancer patients who developed an initial venous thromboembolism.","Dalteparin","Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.","Standard/Usual Care- Oral anticoagulant therapy (Vitamin K antagonists)","NE"
"2017-01-23778","2017","Dranitsaris 2017 Support Care Cancer","7800","Dalteparin VERSUS Standard/Usual Care- Oral anticoagulant therapy (Vitamin K antagonists) IN Specific disease- Venous Thromboembolism; Age- Unknown; Gender- Both; Country- France; Other- Cancer patients who developed an initial venous thromboembolism.","28204995","Specific disease- Venous Thromboembolism; Age- Unknown; Gender- Both; Country- France; Other- Cancer patients who developed an initial venous thromboembolism.","Dalteparin","Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.","Standard/Usual Care- Oral anticoagulant therapy (Vitamin K antagonists)","NE"
"2016-01-19654","2016","Boiron 2016 BMC Infect Dis","23000","9-valent HPV vaccine associated with current cervical cancer screening VERSUS 4-valent vaccine associated with current cervical cancer screening IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Austria; Other- 8,507,786 estimated target population.","27084683","Healthy; Age- 0 to 18 years; Gender- Both; Country- Austria; Other- 8,507,786 estimated target population.","9-valent HPV vaccine associated with current cervical cancer screening","Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.","4-valent vaccine associated with current cervical cancer screening","NE"
"2015-01-20456","2015","Jahn 2015 Springerplus","24000","21-gene assay used in conjunction with an Adjuvent!Online treatment decision aid VERSUS 21-gene assay used in conjunction with an Adjuvent!Online decision aid sccore in patients with a decision-aid defined intermediate and high risk. IN Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","26693110","Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","21-gene assay used in conjunction with an Adjuvent!Online treatment decision aid","Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.","21-gene assay used in conjunction with an Adjuvent!Online decision aid sccore in patients with a decision-aid defined intermediate and high risk.","NE"
"2015-01-20456","2015","Jahn 2015 Springerplus","2500","21-gene assay used in conjunction with an Adjuvent!Online treatment decision aid VERSUS Standard/Usual Care IN Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","26693110","Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","21-gene assay used in conjunction with an Adjuvent!Online treatment decision aid","Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.","Standard/Usual Care","NE"
"2015-01-20456","2015","Jahn 2015 Springerplus","2800","21-gene assay used in conjunction with an Adjuvent!Online treatment decision aid VERSUS Standard/Usual Care IN Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","26693110","Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","21-gene assay used in conjunction with an Adjuvent!Online treatment decision aid","Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.","Standard/Usual Care","NE"
"2015-01-20456","2015","Jahn 2015 Springerplus","3000","21-gene assay used in conjunction with an Adjuvent!Online treatment decision aid VERSUS Standard/Usual Care IN Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","26693110","Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","21-gene assay used in conjunction with an Adjuvent!Online treatment decision aid","Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.","Standard/Usual Care","NE"
"2015-01-20456","2015","Jahn 2015 Springerplus","330000","21-gene assay used in conjunction with an Adjuvent!Online treatment decision aid VERSUS 21-gene assay used in conjunction with an Adjuvent!Online decision aid sccore in patients with a decision-aid defined intermediate and high risk. IN Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","26693110","Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","21-gene assay used in conjunction with an Adjuvent!Online treatment decision aid","Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.","21-gene assay used in conjunction with an Adjuvent!Online decision aid sccore in patients with a decision-aid defined intermediate and high risk.","NE"
"2015-01-20456","2015","Jahn 2015 Springerplus","Dominated","21-gene assay used in conjunction with an Adjuvent! Online treatment decision aid VERSUS 21-gene assay used in conjunction with an Adjuvent!Online decision aid sccore in patients with a decision-aid defined intermediate and high risk. IN Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","26693110","Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","21-gene assay used in conjunction with an Adjuvent! Online treatment decision aid","Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.","21-gene assay used in conjunction with an Adjuvent!Online decision aid sccore in patients with a decision-aid defined intermediate and high risk.","NW"
"2015-01-20456","2015","Jahn 2015 Springerplus","Dominated","21-gene assay used in conjunction with an Adjuvent!Online decision treatment aid VERSUS 21-gene assay used in conjunction with an Adjuvent!Online decision aid sccore in patients with a decision-aid defined intermediate and high risk. IN Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","26693110","Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- Austria; Other- diagnosed with estrogen receptor and/or progesterone receptor positive, HER-2/neu negative, and lymph node negative breast cancer.","21-gene assay used in conjunction with an Adjuvent!Online decision treatment aid","Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.","21-gene assay used in conjunction with an Adjuvent!Online decision aid sccore in patients with a decision-aid defined intermediate and high risk.","NW"
"2015-01-19013","2015","Rochau 2015 Leuk Lymphoma","170000","Nilotinib without second-line tyrosine kinase inhibitor treatment after Nilotinib failure VERSUS Imatinib without second-line tyrosine kinase inhibitor treatment after Imatinib failure IN Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","25393806","Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","Nilotinib without second-line tyrosine kinase inhibitor treatment after Nilotinib failure","Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.","Imatinib without second-line tyrosine kinase inhibitor treatment after Imatinib failure","NE"
"2015-01-19013","2015","Rochau 2015 Leuk Lymphoma","180000","Imatinib followed by Nilotinib after Imatinib failure VERSUS Nilotinib without second-line tyrosine kinase inhibitor treatment after Nilotinib failure IN Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","25393806","Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","Imatinib followed by Nilotinib after Imatinib failure","Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.","Nilotinib without second-line tyrosine kinase inhibitor treatment after Nilotinib failure","NE"
"2015-01-19013","2015","Rochau 2015 Leuk Lymphoma","210000","Nilotinib followed by Dasatinib after Nilotinib failure VERSUS Imatinib followed by Nilotinib after Imatinib failure IN Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","25393806","Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","Nilotinib followed by Dasatinib after Nilotinib failure","Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.","Imatinib followed by Nilotinib after Imatinib failure","NE"
"2015-01-19013","2015","Rochau 2015 Leuk Lymphoma","280000","Imatinib followed by Dasatinib after Imatinib failure VERSUS Imatinib followed by Nilotinib after Imatinib failure IN Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","25393806","Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","Imatinib followed by Dasatinib after Imatinib failure","Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.","Imatinib followed by Nilotinib after Imatinib failure","NE"
"2015-01-19013","2015","Rochau 2015 Leuk Lymphoma","Dominated","Dasatinib followed by Nilotinib after Dasatinib failure VERSUS Nilotinib followed by Dasatinib after Nilotinib failure IN Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","25393806","Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","Dasatinib followed by Nilotinib after Dasatinib failure","Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.","Nilotinib followed by Dasatinib after Nilotinib failure","NW"
"2015-01-19013","2015","Rochau 2015 Leuk Lymphoma","Dominated","Dasatinib without second-line tyrosine kinase inhibitor treatment after Dasatinib failure VERSUS Imatinib followed by Nilotinib after Imatinib failure IN Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","25393806","Specific disease- Chronic myeloid leukemia; Age- 41 to 64 years; Gender- Both; Country- Austria.","Dasatinib without second-line tyrosine kinase inhibitor treatment after Dasatinib failure","Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.","Imatinib followed by Nilotinib after Imatinib failure","NW"
"2014-01-15542","2014","Blank 2014 Pharmacoeconomics","Cost-Saving","2007 National Comprehensive Cancer Center Network breast cancer guidelines and Endo-Predict test VERSUS Standard/Usual Care- German S3 guideline for the management of breast cancer IN Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive.","25404424","Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive.","2007 National Comprehensive Cancer Center Network breast cancer guidelines and Endo-Predict test","Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.","Standard/Usual Care- German S3 guideline for the management of breast cancer","SE"
"2014-01-15542","2014","Blank 2014 Pharmacoeconomics","Cost-Saving","Endo-Predict test VERSUS Standard/Usual Care- German S3 guideline for the management of breast cancer IN Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive with unknown recurrence in risk.","25404424","Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive with unknown recurrence in risk.","Endo-Predict test","Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.","Standard/Usual Care- German S3 guideline for the management of breast cancer","SE"
"2014-01-15542","2014","Blank 2014 Pharmacoeconomics","Cost-Saving","German S3 guidelines for chemotherapy and Endo-Predict test VERSUS Standard/Usual Care- German S3 guideline for the management of breast cancer IN Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive.","25404424","Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive.","German S3 guidelines for chemotherapy and Endo-Predict test","Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.","Standard/Usual Care- German S3 guideline for the management of breast cancer","SE"
"2014-01-15542","2014","Blank 2014 Pharmacoeconomics","Cost-Saving","St. Gallen guidelines and Endo-Predict test VERSUS Standard/Usual Care- German S3 guideline for the management of breast cancer IN Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive.","25404424","Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive.","St. Gallen guidelines and Endo-Predict test","Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.","Standard/Usual Care- German S3 guideline for the management of breast cancer","SE"
"2014-01-15542","2014","Blank 2014 Pharmacoeconomics","Dominated","2007 National Comprehensive Cancer Center Network breast cancer guidelines for chemotherapy VERSUS Standard/Usual Care- German S3 guideline for the management of breast cancer IN Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive.","25404424","Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive.","2007 National Comprehensive Cancer Center Network breast cancer guidelines for chemotherapy","Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.","Standard/Usual Care- German S3 guideline for the management of breast cancer","NW"
"2014-01-15542","2014","Blank 2014 Pharmacoeconomics","Dominated","St. Gallen breast cancer guidelines for chemotherapy VERSUS Standard/Usual Care- German S3 guideline for the management of breast cancer IN Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive.","25404424","Specific disease- Breast cancer; Age- Adult; Gender- Female; Country- Germany; Other- Early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) nodenegative or node-positive.","St. Gallen breast cancer guidelines for chemotherapy","Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.","Standard/Usual Care- German S3 guideline for the management of breast cancer","NW"
"2014-01-15040","2014","Bresse                           2014 Expert Rev Pharmacoecon Outcomes Res","15000","Quadrivalent Human papillomavirus vaccine combined with current cervical cancer screening and HPV disease management practices VERSUS Standard/Usual Care- Cervical cancer screening and HPV disease management practices IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Austria.","24450951","Healthy; Age- 0 to 18 years; Gender- Both; Country- Austria.","Quadrivalent Human papillomavirus vaccine combined with current cervical cancer screening and HPV disease management practices","Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis.","Standard/Usual Care- Cervical cancer screening and HPV disease management practices","NE"
"2014-01-15040","2014","Bresse                           2014 Expert Rev Pharmacoecon Outcomes Res","24000","Quadrivalent Human papillomavirus vaccine combined with current cervical cancer screening and HPV disease management practices (but excluding: anal, oropharyngeal and penile cancers). VERSUS Standard/Usual Care- Cervical cancer screening and HPV disease management practices IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Austria.","24450951","Healthy; Age- 0 to 18 years; Gender- Both; Country- Austria.","Quadrivalent Human papillomavirus vaccine combined with current cervical cancer screening and HPV disease management practices (but excluding: anal, oropharyngeal and penile cancers).","Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis.","Standard/Usual Care- Cervical cancer screening and HPV disease management practices","NE"
"2014-01-15040","2014","Bresse                           2014 Expert Rev Pharmacoecon Outcomes Res","41000","Quadrivalent human papillomavirus vaccination VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Austria.","24450951","Healthy; Age- 0 to 18 years; Gender- Both; Country- Austria.","Quadrivalent human papillomavirus vaccination","Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis.","None","NE"
"2011-01-07142","2011","Haller 2011 Nephrol Dial Transplant","Cost-Saving","20% of the incident, ESRD patients were allocated to peritoneal dialysis VERSUS Current assignment policy in Austria: 90.6% of new ESRD patients were treated with haemodialysis (HD), 7.2% with peritoneal dialysis (PD), 0.1% received a renal transplantation from a live donor (TL) and 2.1% from a deceased donor (TD) IN Austrian patients requiring renal replacement therapy for end-stage renal disease (ESRD)","21310740","Austrian patients requiring renal replacement therapy for end-stage renal disease (ESRD)","20% of the incident, ESRD patients were allocated to peritoneal dialysis","Cost-effectiveness analysis of renal replacement therapy in Austria.","Current assignment policy in Austria: 90.6% of new ESRD patients were treated with haemodialysis (HD), 7.2% with peritoneal dialysis (PD), 0.1% received a renal transplantation from a live donor (TL) and 2.1% from a deceased donor (TD)","SE"
"2010-01-06778","2010","Delea 2010 Clin Breast Cancer","Cost-Saving","Adjuvant endocrine therapy plus 4 mg of zoledronic acid every 6 months for up to 3 years VERSUS Adjuvant endocrine therapy with goserlin and tamoxifen or anatrazole for up to 3 years IN US premenopausal women with hormone-responsive positive early breast cancer","20705558","US premenopausal women with hormone-responsive positive early breast cancer","Adjuvant endocrine therapy plus 4 mg of zoledronic acid every 6 months for up to 3 years","Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.","Adjuvant endocrine therapy with goserlin and tamoxifen or anatrazole for up to 3 years","SE"
"2009-01-05424","2009","Anselmino 2009 Obes Surg","2400","Gastric banding VERSUS Conventional treatment IN Patients with BMI >=35 and type 2 diabetes mellitus in Spain","19756896","Patients with BMI >=35 and type 2 diabetes mellitus in Spain","Gastric banding","Cost-effectiveness and Budget Impact of Obesity Surgery in Patients with Type 2 Diabetes in Three European Countries(II).","Conventional treatment","NE"
"2009-01-05424","2009","Anselmino 2009 Obes Surg","4300","Gastric bypass VERSUS Conventional treatment IN Patients with BMI >=35 and type 2 diabetes mellitus in Spain","19756896","Patients with BMI >=35 and type 2 diabetes mellitus in Spain","Gastric bypass","Cost-effectiveness and Budget Impact of Obesity Surgery in Patients with Type 2 Diabetes in Three European Countries(II).","Conventional treatment","NE"
"2009-01-05424","2009","Anselmino 2009 Obes Surg","Cost-Saving","Gastric banding and gastric bypass VERSUS Conventional treatment IN Patients with BMI >=35 and type 2 diabetes mellitus in Austria","19756896","Patients with BMI >=35 and type 2 diabetes mellitus in Austria","Gastric banding and gastric bypass","Cost-effectiveness and Budget Impact of Obesity Surgery in Patients with Type 2 Diabetes in Three European Countries(II).","Conventional treatment","SE"
"2009-01-05424","2009","Anselmino 2009 Obes Surg","Cost-Saving","Gastric banding and gastric bypass VERSUS Conventional treatment IN Patients with BMI >=35 and type 2 diabetes mellitus in Italy","19756896","Patients with BMI >=35 and type 2 diabetes mellitus in Italy","Gastric banding and gastric bypass","Cost-effectiveness and Budget Impact of Obesity Surgery in Patients with Type 2 Diabetes in Three European Countries(II).","Conventional treatment","SE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","18000","Adding sitagliptin to metformin therapy VERSUS Adding sulfonylurea to metformin therapy IN UK patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","UK patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding sulfonylurea to metformin therapy","NE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","19000","Adding sitagliptin to metformin therapy VERSUS Adding sulfonylurea to metformin therapy IN Swedish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","Swedish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding sulfonylurea to metformin therapy","NE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","21000","Adding sitagliptin to metformin therapy VERSUS Adding sulfonylurea to metformin therapy IN Finnish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","Finnish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding sulfonylurea to metformin therapy","NE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","21000","Adding sitagliptin to metformin therapy VERSUS Adding sulfonylurea to metformin therapy IN Spanish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","Spanish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding sulfonylurea to metformin therapy","NE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","230","Adding sitagliptin to metformin therapy VERSUS Adding rosiglotazone to metformin therapy IN Spanish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","Spanish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding rosiglotazone to metformin therapy","NE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","32000","Adding sitagliptin to metformin therapy VERSUS Adding sulfonylurea to metformin therapy IN Austrian patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","Austrian patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding sulfonylurea to metformin therapy","NE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","3500","Adding sitagliptin to metformin therapy VERSUS Adding rosiglotazone to metformin therapy IN UK patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","UK patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding rosiglotazone to metformin therapy","NE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","7500","Adding sitagliptin to metformin therapy VERSUS Adding rosiglotazone to metformin therapy IN Finnish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","Finnish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding rosiglotazone to metformin therapy","NE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","9300","Adding sitagliptin to metformin therapy VERSUS Adding sulfonylurea to metformin therapy IN Portugese patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","Portugese patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding sulfonylurea to metformin therapy","NE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","Cost-Saving","Adding sitagliptin to metformin therapy VERSUS Adding rosiglotazone to metformin therapy IN Austrian patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","Austrian patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding rosiglotazone to metformin therapy","SE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","Cost-Saving","Adding sitagliptin to metformin therapy VERSUS Adding rosiglotazone to metformin therapy IN Portugal patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","Portugal patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding rosiglotazone to metformin therapy","SE"
"2008-01-03792","2008","Schwarz 2008 Diabetes Obes Metab","Cost-Saving","Adding sitagliptin to metformin therapy VERSUS Adding rosiglotazone to metformin therapy IN Swedish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","18435673","Swedish patients with type 2 diabetes and hemoglobin A1c above target level on metformin monotherapy","Adding sitagliptin to metformin therapy","Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.","Adding rosiglotazone to metformin therapy","SE"
"2008-01-03706","2008","Resch 2008 Clin Ther","18000","Prophylaxis therapy with Palivizumab VERSUS No prophylaxis IN Infant and children at high risk for Respiratory syncytial viral infection in Austria (CHD)","18498923","Infant and children at high risk for Respiratory syncytial viral infection in Austria (CHD)","Prophylaxis therapy with Palivizumab","Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria.","No prophylaxis","NE"
"2008-01-03706","2008","Resch 2008 Clin Ther","32000","Prophylaxis therapy with Palivizumab VERSUS No prophylaxis IN Infant and children at high risk for Respiratory syncytial viral infection in Austria (Prematurity)","18498923","Infant and children at high risk for Respiratory syncytial viral infection in Austria (Prematurity)","Prophylaxis therapy with Palivizumab","Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria.","No prophylaxis","NE"
"2017-01-24883","2017","Arora 2017 Spinal Cord","740","Telephone-based support VERSUS Standard/Usual Care- Usual care IN Specific disease- Spinal cord injury and Pressure Ulcer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- India; Other- Patients had at least one pressure ulcer (on the sacrum, ischial tuberosity or greater trochanter of the femur).","28809389","Specific disease- Spinal cord injury and Pressure Ulcer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- India; Other- Patients had at least one pressure ulcer (on the sacrum, ischial tuberosity or greater trochanter of the femur).","Telephone-based support","Cost-effectiveness analysis of telephone-based support for the management of pressure ulcers in people with spinal cord injury in India and Bangladesh.","Standard/Usual Care- Usual care","NE"
"2014-01-14658","2014","Miners 2014 J Viral Hepat","31000","Hepatitic C Virus Screening VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- Migrants from the Indian subcontinent, primarily Bangladesh, India and Pakistan.","24215210","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- Migrants from the Indian subcontinent, primarily Bangladesh, India and Pakistan.","Hepatitic C Virus Screening","Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK  migrant populations and the value of further research.","None","NE"
"2011-01-07814","2011","Begh                   2011 Trials","14000","smoking cessation program VERSUS Standard or care IN Pakistani and Bangladeshi men living in UK","21854596","Pakistani and Bangladeshi men living in UK","smoking cessation program","Promoting smoking cessation in Pakistani and Bangladeshi men in the UK: pilot cluster randomised controlled trial of trained community outreach workers.","Standard or care","NE"
"2014-01-16135","2014","Handschu 2014 J Neurol","730","Video-based teleconsultation VERSUS Telephone advice (TA) IN Specific disease- Acute stroke; Age- Adult; Gender- Not Specified; Country- United States.","25082628","Specific disease- Acute stroke; Age- Adult; Gender- Not Specified; Country- United States.","Video-based teleconsultation","Teleneurology in stroke management: costs of service in different organizational  models.","Telephone advice (TA)","NE"
"2012-01-09996","2012","Reynolds 2012 J Am Coll Cardiol","89000","Transcatheter aortic valve replacement (TAVR) VERSUS Surgical aortic valve replacement (AVR) IN US patients with severe aortic stenosis and high surgical risk","23122802","US patients with severe aortic stenosis and high surgical risk","Transcatheter aortic valve replacement (TAVR)","Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis: Results of the PARTNER (Placement of Aortic Transcatheter Valves) Trial (Cohort A).","Surgical aortic valve replacement (AVR)","NE"
"2012-01-09996","2012","Reynolds 2012 J Am Coll Cardiol","Cost-Saving","Transcatheter aortic valve replacement (TAVR) VERSUS Surgical aortic valve replacement (AVR) IN US patients with severe aortic stenosis and high surgical risk in transfemoral cohort","23122802","US patients with severe aortic stenosis and high surgical risk in transfemoral cohort","Transcatheter aortic valve replacement (TAVR)","Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis: Results of the PARTNER (Placement of Aortic Transcatheter Valves) Trial (Cohort A).","Surgical aortic valve replacement (AVR)","SE"
"2012-01-09996","2012","Reynolds 2012 J Am Coll Cardiol","Dominated","Transcatheter aortic valve replacement (TAVR) VERSUS Surgical aortic valve replacement (AVR) IN US patients with severe aortic stenosis and high surgical risk in transapical cohort","23122802","US patients with severe aortic stenosis and high surgical risk in transapical cohort","Transcatheter aortic valve replacement (TAVR)","Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis: Results of the PARTNER (Placement of Aortic Transcatheter Valves) Trial (Cohort A).","Surgical aortic valve replacement (AVR)","NW"
"2018-01-27531","2018","Neyt 2018 PLoS One","120000","Bevacizumab  VERSUS Standard/Usual Care- Standard chemotherapy alone IN Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- ICON7 HR Clinical Trial; High risk group.","29630612","Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- ICON7 HR Clinical Trial; High risk group.","Bevacizumab","First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.","Standard/Usual Care- Standard chemotherapy alone","NE"
"2018-01-27531","2018","Neyt 2018 PLoS One","220000","Bevacizumab + standard chemotherapy VERSUS Standard/Usual Care- Standard chemotherapy alone IN Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- GOG-0218 Clinical Trial.","29630612","Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- GOG-0218 Clinical Trial.","Bevacizumab + standard chemotherapy","First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.","Standard/Usual Care- Standard chemotherapy alone","NE"
"2018-01-27531","2018","Neyt 2018 PLoS One","240000","Bevacizumab + standard chemotherapy VERSUS Standard/Usual Care- Standard chemotherapy alone IN Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- AURELIA Clinical Trial.","29630612","Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- AURELIA Clinical Trial.","Bevacizumab + standard chemotherapy","First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.","Standard/Usual Care- Standard chemotherapy alone","NE"
"2018-01-27531","2018","Neyt 2018 PLoS One","550000","Bevacizumab + standard chemotherapy VERSUS Standard/Usual Care- Standard chemotherapy alone IN Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- ICON7 Clinical Trial.","29630612","Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- ICON7 Clinical Trial.","Bevacizumab + standard chemotherapy","First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.","Standard/Usual Care- Standard chemotherapy alone","NE"
"2018-01-27531","2018","Neyt 2018 PLoS One","73000","Bevacizumab + standard chemotherapy VERSUS Standard/Usual Care- Standard chemotherapy alone IN Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- GOG-0218 st.IV Clinical Trial.","29630612","Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- GOG-0218 st.IV Clinical Trial.","Bevacizumab + standard chemotherapy","First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.","Standard/Usual Care- Standard chemotherapy alone","NE"
"2018-01-27531","2018","Neyt 2018 PLoS One","830000","Bevacizumab + standard chemotherapy VERSUS Standard/Usual Care- Standard chemotherapy alone IN Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- OCEANS Clinical Trial.","29630612","Specific disease- Ovarian Cancer; Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- OCEANS Clinical Trial.","Bevacizumab + standard chemotherapy","First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.","Standard/Usual Care- Standard chemotherapy alone","NE"
"2018-01-27500","2018","Fobelets 2018 BMC Pregnancy Childbirth","15000","Vaginal birth after caesarean VERSUS Elective repeat caesarean delivery IN Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Germany; Other- Previous Caesarean Delivery.","29642858","Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Germany; Other- Previous Caesarean Delivery.","Vaginal birth after caesarean","Vaginal birth after caesarean versus elective repeat caesarean delivery after one previous caesarean section: a cost-effectiveness analysis in four European countries.","Elective repeat caesarean delivery","NE"
"2018-01-27500","2018","Fobelets 2018 BMC Pregnancy Childbirth","4300","Vaginal birth after caesarean VERSUS Elective repeat caesarean delivery IN Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Belgium.","29642858","Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Belgium.","Vaginal birth after caesarean","Vaginal birth after caesarean versus elective repeat caesarean delivery after one previous caesarean section: a cost-effectiveness analysis in four European countries.","Elective repeat caesarean delivery","NE"
"2018-01-27500","2018","Fobelets 2018 BMC Pregnancy Childbirth","Cost-Saving","Vaginal birth after caesarean VERSUS Elective repeat caesarean delivery IN Specific disease- Pregnant Women; Age- Adult; Gender- Female; Country- Ireland; Other- Previous Caesarean Delivery.","29642858","Specific disease- Pregnant Women; Age- Adult; Gender- Female; Country- Ireland; Other- Previous Caesarean Delivery.","Vaginal birth after caesarean","Vaginal birth after caesarean versus elective repeat caesarean delivery after one previous caesarean section: a cost-effectiveness analysis in four European countries.","Elective repeat caesarean delivery","SE"
"2018-01-27500","2018","Fobelets 2018 BMC Pregnancy Childbirth","Cost-Saving","Vaginal Birth after Caesarean VERSUS Elective Repeat Caesarean Delivery IN Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Belgium; Other- Previous Caesarean Births.","29642858","Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Belgium; Other- Previous Caesarean Births.","Vaginal Birth after Caesarean","Vaginal birth after caesarean versus elective repeat caesarean delivery after one previous caesarean section: a cost-effectiveness analysis in four European countries.","Elective Repeat Caesarean Delivery","SE"
"2018-01-27500","2018","Fobelets 2018 BMC Pregnancy Childbirth","Cost-Saving","Vaginal Birth After Caesarean VERSUS Elective repeat caesarean delivery IN Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Germany; Other- Previous Caesarean Delivery.","29642858","Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Germany; Other- Previous Caesarean Delivery.","Vaginal Birth After Caesarean","Vaginal birth after caesarean versus elective repeat caesarean delivery after one previous caesarean section: a cost-effectiveness analysis in four European countries.","Elective repeat caesarean delivery","SE"
"2018-01-27500","2018","Fobelets 2018 BMC Pregnancy Childbirth","Cost-Saving","Vaginal birth after caesarean VERSUS Elective repeat caesarean delivery IN Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Ireland; Other- Previous Caesarean Delivery.","29642858","Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Ireland; Other- Previous Caesarean Delivery.","Vaginal birth after caesarean","Vaginal birth after caesarean versus elective repeat caesarean delivery after one previous caesarean section: a cost-effectiveness analysis in four European countries.","Elective repeat caesarean delivery","SE"
"2018-01-27500","2018","Fobelets 2018 BMC Pregnancy Childbirth","Cost-Saving","Vaginal birth after caesarean VERSUS Elective repeat caesarean delivery IN Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Italy; Other- Previous Caesarean Delivery.","29642858","Specific disease- Pregnant; Age- Adult; Gender- Female; Country- Italy; Other- Previous Caesarean Delivery.","Vaginal birth after caesarean","Vaginal birth after caesarean versus elective repeat caesarean delivery after one previous caesarean section: a cost-effectiveness analysis in four European countries.","Elective repeat caesarean delivery","SE"
"2018-01-26823","2018","Marbaix 2018 PLoS One","20000","13-valent pneumococcal conjugate vaccine VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Belgium; Other- Elevated risk (moderate/high-risk) of pneumococcal infection.","29979689","Healthy; Age- >=65 years; Gender- Both; Country- Belgium; Other- Elevated risk (moderate/high-risk) of pneumococcal infection.","13-valent pneumococcal conjugate vaccine","Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection.","None","NE"
"2018-01-26131","2018","Borisenko 2018 J Med Econ","4000","Bariatric Surgery VERSUS Standard/Usual Care- Conventional Medial Management IN Specific disease- Morbid Obesity; Age- Adult; Gender- Both; Country- Belgium.","29271279","Specific disease- Morbid Obesity; Age- Adult; Gender- Both; Country- Belgium.","Bariatric Surgery","Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium.","Standard/Usual Care- Conventional Medial Management","NE"
"2018-01-26131","2018","Borisenko 2018 J Med Econ","Cost-Saving","Bariatric Surgery VERSUS Standard/Usual Care- Conventional Medial Management IN Specific disease- Morbid Obesity; Age- Adult; Gender- Both; Country- Belgium.","29271279","Specific disease- Morbid Obesity; Age- Adult; Gender- Both; Country- Belgium.","Bariatric Surgery","Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium.","Standard/Usual Care- Conventional Medial Management","SE"
"2018-01-25952","2018","Willem                           2018 Hum Vaccin Immunother","61000","PPV23 vaccination (ages 75-84) VERSUS PCV13 vaccination IN Healthy; Age- >=65 years; Gender- Both; Country- Belgium.","29420161","Healthy; Age- >=65 years; Gender- Both; Country- Belgium.","PPV23 vaccination (ages 75-84)","Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.","PCV13 vaccination","NE"
"2018-01-25952","2018","Willem                           2018 Hum Vaccin Immunother","71000","PPV23 vaccination (ages 65 to 74) VERSUS PCV13 vaccination IN Healthy; Age- >=65 years; Gender- Both; Country- Belgium.","29420161","Healthy; Age- >=65 years; Gender- Both; Country- Belgium.","PPV23 vaccination (ages 65 to 74)","Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.","PCV13 vaccination","NE"
"2018-01-25952","2018","Willem                           2018 Hum Vaccin Immunother","98000","PPV23 vaccination (50 to 64 year olds) VERSUS PCV13 vaccination IN Healthy; Age- 41 to 64 years, Adult; Gender- Both; Country- Belgium.","29420161","Healthy; Age- 41 to 64 years, Adult; Gender- Both; Country- Belgium.","PPV23 vaccination (50 to 64 year olds)","Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.","PCV13 vaccination","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","100000","Biosimilar-infliximab (bsIFX) and Vedolizumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","Biosimilar-infliximab (bsIFX) and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","110000","Biosimilar-infliximab (bsIFX) and Adalimumab (ADA) andVedolizumab VERSUS Biosimilar-infliximab and Adalimumab  IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","Biosimilar-infliximab (bsIFX) and Adalimumab (ADA) andVedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab and Adalimumab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","45000","Biosimilar-infliximab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","Biosimilar-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","45000","Originator-infliximab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","Originator-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","75000","Biosimilar-infliximab (bsIFX) and Adalimumab  VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","Biosimilar-infliximab (bsIFX) and Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","79000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","99000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Belgium.","Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2017-01-25840","2017","Valenzuela Espinoza 2017 JMIR Mhealth Uhealth","230000","Current standard stroke care supplemented with in-ambulance telemedicine VERSUS Standard/Usual Care- Standard stroke care IN Specific disease- Stroke; Age- Unknown; Gender- Both; Country- Belgium.","29175808","Specific disease- Stroke; Age- Unknown; Gender- Both; Country- Belgium.","Current standard stroke care supplemented with in-ambulance telemedicine","Time Gain Needed for In-Ambulance Telemedicine: Cost-Utility Model.","Standard/Usual Care- Standard stroke care","NE"
"2017-01-24583","2017","Akpo 2017 Front Pharmacol","Cost-Saving","Lipegfilgrastim VERSUS Pegfilgrastim IN Specific disease- Chemotherapy-induced neutropenia (CIN); Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- Stage II, III, and IV breast cancer.","28955224","Specific disease- Chemotherapy-induced neutropenia (CIN); Age- 41 to 64 years; Gender- Female; Country- Belgium; Other- Stage II, III, and IV breast cancer.","Lipegfilgrastim","Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.","Pegfilgrastim","SE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","190000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","Vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care"," "
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","220000","biosimilar infliximab and vedolizumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","biosimilar infliximab and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","250000","biosimilar infliximab, adalimumab, and vedolizumab VERSUS Biosimilar infliximab and adalimumab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","biosimilar infliximab, adalimumab, and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab and adalimumab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","44000","Biosimilar infliximab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","Biosimilar infliximab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","44000","Infliximab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","Infliximab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","87000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","Adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","90000","biosimilar infliximab and adalimumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Belgium.","biosimilar infliximab and adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2016-01-21972","2016","Odnoletkova 2016 PLoS One","5200","The COACH Program: A risk factor target-driven telephone counselling intervention VERSUS Standard/Usual Care IN Specific disease- Type 2 Diabetes; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Belgium; Other- In Elevated Hemoglobin (HbA1C) subgroup.","27727281","Specific disease- Type 2 Diabetes; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Belgium; Other- In Elevated Hemoglobin (HbA1C) subgroup.","The COACH Program: A risk factor target-driven telephone counselling intervention","Delivering Diabetes Education through Nurse-Led Telecoaching. Cost-Effectiveness  Analysis.","Standard/Usual Care","NW"
"2016-01-21972","2016","Odnoletkova 2016 PLoS One","8000","The COACH Program: A risk factor target-driven telephone counselling intervention VERSUS Standard/Usual Care IN Specific disease- Type 2 Diabetes; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Belgium; Other- Base Case scenario.","27727281","Specific disease- Type 2 Diabetes; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Belgium; Other- Base Case scenario.","The COACH Program: A risk factor target-driven telephone counselling intervention","Delivering Diabetes Education through Nurse-Led Telecoaching. Cost-Effectiveness  Analysis.","Standard/Usual Care","NE"
"2016-01-21513","2016","Fust 2016 Pharmacoeconomics","11000","Primary prophylaxis with peg?lgrastim VERSUS secondary prophylaxis with peg?lgrastim IN Specific disease- Non-Hodgkin lymphoma; Age- Adult; Gender- Both; Country- Belgium; Other- non-Hodgkin lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).","27928760","Specific disease- Non-Hodgkin lymphoma; Age- Adult; Gender- Both; Country- Belgium; Other- non-Hodgkin lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).","Primary prophylaxis with peg?lgrastim","Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.","secondary prophylaxis with peg?lgrastim","NE"
"2016-01-21513","2016","Fust 2016 Pharmacoeconomics","Dominated","Secondary prophylaxis with lenograstim (6-day) VERSUS secondary prophylaxis with peg?lgrastim IN Specific disease- Non-Hodgkin lymphoma; Age- Adult; Gender- Both; Country- Belgium; Other- Non-Hodgkin lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).","27928760","Specific disease- Non-Hodgkin lymphoma; Age- Adult; Gender- Both; Country- Belgium; Other- Non-Hodgkin lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).","Secondary prophylaxis with lenograstim (6-day)","Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.","secondary prophylaxis with peg?lgrastim","NW"
"2016-01-21513","2016","Fust 2016 Pharmacoeconomics","Dominated","Secondary prophylaxis with lipeg?lgrastim VERSUS secondary prophylaxis with peg?lgrastim IN Specific disease- Breast Cancer; Age- Adult; Gender- Female; Country- Belgium; Other- stage II breast cancer treated with TC (docetaxel and cyclophosphamide).","27928760","Specific disease- Breast Cancer; Age- Adult; Gender- Female; Country- Belgium; Other- stage II breast cancer treated with TC (docetaxel and cyclophosphamide).","Secondary prophylaxis with lipeg?lgrastim","Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.","secondary prophylaxis with peg?lgrastim","NW"
"2016-01-21513","2016","Fust 2016 Pharmacoeconomics","Dominated","Secondary prophylaxis with lipeg?lgrastim VERSUS secondary prophylaxis with peg?lgrastim IN Specific disease- Non-Hodgkin lymphoma; Age- Adult; Gender- Both; Country- Belgium; Other- Non-Hodgkin lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).","27928760","Specific disease- Non-Hodgkin lymphoma; Age- Adult; Gender- Both; Country- Belgium; Other- Non-Hodgkin lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).","Secondary prophylaxis with lipeg?lgrastim","Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.","secondary prophylaxis with peg?lgrastim","NW"
"2016-01-19498","2016","Pil 2016 Eur J Intern Med","2400","Biennial immunochemical faecal occult blood screening for colorectal cancer VERSUS No screening IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- Belgium.","27157827","Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- Belgium.","Biennial immunochemical faecal occult blood screening for colorectal cancer","Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer.","No screening","NE"
"2016-01-19498","2016","Pil 2016 Eur J Intern Med","4500","Biennial immunochemical faecal occult blood screening for colorectal cancer VERSUS No screening IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Belgium.","27157827","Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Belgium.","Biennial immunochemical faecal occult blood screening for colorectal cancer","Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer.","No screening","NE"
"2015-01-20153","2015","Annemans 2015 Prev Med Rep","Cost-Saving","1 quit attempt with varenicline followed by retreatment with varenicline, if the patient fails with or relapses after initial treatment (=2 quit attempts varenicline) VERSUS 1 quit attempt with bupropion followed by bupropion retreatment in case of failure or relapse (=2 quit atttempts bupropion) IN Specific disease- smoking addiction; Age- Unknown; Gender- Both; Country- Belgium.","26844072","Specific disease- smoking addiction; Age- Unknown; Gender- Both; Country- Belgium.","1 quit attempt with varenicline followed by retreatment with varenicline, if the patient fails with or relapses after initial treatment (=2 quit attempts varenicline)","Cost-effectiveness of retreatment with varenicline after failure with or relapse  after initial treatment for smoking cessation.","1 quit attempt with bupropion followed by bupropion retreatment in case of failure or relapse (=2 quit atttempts bupropion)","SE"
"2015-01-20153","2015","Annemans 2015 Prev Med Rep","Cost-Saving","1 quit attempt with varenicline followed by retreatment with varenicline, if the patient fails with or relapses after initial treatment (=2 quit attempts varenicline) VERSUS 1 quit attempt with nicotime replacement therapy (NRT) followed by NRT retreatment in case of failure or relapse (=2 quit atttempts NRT) IN Specific disease- smoking addiction; Age- Unknown; Gender- Both; Country- Belgium.","26844072","Specific disease- smoking addiction; Age- Unknown; Gender- Both; Country- Belgium.","1 quit attempt with varenicline followed by retreatment with varenicline, if the patient fails with or relapses after initial treatment (=2 quit attempts varenicline)","Cost-effectiveness of retreatment with varenicline after failure with or relapse  after initial treatment for smoking cessation.","1 quit attempt with nicotime replacement therapy (NRT) followed by NRT retreatment in case of failure or relapse (=2 quit atttempts NRT)","SE"
"2015-01-20153","2015","Annemans 2015 Prev Med Rep","Cost-Saving","1 quit attempt with varenicline followed by retreatment with varenicline, if the patient fails with or relapses after initial treatment (=2 quit attempts varenicline) VERSUS 1 quit attempt with placebo followed by placebo retreatment in case of failure or relapse (=2 quit atttempts placebo) IN Specific disease- smoking addiction; Age- Unknown; Gender- Both; Country- Belgium.","26844072","Specific disease- smoking addiction; Age- Unknown; Gender- Both; Country- Belgium.","1 quit attempt with varenicline followed by retreatment with varenicline, if the patient fails with or relapses after initial treatment (=2 quit attempts varenicline)","Cost-effectiveness of retreatment with varenicline after failure with or relapse  after initial treatment for smoking cessation.","1 quit attempt with placebo followed by placebo retreatment in case of failure or relapse (=2 quit atttempts placebo)","SE"
"2015-01-20153","2015","Annemans 2015 Prev Med Rep","Cost-Saving","1 quit attempt with varenicline followed by retreatment with varenicline, if the patient fails with or relapses after initial treatment (=2 quit attempts varenicline) VERSUS 1 quit attempt with varenicline followed by 1 quit attempt with placebo (1 quit attempt varenicline). IN Specific disease- smoking addiction; Age- Unknown; Gender- Both; Country- Belgium.","26844072","Specific disease- smoking addiction; Age- Unknown; Gender- Both; Country- Belgium.","1 quit attempt with varenicline followed by retreatment with varenicline, if the patient fails with or relapses after initial treatment (=2 quit attempts varenicline)","Cost-effectiveness of retreatment with varenicline after failure with or relapse  after initial treatment for smoking cessation.","1 quit attempt with varenicline followed by 1 quit attempt with placebo (1 quit attempt varenicline).","SE"
"2014-01-16969","2014","Annemans 2014 Pharmacoeconomics","8300","Escitalopram VERSUS Venlafaxine, 75 mg once per day IN Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","24554474","Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","Escitalopram","Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.","Venlafaxine, 75 mg once per day","SW"
"2014-01-16969","2014","Annemans 2014 Pharmacoeconomics","Cost-Saving","Escitalopram VERSUS Citalopram, 40.50 mg once per day IN Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","24554474","Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","Escitalopram","Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.","Citalopram, 40.50 mg once per day","SE"
"2014-01-16969","2014","Annemans 2014 Pharmacoeconomics","Cost-Saving","Escitalopram VERSUS Duloxetine, 40.50 mg once per day IN Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","24554474","Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","Escitalopram","Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.","Duloxetine, 40.50 mg once per day","SE"
"2014-01-16969","2014","Annemans 2014 Pharmacoeconomics","Cost-Saving","Escitalopram VERSUS Fluoxetine, 40.21 mg once per day IN Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","24554474","Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","Escitalopram","Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.","Fluoxetine, 40.21 mg once per day","SE"
"2014-01-16969","2014","Annemans 2014 Pharmacoeconomics","Cost-Saving","Escitalopram VERSUS Mirtazapine, 30 mg once per day IN Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","24554474","Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","Escitalopram","Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.","Mirtazapine, 30 mg once per day","SE"
"2014-01-16969","2014","Annemans 2014 Pharmacoeconomics","Cost-Saving","Escitalopram VERSUS Paroxetine, 20 mg once per day IN Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","24554474","Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","Escitalopram","Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.","Paroxetine, 20 mg once per day","SE"
"2014-01-16969","2014","Annemans 2014 Pharmacoeconomics","Cost-Saving","Escitalopram VERSUS Sertraline, 43.02 mg once per day IN Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","24554474","Specific disease- Major depressive disorder (MDD); Age- Unknown; Gender- Not Specified; Country- Belgium.","Escitalopram","Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.","Sertraline, 43.02 mg once per day","SE"
"2014-01-16489","2014","Weber 2014 Radiother Oncol","5400","Basic Quality Assurance in Radiotherapy (QART) with dummy run plus prospective individual case reviews (ICRs) for all patients VERSUS QART with dummy run IN Specific disease- head and neck (H&N) cancer; Age- Adult; Gender- Not Specified; Country- Switzerland, France, Netherland, Germany, Belgium.","24861631","Specific disease- head and neck (H&N) cancer; Age- Adult; Gender- Not Specified; Country- Switzerland, France, Netherland, Germany, Belgium.","Basic Quality Assurance in Radiotherapy (QART) with dummy run plus prospective individual case reviews (ICRs) for all patients","Outcome impact and cost-effectiveness of quality assurance for radiotherapy planned for the EORTC 22071-24071 prospective study for head and neck cancer.","QART with dummy run","NE"
"2014-01-16489","2014","Weber 2014 Radiother Oncol","8300","Basic Quality Assurance in Radiotherapy (QART) with dummy run plus prospective individual case reviews (ICRs) for all patients VERSUS QART with dummy run plus prospective individual case reviews (ICRs) for 15% of patients IN Specific disease- head and neck (H&N) cancer; Age- Adult; Gender- Not Specified; Country- Switzerland, France, Netherland, Germany, Belgium.","24861631","Specific disease- head and neck (H&N) cancer; Age- Adult; Gender- Not Specified; Country- Switzerland, France, Netherland, Germany, Belgium.","Basic Quality Assurance in Radiotherapy (QART) with dummy run plus prospective individual case reviews (ICRs) for all patients","Outcome impact and cost-effectiveness of quality assurance for radiotherapy planned for the EORTC 22071-24071 prospective study for head and neck cancer.","QART with dummy run plus prospective individual case reviews (ICRs) for 15% of patients","NE"
"2014-01-16438","2014","van Boven 2014 Respir Res","Cost-Saving","""PHARMACOP"" (Pharmaceutical care for COPD)- pharmacist interventions focused on improving medication adherence and inhaler technique VERSUS Standard/Usual Care IN Specific disease- chronic obstructive pulmonary disease; Age- >=65 years; Gender- Both; Country- Belgium.","24929799","Specific disease- chronic obstructive pulmonary disease; Age- >=65 years; Gender- Both; Country- Belgium.","""PHARMACOP"" (Pharmaceutical care for COPD)- pharmacist interventions focused on improving medication adherence and inhaler technique","Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.","Standard/Usual Care","SE"
"2014-01-16155","2014","Hiligsmann 2014 Eur J Public Health","11000","Vitamin D and calcium supplementation VERSUS None IN Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Belgium; Other- Bone mineral density (BMD) T-score <-2.5.","25096255","Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Belgium; Other- Bone mineral density (BMD) T-score <-2.5.","Vitamin D and calcium supplementation","Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis.","None","NE"
"2017-01-21685","2017","Venkatesh 2017 Surgery","4700","hemithyroidectomy VERSUS nonoperative active surveillance IN Specific disease- micropapillary thyroid cancer (mPTC); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States; Other- biopsy-proven, unifocal mPTC without features that would necessitate immediate operation (such as unfavorable location near the trachea or recurrent laryngeal nerve, high-grade features on biopsy, or nodal disease).","27839930","Specific disease- micropapillary thyroid cancer (mPTC); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States; Other- biopsy-proven, unifocal mPTC without features that would necessitate immediate operation (such as unfavorable location near the trachea or recurrent laryngeal nerve, high-grade features on biopsy, or nodal disease).","hemithyroidectomy","Cost-effectiveness of active surveillance versus hemithyroidectomy for micropapillary thyroid cancer.","nonoperative active surveillance","NE"
"2018-01-25898","2018","Dorji 2018 Vaccine","37","10-valent Pneumococcal Conjugate Vaccine (PCV10) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Bhutan.","29478752","Healthy; Age- 0 to 18 years; Gender- Both; Country- Bhutan.","10-valent Pneumococcal Conjugate Vaccine (PCV10)","Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.","None","NE"
"2018-01-25898","2018","Dorji 2018 Vaccine","41","13-valent Pneumococcal Conjugate Vaccine VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Bhutan.","29478752","Healthy; Age- 0 to 18 years; Gender- Both; Country- Bhutan.","13-valent Pneumococcal Conjugate Vaccine","Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.","None","NE"
"2014-01-17020","2014","Ament 2014 J Neurosurg Spine","13000","A non-governmental organization supports spinal procedures VERSUS None IN Specific disease- Spinal injuries; Age- 41 to 64 years; Gender- Both; Country- Bolivia.","24527825","Specific disease- Spinal injuries; Age- 41 to 64 years; Gender- Both; Country- Bolivia.","A non-governmental organization supports spinal procedures","Health impact and economic analysis of NGO-supported neurosurgery in Bolivia.","None","NE"
"2018-01-28160","2018","Stella 2018 Int J Qual Health Care","2900","Fractional flow reserve-guided percutaneous coronary intervention VERSUS Angiography-guided percutaneous coronary intervention IN Specific disease- Multivessel coronary artery disease; Age- Adult; Gender- Both; Country- Brazil.","30576452","Specific disease- Multivessel coronary artery disease; Age- Adult; Gender- Both; Country- Brazil.","Fractional flow reserve-guided percutaneous coronary intervention","Cost utility of fractional flow reserve-guided percutaneous coronary intervention in multivessel coronary artery disease in Brazil.","Angiography-guided percutaneous coronary intervention","NE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","1800","Heart Failure disease management programs VERSUS Standard/Usual Care- Control group  IN Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil; Other- New York Heart Association functional class <3.","29723595","Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil; Other- New York Heart Association functional class <3.","Heart Failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","NE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","380000","Heart Failure disease management programs VERSUS Standard/Usual Care- Control group IN Specific disease- Heart failure; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Brazil.","29723595","Specific disease- Heart failure; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Brazil.","Heart Failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","SW"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","490","Heart Failure disease management programs VERSUS Standard/Usual Care- Control group IN Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil; Other- Left ventricular ejection fraction >=35%.","29723595","Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil; Other- Left ventricular ejection fraction >=35%.","Heart Failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","NE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","Cost-Saving","Heart failure disease management program (overall) VERSUS Standard/Usual Care-  Control group  IN Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil.","29723595","Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil.","Heart failure disease management program (overall)","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care-  Control group","SE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","Cost-Saving","Heart failure disease management programs VERSUS Control group IN Specific disease- Heart failure; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil.","29723595","Specific disease- Heart failure; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil.","Heart failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Control group","SE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","Cost-Saving","Heart Failure disease management programs VERSUS Standard/Usual Care- Control group  IN Specific disease- Heart failure ; Age- Adult; Gender- Both; Country- Brazil; Other- Black/mulatto race.","29723595","Specific disease- Heart failure ; Age- Adult; Gender- Both; Country- Brazil; Other- Black/mulatto race.","Heart Failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","SE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","Cost-Saving","Heart Failure disease management programs VERSUS Standard/Usual Care- Control group  IN Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil; Other- White/yellow race.","29723595","Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil; Other- White/yellow race.","Heart Failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","SE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","Cost-Saving","Heart Failure disease management programs VERSUS Standard/Usual Care- Control group IN Specific disease- ; Age- Adult; Gender- Both; Country- Brazil; Other- Left ventricular ejection fraction <35%.","29723595","Specific disease- ; Age- Adult; Gender- Both; Country- Brazil; Other- Left ventricular ejection fraction <35%.","Heart Failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","SE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","Cost-Saving","Heart Failure disease management programs VERSUS Standard/Usual Care- Control group IN Specific disease- Heart failure ; Age- Adult; Gender- Both; Country- Brazil; Other- Non - Ischemic.","29723595","Specific disease- Heart failure ; Age- Adult; Gender- Both; Country- Brazil; Other- Non - Ischemic.","Heart Failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","SE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","Cost-Saving","Heart Failure disease management programs VERSUS Standard/Usual Care- Control group IN Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil; Other- Ischemic.","29723595","Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil; Other- Ischemic.","Heart Failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","SE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","Cost-Saving","Heart Failure disease management programs VERSUS Standard/Usual Care- Control group IN Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil; Other- New York Heart Association functional class >=3.","29723595","Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Brazil; Other- New York Heart Association functional class >=3.","Heart Failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","SE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","Cost-Saving","Heart failure disease management programs VERSUS Standard/Usual Care- Control group IN Specific disease- Heart failure; Age- Adult; Gender- Female; Country- Brazil.","29723595","Specific disease- Heart failure; Age- Adult; Gender- Female; Country- Brazil.","Heart failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","SE"
"2018-01-27287","2018","Bocchi 2018 J Card Fail","Cost-Saving","Heart failure disease management programs VERSUS Standard/Usual Care- Control group IN Specific disease- Heart failure; Age- Adult; Gender- Male; Country- Brazil.","29723595","Specific disease- Heart failure; Age- Adult; Gender- Male; Country- Brazil.","Heart failure disease management programs","Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.","Standard/Usual Care- Control group","SE"
"2018-01-27070","2018","Aguiar 2018 JAMA Oncol","130000","Osimertinib VERSUS Standard/Usual Care- Erlotinib  IN Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- Brazil; Other- Treatment-naive.","29852038","Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- Brazil; Other- Treatment-naive.","Osimertinib","Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.","Standard/Usual Care- Erlotinib","NE"
"2018-01-27070","2018","Aguiar 2018 JAMA Oncol","140000","Osimertinib VERSUS Standard/Usual Care- Afatinib IN Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- Brazil; Other- Treatment-naive.","29852038","Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- Brazil; Other- Treatment-naive.","Osimertinib","Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.","Standard/Usual Care- Afatinib","NE"
"2018-01-27070","2018","Aguiar 2018 JAMA Oncol","150000","Osimertinib VERSUS Standard/Usual Care- Afatinib IN Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- United States; Other- Treatment-naive.","29852038","Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- United States; Other- Treatment-naive.","Osimertinib","Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.","Standard/Usual Care- Afatinib","NE"
"2018-01-27070","2018","Aguiar 2018 JAMA Oncol","150000","Osimertinib VERSUS Standard/Usual Care- Erlotinib IN Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- United States; Other- Treatment-naive patients.","29852038","Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- United States; Other- Treatment-naive patients.","Osimertinib","Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.","Standard/Usual Care- Erlotinib","NE"
"2018-01-27070","2018","Aguiar 2018 JAMA Oncol","150000","Osimertinib VERSUS Standard/Usual Care- Gefitinib IN Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- Brazil; Other- Treatment-naive.","29852038","Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- Brazil; Other- Treatment-naive.","Osimertinib","Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.","Standard/Usual Care- Gefitinib","NE"
"2018-01-27070","2018","Aguiar 2018 JAMA Oncol","160000","Osimertinib VERSUS Standard/Usual Care- Gefitinib IN Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- United States; Other- Treatment-naive patients.","29852038","Specific disease- Non-small cell lung cancer; Age- Adult; Gender- Both; Country- United States; Other- Treatment-naive patients.","Osimertinib","Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.","Standard/Usual Care- Gefitinib","NE"
"2018-01-26375","2018","Scudeler 2018 Int J Cardiol","13000","On-pump CABG VERSUS Off-pump CABG IN Specific disease- Coronary artery disease; Age- Adult; Gender- Both; Country- Brazil.","30158068","Specific disease- Coronary artery disease; Age- Adult; Gender- Both; Country- Brazil.","On-pump CABG","Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: Results from the MASS III trial.","Off-pump CABG","NE"
"2017-01-24933","2017","Truzzi 2017 Int Braz J Urol","40000","Hydrophilic coated polyvinylchloride VERSUS Standard/Usual Care- Conventional uncoated polyvinylchloride IN Healthy; Age- Adult; Gender- Male; Country- Brazil.","28792195","Healthy; Age- Adult; Gender- Male; Country- Brazil.","Hydrophilic coated polyvinylchloride","Can hydrophilic coated catheters be beneficial for the public healthcare system in Brazil? - A cost-effectiveness analysis in patients with spinal cord injuries.","Standard/Usual Care- Conventional uncoated polyvinylchloride","NE"
"2017-01-24318","2017","Aguiar 2017 Einstein (Sao Paulo)","12000","Androgen deprivation therapy with docetaxel VERSUS Androgen deprivation therapy IN Specific disease- Prostate Cancer; Age- Adult; Gender- Male; Country- Brazil; Other- Metastatic disease.","29091159","Specific disease- Prostate Cancer; Age- Adult; Gender- Male; Country- Brazil; Other- Metastatic disease.","Androgen deprivation therapy with docetaxel","Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer.","Androgen deprivation therapy","NE"
"2017-01-24318","2017","Aguiar 2017 Einstein (Sao Paulo)","53000","Docetaxel and androgen deprivation therapy (ADT) VERSUS Androgen deprivation therapy (ADT) IN Specific disease- Prostate cancer; Age- Adult; Gender- Male; Country- Brazil; Other- High-risk non-metastatic disease.","29091159","Specific disease- Prostate cancer; Age- Adult; Gender- Male; Country- Brazil; Other- High-risk non-metastatic disease.","Docetaxel and androgen deprivation therapy (ADT)","Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer.","Androgen deprivation therapy (ADT)","NE"
"2017-01-24318","2017","Aguiar 2017 Einstein (Sao Paulo)","8900","Androgen deprivation therapy plus docetaxel VERSUS Androgen deprivation therapy IN Specific disease- Prostate Cancer; Age- Adult; Gender- Male; Country- Brazil; Other- High-volume metastatic disease.","29091159","Specific disease- Prostate Cancer; Age- Adult; Gender- Male; Country- Brazil; Other- High-volume metastatic disease.","Androgen deprivation therapy plus docetaxel","Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer.","Androgen deprivation therapy","NE"
"2017-01-23167","2017","Cohen 2017 Surg Obes Relat Dis","780","Prompt surgery VERSUS No surgery IN Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- .","28499887","Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- .","Prompt surgery","What is the impact on the healthcare system if access to bariatric surgery is delayed?","No surgery","NE"
"2017-01-23167","2017","Cohen 2017 Surg Obes Relat Dis","Dominated","1 year surgery delay VERSUS Prompt surgery IN Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- .","28499887","Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- .","1 year surgery delay","What is the impact on the healthcare system if access to bariatric surgery is delayed?","Prompt surgery","NW"
"2017-01-23167","2017","Cohen 2017 Surg Obes Relat Dis","Dominated","2 year surgery delay VERSUS Prompt surgery IN Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- .","28499887","Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- .","2 year surgery delay","What is the impact on the healthcare system if access to bariatric surgery is delayed?","Prompt surgery","NW"
"2017-01-23167","2017","Cohen 2017 Surg Obes Relat Dis","Dominated","4 year surgery delay VERSUS Prompt surgery IN Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- .","28499887","Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- .","4 year surgery delay","What is the impact on the healthcare system if access to bariatric surgery is delayed?","Prompt surgery","NW"
"2017-01-23167","2017","Cohen 2017 Surg Obes Relat Dis","Dominated","7 year surgery delay VERSUS Prompt surgery IN Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- .","28499887","Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- .","7 year surgery delay","What is the impact on the healthcare system if access to bariatric surgery is delayed?","Prompt surgery","NW"
"2017-01-23101","2017","Suzuki 2017 J Med Econ","17000","Standard-of-care therapy+omalizumab VERSUS Standard/Usual Care IN Specific disease- severe allergic asthma; Age- Adult; Gender- Both; Country- Brazil; Other- The Brazilian population with severe, allergic, uncontrolled
asthma.","28532191","Specific disease- severe allergic asthma; Age- Adult; Gender- Both; Country- Brazil; Other- The Brazilian population with severe, allergic, uncontrolled
asthma.","Standard-of-care therapy+omalizumab","Cost effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.","Standard/Usual Care","NE"
"2016-01-22545","2016","Gibson 2016 J Mark Access Health Policy","11000","Current Vaccination Practice + Pediatric vaccination with live attenuated influenza vaccine (LAIV) VERSUS Standard/Usual Care- Current Vaccination practice IN Specific disease- Influenza; Age- 0 to 18 years; Gender- Both; Country- United Kingdom.","27429720","Specific disease- Influenza; Age- 0 to 18 years; Gender- Both; Country- United Kingdom.","Current Vaccination Practice + Pediatric vaccination with live attenuated influenza vaccine (LAIV)","Cost-effectiveness analysis of the direct and indirect impact of intranasal live  attenuated influenza vaccination strategies in children: alternative country profiles.","Standard/Usual Care- Current Vaccination practice","NE"
"2016-01-22545","2016","Gibson 2016 J Mark Access Health Policy","4900","Current Vaccination Practice + Pediatric vaccination with live attenuated influenza vaccine (LAIV) VERSUS Standard/Usual Care- Current Vaccination practice IN Specific disease- Influenza; Age- 0 to 18 years; Gender- Both; Country- Brazil.","27429720","Specific disease- Influenza; Age- 0 to 18 years; Gender- Both; Country- Brazil.","Current Vaccination Practice + Pediatric vaccination with live attenuated influenza vaccine (LAIV)","Cost-effectiveness analysis of the direct and indirect impact of intranasal live  attenuated influenza vaccination strategies in children: alternative country profiles.","Standard/Usual Care- Current Vaccination practice","NE"
"2016-01-22545","2016","Gibson 2016 J Mark Access Health Policy","Cost-Saving","Current Vaccination Practice + Pediatric vaccination with live attenuated influenza vaccine (LAIV) VERSUS Standard/Usual Care- Current Vaccination practice IN Specific disease- Influenza; Age- 0 to 18 years; Gender- Both; Country- Spain.","27429720","Specific disease- Influenza; Age- 0 to 18 years; Gender- Both; Country- Spain.","Current Vaccination Practice + Pediatric vaccination with live attenuated influenza vaccine (LAIV)","Cost-effectiveness analysis of the direct and indirect impact of intranasal live  attenuated influenza vaccination strategies in children: alternative country profiles.","Standard/Usual Care- Current Vaccination practice","SE"
"2016-01-22545","2016","Gibson 2016 J Mark Access Health Policy","Cost-Saving","Current Vaccination Practice + Pediatric vaccination with live attenuated influenza vaccine (LAIV) VERSUS Standard/Usual Care- Current Vaccination practice IN Specific disease- Influenza; Age- 0 to 18 years; Gender- Both; Country- Taiwan.","27429720","Specific disease- Influenza; Age- 0 to 18 years; Gender- Both; Country- Taiwan.","Current Vaccination Practice + Pediatric vaccination with live attenuated influenza vaccine (LAIV)","Cost-effectiveness analysis of the direct and indirect impact of intranasal live  attenuated influenza vaccination strategies in children: alternative country profiles.","Standard/Usual Care- Current Vaccination practice","SE"
"2016-01-21367","2016","Guedes 2016 Medicine (Baltimore)","1100","Primary Laser treatment VERSUS Observation IN Specific disease- Early glaucoma; Age- 19 to 40 years; Gender- Both; Country- Brazil.","28033286","Specific disease- Early glaucoma; Age- 19 to 40 years; Gender- Both; Country- Brazil.","Primary Laser treatment","Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity.","Observation","NE"
"2016-01-21367","2016","Guedes 2016 Medicine (Baltimore)","12","Primary Surgical treatment VERSUS Primary Laser treatment IN Specific disease- Moderate glaucoma; Age- 41 to 64 years; Gender- Both; Country- Brazil.","28033286","Specific disease- Moderate glaucoma; Age- 41 to 64 years; Gender- Both; Country- Brazil.","Primary Surgical treatment","Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity.","Primary Laser treatment","NE"
"2016-01-21367","2016","Guedes 2016 Medicine (Baltimore)","1400","Primary Medical Treatment VERSUS Primary Laser treatment IN Specific disease- Early glaucoma; Age- 19 to 40 years; Gender- Both; Country- Brazil.","28033286","Specific disease- Early glaucoma; Age- 19 to 40 years; Gender- Both; Country- Brazil.","Primary Medical Treatment","Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity.","Primary Laser treatment","NE"
"2016-01-21367","2016","Guedes 2016 Medicine (Baltimore)","32000","Primary Medical Treatment VERSUS Primary Surgical treatment IN Specific disease- Moderate glaucoma; Age- 41 to 64 years; Gender- Both; Country- Brazil.","28033286","Specific disease- Moderate glaucoma; Age- 41 to 64 years; Gender- Both; Country- Brazil.","Primary Medical Treatment","Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity.","Primary Surgical treatment","NE"
"2016-01-21367","2016","Guedes 2016 Medicine (Baltimore)","9300","Primary Medical Treatment VERSUS Primary Surgical treatment IN Specific disease- Advanced  glaucoma; Age- 41 to 64 years; Gender- Both; Country- Brazil.","28033286","Specific disease- Advanced  glaucoma; Age- 41 to 64 years; Gender- Both; Country- Brazil.","Primary Medical Treatment","Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity.","Primary Surgical treatment","NE"
"2014-01-14548","2014","Noritomi 2014 Intensive Care Med","Cost-Saving","Multifaceted sepsis education program VERSUS None IN Specific disease- Severe sepsis or septic shock; Age- Adult; Gender- Both; Country- Brazil.","24146003","Specific disease- Severe sepsis or septic shock; Age- Adult; Gender- Both; Country- Brazil.","Multifaceted sepsis education program","Implementation of a multifaceted sepsis education program in an emerging country  setting: clinical outcomes and cost-effectiveness in a long-term follow-up study.","None","SE"
"2013-01-15168","2013","Nebuloni 2013 Mol Clin Oncol","74000","Modified FOLFOX6 regimen VERSUS mFLOX regimen (20 mg/m2 leucovorin (LV) and 500 mg/m2 5-fluorouracil (5-FU) and 85 mg/m2 oxaliplatin) IN Specific disease- metastatic colorectal cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil.","24649143","Specific disease- metastatic colorectal cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil.","Modified FOLFOX6 regimen","Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis.","mFLOX regimen (20 mg/m2 leucovorin (LV) and 500 mg/m2 5-fluorouracil (5-FU) and 85 mg/m2 oxaliplatin)","NE"
"2013-01-14478","2013","Barros 2013 Cost Eff Resour Alloc","Cost-Saving","Peginterferon-alfa-2a + ribavirin VERSUS peginterferon-alfa-2b + ribavirin IN Specific disease- chronic hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- genotype 1.","24103591","Specific disease- chronic hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- genotype 1.","Peginterferon-alfa-2a + ribavirin","Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil.","peginterferon-alfa-2b + ribavirin","SE"
"2013-01-14478","2013","Barros 2013 Cost Eff Resour Alloc","Cost-Saving","Peginterferon-alfa-2a + ribavirin VERSUS peginterferon-alfa-2b + ribavirin IN Specific disease- chronic hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- genotype 2/3.","24103591","Specific disease- chronic hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- genotype 2/3.","Peginterferon-alfa-2a + ribavirin","Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil.","peginterferon-alfa-2b + ribavirin","SE"
"2013-01-14370","2013","Fonseca 2013 Rev Assoc Med Bras","1400","Human papillomavirus (HPV) vaccine + 10 screenings VERSUS only screening IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Brazil.","24041909","Healthy; Age- 0 to 18 years; Gender- Female; Country- Brazil.","Human papillomavirus (HPV) vaccine + 10 screenings","Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region.","only screening","NE"
"2013-01-14370","2013","Fonseca 2013 Rev Assoc Med Bras","900","Human papillomavirus (HPV) vaccine + 3 screenings VERSUS only screening IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Brazil.","24041909","Healthy; Age- 0 to 18 years; Gender- Female; Country- Brazil.","Human papillomavirus (HPV) vaccine + 3 screenings","Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region.","only screening","NE"
"2013-01-14370","2013","Fonseca 2013 Rev Assoc Med Bras","Cost-Saving","Human papillomavirus (HPV) vaccine VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Brazil.","24041909","Healthy; Age- 0 to 18 years; Gender- Female; Country- Brazil.","Human papillomavirus (HPV) vaccine","Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region.","None","SE"
"2013-01-14218","2013","Souza 2013 Springerplus","20000","Full-field digital mammography (FFDM) annually until 49 years & screen-film mammography (SFM) annually from 50 to 69 years VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Brazil.","23961428","Healthy; Age- 41 to 64 years; Gender- Female; Country- Brazil.","Full-field digital mammography (FFDM) annually until 49 years & screen-film mammography (SFM) annually from 50 to 69 years","Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model.","Standard/Usual Care","NE"
"2013-01-14218","2013","Souza 2013 Springerplus","8600","Screen-film mammography (SFM) annually VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Brazil.","23961428","Healthy; Age- 41 to 64 years; Gender- Female; Country- Brazil.","Screen-film mammography (SFM) annually","Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model.","Standard/Usual Care","NE"
"2013-01-14218","2013","Souza 2013 Springerplus","990","Screen-film mammography (SFM) every 2 years VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Brazil.","23961428","Healthy; Age- 41 to 64 years; Gender- Female; Country- Brazil.","Screen-film mammography (SFM) every 2 years","Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model.","Standard/Usual Care","NE"
"2013-01-11661","2013","Wiens 2013 Braz J Infect Dis","2900","Pegylated interferon-alpha, all patients VERSUS None IN Specific disease- Hepatitis B; Age- Adult; Gender- Both; Country- Brazil.","23849851","Specific disease- Hepatitis B; Age- Adult; Gender- Both; Country- Brazil.","Pegylated interferon-alpha, all patients","Economic evaluation of treatments for chronic hepatitis B.","None","NE"
"2013-01-11661","2013","Wiens 2013 Braz J Infect Dis","7100","Pegylated interferon-alpha, HBeAg positive patients VERSUS None IN Specific disease- Hepatitis B; Age- Adult; Gender- Both; Country- Brazil.","23849851","Specific disease- Hepatitis B; Age- Adult; Gender- Both; Country- Brazil.","Pegylated interferon-alpha, HBeAg positive patients","Economic evaluation of treatments for chronic hepatitis B.","None","NE"
"2013-01-11661","2013","Wiens 2013 Braz J Infect Dis","7800","Interferon-alpha HBeAg positive patients VERSUS None IN Specific disease- Hepatitis B; Age- Adult; Gender- Both; Country- Brazil.","23849851","Specific disease- Hepatitis B; Age- Adult; Gender- Both; Country- Brazil.","Interferon-alpha HBeAg positive patients","Economic evaluation of treatments for chronic hepatitis B.","None","NE"
"2013-01-11661","2013","Wiens 2013 Braz J Infect Dis","7900","Interferon-alpha, all patients VERSUS None IN Specific disease- Hepatitis B; Age- Adult; Gender- Both; Country- Brazil.","23849851","Specific disease- Hepatitis B; Age- Adult; Gender- Both; Country- Brazil.","Interferon-alpha, all patients","Economic evaluation of treatments for chronic hepatitis B.","None","NE"
"2012-01-09556","2012","De Smedt               2012 Eur Heart J","10000","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Croatia","22843446","Patients hospitalized for acute coronary event or cardiac procedure in Croatia","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)","Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.","Usual care","NE"
"2012-01-09556","2012","De Smedt               2012 Eur Heart J","15000","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Finland","22843446","Patients hospitalized for acute coronary event or cardiac procedure in Finland","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)","Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.","Usual care","NE"
"2012-01-09556","2012","De Smedt               2012 Eur Heart J","18000","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Italy","22843446","Patients hospitalized for acute coronary event or cardiac procedure in Italy","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)","Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.","Usual care","NE"
"2012-01-09556","2012","De Smedt               2012 Eur Heart J","19000","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Europe","22843446","Patients hospitalized for acute coronary event or cardiac procedure in Europe","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)","Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.","Usual care","NE"
"2012-01-09556","2012","De Smedt               2012 Eur Heart J","20000","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Belgium","22843446","Patients hospitalized for acute coronary event or cardiac procedure in Belgium","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)","Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.","Usual care","NE"
"2012-01-09556","2012","De Smedt               2012 Eur Heart J","20000","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in France","22843446","Patients hospitalized for acute coronary event or cardiac procedure in France","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)","Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.","Usual care","NE"
"2012-01-09556","2012","De Smedt               2012 Eur Heart J","27000","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in UK","22843446","Patients hospitalized for acute coronary event or cardiac procedure in UK","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)","Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.","Usual care","NE"
"2012-01-09556","2012","De Smedt               2012 Eur Heart J","8800","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Bulgaria","22843446","Patients hospitalized for acute coronary event or cardiac procedure in Bulgaria","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)","Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.","Usual care","NE"
"2012-01-09556","2012","De Smedt               2012 Eur Heart J","9100","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Poland","22843446","Patients hospitalized for acute coronary event or cardiac procedure in Poland","Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)","Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.","Usual care","NE"
"2006-01-02265","2006","Balabanov 2006 Folia Med (Plovdiv)","2500","VERSUS  IN Patients with recently found and clinically diagnosed epilepsy","17408075","Patients with recently found and clinically diagnosed epilepsy"," ","A pharmacoeconomic comparison of monotherapy with Tegretol, Finlepsin and Trileptal (preliminary data)."," ","NE"
"2006-01-02265","2006","Balabanov 2006 Folia Med (Plovdiv)","Dominated","VERSUS  IN Patients with recently found and clinically diagnosed epilepsy","17408075","Patients with recently found and clinically diagnosed epilepsy"," ","A pharmacoeconomic comparison of monotherapy with Tegretol, Finlepsin and Trileptal (preliminary data)."," ","NW"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6000","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Cape Verde.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Cape Verde.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6300","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Cape Verde.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Cape Verde.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","7500","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Cape Verde.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Cape Verde.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2017-01-23296","2017","Moran 2017 World J Surg","Cost-Saving","Craniotomy VERSUS Standard/Usual Care- Craniotomy unavailable IN Specific disease- Epidural hematoma; Age- Adult; Gender- Both; Country- Cambodia; Other- From societal perspective including indirect costs.","28444463","Specific disease- Epidural hematoma; Age- Adult; Gender- Both; Country- Cambodia; Other- From societal perspective including indirect costs.","Craniotomy","Cost-Effectiveness of Craniotomy for Epidural Hematomas at a Major Government Hospital in Cambodia.","Standard/Usual Care- Craniotomy unavailable","SE"
"2018-01-28857","2018","Robin 2018 Thromb Res","2500","F-Fluorodesoxyglucose Positron Emission/Computed Tomography pus limited screening VERSUS Limited screening for occult cancer IN Specific disease- Venous thromboembolism; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- France.","30268859","Specific disease- Venous thromboembolism; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- France.","F-Fluorodesoxyglucose Positron Emission/Computed Tomography pus limited screening","In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.","Limited screening for occult cancer","NE"
"2018-01-28857","2018","Robin 2018 Thromb Res","2700","F-Fluorodesoxyglucose Positron Emission/Computed Tomography plus limited screening VERSUS Limited screening for occult cancer IN Specific disease- Venous thromboembolism; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada.","30268859","Specific disease- Venous thromboembolism; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada.","F-Fluorodesoxyglucose Positron Emission/Computed Tomography plus limited screening","In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.","Limited screening for occult cancer","NE"
"2018-01-28746","2018","Cipriano 2018 Drug Alcohol Depend","57000","Naloxone nasal spray kit VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Canada.","30321745","Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Canada.","Naloxone nasal spray kit","Cost-effectiveness of naloxone kits in secondary schools.","None","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","100000","Telemonitoring screening for diabetic foot ulcer; population-based approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.80.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.80.","Telemonitoring screening for diabetic foot ulcer; population-based approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","140000","Telemonitoring screening for diabetic foot ulcer; population-based approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.85.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.85.","Telemonitoring screening for diabetic foot ulcer; population-based approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","20000","Telemonitoring screening for diabetic foot ulcer; high-risk approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.90 .","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.90 .","Telemonitoring screening for diabetic foot ulcer; high-risk approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","220000","Telemonitoring screening for diabetic foot ulcer; population-based approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.90.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.90.","Telemonitoring screening for diabetic foot ulcer; population-based approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","42000","Telemonitoring screening for diabetic foot ulcer; population-based approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.60.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.60.","Telemonitoring screening for diabetic foot ulcer; population-based approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","450000","Telemonitoring screening for diabetic foot ulcer; population-based approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.95.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.95.","Telemonitoring screening for diabetic foot ulcer; population-based approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","50000","Telemonitoring screening for diabetic foot ulcer; population-based approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.65.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.65.","Telemonitoring screening for diabetic foot ulcer; population-based approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","61000","Telemonitoring screening for diabetic foot ulcer; population-based approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.70.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.70.","Telemonitoring screening for diabetic foot ulcer; population-based approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","77000","Telemonitoring screening for diabetic foot ulcer; population-based approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.75.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.75.","Telemonitoring screening for diabetic foot ulcer; population-based approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","95000","Telemonitoring screening for diabetic foot ulcer; high-risk approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.95.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.95.","Telemonitoring screening for diabetic foot ulcer; high-risk approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","NE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","Cost-Saving","Telemonitoring screening for diabetic foot ulcer; high-risk approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.60.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.60.","Telemonitoring screening for diabetic foot ulcer; high-risk approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","SE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","Cost-Saving","Telemonitoring screening for diabetic foot ulcer; high-risk approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.65.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.65.","Telemonitoring screening for diabetic foot ulcer; high-risk approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","SE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","Cost-Saving","Telemonitoring screening for diabetic foot ulcer; high-risk approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.70.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.70.","Telemonitoring screening for diabetic foot ulcer; high-risk approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","SE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","Cost-Saving","Telemonitoring screening for diabetic foot ulcer; high-risk approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.75.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.75.","Telemonitoring screening for diabetic foot ulcer; high-risk approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","SE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","Cost-Saving","Telemonitoring screening for diabetic foot ulcer; high-risk approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.80.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.80.","Telemonitoring screening for diabetic foot ulcer; high-risk approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","SE"
"2018-01-28714","2018","Boodoo 2018 CMAJ Open","Cost-Saving","Telemonitoring screening for diabetic foot ulcer; high-risk approach VERSUS Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening IN Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.85.","30337474","Specific disease- Diabetes; Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Relative risk of 0.85.","Telemonitoring screening for diabetic foot ulcer; high-risk approach","Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model.","Standard/Usual Care- In-person visits to a physician for diabetic foot ulcer screening","SE"
"2018-01-28496","2018","Ezeife 2018 Lung Cancer","170000","First Line Osimertinib VERSUS Standard/Usual Care- Gefitinib/Afatinib [Tyrosine kinase inhibitors] IN Specific disease- Lung Cancer; Age- Unknown; Gender- Both; Country- Canada; Other- EGRF-mutant advanced non-small cell lung cancer.","30429004","Specific disease- Lung Cancer; Age- Unknown; Gender- Both; Country- Canada; Other- EGRF-mutant advanced non-small cell lung cancer.","First Line Osimertinib","Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.","Standard/Usual Care- Gefitinib/Afatinib [Tyrosine kinase inhibitors]","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","160000","Hepatocellular carcinoma ultrasound surveillance every 6 months VERSUS No hepatocellular carcinoma surveillance IN Specific disease- Advanced fibrosis (F3); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Advanced fibrosis (F3); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma ultrasound surveillance every 6 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","28000","Hepatocellular carcinoma ultrasound surveillance every 12 months VERSUS No hepatocellular carcinoma surveillance IN Specific disease- Compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma ultrasound surveillance every 12 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","31000","Hepatocellular carcinoma ultrasound surveillance every 12 months VERSUS No hepatocellular carcinoma surveillance IN Specific disease- Advanced fibrosis (F3) or compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Advanced fibrosis (F3) or compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma ultrasound surveillance every 12 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","350000","Hepatocellular carcinoma ultrasound surveillance every 6 months VERSUS No hepatocellular carcinoma surveillance IN Specific disease- Advanced fibrosis (F3); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Advanced fibrosis (F3); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma ultrasound surveillance every 6 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","36000","Hepatocellular carcinoma ultrasound surveillance every 6 months VERSUS No hepatocellular carcinoma surveillance IN Specific disease- Compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma ultrasound surveillance every 6 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","40000","Hepatocellular carcinoma ultrasound surveillance every 6 months VERSUS No hepatocellular carcinoma surveillance IN Specific disease- Advanced fibrosis (F3) or Compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Advanced fibrosis (F3) or Compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma ultrasound surveillance every 6 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","40000","Hepatocellular carcinoma ultrasound surveillance every 6 months VERSUS No hepatocellular carcinoma surveillance IN Specific disease- Compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma ultrasound surveillance every 6 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","60000","Hepatocellular carcinoma surveillance ultrasound every 12 months VERSUS No hepatocellular carcinoma surveillance IN Specific disease- Advanced fibrosis (F3) or compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Advanced fibrosis (F3) or compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma surveillance ultrasound every 12 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","700000","Hepatocellular carcinoma ultrasound surveillance every 12 months VERSUS No hepatocellular carcinoma surveillance IN Specific disease- Advanced fibrosis (F3); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Advanced fibrosis (F3); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma ultrasound surveillance every 12 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","89000","Hepatocellular carcinoma surveillance ultrasound every 6 months VERSUS No hepatocellular carcinoma surveillance  IN Specific disease- Advanced fibrosis (F3) or compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Advanced fibrosis (F3) or compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma surveillance ultrasound every 6 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","93000","Hepatocellular carcinoma ultrasound surveillance every 12 months VERSUS No hepatocellular carcinoma surveillance IN Specific disease- Advanced fibrosis (F3); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Advanced fibrosis (F3); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma ultrasound surveillance every 12 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma surveillance","NE"
"2018-01-28147","2018","Farhang Zangneh 2018 Clin Gastroenterol Hepatol","Cost-Saving","Hepatocellular carcinoma ultrasound surveillance every 12 months VERSUS No hepatocellular carcinoma ultrasound surveillance  IN Specific disease- Compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","30580095","Specific disease- Compensated cirrhosis (F4); Age- 41 to 64 years; Gender- Both; Country- Canada; Other- Achieved sustained virologic response for chronic Hepatitis C virus infection.","Hepatocellular carcinoma ultrasound surveillance every 12 months","Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.","No hepatocellular carcinoma ultrasound surveillance","SE"
"2018-01-28131","2018","Li 2018 Mov Disord","100000","Magnetic Resonance-Guided Focused Ultrasound VERSUS Deep Brain Stimulation  IN Specific disease- Moderate to severe medication-refractory essential tremor; Age- Adult; Gender- Both; Country- Canada; Other- Ineligible for invasive neurosurgery .","30589951","Specific disease- Moderate to severe medication-refractory essential tremor; Age- Adult; Gender- Both; Country- Canada; Other- Ineligible for invasive neurosurgery .","Magnetic Resonance-Guided Focused Ultrasound","Cost-Effectiveness of Magnetic Resonance-Guided Focused Ultrasound for Essential  Tremor.","Deep Brain Stimulation","SW"
"2018-01-28131","2018","Li 2018 Mov Disord","36000","Magnetic Resonance-Guided Focused Ultrasound  VERSUS No Surgery IN Specific disease- Moderate to severe medication-refractory essential tremor; Age- Adult; Gender- Both; Country- Canada; Other- Ineligible for invasive neurosurgery .","30589951","Specific disease- Moderate to severe medication-refractory essential tremor; Age- Adult; Gender- Both; Country- Canada; Other- Ineligible for invasive neurosurgery .","Magnetic Resonance-Guided Focused Ultrasound","Cost-Effectiveness of Magnetic Resonance-Guided Focused Ultrasound for Essential  Tremor.","No Surgery","NE"
"2018-01-28131","2018","Li 2018 Mov Disord","94000","Magnetic Resonance-Guided Focused Ultrasound VERSUS Radiofrequency Thalamotomy IN Specific disease- Moderate to severe medication-refractory essential tremor; Age- Adult; Gender- Both; Country- Canada; Other- Ineligible for invasive neurosurgery .","30589951","Specific disease- Moderate to severe medication-refractory essential tremor; Age- Adult; Gender- Both; Country- Canada; Other- Ineligible for invasive neurosurgery .","Magnetic Resonance-Guided Focused Ultrasound","Cost-Effectiveness of Magnetic Resonance-Guided Focused Ultrasound for Essential  Tremor.","Radiofrequency Thalamotomy","NE"
"2018-01-27846","2018","Tam 2018 J Thorac Cardiovasc Surg","36000","Transcatheter aortic valve implantation VERSUS Surgical aortic valve replacement IN Specific disease- Severe aortic stenosis; Age- 0 to 18 years, Adult; Gender- Both; Country- Canada; Other- Intermediate surgical risk.","29454487","Specific disease- Severe aortic stenosis; Age- 0 to 18 years, Adult; Gender- Both; Country- Canada; Other- Intermediate surgical risk.","Transcatheter aortic valve implantation","A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk.","Surgical aortic valve replacement","NE"
"2018-01-27663","2018","Habbous 2018 Value Health","110000","Sevelamer VERSUS Calcium-based binder IN Specific disease- Chronic kidney disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Dialysis-dependent.","29566839","Specific disease- Chronic kidney disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Dialysis-dependent.","Sevelamer","Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.","Calcium-based binder","NE"
"2018-01-27663","2018","Habbous 2018 Value Health","120000","Lanthanum VERSUS Calcium-based binder IN Specific disease- Chronic kidney disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Dialysis-dependent.","29566839","Specific disease- Chronic kidney disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Dialysis-dependent.","Lanthanum","Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.","Calcium-based binder","NE"
"2018-01-27663","2018","Habbous 2018 Value Health","88000","Sevelamer VERSUS Calcium-based binder IN Specific disease- Chronic kidney disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Non-dialysis-dependent.","29566839","Specific disease- Chronic kidney disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Non-dialysis-dependent.","Sevelamer","Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.","Calcium-based binder","NE"
"2018-01-27663","2018","Habbous 2018 Value Health","98000","Lanthanum VERSUS Calcium-based binder IN Specific disease- Chronic kidney disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Non-dialysis-dependent.","29566839","Specific disease- Chronic kidney disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Non-dialysis-dependent.","Lanthanum","Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.","Calcium-based binder","NE"
"2018-01-26481","2018","Erman 2018 BJU Int","1700","Upfront 5a-reductase with delayed photoselective vaporisation of the prostate using greenlight laser VERSUS Standard/Usual Care- Upfront alpha-blocker with delayed photoselective vaporisation of the prostate using greenlight laser IN Specific disease- Benign prostate hyperplasia; Age- Adult; Gender- Male; Country- Canada.","30113127","Specific disease- Benign prostate hyperplasia; Age- Adult; Gender- Male; Country- Canada.","Upfront 5a-reductase with delayed photoselective vaporisation of the prostate using greenlight laser","Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.","Standard/Usual Care- Upfront alpha-blocker with delayed photoselective vaporisation of the prostate using greenlight laser","NE"
"2018-01-26481","2018","Erman 2018 BJU Int","21000","Upfront tansurethral resection of the prostate VERSUS Upfront photoselective vaporisation of the prostate using greenlight laser IN Specific disease- Benign prostate hyperplasia; Age- Adult; Gender- Male; Country- Canada.","30113127","Specific disease- Benign prostate hyperplasia; Age- Adult; Gender- Male; Country- Canada.","Upfront tansurethral resection of the prostate","Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.","Upfront photoselective vaporisation of the prostate using greenlight laser","NE"
"2018-01-26397","2018","Tarride 2018 Can J Cardiol","3800","Screen with single-lead electrocardiogram VERSUS None IN Specific disease- Atrial Fibrillation; Age- >=65 years; Gender- Both; Country- Canada.","30144961","Specific disease- Atrial Fibrillation; Age- >=65 years; Gender- Both; Country- Canada.","Screen with single-lead electrocardiogram","Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective  in Patients 65 Years and Older?","None","NE"
"2018-01-26397","2018","Tarride 2018 Can J Cardiol","Cost-Saving","Screen with 30 second radial manual pulse check VERSUS None IN Specific disease- Atrial Fibrillation; Age- >=65 years; Gender- Both; Country- Canada.","30144961","Specific disease- Atrial Fibrillation; Age- >=65 years; Gender- Both; Country- Canada.","Screen with 30 second radial manual pulse check","Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective  in Patients 65 Years and Older?","None","SE"
"2018-01-26397","2018","Tarride 2018 Can J Cardiol","Cost-Saving","Screen with blood pressure machine with atrial fibrillation detection VERSUS None IN Specific disease- Atrial Fibrillation; Age- >=65 years; Gender- Both; Country- Canada.","30144961","Specific disease- Atrial Fibrillation; Age- >=65 years; Gender- Both; Country- Canada.","Screen with blood pressure machine with atrial fibrillation detection","Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective  in Patients 65 Years and Older?","None","SE"
"2018-01-26124","2018","Le 2018 Laryngoscope","6100","Floseal VERSUS Standard/Usual Care- Nasal packaging (Merocel, Vaseline gauze, Rhinorocket) IN Specific disease- Anterior epistaxis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada.","29314035","Specific disease- Anterior epistaxis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada.","Floseal","Economic evaluation of floseal compared to nasal packing for the management of anterior epistaxis.","Standard/Usual Care- Nasal packaging (Merocel, Vaseline gauze, Rhinorocket)","NE"
"2018-01-25129","2018","Arbel 2018 Can J Cardiol","Cost-Saving","Dual antiplatelet therapy with aspirin + adenosine diphosphate antagonist (3-6 months) VERSUS Standard/Usual Care- Dual antiplatelet therapy with aspirin + adenosine diphosphate antagonist (12 months) IN Specific disease- Coronary artery disease; Age- Adult; Gender- Both; Country- Canada; Other- Undergoing percutaneous coronary intervention.","29275879","Specific disease- Coronary artery disease; Age- Adult; Gender- Both; Country- Canada; Other- Undergoing percutaneous coronary intervention.","Dual antiplatelet therapy with aspirin + adenosine diphosphate antagonist (3-6 months)","Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention.","Standard/Usual Care- Dual antiplatelet therapy with aspirin + adenosine diphosphate antagonist (12 months)","SE"
"2018-01-25129","2018","Arbel 2018 Can J Cardiol","Dominated","Dual antiplatelet therapy with aspirin + adenosine diphosphate antagonist (36 months) VERSUS Standard/Usual Care- Dual antiplatelet therapy with aspirin + adenosine diphosphate antagonist (12 months) IN Specific disease- Coronary artery disease; Age- Adult; Gender- Both; Country- Canada; Other- Undergoing percutaneous coronary intervention.","29275879","Specific disease- Coronary artery disease; Age- Adult; Gender- Both; Country- Canada; Other- Undergoing percutaneous coronary intervention.","Dual antiplatelet therapy with aspirin + adenosine diphosphate antagonist (36 months)","Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention.","Standard/Usual Care- Dual antiplatelet therapy with aspirin + adenosine diphosphate antagonist (12 months)","NW"
"2017-01-25481","2017","Ekwaru 2017 PLoS One","37000","APPLE School VERSUS Standard/Usual Care IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Canada; Other- School-age children, with a focus on grade 5 (age 10).","28542399","Healthy; Age- 0 to 18 years; Gender- Both; Country- Canada; Other- School-age children, with a focus on grade 5 (age 10).","APPLE School","Cost-effectiveness of a school-based health promotion program in Canada: A life-course modeling approach.","Standard/Usual Care","NE"
"2017-01-25453","2017","Bansback 2017 Ann Intern Med","550000","Biologic therapy (etanercept) combined with methotrexate first VERSUS Standard/Usual Care- First-line treatment with triple therapy of a combination of conventional disease-modifying anti-rheumatic drugs (DMARDs) IN Specific disease- Rheumatoid arthritis; Age- Adult; Gender- Both; Country- Canada; Other- Patients with active rheumatoid arthritis despite at least 12 weeks of methotrexate therapy (unresponsive to methotrexate monotherapy).","28554192","Specific disease- Rheumatoid arthritis; Age- Adult; Gender- Both; Country- Canada; Other- Patients with active rheumatoid arthritis despite at least 12 weeks of methotrexate therapy (unresponsive to methotrexate monotherapy).","Biologic therapy (etanercept) combined with methotrexate first","Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.","Standard/Usual Care- First-line treatment with triple therapy of a combination of conventional disease-modifying anti-rheumatic drugs (DMARDs)","NE"
"2017-01-25385","2017","Goldstein 2017 Oncologist","290000","Bevacizumab + first-line chemotherapy VERSUS Standard/Usual Care- First-line chemotherapy only	 IN Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- Australia; Other- Newly diagnosed.","28592621","Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- Australia; Other- Newly diagnosed.","Bevacizumab + first-line chemotherapy","Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.","Standard/Usual Care- First-line chemotherapy only","NE"
"2017-01-25385","2017","Goldstein 2017 Oncologist","370000","Bevacizumab + first-line chemotherapy VERSUS First-line chemotherapy only	 IN Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- Canada; Other- Newly diagnosed.","28592621","Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- Canada; Other- Newly diagnosed.","Bevacizumab + first-line chemotherapy","Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.","First-line chemotherapy only","NE"
"2017-01-25385","2017","Goldstein 2017 Oncologist","370000","Bevacizumab + first-line chemotherapy VERSUS Standard/Usual Care- First-line chemotherapy only	 IN Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- Israel; Other- Newly diagnosed.","28592621","Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- Israel; Other- Newly diagnosed.","Bevacizumab + first-line chemotherapy","Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.","Standard/Usual Care- First-line chemotherapy only","NE"
"2017-01-25385","2017","Goldstein 2017 Oncologist","370000","Bevacizumab + first-line chemotherapy VERSUS Standard/Usual Care- First-line chemotherapy only	 IN Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Newly diagnosed.","28592621","Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Newly diagnosed.","Bevacizumab + first-line chemotherapy","Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.","Standard/Usual Care- First-line chemotherapy only","NE"
"2017-01-25385","2017","Goldstein 2017 Oncologist","600000","Bevacizumab + first-line chemotherapy VERSUS Standard/Usual Care- First-line chemotherapy only IN Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- United States of America (USA); Other- Newly diagnosed.","28592621","Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- United States of America (USA); Other- Newly diagnosed.","Bevacizumab + first-line chemotherapy","Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.","Standard/Usual Care- First-line chemotherapy only","NE"
"2017-01-25324","2017","Trenaman 2017 Osteoarthritis Cartilage","Cost-Saving","Patient Decision Aid VERSUS Standard/Usual Care IN Specific disease- Osteoarthritis; Age- Adult; Gender- Both; Country- Canada.","28624294","Specific disease- Osteoarthritis; Age- Adult; Gender- Both; Country- Canada.","Patient Decision Aid","Decision aids for patients considering total joint replacement: a cost-effectiveness analysis alongside a randomised controlled trial.","Standard/Usual Care","SE"
"2017-01-25287","2017","Belzile 2017 Clin Med Insights Arthritis Musculoskelet Disord","Cost-Saving","Single-injection regimen (combined corticosteroid-hyaluronic acid) VERSUS Standard/Usual Care- Two-injection regimen (sequential corticosteroid and hyaluronic acid. IN Specific disease- Knee Osteoarthritis ; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Canada.","28638242","Specific disease- Knee Osteoarthritis ; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Canada.","Single-injection regimen (combined corticosteroid-hyaluronic acid)","Cost-Utility of a Single-Injection Combined Corticosteroid-Hyaluronic Acid Formulation vs a 2-Injection Regimen of Sequential Corticosteroid and Hyaluronic  Acid Injections.","Standard/Usual Care- Two-injection regimen (sequential corticosteroid and hyaluronic acid.","SE"
"2017-01-25176","2017","Al Saleh 2017 Can J Hosp Pharm","170000","Apixaban VERSUS Standard/Usual Care- Low-molecular-weight heparin plus vitamin K antagonist IN Specific disease- Deep Venous Thrombosis and Pulmonary Embolism; Age- Adult; Gender- Both; Country- Canada.","28680172","Specific disease- Deep Venous Thrombosis and Pulmonary Embolism; Age- Adult; Gender- Both; Country- Canada.","Apixaban","Direct Oral Anticoagulants and Vitamin K Antagonists for Treatment of Deep Venous Thrombosis and Pulmonary Embolism in the Outpatient Setting: Comparative Economic Evaluation.","Standard/Usual Care- Low-molecular-weight heparin plus vitamin K antagonist","NE"
"2017-01-25176","2017","Al Saleh 2017 Can J Hosp Pharm","270000","Rivaroxaban VERSUS Low-molecular-weight heparin + vitamin K antagonist IN Specific disease- Venous thromboembolism; Age- Adult; Gender- Both; Country- Canada.","28680172","Specific disease- Venous thromboembolism; Age- Adult; Gender- Both; Country- Canada.","Rivaroxaban","Direct Oral Anticoagulants and Vitamin K Antagonists for Treatment of Deep Venous Thrombosis and Pulmonary Embolism in the Outpatient Setting: Comparative Economic Evaluation.","Low-molecular-weight heparin + vitamin K antagonist","NE"
"2017-01-24811","2017","Kittikraisak 2017 PLoS One","17000","Vaccination  VERSUS No Vaccination  IN Specific disease- Influenza ; Age- 0 to 18 years; Gender- Both; Country- Thailand.","28837594","Specific disease- Influenza ; Age- 0 to 18 years; Gender- Both; Country- Thailand.","Vaccination","Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children","No Vaccination","NE"
"2017-01-24811","2017","Kittikraisak 2017 PLoS One","26000","Vaccination  VERSUS No vaccination  IN Specific disease- Influenza ; Age- 0 to 18 years; Gender- Both; Country- Thailand.","28837594","Specific disease- Influenza ; Age- 0 to 18 years; Gender- Both; Country- Thailand.","Vaccination","Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children","No vaccination","NE"
"2017-01-24811","2017","Kittikraisak 2017 PLoS One","590","Vaccination  VERSUS No Vaccination  IN Specific disease- Influenza ; Age- 0 to 18 years; Gender- Both; Country- Thailand.","28837594","Specific disease- Influenza ; Age- 0 to 18 years; Gender- Both; Country- Thailand.","Vaccination","Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children","No Vaccination","NE"
"2017-01-24176","2017","Ament 2017 World Neurosurg","Cost-Saving","Endoscopic transsphenoidal surgery VERSUS Microscopic Transsphenoidal Surgery IN Specific disease- Pituitary tumors; Age- 41 to 64 years; Gender- Both; Country- United States of America (USA); Other- 45 year old patient with pituitary pathology that had a planned primary or secondary transsphenoidal surgery in the outpatient neurosurgical setting.","29158096","Specific disease- Pituitary tumors; Age- 41 to 64 years; Gender- Both; Country- United States of America (USA); Other- 45 year old patient with pituitary pathology that had a planned primary or secondary transsphenoidal surgery in the outpatient neurosurgical setting.","Endoscopic transsphenoidal surgery","Cost-effectiveness of endoscopic versus microscopic transsphenoidal surgery for pituitary adenoma.","Microscopic Transsphenoidal Surgery","SE"
"2016-01-22787","2016","Miller 2016 Clinicoecon Outcomes Res","Cost-Saving","Edoxaban VERSUS Rivaroxaban IN Specific disease- Atrial fibrillation; Age- >=65 years; Gender- Both; Country- United States; Other- Nonvalvular atrial fibrillation (NVAF) patients, high risk of stroke.","27284259","Specific disease- Atrial fibrillation; Age- >=65 years; Gender- Both; Country- United States; Other- Nonvalvular atrial fibrillation (NVAF) patients, high risk of stroke.","Edoxaban","Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US.","Rivaroxaban","SE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord"," ","Rivaroxaban VERSUS Standard/Usual Care- Apixaban IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Rivaroxaban","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Apixaban","SE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","11000","Aspirin VERSUS Standard/Usual Care- Dabigatran 150 mg IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Dabigatran 150 mg","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","11000","Aspirin VERSUS Standard/Usual Care- Rivaroxaban IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Rivaroxaban","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","11000","Dabigatran 150 mg VERSUS Standard/Usual Care- Aspirin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Dabigatran 150 mg","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Aspirin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","11000","Rivaroxaban VERSUS Standard/Usual Care- Aspirin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Rivaroxaban","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Aspirin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","12000","Aspirin VERSUS Standard/Usual Care- Dabigatran 110 mg IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Dabigatran 110 mg","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","12000","Dabigatran 110 mg VERSUS Standard/Usual Care- Aspirin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Dabigatran 110 mg","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Aspirin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","13000","Apixaban VERSUS Standard/Usual Care- Aspirin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Apixaban","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Aspirin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","13000","Aspirin VERSUS Standard/Usual Care- Apixaban IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Apixaban","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","18000","Dabigatran 110 mg VERSUS Standard/Usual Care- Apixaban IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Dabigatran 110 mg","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Apixaban","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","18000","Transcatheter left atrial appendage occlusion (LAAO) VERSUS Rivaroxaban IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Transcatheter left atrial appendage occlusion (LAAO)","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Rivaroxaban","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","25000","Apixaban VERSUS Standard/Usual Care- Dabigatran 150 mg IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Apixaban","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Dabigatran 150 mg","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","25000","Dabigatran 150 mg VERSUS Standard/Usual Care- Apixaban IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Dabigatran 150 mg","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Apixaban","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","2600","Clopidogrel plus Aspirin VERSUS Standard/Usual Care- Left Atrial Appendage (LAA) Occlusion IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Clopidogrel plus Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Left Atrial Appendage (LAA) Occlusion","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","2600","Transcatheter left atrial appendage occlusion (LAAO) VERSUS Clopidogrel plus Aspirin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Transcatheter left atrial appendage occlusion (LAAO)","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Clopidogrel plus Aspirin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","4800","Aspirin VERSUS Standard/Usual Care- Warfarin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Warfarin","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","4800","Warfarin VERSUS Standard/Usual Care- Aspirin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Warfarin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Aspirin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","5400","Aspirin VERSUS Standard/Usual Care- Left Atrial Appendage (LAA) Occlusion IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Left Atrial Appendage (LAA) Occlusion","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","5400","Transcatheter left atrial appendage occlusion (LAAO) VERSUS Aspirin alone IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Transcatheter left atrial appendage occlusion (LAAO)","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Aspirin alone","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","5500","Dabigatran 110 mg VERSUS Standard/Usual Care- Dabigatran 150 mg IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Dabigatran 110 mg","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Dabigatran 150 mg","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","5500","Dabigatran 150 mg VERSUS Standard/Usual Care- Dabigatran 110 mg IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Dabigatran 150 mg","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Dabigatran 110 mg","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","59000","Dabigatran 150 mg VERSUS Standard/Usual Care- Left Atrial Appendage (LAA) Occlusion IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Dabigatran 150 mg","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Left Atrial Appendage (LAA) Occlusion","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","59000","Warfarin VERSUS Standard/Usual Care- Rivaroxaban IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Warfarin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Rivaroxaban","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","610","Clopidogrel plus Aspirin VERSUS Standard/Usual Care- Warfarin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Clopidogrel plus Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Warfarin","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","610","Warfarin VERSUS Standard/Usual Care- Clopidogrel plus aspirin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Warfarin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Clopidogrel plus aspirin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","6700","Transcatheter left atrial appendage occlusion (LAAO) VERSUS Warfarin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Transcatheter left atrial appendage occlusion (LAAO)","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Warfarin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","6700","Warfarin VERSUS Standard/Usual Care- Left Atrial Appendage (LAA) Occlusion IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Warfarin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Left Atrial Appendage (LAA) Occlusion","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","6900","Clopidogrel plus Aspirin VERSUS Standard/Usual Care- Dabigatran 150 mg IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Clopidogrel plus Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Dabigatran 150 mg","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","6900","Dabigatran 150 mg VERSUS Standard/Usual Care- Clopidogrel plus aspirin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Dabigatran 150 mg","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Clopidogrel plus aspirin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","7100","Clopidogrel plus Aspirin VERSUS Standard/Usual Care- Dabigatran 110 mg IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Clopidogrel plus Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Dabigatran 110 mg","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","7100","Dabigatran 110 mg VERSUS Standard/Usual Care- Clopidogrel plus aspirin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Dabigatran 110 mg","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Clopidogrel plus aspirin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","7400","Clopidogrel plus Aspirin VERSUS Standard/Usual Care- Rivaroxaban IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Clopidogrel plus Aspirin","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Rivaroxaban","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","7400","Rivaroxaban VERSUS Standard/Usual Care- Clopidogrel plus aspirin IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Rivaroxaban","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Clopidogrel plus aspirin","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","8100","Dabigatran 110 mg VERSUS Standard/Usual Care- Rivaroxaban IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Dabigatran 110 mg","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Rivaroxaban","SW"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","8100","Rivaroxaban VERSUS Standard/Usual Care- Dabigatran 110 mg IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Rivaroxaban","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Dabigatran 110 mg","NE"
"2016-01-22231","2016","Lee 2016 BMC Cardiovasc Disord","Dominated","Rivaroxaban VERSUS Standard/Usual Care- Left Atrial Appendage (LAA) Occlusion IN Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","27581874","Specific disease- Stroke Prophylaxis in Non-Valvular Atrial Fibrillation (NVAF); Age- >=65 years; Gender- Both; Country- United States.","Rivaroxaban","Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.","Standard/Usual Care- Left Atrial Appendage (LAA) Occlusion","NW"
"2016-01-21614","2016","Athanasakis                      2016 Am J Cardiovasc Drugs","17000","Warfarin VERSUS Apixaban IN Specific disease- Stroke; Age- Adult; Gender- Both; Country- Greek; Other- Patients with Atrial Fibrillation.","27882517","Specific disease- Stroke; Age- Adult; Gender- Both; Country- Greek; Other- Patients with Atrial Fibrillation.","Warfarin","Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.","Apixaban","SW"
"2016-01-21614","2016","Athanasakis                      2016 Am J Cardiovasc Drugs","8400","Aspirin VERSUS Apixaban IN Specific disease- Stroke; Age- Adult; Gender- Both; Country- Greek; Other- Patients with Atrial Fibrillation (AF).","27882517","Specific disease- Stroke; Age- Adult; Gender- Both; Country- Greek; Other- Patients with Atrial Fibrillation (AF).","Aspirin","Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.","Apixaban","SW"
"2016-01-20729","2016","Salata 2016 Am J Cardiol","24000","Dabigatran 150 mg twice daily VERSUS Warfarin IN Specific disease- Ischemic stroke (IS) nonvalvular atrial fibrillation (NVAF); Age- >=65 years; Gender- Not Specified; Country- .","26552509","Specific disease- Ischemic stroke (IS) nonvalvular atrial fibrillation (NVAF); Age- >=65 years; Gender- Not Specified; Country- .","Dabigatran 150 mg twice daily","Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients >/= 65 Years With Nonvalvular Atrial Fibrillation.","Warfarin","NE"
"2016-01-20685","2016","Shepard 2016 Addiction","41000","Significant other motivational intervention (SOMI) VERSUS Individual motivational intervention (IMI) IN Specific disease- alcoholism (alcohol misuse); Age- Adult; Gender- Both; Country- United States.","26574195","Specific disease- alcoholism (alcohol misuse); Age- Adult; Gender- Both; Country- United States.","Significant other motivational intervention (SOMI)","Cost-effectiveness of motivational intervention with significant others for patients with alcohol misuse.","Individual motivational intervention (IMI)","NE"
"2016-01-20314","2016","Diamantopoulos                   2016 Int J Stroke","30000","Insertable cardial monitor (ICM) VERSUS Standard/Usual Care- Electrocardiogram and stress testing IN Specific disease- Cryptogenic stroke; Age- Adult; Gender- Both; Country- United Kingdom.","26763916","Specific disease- Cryptogenic stroke; Age- Adult; Gender- Both; Country- United Kingdom.","Insertable cardial monitor (ICM)","Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke.","Standard/Usual Care- Electrocardiogram and stress testing","NE"
"2016-01-19950","2016","Kimura 2016 J Cardiol","57000","Treatment with Warfarin + ablation VERSUS Treatment with Warfarin IN Specific disease- paroxysmal atrial fibrillation; Age- 41 to 64 years; Gender- Not Specified; Country- Japan; Other- CHADS2 = 0.","26947099","Specific disease- paroxysmal atrial fibrillation; Age- 41 to 64 years; Gender- Not Specified; Country- Japan; Other- CHADS2 = 0.","Treatment with Warfarin + ablation","A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan.","Treatment with Warfarin","NE"
"2016-01-19950","2016","Kimura 2016 J Cardiol","60000","Treatment with dabigatran + ablation VERSUS Treatment with Warfarin IN Specific disease- paroxysmal atrial fibrillation; Age- 41 to 64 years; Gender- Not Specified; Country- Japan; Other- CHADS2 = 0.","26947099","Specific disease- paroxysmal atrial fibrillation; Age- 41 to 64 years; Gender- Not Specified; Country- Japan; Other- CHADS2 = 0.","Treatment with dabigatran + ablation","A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan.","Treatment with Warfarin","NE"
"2016-01-19950","2016","Kimura 2016 J Cardiol","Dominated","Treatment with Dabigatran VERSUS Treatment with warfarin IN Specific disease- paroxysmal atrial fibrillation; Age- 41 to 64 years; Gender- Not Specified; Country- Japan; Other- CHADS2 = 0.","26947099","Specific disease- paroxysmal atrial fibrillation; Age- 41 to 64 years; Gender- Not Specified; Country- Japan; Other- CHADS2 = 0.","Treatment with Dabigatran","A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan.","Treatment with warfarin","NW"
"2016-01-19800","2016","Nguyen 2016 Pharmacotherapy","Cost-Saving","High-dose edoxaban VERSUS Adjusted-dose warfarin IN Specific disease- Nonvalvular atrial fibrillation; Age- >=65 years; Gender- Both; Country- United States; Other- Creatinine clearance of 15-95 mL/minute.","27015873","Specific disease- Nonvalvular atrial fibrillation; Age- >=65 years; Gender- Both; Country- United States; Other- Creatinine clearance of 15-95 mL/minute.","High-dose edoxaban","Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.","Adjusted-dose warfarin","SE"
"2016-01-19613","2016","Shah 2016 Stroke","27000","Apixaban (5mg BID) VERSUS Adjusted dose warfarin IN Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- United States; Other- persons with a CHADS score (congestive heart failure [1 point], hypertension [1 point], age =75 years [1 point], diabetes mellitus [1 point], stroke [2 points]) of =1. Atrial Fibrillation new onset.","27103018","Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- United States; Other- persons with a CHADS score (congestive heart failure [1 point], hypertension [1 point], age =75 years [1 point], diabetes mellitus [1 point], stroke [2 points]) of =1. Atrial Fibrillation new onset.","Apixaban (5mg BID)","Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.","Adjusted dose warfarin","NE"
"2016-01-19613","2016","Shah 2016 Stroke","29000","Edoxaban (60 mg QD) VERSUS Adjusted dose warfarin IN Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- United States; Other- persons with a CHADS score (congestive heart failure [1 point], hypertension [1 point], age =75 years [1 point], diabetes mellitus [1 point], stroke [2 points]) of =1. Atrial Fibrillation new onset.","27103018","Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- United States; Other- persons with a CHADS score (congestive heart failure [1 point], hypertension [1 point], age =75 years [1 point], diabetes mellitus [1 point], stroke [2 points]) of =1. Atrial Fibrillation new onset.","Edoxaban (60 mg QD)","Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.","Adjusted dose warfarin","NE"
"2016-01-19613","2016","Shah 2016 Stroke","33000","Dabigatran (150 mg BID) VERSUS Adjusted dose warfarin IN Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- United States; Other- persons with a CHADS score (congestive heart failure [1 point], hypertension [1 point], age =75 years [1 point], diabetes mellitus [1 point], stroke [2 points]) of =1. Atrial Fibrillation new onset.","27103018","Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- United States; Other- persons with a CHADS score (congestive heart failure [1 point], hypertension [1 point], age =75 years [1 point], diabetes mellitus [1 point], stroke [2 points]) of =1. Atrial Fibrillation new onset.","Dabigatran (150 mg BID)","Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.","Adjusted dose warfarin","NE"
"2016-01-19613","2016","Shah 2016 Stroke","61000","Rivaroxaban (20 mg QD) VERSUS Adjusted dose warfarin IN Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- United States; Other- persons with a CHADS score (congestive heart failure [1 point], hypertension [1 point], age =75 years [1 point], diabetes mellitus [1 point], stroke [2 points]) of =1. Atrial Fibrillation new onset.","27103018","Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- United States; Other- persons with a CHADS score (congestive heart failure [1 point], hypertension [1 point], age =75 years [1 point], diabetes mellitus [1 point], stroke [2 points]) of =1. Atrial Fibrillation new onset.","Rivaroxaban (20 mg QD)","Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.","Adjusted dose warfarin","NE"
"2015-01-20492","2015","Magnuson 2015 Am Heart J","40000","Edoxaban treatment VERSUS warfarin IN Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- United States; Other- Creatinine clearance =95 mL/min in ENGAGE AFTIMI 48 trial.","26678636","Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- United States; Other- Creatinine clearance =95 mL/min in ENGAGE AFTIMI 48 trial.","Edoxaban treatment","Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.","warfarin","NE"
"2016-01-21900","2016","Lanas 2016 J Clin Epidemiol","25000","Apixaban VERSUS Acenocoumarol IN Specific disease- Atrial fibrillation (AF); Age- >=65 years; Gender- Both; Country- Chile; Other- Patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism.","27756577","Specific disease- Atrial fibrillation (AF); Age- >=65 years; Gender- Both; Country- Chile; Other- Patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism.","Apixaban","Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile.","Acenocoumarol","NE"
"2016-01-21443","2016","De la Puente 2016 J Clin Epidemiol","11000","Ticagrelor VERSUS Clopidogrel IN Specific disease- Acute coronary syndrome; Age- Adult; Gender- Both; Country- Chile.","27989953","Specific disease- Acute coronary syndrome; Age- Adult; Gender- Both; Country- Chile.","Ticagrelor","Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile.","Clopidogrel","NE"
"2015-01-20753","2015","Vargas 2015 PLoS One","13000","Peginterferon/Ribavirin with protease inhibitors VERSUS Standard/Usual Care- Peginterferon/Ribavirin IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Chile; Other- Genotype 1b, treatment-naÃ¯ve.","26544203","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Chile; Other- Genotype 1b, treatment-naÃ¯ve.","Peginterferon/Ribavirin with protease inhibitors","Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and  Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naive Patients in Chile.","Standard/Usual Care- Peginterferon/Ribavirin","NE"
"2015-01-20753","2015","Vargas 2015 PLoS One","21000","Daclatasvir/Asunaprevir VERSUS Peginterferon/Ribavirin with protease inhibitors IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Chile; Other- Genotype 1b, treatment-naÃ¯ve.","26544203","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Chile; Other- Genotype 1b, treatment-naÃ¯ve.","Daclatasvir/Asunaprevir","Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and  Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naive Patients in Chile.","Peginterferon/Ribavirin with protease inhibitors","NE"
"2014-01-15570","2014","Gomez 2014 BMC Public Health","130","Human Papilloma Virus-6/18 vaccine and current screening practice VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Chile.","25424716","Healthy; Age- 0 to 18 years; Gender- Female; Country- Chile.","Human Papilloma Virus-6/18 vaccine and current screening practice","Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.","None","NE"
"2014-01-15570","2014","Gomez 2014 BMC Public Health","620","Human Papilloma Virus-6/11/16/18 vaccine and current screening practice VERSUS Human Papilloma Virus-6/18 vaccine and current screening practice IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Chile.","25424716","Healthy; Age- 0 to 18 years; Gender- Female; Country- Chile.","Human Papilloma Virus-6/11/16/18 vaccine and current screening practice","Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.","Human Papilloma Virus-6/18 vaccine and current screening practice","NE"
"2014-01-15570","2014","Gomez 2014 BMC Public Health","620","Human Papilloma Virus-6/11/16/18 vaccine and current screening practice VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Chile.","25424716","Healthy; Age- 0 to 18 years; Gender- Female; Country- Chile.","Human Papilloma Virus-6/11/16/18 vaccine and current screening practice","Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.","None","NE"
"2014-01-15570","2014","Gomez 2014 BMC Public Health","Cost-Saving","Human Papilloma Virus-6/18 vaccines and current screening practice VERSUS Human Paoilloma Virus-6/11/16/18 vaccine and current screening practice IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Chile.","25424716","Healthy; Age- 0 to 18 years; Gender- Female; Country- Chile.","Human Papilloma Virus-6/18 vaccines and current screening practice","Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.","Human Paoilloma Virus-6/11/16/18 vaccine and current screening practice","SE"
"2014-01-15394","2014","Jia 2014 Hum Vaccin Immunother","Cost-Saving","Hepatitis B follow-up for children with incomplete immunization schedule VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Chile.","25483678","Healthy; Age- 0 to 18 years; Gender- Both; Country- Chile.","Hepatitis B follow-up for children with incomplete immunization schedule","Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.","None","SE"
"2011-01-08056","2011","Dom?nguez                        2011 Transplant Proc","Cost-Saving","Kidney transplantation VERSUS Dialysis IN Patients with end-stage renal disease in Chile","21839259","Patients with end-stage renal disease in Chile","Kidney transplantation","Cost-benefit estimation of cadaveric kidney transplantation: the case of a developing country.","Dialysis","SE"
"2010-01-06893","2010","Siskind 2010 Br J Psychiatry","150","Usual depression care (primary care and psychiatry conconsult if necessary, psycopharmacology if necessary) VERSUS None IN Chilean women, aged 18 years","20884952","Chilean women, aged 18 years","Usual depression care (primary care and psychiatry conconsult if necessary, psycopharmacology if necessary)","Cost-effectiveness of improved primary care treatment of depression in women in Chile.","None","NE"
"2010-01-06893","2010","Siskind 2010 Br J Psychiatry","390","Stepped depression therapy (Usual care plus psychoeducational groups) VERSUS Usual depression care (primary care and psychiatry conconsult if necessary, psycopharmacology if necessary) IN Chilean women, aged 18 years","20884952","Chilean women, aged 18 years","Stepped depression therapy (Usual care plus psychoeducational groups)","Cost-effectiveness of improved primary care treatment of depression in women in Chile.","Usual depression care (primary care and psychiatry conconsult if necessary, psycopharmacology if necessary)","NE"
"2018-01-28937","2018","Li 2018 J Bone Oncol","Cost-Saving","Low Dose Chemotherapy for Solitary Bone Lesions  VERSUS Surgery for Solitary Bone Lesions IN Specific disease- Langerhans cell histiocytosis; Age- 0 to 18 years; Gender- Both; Country- China.","30237968","Specific disease- Langerhans cell histiocytosis; Age- 0 to 18 years; Gender- Both; Country- China.","Low Dose Chemotherapy for Solitary Bone Lesions","Comparison between low-dose chemotherapy and surgery for the treatment of extremity-associated solitary bone lesions in children with Langerhans cell histiocytosis in South China: A case-control study.","Surgery for Solitary Bone Lesions","SE"
"2018-01-28770","2018","Wang 2018 Spine (Phila Pa 1976)","22000","Percutaneous endoscopic interlaminar discectomy VERSUS Percutaneous endoscopic transforaminal discectomy IN Specific disease- Lumbar Disc Herniation; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Patients with a minimum follow-up of 1 year and a diagnosis of L5-S1 LDH.","30312274","Specific disease- Lumbar Disc Herniation; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Patients with a minimum follow-up of 1 year and a diagnosis of L5-S1 LDH.","Percutaneous endoscopic interlaminar discectomy","A Cost-Utility Analysis of Percutaneous Endoscopic Lumbar Discectomy for L5-S1 Lumbar Disc Herniation: Transforaminal vs Interlaminar.","Percutaneous endoscopic transforaminal discectomy","NE"
"2018-01-28743","2018","Huang 2018 Cancer Manag Res","48000","Gemcitabine + Capecitabine VERSUS Gemcitabine monotherapy IN Specific disease- Pancreatic cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Patients who had undergone complete resection for pancreatic cancer.","30323662","Specific disease- Pancreatic cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Patients who had undergone complete resection for pancreatic cancer.","Gemcitabine + Capecitabine","Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer  in China based on the ESPAC-4 trial.","Gemcitabine monotherapy","NE"
"2018-01-28677","2018","Lu 2018 PLoS One","14000","Multiplex polymerase chain reaction testing, followed by Crizotinib with Patient Assistance Program VERSUS Pemetrexed plus cisplatin IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- China; Other- Confirmed stage IIIB/IV.","30352060","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- China; Other- Confirmed stage IIIB/IV.","Multiplex polymerase chain reaction testing, followed by Crizotinib with Patient Assistance Program","Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.","Pemetrexed plus cisplatin","NE"
"2018-01-28677","2018","Lu 2018 PLoS One","15000","Next-generation sequencing panel tests, followed by Crizotinib with Patient Assistance Program VERSUS Pemetrxed plus cisplatin IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- China; Other- Confirmed stage IIIB/IV.","30352060","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- China; Other- Confirmed stage IIIB/IV.","Next-generation sequencing panel tests, followed by Crizotinib with Patient Assistance Program","Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.","Pemetrxed plus cisplatin","NE"
"2018-01-28677","2018","Lu 2018 PLoS One","180000","Multiplex polymerase chain reaction testing, Crizotinib without Patient Assistance Program VERSUS Pemetrexed plus cisplatin IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- China; Other- Confirmed stage IIIB/IV.","30352060","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- China; Other- Confirmed stage IIIB/IV.","Multiplex polymerase chain reaction testing, Crizotinib without Patient Assistance Program","Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.","Pemetrexed plus cisplatin","NE"
"2018-01-28677","2018","Lu 2018 PLoS One","180000","Next-generation sequencing panel tests, followed by Crizotinib without Patient Assistance Program VERSUS Pemetrexed plus cisplatin IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- China; Other- Confirmed stage IIIB/IV.","30352060","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- China; Other- Confirmed stage IIIB/IV.","Next-generation sequencing panel tests, followed by Crizotinib without Patient Assistance Program","Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.","Pemetrexed plus cisplatin","NE"
"2018-01-28646","2018","Sun 2018 Int J Cancer","Dominated","Breast cancer screening every 3 years VERSUS No breast cancer screening IN Healthy; Age- 19 to 40 years; Gender- Female; Country- China; Other- Rural.","30367451","Healthy; Age- 19 to 40 years; Gender- Female; Country- China; Other- Rural.","Breast cancer screening every 3 years","Cost-effectiveness of breast cancer screening programme for women in rural China.","No breast cancer screening","NW"
"2018-01-28601","2018","Li 2018 Adv Ther","22000","Statin treatment (atorvastatin) VERSUS No statin management IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- China.","30390239","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- China.","Statin treatment (atorvastatin)","Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes.","No statin management","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","19000","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from China.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from China.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6700","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from China.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from China.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6700","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from China.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from China.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28562","2018","Wu                               2018 Curr Med Res Opin","12000","Sofosbuvir + ribavirin  VERSUS Pegylated interferon alpha + ribavirin  IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 3.","30409038","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 3.","Sofosbuvir + ribavirin","Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis  C.","Pegylated interferon alpha + ribavirin","NE"
"2018-01-28562","2018","Wu                               2018 Curr Med Res Opin","15000","Sofosbuvir + daclatasvir  VERSUS Pegylated interferon alpha + ribavirin IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 2.","30409038","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 2.","Sofosbuvir + daclatasvir","Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis  C.","Pegylated interferon alpha + ribavirin","NE"
"2018-01-28562","2018","Wu                               2018 Curr Med Res Opin","24000","Sofosbuvir + pegylated interferon alpha + ribavirin  VERSUS Asunaprevir + daclatasvir IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 1b.","30409038","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 1b.","Sofosbuvir + pegylated interferon alpha + ribavirin","Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis  C.","Asunaprevir + daclatasvir","NE"
"2018-01-28562","2018","Wu                               2018 Curr Med Res Opin","30000","Sofosbuvir + ribavirin VERSUS Pegylated interferon alpha + ribavirin IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 2.","30409038","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 2.","Sofosbuvir + ribavirin","Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis  C.","Pegylated interferon alpha + ribavirin","NE"
"2018-01-28562","2018","Wu                               2018 Curr Med Res Opin","46000","Sofosbuvir + daclatasvir VERSUS Asunaprevir + daclatasvir  IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 1b.","30409038","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 1b.","Sofosbuvir + daclatasvir","Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis  C.","Asunaprevir + daclatasvir","NE"
"2018-01-28562","2018","Wu                               2018 Curr Med Res Opin","47000","Sofosbuvir + pegylated interferon alpha + ribavirin  VERSUS Sofosbuvir + ribavirin  IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 3.","30409038","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 3.","Sofosbuvir + pegylated interferon alpha + ribavirin","Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis  C.","Sofosbuvir + ribavirin","NE"
"2018-01-28562","2018","Wu                               2018 Curr Med Res Opin","74000","Sofosbuvir + daclatasvir VERSUS Sofosbuvir + pegylated interferon alpha + ribavirin  IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 3.","30409038","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 3.","Sofosbuvir + daclatasvir","Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis  C.","Sofosbuvir + pegylated interferon alpha + ribavirin","NE"
"2018-01-28562","2018","Wu                               2018 Curr Med Res Opin","Cost-Saving","Asunaprevir + daclatasvir VERSUS Pegylated interferon alpha + ribavirin  IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 1b.","30409038","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 1b.","Asunaprevir + daclatasvir","Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis  C.","Pegylated interferon alpha + ribavirin","SE"
"2018-01-28562","2018","Wu                               2018 Curr Med Res Opin","Cost-Saving","Ombitasvir/paritaprevir/ritonavir + dasabuvir VERSUS Asunaprevir + daclatasvir IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 1b.","30409038","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 1b.","Ombitasvir/paritaprevir/ritonavir + dasabuvir","Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis  C.","Asunaprevir + daclatasvir","SE"
"2018-01-28562","2018","Wu                               2018 Curr Med Res Opin","Cost-Saving","Sofosbuvir + ribavirin  VERSUS Pegylated interferon alpha + ribavirin IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 6.","30409038","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China; Other- Genotype 6.","Sofosbuvir + ribavirin","Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis  C.","Pegylated interferon alpha + ribavirin","SE"
"2018-01-28459","2018","Wu                               2018 J Immunother Cancer","130000","Nivolumab + ipilimumab VERSUS Sunitinib IN Specific disease- Advanced renal-cell carcinoma; Age- 41 to 64 years; Gender- Both; Country- United Kingdom.","30458884","Specific disease- Advanced renal-cell carcinoma; Age- 41 to 64 years; Gender- Both; Country- United Kingdom.","Nivolumab + ipilimumab","Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.","Sunitinib","NE"
"2018-01-28459","2018","Wu                               2018 J Immunother Cancer","4800","Nivolumab + ipilimumab VERSUS Sunitinib IN Specific disease- Advanced renal-cell carcinoma; Age- 41 to 64 years; Gender- Both; Country- China.","30458884","Specific disease- Advanced renal-cell carcinoma; Age- 41 to 64 years; Gender- Both; Country- China.","Nivolumab + ipilimumab","Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.","Sunitinib","NE"
"2018-01-28459","2018","Wu                               2018 J Immunother Cancer","88000","Nivolumab + ipilimumab VERSUS Sunitinib IN Specific disease- Advanced renal-cell carcinoma; Age- 41 to 64 years; Gender- Both; Country- United States.","30458884","Specific disease- Advanced renal-cell carcinoma; Age- 41 to 64 years; Gender- Both; Country- United States.","Nivolumab + ipilimumab","Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.","Sunitinib","NE"
"2018-01-28436","2018","Zhang 2018 Clin Ther","6600","Clopidogrel VERSUS Aspirin IN Specific disease- Acute Coronary Syndrome ; Age- >=65 years; Gender- Both; Country- China.","30470579","Specific disease- Acute Coronary Syndrome ; Age- >=65 years; Gender- Both; Country- China.","Clopidogrel","Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer''s Perspective.","Aspirin","NE"
"2018-01-28382","2018","Li 2018 BMC Infect Dis","11000","Pre-exposure prophylaxis (PrEP)- 50% coverage + Test and treat (90-90-90) VERSUS Standard/Usual Care- Current Chinese HIV treatment guidelines  IN Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","30486800","Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","Pre-exposure prophylaxis (PrEP)- 50% coverage + Test and treat (90-90-90)","A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.","Standard/Usual Care- Current Chinese HIV treatment guidelines","NE"
"2018-01-28382","2018","Li 2018 BMC Infect Dis","13000","Pre-exposure prophylaxis (PrEP) - 75% coverage + Test and treat (90-90-90) VERSUS Standard/Usual Care- Current Chinese HIV treatment guidelines  IN Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","30486800","Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","Pre-exposure prophylaxis (PrEP) - 75% coverage + Test and treat (90-90-90)","A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.","Standard/Usual Care- Current Chinese HIV treatment guidelines","NE"
"2018-01-28382","2018","Li 2018 BMC Infect Dis","14000","Pre-exposure prophylaxis (PrEP) - 25% coverage + Expanded testing VERSUS Standard/Usual Care- Current Chinese HIV treatment guidelines  IN Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","30486800","Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","Pre-exposure prophylaxis (PrEP) - 25% coverage + Expanded testing","A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.","Standard/Usual Care- Current Chinese HIV treatment guidelines","NE"
"2018-01-28382","2018","Li 2018 BMC Infect Dis","17000","Pre-exposure prophylaxis (PrEP) - 50% coverage + Expanded testing VERSUS Standard/Usual Care- Current Chinese HIV treatment guidelines  IN Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","30486800","Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","Pre-exposure prophylaxis (PrEP) - 50% coverage + Expanded testing","A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.","Standard/Usual Care- Current Chinese HIV treatment guidelines","NE"
"2018-01-28382","2018","Li 2018 BMC Infect Dis","1800","Test-and-treat (90â90-90) VERSUS Standard/Usual Care- Current Chinese HIV treatment guidelines  IN Specific disease- HIV; Age- Adult; Gender- Male; Country- China.","30486800","Specific disease- HIV; Age- Adult; Gender- Male; Country- China.","Test-and-treat (90â90-90)","A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.","Standard/Usual Care- Current Chinese HIV treatment guidelines","NE"
"2018-01-28382","2018","Li 2018 BMC Infect Dis","18000","Pre-exposure prophylaxis (PrEP) - 25% coverage VERSUS Standard/Usual Care- Current Chinese HIV treatment guidelines  IN Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","30486800","Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","Pre-exposure prophylaxis (PrEP) - 25% coverage","A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.","Standard/Usual Care- Current Chinese HIV treatment guidelines","NE"
"2018-01-28382","2018","Li 2018 BMC Infect Dis","18000","Pre-exposure prophylaxis (PrEP) - 50% coverage VERSUS Standard/Usual Care- Current Chinese HIV treatment guidelines  IN Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","30486800","Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","Pre-exposure prophylaxis (PrEP) - 50% coverage","A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.","Standard/Usual Care- Current Chinese HIV treatment guidelines","NE"
"2018-01-28382","2018","Li 2018 BMC Infect Dis","19000","Pre-exposure prophylaxis (PrEP) - 75% coverage + Expanded testing VERSUS Standard/Usual Care- Current Chinese HIV treatment guidelines  IN Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","30486800","Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","Pre-exposure prophylaxis (PrEP) - 75% coverage + Expanded testing","A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.","Standard/Usual Care- Current Chinese HIV treatment guidelines","NE"
"2018-01-28382","2018","Li 2018 BMC Infect Dis","19000","Pre-exposure prophylaxis (PrEP) - 75% coverage VERSUS Standard/Usual Care- Current Chinese HIV treatment guidelines  IN Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","30486800","Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","Pre-exposure prophylaxis (PrEP) - 75% coverage","A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.","Standard/Usual Care- Current Chinese HIV treatment guidelines","NE"
"2018-01-28382","2018","Li 2018 BMC Infect Dis","7800","Pre-exposure prophylaxis (PrEP) - 25% coverage + Test and treat (90-90-90)  VERSUS Standard/Usual Care- Current Chinese HIV treatment guidelines  IN Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","30486800","Specific disease- HIV; Age- Adult; Gender- Male; Country- China; Other- High-risk men who have sex with men.","Pre-exposure prophylaxis (PrEP) - 25% coverage + Test and treat (90-90-90)","A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.","Standard/Usual Care- Current Chinese HIV treatment guidelines","NE"
"2018-01-28314","2018","Zhou 2018 J Asthma","220000","Omalizumab strategy VERSUS Standard/Usual Care IN Specific disease- Severe Allergic Asthma ; Age- 0 to 18 years; Gender- Both; Country- China.","30507328","Specific disease- Severe Allergic Asthma ; Age- 0 to 18 years; Gender- Both; Country- China.","Omalizumab strategy","Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.","Standard/Usual Care","NE"
"2018-01-28281","2018","Wu 2018 PLoS One","89000","The New Rural Cooperative Medical Scheme  VERSUS Standard/Usual Care- No New Rural Cooperative Medical Scheme  IN Healthy; Age- 19 to 40 years; Gender- Both; Country- China.","30532135","Healthy; Age- 19 to 40 years; Gender- Both; Country- China.","The New Rural Cooperative Medical Scheme","The cost-effectiveness analysis of the New Rural Cooperative Medical Scheme in China.","Standard/Usual Care- No New Rural Cooperative Medical Scheme","NE"
"2018-01-27765","2018","Xie 2018 Prev Med","1200","Intensive hypertension control (medication + lifestyle modification) VERSUS Standard/Usual Care- Standard hypertension control IN Specific disease- Hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China.","29525577","Specific disease- Hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- China.","Intensive hypertension control (medication + lifestyle modification)","Cost-effectiveness analysis of intensive hypertension control in China.","Standard/Usual Care- Standard hypertension control","NE"
"2018-01-27765","2018","Xie 2018 Prev Med","1200","Intensive hypertension control (medication + lifestyle modification) VERSUS Standard/Usual Care- Standard hypertension control IN Specific disease- Hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- China.","29525577","Specific disease- Hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- China.","Intensive hypertension control (medication + lifestyle modification)","Cost-effectiveness analysis of intensive hypertension control in China.","Standard/Usual Care- Standard hypertension control","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","100000","Sequence 4 :Infliximab therapy VERSUS Standard/Usual Care- Conventional therapy IN Specific disease- Moderate to severe ulcerative colitis; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg    .","29718241","Specific disease- Moderate to severe ulcerative colitis; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg    .","Sequence 4 :Infliximab therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","110000","Sequence 9: Golimumab - Tofacitinib therapy VERSUS Standard/Usual Care- Conventional therapy IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg    .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg    .","Sequence 9: Golimumab - Tofacitinib therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","120000","Sequence 2 : Vedolizumab - therapy  VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy  and body weights areassumed to be 62 kg .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy  and body weights areassumed to be 62 kg .","Sequence 2 : Vedolizumab - therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","15000","Sequence 6 : Adalimumab therapy VERSUS Standard/Usual Care- Conventional therapy IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy Sequence 5 :Golimumab  .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy Sequence 5 :Golimumab  .","Sequence 6 : Adalimumab therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","150000","Sequence 5 :Golimumab  therapy VERSUS Standard/Usual Care- Conventional therapy IN Specific disease- Moderate to severe ulcerative colitis; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy  and body weights areassumed to be 77 kg  .","29718241","Specific disease- Moderate to severe ulcerative colitis; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy  and body weights areassumed to be 77 kg  .","Sequence 5 :Golimumab  therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","190000","Sequence 4: Infliximab  therapy VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg  .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg  .","Sequence 4: Infliximab  therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","29000","Sequence 3: Tofacitinib  therapy VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg .","Sequence 3: Tofacitinib  therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","30000","Sequence 10 : Adalimumab - Tofacitinib -  therapy  VERSUS Standard/Usual Care- Conventional therapy IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg  .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg  .","Sequence 10 : Adalimumab - Tofacitinib -  therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","300000","Sequence 5: Golimumab therapy VERSUS Standard/Usual Care- Conventional therapy IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg   .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg   .","Sequence 5: Golimumab therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","31000","Sequence 14 :Tofacitinib - Adalimumab therapy  VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg   .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg   .","Sequence 14 :Tofacitinib - Adalimumab therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","34000","Sequence 3: Tofacitinib  therapy VERSUS Standard/Usual Care- Conventional therapy IN Specific disease- Moderate to severe ulcerative colitis; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg  .","29718241","Specific disease- Moderate to severe ulcerative colitis; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg  .","Sequence 3: Tofacitinib  therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","39000","Sequence 14: Tofacitinib - Adalimumab  therapy  VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- Moderate to severe ulcerative colitis; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg    .","29718241","Specific disease- Moderate to severe ulcerative colitis; Age- 19 to 40 years; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg    .","Sequence 14: Tofacitinib - Adalimumab  therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","41000","Sequence 10: Adalimumab - Tofacitinib  therapy VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years, Unknown; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg    .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years, Unknown; Gender- Both; Country- China; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 62 kg    .","Sequence 10: Adalimumab - Tofacitinib  therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","46000","Sequence 11:Tofacitinib - Vedolizumab therapy  VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg   .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg   .","Sequence 11:Tofacitinib - Vedolizumab therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","48000","Sequence 7 : Vedolizumab - Tofacitinib therapy VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg  .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg  .","Sequence 7 : Vedolizumab - Tofacitinib therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","51000","Sequence 12 :Tofacitinib - Infliximab therapy  VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg   .","29718241","Specific disease- ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg   .","Sequence 12 :Tofacitinib - Infliximab therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","54000","Sequnce 8: Infliximab - Tofacitinib therapy VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg  .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg  .","Sequnce 8: Infliximab - Tofacitinib therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","62000","Sequence 13 Tofacitinib - Golimumab -therapy  VERSUS Standard/Usual Care- Conventional therapy  IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg  .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg  .","Sequence 13 Tofacitinib - Golimumab -therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","62000","Sequence 2 : Vedolizumab therapy VERSUS Standard/Usual Care- Conventional therapy IN Specific disease- Moderate to severe ulcerative colitis; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and Body weights are assumed to be 77 kg .","29718241","Specific disease- Moderate to severe ulcerative colitis; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and Body weights are assumed to be 77 kg .","Sequence 2 : Vedolizumab therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-27299","2018","Wu                               2018 Inflamm Bowel Dis","67000","Sequence 9 :Golimumab - Tofacitinib therapy VERSUS Standard/Usual Care- Conventional therapy IN Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg   .","29718241","Specific disease- Moderate to severe ulcerative colitis ; Age- 19 to 40 years; Gender- Both; Country- United Kingdom; Other- Patients who have experienced failure of at least one prior conventional therapy and body weights areassumed to be 77 kg   .","Sequence 9 :Golimumab - Tofacitinib therapy","Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.","Standard/Usual Care- Conventional therapy","NE"
"2018-01-26663","2018","Ordonez 2018 Curr Med Res Opin","Cost-Saving","Micro-bypass trabecular stent plus Timolol VERSUS Bimatoprost plus Timolol plus Dorzolamide IN Specific disease- Glaucoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Colombia.","30049226","Specific disease- Glaucoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Colombia.","Micro-bypass trabecular stent plus Timolol","Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients  with open-angle glaucoma in Colombia.","Bimatoprost plus Timolol plus Dorzolamide","SE"
"2018-01-26663","2018","Ordonez 2018 Curr Med Res Opin","Cost-Saving","Micro-bypass trabecular stent plus Timolol VERSUS Laser selective trabeculoplasty plus Timolol plus Dorzolamide IN Specific disease- Glaucoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Colombia.","30049226","Specific disease- Glaucoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Colombia.","Micro-bypass trabecular stent plus Timolol","Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients  with open-angle glaucoma in Colombia.","Laser selective trabeculoplasty plus Timolol plus Dorzolamide","SE"
"2018-01-26663","2018","Ordonez 2018 Curr Med Res Opin","Cost-Saving","Micro-bypass trabecular stent plus Timolol VERSUS Latanoprost plus Timolol plus Dorzolamide IN Specific disease- Glaucoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Colombia.","30049226","Specific disease- Glaucoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Colombia.","Micro-bypass trabecular stent plus Timolol","Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients  with open-angle glaucoma in Colombia.","Latanoprost plus Timolol plus Dorzolamide","SE"
"2018-01-26663","2018","Ordonez 2018 Curr Med Res Opin","Cost-Saving","Micro-bypass trabecular stent plus Timolol VERSUS Travoprost plus Timolol plus Dorzolamide IN Specific disease- Glaucoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Colombia.","30049226","Specific disease- Glaucoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Colombia.","Micro-bypass trabecular stent plus Timolol","Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients  with open-angle glaucoma in Colombia.","Travoprost plus Timolol plus Dorzolamide","SE"
"2018-01-26467","2018","Caicedo 2018 World J Urol","4600","Photovaporization of the prostate (PVP) with GreenLight laser 180 W XPS VERSUS Transurethral resection of the prostate with monopolar energy (M-TURP) IN Specific disease- Lower urinary tract symptoms (LUTS) due to benign prostatic enlargement (BPE); Age- 41 to 64 years, >=65 years; Gender- Male; Country- Colombia.","30116964","Specific disease- Lower urinary tract symptoms (LUTS) due to benign prostatic enlargement (BPE); Age- 41 to 64 years, >=65 years; Gender- Male; Country- Colombia.","Photovaporization of the prostate (PVP) with GreenLight laser 180 W XPS","Photovaporization of the prostate with GreenLight laser 180 W XPS versus transurethral resection of the prostate with monopolar energy for the treatment of benign prostatic enlargement: a cost-utility analysis from a healthcare perspective.","Transurethral resection of the prostate with monopolar energy (M-TURP)","NE"
"2017-01-25747","2017","Lasalvia 2017 Value Health Reg Issues","19000","Dulaglutide VERSUS Glargine IN Specific disease- Type 2 Diabetes; Age- Adult; Gender- Both; Country- Colombia.","29254540","Specific disease- Type 2 Diabetes; Age- Adult; Gender- Both; Country- Colombia.","Dulaglutide","Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type  2 Diabetes Mellitus Patients in Colombia.","Glargine","NE"
"2017-01-25747","2017","Lasalvia 2017 Value Health Reg Issues","Cost-Saving","Dulaglutide VERSUS Liraglutide IN Specific disease- Type 2 Diabetes Mellitus; Age- Adult; Gender- Both; Country- Colombia.","29254540","Specific disease- Type 2 Diabetes Mellitus; Age- Adult; Gender- Both; Country- Colombia.","Dulaglutide","Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type  2 Diabetes Mellitus Patients in Colombia.","Liraglutide","SE"
"2017-01-25730","2017","McMurray 2017 Heart","15000","Sacubitril/valsartan VERSUS Standard/Usual Care- Angiotensin-converting-enzyme inhibitor IN Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Colombia; Other- Heart failure with reduced ejection fraction.","29269379","Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Colombia; Other- Heart failure with reduced ejection fraction.","Sacubitril/valsartan","Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.","Standard/Usual Care- Angiotensin-converting-enzyme inhibitor","NE"
"2017-01-25730","2017","McMurray 2017 Heart","27000","Sacubitril/valsartan VERSUS Standard/Usual Care- Angiotensin-converting-enzyme inhibitor IN Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Denmark; Other- Heart failure with reduced ejection fraction.","29269379","Specific disease- Heart failure; Age- Adult; Gender- Both; Country- Denmark; Other- Heart failure with reduced ejection fraction.","Sacubitril/valsartan","Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.","Standard/Usual Care- Angiotensin-converting-enzyme inhibitor","NE"
"2017-01-25730","2017","McMurray 2017 Heart","28000","Sacubitril/valsartan VERSUS Standard/Usual Care- Angiotensin-converting-enzyme inhibitor IN Specific disease- Heart failure; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Heart failure with reduced ejection fraction.","29269379","Specific disease- Heart failure; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Heart failure with reduced ejection fraction.","Sacubitril/valsartan","Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.","Standard/Usual Care- Angiotensin-converting-enzyme inhibitor","NE"
"2017-01-23481","2017","Montes 2017 Otol Neurotol","17000","Hearing aids VERSUS None IN Specific disease- Deafness; Age- 0 to 18 years; Gender- Both; Country- Colombia; Other- Children with bilateral profound sensorineural hearing loss (profound deafness) in Colombia.","28353624","Specific disease- Deafness; Age- 0 to 18 years; Gender- Both; Country- Colombia; Other- Children with bilateral profound sensorineural hearing loss (profound deafness) in Colombia.","Hearing aids","Cochlear Implants Versus Hearing Aids in a Middle-Income Country: Costs, Productivity, and Quality of Life.","None","NE"
"2017-01-23481","2017","Montes 2017 Otol Neurotol","18000","Cochlear implant VERSUS None IN Specific disease- Deafness; Age- 0 to 18 years; Gender- Both; Country- Colombia; Other- Children with bilateral profound sensorineural hearing loss (profound deafness) in Colombia.","28353624","Specific disease- Deafness; Age- 0 to 18 years; Gender- Both; Country- Colombia; Other- Children with bilateral profound sensorineural hearing loss (profound deafness) in Colombia.","Cochlear implant","Cochlear Implants Versus Hearing Aids in a Middle-Income Country: Costs, Productivity, and Quality of Life.","None","NE"
"2016-01-22205","2016","Gomez 2016 Endocrinol Nutr"," ","VERSUS multiple dose insulin injections IN Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Colombia; Other- type 1 diabetes.","27595241","Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Colombia; Other- type 1 diabetes."," ","Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia.","multiple dose insulin injections","NE"
"2016-01-21541","2016","Castro Jaramillo 2016 Int J Technol Assess Health Care","100000","Primary prophylaxis using reecombinant Factor VIII (On demand) VERSUS Primary Prophylaxis IN Specific disease- Severe Hemophilia Type A; Age- Adult; Gender- Both; Country- Colombia.","27919309","Specific disease- Severe Hemophilia Type A; Age- Adult; Gender- Both; Country- Colombia.","Primary prophylaxis using reecombinant Factor VIII (On demand)","COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT,  FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA.","Primary Prophylaxis","NE"
"2016-01-21541","2016","Castro Jaramillo 2016 Int J Technol Assess Health Care","62000","Primary prophylaxis using Factor VIII (On demand) VERSUS Primary Prophylaxis IN Specific disease- Severe Hemophilia Type A; Age- Adult; Gender- Both; Country- Colombia.","27919309","Specific disease- Severe Hemophilia Type A; Age- Adult; Gender- Both; Country- Colombia.","Primary prophylaxis using Factor VIII (On demand)","COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT,  FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA.","Primary Prophylaxis","NE"
"2015-01-20148","2015","Mejia 2015 Biomedica","18000","Aspirin plus ticagrelor with an initial dose of ticagrelor of 180 mg, and then 90 mg twice a day for a year VERSUS Aspirin plus clopidogrel, which is the strategy contemplated in the current protocol of the Columbian health system, with an initial does of clopidogrel of 300 mg, and then 75 mg per day for a year IN Specific disease- acute cornary syndrome; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- colombia.","26844442","Specific disease- acute cornary syndrome; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- colombia.","Aspirin plus ticagrelor with an initial dose of ticagrelor of 180 mg, and then 90 mg twice a day for a year","Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.","Aspirin plus clopidogrel, which is the strategy contemplated in the current protocol of the Columbian health system, with an initial does of clopidogrel of 300 mg, and then 75 mg per day for a year","NE"
"2014-01-16308","2014","Rodriguez-Martinez 2014 Pediatr Pulmonol","Cost-Saving","Daily inhaled corticosteroids (ICS) among preschool patients VERSUS Standard/Usual Care- intermittent inhaled corticosteroids (ICS) IN Specific disease- mild-persistent asthma; Age- 0 to 18 years; Gender- Both; Country- United States.","24965279","Specific disease- mild-persistent asthma; Age- 0 to 18 years; Gender- Both; Country- United States.","Daily inhaled corticosteroids (ICS) among preschool patients","Cost-utility analysis of daily versus intermittent inhaled corticosteroids in mild-persistent asthma.","Standard/Usual Care- intermittent inhaled corticosteroids (ICS)","SE"
"2014-01-16308","2014","Rodriguez-Martinez 2014 Pediatr Pulmonol","Cost-Saving","Daily inhaled corticosteroids (ICS) among school patients VERSUS Standard/Usual Care- intermittent inhaled corticosteroids (ICS) IN Specific disease- mild-persistent asthma; Age- 0 to 18 years; Gender- Both; Country- Colombia.","24965279","Specific disease- mild-persistent asthma; Age- 0 to 18 years; Gender- Both; Country- Colombia.","Daily inhaled corticosteroids (ICS) among school patients","Cost-utility analysis of daily versus intermittent inhaled corticosteroids in mild-persistent asthma.","Standard/Usual Care- intermittent inhaled corticosteroids (ICS)","SE"
"2014-01-15253","2014","Corso 2014 Int J Surg","Dominated","Partial thyroidectomy VERSUS Total thyroidectomy IN Specific disease- Thyroid nodule; Age- Adult; Gender- Both; Country- Colombia.","25017947","Specific disease- Thyroid nodule; Age- Adult; Gender- Both; Country- Colombia.","Partial thyroidectomy","Total thyroidectomy versus hemithyroidectomy for patients with follicular neoplasm. A cost-utility analysis.","Total thyroidectomy","NW"
"2013-01-15170","2013","Buendia 2013 Biomedica","82000","Adjuvant trastuzumab (52 weeks) + standard anthracycline/taxane-based chemotherapy VERSUS Standard/Usual Care- standard anthracycline/taxane-based chemotherapy IN Specific disease- early HER2-positive breast cancer; Age- 41 to 64 years; Gender- Female; Country- Colombia.","24652177","Specific disease- early HER2-positive breast cancer; Age- 41 to 64 years; Gender- Female; Country- Colombia.","Adjuvant trastuzumab (52 weeks) + standard anthracycline/taxane-based chemotherapy","An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia.","Standard/Usual Care- standard anthracycline/taxane-based chemotherapy","NE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Bupropion IN Adult smokers attempting to quit smoking in Costa Rica","22406880","Adult smokers attempting to quit smoking in Costa Rica","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Bupropion","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Bupropion IN Adult smokers attempting to quit smoking in El Salvador","22406880","Adult smokers attempting to quit smoking in El Salvador","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Bupropion","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Bupropion IN Adult smokers attempting to quit smoking in Nicaragua","22406880","Adult smokers attempting to quit smoking in Nicaragua","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Bupropion","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Bupropion IN Adult smokers attempting to quit smoking in Panama","22406880","Adult smokers attempting to quit smoking in Panama","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Bupropion","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Bupropion IN Adult smokers attempting to quit smoking in the Dominican Republic","22406880","Adult smokers attempting to quit smoking in the Dominican Republic","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Bupropion","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Nicotine replacement therapy IN Adult smokers attempting to quit smoking in Costa Rica","22406880","Adult smokers attempting to quit smoking in Costa Rica","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Nicotine replacement therapy","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Nicotine replacement therapy IN Adult smokers attempting to quit smoking in El Salvador","22406880","Adult smokers attempting to quit smoking in El Salvador","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Nicotine replacement therapy","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Nicotine replacement therapy IN Adult smokers attempting to quit smoking in Nicaragua","22406880","Adult smokers attempting to quit smoking in Nicaragua","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Nicotine replacement therapy","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Nicotine replacement therapy IN Adult smokers attempting to quit smoking in Panama","22406880","Adult smokers attempting to quit smoking in Panama","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Nicotine replacement therapy","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Nicotine replacement therapy IN Adult smokers attempting to quit smoking in the Domican Republic","22406880","Adult smokers attempting to quit smoking in the Domican Republic","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Nicotine replacement therapy","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Unaided cessation IN Adult smokers attempting to quit smoking in Costa Rica","22406880","Adult smokers attempting to quit smoking in Costa Rica","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Unaided cessation","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Unaided cessation IN Adult smokers attempting to quit smoking in El Salvador","22406880","Adult smokers attempting to quit smoking in El Salvador","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Unaided cessation","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Unaided cessation IN Adult smokers attempting to quit smoking in Nicaragua","22406880","Adult smokers attempting to quit smoking in Nicaragua","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Unaided cessation","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Unaided cessation IN Adult smokers attempting to quit smoking in Panama","22406880","Adult smokers attempting to quit smoking in Panama","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Unaided cessation","SE"
"2012-01-08833","2012","Lutz 2012 Hosp Pract (Minneap)","Cost-Saving","Varenicline VERSUS Unaided cessation IN Adult smokers attempting to quit smoking in the Domnican Republic","22406880","Adult smokers attempting to quit smoking in the Domnican Republic","Varenicline","Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.","Unaided cessation","SE"
"2015-01-18856","2015","Mitropoulou 2015 Pharmacogenomics","44000","Pharmacogenomic (PGx)- guided warfarin therapy VERSUS Non-pharmacogenomic (N-PGx) warfarin therapy IN Specific disease- Ischemic stroke; Age- >=65 years; Gender- Both; Country- Croatia.","25616100","Specific disease- Ischemic stroke; Age- >=65 years; Gender- Both; Country- Croatia.","Pharmacogenomic (PGx)- guided warfarin therapy","Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.","Non-pharmacogenomic (N-PGx) warfarin therapy","NE"
"2009-01-05902","2009","Khazeni 2009 Ann Intern Med","1500","Vaccination in November VERSUS Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC IN A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53%
women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.8(46% attack rate)","19805762","A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53%
women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.8(46% attack rate)","Vaccination in November","Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009.","Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC","NE"
"2009-01-05902","2009","Khazeni 2009 Ann Intern Med","Cost-Saving","Vaccination in November VERSUS Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC IN A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53%
women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.2(19% attack rate)","19805762","A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53%
women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.2(19% attack rate)","Vaccination in November","Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009.","Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC","SE"
"2009-01-05902","2009","Khazeni 2009 Ann Intern Med","Cost-Saving","Vaccination in November VERSUS Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC IN A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53%
women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.5(36% attack rate)","19805762","A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53%
women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.5(36% attack rate)","Vaccination in November","Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009.","Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC","SE"
"2009-01-05902","2009","Khazeni 2009 Ann Intern Med","Cost-Saving","Vaccination in October VERSUS Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC IN A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53% women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.2(19% attack rate)","19805762","A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53% women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.2(19% attack rate)","Vaccination in October","Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009.","Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC","SE"
"2009-01-05902","2009","Khazeni 2009 Ann Intern Med","Cost-Saving","Vaccination in October VERSUS Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC IN A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53%
women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.5(36% attack rate)","19805762","A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53%
women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.5(36% attack rate)","Vaccination in October","Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009.","Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC","SE"
"2009-01-05902","2009","Khazeni 2009 Ann Intern Med","Cost-Saving","Vaccination in October VERSUS Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC IN A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53%
women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.8(46% attack rate)","19805762","A hypothetical cohort of 8.3 million persons living in a large U.S. city with a sex distribution (53%
women), age range (0 to 100 years), and average remaining life expectancy similar to those of the population of New York City. We assumed that 10 000 individuals were infected at that time. We assumed that 10% of the population entered the model immune to the virus and that 90% of individuals entered susceptible to the virus. R0 (number of secondary infections caused by each primary infection in a susceptible population) of pandemic (H1N1) is 1.8(46% attack rate)","Vaccination in October","Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009.","Nonpharmaceutical interventions for pandemic (H1N1) recommended by the CDC","SE"
"2009-01-05687","2009","Khazeni 2009 Ann Intern Med","Cost-Saving","Pandemic influenza (H1N1) vaccination of 40% of the US population in November. VERSUS No vaccination IN US Population residing in a large (~8M people) city.","20008759","US Population residing in a large (~8M people) city.","Pandemic influenza (H1N1) vaccination of 40% of the US population in November.","Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.","No vaccination","SE"
"2009-01-05687","2009","Khazeni 2009 Ann Intern Med","Cost-Saving","Pandemic influenza (H1N1) Vaccination of 40% of the US population in October. VERSUS No vaccination IN US population residing in a large (~8M people) city.","20008759","US population residing in a large (~8M people) city.","Pandemic influenza (H1N1) Vaccination of 40% of the US population in October.","Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.","No vaccination","SE"
"2015-01-18104","2015","Petrou 2015 Expert Opin Pharmacother","130000","Antinib (5mg twice daily) VERSUS Standard/Usual Care- sorafenib (400 mg twice daily) IN Specific disease- renal cell carcinoma; Age- Adult; Gender- Both; Country- Cyprus; Other- patients have been previously treated with sunitinib or cytokines.","25958963","Specific disease- renal cell carcinoma; Age- Adult; Gender- Both; Country- Cyprus; Other- patients have been previously treated with sunitinib or cytokines.","Antinib (5mg twice daily)","Cost-effectiveness analysis of axitinib through a probabilistic decision model.","Standard/Usual Care- sorafenib (400 mg twice daily)","NE"
"2014-01-14978","2014","Petrou 2014 Expert Rev Pharmacoecon Outcomes Res","160000","Sorafenib VERSUS Standard/Usual Care- Best supportive care (BSC) IN Specific disease- Renal cell carcinoma (RCC); Age- Adult; Gender- Both; Country- Cyprus; Other- Usually asymptomatic.","24397606","Specific disease- Renal cell carcinoma (RCC); Age- Adult; Gender- Both; Country- Cyprus; Other- Usually asymptomatic.","Sorafenib","Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus.","Standard/Usual Care- Best supportive care (BSC)","NE"
"2018-01-27550","2018","Villemoes 2018 Eur J Vasc Endovasc Surg","13000","Heparin coasted graft for femoro-femoral or femoro-popliteal bypass surgery VERSUS Standard/Usual Care- Polytetrafluoroethylene standard graft for femoro-femoral or femoro-popliteal bypass surgery IN Specific disease- Peripheral arterial disease; Age- Adult; Gender- Both; Country- Denmark.","29622512","Specific disease- Peripheral arterial disease; Age- Adult; Gender- Both; Country- Denmark.","Heparin coasted graft for femoro-femoral or femoro-popliteal bypass surgery","Cost-Effectiveness Evaluation of Heparin Coated Versus Standard Graft for Bypass  Surgery in Peripheral Artery Disease Alongside a Randomised Controlled Trial.","Standard/Usual Care- Polytetrafluoroethylene standard graft for femoro-femoral or femoro-popliteal bypass surgery","NE"
"2018-01-27550","2018","Villemoes 2018 Eur J Vasc Endovasc Surg","Cost-Saving","Heparin coated graft for femoro-femoral or femoro-popliteal bypass surgery VERSUS Standard/Usual Care- Polytetrafluoroethylene graft for femoro-femoral or femoro-popliteal bypass surgery IN Specific disease- Peripheral arterial disease; Age- Adult; Gender- Both; Country- Denmark; Other- Critical ischemia.","29622512","Specific disease- Peripheral arterial disease; Age- Adult; Gender- Both; Country- Denmark; Other- Critical ischemia.","Heparin coated graft for femoro-femoral or femoro-popliteal bypass surgery","Cost-Effectiveness Evaluation of Heparin Coated Versus Standard Graft for Bypass  Surgery in Peripheral Artery Disease Alongside a Randomised Controlled Trial.","Standard/Usual Care- Polytetrafluoroethylene graft for femoro-femoral or femoro-popliteal bypass surgery","SE"
"2018-01-27550","2018","Villemoes 2018 Eur J Vasc Endovasc Surg","Dominated","Heparin coated graft for femoro-femoral or femoro-popliteal bypass surgery VERSUS Standard/Usual Care- Polytetrafluoroethylene graft for femoro-femoral or femoro-popliteal bypass surgery IN Specific disease- Peripheral arterial disease; Age- Adult; Gender- Both; Country- Denmark; Other- Non-critical ischemia.","29622512","Specific disease- Peripheral arterial disease; Age- Adult; Gender- Both; Country- Denmark; Other- Non-critical ischemia.","Heparin coated graft for femoro-femoral or femoro-popliteal bypass surgery","Cost-Effectiveness Evaluation of Heparin Coated Versus Standard Graft for Bypass  Surgery in Peripheral Artery Disease Alongside a Randomised Controlled Trial.","Standard/Usual Care- Polytetrafluoroethylene graft for femoro-femoral or femoro-popliteal bypass surgery","NW"
"2018-01-27382","2018","Sogaard 2018 Br J Surg","3000","Screening for abdominal aortic aneurysm, peripheral artery disease, and hypertension VERSUS Standard/Usual Care- Ad hoc primary care-based risk assessment IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- Denmark; Other- Living in the Central Denmark Region from October 2008 to January 2011.","29691840","Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- Denmark; Other- Living in the Central Denmark Region from October 2008 to January 2011.","Screening for abdominal aortic aneurysm, peripheral artery disease, and hypertension","Cost-effectiveness of population-based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial.","Standard/Usual Care- Ad hoc primary care-based risk assessment","NE"
"2018-01-26520","2018","Evans 2018 Diabetes Ther","1300","Insulin Degludec VERSUS Insulin Glargine U100 IN Specific disease- Type 1 Diabetes Mellitus; Age- Adult; Gender- Both; Country- United Kingdom.","30097995","Specific disease- Type 1 Diabetes Mellitus; Age- Adult; Gender- Both; Country- United Kingdom.","Insulin Degludec","Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting.","Insulin Glargine U100","NE"
"2018-01-26520","2018","Evans 2018 Diabetes Ther","24000","Insulin Degludec VERSUS Insulin Glargine U100 (100 units/mL) IN Specific disease- Type 2 Diabetes Mellitus; Age- Adult; Gender- Both; Country- United Kingdom.","30097995","Specific disease- Type 2 Diabetes Mellitus; Age- Adult; Gender- Both; Country- United Kingdom.","Insulin Degludec","Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting.","Insulin Glargine U100 (100 units/mL)","NE"
"2018-01-26239","2018","Retel 2018 BMC Cancer","Cost-Saving","Infusion of tumor infiltrating lymphocytes VERSUS Ipilimumab IN Specific disease- Metastatic melanoma; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Netherlands.","30219040","Specific disease- Metastatic melanoma; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Netherlands.","Infusion of tumor infiltrating lymphocytes","Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line  treatment in advanced melanoma: a model-based economic evaluation.","Ipilimumab","SE"
"2017-01-25345","2017","Sopina                           2017 BMJ Open","100000","Aerobic exercise programme VERSUS Standard/Usual Care IN Specific disease- Alzheimer's disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Utilities based on proxy-reported EQ-VAS-5D index.","28615271","Specific disease- Alzheimer's disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Utilities based on proxy-reported EQ-VAS-5D index.","Aerobic exercise programme","Cost-effectiveness of a randomised trial of physical activity in Alzheimer''s disease: a secondary analysis exploring patient and proxy-reported health-related quality of life measures in Denmark.","Standard/Usual Care","NE"
"2017-01-25345","2017","Sopina                           2017 BMJ Open","85000","Aerobic exercise programme VERSUS Standard/Usual Care IN Specific disease- Alzheimer's disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Using patient-reported EQ-VAS scores.","28615271","Specific disease- Alzheimer's disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Using patient-reported EQ-VAS scores.","Aerobic exercise programme","Cost-effectiveness of a randomised trial of physical activity in Alzheimer''s disease: a secondary analysis exploring patient and proxy-reported health-related quality of life measures in Denmark.","Standard/Usual Care","NE"
"2017-01-24853","2017","Wein 2017 Int J Cardiol","Dominated","Basket-Prove II with Prasugrel VERSUS Basket-Prove I with Clopidogrel IN Specific disease- Acute coronary syndrome; Age- Adult; Gender- Both; Country- Switzerland; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.","28823409","Specific disease- Acute coronary syndrome; Age- Adult; Gender- Both; Country- Switzerland; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.","Basket-Prove II with Prasugrel","Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness  analysis from the BASKET-PROVE cohorts.","Basket-Prove I with Clopidogrel","NW"
"2017-01-24853","2017","Wein 2017 Int J Cardiol","Dominated","Basket-Prove II with Prasugrel VERSUS Basket-Prove I with Clopidogrel IN Specific disease- Acute coronary syndromes; Age- Adult; Gender- Both; Country- Denmark; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.","28823409","Specific disease- Acute coronary syndromes; Age- Adult; Gender- Both; Country- Denmark; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.","Basket-Prove II with Prasugrel","Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness  analysis from the BASKET-PROVE cohorts.","Basket-Prove I with Clopidogrel","NW"
"2017-01-24853","2017","Wein 2017 Int J Cardiol","Dominated","Basket-Prove II with Prasugrel VERSUS Basket-Prove I with Clopidogrel IN Specific disease- Acute coronary syndromes; Age- Adult; Gender- Both; Country- Germany; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.","28823409","Specific disease- Acute coronary syndromes; Age- Adult; Gender- Both; Country- Germany; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.","Basket-Prove II with Prasugrel","Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness  analysis from the BASKET-PROVE cohorts.","Basket-Prove I with Clopidogrel","NW"
"2017-01-24750","2017","Borisenko 2017 Dan Med J","3400","Bariatric surgery at ten years time horizon  VERSUS Optimal medical management IN Specific disease- Obesity ; Age- 19 to 40 years; Gender- Both; Country- Denmark.","28869031","Specific disease- Obesity ; Age- 19 to 40 years; Gender- Both; Country- Denmark.","Bariatric surgery at ten years time horizon","Cost analysis of bariatric surgery in Denmark made with a decision-analytic model.","Optimal medical management","NE"
"2017-01-24750","2017","Borisenko 2017 Dan Med J","Cost-Saving","Bariatric surgery at a lifetime horizon  VERSUS Optimal medical management IN Specific disease- Obesity ; Age- 19 to 40 years; Gender- Both; Country- Denmark.","28869031","Specific disease- Obesity ; Age- 19 to 40 years; Gender- Both; Country- Denmark.","Bariatric surgery at a lifetime horizon","Cost analysis of bariatric surgery in Denmark made with a decision-analytic model.","Optimal medical management","SE"
"2017-01-24629","2017","Christensen 2017 Int J Circumpolar Health","Cost-Saving","Decentralized screening VERSUS Centralized screening IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Denmark.","28934900","Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Denmark.","Decentralized screening","Societal costs and effects of implementing population-based mammography screening in Greenland.","Centralized screening","SE"
"2017-01-24629","2017","Christensen 2017 Int J Circumpolar Health","Dominated","Decentralized screening  VERSUS Centralized screening IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Denmark.","28934900","Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Denmark.","Decentralized screening","Societal costs and effects of implementing population-based mammography screening in Greenland.","Centralized screening","NW"
"2017-01-24028","2017","Fernandes 2017 BMC Musculoskelet Disord","Cost-Saving","Supervised pre-surgical neuromuscular exercise program and preoperative educational package VERSUS Standard/Usual Care- Preoperative educational package IN Specific disease- Hip or knee osteoarthritis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark.","28061841","Specific disease- Hip or knee osteoarthritis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark.","Supervised pre-surgical neuromuscular exercise program and preoperative educational package","Supervised neuromuscular exercise prior to hip and knee replacement: 12-month clinical effect and cost-utility analysis alongside a randomised controlled trial.","Standard/Usual Care- Preoperative educational package","SE"
"2017-01-23937","2017","Jensen 2017 Pain","31000","Multifaceted guideline implementation VERSUS Standard/Usual Care- Usual implementation strategy IN Specific disease- Low back pain; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Denmark.","28114182","Specific disease- Low back pain; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Denmark.","Multifaceted guideline implementation","Economic evaluation of an implementation strategy for the management of low back  pain in general practice.","Standard/Usual Care- Usual implementation strategy","SW"
"2017-01-23925","2017","Hansen 2017 Eur J Prev Cardiol","3.7e+006","Cardiac rehabilitation VERSUS None IN Specific disease- Ischaemic heart disease and heart failure; Age- Adult; Gender- Both; Country- Denmark; Other- patients with heart valve surgery.","28121172","Specific disease- Ischaemic heart disease and heart failure; Age- Adult; Gender- Both; Country- Denmark; Other- patients with heart valve surgery.","Cardiac rehabilitation","Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care.","None","SW"
"2017-01-23822","2017","Schroder 2017 J Psychosom Res","38000","Cognitive behavioral group treatment VERSUS Enhanced standard/usual care IN Specific disease- Functional somatic syndromes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Denmark; Other- Multiple symptoms for at least 2 years.","28183406","Specific disease- Functional somatic syndromes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Denmark; Other- Multiple symptoms for at least 2 years.","Cognitive behavioral group treatment","Long-term economic evaluation of cognitive-behavioural group treatment versus enhanced usual care for functional somatic syndromes.","Enhanced standard/usual care","NE"
"2017-01-23443","2017","Dijkstra 2017 BJU Int","Cost-Saving","patients with elevated PSA level (>3 ng/mL) undergo SelectMDx text followed by a systematic TRUS-guided biopsy if positive VERSUS Standard/Usual Care- patients with elevated PSA level (>3 ng/mL) undergo a systematic TRUS-guided biopsy IN Healthy; Age- Adult; Gender- Male; Country- Denmark; Other- Men with an elevated prostate-specific antigen level (>3 ng/mL).","28370948","Healthy; Age- Adult; Gender- Male; Country- Denmark; Other- Men with an elevated prostate-specific antigen level (>3 ng/mL).","patients with elevated PSA level (>3 ng/mL) undergo SelectMDx text followed by a systematic TRUS-guided biopsy if positive","Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.","Standard/Usual Care- patients with elevated PSA level (>3 ng/mL) undergo a systematic TRUS-guided biopsy","SE"
"2017-01-23314","2017","Roze 2017 Diabetes Res Clin Pract","14000","Sensor-augmented pump therapy and low glucose suspend VERSUS Standard/Usual Care- Continuous subcutaneous insulin infusion IN Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Increased risk for hypoglycemia cohort.","28432898","Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Increased risk for hypoglycemia cohort.","Sensor-augmented pump therapy and low glucose suspend","Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump  therapy in patients with type 1 diabetes in Denmark.","Standard/Usual Care- Continuous subcutaneous insulin infusion","NE"
"2017-01-23314","2017","Roze 2017 Diabetes Res Clin Pract","25000","Sensor-augmented pump therapy and low glucose suspend VERSUS Continuous subcutaneous insulin infusion IN Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Hyperglycemic.","28432898","Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Hyperglycemic.","Sensor-augmented pump therapy and low glucose suspend","Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump  therapy in patients with type 1 diabetes in Denmark.","Continuous subcutaneous insulin infusion","NE"
"2017-01-23218","2017","Klinge 2017 J Neurogastroenterol Motil","780","Gastric electrical stimulation VERSUS None IN Specific disease- Nausea and vomiting; Age- Adult; Gender- Both; Country- Denmark; Other- Type 1 and 2 diabetes patients with severe recurrent nausea and vomiting.","28478663","Specific disease- Nausea and vomiting; Age- Adult; Gender- Both; Country- Denmark; Other- Type 1 and 2 diabetes patients with severe recurrent nausea and vomiting.","Gastric electrical stimulation","Early Assessment of Cost-effectiveness of Gastric Electrical Stimulation for Diabetic Nausea and Vomiting.","None","NE"
"2017-01-23133","2017","Witt Udsen 2017 BMJ Open","78000","Set of telehealthcare equipment and monitering by municipality-based healthcare team in addition to usual care VERSUS Standard/Usual Care IN Specific disease- Chronic obstructive pulmonary disease; Age- Adult; Gender- Both; Country- Denmark.","28515193","Specific disease- Chronic obstructive pulmonary disease; Age- Adult; Gender- Both; Country- Denmark.","Set of telehealthcare equipment and monitering by municipality-based healthcare team in addition to usual care","Cost-effectiveness of telehealthcare to patients with chronic obstructive pulmonary disease: results from the Danish ''TeleCare North'' cluster-randomised trial.","Standard/Usual Care","NE"
"2016-01-22716","2016","Pedersen-Bjergaard 2016 Curr Med Res Opin","4400","Insulin analogue (insulin detemir and insulin aspart) VERSUS Human insulin (neutral protamine Hagedorn [NPH] insulin and regular insulin) IN Specific disease- Type I diabetes mellitus (TIDM); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Prone to recurrent severe hypoglycemia.","27326862","Specific disease- Type I diabetes mellitus (TIDM); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Prone to recurrent severe hypoglycemia.","Insulin analogue (insulin detemir and insulin aspart)","Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia.","Human insulin (neutral protamine Hagedorn [NPH] insulin and regular insulin)","NE"
"2016-01-22307","2016","Evans 2016 Diabetes Ther","13000","Insulin Degludec/Insulin Aspart (IDegAsp) VERSUS Biphasic Insulin Aspart (BIAsp 30) IN Specific disease- Type 2 Diabetes Mellitus (T2DM); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark.","27553066","Specific disease- Type 2 Diabetes Mellitus (T2DM); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark.","Insulin Degludec/Insulin Aspart (IDegAsp)","Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.","Biphasic Insulin Aspart (BIAsp 30)","NE"
"2016-01-22003","2016","Pollock                          2016 J Med Econ","34000","Insulin degludec VERSUS Insulin glargine IN Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 2 diabetes on a basal-bolus regimen.","27705031","Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 2 diabetes on a basal-bolus regimen.","Insulin degludec","A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.","Insulin glargine","NE"
"2016-01-22003","2016","Pollock                          2016 J Med Econ","Cost-Saving","Insulin degludec VERSUS Insulin glargine IN Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 1 diabetes on a basal-bolus regimen.","27705031","Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 1 diabetes on a basal-bolus regimen.","Insulin degludec","A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.","Insulin glargine","SE"
"2016-01-22003","2016","Pollock                          2016 J Med Econ","Cost-Saving","Insulin degludec VERSUS Insulin glargine IN Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 2 diabetes on a basal-only regimen.","27705031","Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 2 diabetes on a basal-only regimen.","Insulin degludec","A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.","Insulin glargine","SE"
"2016-01-19643","2016","Joergensen 2016 Pancreatology","53000","Annual endoscopic ultrasonography and carbohydrate antigen 19-9 (CA19-9) screening VERSUS Standard/Usual Care IN Specific disease- patients with hereditary pancreatitis or with a disposition of hereditary pancreatitis and first-degree relative of patients with familial pancreatic cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Only patients who could endure a pancreatic resection were included..","27090585","Specific disease- patients with hereditary pancreatitis or with a disposition of hereditary pancreatitis and first-degree relative of patients with familial pancreatic cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Only patients who could endure a pancreatic resection were included..","Annual endoscopic ultrasonography and carbohydrate antigen 19-9 (CA19-9) screening","Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program.","Standard/Usual Care","NE"
"2015-01-18687","2015","Olsen 2015 Cost Eff Resour Alloc","5100","Persistent human papillomavirus (HPV) vaccination VERSUS Screening alone IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Denmark.","25694771","Healthy; Age- 0 to 18 years; Gender- Female; Country- Denmark.","Persistent human papillomavirus (HPV) vaccination","Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males  and females.","Screening alone","NE"
"2015-01-18687","2015","Olsen 2015 Cost Eff Resour Alloc","60000","Persistent human papillomavirus (HPV) vaccination for boys and girls VERSUS Persistent human papillomavirus (HPV) vaccination for 12-year-old girls only IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Denmark.","25694771","Healthy; Age- 0 to 18 years; Gender- Both; Country- Denmark.","Persistent human papillomavirus (HPV) vaccination for boys and girls","Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males  and females.","Persistent human papillomavirus (HPV) vaccination for 12-year-old girls only","NE"
"2015-01-16546","2015","Sabale 2015 Prim Care Diabetes","11000","Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin VERSUS Sulfonylurea (SU) added to metformin IN Specific disease- Type 2 diabetes mellitus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Average duration of diabetes is 6 years and 18% are smokers.","24840612","Specific disease- Type 2 diabetes mellitus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Average duration of diabetes is 6 years and 18% are smokers.","Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin","Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.","Sulfonylurea (SU) added to metformin","NE"
"2015-01-16546","2015","Sabale 2015 Prim Care Diabetes","6800","Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin VERSUS Oral sulfonylurea (SU) added to metformin IN Specific disease- Type 2 diabetes mellitus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Norway; Other- Average duration of diabetes is 6 years and 18% are smokers.","24840612","Specific disease- Type 2 diabetes mellitus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Norway; Other- Average duration of diabetes is 6 years and 18% are smokers.","Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin","Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.","Oral sulfonylurea (SU) added to metformin","NE"
"2013-01-10857","2013","Ridderstrale 2013 J Med Econ","35000","Insulin determir VERSUS Neutral protamine hagedorn (NPH) IN Specific disease- Type 2 diabetes mellitus; Age- Adult; Gender- Both; Country- Sweden; Other- Insulin naÃ¯ve.","23384160","Specific disease- Type 2 diabetes mellitus; Age- Adult; Gender- Both; Country- Sweden; Other- Insulin naÃ¯ve.","Insulin determir","Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.","Neutral protamine hagedorn (NPH)","NE"
"2013-01-10857","2013","Ridderstrale 2013 J Med Econ","40000","Insulin determir VERSUS Neutral protamine hagedorn (NPH) IN Specific disease- Type 2 diabetes mellitus; Age- Unknown; Gender- Both; Country- Finland; Other- Insulin naÃ¯ve.","23384160","Specific disease- Type 2 diabetes mellitus; Age- Unknown; Gender- Both; Country- Finland; Other- Insulin naÃ¯ve.","Insulin determir","Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.","Neutral protamine hagedorn (NPH)","NE"
"2013-01-10743","2013","Klok 2013 Clin Ther","Cost-Saving","National immunization programs (NIPs) with 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13) VERSUS NIP containing PCV10 IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Denmark.","23312274","Healthy; Age- 0 to 18 years; Gender- Both; Country- Denmark.","National immunization programs (NIPs) with 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13)","Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.","NIP containing PCV10","SE"
"2013-01-10743","2013","Klok 2013 Clin Ther","Cost-Saving","National immunization programs (NIPs) with 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13) VERSUS NIP containing PCV10 IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Sweden.","23312274","Healthy; Age- 0 to 18 years; Gender- Both; Country- Sweden.","National immunization programs (NIPs) with 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13)","Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.","NIP containing PCV10","SE"
"2012-01-09934","2012","Mistry                           2012 BMJ Open","Dominated","EUROACTION: a nurse-coordinated preventive cardiology programme for coronary patients in hospital and high-risk individuals in general practice VERSUS Usual care IN Patients attending general practices without any cardiovascular disease in Denmark, Italy, Netherlands, Poland, Spain and UK","23065443","Patients attending general practices without any cardiovascular disease in Denmark, Italy, Netherlands, Poland, Spain and UK","EUROACTION: a nurse-coordinated preventive cardiology programme for coronary patients in hospital and high-risk individuals in general practice","Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach.","Usual care","NW"
"2012-01-09815","2012","Haesum 2012 Telemed J E Health","Cost-Saving","Telerehabilitation program (patient would receive telehealth monitor installed in home to conduct measurements of lung function, weight, oxygen level, blood pressure, etc and receive assistance from doctor on how to measure values) VERSUS Control group (no assistance from doctor) IN Patients with chronic obstructive pulmonary disease (COPD) in Denmark","23020647","Patients with chronic obstructive pulmonary disease (COPD) in Denmark","Telerehabilitation program (patient would receive telehealth monitor installed in home to conduct measurements of lung function, weight, oxygen level, blood pressure, etc and receive assistance from doctor on how to measure values)","Cost-Utility Analysis of a Telerehabilitation Program: A Case Study of COPD Patients.","Control group (no assistance from doctor)","SE"
"2012-01-09618","2012","Bank 2012 Eur J Clin Microbiol Infect Dis","10000","Examining throat swabs for Fusobacterium necrophorum, followed by antibiotic treatment for those who are positive VERSUS Usual care IN 15-24-year-olds who present with a sore throat and receiving a throat swab","22886057","15-24-year-olds who present with a sore throat and receiving a throat swab","Examining throat swabs for Fusobacterium necrophorum, followed by antibiotic treatment for those who are positive","A cost-effectiveness analysis of identifying Fusobacterium necrophorum in throat  swabs followed by antibiotic treatment to reduce the incidence of Lemierre''s syndrome and peritonsillar abscesses.","Usual care","NE"
"2012-01-09618","2012","Bank 2012 Eur J Clin Microbiol Infect Dis","29000","Empirically treated with amoxicillin (500 mg three times a day) for 8 days if they had symptoms of pharyngitis (no examination of throat swabs) VERSUS Usual care IN 15-24-year-olds who present with a sore throat and receiving a throat swab","22886057","15-24-year-olds who present with a sore throat and receiving a throat swab","Empirically treated with amoxicillin (500 mg three times a day) for 8 days if they had symptoms of pharyngitis (no examination of throat swabs)","A cost-effectiveness analysis of identifying Fusobacterium necrophorum in throat  swabs followed by antibiotic treatment to reduce the incidence of Lemierre''s syndrome and peritonsillar abscesses.","Usual care","NE"
"2012-01-09012","2012","Westerhout 2012 J Med Econ","23000","Immunotherapy with Oralair (OA) VERSUS Symptomatic treatment (no pharmacotherapy) IN Adult patients suffering from moderate-severe seasonal grass pollen allergic rhinoconjunctivitis in Germany","22533527","Adult patients suffering from moderate-severe seasonal grass pollen allergic rhinoconjunctivitis in Germany","Immunotherapy with Oralair (OA)","Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.","Symptomatic treatment (no pharmacotherapy)","NE"
"2012-01-09012","2012","Westerhout 2012 J Med Econ","Cost-Saving","Immunotherapy with Oralair (OA) VERSUS Immunotherapy with ALK Depot IN Adult patients suffering from moderate-severe seasonal grass pollen allergic rhinoconjunctivitis in Germany","22533527","Adult patients suffering from moderate-severe seasonal grass pollen allergic rhinoconjunctivitis in Germany","Immunotherapy with Oralair (OA)","Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.","Immunotherapy with ALK Depot","SE"
"2012-01-09012","2012","Westerhout 2012 J Med Econ","Cost-Saving","Immunotherapy with Oralair (OA) VERSUS Immunotherapy with Grazax (GRZ) IN Adult patients suffering from moderate-severe seasonal grass pollen allergic rhinoconjunctivitis in Germany","22533527","Adult patients suffering from moderate-severe seasonal grass pollen allergic rhinoconjunctivitis in Germany","Immunotherapy with Oralair (OA)","Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.","Immunotherapy with Grazax (GRZ)","SE"
"2012-01-08908","2012","Oddershede 2012 Ann Thorac Surg","89000","Endoscopic vein harvest VERSUS Open vein harvest IN Coronary artery bypass grafting (CABG) patients in Denmark","22450070","Coronary artery bypass grafting (CABG) patients in Denmark","Endoscopic vein harvest","Economic evaluation of endoscopic versus open vein harvest for coronary artery bypass grafting.","Open vein harvest","NE"
"2012-01-08820","2012","Langkilde 2012 J Med Econ","11000","Dabigatran etexilate VERSUS Warfarin IN Patients with non-valvular atrial fibrillation (AF)","22397590","Patients with non-valvular atrial fibrillation (AF)","Dabigatran etexilate","Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.","Warfarin","NE"
"2012-01-07928","2012","Valentine 2012 Diabet Med","19000","Insulin detemir VERSUS Neutral protamine hagedorn insulin IN Patients with type 1 diabetes with mild hypoglycaemia in Denmark","21951030","Patients with type 1 diabetes with mild hypoglycaemia in Denmark","Insulin detemir","Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.","Neutral protamine hagedorn insulin","NE"
"2012-01-07928","2012","Valentine 2012 Diabet Med","19000","Insulin detemir VERSUS Neutral protamine hagedorn insulin IN Patients with type 1 diabetes with mild hypoglycaemia in Netherlands","21951030","Patients with type 1 diabetes with mild hypoglycaemia in Netherlands","Insulin detemir","Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.","Neutral protamine hagedorn insulin","NE"
"2012-01-07928","2012","Valentine 2012 Diabet Med","19000","Insulin detemir VERSUS Neutral protamine hagedorn insulin IN Patients with type 1 diabetes with mild hypoglycaemia in Sweden","21951030","Patients with type 1 diabetes with mild hypoglycaemia in Sweden","Insulin detemir","Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.","Neutral protamine hagedorn insulin","NE"
"2012-01-07928","2012","Valentine 2012 Diabet Med","25000","Insulin detemir VERSUS Neutral protamine hagedorn insulin IN Patients with type 1 diabetes with mild hypoglycaemia in Finland","21951030","Patients with type 1 diabetes with mild hypoglycaemia in Finland","Insulin detemir","Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.","Neutral protamine hagedorn insulin","NE"
"2011-01-08205","2011","Valentine 2011 Clin Ther","12000","Liraglutide (1.8 mg, once daily) VERSUS Exenatide (10ug, twice daily) IN Patients with type II diabetes failing to improve with metformin and sulfonylurea in Switzerland","22018679","Patients with type II diabetes failing to improve with metformin and sulfonylurea in Switzerland","Liraglutide (1.8 mg, once daily)","Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.","Exenatide (10ug, twice daily)","NE"
"2011-01-08205","2011","Valentine 2011 Clin Ther","14000","Liraglutide (1.8 mg, once daily) VERSUS Exenatide (10ug, twice daily) IN Patients with type II diabetes failing to improve with metformin and sulfonylurea in Netherlands","22018679","Patients with type II diabetes failing to improve with metformin and sulfonylurea in Netherlands","Liraglutide (1.8 mg, once daily)","Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.","Exenatide (10ug, twice daily)","NE"
"2011-01-08205","2011","Valentine 2011 Clin Ther","15000","Liraglutide (1.8 mg, once daily) VERSUS Exenatide (10ug, twice daily) IN Patients with type II diabetes failing to improve with metformin and sulfonylurea in Austria","22018679","Patients with type II diabetes failing to improve with metformin and sulfonylurea in Austria","Liraglutide (1.8 mg, once daily)","Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.","Exenatide (10ug, twice daily)","NE"
"2017-01-24358","2017","Elsisi 2017 Value Health Reg Issues","2400","Sofosbuvir(SOF)+ledipasvir(LDV)+ribavirin (RBV) VERSUS Standard/Usual Care- Sofosbuvir(SOF)+pegylated interferonalfa(pegIFN)+ribavirin (RBV) IN Specific disease- Hepatitis  C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Noncirrhotic patients .","29073993","Specific disease- Hepatitis  C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Noncirrhotic patients .","Sofosbuvir(SOF)+ledipasvir(LDV)+ribavirin (RBV)","Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.","Standard/Usual Care- Sofosbuvir(SOF)+pegylated interferonalfa(pegIFN)+ribavirin (RBV)","NE"
"2017-01-24358","2017","Elsisi 2017 Value Health Reg Issues","Cost-Saving","Sofosbuvir(SOF) +daclatasvir (DCV) VERSUS Standard/Usual Care- Sofosbuvir(SOF)+pegylated interferonalfa(pegIFN)+ribavirin (RBV) IN Specific disease- Hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Noncirrhotic patients .","29073993","Specific disease- Hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Noncirrhotic patients .","Sofosbuvir(SOF) +daclatasvir (DCV)","Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.","Standard/Usual Care- Sofosbuvir(SOF)+pegylated interferonalfa(pegIFN)+ribavirin (RBV)","SE"
"2017-01-24358","2017","Elsisi 2017 Value Health Reg Issues","Cost-Saving","Sofosbuvir(SOF)+daclatasvir (DCV) VERSUS Standard/Usual Care- Sofosbuvir(SOF)+pegylated interferonalfa(pegIFN) +ribavirin (RBV) IN Specific disease- Hepatitis C ; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Cirrhotic patients .","29073993","Specific disease- Hepatitis C ; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Cirrhotic patients .","Sofosbuvir(SOF)+daclatasvir (DCV)","Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.","Standard/Usual Care- Sofosbuvir(SOF)+pegylated interferonalfa(pegIFN) +ribavirin (RBV)","SE"
"2017-01-24358","2017","Elsisi 2017 Value Health Reg Issues","Cost-Saving","Sofosbuvir(SOF)+ledipasvir(LDV)+ribavirin (RBV) VERSUS Standard/Usual Care- Sofosbuvir(SOF)+pegylated interferonalfa(pegIFN) +ribavirin (RBV) IN Specific disease- Hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Cirrhotic patients .","29073993","Specific disease- Hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Cirrhotic patients .","Sofosbuvir(SOF)+ledipasvir(LDV)+ribavirin (RBV)","Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.","Standard/Usual Care- Sofosbuvir(SOF)+pegylated interferonalfa(pegIFN) +ribavirin (RBV)","SE"
"2017-01-24358","2017","Elsisi 2017 Value Health Reg Issues","Dominated","Sofoasbuvir+Ribavirin VERSUS Standard/Usual Care- Sofoasbuvir+Pegylated interferon+Ribavirin IN Specific disease- Hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Cirrhotic patients .","29073993","Specific disease- Hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Cirrhotic patients .","Sofoasbuvir+Ribavirin","Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.","Standard/Usual Care- Sofoasbuvir+Pegylated interferon+Ribavirin","NW"
"2017-01-24358","2017","Elsisi 2017 Value Health Reg Issues","Dominated","Sofosbuvir(SOF)+ribavirin (RBV) VERSUS Standard/Usual Care- Sofosbuvir(SOF)+pegylated interferonalfa(pegIFN)+ribavirin (RBV) IN Specific disease- Hepatitis C ; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Noncirrhotic patients .","29073993","Specific disease- Hepatitis C ; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Egypt; Other- Noncirrhotic patients .","Sofosbuvir(SOF)+ribavirin (RBV)","Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.","Standard/Usual Care- Sofosbuvir(SOF)+pegylated interferonalfa(pegIFN)+ribavirin (RBV)","NW"
"2014-01-16998","2014","Obach 2014 Clin Infect Dis","2100","Treat F4 VERSUS No treatment IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","24510934","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","Treat F4","Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.","No treatment","NE"
"2014-01-16998","2014","Obach 2014 Clin Infect Dis","Dominated","No treatment VERSUS Treat immediately (F1) IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","24510934","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","No treatment","Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.","Treat immediately (F1)","NW"
"2014-01-16998","2014","Obach 2014 Clin Infect Dis","Dominated","No treatment VERSUS Treat immediately (F2) IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","24510934","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","No treatment","Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.","Treat immediately (F2)","NW"
"2014-01-16998","2014","Obach 2014 Clin Infect Dis","Dominated","No treatment VERSUS Treat immediately (F3) IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","24510934","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","No treatment","Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.","Treat immediately (F3)","NW"
"2014-01-16998","2014","Obach 2014 Clin Infect Dis","Dominated","Treat in stage F2 VERSUS Treat immediately (F1) IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","24510934","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","Treat in stage F2","Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.","Treat immediately (F1)","NW"
"2014-01-16998","2014","Obach 2014 Clin Infect Dis","Dominated","Wait until stage F3 to treat VERSUS Treat immediately (F1) IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","24510934","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","Wait until stage F3 to treat","Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.","Treat immediately (F1)","NW"
"2014-01-16998","2014","Obach 2014 Clin Infect Dis","Dominated","Wait until stage F3 to treat VERSUS Treat immediately (F2) IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","24510934","Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Egypt.","Wait until stage F3 to treat","Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.","Treat immediately (F2)","NW"
"2017-01-24682","2017","Vorno 2017 Vaccine","13000","Nonavalent Human papillomavirus vaccine + cervical cancer screening VERSUS Cervical cancer screening IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.","28899625","Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.","Nonavalent Human papillomavirus vaccine + cervical cancer screening","Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.","Cervical cancer screening","NE"
"2017-01-24682","2017","Vorno 2017 Vaccine","16000","Bivalent Human papillomavirus vaccine + cervical cancer screening VERSUS Cervical cancer screening IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.","28899625","Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.","Bivalent Human papillomavirus vaccine + cervical cancer screening","Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.","Cervical cancer screening","NE"
"2017-01-24682","2017","Vorno 2017 Vaccine","16000","Quadrivalent Human papillomavirus vaccine + cervical cancer screening VERSUS Placebo IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.","28899625","Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.","Quadrivalent Human papillomavirus vaccine + cervical cancer screening","Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.","Placebo","NE"
"2013-01-11597","2013","Uuskula 2013 BMC Infect Dis","7600","Routine vaccination VERSUS None IN Healthy; Age- Unknown; Gender- Female; Country- estonia.","23819789","Healthy; Age- Unknown; Gender- Female; Country- estonia.","Routine vaccination","The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia.","None","NE"
"2018-01-27009","2018","Soini 2018 Clinicoecon Outcomes Res","120000","Proposed osteoporosis management, pathway A  VERSUS Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed) IN Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","29881300","Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","Proposed osteoporosis management, pathway A","Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management.","Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed)","SW"
"2018-01-27009","2018","Soini 2018 Clinicoecon Outcomes Res","150000","Proposed osteoporosis management, pathway A  VERSUS Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed) IN Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","29881300","Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","Proposed osteoporosis management, pathway A","Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management.","Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed)","SW"
"2018-01-27009","2018","Soini 2018 Clinicoecon Outcomes Res","360000","Proposed osteoporosis management, pathway A VERSUS Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed) IN Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","29881300","Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","Proposed osteoporosis management, pathway A","Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management.","Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed)","SE"
"2018-01-27009","2018","Soini 2018 Clinicoecon Outcomes Res","62000","Proposed osteoporosis management, pathway A  VERSUS Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed) IN Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","29881300","Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","Proposed osteoporosis management, pathway A","Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management.","Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed)","SW"
"2018-01-27009","2018","Soini 2018 Clinicoecon Outcomes Res","Cost-Saving","Proposed osteoporosis management, pathway B  VERSUS Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed) IN Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","29881300","Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","Proposed osteoporosis management, pathway B","Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management.","Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed)","SE"
"2018-01-27009","2018","Soini 2018 Clinicoecon Outcomes Res","Cost-Saving","Proposed osteoporosis management, pathway B VERSUS Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed) IN Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","29881300","Specific disease- Osteoporosis ; Age- >=65 years; Gender- Female; Country- Finland.","Proposed osteoporosis management, pathway B","Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management.","Standard/Usual Care- Conventional osteoporosis management (FRAX -> DXA-if-needed -> FPT-if-needed)","SE"
"2017-01-25198","2017","Poston 2017","560000","Dietary and physical activity intervention VERSUS Standard/Usual Care- Routine care  IN Specific disease- Gestational diabetes mellitus; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- United Kingdom (UK).","28671801","Specific disease- Gestational diabetes mellitus; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- United Kingdom (UK).","Dietary and physical activity intervention"," ","Standard/Usual Care- Routine care","NE"
"2017-01-24530","2017","Soini 2017 Adv Ther","Cost-Saving","Certolizumab pegol (CZP) VERSUS Standard/Usual Care- Disease-modifying antirheumatic drugs (bDMARDs; abatacept, adalimumab, certolizumab pegol (CZP), etanercept, golimumab, infliximab, tocilizumab) IN Specific disease- Rheumatoid arthritis (RA); Age- Adult; Gender- Both; Country- Finland; Other- Moderate-to-severe disease after inadequate response to a conventional disease- modifying antirheumatic drug (cDMARD).","28975568","Specific disease- Rheumatoid arthritis (RA); Age- Adult; Gender- Both; Country- Finland; Other- Moderate-to-severe disease after inadequate response to a conventional disease- modifying antirheumatic drug (cDMARD).","Certolizumab pegol (CZP)","Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing  Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.","Standard/Usual Care- Disease-modifying antirheumatic drugs (bDMARDs; abatacept, adalimumab, certolizumab pegol (CZP), etanercept, golimumab, infliximab, tocilizumab)","SE"
"2017-01-23772","2017","Soini 2017 Clin Ther","110000","dimethyl fumarate VERSUS Teriflunomide IN Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","28209373","Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","dimethyl fumarate","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Teriflunomide","NE"
"2017-01-23772","2017","Soini 2017 Clin Ther","34000","Best supportive care VERSUS Teriflunomide IN Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","28209373","Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","Best supportive care","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Teriflunomide","SW"
"2017-01-23772","2017","Soini 2017 Clin Ther","34000","Teriflunomide VERSUS Standard/Usual Care- Best supportive care IN Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","28209373","Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","Teriflunomide","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Standard/Usual Care- Best supportive care","NE"
"2017-01-23772","2017","Soini 2017 Clin Ther","340000","Intramuscular Interferon [IFN]-Ã1a VERSUS Standard/Usual Care- Best supportive care IN Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","28209373","Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","Intramuscular Interferon [IFN]-Ã1a","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Standard/Usual Care- Best supportive care","NE"
"2017-01-23772","2017","Soini 2017 Clin Ther","350000","Glatiramer acetate VERSUS Standard/Usual Care- best supportive care IN Specific disease- relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","28209373","Specific disease- relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","Glatiramer acetate","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Standard/Usual Care- best supportive care","NE"
"2017-01-23772","2017","Soini 2017 Clin Ther","48000","Dimethyl fumarate VERSUS Standard/Usual Care- Best supportive care IN Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Unknown; Gender- Both; Country- Finland.","28209373","Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Unknown; Gender- Both; Country- Finland.","Dimethyl fumarate","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Standard/Usual Care- Best supportive care","NE"
"2017-01-23772","2017","Soini 2017 Clin Ther","81000","interferon [IFN]-Ã1a VERSUS Standard/Usual Care- Best supportive care IN Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","28209373","Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","interferon [IFN]-Ã1a","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Standard/Usual Care- Best supportive care","NE"
"2017-01-23772","2017","Soini 2017 Clin Ther","Dominated","Glatiramer acetate VERSUS Teriflunomide IN Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","28209373","Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","Glatiramer acetate","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Teriflunomide","NW"
"2017-01-23772","2017","Soini 2017 Clin Ther","Dominated","Intramuscular Interferon [IFN]-Ã1a VERSUS Teriflunomide IN Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","28209373","Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","Intramuscular Interferon [IFN]-Ã1a","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Teriflunomide","NW"
"2017-01-23772","2017","Soini 2017 Clin Ther","Dominated","Subcutaneous Interferon (IFN) -Ã1a VERSUS Teriflunomide IN Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","28209373","Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","Subcutaneous Interferon (IFN) -Ã1a","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Teriflunomide","NW"
"2017-01-23772","2017","Soini 2017 Clin Ther","Dominated","Subcutaneous Interferon (IFN)-Ã1b VERSUS Standard/Usual Care- Best supportive care IN Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","28209373","Specific disease- Relapsing-Remitting Multiple Sclerosis; Age- Adult; Gender- Both; Country- Finland.","Subcutaneous Interferon (IFN)-Ã1b","Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.","Standard/Usual Care- Best supportive care","NW"
"2016-01-22664","2016","Joensuu 2016 Rheumatology (Oxford)","1.4e+006","biological disease-modifying anti-rheumatic drugs (bDMARDs): :Infliximab, Abatacept, Rituximab, Tocilizumab VERSUS conventional synthetic DMARDs (csDMARDs) IN Specific disease- rheumatoid arthritis; Age- Adult; Gender- Both; Country- Finland.","27354689","Specific disease- rheumatoid arthritis; Age- Adult; Gender- Both; Country- Finland.","biological disease-modifying anti-rheumatic drugs (bDMARDs): :Infliximab, Abatacept, Rituximab, Tocilizumab","Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.","conventional synthetic DMARDs (csDMARDs)","NE"
"2016-01-22217","2016","Hallinen 2016 Springerplus","2600","Apixiban VERSUS Standard/Usual Care- Warfarin IN Specific disease- Atrial Fibrillation (AF) Associated Thromboembolic Complications; Age- Adult; Gender- Both; Country- Finland.","27588247","Specific disease- Atrial Fibrillation (AF) Associated Thromboembolic Complications; Age- Adult; Gender- Both; Country- Finland.","Apixiban","Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients.","Standard/Usual Care- Warfarin","NE"
"2016-01-21931","2016","Vottonen 2016 Acta Ophthalmol","1.1e+006","Bevacizumab PRN (pro re nata) VERSUS Standard/Usual Care- Afllibercept IN Specific disease- Wet age-related macular degeneration (AMD); Age- Adult; Gender- Both; Country- Finland.","27481048","Specific disease- Wet age-related macular degeneration (AMD); Age- Adult; Gender- Both; Country- Finland.","Bevacizumab PRN (pro re nata)","Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.","Standard/Usual Care- Afllibercept","SW"
"2016-01-21931","2016","Vottonen 2016 Acta Ophthalmol","2.1e+006","Bevacizumab monthly VERSUS Standard/Usual Care- Afllibercept IN Specific disease- Wet age-related macular degeneration (wAMD); Age- Adult; Gender- Both; Country- Finland.","27481048","Specific disease- Wet age-related macular degeneration (wAMD); Age- Adult; Gender- Both; Country- Finland.","Bevacizumab monthly","Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.","Standard/Usual Care- Afllibercept","SW"
"2016-01-21931","2016","Vottonen 2016 Acta Ophthalmol","Dominated","Ranibizumab monthly VERSUS Standard/Usual Care- Afllibercept IN Specific disease- Wet age-related macular degeneration (AMD); Age- Adult; Gender- Both; Country- Finland.","27481048","Specific disease- Wet age-related macular degeneration (AMD); Age- Adult; Gender- Both; Country- Finland.","Ranibizumab monthly","Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.","Standard/Usual Care- Afllibercept","NW"
"2016-01-21931","2016","Vottonen 2016 Acta Ophthalmol","Dominated","Ranibizumab PRN (pro re nata) VERSUS Standard/Usual Care- Afllibercept IN Specific disease- Wet age-related macular degeneration (AMD); Age- Adult; Gender- Both; Country- Finland.","27481048","Specific disease- Wet age-related macular degeneration (AMD); Age- Adult; Gender- Both; Country- Finland.","Ranibizumab PRN (pro re nata)","Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.","Standard/Usual Care- Afllibercept","NW"
"2016-01-21084","2016","Einarson 2016 J Med Econ","Dominated","Aripiprazole VERSUS Paliperidone IN Specific disease- Acutely relapsed chronic schizophrenia; Age- Adult; Gender- Both; Country- Finland; Other- Patients started hospitalized in relapse. Those who responded cointinued treatment while those who did not were switched to secondary drugs.","26414966","Specific disease- Acutely relapsed chronic schizophrenia; Age- Adult; Gender- Both; Country- Finland; Other- Patients started hospitalized in relapse. Those who responded cointinued treatment while those who did not were switched to secondary drugs.","Aripiprazole","Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.","Paliperidone","NW"
"2016-01-21084","2016","Einarson 2016 J Med Econ","Dominated","Olanzapine VERSUS Paliperidone IN Specific disease- Acutely relapsed chronic schizophrenia; Age- Adult; Gender- Both; Country- Finland; Other- Patients started hospitalized in relapse. Those who responded cointinued treatment while those who did not were switched to secondary drugs.","26414966","Specific disease- Acutely relapsed chronic schizophrenia; Age- Adult; Gender- Both; Country- Finland; Other- Patients started hospitalized in relapse. Those who responded cointinued treatment while those who did not were switched to secondary drugs.","Olanzapine","Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.","Paliperidone","NW"
"2016-01-21084","2016","Einarson 2016 J Med Econ","Dominated","Risperidone VERSUS Paliperidone IN Specific disease- Acutely relapsed chronic schizophrenia; Age- Adult; Gender- Both; Country- Finland; Other- Patients started hospitalized in relapse. Those who responded cointinued treatment while those who did not were switched to secondary drugs.","26414966","Specific disease- Acutely relapsed chronic schizophrenia; Age- Adult; Gender- Both; Country- Finland; Other- Patients started hospitalized in relapse. Those who responded cointinued treatment while those who did not were switched to secondary drugs.","Risperidone","Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.","Paliperidone","NW"
"2016-01-19897","2016","Soini 2016 Clin Ther","120000","Ofatamumab IV + Chlorambucil po VERSUS Chlorambucil alone p o (0.5/kg x2) IN Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","26970696","Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","Ofatamumab IV + Chlorambucil po","Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.","Chlorambucil alone p o (0.5/kg x2)","NE"
"2016-01-19897","2016","Soini 2016 Clin Ther","16000","Obinutuzumab IV + chlorambucil po VERSUS Rituximab IV (cycle 1, 375/m2 for 2 d; later, 500/m2 for 1 d) + Bendamustine IV (90/m2 x 2, 2 d/cycle) IN Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","26970696","Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","Obinutuzumab IV + chlorambucil po","Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.","Rituximab IV (cycle 1, 375/m2 for 2 d; later, 500/m2 for 1 d) + Bendamustine IV (90/m2 x 2, 2 d/cycle)","NE"
"2016-01-19897","2016","Soini 2016 Clin Ther","22000","Obinutuzumab IV + chlorambucil po VERSUS Ofatamumab IV ( cycle 1, 1300 for 2 d; later,, 1000 for 1 d) + Chlorambucil po (10/m2 x 7) IN Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","26970696","Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","Obinutuzumab IV + chlorambucil po","Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.","Ofatamumab IV ( cycle 1, 1300 for 2 d; later,, 1000 for 1 d) + Chlorambucil po (10/m2 x 7)","NE"
"2016-01-19897","2016","Soini 2016 Clin Ther","28000","Obinutuzumab IV + chlorambucil po VERSUS Rituximab IV (cycle 1, 375/m2 for 2 d; later, 500/m2 for 1 d) + chlorambucil po (0.5/kg x 2) IN Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","26970696","Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","Obinutuzumab IV + chlorambucil po","Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.","Rituximab IV (cycle 1, 375/m2 for 2 d; later, 500/m2 for 1 d) + chlorambucil po (0.5/kg x 2)","NE"
"2016-01-19897","2016","Soini 2016 Clin Ther","32000","Obinutuzumab IV + chlorambucil po VERSUS Chlorambucil alone p o (0.5/kg x2) IN Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","26970696","Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","Obinutuzumab IV + chlorambucil po","Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.","Chlorambucil alone p o (0.5/kg x2)","NE"
"2016-01-19897","2016","Soini 2016 Clin Ther","62000","Rituximab IV + chlorambucil po VERSUS Chlorambucil alone p o (0.5/kg x2) IN Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","26970696","Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","Rituximab IV + chlorambucil po","Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.","Chlorambucil alone p o (0.5/kg x2)","NE"
"2016-01-19897","2016","Soini 2016 Clin Ther","84000","Rituximab IV + Bendamustine IV VERSUS Chlorambucil alone p o (0.5/kg x2) IN Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","26970696","Specific disease- Chronic lymphocytic Leukemia previously untreated; Age- >=65 years; Gender- Both; Country- Finland; Other- 50% male, Distribution by Binet stages A, B, and C were 22%, 42%, and 36%, respectively.  Mean weight and height were 73.7 kg, and 166.7 cm.  The mean body surface area was 1.8 m2..","Rituximab IV + Bendamustine IV","Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.","Chlorambucil alone p o (0.5/kg x2)","NE"
"2015-01-18849","2015","Aarnio 2015 Atherosclerosis","62000","Statin therapy VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Male; Country- Finland.","25618032","Healthy; Age- 41 to 64 years; Gender- Male; Country- Finland.","Statin therapy","Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register.","None","NE"
"2015-01-18849","2015","Aarnio 2015 Atherosclerosis","72000","Statin therapy VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Finland.","25618032","Healthy; Age- 41 to 64 years; Gender- Female; Country- Finland.","Statin therapy","Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register.","None","NE"
"2015-01-16546","2015","Sabale 2015 Prim Care Diabetes","7800","Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin VERSUS Oral sulfonylurea (SU) added to metformin IN Specific disease- Type 2 diabetes mellitus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Finland; Other- Average duration of diabetes is 6 years and 18% are smokers.","24840612","Specific disease- Type 2 diabetes mellitus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Finland; Other- Average duration of diabetes is 6 years and 18% are smokers.","Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin","Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.","Oral sulfonylurea (SU) added to metformin","NE"
"2012-01-09124","2012","Malmivaara                       2012 Eur J Neurol","2600","Intensive healthcare resource utilization (neurosurgical treatment) VERSUS None IN Patients with aneurysmal subarachnoid haemorrhage (SAH) at Helsinki Department of Neurosurgery in Finland","22591408","Patients with aneurysmal subarachnoid haemorrhage (SAH) at Helsinki Department of Neurosurgery in Finland","Intensive healthcare resource utilization (neurosurgical treatment)","Health-related quality of life and cost-effectiveness of treatment in subarachnoid haemorrhage.","None","NE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","2800","Tocilizumab plus methotrexate VERSUS Adalimumab plus methotrexate IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","Tocilizumab plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Adalimumab plus methotrexate","NE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","29000","Tocilizumab plus methotrexate VERSUS Methotrexate alone IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","Tocilizumab plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Methotrexate alone","NE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","29000","Tocilizumab plus methotrexate VERSUS Methotrexate alone IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","Tocilizumab plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Methotrexate alone","NE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","32000","Etanercept plus methotrexate VERSUS Methotrexate alone IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","Etanercept plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Methotrexate alone","NE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","32000","Etanercept plus methotrexate VERSUS Methotrexate alone IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","Etanercept plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Methotrexate alone","NE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","33000","Adalimumab plus methotrexate VERSUS Methotrexate alone IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","Adalimumab plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Methotrexate alone","NE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","33000","Adalimumab plus methotrexate VERSUS Methotrexate alone IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","Adalimumab plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Methotrexate alone","NE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","4200","Tocilizumab plus methotrexate VERSUS Etanercept plus methotrexate IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","Tocilizumab plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Etanercept plus methotrexate","NE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","9300","Tocilizumab plus methotrexate VERSUS Etanercept plus methotrexate IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","Tocilizumab plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Etanercept plus methotrexate","NE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","Cost-Saving","Tocilizumab plus methotrexate VERSUS Adalimumab plus methotrexate IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","Tocilizumab plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Adalimumab plus methotrexate","SE"
"2012-01-08421","2012","Soini                            2012 J Med Econ","Dominated","Adalimumab plus methotrexate VERSUS Etanercept plus methotrexate IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: healthcare perspective","Adalimumab plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Etanercept plus methotrexate","NW"
"2012-01-08421","2012","Soini                            2012 J Med Econ","Dominated","Adalimumab plus methotrexate VERSUS Etanercept plus methotrexate IN Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","22168785","Patients with moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs: societal perspective","Adalimumab plus methotrexate","Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.","Etanercept plus methotrexate","NW"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","1.4e+006","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Lower 50% on ADAS-Cog.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Lower 50% on ADAS-Cog.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","110000","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living with someone.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living with someone.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","160000","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living in a care home.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living in a care home.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","17000","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living alone.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living alone.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","SW"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","2.7e+006","Maintenance cognitive stimulation therapy VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living with someone.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living with someone.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","26000","Maintenance cognitive stimulation therapy for those in upper 50% on ADAS-Cog VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Upper 50% on ADAS-Cog.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Upper 50% on ADAS-Cog.","Maintenance cognitive stimulation therapy for those in upper 50% on ADAS-Cog","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","410000","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living with someone.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living with someone.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","420000","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Upper 50% on ADAS-Cog.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Upper 50% on ADAS-Cog.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","510000","Maintenance cognitive stimulation therapy VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Lower 50% on ADAS-Cog.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Lower 50% on ADAS-Cog.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","540000","Maintenance cognitive stimulation  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living with someone.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living with someone.","Maintenance cognitive stimulation","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","55000","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Upper 50% on ADAS-Cog.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Upper 50% on ADAS-Cog.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","83000","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Upper 50% on ADAS-Cog.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Upper 50% on ADAS-Cog.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","Cost-Saving","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living alone.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living alone.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","SE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","Cost-Saving","Maintenance cognitive stimulation therapy VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living alone.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living alone.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","SE"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","Dominated","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living in a care home.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Living in a care home.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NW"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","Dominated","Maintenance cognitive stimulation therapy  VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Lower 50% on ADAS-Cog.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Lower 50% on ADAS-Cog.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NW"
"2018-01-27758","2018","Brown 2018 Aging Ment Health","Dominated","Maintenance cognitive stimulation therapy VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Lower 50% on ADAS-Cog.","29528689","Specific disease- Dementia; Age- Adult; Gender- Both; Country- United Kingdom; Other- Lower 50% on ADAS-Cog.","Maintenance cognitive stimulation therapy","A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.","Standard/Usual Care- Treatment as usual","NW"
"2018-01-27712","2018","Maunoury 2018 PLoS One","18000","Elbasvir/grazoprevir regimen VERSUS None IN Specific disease- Hepatitis C infection; Age- Adult; Gender- Both; Country- France; Other- Severe and end stage renal disease.","29543897","Specific disease- Hepatitis C infection; Age- Adult; Gender- Both; Country- France; Other- Severe and end stage renal disease.","Elbasvir/grazoprevir regimen","Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.","None","NE"
"2018-01-27464","2018","Cousien 2018 J Viral Hepat","120000","Improved harm reduction and cascade of care for Hepatitis C virus; treatment initiated at F0 VERSUS Improved testing and linkage to care for HCV; treatment was initiated from F0 IN Specific disease- Hepatitis C virus; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France.","29660211","Specific disease- Hepatitis C virus; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France.","Improved harm reduction and cascade of care for Hepatitis C virus; treatment initiated at F0","Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.","Improved testing and linkage to care for HCV; treatment was initiated from F0","NE"
"2018-01-27464","2018","Cousien 2018 J Viral Hepat","6200","Improved testing/linkage to care for Hepatitis C virus with treatment initiation from F0 VERSUS Standard/Usual Care- Current practice IN Specific disease- Hepatitis C virus; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France.","29660211","Specific disease- Hepatitis C virus; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France.","Improved testing/linkage to care for Hepatitis C virus with treatment initiation from F0","Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.","Standard/Usual Care- Current practice","NE"
"2018-01-27464","2018","Cousien 2018 J Viral Hepat","63000","Improved risk reduction interventions for Hepatitis C virus VERSUS Standard/Usual Care- Current practice IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France; Other- Injected drugs in the last month; susceptible to Hepatitis C.","29660211","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France; Other- Injected drugs in the last month; susceptible to Hepatitis C.","Improved risk reduction interventions for Hepatitis C virus","Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.","Standard/Usual Care- Current practice","NE"
"2018-01-27464","2018","Cousien 2018 J Viral Hepat","7100","Improved testing/linkage to care for Hepatitis C virus VERSUS Standard/Usual Care- Current practice IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France; Other- Injected drugs in the last month; susceptible to Hepatitis C.","29660211","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France; Other- Injected drugs in the last month; susceptible to Hepatitis C.","Improved testing/linkage to care for Hepatitis C virus","Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.","Standard/Usual Care- Current practice","NE"
"2018-01-27464","2018","Cousien 2018 J Viral Hepat","8300","Treatment initiation for Hepatitis C virus at fibrosis >=F0 VERSUS Standard/Usual Care- Current practice IN Specific disease- Hepatitis C virus; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France; Other- Fibrosis >=F0.","29660211","Specific disease- Hepatitis C virus; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France; Other- Fibrosis >=F0.","Treatment initiation for Hepatitis C virus at fibrosis >=F0","Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.","Standard/Usual Care- Current practice","NE"
"2018-01-27339","2018","Paix 2018 Radiother Oncol","Cost-Saving","Stereotactic body radiotherapy VERSUS Standard/Usual Care- Lobectomy IN Specific disease- Lung cancer; Age- >=65 years; Gender- Both; Country- France.","29706462","Specific disease- Lung cancer; Age- >=65 years; Gender- Both; Country- France.","Stereotactic body radiotherapy","Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.","Standard/Usual Care- Lobectomy","SE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","110000","Quadrivalent influenza vaccines VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","29708843","Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","110000","Quadrivalent influenza vaccines VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Italy; Other- At risk of  seasonal influenza.","29708843","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Italy; Other- At risk of  seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","130000","Quadrivalent influenza vaccines VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","29708843","Healthy; Age- 0 to 18 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","170000","Quadrivalent influenza vaccines VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Italy; Other- At risk of  seasonal influenza.","29708843","Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Italy; Other- At risk of  seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","22000","Quadrivalent influenza vaccines  VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- >=65 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","29708843","Healthy; Age- >=65 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","22000","Quadrivalent influenza vaccines VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- >=65 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","29708843","Healthy; Age- >=65 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","24000","Quadrivalent influenza vaccines VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","29708843","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","27000","Quadrivalent influenza vaccines VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","29708843","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","36000","Quadrivalent influenza vaccines  VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","29708843","Healthy; Age- 41 to 64 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","59000","Quadrivalent influenza vaccines VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Italy; Other- At risk of  seasonal influenza.","29708843","Healthy; Age- 41 to 64 years; Gender- Both; Country- Italy; Other- At risk of  seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27331","2018","Mennini 2018 Hum Vaccin Immunother","66000","Quadrivalent influenza vaccines VERSUS Standard/Usual Care- Trivalent influenza vaccines IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","29708843","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Italy; Other- At risk of seasonal influenza.","Quadrivalent influenza vaccines","Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.","Standard/Usual Care- Trivalent influenza vaccines","NE"
"2018-01-27242","2018","Bulsei 2018 Respir Res","88000","First-Line Coil Treatment VERSUS Second-Coil Treatment IN Specific disease- Emphysema; Age- Adult; Gender- Both; Country- France.","29743071","Specific disease- Emphysema; Age- Adult; Gender- Both; Country- France.","First-Line Coil Treatment","Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study).","Second-Coil Treatment","NE"
"2018-01-26216","2018","Deuffic-Burban 2018 J Hepatol","170000","Screening all individuals aged 18-80 VERSUS Screening high risk individuals and all individuals aged 40-80 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- France.","30227916","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- France.","Screening all individuals aged 18-80","Assessing the cost-effectiveness of hepatitis C screening strategies in France.","Screening high risk individuals and all individuals aged 40-80","NE"
"2018-01-26216","2018","Deuffic-Burban 2018 J Hepatol","25000","Screening high risk individuals + all individuals aged 40-59 + all men aged 18-59 VERSUS Screening high-risk individuals IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France; Other- High-risk.","30227916","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- France; Other- High-risk.","Screening high risk individuals + all individuals aged 40-59 + all men aged 18-59","Assessing the cost-effectiveness of hepatitis C screening strategies in France.","Screening high-risk individuals","NE"
"2018-01-26216","2018","Deuffic-Burban 2018 J Hepatol","25000","Screening high risk individuals + all individuals aged 40-80 VERSUS Screening high-risk individuals IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- France.","30227916","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- France.","Screening high risk individuals + all individuals aged 40-80","Assessing the cost-effectiveness of hepatitis C screening strategies in France.","Screening high-risk individuals","NE"
"2018-01-25585","2018","N'Diaye 2018 Vaccine","23000","Routine vaccination against cytomegalovirus of all 14-year-old female adolescents VERSUS Routine screening. Vaccination against cytomegalovirus for seronegative only. IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- France.","29397227","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- France.","Routine vaccination against cytomegalovirus of all 14-year-old female adolescents","Cost-effectiveness of vaccination against cytomegalovirus (CMV) in adolescent girls to prevent infections in pregnant women living in France.","Routine screening. Vaccination against cytomegalovirus for seronegative only.","NE"
"2018-01-25585","2018","N'Diaye 2018 Vaccine","8500","Routine screening. Vaccination against cytomegalovirus for seronegative only.  VERSUS Standard/Usual Care- No vaccination (current practice) IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- France; Other- Pregnant women.","29397227","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- France; Other- Pregnant women.","Routine screening. Vaccination against cytomegalovirus for seronegative only.","Cost-effectiveness of vaccination against cytomegalovirus (CMV) in adolescent girls to prevent infections in pregnant women living in France.","Standard/Usual Care- No vaccination (current practice)","NE"
"2017-01-25762","2017","Pages 2017 Value Health","110000","Empirical echinocandin with polymerase chain reaction (PCR) detection of C. krusei and C. glabrata VERSUS Empirical fluconazole with polymerase chain reaction detection of all Candida species IN Specific disease- Fungal Peritonitis; Age- Adult; Gender- Both; Country- France; Other- Patients in intensive care units .","29241891","Specific disease- Fungal Peritonitis; Age- Adult; Gender- Both; Country- France; Other- Patients in intensive care units .","Empirical echinocandin with polymerase chain reaction (PCR) detection of C. krusei and C. glabrata","Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit.","Empirical fluconazole with polymerase chain reaction detection of all Candida species","NE"
"2017-01-25762","2017","Pages 2017 Value Health","120000","Empirical echinocandin with polymerase chain reaction (PCR) detection of all Candida species VERSUS Empirical fluconazole with polymerase chain reaction detection of all Candida species IN Specific disease- Fungal Peritonitis; Age- Adult; Gender- Both; Country- France; Other- Patients in intensive care units .","29241891","Specific disease- Fungal Peritonitis; Age- Adult; Gender- Both; Country- France; Other- Patients in intensive care units .","Empirical echinocandin with polymerase chain reaction (PCR) detection of all Candida species","Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit.","Empirical fluconazole with polymerase chain reaction detection of all Candida species","NE"
"2017-01-25762","2017","Pages 2017 Value Health","47000","Empirical fluconazole with polymerase chain reaction (PCR) detection of all Candida species VERSUS Empirical fluconazole without polymerase chain reaction IN Specific disease- Fungal Peritonitis; Age- Adult; Gender- Both; Country- France; Other- Patients in intensive care units .","29241891","Specific disease- Fungal Peritonitis; Age- Adult; Gender- Both; Country- France; Other- Patients in intensive care units .","Empirical fluconazole with polymerase chain reaction (PCR) detection of all Candida species","Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit.","Empirical fluconazole without polymerase chain reaction","NE"
"2017-01-25762","2017","Pages 2017 Value Health","Dominated","Empirical echinocandin without polymerase chain reaction (PCR)  VERSUS Empirical echinocandin with polymerase chain reaction detection of C. krusei and C. glabrata IN Specific disease- Fungal Peritonitis; Age- Adult; Gender- Both; Country- France; Other- Patients in intensive care units.","29241891","Specific disease- Fungal Peritonitis; Age- Adult; Gender- Both; Country- France; Other- Patients in intensive care units.","Empirical echinocandin without polymerase chain reaction (PCR)","Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit.","Empirical echinocandin with polymerase chain reaction detection of C. krusei and C. glabrata","NW"
"2017-01-25762","2017","Pages 2017 Value Health","Dominated","Empirical fluconazole with polymerase chain reaction (PCR) detection of C. krusei and C. glabrata VERSUS Empirical fluconazole with polymerase chain reaction detection of all Candida species IN Specific disease- Fungal Peritonitis; Age- Adult; Gender- Both; Country- France; Other- Patients in intensive care units.","29241891","Specific disease- Fungal Peritonitis; Age- Adult; Gender- Both; Country- France; Other- Patients in intensive care units.","Empirical fluconazole with polymerase chain reaction (PCR) detection of C. krusei and C. glabrata","Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit.","Empirical fluconazole with polymerase chain reaction detection of all Candida species","NW"
"2017-01-25525","2017","Bowman 2017 Arthritis Rheumatol","Dominated","Rituximab VERSUS Placebo IN Specific disease- Primary Sjogrens Syndrome; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom (UK).","28296257","Specific disease- Primary Sjogrens Syndrome; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom (UK).","Rituximab","Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren''s Syndrome.","Placebo","NW"
"2017-01-25051","2017","Kondili 2017 Hepatology","12000","Treating all patients (Universal) VERSUS Standard/Usual Care- Treating only prioritized patients.  IN Specific disease- Hepatitis C Virus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","28741307","Specific disease- Hepatitis C Virus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","Treating all patients (Universal)","Modeling cost-effectiveness and health gains of a ""universal"" versus ""prioritized"" hepatitis C virus treatment policy in a real-life cohort.","Standard/Usual Care- Treating only prioritized patients.","NE"
"2017-01-25049","2017","Tadmouri 2017 ESC Heart Fail","170000","Left Ventricular Assist Device (deterministic analysis) VERSUS Standard/Usual Care- No Left Ventricular Assist Device. IN Specific disease- End-Stage Heart Failure; Age- Adult; Gender- Both; Country- France.","28741873","Specific disease- End-Stage Heart Failure; Age- Adult; Gender- Both; Country- France.","Left Ventricular Assist Device (deterministic analysis)","Cost-effectiveness of left ventricular assist devices for patients with end-stage heart failure: analysis of the French hospital discharge database.","Standard/Usual Care- No Left Ventricular Assist Device.","NE"
"2017-01-25049","2017","Tadmouri 2017 ESC Heart Fail","180000","Left Ventricular Assist Device (probabilistic analysis) VERSUS Standard/Usual Care- No Left Ventricular Assist Device. IN Specific disease- End-Stage Heart Failure; Age- Adult; Gender- Both; Country- France.","28741873","Specific disease- End-Stage Heart Failure; Age- Adult; Gender- Both; Country- France.","Left Ventricular Assist Device (probabilistic analysis)","Cost-effectiveness of left ventricular assist devices for patients with end-stage heart failure: analysis of the French hospital discharge database.","Standard/Usual Care- No Left Ventricular Assist Device.","NE"
"2017-01-25048","2017","Pialoux 2017 Expert Rev Pharmacoecon Outcomes Res","8200","Dolutegravir in combination with abacavir and lamivudine VERSUS Standard/Usual Care- Efavirenz IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","28741965","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","Dolutegravir in combination with abacavir and lamivudine","Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.","Standard/Usual Care- Efavirenz","NE"
"2017-01-25048","2017","Pialoux 2017 Expert Rev Pharmacoecon Outcomes Res","Cost-Saving","Dolutegravir in combination with abacavir and lamivudine VERSUS Standard/Usual Care- Atazanavir/Ritonavir IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","28741965","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","Dolutegravir in combination with abacavir and lamivudine","Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.","Standard/Usual Care- Atazanavir/Ritonavir","SE"
"2017-01-25048","2017","Pialoux 2017 Expert Rev Pharmacoecon Outcomes Res","Cost-Saving","Dolutegravir in combination with abacavir and lamivudine VERSUS Standard/Usual Care- Darunavir/Ritonavir IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","28741965","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","Dolutegravir in combination with abacavir and lamivudine","Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.","Standard/Usual Care- Darunavir/Ritonavir","SE"
"2017-01-25048","2017","Pialoux 2017 Expert Rev Pharmacoecon Outcomes Res","Cost-Saving","Dolutegravir in combination with abacavir and lamivudine VERSUS Standard/Usual Care- Elvitegravir/Cobicistat IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","28741965","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","Dolutegravir in combination with abacavir and lamivudine","Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.","Standard/Usual Care- Elvitegravir/Cobicistat","SE"
"2017-01-25048","2017","Pialoux 2017 Expert Rev Pharmacoecon Outcomes Res","Cost-Saving","Dolutegravir in combination with abacavir and lamivudine VERSUS Standard/Usual Care- Lopinavir/Ritonavir IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- HIV Infected adults and adolescents.","28741965","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- HIV Infected adults and adolescents.","Dolutegravir in combination with abacavir and lamivudine","Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.","Standard/Usual Care- Lopinavir/Ritonavir","SE"
"2017-01-25048","2017","Pialoux 2017 Expert Rev Pharmacoecon Outcomes Res","Cost-Saving","Dolutegravir in combination with abacavir and lamivudine VERSUS Standard/Usual Care- Raltegravir IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","28741965","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","Dolutegravir in combination with abacavir and lamivudine","Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.","Standard/Usual Care- Raltegravir","SE"
"2017-01-25048","2017","Pialoux 2017 Expert Rev Pharmacoecon Outcomes Res","Cost-Saving","Dolutegravir in combination with abacavir and lamivudine VERSUS Standard/Usual Care- Rilpivirine IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","28741965","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- France; Other- Treatment-naive.","Dolutegravir in combination with abacavir and lamivudine","Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.","Standard/Usual Care- Rilpivirine","SE"
"2017-01-25000","2017","Restelli 2017 BMJ Open","74000","Netupitant + palonosetron VERSUS Aprepitant + ondasetron IN Specific disease- Cancer; Age- Adult; Gender- Both; Country- Italy; Other- Receiving highly emetogenic chemotherapy.","28765126","Specific disease- Cancer; Age- Adult; Gender- Both; Country- Italy; Other- Receiving highly emetogenic chemotherapy.","Netupitant + palonosetron","Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy.","Aprepitant + ondasetron"," "
"2017-01-24767","2017","Taipale 2017 Clinicoecon Outcomes Res","120000","Pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 - pemetrexed 500 mg/m2 VERSUS Pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 - Best Supportive Care IN Specific disease- Nonsquamous non-small-cell lung cancer; Age- Adult; Gender- Both; Country- France.","28860832","Specific disease- Nonsquamous non-small-cell lung cancer; Age- Adult; Gender- Both; Country- France.","Pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 - pemetrexed 500 mg/m2","A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.","Pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 - Best Supportive Care","NE"
"2017-01-25353","2017","Gourzoulidis 2017 Clin Drug Investig","230","Rivaroxaban  VERSUS Standard/Usual Care- Enoxaparin/Vitamin K antagonist IN Specific disease- Pulmonary Embolism; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece; Other- Patients admitted to hospital with symptomatic venous thromboembolism event.","28608312","Specific disease- Pulmonary Embolism; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece; Other- Patients admitted to hospital with symptomatic venous thromboembolism event.","Rivaroxaban","Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis  and Pulmonary Embolism in Greece.","Standard/Usual Care- Enoxaparin/Vitamin K antagonist","NE"
"2017-01-25353","2017","Gourzoulidis 2017 Clin Drug Investig","Cost-Saving","Rivaroxaban  VERSUS Standard/Usual Care- Enoxaparin/Vitamin K antagonist IN Specific disease- Deep Vein Thrombosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece; Other- Patients admitted to hospital with symptomatic venous thromboembolism event.","28608312","Specific disease- Deep Vein Thrombosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece; Other- Patients admitted to hospital with symptomatic venous thromboembolism event.","Rivaroxaban","Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis  and Pulmonary Embolism in Greece.","Standard/Usual Care- Enoxaparin/Vitamin K antagonist","SE"
"2017-01-24342","2017","Tzanetakos 2017 Clin Drug Investig","3300","Exenatide Once Weekly VERSUS Standard/Usual Care- Liraglutide 1.2mg  IN Specific disease- Type 2 Diabetes; Age- Adult; Gender- Both; Country- Greece.","29080210","Specific disease- Type 2 Diabetes; Age- Adult; Gender- Both; Country- Greece.","Exenatide Once Weekly","Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.","Standard/Usual Care- Liraglutide 1.2mg","NE"
"2017-01-24342","2017","Tzanetakos 2017 Clin Drug Investig","5200","Exenatide  VERSUS Standard/Usual Care- Insulin glargine(IG) IN Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Greece.","29080210","Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Greece.","Exenatide","Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.","Standard/Usual Care- Insulin glargine(IG)","NE"
"2016-01-21811","2016","Athanasakis                      2016 Clinicoecon Outcomes Res","2300","Eplerenone VERSUS Standard/Usual Care IN Specific disease- Chronic heart failure patients; Age- Adult; Gender- Both; Country- Greece; Other- New York Hear Association Class II with reduced left ventricular ejection fraction.","27785081","Specific disease- Chronic heart failure patients; Age- Adult; Gender- Both; Country- Greece; Other- New York Hear Association Class II with reduced left ventricular ejection fraction.","Eplerenone","Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients  with reduced LVEF: an analysis for Greece.","Standard/Usual Care","NE"
"2016-01-20082","2016","Sandhu 2016 JACC Heart Fail","51000","CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure VERSUS Standard/Usual Care IN Specific disease- chronic heart failure (CHF); Age- Adult; Gender- Both; Country- United States; Other- CHARM (Candesartan in Heart failure: Reduction in Mortality and Morbidity) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with preserved ejection fraction (21.7%).","26874380","Specific disease- chronic heart failure (CHF); Age- Adult; Gender- Both; Country- United States; Other- CHARM (Candesartan in Heart failure: Reduction in Mortality and Morbidity) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with preserved ejection fraction (21.7%).","CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure","Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure.","Standard/Usual Care","NE"
"2016-01-20082","2016","Sandhu 2016 JACC Heart Fail","76000","CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure VERSUS Standard/Usual Care IN Specific disease- chronic heart failure (CHF); Age- Adult; Gender- Both; Country- United States; Other- CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with preserved ejection fraction (21.7%) or reduced ejection fraction (78.3%).","26874380","Specific disease- chronic heart failure (CHF); Age- Adult; Gender- Both; Country- United States; Other- CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with preserved ejection fraction (21.7%) or reduced ejection fraction (78.3%).","CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure","Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure.","Standard/Usual Care","NE"
"2016-01-20082","2016","Sandhu 2016 JACC Heart Fail","87000","CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure VERSUS Standard/Usual Care IN Specific disease- chronic heart failure (CHF); Age- Adult; Gender- Both; Country- United States; Other- CHARM (Candesartan in Heart failure: Reduction in Mortality and Morbidity) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with reduced ejection fraction (78.3%).","26874380","Specific disease- chronic heart failure (CHF); Age- Adult; Gender- Both; Country- United States; Other- CHARM (Candesartan in Heart failure: Reduction in Mortality and Morbidity) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with reduced ejection fraction (78.3%).","CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure","Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure.","Standard/Usual Care","NE"
"2016-01-19662","2016","Kourlaba 2016 Cost Eff Resour Alloc","Cost-Saving","ranibizumab 0.5 mg (pro re nata) VERSUS aflibercept IN Specific disease-  diabetic macular edema; Age- Adult; Gender- Both; Country- Greece; Other- general population of patients with visual impairmen(VI) due to  diabetic macular edema(DME). At least one eye with a Best Corrected Visual Acuity (BCVA) score between 78 and 39 letters,.","27081372","Specific disease-  diabetic macular edema; Age- Adult; Gender- Both; Country- Greece; Other- general population of patients with visual impairmen(VI) due to  diabetic macular edema(DME). At least one eye with a Best Corrected Visual Acuity (BCVA) score between 78 and 39 letters,.","ranibizumab 0.5 mg (pro re nata)","Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema.","aflibercept","SE"
"2016-01-19662","2016","Kourlaba 2016 Cost Eff Resour Alloc","Cost-Saving","ranibizumab 0.5 mg  treat and extend (RAN T&E) VERSUS alibercept 2 mg (every 8 weeks after initial doses) IN Specific disease-  diabetic macular edema; Age- Adult; Gender- Both; Country- Greece; Other- general population of patients with visual impairmen(VI) due to  diabetic macular edema(DME).  at least one eye with a Best Corrected Visual Acuity (BCVA) score between 78 and 39 letters.","27081372","Specific disease-  diabetic macular edema; Age- Adult; Gender- Both; Country- Greece; Other- general population of patients with visual impairmen(VI) due to  diabetic macular edema(DME).  at least one eye with a Best Corrected Visual Acuity (BCVA) score between 78 and 39 letters.","ranibizumab 0.5 mg  treat and extend (RAN T&E)","Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema.","alibercept 2 mg (every 8 weeks after initial doses)","SE"
"2016-01-19558","2016","Rothschild 2016 Am J Ophthalmol","Cost-Saving","100% screening coverage + standard care VERSUS Standard/Usual Care- Current levels of screening and treatment of retinopathy of prematurity (52%) IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Mexico; Other- Low birth weight infants weighing <1500 g, at risk of having retinopathy of prematurity.","27130372","Healthy; Age- 0 to 18 years; Gender- Both; Country- Mexico; Other- Low birth weight infants weighing <1500 g, at risk of having retinopathy of prematurity.","100% screening coverage + standard care","The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States.","Standard/Usual Care- Current levels of screening and treatment of retinopathy of prematurity (52%)","SE"
"2016-01-19558","2016","Rothschild 2016 Am J Ophthalmol","Cost-Saving","100% screening coverage + standard care VERSUS Standard/Usual Care- current levels of screening and treatment of retinopathy of prematurity (52%) IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- Low birth weight infants weighing <1500 g, at risk of having retinopathy of prematurity.","27130372","Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- Low birth weight infants weighing <1500 g, at risk of having retinopathy of prematurity.","100% screening coverage + standard care","The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States.","Standard/Usual Care- current levels of screening and treatment of retinopathy of prematurity (52%)","SE"
"2016-01-19389","2016","Tzanetakos 2016 Clin Drug Investig","12000","Dapagliflozin (average daily dose of 10mg) and metformin VERSUS Sulfonylurea (SU) and metformin IN Specific disease- Type 2 Diabetes Mellitus (T2DM); Age- Adult; Gender- Both; Country- Greece.","27221806","Specific disease- Type 2 Diabetes Mellitus (T2DM); Age- Adult; Gender- Both; Country- Greece.","Dapagliflozin (average daily dose of 10mg) and metformin","Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.","Sulfonylurea (SU) and metformin","NE"
"2016-01-19389","2016","Tzanetakos 2016 Clin Drug Investig","21000","Dapagliflozin (average daily dose of 10mg) and metformin VERSUS dipeptidyl peptidase-4 inhibitor (DPP-4i) + metformin IN Specific disease- Type 2 Diabetes Mellitus (T2DM); Age- Adult; Gender- Both; Country- Greece.","27221806","Specific disease- Type 2 Diabetes Mellitus (T2DM); Age- Adult; Gender- Both; Country- Greece.","Dapagliflozin (average daily dose of 10mg) and metformin","Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.","dipeptidyl peptidase-4 inhibitor (DPP-4i) + metformin","NE"
"2015-01-20484","2015","Kourlaba 2015 BMC Health Serv Res","6500","Ranolazine as add-on treatment VERSUS Standard/Usual Care- Standard care for stable angina IN Specific disease- Chronic angina pectarisin; Age- Adult; Gender- Both; Country- Greece.","26684327","Specific disease- Chronic angina pectarisin; Age- Adult; Gender- Both; Country- Greece.","Ranolazine as add-on treatment","Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.","Standard/Usual Care- Standard care for stable angina","NE"
"2015-01-17524","2015","Kourlaba 2015 BMC Health Serv Res","Cost-Saving","Everolimus plus exemestane VERSUS Bevacizumab-based chemotherapy: bevacizumab + capecitabine IN Specific disease- Hormone receptor-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Greece.","26239115","Specific disease- Hormone receptor-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Greece.","Everolimus plus exemestane","Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line  treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.","Bevacizumab-based chemotherapy: bevacizumab + capecitabine","SE"
"2015-01-17524","2015","Kourlaba 2015 BMC Health Serv Res","Cost-Saving","Everolimus plus exemestane VERSUS Bevacizumab-based chemotherapy: bevacizumab + paclitaxel IN Specific disease- Hormone receptor-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Greece.","26239115","Specific disease- Hormone receptor-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Greece.","Everolimus plus exemestane","Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line  treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.","Bevacizumab-based chemotherapy: bevacizumab + paclitaxel","SE"
"2014-01-17001","2014","Kourlaba 2014 Cost Eff Resour Alloc","Cost-Saving","Rivaroxaban VERSUS Vitamin-K-antagonists (VKAs) IN Specific disease- Non-valvular atrial fibrillation (AF); Age- Adult; Gender- Both; Country- Greece.","24512351","Specific disease- Non-valvular atrial fibrillation (AF); Age- Adult; Gender- Both; Country- Greece.","Rivaroxaban","Economic evaluation of rivaroxaban in stroke prevention for patients with atrial  fibrillation in Greece.","Vitamin-K-antagonists (VKAs)","SE"
"2014-01-15835","2014","Tzanetakos 2014 BMC Health Serv Res","22000","Liraglutide VERSUS Sitagliptin IN Specific disease- Type 2 diabetes; Age- Unknown; Gender- Not Specified; Country- Greece.","25245666","Specific disease- Type 2 diabetes; Age- Unknown; Gender- Not Specified; Country- Greece.","Liraglutide","Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs  in Greece.","Sitagliptin","NE"
"2014-01-15835","2014","Tzanetakos 2014 BMC Health Serv Res","9800","Liraglutide VERSUS Exenatide BID IN Specific disease- Type 2 diabetes; Age- Unknown; Gender- Not Specified; Country- Greece.","25245666","Specific disease- Type 2 diabetes; Age- Unknown; Gender- Not Specified; Country- Greece.","Liraglutide","Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs  in Greece.","Exenatide BID","NE"
"2014-01-15481","2014","McCann 2014 Gynecol Oncol","Cost-Saving","Radical vulvectomy and sentinel lymph node biopsy VERSUS Radical vulvectomy + universal inguinofemoral lymphadenectomy (LND) IN Specific disease- Early-stage vulvar cancer; Age- Unknown; Gender- Female; Country- United States; Other- Newly diagnosed, early-stage vulvar cancer.","25478927","Specific disease- Early-stage vulvar cancer; Age- Unknown; Gender- Female; Country- United States; Other- Newly diagnosed, early-stage vulvar cancer.","Radical vulvectomy and sentinel lymph node biopsy","Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis.","Radical vulvectomy + universal inguinofemoral lymphadenectomy (LND)","SE"
"2014-01-15424","2014","Kourlaba 2014 BMC Health Serv Res","14000","Ivabradine plus standard of care VERSUS Standard/Usual Care IN Specific disease- Chronic Heart Failure; Age- Adult; Gender- Both; Country- Greece.","25496716","Specific disease- Chronic Heart Failure; Age- Adult; Gender- Both; Country- Greece.","Ivabradine plus standard of care","Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.","Standard/Usual Care","NE"
"2013-01-15118","2013","Demaerschalk 2013 Am J Manag Care","Cost-Saving","Managing acute ischemic stroke (AIS) with a telestroke network: a hub-and-spoke telestroke network (1 hub and 7 spokes) VERSUS Standard/Usual Care IN Specific disease- acute ischemic stroke; Age- Unknown; Gender- Not Specified; Country- United States.","24512034","Specific disease- acute ischemic stroke; Age- Unknown; Gender- Not Specified; Country- United States.","Managing acute ischemic stroke (AIS) with a telestroke network: a hub-and-spoke telestroke network (1 hub and 7 spokes)","Cost utility of hub-and-spoke telestroke networks from societal perspective.","Standard/Usual Care","SE"
"2013-01-11342","2013","Maniadakis 2013 BMC Health Serv Res","2000","Agomelatine VERSUS Generic Venlafaxine IN Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","23663281","Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","Agomelatine","Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.","Generic Venlafaxine","NE"
"2013-01-11342","2013","Maniadakis 2013 BMC Health Serv Res","4600","Agomelatine VERSUS Generic Escitalopram IN Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","23663281","Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","Agomelatine","Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.","Generic Escitalopram","NE"
"2013-01-11342","2013","Maniadakis 2013 BMC Health Serv Res","770","Agomelatine VERSUS Venlafaxine IN Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","23663281","Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","Agomelatine","Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.","Venlafaxine","NE"
"2013-01-11342","2013","Maniadakis 2013 BMC Health Serv Res","Cost-Saving","Agomelatine VERSUS Escitalopram IN Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","23663281","Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","Agomelatine","Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.","Escitalopram","SE"
"2013-01-11342","2013","Maniadakis 2013 BMC Health Serv Res","Cost-Saving","Agomelatine VERSUS Fluoxetine generic IN Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","23663281","Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","Agomelatine","Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.","Fluoxetine generic","SE"
"2013-01-11342","2013","Maniadakis 2013 BMC Health Serv Res","Cost-Saving","Agomelatine VERSUS Fluoxetine IN Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","23663281","Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","Agomelatine","Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.","Fluoxetine","SE"
"2013-01-11342","2013","Maniadakis 2013 BMC Health Serv Res","Cost-Saving","Agomelatine VERSUS Generic Sertraline IN Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","23663281","Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","Agomelatine","Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.","Generic Sertraline","SE"
"2013-01-11342","2013","Maniadakis 2013 BMC Health Serv Res","Cost-Saving","Agomelatine VERSUS Sertraline IN Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","23663281","Specific disease- major depressive disorders; Age- Adult; Gender- Both; Country- Greece.","Agomelatine","Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.","Sertraline","SE"
"2013-01-10800","2013","Sgourakis 2013 Surg Endosc","6","Laparoscopic totally extraperitoneal hernia repair (TEP) VERSUS Open preperitoneal mesh repair according to Nyhus procedure (incorporating a preperitoneal prosthetic mesh + approximation of the transversalis fascia to Cooperâs ligament) IN Specific disease- inguinal hernia; Age- Adult; Gender- Both; Country- Greece; Other- recurrent.","23344511","Specific disease- inguinal hernia; Age- Adult; Gender- Both; Country- Greece; Other- recurrent.","Laparoscopic totally extraperitoneal hernia repair (TEP)","Laparoscopic totally extraperitoneal versus open preperitoneal mesh repair for inguinal hernia recurrence: a decision analysis based on net health benefits.","Open preperitoneal mesh repair according to Nyhus procedure (incorporating a preperitoneal prosthetic mesh + approximation of the transversalis fascia to Cooperâs ligament)","NE"
"2013-01-10800","2013","Sgourakis 2013 Surg Endosc","Dominated","Open preperitoneal mesh repair according to Stoppa procedure (integrated the use of mesh) VERSUS Open preperitoneal mesh repair according to Nyhus procedure (incorporating a preperitoneal prosthetic mesh + approximation of the transversalis fascia to Cooperâs ligament) IN Specific disease- inguinal hernia; Age- Adult; Gender- Both; Country- Greece; Other- recurrent.","23344511","Specific disease- inguinal hernia; Age- Adult; Gender- Both; Country- Greece; Other- recurrent.","Open preperitoneal mesh repair according to Stoppa procedure (integrated the use of mesh)","Laparoscopic totally extraperitoneal versus open preperitoneal mesh repair for inguinal hernia recurrence: a decision analysis based on net health benefits.","Open preperitoneal mesh repair according to Nyhus procedure (incorporating a preperitoneal prosthetic mesh + approximation of the transversalis fascia to Cooperâs ligament)","NW"
"2012-01-09568","2012","Kourlaba 2012 Appl Health Econ Health Policy","6800","Clopidogrel (treatment effect only last 2 years within the Markov model) VERSUS Aspirin IN Patients with atherothrombosis with peripheral arterial disease, a recent ischemic stroke, or a recent myocardial infarction in Greece","22853743","Patients with atherothrombosis with peripheral arterial disease, a recent ischemic stroke, or a recent myocardial infarction in Greece","Clopidogrel (treatment effect only last 2 years within the Markov model)","Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.","Aspirin","NE"
"2012-01-09520","2012","Athanasakis                      2012 Clin Ther","Cost-Saving","Varenicline VERSUS Bupropion IN Adults who smoke cigarettes in Greece","22818870","Adults who smoke cigarettes in Greece","Varenicline","Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.","Bupropion","SE"
"2012-01-09520","2012","Athanasakis                      2012 Clin Ther","Cost-Saving","Varenicline VERSUS Nicotine replacement therapy IN Adults who smoke cigarettes in Greece","22818870","Adults who smoke cigarettes in Greece","Varenicline","Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.","Nicotine replacement therapy","SE"
"2012-01-09520","2012","Athanasakis                      2012 Clin Ther","Cost-Saving","Varenicline VERSUS Unaided cessation IN Adults who smoke cigarettes in Greece","22818870","Adults who smoke cigarettes in Greece","Varenicline","Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.","Unaided cessation","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Atorvastatin VERSUS Pravastatin IN Female patients with high-risk cardiovascular disease in Greece","22719213","Female patients with high-risk cardiovascular disease in Greece","Atorvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Pravastatin","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Atorvastatin VERSUS Pravastatin IN Male patients with high-risk cardiovascular disease in Greece","22719213","Male patients with high-risk cardiovascular disease in Greece","Atorvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Pravastatin","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Atorvastatin VERSUS Simvastatin IN Female patients with high-risk cardiovascular disease in Greece","22719213","Female patients with high-risk cardiovascular disease in Greece","Atorvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Simvastatin","SE"
"2018-01-28860","2018","Hofer 2018 Lung Cancer","35000","Population-based annual lung cancer screening program using low-dose computed tomography VERSUS Standard/Usual Care- Standard clinical care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Germany; Other- Heavy former and current smokers (20+ cigarettes per day).","30268459","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Germany; Other- Heavy former and current smokers (20+ cigarettes per day).","Population-based annual lung cancer screening program using low-dose computed tomography","Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach.","Standard/Usual Care- Standard clinical care","NE"
"2018-01-27645","2018","Richter 2018 Eur J Health Econ","4000","Increase subcutaneous immunotherapy treatment rate VERSUS Standard/Usual Care- Remain subcutaneous immunotherapy treatment rate IN Specific disease- Allergic rhinitis, allergic asthma; Age- Unknown; Gender- Both; Country- Germany.","29574666","Specific disease- Allergic rhinitis, allergic asthma; Age- Unknown; Gender- Both; Country- Germany.","Increase subcutaneous immunotherapy treatment rate","Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach.","Standard/Usual Care- Remain subcutaneous immunotherapy treatment rate","NE"
"2018-01-27068","2018","Butenschon 2018 Neurosurg Focus","52000","Navigated transcranial magnetic stimulation VERSUS Standard/Usual Care- Motor mapping without navigated transcranial magnetic brain stimulation IN Specific disease- High-grade glioma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany.","29852777","Specific disease- High-grade glioma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany.","Navigated transcranial magnetic stimulation","Cost-effectiveness of preoperative motor mapping with navigated transcranial magnetic brain stimulation in patients with high-grade glioma.","Standard/Usual Care- Motor mapping without navigated transcranial magnetic brain stimulation","NE"
"2018-01-26437","2018","Van Oorschot 2018 Hum Vaccin Immunother","43000","Adjuvanted Recombinant Zoster Vaccine VERSUS Standard/Usual Care- No vaccine IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Germany.","30130448","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Germany.","Adjuvanted Recombinant Zoster Vaccine","Cost-effectiveness of the recombinant zoster vaccine in the German population aged >/=60 years old.","Standard/Usual Care- No vaccine","NE"
"2018-01-26437","2018","Van Oorschot 2018 Hum Vaccin Immunother","51000","Adjuvanted Recombinant Zoster Vaccine VERSUS Standard/Usual Care- No vaccine IN Healthy; Age- >=65 years; Gender- Both; Country- Germany.","30130448","Healthy; Age- >=65 years; Gender- Both; Country- Germany.","Adjuvanted Recombinant Zoster Vaccine","Cost-effectiveness of the recombinant zoster vaccine in the German population aged >/=60 years old.","Standard/Usual Care- No vaccine","NE"
"2018-01-25910","2018","Waschke 2018 J Neurooncol","410000","Temozolomide (long-term use) VERSUS Standard/Usual Care- Concomitant radiochemotherapy followed by six cycles of temozolomide (= short term) IN Specific disease- Glioblastoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany.","29468446","Specific disease- Glioblastoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany.","Temozolomide (long-term use)","Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.","Standard/Usual Care- Concomitant radiochemotherapy followed by six cycles of temozolomide (= short term)","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","100000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","100000","Biosimilar-infliximab (bsIFX) and Vedolizumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Italy.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Italy.","Biosimilar-infliximab (bsIFX) and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","100000","Biosimilar-infliximab and Adalimumab and Vedolizumab VERSUS Biosimilar-infliximab and Adalimumab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Netherlands.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Netherlands.","Biosimilar-infliximab and Adalimumab and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab and Adalimumab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","100000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Italy.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Italy.","Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","100000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Netherlands.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Netherlands.","Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","110000","Biosimilar-infliximab and Adalimumab and Vedolizumab  VERSUS Biosimilar-infliximab and Adalimumab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Italy.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Italy.","Biosimilar-infliximab and Adalimumab and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab and Adalimumab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","110000","Originator-infliximab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","Originator-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","120000","Biosimilar-infliximab (bsIFX) and Vedolizumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","Biosimilar-infliximab (bsIFX) and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","130000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","130000","Biosimilar-infliximab (bsIFX) and Vedolizumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- France.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- France.","Biosimilar-infliximab (bsIFX) and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","130000","Biosimilar-infliximab and Adalimumab and Vedolizumab VERSUS Biosimilar-infliximab and Adalimumab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","Biosimilar-infliximab and Adalimumab and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab and Adalimumab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","130000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- France.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- France.","Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","130000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","140000","Biosimilar-infliximab (bsIFX) and Vedolizumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","Biosimilar-infliximab (bsIFX) and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","140000","Biosimilar-infliximab (bsIFX) and Vedolizumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","Biosimilar-infliximab (bsIFX) and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","140000","Biosimilar-infliximab (bsIFX) and Vedolizumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- United Kingdom.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- United Kingdom.","Biosimilar-infliximab (bsIFX) and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","140000","Biosimilar-infliximab and Adalimumab and Vedolizumab  VERSUS Biosimilar-infliximab and Adalimumab  IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- France.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- France.","Biosimilar-infliximab and Adalimumab and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab and Adalimumab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","140000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","150000","Biosimilar-infliximab and Adalimumab and Vedolizumab  VERSUS Biosimilar-infliximab and Adalimumab  IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- United Kingdom; Other- Patients with fistulising active Crohn's Disease (CD) who were eligible for biological treatment.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- United Kingdom; Other- Patients with fistulising active Crohn's Disease (CD) who were eligible for biological treatment.","Biosimilar-infliximab and Adalimumab and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab and Adalimumab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","150000","Biosimilar-infliximab and Adalimumab and Vedolizumab VERSUS Biosimilar-infliximab and Adalimumab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","Biosimilar-infliximab and Adalimumab and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab and Adalimumab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","150000","Biosimilar-infliximab and Adalimumab and Vedolizumab VERSUS Biosimilar-infliximab and Adalimumab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","Biosimilar-infliximab and Adalimumab and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab and Adalimumab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","150000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","150000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- United Kingdom.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- United Kingdom.","Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","160000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","160000","Biosimilar-infliximab (bsIFX) and Adalimumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","Biosimilar-infliximab (bsIFX) and Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","76000","Originator-infliximab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","Originator-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","78000","Biosimilar-infliximab (bsIFX) and Adalimumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","Biosimilar-infliximab (bsIFX) and Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","82000","Biosimilar-infliximab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","Biosimilar-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","82000","Originator-infliximab  VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- United Kingdom.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- United Kingdom.","Originator-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","85000","Biosimilar-infliximab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Germany.","Biosimilar-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","87000","Biosimilar-infliximab (bsIFX) and Adalimumab  VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Italy.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Italy.","Biosimilar-infliximab (bsIFX) and Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","89000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- United Kingdom.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- United Kingdom.","Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","91000","Biosimilar-infliximab (bsIFX) and Adalimumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Netherlands.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Netherlands.","Biosimilar-infliximab (bsIFX) and Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","91000","Biosimilar-infliximab (bsIFX) and Adalimumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","Biosimilar-infliximab (bsIFX) and Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","92000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Italy.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Italy.","Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","92000","Biosimilar-infliximab (bsIFX) and Adalimumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","Biosimilar-infliximab (bsIFX) and Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","94000","Originator-infliximab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Sweden.","Originator-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","99000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Netherlands.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Netherlands.","Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","99000","Biosimilar-infliximab (bsIFX) and Vedolizumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Netherlands.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Netherlands.","Biosimilar-infliximab (bsIFX) and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25659","2018","Gaultney 2018 Pharmacogenomics","Cost-Saving","Risk-stratified treatment: FISH+ISS+SKY92: stratified using any biomarker VERSUS Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly IN Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany; Other- Newly diagnosed,  transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","29334316","Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany; Other- Newly diagnosed,  transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","Risk-stratified treatment: FISH+ISS+SKY92: stratified using any biomarker","Potential therapeutic and economic value of risk-stratified treatment as initial  treatment of multiple myeloma in Europe.","Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly","SE"
"2018-01-25659","2018","Gaultney 2018 Pharmacogenomics","Cost-Saving","Risk-stratified treatment: Florescent in situ hybridization+International Staging System VERSUS Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly IN Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany; Other- Newly diagnosed, transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","29334316","Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany; Other- Newly diagnosed, transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","Risk-stratified treatment: Florescent in situ hybridization+International Staging System","Potential therapeutic and economic value of risk-stratified treatment as initial  treatment of multiple myeloma in Europe.","Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly","SE"
"2018-01-25659","2018","Gaultney 2018 Pharmacogenomics","Cost-Saving","Risk-stratified treatment: SKY92 molecular test VERSUS Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly IN Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany; Other- Newly diagnosed, transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","29334316","Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany; Other- Newly diagnosed, transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","Risk-stratified treatment: SKY92 molecular test","Potential therapeutic and economic value of risk-stratified treatment as initial  treatment of multiple myeloma in Europe.","Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly","SE"
"2017-01-25759","2017","Huber 2017 Addiction","380","Current investment: includes all currently implemented smoking cessation interventions VERSUS Standard/Usual Care- Zero investment: only the top-level policies (i.e. indoor smoking ban in public places and tobacco taxes; both at their current levels) IN Specific disease- Smoking; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany.","29243347","Specific disease- Smoking; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Germany.","Current investment: includes all currently implemented smoking cessation interventions","Cost-effectiveness of increasing the reach of smoking cessation interventions in  Germany: results from the EQUIPTMOD.","Standard/Usual Care- Zero investment: only the top-level policies (i.e. indoor smoking ban in public places and tobacco taxes; both at their current levels)","NE"
"2015-01-18262","2015","VanDeusen 2015 BMC Infect Dis","880","Option B+: HIV-infected pregnant women receive lifelong antiretroviral therapy beginning at their first pregnancy. Infants born to HIV+ women receive daily zidovudine (AZT) for the first 4-6 weeks of life VERSUS Option B: antiretroviral prophylaxis that begins early in gestation and continues through breastfeeding for women with a CD4 count above 350 cells/mm3, and lifetime antiretroviral therapy for women with a CD4 count below 350 cells/mm3. Infants born to HIV+ women receive daily zidovudine (AZT) for the first 4-6 weeks of life IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Ghana; Other- HIV-infected pregnant women in Ghana, who are pregnant with their first child.","25887574","Specific disease- HIV; Age- Adult; Gender- Female; Country- Ghana; Other- HIV-infected pregnant women in Ghana, who are pregnant with their first child.","Option B+: HIV-infected pregnant women receive lifelong antiretroviral therapy beginning at their first pregnancy. Infants born to HIV+ women receive daily zidovudine (AZT) for the first 4-6 weeks of life","Cost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, Ghana.","Option B: antiretroviral prophylaxis that begins early in gestation and continues through breastfeeding for women with a CD4 count above 350 cells/mm3, and lifetime antiretroviral therapy for women with a CD4 count below 350 cells/mm3. Infants born to HIV+ women receive daily zidovudine (AZT) for the first 4-6 weeks of life","NE"
"2017-01-24675","2017","Kousoulakou 2017 Cost Eff Resour Alloc","Cost-Saving","Vidagliptin + metformin in second line treatment VERSUS Glimepiride + metformin in second line treatment IN Specific disease- Type 2 diabetes mellitus; Age- Adult; Gender- Both; Country- Greece; Other- Patients with failed metformin monotherapy.","28904527","Specific disease- Type 2 diabetes mellitus; Age- Adult; Gender- Both; Country- Greece; Other- Patients with failed metformin monotherapy.","Vidagliptin + metformin in second line treatment","Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece.","Glimepiride + metformin in second line treatment","SE"
"2017-01-23282","2017","Athanasakis                      2017 Clin Ther","13000","Ingenol mebutate (0.015%) VERSUS Imiquimod 5% (4 weeks) IN Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","28449867","Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","Ingenol mebutate (0.015%)","Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.","Imiquimod 5% (4 weeks)","NE"
"2017-01-23282","2017","Athanasakis                      2017 Clin Ther","1500","Ingenol mebutate (0.05%) VERSUS Diclofenac 3% (12 weeks) IN Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","28449867","Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","Ingenol mebutate (0.05%)","Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.","Diclofenac 3% (12 weeks)","SW"
"2017-01-23282","2017","Athanasakis                      2017 Clin Ther","1800","Ingenol mebutate (0.05%) VERSUS Diclofenac 3% (8 weeks) IN Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","28449867","Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","Ingenol mebutate (0.05%)","Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.","Diclofenac 3% (8 weeks)","SW"
"2017-01-23282","2017","Athanasakis                      2017 Clin Ther","190","Ingenol mebutate (0.015%) VERSUS Diclofenac 3% (12 weeks) IN Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","28449867","Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","Ingenol mebutate (0.015%)","Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.","Diclofenac 3% (12 weeks)","NE"
"2017-01-23282","2017","Athanasakis                      2017 Clin Ther","230","Ingenol mebutate (0.015%) VERSUS Diclofenac 3% (8 weeks) IN Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","28449867","Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","Ingenol mebutate (0.015%)","Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.","Diclofenac 3% (8 weeks)","NE"
"2017-01-23282","2017","Athanasakis                      2017 Clin Ther","Cost-Saving","Ingenol mebutate (0.015%) VERSUS Imiquimod 5% (8 weeks) IN Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","28449867","Specific disease- Actinic keratosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece.","Ingenol mebutate (0.015%)","Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.","Imiquimod 5% (8 weeks)","SE"
"2017-01-23120","2017","Tzanetakos 2017 Rheumatol Int","4500","Certolizumabpegol+MTX VERSUS Etanercept+MTX IN Specific disease- patients with moderate-to severe active rheumatoid arthritis (RA); Age- Adult; Gender- Both; Country- Greece.","28523420","Specific disease- patients with moderate-to severe active rheumatoid arthritis (RA); Age- Adult; Gender- Both; Country- Greece.","Certolizumabpegol+MTX","Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.","Etanercept+MTX","NE"
"2017-01-23120","2017","Tzanetakos 2017 Rheumatol Int","Cost-Saving","Certolizumab pegol+MTX VERSUS Golimumab+MTX IN Specific disease- patients with moderate-to severe active rheumatoid arthritis (RA); Age- Adult; Gender- Both; Country- Greece.","28523420","Specific disease- patients with moderate-to severe active rheumatoid arthritis (RA); Age- Adult; Gender- Both; Country- Greece.","Certolizumab pegol+MTX","Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.","Golimumab+MTX","SE"
"2017-01-23120","2017","Tzanetakos 2017 Rheumatol Int","Cost-Saving","Certolizumabpegol+MTX VERSUS Adalimumab+MTX IN Specific disease- patients with moderate-to severe active rheumatoid arthritis (RA); Age- Adult; Gender- Both; Country- Greece.","28523420","Specific disease- patients with moderate-to severe active rheumatoid arthritis (RA); Age- Adult; Gender- Both; Country- Greece.","Certolizumabpegol+MTX","Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.","Adalimumab+MTX","SE"
"2015-01-18465","2015","Athanasakis                      2015 Rheumatol Int","41000","Treatment pathway initiated with tocilizumab VERSUS Standard/Usual Care IN Specific disease- Active rheumatoid arthritis; Age- Adult; Gender- Both; Country- Greece.","25794569","Specific disease- Active rheumatoid arthritis; Age- Adult; Gender- Both; Country- Greece.","Treatment pathway initiated with tocilizumab","Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece.","Standard/Usual Care","NE"
"2015-01-17960","2015","Athanasakis                      2015 Clin Ther","14000","Pegylated interferon + ribavirin + boceprevir (peg + rbv + boc) for 48 weeks VERSUS Standard/Usual Care- Pegylated Interferon + Ribavirin (PEG + RBV) for 48 weeks IN Specific disease- Hepatitis C Virus (HCV); Age- Adult; Gender- Both; Country- Greece; Other- Chronic geneotype 1 virus (G1 HCV), treatment naÃ¯ve patients.","26031617","Specific disease- Hepatitis C Virus (HCV); Age- Adult; Gender- Both; Country- Greece; Other- Chronic geneotype 1 virus (G1 HCV), treatment naÃ¯ve patients.","Pegylated interferon + ribavirin + boceprevir (peg + rbv + boc) for 48 weeks","Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.","Standard/Usual Care- Pegylated Interferon + Ribavirin (PEG + RBV) for 48 weeks","NE"
"2015-01-17960","2015","Athanasakis                      2015 Clin Ther","16000","Pegylated interferon + ribavirin + boceprevir (peg + rbv + boc) for 48 weeks VERSUS Standard/Usual Care- Pegylated Interferon + Ribavirin (PEG + RBV) for 48 weeks IN Specific disease- Hepatitis C Virus (HCV); Age- Adult; Gender- Both; Country- Greece; Other- Chronic geneotype 1 virus (G1 HCV), treatment experienced patients.","26031617","Specific disease- Hepatitis C Virus (HCV); Age- Adult; Gender- Both; Country- Greece; Other- Chronic geneotype 1 virus (G1 HCV), treatment experienced patients.","Pegylated interferon + ribavirin + boceprevir (peg + rbv + boc) for 48 weeks","Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.","Standard/Usual Care- Pegylated Interferon + Ribavirin (PEG + RBV) for 48 weeks","NE"
"2015-01-17208","2015","Athanasakis                      2015 Clin Drug Investig","14000","Apixaban 5 mg twice daily VERSUS Dabigatran 110 mg twice daily IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","26385756","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Apixaban 5 mg twice daily","Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting.","Dabigatran 110 mg twice daily","NE"
"2015-01-17208","2015","Athanasakis                      2015 Clin Drug Investig","20000","Apixaban 5 mg twice daily VERSUS Dabigatran 150 mg twice daily IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","26385756","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Apixaban 5 mg twice daily","Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting.","Dabigatran 150 mg twice daily","NE"
"2015-01-17208","2015","Athanasakis                      2015 Clin Drug Investig","9900","Apixaban 5 mg twice daily VERSUS Rivaroxaban 20 mg daily IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","26385756","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Apixaban 5 mg twice daily","Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting.","Rivaroxaban 20 mg daily","NE"
"2013-01-11760","2013","Andrikopoulos 2013 Hellenic J Cardiol","10000","Dabigatran 110 mg VERSUS Standard/Usual Care- Acetylsalicylic acid and clopidogrel IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","23912921","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Dabigatran 110 mg","Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.","Standard/Usual Care- Acetylsalicylic acid and clopidogrel","NE"
"2013-01-11760","2013","Andrikopoulos 2013 Hellenic J Cardiol","16000","Dabigatran 150 mg VERSUS Standard/Usual Care- Acenocoumarol IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","23912921","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Dabigatran 150 mg","Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.","Standard/Usual Care- Acenocoumarol","NE"
"2013-01-11760","2013","Andrikopoulos 2013 Hellenic J Cardiol","16000","Dabigatran 150 mg VERSUS Standard/Usual Care- Warfarin IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","23912921","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Dabigatran 150 mg","Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.","Standard/Usual Care- Warfarin","NE"
"2013-01-11760","2013","Andrikopoulos 2013 Hellenic J Cardiol","17000","Dabigatran 150 mg VERSUS Standard/Usual Care- Acetylsalicylic acid IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","23912921","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Dabigatran 150 mg","Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.","Standard/Usual Care- Acetylsalicylic acid","NE"
"2013-01-11760","2013","Andrikopoulos 2013 Hellenic J Cardiol","21000","Dabigatran 110 mg VERSUS Standard/Usual Care- Acetylsalicylic acid IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","23912921","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Dabigatran 110 mg","Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.","Standard/Usual Care- Acetylsalicylic acid","NE"
"2013-01-11760","2013","Andrikopoulos 2013 Hellenic J Cardiol","23000","Dabigatran 110 mg VERSUS Standard/Usual Care- Acenocoumarol IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","23912921","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Dabigatran 110 mg","Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.","Standard/Usual Care- Acenocoumarol","NE"
"2013-01-11760","2013","Andrikopoulos 2013 Hellenic J Cardiol","23000","Dabigatran 110 mg VERSUS Standard/Usual Care- Warfarin IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","23912921","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Dabigatran 110 mg","Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.","Standard/Usual Care- Warfarin","NE"
"2013-01-11760","2013","Andrikopoulos 2013 Hellenic J Cardiol","7800","Dabigatran 150 mg VERSUS Standard/Usual Care- Acetylsalicylic acid and clopidogrel IN Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","23912921","Specific disease- Non-valvular atrial fibrillation; Age- Adult; Gender- Both; Country- Greece.","Dabigatran 150 mg","Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.","Standard/Usual Care- Acetylsalicylic acid and clopidogrel","NE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Atorvastatin VERSUS Simvastatin IN Male patients with high-risk cardiovascular disease in Greece","22719213","Male patients with high-risk cardiovascular disease in Greece","Atorvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Simvastatin","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Rosuvastatin VERSUS Atorvastatin IN Female patients with high-risk cardiovascular disease in Greece","22719213","Female patients with high-risk cardiovascular disease in Greece","Rosuvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Atorvastatin","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Rosuvastatin VERSUS Atorvastatin IN Male patients with high-risk cardiovascular disease in Greece","22719213","Male patients with high-risk cardiovascular disease in Greece","Rosuvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Atorvastatin","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Rosuvastatin VERSUS Pravastatin IN Female patients with high-risk cardiovascular disease in Greece","22719213","Female patients with high-risk cardiovascular disease in Greece","Rosuvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Pravastatin","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Rosuvastatin VERSUS Pravastatin IN Male patients with high-risk cardiovascular disease in Greece","22719213","Male patients with high-risk cardiovascular disease in Greece","Rosuvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Pravastatin","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Rosuvastatin VERSUS Simvastatin IN Female patients with high-risk cardiovascular disease in Greece","22719213","Female patients with high-risk cardiovascular disease in Greece","Rosuvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Simvastatin","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Rosuvastatin VERSUS Simvastatin IN Male patients with high-risk cardiovascular disease in Greece","22719213","Male patients with high-risk cardiovascular disease in Greece","Rosuvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Simvastatin","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Simvastatin VERSUS Pravastatin IN Female patients with high-risk cardiovascular disease in Greece","22719213","Female patients with high-risk cardiovascular disease in Greece","Simvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Pravastatin","SE"
"2012-01-09379","2012","Fragoulakis 2012 Clinicoecon Outcomes Res","Cost-Saving","Simvastatin VERSUS Pravastatin IN Male patients with high-risk cardiovascular disease in Greece","22719213","Male patients with high-risk cardiovascular disease in Greece","Simvastatin","Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.","Pravastatin","SE"
"2012-01-09298","2012","Kourlaba 2012 Appl Health Econ Health Policy","4600","Aspirin + clopidogrel VERSUS Aspirin IN Men who had suffered from a non-ST segment elevation myocardial infarction in Greece","22667992","Men who had suffered from a non-ST segment elevation myocardial infarction in Greece","Aspirin + clopidogrel","Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.","Aspirin","NE"
"2012-01-09298","2012","Kourlaba 2012 Appl Health Econ Health Policy","5000","Aspirin + clopidogrel VERSUS Aspirin IN Total population (men and women) who had suffered from a non-ST segment elevation myocardial infarction in Greece","22667992","Total population (men and women) who had suffered from a non-ST segment elevation myocardial infarction in Greece","Aspirin + clopidogrel","Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.","Aspirin","NE"
"2012-01-09298","2012","Kourlaba 2012 Appl Health Econ Health Policy","6700","Aspirin + clopidogrel VERSUS Aspirin IN Women who had suffered from a non-ST segment elevation myocardial infarction in Greece","22667992","Women who had suffered from a non-ST segment elevation myocardial infarction in Greece","Aspirin + clopidogrel","Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.","Aspirin","NE"
"2012-01-08576","2012","Athanasakis                      2012 Clin Ther","17000","Ranibizumab VERSUS Pegaptanib IN Patients with age-related macular degeneration (AMD) patients with minimally classic lesions","22289279","Patients with age-related macular degeneration (AMD) patients with minimally classic lesions","Ranibizumab","Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece.","Pegaptanib","NE"
"2012-01-08576","2012","Athanasakis                      2012 Clin Ther","19000","Ranibizumab VERSUS Best supportive care (BSC) IN Patients with age-related macular degeneration (AMD) patients with predominantly classic lesions","22289279","Patients with age-related macular degeneration (AMD) patients with predominantly classic lesions","Ranibizumab","Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece.","Best supportive care (BSC)","NE"
"2012-01-08576","2012","Athanasakis                      2012 Clin Ther","29000","Ranibizumab VERSUS Best supportive care (BSC) IN Patients with age-related macular degeneration (AMD) patients with minimally classic lesions","22289279","Patients with age-related macular degeneration (AMD) patients with minimally classic lesions","Ranibizumab","Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece.","Best supportive care (BSC)","NE"
"2012-01-08576","2012","Athanasakis                      2012 Clin Ther","30000","Ranibizumab VERSUS Best supportive care (BSC) IN Patients with age-related macular degeneration (AMD) patients with occult lesions","22289279","Patients with age-related macular degeneration (AMD) patients with occult lesions","Ranibizumab","Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece.","Best supportive care (BSC)","NE"
"2012-01-08576","2012","Athanasakis                      2012 Clin Ther","39000","Ranibizumab VERSUS Pegaptanib IN Patients with age-related macular degeneration (AMD) patients with occult lesions","22289279","Patients with age-related macular degeneration (AMD) patients with occult lesions","Ranibizumab","Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece.","Pegaptanib","NE"
"2012-01-08576","2012","Athanasakis                      2012 Clin Ther","8900","Ranibizumab VERSUS Verteporfin photodynamic therapy (PDT) IN Patients with age-related macular degeneration (AMD) patients with predominantly classic lesions","22289279","Patients with age-related macular degeneration (AMD) patients with predominantly classic lesions","Ranibizumab","Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece.","Verteporfin photodynamic therapy (PDT)","NE"
"2014-01-16901","2014","Pletcher 2014 Circ Cardiovasc Qual Outcomes","24000","Statin Treatment if coronary artery calcium (CAC) score>100 VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Female; Country- United States.","24619318","Healthy; Age- 41 to 64 years; Gender- Female; Country- United States.","Statin Treatment if coronary artery calcium (CAC) score>100","Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.","None","NE"
"2014-01-16901","2014","Pletcher 2014 Circ Cardiovasc Qual Outcomes","68","Statin Treatment regardless of coronary artery calcium (CAC) score VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Female; Country- United States.","24619318","Healthy; Age- 41 to 64 years; Gender- Female; Country- United States.","Statin Treatment regardless of coronary artery calcium (CAC) score","Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.","None","NE"
"2014-01-16901","2014","Pletcher 2014 Circ Cardiovasc Qual Outcomes","870000","Statin Treatment if coronary artery calcium (CAC) score>300 VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Female; Country- United States.","24619318","Healthy; Age- 41 to 64 years; Gender- Female; Country- United States.","Statin Treatment if coronary artery calcium (CAC) score>300","Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.","None","NE"
"2014-01-16901","2014","Pletcher 2014 Circ Cardiovasc Qual Outcomes","Cost-Saving","Statin Treatment if coronary artery calcium (CAC) score >0 VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Female; Country- United States.","24619318","Healthy; Age- 41 to 64 years; Gender- Female; Country- United States.","Statin Treatment if coronary artery calcium (CAC) score >0","Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.","None","SE"
"2008-01-04125","2008","Newman 2008 Prev Cardiol","Dominated","Combination treatment with simvastatin, captopril, hydrochlorthiazide and atenolol to prevent cardiovascular disease onset VERSUS No preventive treatment IN Men in the United States aged >55 years without cardiovascular disease, hypertension or dyslipidemia","18174790","Men in the United States aged >55 years without cardiovascular disease, hypertension or dyslipidemia","Combination treatment with simvastatin, captopril, hydrochlorthiazide and atenolol to prevent cardiovascular disease onset","Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model.","No preventive treatment","NW"
"2010-01-06839","2010","Yazdanpanah 2010 PLoS One","100000","Risk-factor based HIV testing (current situtation) and one time, voluntary HIV screening VERSUS Risk-factor based HIV testing (current situtation) IN French adults ageed 18-69 years, accounting for primary HIV transmission only","20976112","French adults ageed 18-69 years, accounting for primary HIV transmission only","Risk-factor based HIV testing (current situtation) and one time, voluntary HIV screening","Routine HIV screening in France: clinical impact and cost-effectiveness.","Risk-factor based HIV testing (current situtation)","NE"
"2010-01-06839","2010","Yazdanpanah 2010 PLoS One","550000","Risk-factor based HIV testing (current situtation) and an HIV screen every 5 years VERSUS Risk-factor based HIV testing (current situtation) and one time, voluntary HIV screening IN French adults ageed 18-69 years, accounting for primary and secondary transmission of HIV","20976112","French adults ageed 18-69 years, accounting for primary and secondary transmission of HIV","Risk-factor based HIV testing (current situtation) and an HIV screen every 5 years","Routine HIV screening in France: clinical impact and cost-effectiveness.","Risk-factor based HIV testing (current situtation) and one time, voluntary HIV screening","NE"
"2010-01-06839","2010","Yazdanpanah 2010 PLoS One","740000","Risk-factor based HIV testing (current situtation) and an HIV screen every 5 years VERSUS Risk-factor based HIV testing (current situtation) and one time, voluntary HIV screening IN French adults ageed 18-69 years, accounting for primary HIV transmission only","20976112","French adults ageed 18-69 years, accounting for primary HIV transmission only","Risk-factor based HIV testing (current situtation) and an HIV screen every 5 years","Routine HIV screening in France: clinical impact and cost-effectiveness.","Risk-factor based HIV testing (current situtation) and one time, voluntary HIV screening","NE"
"2010-01-06839","2010","Yazdanpanah 2010 PLoS One","83000","Risk-factor based HIV testing (current situtation) and one time, voluntary HIV screening VERSUS Risk-factor based HIV testing (current situtation) IN French adults ageed 18-69 years, accounting for primary and secondary transmission of HIV","20976112","French adults ageed 18-69 years, accounting for primary and secondary transmission of HIV","Risk-factor based HIV testing (current situtation) and one time, voluntary HIV screening","Routine HIV screening in France: clinical impact and cost-effectiveness.","Risk-factor based HIV testing (current situtation)","NE"
"2010-01-06839","2010","Yazdanpanah 2010 PLoS One","Dominated","Risk-factor based HIV testing (current situtation) and an HIV screen annually VERSUS Risk-factor based HIV testing (current situtation) and an HIV screen every 5 years IN French adults ageed 18-69 years, accounting for primary and secondary transmission of HIV","20976112","French adults ageed 18-69 years, accounting for primary and secondary transmission of HIV","Risk-factor based HIV testing (current situtation) and an HIV screen annually","Routine HIV screening in France: clinical impact and cost-effectiveness.","Risk-factor based HIV testing (current situtation) and an HIV screen every 5 years","NW"
"2010-01-06839","2010","Yazdanpanah 2010 PLoS One","Dominated","Risk-factor based HIV testing (current situtation) and an HIV screen annually VERSUS Risk-factor based HIV testing (current situtation) and an HIV screen every 5 years IN French adults ageed 18-69 years, accounting for primary HIV transmission only","20976112","French adults ageed 18-69 years, accounting for primary HIV transmission only","Risk-factor based HIV testing (current situtation) and an HIV screen annually","Routine HIV screening in France: clinical impact and cost-effectiveness.","Risk-factor based HIV testing (current situtation) and an HIV screen every 5 years","NW"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","130","Universal antenatal HIV testing VERSUS Focused HIV testing IN Specific disease- HIV; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Viet Nam; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","27978939","Specific disease- HIV; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Viet Nam; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Focused HIV testing","NE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","28","Universal antenatal HIV testing VERSUS Highly focused HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Viet Nam; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Viet Nam; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Highly focused HIV testing","NE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","Cost-Saving","Universal antenatal HIV testing VERSUS Current HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Haiti; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Haiti; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Current HIV testing","SE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","Cost-Saving","Universal antenatal HIV testing VERSUS Current HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Kenya; Other- Pregnant women; HIV prevalence among pregnant women, 7%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Kenya; Other- Pregnant women; HIV prevalence among pregnant women, 7%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Current HIV testing","SE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","Cost-Saving","Universal antenatal HIV testing VERSUS Current HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Namibia; Other- Pregnant women; HIV prevalence among pregnant women, 17%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Namibia; Other- Pregnant women; HIV prevalence among pregnant women, 17%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Current HIV testing","SE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","Cost-Saving","Universal antenatal HIV testing VERSUS Current HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Viet Nam; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Viet Nam; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Current HIV testing","SE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","Cost-Saving","Universal antenatal HIV testing VERSUS Focused HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Haiti; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Haiti; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Focused HIV testing","SE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","Cost-Saving","Universal antenatal HIV testing VERSUS Focused HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Kenya; Other- Pregnant women; HIV prevalence among pregnant women, 7%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Kenya; Other- Pregnant women; HIV prevalence among pregnant women, 7%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Focused HIV testing","SE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","Cost-Saving","Universal antenatal HIV testing VERSUS Focused HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Namibia; Other- Pregnant women; HIV prevalence among pregnant women, 17%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Namibia; Other- Pregnant women; HIV prevalence among pregnant women, 17%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Focused HIV testing","SE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","Cost-Saving","Universal antenatal HIV testing VERSUS Highly focused HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Haiti; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Haiti; Other- Pregnant women; HIV prevalence among pregnant women, 3%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Highly focused HIV testing","SE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","Cost-Saving","Universal antenatal HIV testing VERSUS Highly focused HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Kenya; Other- Pregnant women; HIV prevalence among pregnant women, 7%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Kenya; Other- Pregnant women; HIV prevalence among pregnant women, 7%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Highly focused HIV testing","SE"
"2016-01-21471","2016","Ishikawa 2016 J Int AIDS Soc","Cost-Saving","Universal antenatal HIV testing VERSUS Highly focused HIV testing IN Specific disease- HIV; Age- Adult; Gender- Female; Country- Namibia; Other- Pregnant women; HIV prevalence among pregnant women, 17%.","27978939","Specific disease- HIV; Age- Adult; Gender- Female; Country- Namibia; Other- Pregnant women; HIV prevalence among pregnant women, 17%.","Universal antenatal HIV testing","Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.","Highly focused HIV testing","SE"
"2002-01-01171","2002","Khan 2002 N Engl J Med","1900","Tuberculin skin testing and treatment with rifampin and pyrazinamide daily for 2 months for positive test results VERSUS Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results IN Documented immigrants 18 years of age or older who entered the US from developing nations (China) int he year 2000","12466510","Documented immigrants 18 years of age or older who entered the US from developing nations (China) int he year 2000","Tuberculin skin testing and treatment with rifampin and pyrazinamide daily for 2 months for positive test results","Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States.","Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results","NE"
"2002-01-01171","2002","Khan 2002 N Engl J Med","21000","Tuberculin skin testing and treatment with rifampin daily for 4 months for positive test results VERSUS Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results IN Documented immigrants 18 years of age or older who enetered the US from developing nations (China) n the year 2000","12466510","Documented immigrants 18 years of age or older who enetered the US from developing nations (China) n the year 2000","Tuberculin skin testing and treatment with rifampin daily for 4 months for positive test results","Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States.","Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results","NE"
"2002-01-01171","2002","Khan 2002 N Engl J Med","Cost-Saving","Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results VERSUS No treatment IN Documented immigrants 18 years of age or older who enetered the US from developing nations (China) n the year 2000","12466510","Documented immigrants 18 years of age or older who enetered the US from developing nations (China) n the year 2000","Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results","Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States.","No treatment","SE"
"2012-01-08958","2012","Karow 2012 J Clin Psychiatry","Cost-Saving","Assertive community treatment (ACT)- specialized psychosis inpatient unit, 2-day-clinics, a psychosis outpatient center, occupational therapy center and a network of 6 private psychiatrists VERSUS Standard of care- treatment network of open and closed inpatient wards, day clinics, an outpatient center, and 8 private psychiatrists IN Patients aged 18-65 years with schizophrenia spectrum disorder, newly initiated or on current therapy of quetiapine immediate release (IR) in Germany","22490266","Patients aged 18-65 years with schizophrenia spectrum disorder, newly initiated or on current therapy of quetiapine immediate release (IR) in Germany","Assertive community treatment (ACT)- specialized psychosis inpatient unit, 2-day-clinics, a psychosis outpatient center, occupational therapy center and a network of 6 private psychiatrists","Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).","Standard of care- treatment network of open and closed inpatient wards, day clinics, an outpatient center, and 8 private psychiatrists","SE"
"2012-01-09611","2012","Casciano 2012 J Med Econ","39000","Everolimus (10mg daily) VERSUS Sunitinib (37.5mg daily) IN Patients with advanced progressive pancreatic neuroendocrine tumors","22881362","Patients with advanced progressive pancreatic neuroendocrine tumors","Everolimus (10mg daily)","Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.","Sunitinib (37.5mg daily)","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","41000","Biosimilar-infliximab  VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","Biosimilar-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","58000","Originator-infliximab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","Originator-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","71000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Hungary.","Adalimumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","100000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Italy.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Italy.","Adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","100000","biosimilar infliximab and adalimumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Italy.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Italy.","biosimilar infliximab and adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","100000","Infliximab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","Infliximab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","110000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Netherlands.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Netherlands.","Adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","110000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Spain.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Spain.","Adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","110000","biosimilar infliximab and adalimumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Netherlands.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Netherlands.","biosimilar infliximab and adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","110000","biosimilar infliximab and adalimumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Spain.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Spain.","biosimilar infliximab and adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","110000","Infliximab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","Infliximab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","120000","biosimilar infliximab and adalimumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","biosimilar infliximab and adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","150000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","Adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","170000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","Adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","190000","biosimilar infliximab and adalimumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","biosimilar infliximab and adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","200000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Italy.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Italy.","Vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care"," "
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","200000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Netherlands.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Netherlands.","Vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care"," "
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","210000","biosimilar infliximab and vedolizumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Netherlands.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Netherlands.","biosimilar infliximab and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","220000","biosimilar infliximab and vedolizumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Italy.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Italy.","biosimilar infliximab and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","240000","biosimilar infliximab, adalimumab, and vedolizumab VERSUS Biosimilar infliximab and adalimumab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Netherlands.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Netherlands.","biosimilar infliximab, adalimumab, and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab and adalimumab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","240000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Hungary.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Hungary.","Vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care"," "
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","250000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in France.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in France.","Vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care"," "
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","260000","biosimilar infliximab, adalimumab, and vedolizumab VERSUS Biosimilar infliximab and adalimumab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Italy.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Italy.","biosimilar infliximab, adalimumab, and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab and adalimumab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","270000","biosimilar infliximab and vedolizumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","biosimilar infliximab and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","270000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","Vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care"," "
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","290000","biosimilar infliximab and vedolizumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in France.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in France.","biosimilar infliximab and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","290000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in United Kingdom.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in United Kingdom.","Vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care"," "
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","300000","biosimilar infliximab and vedolizumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","biosimilar infliximab and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","300000","biosimilar infliximab and vedolizumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Hungary.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Hungary.","biosimilar infliximab and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","300000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","Vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care"," "
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","310000","biosimilar infliximab and vedolizumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in United Kingdom.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in United Kingdom.","biosimilar infliximab and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","320000","biosimilar infliximab, adalimumab, and vedolizumab VERSUS Biosimilar infliximab and adalimumab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","biosimilar infliximab, adalimumab, and vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab and adalimumab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","330000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Spain.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Spain.","Vedolizumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care"," "
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","81000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Hungary.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Hungary.","Adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","83000","biosimilar infliximab and adalimumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in France.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in France.","biosimilar infliximab and adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","84000","Infliximab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in United Kingdom.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in United Kingdom.","Infliximab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","85000","Biosimilar infliximab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Germany.","Biosimilar infliximab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","86000","biosimilar infliximab and adalimumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in United Kingdom.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in United Kingdom.","biosimilar infliximab and adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","91000","Biosimilar infliximab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Sweden.","Biosimilar infliximab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","93000","biosimilar infliximab and adalimumab VERSUS Biosimilar infliximab IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Hungary.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in Hungary.","biosimilar infliximab and adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Biosimilar infliximab","NE"
"2017-01-23311","2017","Rencz 2017 Expert Rev Pharmacoecon Outcomes Res","98000","Adalimumab VERSUS Standard/Usual Care IN Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in United Kingdom.","28434387","Specific disease- Luminal Crohn's disease; Age- Adult; Gender- Both; Country- Europe; Other- Patients with active luminal CD who were eligible for biological treatment in United Kingdom.","Adalimumab","Cost-utility of biological treatment sequences for luminal Crohn''s disease in Europe.","Standard/Usual Care","NE"
"2016-01-20284","2016","Zemplenyi 2016 Eur J Cancer Care (Engl)","Cost-Saving","High-dose intensity-modulated radiotherapy VERSUS Standard/Usual Care- Conventional dose 3DCRT (radiation therapy) IN Specific disease- localised prostate cancer; Age- Adult; Gender- Male; Country- Hungary.","26782759","Specific disease- localised prostate cancer; Age- Adult; Gender- Male; Country- Hungary.","High-dose intensity-modulated radiotherapy","Cost-effectiveness analysis of intensity-modulated radiation therapy with normal  and hypofractionated schemes for the treatment of localised prostate cancer.","Standard/Usual Care- Conventional dose 3DCRT (radiation therapy)","SE"
"2016-01-20284","2016","Zemplenyi 2016 Eur J Cancer Care (Engl)","Cost-Saving","Hypofractionated intensity-modulated radiation therapy VERSUS Standard/Usual Care- conventional dose 3DCRT (radiation therapy) IN Specific disease- localised prostate cancer; Age- Adult; Gender- Male; Country- Hungary.","26782759","Specific disease- localised prostate cancer; Age- Adult; Gender- Male; Country- Hungary.","Hypofractionated intensity-modulated radiation therapy","Cost-effectiveness analysis of intensity-modulated radiation therapy with normal  and hypofractionated schemes for the treatment of localised prostate cancer.","Standard/Usual Care- conventional dose 3DCRT (radiation therapy)","SE"
"2014-01-15139","2014","Nagy 2014 Eur J Obstet Gynecol Reprod Biol","27000","Preoperative ulipristal acetate VERSUS Standard/Usual Care- Standard pre-surgical observation IN Specific disease- Moderate to severe symptoms of uterine fibroids; Age- 41 to 64 years, Adult; Gender- Female; Country- Hungary.","24568866","Specific disease- Moderate to severe symptoms of uterine fibroids; Age- 41 to 64 years, Adult; Gender- Female; Country- Hungary.","Preoperative ulipristal acetate","The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids.","Standard/Usual Care- Standard pre-surgical observation","NE"
"2014-01-15139","2014","Nagy 2014 Eur J Obstet Gynecol Reprod Biol","5000","Preoperative ulipristal acetate VERSUS Immediate hysterectomy IN Specific disease- Moderate to severe symptoms of uterine fibroids; Age- Adult; Gender- Female; Country- Hungary.","24568866","Specific disease- Moderate to severe symptoms of uterine fibroids; Age- Adult; Gender- Female; Country- Hungary.","Preoperative ulipristal acetate","The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids.","Immediate hysterectomy","NE"
"2012-01-09982","2012","Vok?                             2012 BMC Public Health","32000","Participation in the HPV vaccination program (coverage=80%) VERSUS None IN 12 year old girls at risk for human papillomavirus infection (HPV) in Hungary","23110361","12 year old girls at risk for human papillomavirus infection (HPV) in Hungary","Participation in the HPV vaccination program (coverage=80%)","Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.","None","NE"
"2012-01-08532","2012","Vok?                             2012 Value Health","22000","Pap smear VERSUS None IN Women aged 25-64 years in Hungary","22264970","Women aged 25-64 years in Hungary","Pap smear","Modeling cost-effectiveness of cervical cancer screening in hungary.","None","NE"
"2012-01-08532","2012","Vok?                             2012 Value Health","38000","Intensified current screening- current practice of screening by cytology and colposcopy in outpatient services along with active communication campaign to reach and motivate women VERSUS None IN Women aged 25-64 years in Hungary","22264970","Women aged 25-64 years in Hungary","Intensified current screening- current practice of screening by cytology and colposcopy in outpatient services along with active communication campaign to reach and motivate women","Modeling cost-effectiveness of cervical cancer screening in hungary.","None","NE"
"2010-01-06161","2010","Dasbach 2010 J Med Econ","15000","Quadrivalent human paillomavirus vaccine (6/11/16/18) at age 12 VERSUS No vaccination IN Girls aged 12 years in Hungary","20085477","Girls aged 12 years in Hungary","Quadrivalent human paillomavirus vaccine (6/11/16/18) at age 12","The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.","No vaccination","NE"
"2010-01-06161","2010","Dasbach 2010 J Med Econ","17000","Quadrivalent human paillomavirus vaccine (6/11/16/18) at age 12 VERSUS Quadrivalent human paillomavirus vaccine (6/11/16/18) at age 12 plus a temporary catch-up program for girls and women aged 12-24 IN Girls aged 12 years in Hungary","20085477","Girls aged 12 years in Hungary","Quadrivalent human paillomavirus vaccine (6/11/16/18) at age 12","The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.","Quadrivalent human paillomavirus vaccine (6/11/16/18) at age 12 plus a temporary catch-up program for girls and women aged 12-24","NE"
"2009-01-05027","2009","Inotai 2009 Int J Technol Assess Health Care","24000","Nonsteroidal anti-inflammatory drugs with proton pump inhibitors VERSUS Nonsteroidal anti-inflammatory drugs alone IN Rheumatoid arthritis patients in Hungary","19366498","Rheumatoid arthritis patients in Hungary","Nonsteroidal anti-inflammatory drugs with proton pump inhibitors","Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.","Nonsteroidal anti-inflammatory drugs alone","NE"
"2009-01-13521","2009","Oddsson 2009 Acta Obstet Gynecol Scand","29","Human papillomavirus (HPV) vaccination VERSUS None IN Population of 12-year-old girls in the Icelandic population.","19900074","Population of 12-year-old girls in the Icelandic population.","Human papillomavirus (HPV) vaccination","Cost-effectiveness of human papilloma virus vaccination in Iceland.","None","NE"
"2018-01-27426","2018","John 2018 Biol Blood Marrow Transplant","1600","Hematopoietic stem cell transplantation with an HLA-identical matched unrelated donor VERSUS Standard/Usual Care- Transfusion-chelation IN Specific disease- Thalassemia Major; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- India.","29673692","Specific disease- Thalassemia Major; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- India.","Hematopoietic stem cell transplantation with an HLA-identical matched unrelated donor","Cost Effectiveness of Hematopoietic Stem Cell Transplantation Compared with Transfusion Chelation for Treatment of Thalassemia Major.","Standard/Usual Care- Transfusion-chelation","NE"
"2018-01-27426","2018","John 2018 Biol Blood Marrow Transplant","500","Hematopoietic stem cell transplantation with an HLA-identical matched related donor VERSUS Standard/Usual Care- Transfusion-chelation IN Specific disease- Thalassemia major; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- India.","29673692","Specific disease- Thalassemia major; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- India.","Hematopoietic stem cell transplantation with an HLA-identical matched related donor","Cost Effectiveness of Hematopoietic Stem Cell Transplantation Compared with Transfusion Chelation for Treatment of Thalassemia Major.","Standard/Usual Care- Transfusion-chelation","NE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","170","Pan-Genotypic direct-acting antiviral agent regimen VERSUS Standard/Usual Care- Genotype-Dependent direct-acting antiviral agent regimen IN Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Cirrhosis (F4); Genotype 4.","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Cirrhosis (F4); Genotype 4.","Pan-Genotypic direct-acting antiviral agent regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","Standard/Usual Care- Genotype-Dependent direct-acting antiviral agent regimen","NE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","180","Pan-Genotypic direct-acting antiviral agent regimen VERSUS Standard/Usual Care- Genotype-Dependent direct-acting antiviral agent regimen IN Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Cirrhosis (F4); Genotype 1.","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Cirrhosis (F4); Genotype 1.","Pan-Genotypic direct-acting antiviral agent regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","Standard/Usual Care- Genotype-Dependent direct-acting antiviral agent regimen","NE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","250","Pan-Genotypic direct-acting antiviral agent regimen VERSUS Standard/Usual Care- Genotype-Dependent direct-acting antiviral agent regimen IN Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- All patients.","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- All patients.","Pan-Genotypic direct-acting antiviral agent regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","Standard/Usual Care- Genotype-Dependent direct-acting antiviral agent regimen","NE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","360","Pan-Genotypic direct-acting antiviral regimen VERSUS Standard/Usual Care- Genotype-Dependent direct-acting antiviral regimen IN Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Non-cirrhosis (F0âF3); Genotype 3.","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Non-cirrhosis (F0âF3); Genotype 3.","Pan-Genotypic direct-acting antiviral regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","Standard/Usual Care- Genotype-Dependent direct-acting antiviral regimen","NE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","390","Pan-Genotypic direct-acting antiviral regimen VERSUS Standard/Usual Care- Genotype-Dependent direct-acting antiviral regimen IN Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Non-cirrhosis (F0âF3); all genotypes.","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Non-cirrhosis (F0âF3); all genotypes.","Pan-Genotypic direct-acting antiviral regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","Standard/Usual Care- Genotype-Dependent direct-acting antiviral regimen","NE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","470","Pan-genotypic direct-acting antiviral regimen VERSUS Standard/Usual Care- Genotype-dependent direct-acting antiviral regimen IN Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Non-cirrhosis (F0âF3); Genotype 1.","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Non-cirrhosis (F0âF3); Genotype 1.","Pan-genotypic direct-acting antiviral regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","Standard/Usual Care- Genotype-dependent direct-acting antiviral regimen","NE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","490","Pan-Genotypic direct-acting antiviral regimen VERSUS Standard/Usual Care- Genotype-Dependent direct-acting antiviral regimen IN Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Non-cirrhosis (F0âF3); Genotype 4.","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Non-cirrhosis (F0âF3); Genotype 4.","Pan-Genotypic direct-acting antiviral regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","Standard/Usual Care- Genotype-Dependent direct-acting antiviral regimen","NE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","Cost-Saving","Genotype-Dependent direct-acting antiviral agent regimen  VERSUS None IN Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- All patients.","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- All patients.","Genotype-Dependent direct-acting antiviral agent regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","None","SE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","Cost-Saving","Pan-Genotypic direct-acting antiviral agent regimen VERSUS None IN Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- All patients.","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- All patients.","Pan-Genotypic direct-acting antiviral agent regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","None","SE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","Cost-Saving","Pan-Genotypic direct-acting antiviral agent regimen VERSUS Standard/Usual Care- Genotype-Dependent direct-acting antiviral agent regimen IN Specific disease- Hepatitis C; Age- 19 to 40 years; ; Country- India; Other- Cirrhosis (F4); Genotype 3.","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; ; Country- India; Other- Cirrhosis (F4); Genotype 3.","Pan-Genotypic direct-acting antiviral agent regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","Standard/Usual Care- Genotype-Dependent direct-acting antiviral agent regimen","SE"
"2018-01-27036","2018","Goel 2018 J Gastroenterol Hepatol","Cost-Saving","Pan-Genotypic direct-acting antiviral agent regimen VERSUS Standard/Usual Care- Genotype-Dependent direct-acting antiviral agent regimen IN Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Cirrhosis (F4); all Genotype .","29864213","Specific disease- Hepatitis C; Age- 19 to 40 years; Gender- Both; Country- India; Other- Cirrhosis (F4); all Genotype .","Pan-Genotypic direct-acting antiviral agent regimen","Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.","Standard/Usual Care- Genotype-Dependent direct-acting antiviral agent regimen","SE"
"2018-01-26666","2018","Mateti 2018 Postgrad Med","1300","Pharmaceutical care group: pharmaceutical education designed by trained pharmacist VERSUS Standard/Usual Care- Usual care for hemodialysis patients IN Specific disease- Hemodialysis patients; Age- Adult; Gender- Both; Country- India; Other- Academic hospital patients.","30047816","Specific disease- Hemodialysis patients; Age- Adult; Gender- Both; Country- India; Other- Academic hospital patients.","Pharmaceutical care group: pharmaceutical education designed by trained pharmacist","Cost-effectiveness of pharmaceutical care on patients undergoing maintenance hemodialysis - a multicenter randomized controlled study.","Standard/Usual Care- Usual care for hemodialysis patients","NE"
"2018-01-26666","2018","Mateti 2018 Postgrad Med","1400","Pharmaceutical care group: pharmaceutical education designed by trained pharmacist VERSUS Standard/Usual Care- Usual care for hemodialysis patients IN Specific disease- Hemodialysis patients; Age- Adult; Gender- Both; Country- India; Other- Corporate hospital patients.","30047816","Specific disease- Hemodialysis patients; Age- Adult; Gender- Both; Country- India; Other- Corporate hospital patients.","Pharmaceutical care group: pharmaceutical education designed by trained pharmacist","Cost-effectiveness of pharmaceutical care on patients undergoing maintenance hemodialysis - a multicenter randomized controlled study.","Standard/Usual Care- Usual care for hemodialysis patients","NE"
"2018-01-26666","2018","Mateti 2018 Postgrad Med","3600","Pharmaceutical care group: pharmaceutical education designed by trained pharmacist VERSUS Standard/Usual Care- Usual care for hemodialysis patients IN Specific disease- Hemodialysis patients; Age- Adult; Gender- Both; Country- India; Other- Government hospital patients.","30047816","Specific disease- Hemodialysis patients; Age- Adult; Gender- Both; Country- India; Other- Government hospital patients.","Pharmaceutical care group: pharmaceutical education designed by trained pharmacist","Cost-effectiveness of pharmaceutical care on patients undergoing maintenance hemodialysis - a multicenter randomized controlled study.","Standard/Usual Care- Usual care for hemodialysis patients","NE"
"2017-01-23802","2017","Prinja 2017 Indian J Hematol Blood Transfus","9400","Autologous stem cell transplantation (ASCT) along with high dose chemotherapy (HDC).  VERSUS Standard/Usual Care- Conventional chemotherapy alone IN Specific disease- Multiple myeloma; Age- Adult; Gender- Both; Country- India.","28194053","Specific disease- Multiple myeloma; Age- Adult; Gender- Both; Country- India.","Autologous stem cell transplantation (ASCT) along with high dose chemotherapy (HDC).","Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional  Chemotherapy for Treatment of Multiple Myeloma in India.","Standard/Usual Care- Conventional chemotherapy alone","NE"
"2017-01-23229","2017","Prinja 2017 Cancer"," ","Human papilloma virus (HPV) vaccination VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Female; Country- India; Other- 11-year-old preadolescent girls in Punjab state.","28472550","Healthy; Age- 0 to 18 years; Gender- Female; Country- India; Other- 11-year-old preadolescent girls in Punjab state.","Human papilloma virus (HPV) vaccination","Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India''s universal immunization program.","None","NE"
"2017-01-23128","2017","Aggarwal 2017 PLoS One","Cost-Saving","directly-acting antivirals (DAAs) All patients VERSUS None IN Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","28520728","Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","directly-acting antivirals (DAAs) All patients","Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.","None","SE"
"2017-01-23128","2017","Aggarwal 2017 PLoS One","Cost-Saving","directly-acting antivirals (DAAs) Cirrhosis (F4) All F4 VERSUS None IN Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","28520728","Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","directly-acting antivirals (DAAs) Cirrhosis (F4) All F4","Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.","None","SE"
"2017-01-23128","2017","Aggarwal 2017 PLoS One","Cost-Saving","directly-acting antivirals (DAAs) Cirrhosis (F4) Genotype1 VERSUS None IN Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","28520728","Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","directly-acting antivirals (DAAs) Cirrhosis (F4) Genotype1","Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.","None","SE"
"2017-01-23128","2017","Aggarwal 2017 PLoS One","Cost-Saving","directly-acting antivirals (DAAs) Cirrhosis (F4) Genotype3 VERSUS None IN Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","28520728","Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","directly-acting antivirals (DAAs) Cirrhosis (F4) Genotype3","Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.","None","SE"
"2017-01-23128","2017","Aggarwal 2017 PLoS One","Cost-Saving","directly-acting antivirals (DAAs) Cirrhosis (F4) Genotype4 VERSUS None IN Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","28520728","Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","directly-acting antivirals (DAAs) Cirrhosis (F4) Genotype4","Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.","None","SE"
"2017-01-23128","2017","Aggarwal 2017 PLoS One","Cost-Saving","directly-acting antivirals (DAAs) Non-cirrhosis (F0-F3) All F0-F3 VERSUS None IN Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","28520728","Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","directly-acting antivirals (DAAs) Non-cirrhosis (F0-F3) All F0-F3","Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.","None","SE"
"2017-01-23128","2017","Aggarwal 2017 PLoS One","Cost-Saving","directly-acting antivirals (DAAs) Non-cirrhosis (F0-F3) Genotype 1 VERSUS None IN Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","28520728","Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","directly-acting antivirals (DAAs) Non-cirrhosis (F0-F3) Genotype 1","Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.","None","SE"
"2017-01-23128","2017","Aggarwal 2017 PLoS One","Cost-Saving","directly-acting antivirals (DAAs) Non-cirrhosis (F0-F3) Genotype 3 VERSUS None IN Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","28520728","Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","directly-acting antivirals (DAAs) Non-cirrhosis (F0-F3) Genotype 3","Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.","None","SE"
"2017-01-23128","2017","Aggarwal 2017 PLoS One","Cost-Saving","directly-acting antivirals (DAAs) Non-cirrhosis (F0-F3) Genotype 4 VERSUS None IN Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","28520728","Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- India.","directly-acting antivirals (DAAs) Non-cirrhosis (F0-F3) Genotype 4","Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.","None","SE"
"2015-01-21043","2015","Maddali 2015 J Int AIDS Soc","470","Early antiretroviral therapy (ART) initiation (CD4 >/= 350 cells/mm3) VERSUS Initiating ART at CD4 5350 cells/mm3 IN Specific disease- Human immunodeficiency virus (HIV); Age- Adult; Gender- Both; Country- India.","26434780","Specific disease- Human immunodeficiency virus (HIV); Age- Adult; Gender- Both; Country- India.","Early antiretroviral therapy (ART) initiation (CD4 >/= 350 cells/mm3)","Economic and epidemiological impact of early antiretroviral therapy initiation in India.","Initiating ART at CD4 5350 cells/mm3","NE"
"2015-01-19001","2015","Gupta 2015 J Med Econ","210","BIAsp 30, biphasic insulin aspart 30 VERSUS NPH, neutral protamine Hagedorn IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- India.","25426701","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- India.","BIAsp 30, biphasic insulin aspart 30","An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.","NPH, neutral protamine Hagedorn","NE"
"2015-01-19001","2015","Gupta 2015 J Med Econ","240","BIAsp 30, biphasic insulin aspart 30 VERSUS BHI, biphasic human insulin 30 IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Saudia Arabia.","25426701","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Saudia Arabia.","BIAsp 30, biphasic insulin aspart 30","An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.","BHI, biphasic human insulin 30","NE"
"2015-01-19001","2015","Gupta 2015 J Med Econ","380","BIAsp 30, biphasic insulin aspart 30 VERSUS BHI, biphasic human insulin 30 IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- India.","25426701","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- India.","BIAsp 30, biphasic insulin aspart 30","An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.","BHI, biphasic human insulin 30","NE"
"2015-01-19001","2015","Gupta 2015 J Med Econ","5000","BIAsp 30, biphasic insulin aspart 30 VERSUS BHI, biphasic human insulin 30 IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Indonesia.","25426701","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Indonesia.","BIAsp 30, biphasic insulin aspart 30","An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.","BHI, biphasic human insulin 30","NE"
"2015-01-19001","2015","Gupta 2015 J Med Econ","Cost-Saving","BIAsp 30, biphasic insulin aspart 30 VERSUS IGlar, insulin glargine IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- India.","25426701","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- India.","BIAsp 30, biphasic insulin aspart 30","An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.","IGlar, insulin glargine","SE"
"2015-01-19001","2015","Gupta 2015 J Med Econ","Cost-Saving","BIAsp 30, biphasic insulin aspart 30 VERSUS IGlar, insulin glargine IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Saudia Arabia.","25426701","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Saudia Arabia.","BIAsp 30, biphasic insulin aspart 30","An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.","IGlar, insulin glargine","SE"
"2015-01-19001","2015","Gupta 2015 J Med Econ","Cost-Saving","BIAsp 30, biphasic insulin aspart 30 VERSUS NPH, neutral protamine Hagedorn IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Saudia Arabia.","25426701","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Saudia Arabia.","BIAsp 30, biphasic insulin aspart 30","An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.","NPH, neutral protamine Hagedorn","SE"
"2015-01-17699","2015","Rosenthal 2015 Am J Infect Control","Cost-Saving","Split septum and single-use prefilled flushing device on IV VERSUS 3-way stopcock on central line of IV IN Healthy; Age- Adult; Gender- Both; Country- India; Other- Patients using IV.","26164769","Healthy; Age- Adult; Gender- Both; Country- India; Other- Patients using IV.","Split septum and single-use prefilled flushing device on IV","Clinical impact and cost-effectiveness of split-septum and single-use prefilled flushing device vs 3-way stopcock on central line-associated bloodstream infection rates in India: a randomized clinical trial conducted by the International Nosocomial Infection Control Consortium (INICC).","3-way stopcock on central line of IV","SE"
"2015-01-17472","2015","Suen 2015 Int J Tuberc Lung Dis","1200","Private-public mix intervention with GeneXpert for all diagnosis VERSUS Private-public mix intervention where some patients entering private clinics may be referred to public clinics plus diagnosis with GeneXpert for drug susceptibility testing IN Specific disease- Tuberculosis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- .","26260835","Specific disease- Tuberculosis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- .","Private-public mix intervention with GeneXpert for all diagnosis","Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India.","Private-public mix intervention where some patients entering private clinics may be referred to public clinics plus diagnosis with GeneXpert for drug susceptibility testing","NE"
"2015-01-17472","2015","Suen 2015 Int J Tuberc Lung Dis","130","Private-public mix intervention with GeneXpert for drug susceptibility testing VERSUS Private-public mix intervention where some patients entering private clinics may be referred to public clinics IN Specific disease- Tuberculosis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- .","26260835","Specific disease- Tuberculosis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- .","Private-public mix intervention with GeneXpert for drug susceptibility testing","Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India.","Private-public mix intervention where some patients entering private clinics may be referred to public clinics","NE"
"2015-01-17472","2015","Suen 2015 Int J Tuberc Lung Dis","78","Private-public mix intervention VERSUS None IN Specific disease- Tuberculosis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- .","26260835","Specific disease- Tuberculosis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- .","Private-public mix intervention","Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","10000","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Indonesia.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Indonesia.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","12000","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Indonesia.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Indonesia.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","8400","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Indonesia.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Indonesia.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","10000","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN) VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NE"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","10000","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN) VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NE"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","18000","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN) VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NE"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","38000","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN) VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NE"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Cost-Saving","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA1 + APR)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA1 + APR)","SE"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Cost-Saving","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) VERSUS Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1)","SE"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Cost-Saving","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) VERSUS Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1)","SE"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Cost-Saving","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) VERSUS Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1)","SE"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.","Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple VERSUS Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple VERSUS Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple VERSUS Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.","Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple VERSUS Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2)  VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.","Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2)  VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.","Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NW"
"2018-01-26483","2018","Chanthawong 2018 Support Care Cancer","Dominated","Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2)  VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)  IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","30112718","Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.","Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2)","Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.","Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN)","NW"
"2017-01-25475","2017","Afiatin 2017 PLoS One","13000","Peritoneal dialysis-first policy VERSUS Supportive care (fluid restriction, high-dose diuretics, hypertensive drugs, calcium bicarbonate, ferrous sulfate, and blood transfusion) IN Specific disease- End-stage renal disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Indonesia; Other- Patients who cannot afford dialysis or kidney transplantation.","28545094","Specific disease- End-stage renal disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Indonesia; Other- Patients who cannot afford dialysis or kidney transplantation.","Peritoneal dialysis-first policy","Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia.","Supportive care (fluid restriction, high-dose diuretics, hypertensive drugs, calcium bicarbonate, ferrous sulfate, and blood transfusion)","NE"
"2017-01-25475","2017","Afiatin 2017 PLoS One","14000","Hemodialysis-first policy VERSUS Supportive care (fluid restriction, high-dose diuretics, hypertensive drugs, calcium bicarbonate, ferrous sulfate, and blood transfusion) IN Specific disease- End-stage renal disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Indonesia; Other- Patients who cannot afford dialysis or kidney transplantation.","28545094","Specific disease- End-stage renal disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Indonesia; Other- Patients who cannot afford dialysis or kidney transplantation.","Hemodialysis-first policy","Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia.","Supportive care (fluid restriction, high-dose diuretics, hypertensive drugs, calcium bicarbonate, ferrous sulfate, and blood transfusion)","NE"
"2017-01-25032","2017","Kosen 2017 Asian Pac J Cancer Prev","410","Quadrivalent Human Papillomavirus With Catch Up. VERSUS Standard/Usual Care-  Quadrivalent Human Papillomavirus Without Catch Up. IN Specific disease-  Human Papillomavirus ; Age- 0 to 18 years; Gender- Female; Country- Indonesia.","28749644","Specific disease-  Human Papillomavirus ; Age- 0 to 18 years; Gender- Female; Country- Indonesia.","Quadrivalent Human Papillomavirus With Catch Up.","The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia","Standard/Usual Care-  Quadrivalent Human Papillomavirus Without Catch Up.","NE"
"2017-01-25032","2017","Kosen 2017 Asian Pac J Cancer Prev","480","Human Papillomavirus Quadrivalent Vaccination. VERSUS Standard/Usual Care- Screening only IN Specific disease- Human Papillomavirus ; Age- 0 to 18 years; Gender- Female; Country- Indonesia.","28749644","Specific disease- Human Papillomavirus ; Age- 0 to 18 years; Gender- Female; Country- Indonesia.","Human Papillomavirus Quadrivalent Vaccination.","The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia","Standard/Usual Care- Screening only","NE"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","110000","PRIAS Biopsy Schedule VERSUS Biopsy every 5 years IN Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","30425010","Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","PRIAS Biopsy Schedule","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","Biopsy every 5 years","NE"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","12000","Biopsy every 5 years VERSUS Watchful Waiting IN Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","30425010","Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","Biopsy every 5 years","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","Watchful Waiting","NE"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","220000","Biennial Biopsy VERSUS Biopsy Every 3 years IN Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","30425010","Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","Biennial Biopsy","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","Biopsy Every 3 years","NE"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","490000","PRIAS MRI schedule VERSUS MRI every 5 years IN Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","30425010","Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","PRIAS MRI schedule","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","MRI every 5 years","NE"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","6.4e+006","Biennial MRI  VERSUS PRIAS MRI schedule for Men with Low-risk Prostate Cancer. IN Specific disease- Prostate Cancer.; Age-; Gender- Male; Country- United States.","30425010","Specific disease- Prostate Cancer.; Age-; Gender- Male; Country- United States.","Biennial MRI","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","PRIAS MRI schedule for Men with Low-risk Prostate Cancer.","NE"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","660000","Annual Biopsy VERSUS Biennial Biopsy IN Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","30425010","Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","Annual Biopsy","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","Biennial Biopsy","NE"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","94000","MRI every 5 years VERSUS Biopsy every 5 years IN Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","30425010","Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","MRI every 5 years","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","Biopsy every 5 years","NE"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","Dominated","Annual MRI VERSUS Biennial MRI IN Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States.","30425010","Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States.","Annual MRI","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","Biennial MRI","NW"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","Dominated","Biopsy Every 3 years VERSUS PRAIS biopsy schedule IN Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","30425010","Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","Biopsy Every 3 years","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","PRAIS biopsy schedule","NW"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","Dominated","Immediate Treatment VERSUS MRI every 3 years IN Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States.","30425010","Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States.","Immediate Treatment","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","MRI every 3 years","NW"
"2018-01-28508","2018","Sathianathen 2018 Eur Urol","Dominated","MRI every 3 years VERSUS PRAIS MRI Schedule IN Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","30425010","Specific disease- Prostate Cancer; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Low-Risk.","MRI every 3 years","Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.","PRAIS MRI Schedule","NW"
"2018-01-28377","2018","Sherman 2018 JAMA Oncol","730000","Capecitabine and bevacizumab maintenance therapy VERSUS Standard/Usual Care- Standard metastatic colorectal cancer treatment IN Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- United States.","30489611","Specific disease- Metastatic Colorectal Cancer; Age- Adult; Gender- Both; Country- United States.","Capecitabine and bevacizumab maintenance therapy","Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.","Standard/Usual Care- Standard metastatic colorectal cancer treatment","NE"
"2018-01-26964","2018","Sathianathen 2018 J Urol","60000","EPI- ExoDx Prostate Biomarker test used to determine whether biopsy required VERSUS Standard/Usual Care- Prostate Health Index used to determine whether biopsy required IN Healthy; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Elevated prostate specific antigen.","29906434","Healthy; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Elevated prostate specific antigen.","EPI- ExoDx Prostate Biomarker test used to determine whether biopsy required","Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.","Standard/Usual Care- Prostate Health Index used to determine whether biopsy required","NE"
"2018-01-26964","2018","Sathianathen 2018 J Urol","Dominated","4kscore Prostate biomarker test used to determine whether biopsy required VERSUS Standard/Usual Care- EPI -ExoDx Prostate biomarker test used to determine whether biopsy required IN Healthy; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Elevated prostate specific antigen.","29906434","Healthy; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Elevated prostate specific antigen.","4kscore Prostate biomarker test used to determine whether biopsy required","Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.","Standard/Usual Care- EPI -ExoDx Prostate biomarker test used to determine whether biopsy required","NW"
"2018-01-26964","2018","Sathianathen 2018 J Urol","Dominated","Current standard of care (all patients undergo biopsy) VERSUS Standard/Usual Care- EPI - ExoDx Prostate biomarker test used to determine whether biopsy required IN Healthy; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Elevated prostate specific antigen.","29906434","Healthy; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Elevated prostate specific antigen.","Current standard of care (all patients undergo biopsy)","Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.","Standard/Usual Care- EPI - ExoDx Prostate biomarker test used to determine whether biopsy required","NW"
"2018-01-26964","2018","Sathianathen 2018 J Urol","Dominated","Prostate Health Index biomarker test used to determine whether biopsy required VERSUS Standard/Usual Care- SelectMDx biomarker test biomarker test used to determine whether biopsy required IN Healthy; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Elevated prostate specific antigen.","29906434","Healthy; Age- 41 to 64 years; Gender- Male; Country- United States; Other- Elevated prostate specific antigen.","Prostate Health Index biomarker test used to determine whether biopsy required","Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.","Standard/Usual Care- SelectMDx biomarker test biomarker test used to determine whether biopsy required","NW"
"2018-01-26750","2018","Melegaro 2018 BMC Med","10000","Temporary Immunity: routine varicella + HZ vaccinations with HZ catch-up campaign VERSUS Routine varicella vaccination IN Healthy; Age- Adult; Gender- Both; Country- Italy; Other- Herpes vaccine.","30012132","Healthy; Age- Adult; Gender- Both; Country- Italy; Other- Herpes vaccine.","Temporary Immunity: routine varicella + HZ vaccinations with HZ catch-up campaign","The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.","Routine varicella vaccination","NE"
"2018-01-26750","2018","Melegaro 2018 BMC Med","10000","Temporary Immunity: routine varicella and HZ vaccinations VERSUS Routine varicella vaccination IN Healthy; Age- Adult; Gender- Both; Country- Italy; Other- Herpes vaccine.","30012132","Healthy; Age- Adult; Gender- Both; Country- Italy; Other- Herpes vaccine.","Temporary Immunity: routine varicella and HZ vaccinations","The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.","Routine varicella vaccination","NE"
"2018-01-26750","2018","Melegaro 2018 BMC Med","Cost-Saving","Temporary Immunity: Routine varicella vaccination VERSUS None IN Healthy; Age- Adult; Gender- Both; Country- Italy; Other- Herpes vaccine.","30012132","Healthy; Age- Adult; Gender- Both; Country- Italy; Other- Herpes vaccine.","Temporary Immunity: Routine varicella vaccination","The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.","None","SE"
"2018-01-26750","2018","Melegaro 2018 BMC Med","Dominated","Temporary Immunity: routine HZ vaccination VERSUS Routine varicella and HZ vaccinations IN Healthy; Age- Adult; Gender- Both; Country- Italy; Other- Herpes vaccine.","30012132","Healthy; Age- Adult; Gender- Both; Country- Italy; Other- Herpes vaccine.","Temporary Immunity: routine HZ vaccination","The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.","Routine varicella and HZ vaccinations","NW"
"2018-01-26750","2018","Melegaro 2018 BMC Med","Dominated","Temporary Immunity: routine HZ vaccination with HZ catch-up campaign VERSUS Routine varicella and HZ vaccinations with HZ catch-up campaign IN Healthy; Age- Adult; Gender- Both; Country- Italy; Other- Herpes vaccine.","30012132","Healthy; Age- Adult; Gender- Both; Country- Italy; Other- Herpes vaccine.","Temporary Immunity: routine HZ vaccination with HZ catch-up campaign","The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.","Routine varicella and HZ vaccinations with HZ catch-up campaign","NW"
"2017-01-25966","2017","Ebadi Fard Azar 2017 Med J Islam Repub Iran","510000","Teriparatide VERSUS Risedronate IN Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Iran; Other- Postmenopausal.","29445668","Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Iran; Other- Postmenopausal.","Teriparatide","Cost-effectiveness of teriparatide compared with alendronate and risedronate for  the treatment of postmenopausal osteoporosis patients in Iran.","Risedronate","NE"
"2017-01-25966","2017","Ebadi Fard Azar 2017 Med J Islam Repub Iran","Cost-Saving","Alendronate VERSUS Risedronate IN Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Iran; Other- Postmenopausal.","29445668","Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Iran; Other- Postmenopausal.","Alendronate","Cost-effectiveness of teriparatide compared with alendronate and risedronate for  the treatment of postmenopausal osteoporosis patients in Iran.","Risedronate","SE"
"2017-01-25253","2017","Bayazidi 2017 Value Health Reg Issues","470","Multi-fraction palliative radiotherapy  VERSUS Single-fraction palliative radiotherapy IN Specific disease- Painful Bone Metastases; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Iran.","28648321","Specific disease- Painful Bone Metastases; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Iran.","Multi-fraction palliative radiotherapy","Cost-Utility Analysis of Single-Fraction Versus Multiple-Fraction Radiotherapy in Patients with Painful Bone Metastases: An Iranian Patient''s Perspective Study.","Single-fraction palliative radiotherapy","NE"
"2017-01-25211","2017","Qian 2017 Neuro Oncol","11000","Radiotherapy (RT) +procarbazine, lomustine, vincristine (PCV) chemotherapy VERSUS Standard/Usual Care- Radiotherapy (RT) IN Specific disease- Low-grade glioma; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United States of America (USA).","28666368","Specific disease- Low-grade glioma; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United States of America (USA).","Radiotherapy (RT) +procarbazine, lomustine, vincristine (PCV) chemotherapy","Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma.","Standard/Usual Care- Radiotherapy (RT)","NE"
"2017-01-24925","2017","Ansaripour 2017 Pharmacoeconomics","15000","6 months of trastuzumab VERSUS Standard/Usual Care- No trastuzumab IN Specific disease- HER2-Positive Breast cancer ; Age-; Gender- Both; Country- Iran.","28795341","Specific disease- HER2-Positive Breast cancer ; Age-; Gender- Both; Country- Iran.","6 months of trastuzumab","Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.","Standard/Usual Care- No trastuzumab","NE"
"2017-01-24925","2017","Ansaripour 2017 Pharmacoeconomics","19000","1 year of trastuzumab VERSUS Standard/Usual Care- No  trastuzumab IN Specific disease- HER2-Positive Breast cancer ; Age- Adult; Gender- Female; Country- Iran.","28795341","Specific disease- HER2-Positive Breast cancer ; Age- Adult; Gender- Female; Country- Iran.","1 year of trastuzumab","Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.","Standard/Usual Care- No  trastuzumab","NE"
"2017-01-24925","2017","Ansaripour 2017 Pharmacoeconomics","19000","9 month of trastuzumab  VERSUS Standard/Usual Care- No trastuzumab  IN Specific disease- HER2-Positive Breast cancer ; Age- Adult; Gender- Both; Country- Iran.","28795341","Specific disease- HER2-Positive Breast cancer ; Age- Adult; Gender- Both; Country- Iran.","9 month of trastuzumab","Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.","Standard/Usual Care- No trastuzumab","NE"
"2017-01-24667","2017","Martes-Martinez 2017 P R Health Sci J","100000","Warfarin (PGx) VERSUS Standard/Usual Care- Standard care IN Specific disease- Thromboembolic event; Age- Unknown; Gender- Both; Country- United States of America (USA); Other- Puerto Rican population, Cytochrome P450 Isoform 2C9.","28915306","Specific disease- Thromboembolic event; Age- Unknown; Gender- Both; Country- United States of America (USA); Other- Puerto Rican population, Cytochrome P450 Isoform 2C9.","Warfarin (PGx)","Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.","Standard/Usual Care- Standard care","NE"
"2017-01-24667","2017","Martes-Martinez 2017 P R Health Sci J","140000","Pharmacogenetic-guided dosing of warfarin VERSUS Standard/Usual Care- Standard emperical dosing of warfarin IN Healthy; Age- Adult; Gender- Both; Country- United States of America (USA); Other- Puerto Rican population  VKORC1 AA/AB.","28915306","Healthy; Age- Adult; Gender- Both; Country- United States of America (USA); Other- Puerto Rican population  VKORC1 AA/AB.","Pharmacogenetic-guided dosing of warfarin","Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.","Standard/Usual Care- Standard emperical dosing of warfarin","NE"
"2017-01-24667","2017","Martes-Martinez 2017 P R Health Sci J","140000","Warfarin (PGx) VERSUS Standard/Usual Care IN Specific disease- Thromboembolic event; Age- Unknown; Gender- Both; Country- United States of America (USA); Other- Puerto Rican population.","28915306","Specific disease- Thromboembolic event; Age- Unknown; Gender- Both; Country- United States of America (USA); Other- Puerto Rican population.","Warfarin (PGx)","Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.","Standard/Usual Care","NE"
"2016-01-22796","2016","Farshchi 2016 BMC Endocr Disord","Cost-Saving","Biphasic insulin Aspart 30 VERSUS Standard/Usual Care- NPH plus regular human insulin IN Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Iran; Other- Type 2 diabetes mellitus patients with HbA1c > 80% despite oral glucose lowering drugs and lifestyle modification.","27278922","Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Iran; Other- Type 2 diabetes mellitus patients with HbA1c > 80% despite oral glucose lowering drugs and lifestyle modification.","Biphasic insulin Aspart 30","Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes  patients; a cost-effectiveness study.","Standard/Usual Care- NPH plus regular human insulin","SE"
"2016-01-22642","2016","Haghighat 2016 Iran J Cancer Prev","130000","Screening for breast cancer, second round VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Iran.","27366315","Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Iran.","Screening for breast cancer, second round","Cost-Effectiveness of Three Rounds of Mammography Breast Cancer Screening in Iranian Women.","Standard/Usual Care","NE"
"2016-01-22642","2016","Haghighat 2016 Iran J Cancer Prev","41000","Screening for breast cancer, first round VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Iran.","27366315","Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Iran.","Screening for breast cancer, first round","Cost-Effectiveness of Three Rounds of Mammography Breast Cancer Screening in Iranian Women.","Standard/Usual Care","NE"
"2016-01-22642","2016","Haghighat 2016 Iran J Cancer Prev","600000","Screening for breast cancer, third round VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Iran.","27366315","Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Iran.","Screening for breast cancer, third round","Cost-Effectiveness of Three Rounds of Mammography Breast Cancer Screening in Iranian Women.","Standard/Usual Care","NE"
"2016-01-21619","2016","Hashemi-Meshkini 2016 Value Health Reg Issues","64000","Tocilizumab plus methotrexate VERSUS Infliximab plus methotrexate IN Specific disease- Rheumatoid arthritis (RA); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Iran; Other- Patients with rheumatoid arthritis with inadequate response to traditional disease-modifying antirheumatic drugs (tDMARDs).","27881258","Specific disease- Rheumatoid arthritis (RA); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Iran; Other- Patients with rheumatoid arthritis with inadequate response to traditional disease-modifying antirheumatic drugs (tDMARDs).","Tocilizumab plus methotrexate","Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model.","Infliximab plus methotrexate","NE"
"2016-01-20187","2016","Sanyal 2016 Cancer","8600","Intensity-modulated radiotherapy treatment VERSUS Radical prostatectomy treatment IN Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- intermediate risk.","26828716","Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- intermediate risk.","Intensity-modulated radiotherapy treatment","Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.","Radical prostatectomy treatment","NE"
"2016-01-20187","2016","Sanyal 2016 Cancer","Cost-Saving","Active surveillance VERSUS Radical prostatectomy treatment IN Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- low risk.","26828716","Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- low risk.","Active surveillance","Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.","Radical prostatectomy treatment","SE"
"2016-01-20187","2016","Sanyal 2016 Cancer","Cost-Saving","Intensity-modulated radiotherapy + androgen deprivation therapy + brachytherapy treatment VERSUS Radical prostatectomy treatment IN Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- high risk.","26828716","Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- high risk.","Intensity-modulated radiotherapy + androgen deprivation therapy + brachytherapy treatment","Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.","Radical prostatectomy treatment","SE"
"2016-01-20187","2016","Sanyal 2016 Cancer","Cost-Saving","Intensity-modulated radiotherapy + androgen deprivation therapy treatment VERSUS Radical prostatectomy treatment IN Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- high risk.","26828716","Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- high risk.","Intensity-modulated radiotherapy + androgen deprivation therapy treatment","Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.","Radical prostatectomy treatment","SE"
"2016-01-20187","2016","Sanyal 2016 Cancer","Dominated","Brachytherapy treatment VERSUS Radical prostatectomy treatment IN Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- low risk.","26828716","Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- low risk.","Brachytherapy treatment","Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.","Radical prostatectomy treatment","NW"
"2016-01-20187","2016","Sanyal 2016 Cancer","Dominated","Intensity-modulated radiotherapy + androgen deprivation therapy treatment VERSUS Radical prostatectomy treatment IN Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- intermediate risk.","26828716","Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- intermediate risk.","Intensity-modulated radiotherapy + androgen deprivation therapy treatment","Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.","Radical prostatectomy treatment","NW"
"2016-01-20187","2016","Sanyal 2016 Cancer","Dominated","Intensity-modulated radiotherapy + brachytherapy treatment VERSUS Radical prostatectomy treatment IN Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- intermediate risk.","26828716","Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- intermediate risk.","Intensity-modulated radiotherapy + brachytherapy treatment","Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.","Radical prostatectomy treatment","NW"
"2016-01-20187","2016","Sanyal 2016 Cancer","Dominated","Intensity-modulated radiotherapy treatment VERSUS Radical prostatectomy treatment IN Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- low risk.","26828716","Specific disease- Advanced prostate cancer
Cancer; Age- >=65 years; Gender- Male; Country- Canada; Other- low risk.","Intensity-modulated radiotherapy treatment","Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.","Radical prostatectomy treatment","NW"
"2016-01-19701","2016","Nolan 2016 Int J Cardiol","Cost-Saving","Strain-guided cardioprotection for prevention ofchemotherapy-induced cardiotoxicity VERSUS Universal cardioprotection IN Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- United States; Other- Stage II breast cancer receiving sequential anthracycline and trastuzumab therapy.","27060722","Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- United States; Other- Stage II breast cancer receiving sequential anthracycline and trastuzumab therapy.","Strain-guided cardioprotection for prevention ofchemotherapy-induced cardiotoxicity","Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity.","Universal cardioprotection","SE"
"2016-01-19701","2016","Nolan 2016 Int J Cardiol","Cost-Saving","Strain-guided cardioprotection for prevention ofchemotherapy-induced cardiotoxicity. VERSUS Standard/Usual Care- Initiating cardioprotection medications after diagnosis of EF-CTX or symptomatic heart failure IN Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- United States; Other- Stage II breast cancer receiving sequential anthracycline and trastuzumab therapy.","27060722","Specific disease- Breast cancer; Age- 41 to 64 years; Gender- Female; Country- United States; Other- Stage II breast cancer receiving sequential anthracycline and trastuzumab therapy.","Strain-guided cardioprotection for prevention ofchemotherapy-induced cardiotoxicity.","Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity.","Standard/Usual Care- Initiating cardioprotection medications after diagnosis of EF-CTX or symptomatic heart failure","SE"
"2016-01-19546","2016","Ahmadiani 2016 Rheumatol Int","2","Rituximab VERSUS conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate IN Specific disease- rheumatoid arthritis; Age- Adult; Gender- Both; Country- ; Other- Refractory Rheumatoid Arthritis.","27136919","Specific disease- rheumatoid arthritis; Age- Adult; Gender- Both; Country- ; Other- Refractory Rheumatoid Arthritis.","Rituximab","Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis.","conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate","NE"
"2015-01-20571","2015","Hatam 2015 Iran J Cancer Prev","Cost-Saving","Ifosfamide, epirubicin and etoposide (IEV Treatment) VERSUS etoposide, methylprednisolone, high-dose cytarabine, and cisplatin (ESHAP Treatment) IN Specific disease- Non-Hodgkinâs Lymphoma; Age- Unknown; Gender- Both; Country- Iran.","26634115","Specific disease- Non-Hodgkinâs Lymphoma; Age- Unknown; Gender- Both; Country- Iran.","Ifosfamide, epirubicin and etoposide (IEV Treatment)","Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin's Lymphoma in Iran.","etoposide, methylprednisolone, high-dose cytarabine, and cisplatin (ESHAP Treatment)","SE"
"2015-01-20402","2015","Amirsadri 2015 Daru","1200","Simvastatin 10 mg VERSUS None IN Specific disease- Myocardial infarction; Age- 41 to 64 years; Gender- Male; Country- iran; Other- 15% 10-year risk of cardiovascular disease.","26717884","Specific disease- Myocardial infarction; Age- 41 to 64 years; Gender- Male; Country- iran; Other- 15% 10-year risk of cardiovascular disease.","Simvastatin 10 mg","Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for  the primary prevention of myocardial infarction in Iranian men.","None","NE"
"2015-01-20358","2015","Hatam 2015 Asian Pac J Cancer Prev","Cost-Saving","Neoadjuvant chemotherapy regimens containing doxorubicin and cyclophosphamide (AC) VERSUS Paclitaxel and gemcitabine (PG) IN Specific disease- Breast Cancer; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Iran.","26745071","Specific disease- Breast Cancer; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Iran.","Neoadjuvant chemotherapy regimens containing doxorubicin and cyclophosphamide (AC)","Cost-Utility of ""Doxorubicin and Cyclophosphamide"" versus ""Gemcitabine and Paclitaxel"" for Treatment of Patients with Breast Cancer in Iran.","Paclitaxel and gemcitabine (PG)","SE"
"2015-01-18306","2015","Tirani 2015 PLoS One","540000","Bexsero vaccinaiton to prevent group b meningococcal disease VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Italy; Other- Born into a susceptible unvaccinated state.","25874805","Healthy; Age- 0 to 18 years; Gender- Both; Country- Italy; Other- Born into a susceptible unvaccinated state.","Bexsero vaccinaiton to prevent group b meningococcal disease","Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.","None","NE"
"2018-01-28253","2018","Hunter 2018 Int J Behav Nutr Phys Act","Dominated","The Physical Activity Loyalty Scheme intervention VERSUS Standard/Usual Care- Control group IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Ireland; Other- Public sector employees.","30541563","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Ireland; Other- Public sector employees.","The Physical Activity Loyalty Scheme intervention","Effectiveness and cost-effectiveness of a loyalty scheme for physical activity behaviour change maintenance: results from a cluster randomised controlled trial.","Standard/Usual Care- Control group","NW"
"2018-01-25945","2018","Teljeur 2018 Pediatr Infect Dis J","200000","Selective vaccination strategy for TB VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Ireland; Other- Infants at high risk of exposure to TB infection.","29432385","Healthy; Age- 0 to 18 years; Gender- Both; Country- Ireland; Other- Infants at high risk of exposure to TB infection.","Selective vaccination strategy for TB","Economic Evaluation of Selective Neonatal BCG Vaccination of High-Risk Infants in Ireland.","None","NE"
"2018-01-25945","2018","Teljeur 2018 Pediatr Infect Dis J","3.6e+006","Universal vaccination strategy for TB VERSUS Selective vaccination strategy for TB IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Ireland; Other- infants at high risk of exposure to TB infection.","29432385","Healthy; Age- 0 to 18 years; Gender- Both; Country- Ireland; Other- infants at high risk of exposure to TB infection.","Universal vaccination strategy for TB","Economic Evaluation of Selective Neonatal BCG Vaccination of High-Risk Infants in Ireland.","Selective vaccination strategy for TB","NE"
"2017-01-24985","2017","Chawla 2017 Bone Joint J","3300","Patellofemoral arthroplasty VERSUS Total knee arthroplasty IN Specific disease- Patellofemoral osteoarthritis; Age- 41 to 64 years; Gender- Both; Country- United States of America (USA).","28768779","Specific disease- Patellofemoral osteoarthritis; Age- 41 to 64 years; Gender- Both; Country- United States of America (USA).","Patellofemoral arthroplasty","Cost effectiveness of patellofemoral versus total knee arthroplasty in younger patients.","Total knee arthroplasty","NE"
"2017-01-23143","2017","Agus 2017 Crit Care","Cost-Saving","Once-daily simvastatin (at a dose of 80 mg) VERSUS Placebo IN Specific disease- Acute respiratory distress syndrome; Age- Adult; Gender- Both; Country- United Kingdom; Other- Patients  were intubated and mechanically ventilated and were within 48 hours of onset of Acute respiratory distress syndrome.","28511660","Specific disease- Acute respiratory distress syndrome; Age- Adult; Gender- Both; Country- United Kingdom; Other- Patients  were intubated and mechanically ventilated and were within 48 hours of onset of Acute respiratory distress syndrome.","Once-daily simvastatin (at a dose of 80 mg)","Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial.","Placebo","SE"
"2016-01-21448","2016","Moran 2016 Value Health","32000","Annual opportunistic aarial fibrillation (AF) screening program VERSUS None IN Specific disease- Atrial fibrillation (AF); Age- >=65 years; Gender- Both; Country- Ireland; Other- with irregular pulse.","27987649","Specific disease- Atrial fibrillation (AF); Age- >=65 years; Gender- Both; Country- Ireland; Other- with irregular pulse.","Annual opportunistic aarial fibrillation (AF) screening program","Cost-Effectiveness of a National Opportunistic Screening Program for Atrial Fibrillation in Ireland.","None","NE"
"2016-01-20504","2016","Danyliv 2016 Diabetologia","Cost-Saving","Screening for gestational diabetes mellitus in general practitioners office VERSUS None IN Healthy; Age- Adult; Gender- Female; Country- Ireland.","26670162","Healthy; Age- Adult; Gender- Female; Country- Ireland.","Screening for gestational diabetes mellitus in general practitioners office","The cost-effectiveness of screening for gestational diabetes mellitus in primary  and secondary care in the Republic of Ireland.","None","SE"
"2016-01-20504","2016","Danyliv 2016 Diabetologia","Cost-Saving","Screening for gestational diabetes mellitus in hospital VERSUS None IN Healthy; Age- Adult; Gender- Female; Country- Ireland.","26670162","Healthy; Age- Adult; Gender- Female; Country- Ireland.","Screening for gestational diabetes mellitus in hospital","The cost-effectiveness of screening for gestational diabetes mellitus in primary  and secondary care in the Republic of Ireland.","None","SE"
"2014-01-16432","2014","Gillespie                        2014 Trials","32000","Group follow-up after structured education VERSUS Standard/Usual Care- individual follow-up IN Specific disease- type 1 diabetes; Age- Adult; Gender- Both; Country- Ireland.","24927851","Specific disease- type 1 diabetes; Age- Adult; Gender- Both; Country- Ireland.","Group follow-up after structured education","Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial.","Standard/Usual Care- individual follow-up","SW"
"2014-01-15126","2014","Mason 2014 PLoS One"," ","Prophylactic Antibiotics VERSUS Placebo IN Specific disease- Cellulitis of the Leg; Age- Unknown; Gender- Both; Country- United Kingdom.","24551029","Specific disease- Cellulitis of the Leg; Age- Unknown; Gender- Both; Country- United Kingdom.","Prophylactic Antibiotics","Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials.","Placebo","NE"
"2014-01-15079","2014","Teljeur 2014 Int J Technol Assess Health Care","34000","Radical prostatectomy VERSUS Standard/Usual Care- Mixture of open and laparoscopic surgical methods in  men requiring radical prostatectomy
mix of open and laparoscopic surgery IN Specific disease- Prostate cancer; Age- Adult; Gender- Male; Country- Ireland.","24472222","Specific disease- Prostate cancer; Age- Adult; Gender- Male; Country- Ireland.","Radical prostatectomy","Using prediction intervals from random-effects meta-analyses in an economic model.","Standard/Usual Care- Mixture of open and laparoscopic surgical methods in  men requiring radical prostatectomy
mix of open and laparoscopic surgery","NE"
"2014-01-14857","2014","Spackman 2014 Eur J Haematol","85000","Preoperative transfusion VERSUS No preoperative transfusion IN Specific disease- Sickle cell anaemia; Age- Unknown; Gender- Both; Country- Netherlands, England, Ireland, Canada.","24329965","Specific disease- Sickle cell anaemia; Age- Unknown; Gender- Both; Country- Netherlands, England, Ireland, Canada.","Preoperative transfusion","Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial.","No preoperative transfusion","SW"
"2014-01-14842","2014","Ashby 2014 Lancet","Cost-Saving","Two-layer compression hosiery VERSUS Standard/Usual Care- Four-layer compression bandages IN Specific disease- Venous leg Ulcer; Age- Adult; Gender- Both; Country- England and Northern Ireland.","24315520","Specific disease- Venous leg Ulcer; Age- Adult; Gender- Both; Country- England and Northern Ireland.","Two-layer compression hosiery","Clinical and cost-effectiveness of compression hosiery versus compression bandages in treatment of venous leg ulcers (Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial.","Standard/Usual Care- Four-layer compression bandages","SE"
"2014-01-14512","2014","Candon 2014 Acta Oncol","39000","Adjuvant Lapatinib VERSUS Standard/Usual Care- Trastuzumab IN Healthy; Age-; Gender- Female; Country- Ireland; Other-  HER2-positive early-stage breast cancer.","24125103","Healthy; Age-; Gender- Female; Country- Ireland; Other-  HER2-positive early-stage breast cancer.","Adjuvant Lapatinib","Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.","Standard/Usual Care- Trastuzumab","NE"
"2013-01-14940","2013","Diwakar 2013 PLoS One","26000","Vesico Amniotic Shunt VERSUS conservative management IN Specific disease- lower urinary tract obstruction; Age- Adult; Gender- Female; Country- United Kingdom.","24376546","Specific disease- lower urinary tract obstruction; Age- Adult; Gender- Female; Country- United Kingdom.","Vesico Amniotic Shunt","Evaluation of the cost effectiveness of vesico-amniotic shunting in the management of congenital lower urinary tract obstruction (based on data from the  PLUTO Trial).","conservative management","NE"
"2013-01-14776","2013","Gillespie                        2013 BMJ Open","770000","Structured education pulmonary rehabilitation programme (SEPRP) VERSUS Standard/Usual Care IN Specific disease- chronic obstructive pulmonary disease; Age- Adult; Gender- Both; Country- Ireland.","24282243","Specific disease- chronic obstructive pulmonary disease; Age- Adult; Gender- Both; Country- Ireland.","Structured education pulmonary rehabilitation programme (SEPRP)","The cost-effectiveness of a structured education pulmonary rehabilitation programme for chronic obstructive pulmonary disease in primary care: the PRINCE cluster randomised trial.","Standard/Usual Care","NE"
"2013-01-14491","2013","Dallat 2013 BMC Public Health","6100","Financial incentive for increasing physical activity in the workplace VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Ireland.","24112295","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Ireland.","Financial incentive for increasing physical activity in the workplace","A lesson in business: cost-effectiveness analysis of a novel financial incentive  intervention for increasing physical activity in the workplace.","None","NE"
"2013-01-11666","2013","Lee 2013 Appl Health Econ Health Policy","Cost-Saving","Romiplostim VERSUS Eltrombopag IN Specific disease- Chronic Immune Thrombocytopenia; Age- Adult; Gender- Both; Country- Ireland.","23857462","Specific disease- Chronic Immune Thrombocytopenia; Age- Adult; Gender- Both; Country- Ireland.","Romiplostim","Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.","Eltrombopag","SE"
"2013-01-11666","2013","Lee 2013 Appl Health Econ Health Policy","Cost-Saving","Romiplostim VERSUS Standard/Usual Care IN Specific disease- Chronic Immune Thrombocytopenia; Age- Adult; Gender- Both; Country- Ireland.","23857462","Specific disease- Chronic Immune Thrombocytopenia; Age- Adult; Gender- Both; Country- Ireland.","Romiplostim","Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.","Standard/Usual Care","SE"
"2013-01-11006","2013","Fawsitt 2013 PLoS One","Cost-Saving","Trial of Labour after caeserean (TOLAC) VERSUS Elective repeat ceaserean delivery (ERCD) IN Specific disease- pregnant women; Age- Adult; Gender- Female; Country- Ireland; Other- Previous caeserean delivery.","23484038","Specific disease- pregnant women; Age- Adult; Gender- Female; Country- Ireland; Other- Previous caeserean delivery.","Trial of Labour after caeserean (TOLAC)","At what price? A cost-effectiveness analysis comparing trial of labour after previous caesarean versus elective repeat caesarean delivery.","Elective repeat ceaserean delivery (ERCD)","SE"
"2012-01-09908","2012","Hettle                 2012 Respir Med","28000","Tiotropium plus usual care VERSUS Usual care IN Patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in England","23040833","Patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in England","Tiotropium plus usual care","Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.","Usual care","NE"
"2012-01-09908","2012","Hettle                 2012 Respir Med","28000","Tiotropium plus usual care VERSUS Usual care IN UK patients with moderate to very severe chronic obstructive pulmonary disease (COPD)","23040833","UK patients with moderate to very severe chronic obstructive pulmonary disease (COPD)","Tiotropium plus usual care","Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.","Usual care","NE"
"2012-01-09908","2012","Hettle                 2012 Respir Med","33000","Tiotropium plus usual care VERSUS Usual care IN Patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in Belgium","23040833","Patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in Belgium","Tiotropium plus usual care","Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.","Usual care","NE"
"2012-01-09855","2012","McCullagh 2012 Pharmacoeconomics","3200","Dabigatran etexiliate VERSUS Enoxaparin sodium IN Patients undergoing major orthopaedic surgery at risk of venous thromboembolism (VTE)","22667458","Patients undergoing major orthopaedic surgery at risk of venous thromboembolism (VTE)","Dabigatran etexiliate","Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the irish healthcare setting.","Enoxaparin sodium"," "
"2012-01-09855","2012","McCullagh 2012 Pharmacoeconomics","Cost-Saving","Rivaroxaban VERSUS Dabigatran etexiliate IN Patients undergoing major orthopaedic surgery at risk of venous thromboembolism (VTE)","22667458","Patients undergoing major orthopaedic surgery at risk of venous thromboembolism (VTE)","Rivaroxaban","Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the irish healthcare setting.","Dabigatran etexiliate","SE"
"2012-01-09855","2012","McCullagh 2012 Pharmacoeconomics","Cost-Saving","Rivaroxaban VERSUS Enoxaparin sodium IN Patients undergoing major orthopaedic surgery at risk of venous thromboembolism (VTE)","22667458","Patients undergoing major orthopaedic surgery at risk of venous thromboembolism (VTE)","Rivaroxaban","Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the irish healthcare setting.","Enoxaparin sodium","SE"
"2012-01-09587","2012","Hiligsmann 2012 Value Health","11000","Full adherence to osteoporosis medications VERSUS None IN Patients older than 55 years who started osteoporosis medications in Ireland","22867768","Patients older than 55 years who started osteoporosis medications in Ireland","Full adherence to osteoporosis medications","The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.","None","NE"
"2012-01-09587","2012","Hiligsmann 2012 Value Health","20000","Real-world adherence to osteoporosis medications VERSUS None IN Patients older than 55 years who started osteoporosis medications in Ireland","22867768","Patients older than 55 years who started osteoporosis medications in Ireland","Real-world adherence to osteoporosis medications","The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.","None","NE"
"2012-01-09587","2012","Hiligsmann 2012 Value Health","Cost-Saving","Full adherence to osteoporosis medications VERSUS Real-world adherence IN Patients older than 55 years who started osteoporosis medications in Ireland","22867768","Patients older than 55 years who started osteoporosis medications in Ireland","Full adherence to osteoporosis medications","The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.","Real-world adherence","SE"
"2012-01-09238","2012","Barton 2012 QJM","Cost-Saving","Treating 50% of eligible patients with thrombolysis VERSUS Standard of care- treating 10% of eligible patients with thrombolysis IN Patients suffering from an ischaemic stroke in Ireland","22383688","Patients suffering from an ischaemic stroke in Ireland","Treating 50% of eligible patients with thrombolysis","Is it beneficial to increase the provision of thrombolysis?-- a discrete-event simulation model.","Standard of care- treating 10% of eligible patients with thrombolysis","SE"
"2012-01-09142","2012","Gillespie                        2012 Int J Technol Assess Health Care","Cost-Saving","Group-based peer support in addition to standardized diabetes care VERSUS Standardized diabetes care IN Patients with type 2 diabetes in Ireland","22617733","Patients with type 2 diabetes in Ireland","Group-based peer support in addition to standardized diabetes care","Cost effectiveness of peer support for type 2 diabetes.","Standardized diabetes care","SE"
"2017-01-23752","2017","Chowers 2017 Sex Transm Infect","Cost-Saving","Universal prenatal HIV screening VERSUS Standard/Usual Care- Current policy IN Healthy; Age- Adult; Gender- Female; Country- Israel; Other- Pregnant women.","28213577","Healthy; Age- Adult; Gender- Female; Country- Israel; Other- Pregnant women.","Universal prenatal HIV screening","Economic evaluation of universal prenatal HIV screening compared with current ''at risk'' policy in a very low prevalence country.","Standard/Usual Care- Current policy","SE"
"2014-01-16348","2014","Yamin 2014 Vaccine","11000","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination VERSUS Standard/Usual Care- no vaccination IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Israel.","24930716","Healthy; Age- 0 to 18 years; Gender- Both; Country- Israel.","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination","Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.","Standard/Usual Care- no vaccination","NE"
"2014-01-16348","2014","Yamin 2014 Vaccine","3200","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination VERSUS Standard/Usual Care- no vaccination IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Israel.","24930716","Healthy; Age- 41 to 64 years; Gender- Both; Country- Israel.","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination","Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.","Standard/Usual Care- no vaccination","NE"
"2014-01-16348","2014","Yamin 2014 Vaccine","36000","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination VERSUS Standard/Usual Care- no vaccination IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Israel.","24930716","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Israel.","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination","Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.","Standard/Usual Care- no vaccination","NE"
"2014-01-16348","2014","Yamin 2014 Vaccine","64000","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination VERSUS Standard/Usual Care- no vaccination IN Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Israel.","24930716","Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Israel.","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination","Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.","Standard/Usual Care- no vaccination","NE"
"2014-01-16348","2014","Yamin 2014 Vaccine","Cost-Saving","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination VERSUS Standard/Usual Care- no vaccination IN Healthy; Age- >=65 years; Gender- Both; Country- Israel.","24930716","Healthy; Age- >=65 years; Gender- Both; Country- Israel.","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination","Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.","Standard/Usual Care- no vaccination","SE"
"2014-01-16348","2014","Yamin 2014 Vaccine","Cost-Saving","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination VERSUS Standard/Usual Care- no vaccination IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Israel.","24930716","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Israel.","PLUS policy- recruiting individuals previously infected with pneumonia for influenza vaccination","Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.","Standard/Usual Care- no vaccination","SE"
"2013-01-14358","2013","Shmueli 2013 Value Health","1600","Low dose computed tomography screening VERSUS Standard/Usual Care IN Specific disease- lung cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Israel.","24041342","Specific disease- lung cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Israel.","Low dose computed tomography screening","Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience.","Standard/Usual Care","NE"
"2013-01-10930","2013","Ginsberg 2013 Isr J Health Policy Res","Dominated","Screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease VERSUS Screen only for mothers with risk factors IN Healthy; Age- Adult; Gender- Female; Country- Israel.","23425020","Healthy; Age- Adult; Gender- Female; Country- Israel.","Screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease","Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis.","Screen only for mothers with risk factors","NW"
"2012-01-09656","2012","Ginsberg 2012 Isr J Health Policy Res","15000","Office based community and dietary interventions VERSUS None IN Entire population aged 20 and over in Israel","22913803","Entire population aged 20 and over in Israel","Office based community and dietary interventions","Economic effects of interventions to reduce obesity in Israel.","None","NE"
"2012-01-08494","2012","Shmueli 2012 Prenat Diagn","22000","Universal first-trimester screening for pre-eclampsia using placental markers like placental protein 12 and placental growth factor along with uterine artery Doppler pulsatility index (PI) VERSUS Standard of care IN Pregnant women in Israel","22234821","Pregnant women in Israel","Universal first-trimester screening for pre-eclampsia using placental markers like placental protein 12 and placental growth factor along with uterine artery Doppler pulsatility index (PI)","Economic assessment of screening for pre-eclampsia.","Standard of care","NE"
"2010-01-06356","2010","Klang 2010 Value Health","13000","Oncotype DX assay and recommendations for adjuvant treatment VERSUS Standard care IN Israeli women with estrogen receptor positive, lymph node negative, early stage breast cancer","20412544","Israeli women with estrogen receptor positive, lymph node negative, early stage breast cancer","Oncotype DX assay and recommendations for adjuvant treatment","Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization.","Standard care","NE"
"2009-01-05210","2009","Chodick 2009 Eur J Public Health","13000","Rotarix VERSUS No vaccination IN Israeli children under 5 years of age","19221026","Israeli children under 5 years of age","Rotarix","Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.","No vaccination","NE"
"2009-01-05210","2009","Chodick 2009 Eur J Public Health","37000","Rotateq VERSUS No vaccination IN Israeli children under 5 years of age","19221026","Israeli children under 5 years of age","Rotateq","Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.","No vaccination","NE"
"2008-01-03883","2008","Talmor 2008 Crit Care Med","22000","MUST protocol: EGDT, antibiotics, steroids, assessment for activated protein C therapy, glycemic control, low tidal volume ventilation VERSUS Historical controls prior to implementing the MUST protocol IN Patients with a presenting diagnosis of septic shock to the emergency department","18379243","Patients with a presenting diagnosis of septic shock to the emergency department","MUST protocol: EGDT, antibiotics, steroids, assessment for activated protein C therapy, glycemic control, low tidal volume ventilation","The costs and cost-effectiveness of an integrated sepsis treatment protocol.","Historical controls prior to implementing the MUST protocol","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","11000","PAP smear VERSUS Current scenario IN Israeli women aged 40","17706844","Israeli women aged 40","PAP smear","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","SW"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","130000","Annual PAP/Annual HPV-DNA VERSUS Current scenario IN Israeli women aged 20-65/30-65","17706844","Israeli women aged 20-65/30-65","Annual PAP/Annual HPV-DNA","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","330000","Three doses of human papillomaviruses vaccine, followed by a booster dose every 10 years (six-times a lifetime scenario) VERSUS Current scenario IN Israeli women aged 12, in their school and health centers","17706844","Israeli women aged 12, in their school and health centers","Three doses of human papillomaviruses vaccine, followed by a booster dose every 10 years (six-times a lifetime scenario)","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","35000","Penta-Annual PAP smear VERSUS Current scenario IN Israeli women aged 20-65","17706844","Israeli women aged 20-65","Penta-Annual PAP smear","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","41000","Penta Annual PAP/Annual HPV-DNA VERSUS Current scenario IN Israeli women aged 20-65/30-65","17706844","Israeli women aged 20-65/30-65","Penta Annual PAP/Annual HPV-DNA","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","43000","Tri-Annual PAP smear VERSUS Current scenario IN Israeli women aged 20-65","17706844","Israeli women aged 20-65","Tri-Annual PAP smear","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","57000","HPV-DNA test VERSUS Current scenario IN Israeli women aged 35,40,45","17706844","Israeli women aged 35,40,45","HPV-DNA test","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","59000","Tri Annual PAP/Annual HPV-DNA VERSUS Current scenario IN Israeli women aged 20-65/30-65","17706844","Israeli women aged 20-65/30-65","Tri Annual PAP/Annual HPV-DNA","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","7000","VIA VERSUS Current scenario IN Israeli women aged 40","17706844","Israeli women aged 40","VIA","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","SW"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","74000","VIA VERSUS Current scenario IN Israeli women aged 35, 40, 45","17706844","Israeli women aged 35, 40, 45","VIA","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","7500","HPV-DNA test VERSUS Current scenario IN Israeli women aged 40","17706844","Israeli women aged 40","HPV-DNA test","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","SW"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","79000","Annual PAP smear VERSUS Current scenario IN Israeli women aged 20-65","17706844","Israeli women aged 20-65","Annual PAP smear","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","99000","Three doses of human papillomaviruses vaccine VERSUS Current scenario IN Israeli women aged 12, in their school setting","17706844","Israeli women aged 12, in their school setting","Three doses of human papillomaviruses vaccine","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","NE"
"2007-01-03141","2007","Ginsberg 2007 Vaccine","Cost-Saving","PAP smear VERSUS Current scenario IN Israeli women aged 35,40,45","17706844","Israeli women aged 35,40,45","PAP smear","Cost-utility analysis of vaccination against HPV in Israel.","Current scenario","SE"
"2003-01-00544","2003","Yosefy 2003 Blood Press","Cost-Saving","One-year preventive intervention to control risk factors for cardiovascular disease VERSUS No intervention IN Hypertensive patients from 30 general practice clinics in Israel","14596359","Hypertensive patients from 30 general practice clinics in Israel","One-year preventive intervention to control risk factors for cardiovascular disease","Risk factor profile and achievement of treatment goals among hypertensive patients from the Israeli Blood Pressure Control (IBPC) program--initial cost utility analysis.","No intervention","SE"
"2002-01-01112","2002","Chodick 2002 J Occup Environ Med","100000","Systematic mass vaccination campaign without screening VERSUS Selective vaccination of patients found nonimmune in screening for hepatitis A IN Health care workers (physicians, nurses, and paramedics) in Israel - age 18-39","11851212","Health care workers (physicians, nurses, and paramedics) in Israel - age 18-39","Systematic mass vaccination campaign without screening","Cost-utility analysis of hepatitis A prevention among health-care workers in Israel.","Selective vaccination of patients found nonimmune in screening for hepatitis A","NE"
"2002-01-01112","2002","Chodick 2002 J Occup Environ Med","460000","Systematic mass vaccination campaign without screening VERSUS Selective vaccination of patients found nonimmune in screening for hepatitis A IN Health care workers (physicians, nurses, and paramedics) in Israel - age 40+","11851212","Health care workers (physicians, nurses, and paramedics) in Israel - age 40+","Systematic mass vaccination campaign without screening","Cost-utility analysis of hepatitis A prevention among health-care workers in Israel.","Selective vaccination of patients found nonimmune in screening for hepatitis A","NE"
"2002-01-01112","2002","Chodick 2002 J Occup Environ Med","58000","Selective vaccination of patients found nonimmune in screening for hepatitis A VERSUS Passive immunization (immunoglobulin during a hepatitis A outbreak) IN Health care workers (physicians, nurses, and paramedics) in Israel - age 40+","11851212","Health care workers (physicians, nurses, and paramedics) in Israel - age 40+","Selective vaccination of patients found nonimmune in screening for hepatitis A","Cost-utility analysis of hepatitis A prevention among health-care workers in Israel.","Passive immunization (immunoglobulin during a hepatitis A outbreak)","NE"
"2002-01-01112","2002","Chodick 2002 J Occup Environ Med","82000","Selective vaccination of patients found nonimmune in screening for hepatitis A VERSUS Passive immunization (immunoglobulin during a hepatitis A outbreak) IN Health care workers (physicians, nurses, and paramedics) in Israel - age 18-39","11851212","Health care workers (physicians, nurses, and paramedics) in Israel - age 18-39","Selective vaccination of patients found nonimmune in screening for hepatitis A","Cost-utility analysis of hepatitis A prevention among health-care workers in Israel.","Passive immunization (immunoglobulin during a hepatitis A outbreak)","NE"
"1994-01-01801","1994","Cohen 1994 Circulation","28000","initial stent VERSUS Angioplasty IN 55 yo male with symptomatic single vessle coronary disease","8149551","55 yo male with symptomatic single vessle coronary disease","initial stent","Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model.","Angioplasty","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6300","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Italy.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Italy.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6700","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Italy.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Italy.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","9900","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Italy.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Italy.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-27686","2018","Ruggeri 2018 Pharmacoeconomics","90","Lesinurad/allopurinol as second-line therapeutic strategy VERSUS Febuxostatas second-line therapeutic strategy IN Specific disease- Gout/Hyperuricemia; Age- Adult; Gender- Both; Country- Italy; Other- patients affected by gout and hyperuricemia that did not respond to a first-line therapy based on allopurinol alone.","29557073","Specific disease- Gout/Hyperuricemia; Age- Adult; Gender- Both; Country- Italy; Other- patients affected by gout and hyperuricemia that did not respond to a first-line therapy based on allopurinol alone.","Lesinurad/allopurinol as second-line therapeutic strategy","Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.","Febuxostatas second-line therapeutic strategy","NE"
"2018-01-27372","2018","Rolli 2018 Eur J Health Econ","Cost-Saving","Elbasvir/grazoprevir VERSUS Sofosbuvir+pegylated interferon/ribavirin IN Specific disease- Hepatitis C virus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","29696459","Specific disease- Hepatitis C virus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","Elbasvir/grazoprevir","Economic evaluation of Zepatier for the management of HCV in the Italian scenario.","Sofosbuvir+pegylated interferon/ribavirin","SE"
"2018-01-27220","2018","Nicolucci 2018 Nutr Metab Cardiovasc Dis","48000","Sensor-Augmented Pump Therapy + Automated Insulin Suspension VERSUS Continuous Subcutaneous Insulin Infusion Alone IN Specific disease- Type 1 Diabetes; Age- Adult; Gender- Both; Country- Italy; Other- At increased risk for hypoglycemia.","29753586","Specific disease- Type 1 Diabetes; Age- Adult; Gender- Both; Country- Italy; Other- At increased risk for hypoglycemia.","Sensor-Augmented Pump Therapy + Automated Insulin Suspension","Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy.","Continuous Subcutaneous Insulin Infusion Alone","NE"
"2018-01-27220","2018","Nicolucci 2018 Nutr Metab Cardiovasc Dis","63000","Sensor-Augmented Pump Therapy + Automated Insulin Suspension  VERSUS Continuous Subcutaneous Insulin Infusion IN Specific disease- Type 1 Diabetes; Age- Adult; Gender- Both; Country- Italy; Other- Uncontrolled HbA1c.","29753586","Specific disease- Type 1 Diabetes; Age- Adult; Gender- Both; Country- Italy; Other- Uncontrolled HbA1c.","Sensor-Augmented Pump Therapy + Automated Insulin Suspension","Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy.","Continuous Subcutaneous Insulin Infusion","NE"
"2018-01-27005","2018","Ruggeri 2018 J Med Econ","10000","Mechanical thrombectomy + Intravenous Tissue Plasminogen Activator, 2nd year VERSUS Intravenous Tissue Plasminogen Activator, 2nd year IN Specific disease- Acute ischemic stroke; Age- >=65 years; Gender- Both; Country- Italy.","29882711","Specific disease- Acute ischemic stroke; Age- >=65 years; Gender- Both; Country- Italy.","Mechanical thrombectomy + Intravenous Tissue Plasminogen Activator, 2nd year","Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy.","Intravenous Tissue Plasminogen Activator, 2nd year","NE"
"2018-01-27005","2018","Ruggeri 2018 J Med Econ","1200","Mechanical thrombectomy + Intravenous Tissue Plasminogen Activator, 3rd year VERSUS Intravenous Tissue Plasminogen Activator, 3rd year IN Specific disease- Acute ischemic stroke; Age- >=65 years; Gender- Both; Country- Italy.","29882711","Specific disease- Acute ischemic stroke; Age- >=65 years; Gender- Both; Country- Italy.","Mechanical thrombectomy + Intravenous Tissue Plasminogen Activator, 3rd year","Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy.","Intravenous Tissue Plasminogen Activator, 3rd year","NE"
"2018-01-27005","2018","Ruggeri 2018 J Med Econ","37000","Intravenous Tissue Plasminogen Activation plus Mechanical Throbectomy 1st Year VERSUS Intravenous Tissue Plasminogen Activator, 1st year IN Specific disease- Acute Ischemic Stroke; Age- >=65 years; Gender- Both; Country- Italy.","29882711","Specific disease- Acute Ischemic Stroke; Age- >=65 years; Gender- Both; Country- Italy.","Intravenous Tissue Plasminogen Activation plus Mechanical Throbectomy 1st Year","Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy.","Intravenous Tissue Plasminogen Activator, 1st year","NE"
"2018-01-27005","2018","Ruggeri 2018 J Med Econ","Cost-Saving","Mechanical thrombectomy + Intravenous Tissue Plasminogen Activator, 4th year VERSUS Intravenous Tissue Plasminogen Activator, 4th year IN Specific disease- Acute ischemic stroke; Age- >=65 years; Gender- Both; Country- Italy.","29882711","Specific disease- Acute ischemic stroke; Age- >=65 years; Gender- Both; Country- Italy.","Mechanical thrombectomy + Intravenous Tissue Plasminogen Activator, 4th year","Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy.","Intravenous Tissue Plasminogen Activator, 4th year","SE"
"2018-01-27005","2018","Ruggeri 2018 J Med Econ","Cost-Saving","Mechanical thrombectomy + Intravenous Tissue Plasminogen Activator, 5th year VERSUS Intravenous Tissue Plasminogen Activator, 5th year IN Specific disease- Acute ischemic stroke; Age- >=65 years; Gender- Both; Country- Italy.","29882711","Specific disease- Acute ischemic stroke; Age- >=65 years; Gender- Both; Country- Italy.","Mechanical thrombectomy + Intravenous Tissue Plasminogen Activator, 5th year","Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy.","Intravenous Tissue Plasminogen Activator, 5th year","SE"
"2018-01-26771","2018","Ruggeri 2018 Value Health","9200","Treat all patients with second generation direct acting antivirals VERSUS Strategy 2 (âtreat F3+â): Treat patients who are at stage F3 or F4 and those who are prioritized by the scientific guidelines first and the remaining patients when they reach the F3 stage IN Specific disease- Hepatitis C Virus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy; Other- With or without liver fibrosis.","30005750","Specific disease- Hepatitis C Virus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy; Other- With or without liver fibrosis.","Treat all patients with second generation direct acting antivirals","Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.","Strategy 2 (âtreat F3+â): Treat patients who are at stage F3 or F4 and those who are prioritized by the scientific guidelines first and the remaining patients when they reach the F3 stage","NE"
"2018-01-26719","2018","Mennini 2018 Reprod Biol Endocrinol","11000","Recombinant follicle-stimulating hormone + recombinant luteinising hormone VERSUS Highly purified human Menopausal Gonadotropin IN Specific disease- Infertility; Age- Adult; Gender- Female; Country- Italy.","30021630","Specific disease- Infertility; Age- Adult; Gender- Female; Country- Italy.","Recombinant follicle-stimulating hormone + recombinant luteinising hormone","Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with  recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF.","Highly purified human Menopausal Gonadotropin","NE"
"2018-01-26719","2018","Mennini 2018 Reprod Biol Endocrinol","16000","Recombinant follicle-stimulating hormone + recombinant luteinising hormone VERSUS Highly purified human Menopausal Gonadotropin IN Specific disease- Infertility; Age- Adult; Gender- Female; Country- Italy.","30021630","Specific disease- Infertility; Age- Adult; Gender- Female; Country- Italy.","Recombinant follicle-stimulating hormone + recombinant luteinising hormone","Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with  recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF.","Highly purified human Menopausal Gonadotropin","NE"
"2017-01-25368","2017","Lucchese 2017 Obes Facts","Cost-Saving","Bariatric Surgery VERSUS Standard/Usual Care- Optimal medical management IN Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- Italy; Other- Mean BMI of 46 kg/m 2 and a mean SBP of 140 mm Hg; 25% were male, , 20% had T2DM, and 14% were smokers.","28601866","Specific disease- Obesity; Age- 41 to 64 years; Gender- Both; Country- Italy; Other- Mean BMI of 46 kg/m 2 and a mean SBP of 140 mm Hg; 25% were male, , 20% had T2DM, and 14% were smokers.","Bariatric Surgery","Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling.","Standard/Usual Care- Optimal medical management","SE"
"2017-01-25320","2017","Hunt 2017 Clin Ther","2400","Liraglutide VERSUS Lixisenatide 20 Âµg IN Specific disease- Type 2 Diabetes Mellitus; Age- Adult; Gender- Both; Country- Italy.","28625506","Specific disease- Type 2 Diabetes Mellitus; Age- Adult; Gender- Both; Country- Italy.","Liraglutide","Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of  Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.","Lixisenatide 20 Âµg","NE"
"2017-01-25243","2017","Cortesi 2017 PLoS One","Cost-Saving","Sublingual Fentanyl Citrate (FCSL) VERSUS Fentanyl Buccal Soluble Film (FBSF) IN Specific disease- Breakthrough cancer Pain (BTcP); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","28654672","Specific disease- Breakthrough cancer Pain (BTcP); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","Sublingual Fentanyl Citrate (FCSL)","Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.","Fentanyl Buccal Soluble Film (FBSF)","SE"
"2017-01-25243","2017","Cortesi 2017 PLoS One","Cost-Saving","Sublingual Fentanyl Citrate (FCSL) VERSUS Fentanyl Buccal Tablet (FBT) IN Specific disease- Breakthrough cancer Pain (BTcP); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","28654672","Specific disease- Breakthrough cancer Pain (BTcP); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","Sublingual Fentanyl Citrate (FCSL)","Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.","Fentanyl Buccal Tablet (FBT)","SE"
"2017-01-25243","2017","Cortesi 2017 PLoS One","Cost-Saving","Sublingual Fentanyl Citrate (FCSL) VERSUS Fentanyl Sublingual Tablets (FST) IN Specific disease- Breakthrough cancer Pain (BTcP); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","28654672","Specific disease- Breakthrough cancer Pain (BTcP); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","Sublingual Fentanyl Citrate (FCSL)","Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.","Fentanyl Sublingual Tablets (FST)","SE"
"2017-01-25243","2017","Cortesi 2017 PLoS One","Cost-Saving","Sublingual Fentanyl Citrate (FCSL) VERSUS Oral Transmucosal Fentanyl Citrate (OTFC) IN Specific disease- Breakthrough cancer Pain (BTcP); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","28654672","Specific disease- Breakthrough cancer Pain (BTcP); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Italy.","Sublingual Fentanyl Citrate (FCSL)","Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.","Oral Transmucosal Fentanyl Citrate (OTFC)","SE"
"2017-01-25138","2017","Castiglia 2017 Hum Vaccin Immunother","59000","Pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) VERSUS No vaccination IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Italy.","28700264","Healthy; Age- 0 to 18 years; Gender- Both; Country- Italy.","Pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)","Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.","No vaccination","NE"
"2017-01-25138","2017","Castiglia 2017 Hum Vaccin Immunother","64000","13-valent pneumococcal conjugate vaccine (PCV-13) VERSUS No vaccination IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Italy.","28700264","Healthy; Age- 0 to 18 years; Gender- Both; Country- Italy.","13-valent pneumococcal conjugate vaccine (PCV-13)","Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.","No vaccination","NE"
"2017-01-25138","2017","Castiglia 2017 Hum Vaccin Immunother","Cost-Saving","Pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) VERSUS 13-valent pneumococcal conjugate vaccine (PCV-13) IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Italy.","28700264","Healthy; Age- 0 to 18 years; Gender- Both; Country- Italy.","Pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)","Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.","13-valent pneumococcal conjugate vaccine (PCV-13)","SE"
"2017-01-25090","2017","Restelli 2017 Ther Clin Risk Manag","17000","Dolutegravir plus backbone  VERSUS Raltegravir plus backbone IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment experienced.","28721059","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment experienced.","Dolutegravir plus backbone","Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naive and experienced HIV-positive patients.","Raltegravir plus backbone","NE"
"2017-01-25090","2017","Restelli 2017 Ther Clin Risk Manag","47000","Dolutegravir plus backbone VERSUS Efavirenz/tenofovir/emtricitabine IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment naive.","28721059","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment naive.","Dolutegravir plus backbone","Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naive and experienced HIV-positive patients.","Efavirenz/tenofovir/emtricitabine","NE"
"2017-01-25090","2017","Restelli 2017 Ther Clin Risk Manag","54000","Dolutegravir plus backbone VERSUS Darunavir plus ritonavir plus backbone IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment naive.","28721059","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment naive.","Dolutegravir plus backbone","Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naive and experienced HIV-positive patients.","Darunavir plus ritonavir plus backbone","NE"
"2017-01-25090","2017","Restelli 2017 Ther Clin Risk Manag","8700","Dolutegravir plus backbone  VERSUS Darunavir plus ritonavir plus backbone  IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment naive with high viral load.","28721059","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment naive with high viral load.","Dolutegravir plus backbone","Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naive and experienced HIV-positive patients.","Darunavir plus ritonavir plus backbone","NE"
"2017-01-25090","2017","Restelli 2017 Ther Clin Risk Manag","Cost-Saving","Dolutegravir plus backbone  VERSUS Raltegravir plus backbone IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment naive with high viral load.","28721059","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment naive with high viral load.","Dolutegravir plus backbone","Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naive and experienced HIV-positive patients.","Raltegravir plus backbone","SE"
"2017-01-25090","2017","Restelli 2017 Ther Clin Risk Manag","Cost-Saving","Dolutegravir plus backbone VERSUS Raltegravir plus backbone IN Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment naive.","28721059","Specific disease- Human immunodeficiency virus; Age- Adult; Gender- Both; Country- Italy; Other- Treatment naive.","Dolutegravir plus backbone","Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naive and experienced HIV-positive patients.","Raltegravir plus backbone","SE"
"2017-01-24699","2017","Filipovic-Pierucci 2017 EuroIntervention","Cost-Saving","Drug coated stent VERSUS Bare metal stent IN Healthy; Age- Adult; Gender- Both; Country- France; Other- High risk of bleeding.","28891471","Healthy; Age- Adult; Gender- Both; Country- France; Other- High risk of bleeding.","Drug coated stent","Polymer-Free Drug-Coated Coronary Stents Are Cost-Effective in Patients at High Bleeding Risk: Economic Evaluation of the LEADERS FREE Trial.","Bare metal stent","SE"
"2017-01-24699","2017","Filipovic-Pierucci 2017 EuroIntervention","Cost-Saving","Drug coated stent VERSUS Bare metal stent IN Healthy; Age- Adult; Gender- Both; Country- Germany; Other- High risk of bleeding.","28891471","Healthy; Age- Adult; Gender- Both; Country- Germany; Other- High risk of bleeding.","Drug coated stent","Polymer-Free Drug-Coated Coronary Stents Are Cost-Effective in Patients at High Bleeding Risk: Economic Evaluation of the LEADERS FREE Trial.","Bare metal stent","SE"
"2017-01-24699","2017","Filipovic-Pierucci 2017 EuroIntervention","Cost-Saving","Drug coated stent VERSUS Bare metal stent IN Healthy; Age- Adult; Gender- Both; Country- Italy; Other- High risk of bleeding.","28891471","Healthy; Age- Adult; Gender- Both; Country- Italy; Other- High risk of bleeding.","Drug coated stent","Polymer-Free Drug-Coated Coronary Stents Are Cost-Effective in Patients at High Bleeding Risk: Economic Evaluation of the LEADERS FREE Trial.","Bare metal stent","SE"
"2018-01-28820","2018","Igarashi 2018 J Med Econ","81000","Secukinumab VERSUS Adalimumab: 40 mg IN Specific disease- Psoriasis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Failed to reach adequate control of their psoriasis symptoms with current non-biologic systemic treatments .","30289010","Specific disease- Psoriasis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Failed to reach adequate control of their psoriasis symptoms with current non-biologic systemic treatments .","Secukinumab","Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective.","Adalimumab: 40 mg","NE"
"2018-01-28820","2018","Igarashi 2018 J Med Econ","Dominated","Infliximab VERSUS Secukinumab 300 mg IN Specific disease- Psoriasis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Failed to reach adequate control of their psoriasis symptoms .","30289010","Specific disease- Psoriasis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Failed to reach adequate control of their psoriasis symptoms .","Infliximab","Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective.","Secukinumab 300 mg","NW"
"2018-01-28820","2018","Igarashi 2018 J Med Econ","Dominated","Ustekinumab VERSUS Secukinumab 300 mg IN Specific disease- Psoriasis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Failed to reach adequate control of their psoriasis symptoms .","30289010","Specific disease- Psoriasis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Failed to reach adequate control of their psoriasis symptoms .","Ustekinumab","Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective.","Secukinumab 300 mg","NW"
"2018-01-28335","2018","Kitano 2018 Epidemiol Infect","Cost-Saving","Mumps vaccine (one-dose) VERSUS Current program (mumps vaccine is not included into the NIP) IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Japan.","30501686","Healthy; Age- 0 to 18 years; Gender- Both; Country- Japan.","Mumps vaccine (one-dose)","Dynamic transmission model of routine mumps vaccination in Japan.","Current program (mumps vaccine is not included into the NIP)","SE"
"2018-01-28335","2018","Kitano 2018 Epidemiol Infect","Cost-Saving","Mumps vaccine (two-dose) VERSUS Current program (mumps vaccine is not included into the NIP) IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Japan.","30501686","Healthy; Age- 0 to 18 years; Gender- Both; Country- Japan.","Mumps vaccine (two-dose)","Dynamic transmission model of routine mumps vaccination in Japan.","Current program (mumps vaccine is not included into the NIP)","SE"
"2018-01-27395","2018","Shono 2018 Diabetes Care","Cost-Saving","Walk-in fingertip HbA1c testing available at Specimen Measurement Offices VERSUS Standard/Usual Care- HbA1c testing available only during Specific Health Checkup visits and conventional opportunistic screening in clinics IN Healthy; Age- >=65 years; Gender- Both; Country- Japan.","29686159","Healthy; Age- >=65 years; Gender- Both; Country- Japan.","Walk-in fingertip HbA1c testing available at Specimen Measurement Offices","Cost-effectiveness of a New Opportunistic Screening Strategy for Walk-in Fingertip HbA1c Testing at Community Pharmacies in Japan.","Standard/Usual Care- HbA1c testing available only during Specific Health Checkup visits and conventional opportunistic screening in clinics","SE"
"2018-01-27395","2018","Shono 2018 Diabetes Care","Cost-Saving","Walk-in fingertip HbA1c testing available at Specimen Measurement Offices VERSUS Standard/Usual Care- HbA1c testing available only during Specific Health Checkup visits and conventional opportunistic screening in clinics IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan.","29686159","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan.","Walk-in fingertip HbA1c testing available at Specimen Measurement Offices","Cost-effectiveness of a New Opportunistic Screening Strategy for Walk-in Fingertip HbA1c Testing at Community Pharmacies in Japan.","Standard/Usual Care- HbA1c testing available only during Specific Health Checkup visits and conventional opportunistic screening in clinics","SE"
"2018-01-27395","2018","Shono 2018 Diabetes Care","Cost-Saving","Walk-in fingertip HbA1c testing available at Specimen Measurement Offices VERSUS Standard/Usual Care- HbA1c testing available only during Specific Health Checkup visits and conventional opportunistic screening in clinics IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Japan.","29686159","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Japan.","Walk-in fingertip HbA1c testing available at Specimen Measurement Offices","Cost-effectiveness of a New Opportunistic Screening Strategy for Walk-in Fingertip HbA1c Testing at Community Pharmacies in Japan.","Standard/Usual Care- HbA1c testing available only during Specific Health Checkup visits and conventional opportunistic screening in clinics","SE"
"2018-01-27395","2018","Shono 2018 Diabetes Care","Cost-Saving","Walk-in fingertip HbA1c testing available at Specimen Measurement Offices VERSUS Standard/Usual Care- HbA1c testing available only during Specific Health Checkup visits and conventional opportunistic screening in clinics IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Japan.","29686159","Healthy; Age- 41 to 64 years; Gender- Both; Country- Japan.","Walk-in fingertip HbA1c testing available at Specimen Measurement Offices","Cost-effectiveness of a New Opportunistic Screening Strategy for Walk-in Fingertip HbA1c Testing at Community Pharmacies in Japan.","Standard/Usual Care- HbA1c testing available only during Specific Health Checkup visits and conventional opportunistic screening in clinics","SE"
"2018-01-27337","2018","Lertjanyakun 2018 Pharmacoeconomics","160000","Exemestane plus everolimus VERSUS Exemestane IN Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Non-visceral metastatis; Postmenopausal; HR +/HER2 - metastatic breast cancer.","29707743","Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Non-visceral metastatis; Postmenopausal; HR +/HER2 - metastatic breast cancer.","Exemestane plus everolimus","Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.","Exemestane","NE"
"2018-01-27337","2018","Lertjanyakun 2018 Pharmacoeconomics","160000","Exemestane plus everolimus VERSUS Exemestane IN Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Postmenopausal; HR +/HER2 - metastatic breast cancer.","29707743","Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Postmenopausal; HR +/HER2 - metastatic breast cancer.","Exemestane plus everolimus","Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.","Exemestane","NE"
"2018-01-27337","2018","Lertjanyakun 2018 Pharmacoeconomics","28000","Toremifene VERSUS Exemestane IN Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Non-visceral metastatis; Postmenopausal; HR +/HER2 - metastatic breast cancer.","29707743","Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Non-visceral metastatis; Postmenopausal; HR +/HER2 - metastatic breast cancer.","Toremifene","Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.","Exemestane","NE"
"2018-01-27337","2018","Lertjanyakun 2018 Pharmacoeconomics","28000","Toremifene VERSUS Exemestane IN Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Postmenopausal; HR +/HER2 - metastatic breast cancer.","29707743","Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Postmenopausal; HR +/HER2 - metastatic breast cancer.","Toremifene","Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.","Exemestane","NE"
"2018-01-27337","2018","Lertjanyakun 2018 Pharmacoeconomics","49000","Fulvestrant VERSUS Exemestane IN Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Non-visceral metastatis; Postmenopausal; HR +/HER2 - metastatic breast cancer.","29707743","Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Non-visceral metastatis; Postmenopausal; HR +/HER2 - metastatic breast cancer.","Fulvestrant","Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.","Exemestane","NE"
"2018-01-27337","2018","Lertjanyakun 2018 Pharmacoeconomics","55000","Fulvestrant VERSUS Exemestane IN Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Postmenopausal; HR +/HER2 - metastatic breast cancer.","29707743","Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Postmenopausal; HR +/HER2 - metastatic breast cancer.","Fulvestrant","Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.","Exemestane","NE"
"2018-01-27337","2018","Lertjanyakun 2018 Pharmacoeconomics","Dominated","Fulvestrant: 250mg VERSUS Exemestane IN Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Non-visceral metastatis; postmenopausal; HR +/HER2 - metastatic breast cancer.","29707743","Specific disease- Metastatic breast cancer; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Non-visceral metastatis; postmenopausal; HR +/HER2 - metastatic breast cancer.","Fulvestrant: 250mg","Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.","Exemestane","NW"
"2018-01-27337","2018","Lertjanyakun 2018 Pharmacoeconomics","Dominated","Fulvestrant VERSUS Exemestane  IN Specific disease- Metastatic breast cancer ; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Postmenopausal; HR +/HER2 - metastatic breast cancer.","29707743","Specific disease- Metastatic breast cancer ; Age- 41 to 64 years, >=65 years; Gender- Female; Country- Japan; Other- Postmenopausal; HR +/HER2 - metastatic breast cancer.","Fulvestrant","Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.","Exemestane","NW"
"2018-01-27289","2018","Jiang 2018 J Med Econ","13000","23-valent pneumococcal polysaccharide vaccination VERSUS 23-valent pneumococcal polysaccharide vaccination, Strategy 1 IN Healthy; Age- >=65 years; Gender- Both; Country- Japan.","29723081","Healthy; Age- >=65 years; Gender- Both; Country- Japan.","23-valent pneumococcal polysaccharide vaccination","A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.","23-valent pneumococcal polysaccharide vaccination, Strategy 1","NE"
"2018-01-27289","2018","Jiang 2018 J Med Econ","13000","23-valent pneumococcal polysaccharide vaccination, Strategy 4 VERSUS 23-valent pneumococcal polysaccharide vaccination, Strategy 3 (strategy 1 and vaccinate the 2019 catch-up cohort) IN Healthy; Age- >=65 years; Gender- Both; Country- Japan.","29723081","Healthy; Age- >=65 years; Gender- Both; Country- Japan.","23-valent pneumococcal polysaccharide vaccination, Strategy 4","A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.","23-valent pneumococcal polysaccharide vaccination, Strategy 3 (strategy 1 and vaccinate the 2019 catch-up cohort)","NE"
"2018-01-27289","2018","Jiang 2018 J Med Econ","13000","23-valent pneumococcal polysaccharide vaccination, Strategy 5 VERSUS Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccination, Strategy 4: Catch-up and revaccination for cohorts vaccinated in 2014 and 65 years cohort in 2019 IN Healthy; Age- >=65 years; Gender- Both; Country- Japan.","29723081","Healthy; Age- >=65 years; Gender- Both; Country- Japan.","23-valent pneumococcal polysaccharide vaccination, Strategy 5","A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.","Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccination, Strategy 4: Catch-up and revaccination for cohorts vaccinated in 2014 and 65 years cohort in 2019","NE"
"2018-01-27289","2018","Jiang 2018 J Med Econ","Cost-Saving","23-valent pneumococcal polysaccharide vaccination, Strategy 3 (catch-up and no revaccination) VERSUS Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccination, Strategy 1 (No Revaccination and no catch-up) IN Healthy; Age- >=65 years; Gender- Both; Country- Japan.","29723081","Healthy; Age- >=65 years; Gender- Both; Country- Japan.","23-valent pneumococcal polysaccharide vaccination, Strategy 3 (catch-up and no revaccination)","A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.","Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccination, Strategy 1 (No Revaccination and no catch-up)","SE"
"2018-01-27289","2018","Jiang 2018 J Med Econ","Cost-Saving","23-valent pneumococcal polysaccharide vaccination, Strategy 3 VERSUS 23-valent pneumococcal polysaccharide vaccination, Strategy 1: vaccinate the 2014 and 2019 cohorts IN Healthy; Age- >=65 years; Gender- Both; Country- Japan.","29723081","Healthy; Age- >=65 years; Gender- Both; Country- Japan.","23-valent pneumococcal polysaccharide vaccination, Strategy 3","A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.","23-valent pneumococcal polysaccharide vaccination, Strategy 1: vaccinate the 2014 and 2019 cohorts","SE"
"2018-01-27289","2018","Jiang 2018 J Med Econ","Cost-Saving","23-valent pneumococcal polysaccharide vaccination, Strategy 4 VERSUS Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccination, Strategy 1: No Revaccination and no catch-up IN Healthy; Age- >=65 years; Gender- Both; Country- Japan.","29723081","Healthy; Age- >=65 years; Gender- Both; Country- Japan.","23-valent pneumococcal polysaccharide vaccination, Strategy 4","A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.","Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccination, Strategy 1: No Revaccination and no catch-up","SE"
"2018-01-27289","2018","Jiang 2018 J Med Econ","Cost-Saving","23-valent pneumococcal polysaccharide vaccination, Strategy 5 VERSUS Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccination, Strategy 1 (No Revaccination and no catch-up) IN Healthy; Age- >=65 years; Gender- Both; Country- Japan.","29723081","Healthy; Age- >=65 years; Gender- Both; Country- Japan.","23-valent pneumococcal polysaccharide vaccination, Strategy 5","A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.","Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccination, Strategy 1 (No Revaccination and no catch-up)","SE"
"2018-01-26787","2018","Tsukiyama 2018 Cancer Sci","38000","Aprepitant VERSUS Standard/Usual Care IN Specific disease- Cancer requiring chemotherapy; Age- Adult; Gender- Both; Country- Japan; Other- Out patient setting: Japanese patients with cisplatin-containing highly emetogenic chemotherapy.","29999572","Specific disease- Cancer requiring chemotherapy; Age- Adult; Gender- Both; Country- Japan; Other- Out patient setting: Japanese patients with cisplatin-containing highly emetogenic chemotherapy.","Aprepitant","Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy.","Standard/Usual Care","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","10000","QuantiFERON-TB Gold In-Tube VERSUS None IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated kidney transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated kidney transplant recipients.","QuantiFERON-TB Gold In-Tube","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","None","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","10000","QuantiFERON-TB Gold In-Tube VERSUS None IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated kidney transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated kidney transplant recipients.","QuantiFERON-TB Gold In-Tube","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","None","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","11000","QuantiFERON-TB Gold In-Tube VERSUS Tuberculin skin test IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated lung transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated lung transplant recipients.","QuantiFERON-TB Gold In-Tube","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","Tuberculin skin test","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","11000","Tuberculin skin test VERSUS None IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Non-BCG vaccinated kidney transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Non-BCG vaccinated kidney transplant recipients.","Tuberculin skin test","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","None","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","14000","TSPOT VERSUS Tuberculin skin test IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated lung transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated lung transplant recipients.","TSPOT","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","Tuberculin skin test","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","25000","Liver transplantation: QuantiFERON-TB Gold In-Tube VERSUS Tuberculin skin test IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated liver transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated liver transplant recipients.","Liver transplantation: QuantiFERON-TB Gold In-Tube","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","Tuberculin skin test","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","8600","Tuberculin skin test VERSUS None IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated liver transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated liver transplant recipients.","Tuberculin skin test","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","None","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","8900","Tuberculin skin test VERSUS None IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated lung transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated lung transplant recipients.","Tuberculin skin test","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","None","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","9000","QuantiFERON-TB Gold In-Tub VERSUS None IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated lung transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated lung transplant recipients.","QuantiFERON-TB Gold In-Tub","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","None","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","9000","QuantiFERON-TB Gold In-Tube VERSUS None IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated liver transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated liver transplant recipients.","QuantiFERON-TB Gold In-Tube","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","None","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","9000","TSPOT VERSUS None IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated lung transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated lung transplant recipients.","TSPOT","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","None","NE"
"2018-01-26753","2018","Kowada 2018 J Infect","Dominated","T-SPOT TB Test VERSUS QuantiFERON-TB Gold In-Tube IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated kidney transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated kidney transplant recipients.","T-SPOT TB Test","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","QuantiFERON-TB Gold In-Tube","NW"
"2018-01-26753","2018","Kowada 2018 J Infect","Dominated","TSPOT TB Test VERSUS QuantiFERON-TB Gold In-Tube IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated liver transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Bacillus Calmette-Guerin (BCG) vaccinated liver transplant recipients.","TSPOT TB Test","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","QuantiFERON-TB Gold In-Tube","NW"
"2018-01-26753","2018","Kowada 2018 J Infect","Dominated","TSPOT VERSUS QuantiFERON-TB Gold In-Tube IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated kidney transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated kidney transplant recipients.","TSPOT","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","QuantiFERON-TB Gold In-Tube","NW"
"2018-01-26753","2018","Kowada 2018 J Infect","Dominated","TSPOT VERSUS QuantiFERON-TB Gold In-Tube IN Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated liver transplant recipients.","30009853","Specific disease- Tuberculosis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- non-Bacillus Calmette-Guerin (BCG) vaccinated liver transplant recipients.","TSPOT","Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.","QuantiFERON-TB Gold In-Tube","NW"
"2017-01-25256","2017","Ward 2017 Value Health Reg Issues","630000","Daclatasvir + asunaprevir VERSUS Standard/Usual Care- Sofosbuvir/ledipasvir IN Specific disease- Chronic hepatic virus ; Age- Adult; Gender- Both; Country- Japan.","28648305","Specific disease- Chronic hepatic virus ; Age- Adult; Gender- Both; Country- Japan.","Daclatasvir + asunaprevir","Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic  Hepatitis C Virus Infection in Japan.","Standard/Usual Care- Sofosbuvir/ledipasvir","SW"
"2017-01-24817","2017","Yagi 2017 Eur Spine J","250000","2 Year Postoperative in Japan VERSUS None IN Specific disease- Adult spinal deformity; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Minimum of five fused vertebral levels..","28836012","Specific disease- Adult spinal deformity; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Japan; Other- Minimum of five fused vertebral levels..","2 Year Postoperative in Japan","A cost-effectiveness comparisons of adult spinal deformity surgery in the United  States and Japan.","None","NE"
"2017-01-24817","2017","Yagi 2017 Eur Spine J","570000","2 Year Postoperative in United States of America VERSUS None IN Specific disease- Adult spinal deformity; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United States of America (USA); Other- Minimum of five fused vertebral levels..","28836012","Specific disease- Adult spinal deformity; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United States of America (USA); Other- Minimum of five fused vertebral levels..","2 Year Postoperative in United States of America","A cost-effectiveness comparisons of adult spinal deformity surgery in the United  States and Japan.","None","NE"
"2017-01-24752","2017","Watanabe 2017 Low Urin Tract Symptoms","38000","Hydrophilic-coated catheters VERSUS Standard/Usual Care- Uncoated catheters IN Specific disease- Spinal Cord Injury; Age- 41 to 64 years; Gender- Both; Country- Japan; Other- Spinal Cord Injury patient with chronic urinary retention.","28868661","Specific disease- Spinal Cord Injury; Age- 41 to 64 years; Gender- Both; Country- Japan; Other- Spinal Cord Injury patient with chronic urinary retention.","Hydrophilic-coated catheters","Cost-Effectiveness Analysis of Long-Term Intermittent Self-Catheterization with Hydrophilic-Coated and Uncoated Catheters in Patients with Spinal Cord Injury in  Japan.","Standard/Usual Care- Uncoated catheters","NE"
"2017-01-24437","2017","Kamagata 2017 Clin Drug Investig","7900","Escitalopram VERSUS Sertraline IN Specific disease- Premenstrual Dysphoric Disorder; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Japan; Other- No comorbid mental disorders or medical complications.","29032438","Specific disease- Premenstrual Dysphoric Disorder; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Japan; Other- No comorbid mental disorders or medical complications.","Escitalopram","Improvements in Quality-Adjusted Life Years and Cost-Utility After Pharmacotherapy for Premenstrual Dysphoric Disorder: A Retrospective Study.","Sertraline"," "
"2017-01-24206","2017","Takayama 2017 Ann Vasc Dis","210000","Endovascular aneurysm repair (EVAR)   VERSUS Standard/Usual Care- Open Surgery (OS) IN Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","29147166","Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","Endovascular aneurysm repair (EVAR)","A Cost-Utility Analysis of Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm.","Standard/Usual Care- Open Surgery (OS)","NE"
"2017-01-24206","2017","Takayama 2017 Ann Vasc Dis","210000","Fee-For-Service: EVAR (Quality weight=1) VERSUS Standard/Usual Care- Fee-For-Service: OS (Quality Weight= 1) IN Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","29147166","Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","Fee-For-Service: EVAR (Quality weight=1)","A Cost-Utility Analysis of Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm.","Standard/Usual Care- Fee-For-Service: OS (Quality Weight= 1)","NE"
"2017-01-24206","2017","Takayama 2017 Ann Vasc Dis","240000","Endovascular aneurysm repair (EVAR)   VERSUS Standard/Usual Care-  Open surgery (OS)  IN Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan.","29147166","Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan.","Endovascular aneurysm repair (EVAR)","A Cost-Utility Analysis of Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm.","Standard/Usual Care-  Open surgery (OS)","NE"
"2017-01-24206","2017","Takayama 2017 Ann Vasc Dis","260000","Fee-For-Service: EVAR (Quality weight=0.8) VERSUS Standard/Usual Care- Fee-For-Service: OS (Quality Weight= 0.8) IN Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","29147166","Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","Fee-For-Service: EVAR (Quality weight=0.8)","A Cost-Utility Analysis of Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm.","Standard/Usual Care- Fee-For-Service: OS (Quality Weight= 0.8)","NE"
"2017-01-24206","2017","Takayama 2017 Ann Vasc Dis","270000","Diagnosis Procedure Combination/Per-Diem Payment: Open Surgery (Quality Weight= 0.8) VERSUS Standard/Usual Care- Open Surgery: OS (Quality Weight= 0.8) IN Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","29147166","Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","Diagnosis Procedure Combination/Per-Diem Payment: Open Surgery (Quality Weight= 0.8)","A Cost-Utility Analysis of Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm.","Standard/Usual Care- Open Surgery: OS (Quality Weight= 0.8)","NE"
"2017-01-24206","2017","Takayama 2017 Ann Vasc Dis","300000","Average Institute: Endovascular aneursym repair  VERSUS Standard/Usual Care- Average Institute: Open surgery IN Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","29147166","Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","Average Institute: Endovascular aneursym repair","A Cost-Utility Analysis of Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm.","Standard/Usual Care- Average Institute: Open surgery","NE"
"2017-01-24206","2017","Takayama 2017 Ann Vasc Dis","350000","Fee-For-Service: EVAR (Quality weight=0.6) VERSUS Standard/Usual Care- Fee-For-Service: OS (Quality Weight= 0.6) IN Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divided into the non-ruptured EVAR, OS, and ruptured OS groups..","29147166","Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divided into the non-ruptured EVAR, OS, and ruptured OS groups..","Fee-For-Service: EVAR (Quality weight=0.6)","A Cost-Utility Analysis of Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm.","Standard/Usual Care- Fee-For-Service: OS (Quality Weight= 0.6)","NE"
"2017-01-24206","2017","Takayama 2017 Ann Vasc Dis","360000","Diagnosis Procedure Combination/Per-Diem Payment: Open Surgery (Quality Weight= 0.6) VERSUS Standard/Usual Care- Diagnosis Procedure Combination/Per-Diem Payment: OS (Quality Weight= 0.6) IN Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divided into the non-ruptured EVAR, OS, and ruptured OS groups..","29147166","Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divided into the non-ruptured EVAR, OS, and ruptured OS groups..","Diagnosis Procedure Combination/Per-Diem Payment: Open Surgery (Quality Weight= 0.6)","A Cost-Utility Analysis of Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm.","Standard/Usual Care- Diagnosis Procedure Combination/Per-Diem Payment: OS (Quality Weight= 0.6)","NE"
"2017-01-24206","2017","Takayama 2017 Ann Vasc Dis","400000","Average Institute: Endovascular aneursym repair (Quality weight= 0.6) VERSUS Standard/Usual Care- Average Institute: Open surgery (Quality weight= 0.6) IN Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","29147166","Specific disease- Abdominal Aortic Aneurysm; Age- >=65 years; Gender- Both; Country- Japan; Other- Patients who underwent surgery for AAA were divded into the non-ruptured EVAR, OS, and ruptured OS groups..","Average Institute: Endovascular aneursym repair (Quality weight= 0.6)","A Cost-Utility Analysis of Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm.","Standard/Usual Care- Average Institute: Open surgery (Quality weight= 0.6)","NE"
"2017-01-24203","2017","Shiroiwa 2017 BMC Cancer","Cost-Saving","Oral S-1 Therapy VERSUS Standard/Usual Care- Taxane IN Specific disease- Metastatic Breast Cancer; Age- Adult; Gender- Female; Country- Japan; Other- Patients with HER-2 negative, hormone resistant MBC who were not previously treated with chemotherapy after diagnosis were selected..","29149882","Specific disease- Metastatic Breast Cancer; Age- Adult; Gender- Female; Country- Japan; Other- Patients with HER-2 negative, hormone resistant MBC who were not previously treated with chemotherapy after diagnosis were selected..","Oral S-1 Therapy","Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.","Standard/Usual Care- Taxane","SE"
"2017-01-24186","2017","Kodera 2017 J Cardiol","38000","Transcatheter aortic valve implantation (TAVI) VERSUS Standard/Usual Care- Medical Therapy IN Specific disease- Aortic stenosis; Age- Adult; Gender- Both; Country- Japan; Other- Inoperable patients (30-day mortality and morbidity rate of >50%).","29153740","Specific disease- Aortic stenosis; Age- Adult; Gender- Both; Country- Japan; Other- Inoperable patients (30-day mortality and morbidity rate of >50%).","Transcatheter aortic valve implantation (TAVI)","Cost effectiveness of transcatheter aortic valve implantation in patients with aortic stenosis in Japan.","Standard/Usual Care- Medical Therapy","NE"
"2017-01-24186","2017","Kodera 2017 J Cardiol","73000","Transcatheter aortic valve implantation (TAVI) VERSUS Surgical aortic valve replacement (SAVR) IN Specific disease- Aortic stenosis; Age- Adult; Gender- Both; Country- Japan; Other- Operable patients with intermediate surgical risk (30-day mortality rate of 4%â8%).","29153740","Specific disease- Aortic stenosis; Age- Adult; Gender- Both; Country- Japan; Other- Operable patients with intermediate surgical risk (30-day mortality rate of 4%â8%).","Transcatheter aortic valve implantation (TAVI)","Cost effectiveness of transcatheter aortic valve implantation in patients with aortic stenosis in Japan.","Surgical aortic valve replacement (SAVR)","NE"
"2017-01-23766","2017","Mori 2017 Osteoporos Int","27000","Denosumab (societal perspective, 65 yrs) VERSUS Standard/Usual Care- Alendronate IN Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Japan.","28210776","Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Japan.","Denosumab (societal perspective, 65 yrs)","Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic  women in Japan.","Standard/Usual Care- Alendronate","NE"
"2017-01-23766","2017","Mori 2017 Osteoporos Int","28000","Denosumab (governmental perspective, 65 yrs) VERSUS Standard/Usual Care- Alendronate IN Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Japan.","28210776","Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Japan.","Denosumab (governmental perspective, 65 yrs)","Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic  women in Japan.","Standard/Usual Care- Alendronate","NE"
"2017-01-23766","2017","Mori 2017 Osteoporos Int","31000","Denosumab (healthcare sector perspective, 65 yrs) VERSUS Standard/Usual Care- Alendronate IN Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Japan.","28210776","Specific disease- Osteoporosis; Age- >=65 years; Gender- Female; Country- Japan.","Denosumab (healthcare sector perspective, 65 yrs)","Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic  women in Japan.","Standard/Usual Care- Alendronate","NE"
"2014-01-15710","2014","Shepard 2014 PLoS One","17000","Area-Wide Integrated Pest Management VERSUS None IN Healthy; Age- 0 to 18 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","25338065","Healthy; Age- 0 to 18 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Area-Wide Integrated Pest Management","Economic evaluation of an area-wide integrated pest management program to control the Asian tiger mosquito in New Jersey.","None","NE"
"2011-01-07367","2011","Chen 2011 Can J Cardiol","24000","Clopidogrel plus aspirin VERSUS Aspirin IN Canadian patients with established cardiovascular disease or multiple cardiovascular risk factors","21459271","Canadian patients with established cardiovascular disease or multiple cardiovascular risk factors","Clopidogrel plus aspirin","Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial.","Aspirin","NE"
"2009-01-05296","2009","Eckman 2009 Ann Intern Med","210000","Testing for variant alleles involved in warfarin metabolism to allow for more personalized dosing of warfarin during induction phase VERSUS No genotyping for warfarin-related variant alleles and using standard warfarin induction IN Outpatients or inpatients with newly diagnosed nonvalvular atrial fribrulation and no contraindications to warfarin therapy","19153410","Outpatients or inpatients with newly diagnosed nonvalvular atrial fribrulation and no contraindications to warfarin therapy","Testing for variant alleles involved in warfarin metabolism to allow for more personalized dosing of warfarin during induction phase","Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.","No genotyping for warfarin-related variant alleles and using standard warfarin induction","NE"
"2009-01-05085","2009","Collins 2009 Am J Emerg Med","57000","Observation unit VERSUS Emergency department discharge IN Patients with acute decompensated heart failure and non-high-risk heart failure, 60 year old men, United States","19328373","Patients with acute decompensated heart failure and non-high-risk heart failure, 60 year old men, United States","Observation unit","Cost-effectiveness analysis of ED decision making in patients with non-high-risk heart failure.","Emergency department discharge","NE"
"2009-01-05085","2009","Collins 2009 Am J Emerg Med","880000","Hospital admission VERSUS Emergency department discharge IN Patients withacute decompensated heart failure and non-high-risk heart failure, 60 year old men, United States","19328373","Patients withacute decompensated heart failure and non-high-risk heart failure, 60 year old men, United States","Hospital admission","Cost-effectiveness analysis of ED decision making in patients with non-high-risk heart failure.","Emergency department discharge","NE"
"1999-01-02048","1999","Marin 1999 J Occup Environ Med","280000","Post-exposure chemoprophylaxis program with zidovudine alone VERSUS No treatment IN Health care workers with percutaneous exposure to blood","10491791","Health care workers with percutaneous exposure to blood","Post-exposure chemoprophylaxis program with zidovudine alone","Cost-effectiveness of a post-exposure HIV chemoprophylaxis program for blood exposures in health care workers.","No treatment","NE"
"1999-01-02048","1999","Marin 1999 J Occup Environ Med","300000","Post-exposure chemoprophylaxis program with standard 3-drug regimen VERSUS No treatment IN Health care workers with percutaneous exposure to blood","10491791","Health care workers with percutaneous exposure to blood","Post-exposure chemoprophylaxis program with standard 3-drug regimen","Cost-effectiveness of a post-exposure HIV chemoprophylaxis program for blood exposures in health care workers.","No treatment","NE"
"2018-01-25854","2018","Hayajneh 2018 BMC Infect Dis","79","Vaccination for Hepatitis A (5 years after) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Jordan.","29514609","Healthy; Age- 0 to 18 years; Gender- Both; Country- Jordan.","Vaccination for Hepatitis A (5 years after)","Public health impact and cost effectiveness of routine childhood vaccination for  hepatitis a in Jordan: a dynamic model approach.","None","NE"
"2018-01-25854","2018","Hayajneh 2018 BMC Infect Dis","Cost-Saving","Vaccination for Hepatitis A (10 years after) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Jordan.","29514609","Healthy; Age- 0 to 18 years; Gender- Both; Country- Jordan.","Vaccination for Hepatitis A (10 years after)","Public health impact and cost effectiveness of routine childhood vaccination for  hepatitis a in Jordan: a dynamic model approach.","None","SE"
"2018-01-25854","2018","Hayajneh 2018 BMC Infect Dis","Cost-Saving","Vaccination for Hepatitis A (25 years after) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Jordan.","29514609","Healthy; Age- 0 to 18 years; Gender- Both; Country- Jordan.","Vaccination for Hepatitis A (25 years after)","Public health impact and cost effectiveness of routine childhood vaccination for  hepatitis a in Jordan: a dynamic model approach.","None","SE"
"2018-01-25854","2018","Hayajneh 2018 BMC Infect Dis","Cost-Saving","Vaccination for Hepatitis A (50 years after) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Jordan.","29514609","Healthy; Age- 0 to 18 years; Gender- Both; Country- Jordan.","Vaccination for Hepatitis A (50 years after)","Public health impact and cost effectiveness of routine childhood vaccination for  hepatitis a in Jordan: a dynamic model approach.","None","SE"
"2017-01-25306","2017","Delea 2017 J Med Econ","110000","Blinatumomab VERSUS Standard/Usual Care IN Specific disease- Acute lymphoblastic leukemia ; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United States of America (USA); Other- Patients with Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia .","28631497","Specific disease- Acute lymphoblastic leukemia ; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United States of America (USA); Other- Patients with Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia .","Blinatumomab","Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.","Standard/Usual Care","NE"
"2017-01-25295","2017","Amdahl 2017 PLoS One","Cost-Saving","Pazopanib VERSUS Standard/Usual Care- Sunitinib IN Specific disease- Metastatic renal cell carcinoma ; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Treatment-naÃ¯ve patients.","28636648","Specific disease- Metastatic renal cell carcinoma ; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Treatment-naÃ¯ve patients.","Pazopanib","Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.","Standard/Usual Care- Sunitinib","SE"
"2017-01-24828","2017","Bress 2017 N Engl J Med","48000","Intensive Control VERSUS Standard/Usual Care- Standard Control IN Specific disease- High Blood Pressure; Age- Adult; Gender- Both; Country- United States of America (USA); Other- High risk of cardiovascular disease. .","28834469","Specific disease- High Blood Pressure; Age- Adult; Gender- Both; Country- United States of America (USA); Other- High risk of cardiovascular disease. .","Intensive Control","Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.","Standard/Usual Care- Standard Control","NE"
"2017-01-24788","2017","Sandsund 2017 BMJ Support Palliat Care","15000","Holistic needs assessment (HNA) to develop a care plan VERSUS Standard/Usual Care- Usual rehabilitation care IN Specific disease- Gynaecological cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United Kingdom (UK); Other- Participants have recently completed first-line treatment with radical intent for stage I, II or III gynaecological cancer and reported physical or psychosocial need resulting from the disease or its treatment..","28847853","Specific disease- Gynaecological cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United Kingdom (UK); Other- Participants have recently completed first-line treatment with radical intent for stage I, II or III gynaecological cancer and reported physical or psychosocial need resulting from the disease or its treatment..","Holistic needs assessment (HNA) to develop a care plan","Holistic needs assessment and care plans for women with gynaecological cancer: do they improve cancer-specific health-related quality of life? A randomised controlled trial using mixed methods.","Standard/Usual Care- Usual rehabilitation care","NE"
"2017-01-24782","2017","Wong 2017 CMAJ Open","26000","Screen and treat with interferon-free direct-acting antiviral: Scenario 2 VERSUS No screening: treat with interferon-free direct-acting antiviral if diagnosed IN Specific disease- Hepatitis C Virus Infection; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Immigrant populations with high prevalence.","28851700","Specific disease- Hepatitis C Virus Infection; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Immigrant populations with high prevalence.","Screen and treat with interferon-free direct-acting antiviral: Scenario 2","Model-based projection of health and economic effects of screening for hepatitis  C in Canada.","No screening: treat with interferon-free direct-acting antiviral if diagnosed","NE"
"2017-01-24782","2017","Wong 2017 CMAJ Open","27000","Screen and treat with interferon-free direct-acting antiviral: Scenario 3 VERSUS No screening: treat with interferon-free direct-acting antiviral if diagnosed IN Specific disease- Hepatitis C Virus Infection; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada.","28851700","Specific disease- Hepatitis C Virus Infection; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada.","Screen and treat with interferon-free direct-acting antiviral: Scenario 3","Model-based projection of health and economic effects of screening for hepatitis  C in Canada.","No screening: treat with interferon-free direct-acting antiviral if diagnosed","NE"
"2017-01-24782","2017","Wong 2017 CMAJ Open","29000","Screen and treat with interferon-free direct-acting antiviral: Scenario 4 VERSUS No screening: treat with interferon-free direct-acting antiviral if diagnosed IN Specific disease- Hepatitis C Virus Infection; Age- 41 to 64 years; Gender- Both; Country- Canada.","28851700","Specific disease- Hepatitis C Virus Infection; Age- 41 to 64 years; Gender- Both; Country- Canada.","Screen and treat with interferon-free direct-acting antiviral: Scenario 4","Model-based projection of health and economic effects of screening for hepatitis  C in Canada.","No screening: treat with interferon-free direct-acting antiviral if diagnosed","NE"
"2017-01-24782","2017","Wong 2017 CMAJ Open","42000","Screen and treat with interferon-free direct-acting antiviral: Scenario 1 VERSUS No screening: treat with interferon-free direct-acting antiviral if diagnosed IN Specific disease- Hepatitis C Virus Infection; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Patients with genotype 1 infection.","28851700","Specific disease- Hepatitis C Virus Infection; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Canada; Other- Patients with genotype 1 infection.","Screen and treat with interferon-free direct-acting antiviral: Scenario 1","Model-based projection of health and economic effects of screening for hepatitis  C in Canada.","No screening: treat with interferon-free direct-acting antiviral if diagnosed","NE"
"2017-01-24444","2017","Patrice 2017 Int J Radiat Oncol Biol Phys","Cost-Saving","Thoracic radiation therapy plus Standard treatment VERSUS Standard/Usual Care- chemotherapy and prophylactic cranial irradiation IN Specific disease- Extensive-Stage Small Cell Lung Cancer; Age- Adult; Gender- Both; Country- United States of America (USA); Other- WHO performance status of 0 to 2, and any response to 4 to 6 cycles of platinum-etoposide chemotherapy.","29029885","Specific disease- Extensive-Stage Small Cell Lung Cancer; Age- Adult; Gender- Both; Country- United States of America (USA); Other- WHO performance status of 0 to 2, and any response to 4 to 6 cycles of platinum-etoposide chemotherapy.","Thoracic radiation therapy plus Standard treatment","Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST).","Standard/Usual Care- chemotherapy and prophylactic cranial irradiation","SE"
"2017-01-23644","2017","Schmier 2017 Clin Cardiol","47000","Implantable wireless pulmonary artery pressure monitoring system (CardioMEMS) VERSUS Standard/Usual Care IN Specific disease- Heart failure; Age- Adult; Gender- Both; Country- United States of America (USA).","28272808","Specific disease- Heart failure; Age- Adult; Gender- Both; Country- United States of America (USA).","Implantable wireless pulmonary artery pressure monitoring system (CardioMEMS)","Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System.","Standard/Usual Care","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","13000","Paritaprevir/ritonavir + ombitasvir + dasabuvir for 12 weeks VERSUS Standard/Usual Care- Pegylated interferon-ribavirin alone IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-experienced without cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-experienced without cirrhosis..","Paritaprevir/ritonavir + ombitasvir + dasabuvir for 12 weeks","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","Standard/Usual Care- Pegylated interferon-ribavirin alone","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","14000","Paritaprevir/ritonavir + ombitasvir + dasabuvir + ribavirin for
12 weeks VERSUS Standard/Usual Care- Pegylated interferon-ribavirin alone IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-experienced without cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-experienced without cirrhosis..","Paritaprevir/ritonavir + ombitasvir + dasabuvir + ribavirin for
12 weeks","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","Standard/Usual Care- Pegylated interferon-ribavirin alone","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","15000","Sofosbuvir + ribavirin for 12 wk VERSUS None IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 2, treatment-experienced with cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 2, treatment-experienced with cirrhosis..","Sofosbuvir + ribavirin for 12 wk","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","None","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","15000","Sofosbuvir + ribavirin for 12 wk VERSUS None IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 2, treatment-experienced without cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 2, treatment-experienced without cirrhosis..","Sofosbuvir + ribavirin for 12 wk","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","None","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","17000","Simeprevir for 12 wk and PR used as RGT for 24 or 48 wk VERSUS Standard/Usual Care- Pegylated interferon-ribavirin alone IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-experienced with cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-experienced with cirrhosis..","Simeprevir for 12 wk and PR used as RGT for 24 or 48 wk","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","Standard/Usual Care- Pegylated interferon-ribavirin alone","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","17000","Sofosbuvir + pegylated interferon + ribavirin for 12 wk VERSUS None IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 3, treatment-experienced with cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 3, treatment-experienced with cirrhosis..","Sofosbuvir + pegylated interferon + ribavirin for 12 wk","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","None","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","17000","Sofosbuvir + pegylated interferon + ribavirin for 12 wk VERSUS None IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 3, treatment-experienced without cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 3, treatment-experienced without cirrhosis..","Sofosbuvir + pegylated interferon + ribavirin for 12 wk","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","None","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","170000","Sofosbuvir + ribavirin for 12 wk VERSUS Standard/Usual Care- Pegylated interferon-ribavirin alone IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 2, treatment-naive without cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 2, treatment-naive without cirrhosis..","Sofosbuvir + ribavirin for 12 wk","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","Standard/Usual Care- Pegylated interferon-ribavirin alone","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","22000","Sofosbuvir + ledipasvir + ribavirin for 12 wk VERSUS Standard/Usual Care- Pegylated interferon-ribavirin alone IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-experienced with cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-experienced with cirrhosis..","Sofosbuvir + ledipasvir + ribavirin for 12 wk","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","Standard/Usual Care- Pegylated interferon-ribavirin alone","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","22000","Sofosbuvir + ledipasvir for 12 weeks VERSUS Standard/Usual Care- Pegylated interferon-ribavirin alone IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-naive with cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-naive with cirrhosis..","Sofosbuvir + ledipasvir for 12 weeks","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","Standard/Usual Care- Pegylated interferon-ribavirin alone","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","23000","Daclatasvir and sofosbuvir for 12 wk VERSUS None IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 3, treatment-experienced without cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 3, treatment-experienced without cirrhosis..","Daclatasvir and sofosbuvir for 12 wk","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","None","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","24000","Paritaprevir/ritonavir + ombitasvir + dasabuvir for 12 wk VERSUS Pegylated interferon + ribavirin for 48 weeks IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-naive without cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-naive without cirrhosis..","Paritaprevir/ritonavir + ombitasvir + dasabuvir for 12 wk","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","Pegylated interferon + ribavirin for 48 weeks","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","30000","Simeprevir + sofosbuvir for 12 wk VERSUS Standard/Usual Care- Pegylated interferon-ribavirin alone IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-experienced with cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-experienced with cirrhosis..","Simeprevir + sofosbuvir for 12 wk","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","Standard/Usual Care- Pegylated interferon-ribavirin alone","NE"
"2017-01-23372","2017","Wong 2017 CMAJ Open","31000","Sofosbuvir + ledipasvir for 12 weeks VERSUS Standard/Usual Care- Pegylated interferon-ribavirin alone IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-naive without cirrhosis..","28401125","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada; Other- Genotype 1, treatment-naive without cirrhosis..","Sofosbuvir + ledipasvir for 12 weeks","Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.","Standard/Usual Care- Pegylated interferon-ribavirin alone","NE"
"2016-01-20846","2016","Katz 2016 Osteoarthritis Cartilage","77000","Naproxen Rx (prescription) +  Proton Pump Inhibitor OTC  (over the counter) VERSUS Ibuprofen Rx (prescribed) IN Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","26525846","Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","Naproxen Rx (prescription) +  Proton Pump Inhibitor OTC  (over the counter)","Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.","Ibuprofen Rx (prescribed)","NW"
"2016-01-20846","2016","Katz 2016 Osteoarthritis Cartilage","86000","Naproxen Rx (Prescription) VERSUS Naproxen  OTC (Over the counter)+ Proton pump inhibitor over the counter ( PPI-OTC) IN Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","26525846","Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","Naproxen Rx (Prescription)","Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.","Naproxen  OTC (Over the counter)+ Proton pump inhibitor over the counter ( PPI-OTC)","NW"
"2016-01-20846","2016","Katz 2016 Osteoarthritis Cartilage","Cost-Saving","Ibuprofen Rx (prescribed) VERSUS Standard/Usual Care- Standard of care IN Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","26525846","Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","Ibuprofen Rx (prescribed)","Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.","Standard/Usual Care- Standard of care","SE"
"2016-01-20846","2016","Katz 2016 Osteoarthritis Cartilage","Dominated","Celecoxib VERSUS Naproxen Rx (prescription) +  Proton Pump Inhibitor Rx IN Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","26525846","Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","Celecoxib","Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.","Naproxen Rx (prescription) +  Proton Pump Inhibitor Rx","NW"
"2016-01-20846","2016","Katz 2016 Osteoarthritis Cartilage","Dominated","Ibuprofen OTC (over the counter) VERSUS Ibuprofen Rx (prescribed) IN Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","26525846","Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","Ibuprofen OTC (over the counter)","Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.","Ibuprofen Rx (prescribed)","NE"
"2016-01-20846","2016","Katz 2016 Osteoarthritis Cartilage","Dominated","Ibuprofen OTC (Over the counter)+ Proton pump inhibitor over the counter ( PPI-OTC) VERSUS Ibuprofen Rx (prescription)+ Proton pump inhibitor over the counter ( PPI OTC) IN Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","26525846","Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","Ibuprofen OTC (Over the counter)+ Proton pump inhibitor over the counter ( PPI-OTC)","Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.","Ibuprofen Rx (prescription)+ Proton pump inhibitor over the counter ( PPI OTC)","NW"
"2016-01-20846","2016","Katz 2016 Osteoarthritis Cartilage","Dominated","Tramadol VERSUS Naproxen Rx (Prescription) IN Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","26525846","Specific disease- Knee osteoarthritis; Age- >=65 years; Gender- Both; Country- United States.","Tramadol","Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.","Naproxen Rx (Prescription)","NW"
"2016-01-20357","2016","Losina 2016 Osteoarthritis Cartilage","200000","Nerve Growth Factor Inhibitors (NGFI) : as Tanezumab; Hospital  administered VERSUS Standard/Usual Care IN Specific disease- Knee osteoarthritis; Age- Adult; Gender- Both; Country- United States.","26746146","Specific disease- Knee osteoarthritis; Age- Adult; Gender- Both; Country- United States.","Nerve Growth Factor Inhibitors (NGFI) : as Tanezumab; Hospital  administered","Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.","Standard/Usual Care","NE"
"2016-01-20357","2016","Losina 2016 Osteoarthritis Cartilage","26000","Nerve Growth Factor Inhibitors (NGFI) : as Tanezumab; self administered VERSUS Standard/Usual Care IN Specific disease- Knee osteoarthritis; Age- Adult; Gender- Both; Country- United States.","26746146","Specific disease- Knee osteoarthritis; Age- Adult; Gender- Both; Country- United States.","Nerve Growth Factor Inhibitors (NGFI) : as Tanezumab; self administered","Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.","Standard/Usual Care","NE"
"2016-01-19746","2016","King 2016 JACC Heart Fail","54000","Dual-acting angiotensen receptor neprilysin inhibitor (ARNI) with sacubitril-valsartan VERSUS Angiotensin-converting enzyme inhibitors (ACEI) with enalapril IN Specific disease- Heart failure; Age- 41 to 64 years; Gender- Both; Country- United States; Other- with reduced ejection fraction.","27039128","Specific disease- Heart failure; Age- 41 to 64 years; Gender- Both; Country- United States; Other- with reduced ejection fraction.","Dual-acting angiotensen receptor neprilysin inhibitor (ARNI) with sacubitril-valsartan","Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.","Angiotensin-converting enzyme inhibitors (ACEI) with enalapril","NE"
"2016-01-19598","2016","Smith 2016 Arthritis Care Res (Hoboken)","Cost-Saving","Opiod Sparing VERSUS Tramadol + Oxycodone IN Specific disease- Knee Osteoarthritis; Age- 41 to 64 years; Gender- Both; Country- United States; Other- Kellgren-Lawrence Grade 2 or 3; previously undergone treatment with NSAIDs, PT, and corticosteroid injections.","27111538","Specific disease- Knee Osteoarthritis; Age- 41 to 64 years; Gender- Both; Country- United States; Other- Kellgren-Lawrence Grade 2 or 3; previously undergone treatment with NSAIDs, PT, and corticosteroid injections.","Opiod Sparing","Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis.","Tramadol + Oxycodone","SE"
"2016-01-19598","2016","Smith 2016 Arthritis Care Res (Hoboken)","Cost-Saving","Opiod Sparing VERSUS Tramadol IN Specific disease- Knee Osteoarthritis; Age- 41 to 64 years; Gender- Both; Country- United States; Other- Kellgren-Lawrence Grade 2 or 3; previously undergone treatment with NSAIDs, PT, and corticosteroid injections.","27111538","Specific disease- Knee Osteoarthritis; Age- 41 to 64 years; Gender- Both; Country- United States; Other- Kellgren-Lawrence Grade 2 or 3; previously undergone treatment with NSAIDs, PT, and corticosteroid injections.","Opiod Sparing","Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis.","Tramadol","SE"
"2015-01-18940","2015","Delea 2015 J Manag Care Spec Pharm","Cost-Saving","Pazopanib VERSUS Sunitinib IN Specific disease- Renal cancer; Age- Adult; Gender- Both; Country- United States; Other- Treatment naÃ¯ve patients with metastatic renal cell carcinoma (mRCC).","25562772","Specific disease- Renal cancer; Age- Adult; Gender- Both; Country- United States; Other- Treatment naÃ¯ve patients with metastatic renal cell carcinoma (mRCC).","Pazopanib","Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.","Sunitinib","SE"
"2015-01-18905","2015","Wong 2015 CMAJ","36000","Hepatitis C virus (HCV) screen and treat with pegylated interferon plus ribavirin VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Canada.","25583667","Healthy; Age- 41 to 64 years; Gender- Both; Country- Canada.","Hepatitis C virus (HCV) screen and treat with pegylated interferon plus ribavirin","Cost-effectiveness of screening for hepatitis C in Canada.","None","NE"
"2015-01-18905","2015","Wong 2015 CMAJ","36000","Heptatitis C virus (HCV) screen and treat with interferon-free direct-acting antiviral agent (genotype 1), sofosbuvir plus ribavirin (genotype 2/3) or pegylated interferon plus ribavirin (genotype 4/5/6) VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada.","25583667","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada.","Heptatitis C virus (HCV) screen and treat with interferon-free direct-acting antiviral agent (genotype 1), sofosbuvir plus ribavirin (genotype 2/3) or pegylated interferon plus ribavirin (genotype 4/5/6)","Cost-effectiveness of screening for hepatitis C in Canada.","None","NE"
"2015-01-18905","2015","Wong 2015 CMAJ","37000","Hepatitis C virus (HCV) screen and treat with interferon-free direct-acting antiviral agent (genotype 1), sofosbuvir plus ribavirin (genotype 2/3), pegylated interferon plus ribavirin (genotype 4/5/6) VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Canada.","25583667","Healthy; Age- 41 to 64 years; Gender- Both; Country- Canada.","Hepatitis C virus (HCV) screen and treat with interferon-free direct-acting antiviral agent (genotype 1), sofosbuvir plus ribavirin (genotype 2/3), pegylated interferon plus ribavirin (genotype 4/5/6)","Cost-effectiveness of screening for hepatitis C in Canada.","None","NE"
"2015-01-18905","2015","Wong 2015 CMAJ","40000","Hepatitis C virus (HCV) screen and treat with pegylated interferon plus ribavirin VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada.","25583667","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada.","Hepatitis C virus (HCV) screen and treat with pegylated interferon plus ribavirin","Cost-effectiveness of screening for hepatitis C in Canada.","None","NE"
"2015-01-18905","2015","Wong 2015 CMAJ","44000","Hepatatits C virus (HCV) screen and treat with simeprevir + pegylated interferon plus ribavirin (genotype 1), sofosbuvir plus ribavirin (genotype 2/3) or pegylated interferon plus ribavirin (genotype 4/5/6) VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada.","25583667","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Canada.","Hepatatits C virus (HCV) screen and treat with simeprevir + pegylated interferon plus ribavirin (genotype 1), sofosbuvir plus ribavirin (genotype 2/3) or pegylated interferon plus ribavirin (genotype 4/5/6)","Cost-effectiveness of screening for hepatitis C in Canada.","None","NE"
"2015-01-18905","2015","Wong 2015 CMAJ","46000","Hepatitis C virus (HCV) screen and treat with simeprevir + pegylated interferon plus ribavirin (genotype 1), sofosbuvir plus ribavirin (genotype 2/3), pegylated interferon plus ribavirin (genotype 4/5/6) VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Canada.","25583667","Healthy; Age- 41 to 64 years; Gender- Both; Country- Canada.","Hepatitis C virus (HCV) screen and treat with simeprevir + pegylated interferon plus ribavirin (genotype 1), sofosbuvir plus ribavirin (genotype 2/3), pegylated interferon plus ribavirin (genotype 4/5/6)","Cost-effectiveness of screening for hepatitis C in Canada.","None","NE"
"2015-01-18097","2015","Wong 2015 Breast Cancer Res Treat","130000","Screen-and-treat high-risk only and treat with entecavir, before adjuvant chemotherapy VERSUS None IN Specific disease- Early-stage breast cancer; Age-; Gender- Female; Country- Canada.","25962692","Specific disease- Early-stage breast cancer; Age-; Gender- Female; Country- Canada.","Screen-and-treat high-risk only and treat with entecavir, before adjuvant chemotherapy","Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.","None","NE"
"2017-01-23775","2017","Patel 2017 Medicine (Baltimore)","1100","Mobile phone text message (SMS) interventions to improve adherence to HIV therapy VERSUS Standard/Usual Care- 50% adherence rate to includes 1 or 2 adherence counseling sessions at ART initiation and suggested participation in support groups IN Specific disease- HIV/AIDS; Age- Adult; Gender- Both; Country- Kenya; Other- Initiating ART who own or have access to mobile phones.","28207516","Specific disease- HIV/AIDS; Age- Adult; Gender- Both; Country- Kenya; Other- Initiating ART who own or have access to mobile phones.","Mobile phone text message (SMS) interventions to improve adherence to HIV therapy","Economic evaluation of mobile phone text message interventions to improve adherence to HIV therapy in Kenya.","Standard/Usual Care- 50% adherence rate to includes 1 or 2 adherence counseling sessions at ART initiation and suggested participation in support groups","NE"
"2017-01-23775","2017","Patel 2017 Medicine (Baltimore)","960","Mobile phone text message (SMS) interventions to improve adherence to HIV therapy VERSUS Standard/Usual Care- 40% adherence rate to includes 1 or 2 adherence counseling sessions at ART initiation and suggested participation in support groups IN Specific disease- HIV/AIDS; Age-; Gender- Both; Country- Kenya; Other- Initiating anti-retroviral therapy (ART) who own or have access to mobile phones.","28207516","Specific disease- HIV/AIDS; Age-; Gender- Both; Country- Kenya; Other- Initiating anti-retroviral therapy (ART) who own or have access to mobile phones.","Mobile phone text message (SMS) interventions to improve adherence to HIV therapy","Economic evaluation of mobile phone text message interventions to improve adherence to HIV therapy in Kenya.","Standard/Usual Care- 40% adherence rate to includes 1 or 2 adherence counseling sessions at ART initiation and suggested participation in support groups","NE"
"2014-01-16607","2014","Braithwaite 2014 J Acquir Immune Defic Syndr","2700","Cognitive behavioral therapy (CBT)-based interventions addressing unhealthy alcohol consumption VERSUS None IN Specific disease- HIV; Age- Unknown; Gender- Not Specified; Country- Kenya.","24828269","Specific disease- HIV; Age- Unknown; Gender- Not Specified; Country- Kenya.","Cognitive behavioral therapy (CBT)-based interventions addressing unhealthy alcohol consumption","How inexpensive does an alcohol intervention in Kenya need to be in order to deliver favorable value by reducing HIV-related morbidity and mortality?","None","NE"
"2011-01-08392","2011","Simpson 2011 Value Health","1800","Switching from failing non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen to protease inhibitor-based regimen of lopinavir + ritonavir (LPV/r) + zidovudine (ZDV) and lamivudine (3TC), concurrent use of cotrimoxazole VERSUS Remaining on a failed first antiretroviral (ARV) regimen or discontinuing all ARV drugs IN Antiretroviral-naÃ¯ve patients with history of two WHO stage 3 events or a current WHO stage 4 event in Kenya","22152173","Antiretroviral-naÃ¯ve patients with history of two WHO stage 3 events or a current WHO stage 4 event in Kenya","Switching from failing non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen to protease inhibitor-based regimen of lopinavir + ritonavir (LPV/r) + zidovudine (ZDV) and lamivudine (3TC), concurrent use of cotrimoxazole","Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.","Remaining on a failed first antiretroviral (ARV) regimen or discontinuing all ARV drugs","NE"
"2011-01-08392","2011","Simpson 2011 Value Health","2000","Switching from failing non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen to protease inhibitor-based regimen of lopinavir + ritonavir (LPV/r) + zidovudine (ZDV) and lamivudine (3TC), concurrent use of cotrimoxazole VERSUS Remaining on a failed first antiretroviral (ARV) regimen or discontinuing all ARV drugs IN Antiretroviral-naÃ¯ve patients with history of two WHO stage 3 events or a current WHO stage 4 event in Uganda","22152173","Antiretroviral-naÃ¯ve patients with history of two WHO stage 3 events or a current WHO stage 4 event in Uganda","Switching from failing non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen to protease inhibitor-based regimen of lopinavir + ritonavir (LPV/r) + zidovudine (ZDV) and lamivudine (3TC), concurrent use of cotrimoxazole","Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.","Remaining on a failed first antiretroviral (ARV) regimen or discontinuing all ARV drugs","NE"
"2011-01-07929","2011","King 2011 PLoS Negl Trop Dis","180","Two doses of Praziquantel (40-60mg/Kg) VERSUS One dose of Praziquantel (40-60mg/Kg) IN Patients aged 5-16 years with schistosoma mansoni infection in Kenya","21949893","Patients aged 5-16 years with schistosoma mansoni infection in Kenya","Two doses of Praziquantel (40-60mg/Kg)","Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review.","One dose of Praziquantel (40-60mg/Kg)","NE"
"2011-01-07929","2011","King 2011 PLoS Negl Trop Dis","20","One dose of Praziquantel (40-60mg/Kg) VERSUS None IN Patients aged 5-16 years with schistosoma haematobium infection in Kenya","21949893","Patients aged 5-16 years with schistosoma haematobium infection in Kenya","One dose of Praziquantel (40-60mg/Kg)","Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review.","None","NE"
"2011-01-07929","2011","King 2011 PLoS Negl Trop Dis","21","One dose of Praziquantel (40-60mg/Kg) VERSUS None IN Patients aged 5-16 years with schistosoma mansoni infection in Kenya","21949893","Patients aged 5-16 years with schistosoma mansoni infection in Kenya","One dose of Praziquantel (40-60mg/Kg)","Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review.","None","NE"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","110000","Conventional laboratory methods with antimicrobial stewardship program VERSUS Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","Conventional laboratory methods with antimicrobial stewardship program","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program","SW"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","2000","Molecular rapid diagnostic tests without antimicrobial stewardship program VERSUS Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","Molecular rapid diagnostic tests without antimicrobial stewardship program","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program","NE"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","240000","Blood culture nanotechnology microarray system for Gram-negative bacteria with ASP VERSUS Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","Blood culture nanotechnology microarray system for Gram-negative bacteria with ASP","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program","SW"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","2600","Peptide nucleic acid fluorescent in situ hybridization without antimicrobial stewardship programs VERSUS Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship programs IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","Peptide nucleic acid fluorescent in situ hybridization without antimicrobial stewardship programs","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship programs","NE"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","Cost-Saving","Blood culture nanotechnology microarray system for Gram-positive bacteria with ASP VERSUS Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","Blood culture nanotechnology microarray system for Gram-positive bacteria with ASP","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program","SE"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","Cost-Saving","Diagnosis of suspected bloodstream infection with molecular rapid diagnostic tests VERSUS Standard/Usual Care- Diagnosis with conventional laboratory methods without ASP IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","Diagnosis of suspected bloodstream infection with molecular rapid diagnostic tests","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Diagnosis with conventional laboratory methods without ASP","SE"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","Cost-Saving","Matrix-assisted laser desorption ionizationâtime of flight analysis with ASP VERSUS Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","Matrix-assisted laser desorption ionizationâtime of flight analysis with ASP","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program","SE"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","Cost-Saving","Molecular rapid diagnostic tests with antimicrobial stewardship program VERSUS Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","Molecular rapid diagnostic tests with antimicrobial stewardship program","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program","SE"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","Cost-Saving","PCR with antimicrobial stewardship program VERSUS Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","PCR with antimicrobial stewardship program","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program","SE"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","Cost-Saving","PCR without antimicrobial stewardship program VERSUS Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","PCR without antimicrobial stewardship program","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program","SE"
"2018-01-27075","2018","Pliakos 2018 Clin Microbiol Rev","Cost-Saving","Peptide nucleic acid fluorescent in situ hybridization with antimicrobial stewardship program VERSUS Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","29848775","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Suspected bloodstream infection.","Peptide nucleic acid fluorescent in situ hybridization with antimicrobial stewardship program","The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.","Standard/Usual Care- Conventional laboratory methods without antimicrobial stewardship program","SE"
"2012-01-10107","2012","Winetsky 2012 PLoS Med","1500","Sputum polymerase chain reaction (PCR) screening VERSUS Mass miniature radiography (MMR) with PCR detection of multidrug resistant-tuberculosis (MDR-TB) IN Prisoners in Latvia","23209384","Prisoners in Latvia","Sputum polymerase chain reaction (PCR) screening","Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis.","Mass miniature radiography (MMR) with PCR detection of multidrug resistant-tuberculosis (MDR-TB)","NE"
"2012-01-10107","2012","Winetsky 2012 PLoS Med","160","Mass miniature radiography (MMR) with sputum polymerase chain reaction (PCR) detection of multidrug resistant-tuberculosis (MDR-TB) VERSUS Standard of care (mass miniature radiography (MMR) screening) IN Prisoners in Latvia","23209384","Prisoners in Latvia","Mass miniature radiography (MMR) with sputum polymerase chain reaction (PCR) detection of multidrug resistant-tuberculosis (MDR-TB)","Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis.","Standard of care (mass miniature radiography (MMR) screening)","NE"
"2012-01-10107","2012","Winetsky 2012 PLoS Med","30","Standard of care (mass miniature radiography (MMR) screening) VERSUS Self-referral for tuberculosis IN Prisoners in Latvia","23209384","Prisoners in Latvia","Standard of care (mass miniature radiography (MMR) screening)","Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis.","Self-referral for tuberculosis","NE"
"2011-01-08035","2011","Jouquet                          2011 J Acquir Immune Defic Syndr","980","Tenofovir (TDF) VERSUS Stavudine (d4T)-based regimens IN HIV-positive patients starting on antiretroviral therapy (ART) in Lesotho","21765366","HIV-positive patients starting on antiretroviral therapy (ART) in Lesotho","Tenofovir (TDF)","Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.","Stavudine (d4T)-based regimens","NE"
"2011-01-08035","2011","Jouquet                          2011 J Acquir Immune Defic Syndr","Dominated","Zidovudine VERSUS Stavudine (d4T)-based regimens + Tenofovir (TDF) IN HIV-positive patients starting on antiretroviral therapy (ART) in Lesotho","21765366","HIV-positive patients starting on antiretroviral therapy (ART) in Lesotho","Zidovudine","Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.","Stavudine (d4T)-based regimens + Tenofovir (TDF)","NW"
"2014-01-15335","2014","Alkoshi 2014 Libyan J Med","9800","Rotavirus Vaccination VERSUS None IN Specific disease- Diarrhea; Age- 0 to 18 years; Gender- Both; Country- Malaysia.","25499622","Specific disease- Diarrhea; Age- 0 to 18 years; Gender- Both; Country- Malaysia.","Rotavirus Vaccination","Cost-effectiveness analysis of rotavirus vaccination among Libyan children using  a simple economic model.","None","NE"
"2010-01-12096","2010","Vanagas 2010 Medicina (Kaunas)","110000","Peginterferon alfa-2a VERSUS Lamivudine for 5 years IN Patients with chronic hepatitis B in Lithuania","21532288","Patients with chronic hepatitis B in Lithuania","Peginterferon alfa-2a","Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.","Lamivudine for 5 years","NE"
"2010-01-12096","2010","Vanagas 2010 Medicina (Kaunas)","20000","Peginterferon alfa-2a VERSUS Lamivudine for 48 weeks IN Patients with chronic hepatitis B in Lithuania","21532288","Patients with chronic hepatitis B in Lithuania","Peginterferon alfa-2a","Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.","Lamivudine for 48 weeks","NE"
"2010-01-11939","2010","Vanagas 2010 Medicina (Kaunas)","57000","Six-month methadone maintenance treatment program VERSUS None IN All opioid-addicted persons visiting the outpatient methadone maintenance program for the first time in Lithuania","20571298","All opioid-addicted persons visiting the outpatient methadone maintenance program for the first time in Lithuania","Six-month methadone maintenance treatment program","Cost-utility analysis of methadone maintenance treatment in Lithuania.","None","NE"
"2018-01-25692","2018","Vetrini 2018 PLoS One","430","Screening for diabetic retinopathy, and laser treatment for positive screens VERSUS None IN Specific disease- Diabetes (type I and II); Age- 41 to 64 years, >=65 years; Gender- Both; Country- Malawi.","29300755","Specific disease- Diabetes (type I and II); Age- 41 to 64 years, >=65 years; Gender- Both; Country- Malawi.","Screening for diabetic retinopathy, and laser treatment for positive screens","Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi.","None","NE"
"2017-01-24227","2017","Maheswaran                       2017 Clin Infect Dis","240","Facility HIV Testing and Counseling (HTC)  VERSUS Standard/Usual Care- Facility HIV Testing and Counseling (HTC) 2010 World Health Organization (WHO) Anti-retroviral Treatment IN Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","29136117","Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","Facility HIV Testing and Counseling (HTC)","Cost-effectiveness of community-based HIV self-testing in Blantyre, Malawi.","Standard/Usual Care- Facility HIV Testing and Counseling (HTC) 2010 World Health Organization (WHO) Anti-retroviral Treatment","NE"
"2017-01-24227","2017","Maheswaran                       2017 Clin Infect Dis","250","Facility HIV Testing and Counseling (HTC)  VERSUS Standard/Usual Care- Facility HIV Testing and Counseling (HTC) 2010 World Health Organization (WHO) Anti-retroviral Treatment IN Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","29136117","Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","Facility HIV Testing and Counseling (HTC)","Cost-effectiveness of community-based HIV self-testing in Blantyre, Malawi.","Standard/Usual Care- Facility HIV Testing and Counseling (HTC) 2010 World Health Organization (WHO) Anti-retroviral Treatment","NE"
"2017-01-24227","2017","Maheswaran                       2017 Clin Infect Dis","270","Facility HIV Testing and Counseling (HTC) & HIV Self-Testing (HIVST) VERSUS Standard/Usual Care- Facility HIV Testing and Couseling (HTC) 2015 WHO Anti-retroviral Therapy IN Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","29136117","Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","Facility HIV Testing and Counseling (HTC) & HIV Self-Testing (HIVST)","Cost-effectiveness of community-based HIV self-testing in Blantyre, Malawi.","Standard/Usual Care- Facility HIV Testing and Couseling (HTC) 2015 WHO Anti-retroviral Therapy","NE"
"2017-01-24227","2017","Maheswaran                       2017 Clin Infect Dis","280","Facility HIV Testing and Counseling (HTC) & HIV Self Testing (HVST) VERSUS Standard/Usual Care- Facility HIV Testing and Counseling (HTC) 2015 World Health Organization Anti-retroviral Treatment (ART)   IN Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","29136117","Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","Facility HIV Testing and Counseling (HTC) & HIV Self Testing (HVST)","Cost-effectiveness of community-based HIV self-testing in Blantyre, Malawi.","Standard/Usual Care- Facility HIV Testing and Counseling (HTC) 2015 World Health Organization Anti-retroviral Treatment (ART)","NE"
"2017-01-24227","2017","Maheswaran                       2017 Clin Infect Dis","280","Facility HIV Treatment & Counseling (HTC) & HIV Self Testing (HVST) VERSUS Standard/Usual Care- Facility HIV Treatment & Counseling (HTC) 2015 World Health Organization (WHO) Anti-retroviral Treatment (ART) IN Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","29136117","Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","Facility HIV Treatment & Counseling (HTC) & HIV Self Testing (HVST)","Cost-effectiveness of community-based HIV self-testing in Blantyre, Malawi.","Standard/Usual Care- Facility HIV Treatment & Counseling (HTC) 2015 World Health Organization (WHO) Anti-retroviral Treatment (ART)","NE"
"2017-01-24227","2017","Maheswaran                       2017 Clin Infect Dis","4","Facility HIV Testing and Counseling (HTC) & HIV Self Testing (HVST) VERSUS Standard/Usual Care- Facility HIV Testing and Counseling (HTC) 2015 World Health Organization Anti-retroviral Treatment (ART) IN Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","29136117","Specific disease- HIV; Age- Adult; Gender- Both; Country- Malawi; Other- The population characteristics were estimated from the trial post-intervention survey in control clusters..","Facility HIV Testing and Counseling (HTC) & HIV Self Testing (HVST)","Cost-effectiveness of community-based HIV self-testing in Blantyre, Malawi.","Standard/Usual Care- Facility HIV Testing and Counseling (HTC) 2015 World Health Organization Anti-retroviral Treatment (ART)","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","12000","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Somalia.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Somalia.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","5900","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Somalia.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Somalia.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","5900","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Somalia.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Somalia.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-26764","2018","van Nuland 2018 Breast Cancer Res Treat","Cost-Saving","Monitoring endoxifen serum concentrations and subsequent personalized dosing of tamoxifen VERSUS Standard/Usual Care- No monitoring IN Specific disease- Breast cancer; Age- Adult, Unknown; Gender- Female; Country- Netherlands; Other- Patients adjuvantly treated with tamoxifen.","30006796","Specific disease- Breast cancer; Age- Adult, Unknown; Gender- Female; Country- Netherlands; Other- Patients adjuvantly treated with tamoxifen.","Monitoring endoxifen serum concentrations and subsequent personalized dosing of tamoxifen","Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.","Standard/Usual Care- No monitoring","SE"
"2018-01-26637","2018","Kuo 2018 Surgery","Cost-Saving","Ultrasound surveillance of intermediate-suspicion thyroid nodule VERSUS Standard/Usual Care- Immediate fine needle aspiration biopsy of intermediate-suspicion thyroid nodule IN Specific disease- Thyroid nodule; Age- 19 to 40 years; Gender- Both; Country- United States.","30055789","Specific disease- Thyroid nodule; Age- 19 to 40 years; Gender- Both; Country- United States.","Ultrasound surveillance of intermediate-suspicion thyroid nodule","Cost effectiveness of immediate biopsy versus surveillance of intermediate-suspicion thyroid nodules.","Standard/Usual Care- Immediate fine needle aspiration biopsy of intermediate-suspicion thyroid nodule","SE"
"2018-01-25904","2018","Kanters 2018 Br J Dermatol","25000","Omalizumab VERSUS Standard/Usual Care- Up to four times the daily dose of H1-antihistamines (standard care + placebo) IN Specific disease- Chronic spontaneous urticaria; Age- Adult; Gender- Both; Country- Netherlands.","29476533","Specific disease- Chronic spontaneous urticaria; Age- Adult; Gender- Both; Country- Netherlands.","Omalizumab","Cost-effectiveness of omalizumab for the treatment of Chronic Spontaneous Urticaria.","Standard/Usual Care- Up to four times the daily dose of H1-antihistamines (standard care + placebo)","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","10000","Laparoscopic Roux-en-Y gastric bypass VERSUS None IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Female; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","11000","Laparoscopic adjustable gastric banding VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","Laparoscopic adjustable gastric banding","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","120","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","12000","Laparoscopic Roux-en-Y gastric bypass VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","12000","Laparoscopic sleeve gastrectomy VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Female; Country- United States.","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","12000","Laparoscopic sleeve gastrectomy VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","120000","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic sleeve gastrectomy IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic sleeve gastrectomy","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","13000","Laparoscopic adjustable gastric banding VERSUS None IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Female; Country- United States.","Laparoscopic adjustable gastric banding","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","13000","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic sleeve gastrectomy IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic sleeve gastrectomy","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","13000","Laparoscopic sleeve gastrectomy VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","13000","Laparoscopic sleeve gastrectomy VERSUS None IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Female; Country- United States.","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","1400","Laparoscopic sleeve gastrectomy VERSUS Laparoscopic adjustable gastric banding  IN Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Female; Country- United States.","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","14000","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","14000","Laparoscopic Roux-en-Y gastric bypass VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","14000","Laparoscopic sleeve gastrectomy VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","16000","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","16000","Laparoscopic Roux-en-Y gastric bypass VERSUS None IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","17000","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","17000","Laparoscopic sleeve gastrectomy VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","17000","Laparoscopic sleeve gastrectomy VERSUS None IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","18000","Laparoscopic adjustable gastric banding VERSUS None IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States.","Laparoscopic adjustable gastric banding","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","18000","Laparoscopic sleeve gastrectomy VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","2300","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","2700","Laparoscopic Roux-en-Y gastric bypass VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","2700","Laparoscopic sleeve gastrectomy  VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Female; Country- United States.","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","2900","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","2900","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","3100","Laparoscopic Roux-en-Y gastric bypass VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","3200","Laparoscopic Roux-en-Y gastric bypass VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","3200","Laparoscopic sleeve gastrectomy VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","3300","Laparoscopic adjustable gastric banding VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Female; Country- United States.","Laparoscopic adjustable gastric banding","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","3500","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years; Gender- Male; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","3800","Laparoscopic sleeve gastrectomy VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Male; Country- United States.","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","7700","Laparoscopic adjustable gastric banding VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","Laparoscopic adjustable gastric banding","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","7800","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 41 to 64 years, >=65 years; Gender- Female; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","8000","Laparoscopic sleeve gastrectomy VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States; Other- 18-74.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States; Other- 18-74.","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","8000","Laparoscopic sleeve gastrectomy VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","8000","Laparoscopic sleeve gastrectomy VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years; Gender- Male; Country- United States.","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","8300","Laparoscopic sleeve gastrectomy VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","8600","Laparoscopic adjustable gastric banding VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Laparoscopic adjustable gastric banding","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","8900","laparoscopic adjustable gastric banding VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","laparoscopic adjustable gastric banding","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","9100","Laparoscopic sleeve gastrectomy VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","Laparoscopic sleeve gastrectomy","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","9200","Laparoscopic adjustable gastric banding VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years; Gender- Male; Country- United States.","Laparoscopic adjustable gastric banding","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","950","Laparoscopic Roux-en-Y gastric bypass VERSUS Llaparoscopic sleeve gastrectomy IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years; Gender- Male; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years; Gender- Male; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Llaparoscopic sleeve gastrectomy","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","9700","Laparoscopic adjustable gastric banding VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","Laparoscopic adjustable gastric banding","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","9800","Laparoscopic adjustable gastric banding VERSUS None IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Morbid obesity 1 (BMI 35â39.9 kg/m2).","Laparoscopic adjustable gastric banding","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","None","NE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","Cost-Saving","VERSUS Laparoscopic sleeve gastrectomy IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States."," ","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic sleeve gastrectomy","SE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","Cost-Saving","Laparoscopic Roux-en-Y gastric bypass  VERSUS Laparoscopic sleeve gastrectomy  IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic sleeve gastrectomy","SE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","Cost-Saving","Laparoscopic Roux-en-Y gastric bypass  VERSUS Laparoscopic sleeve gastrectomy  IN Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Female; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic sleeve gastrectomy","SE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","Cost-Saving","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","SE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","Cost-Saving","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic adjustable gastric banding IN Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Female; Country- United States.","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years; Gender- Female; Country- United States.","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic adjustable gastric banding","SE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","Cost-Saving","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic sleeve gastrectomy IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Morbid obesity 2 (BMI 40â49.9 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic sleeve gastrectomy","SE"
"2018-01-25656","2018","Alsumali 2018 Obes Surg","Cost-Saving","Laparoscopic Roux-en-Y gastric bypass VERSUS Laparoscopic sleeve gastrectomy IN Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","29335933","Specific disease- Morbid Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Super obesity (BMI = 50 kg/m2).","Laparoscopic Roux-en-Y gastric bypass","Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.","Laparoscopic sleeve gastrectomy","SE"
"2017-01-25746","2017","Zapata-Vazquez 2017 Value Health Reg Issues","5400","Intracranial pressure (ICP) monitoring VERSUS Control group IN Specific disease- Severe Traumatic Brain Injury; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Mexico; Other- Previously normal psychomotor development and without concomitant chronic diseases.","29254549","Specific disease- Severe Traumatic Brain Injury; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Mexico; Other- Previously normal psychomotor development and without concomitant chronic diseases.","Intracranial pressure (ICP) monitoring","Cost Effectiveness of Intracranial Pressure Monitoring in Pediatric Patients with Severe Traumatic Brain Injury: A Simulation Modeling Approach.","Control group","NE"
"2017-01-24806","2017","Diaby 2017 Breast Cancer Res Treat","230000","pertuzumab plus trastuzumab plus docetaxel [THP]; 2nd line: T-DM1; 3rd line: capecitabine plus lapat VERSUS Sequence 3: (T-DM1, no pertuzumab) IN Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","28840424","Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","pertuzumab plus trastuzumab plus docetaxel [THP]; 2nd line: T-DM1; 3rd line: capecitabine plus lapat","Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.","Sequence 3: (T-DM1, no pertuzumab)","NE"
"2017-01-24806","2017","Diaby 2017 Breast Cancer Res Treat","250000","Pertuzumab, no T-DM1 VERSUS Sequence 3: (T-DM1, no pertuzumab) IN Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","28840424","Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","Pertuzumab, no T-DM1","Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.","Sequence 3: (T-DM1, no pertuzumab)","NE"
"2017-01-24806","2017","Diaby 2017 Breast Cancer Res Treat","270000","1st line: pertuzumab plus trastuzumab plus docetaxel [THP]; 2nd line: T-DM1; 3rd line: capecitabine  VERSUS Sequence 4: (no T-DM1 or pertuzumab) IN Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","28840424","Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","1st line: pertuzumab plus trastuzumab plus docetaxel [THP]; 2nd line: T-DM1; 3rd line: capecitabine","Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.","Sequence 4: (no T-DM1 or pertuzumab)","NE"
"2017-01-24806","2017","Diaby 2017 Breast Cancer Res Treat","280000","1st line: pertuzumab plus trastuzumab plus docetaxel [THP]; 2nd line: T-DM1; 3rd line: capecitabine  VERSUS Sequence 4: (no T-DM1 or pertuzumab) IN Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico.","28840424","Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico.","1st line: pertuzumab plus trastuzumab plus docetaxel [THP]; 2nd line: T-DM1; 3rd line: capecitabine","Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.","Sequence 4: (no T-DM1 or pertuzumab)","NE"
"2017-01-24806","2017","Diaby 2017 Breast Cancer Res Treat","280000","Pertuzumab, no T-DM1 VERSUS Sequence 4: (no T-DM1 or pertuzumab) IN Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","28840424","Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","Pertuzumab, no T-DM1","Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.","Sequence 4: (no T-DM1 or pertuzumab)","NE"
"2017-01-24806","2017","Diaby 2017 Breast Cancer Res Treat","44000","No T-DM1 or pertuzumab VERSUS Sequence 3: (T-DM1, no pertuzumab) IN Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","28840424","Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","No T-DM1 or pertuzumab","Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.","Sequence 3: (T-DM1, no pertuzumab)","NE"
"2017-01-24806","2017","Diaby 2017 Breast Cancer Res Treat","Dominated","Pertuzumab, no T-DM1 VERSUS Sequence 4: (no T-DM1 or pertuzumab) IN Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","28840424","Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","Pertuzumab, no T-DM1","Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.","Sequence 4: (no T-DM1 or pertuzumab)","NW"
"2017-01-24806","2017","Diaby 2017 Breast Cancer Res Treat","Dominated","T-DM1: trastuzumab, lapatinib, pertuzumab, and ado-trastuzumab emtansine, no pertuzumab VERSUS Sequence 4: (no T-DM1 or pertuzumab) IN Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","28840424","Specific disease- HER2-positive metastatic breast cancer; Age- Adult; Gender- Female; Country- Mexico; Other- Newly diagnosed patients.","T-DM1: trastuzumab, lapatinib, pertuzumab, and ado-trastuzumab emtansine, no pertuzumab","Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.","Sequence 4: (no T-DM1 or pertuzumab)","NW"
"2016-01-20898","2016","Carlos                           2016 Hum Vaccin Immunother","310","Two doses vaccination VERSUS None IN Specific disease- Hepatits A Virus (HAV) Infection; Age- 0 to 18 years; Gender- Both; Country- Mexico.","26503702","Specific disease- Hepatits A Virus (HAV) Infection; Age- 0 to 18 years; Gender- Both; Country- Mexico.","Two doses vaccination","Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico.","None","NE"
"2016-01-20898","2016","Carlos                           2016 Hum Vaccin Immunother","5600","Two doses vaccination VERSUS Single dose vaccination IN Specific disease- Hepatits A Virus (HAV) Infection; Age- 0 to 18 years; Gender- Both; Country- Mexico.","26503702","Specific disease- Hepatits A Virus (HAV) Infection; Age- 0 to 18 years; Gender- Both; Country- Mexico.","Two doses vaccination","Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico.","Single dose vaccination","NE"
"2016-01-20898","2016","Carlos                           2016 Hum Vaccin Immunother","Cost-Saving","Single dose vaccination VERSUS None IN Specific disease- Hepatits A Virus (HAV) Infection; Age- 0 to 18 years; Gender- Both; Country- Mexico.","26503702","Specific disease- Hepatits A Virus (HAV) Infection; Age- 0 to 18 years; Gender- Both; Country- Mexico.","Single dose vaccination","Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico.","None","SE"
"2015-01-21085","2015","Kim 2015 Ann Intern Med","1.3e+006","Cytologic test every year VERSUS Cytologic testing every 3 years, cotesting at age >=30 years old every 5 years IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","26414147","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Cytologic test every year","Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.","Cytologic testing every 3 years, cotesting at age >=30 years old every 5 years","NE"
"2015-01-21085","2015","Kim 2015 Ann Intern Med","17000","Cytologic testing every 3 years VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.","26414147","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.","Cytologic testing every 3 years","Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.","None","NE"
"2015-01-21085","2015","Kim 2015 Ann Intern Med","21000","Current Screening practice VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.","26414147","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.","Current Screening practice","Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.","None","NE"
"2015-01-21085","2015","Kim 2015 Ann Intern Med","65000","Cytologic testing every 3 years, cotesting at age >=30 years old every 5 years VERSUS Cytologic testing every 3 years IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.","26414147","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.","Cytologic testing every 3 years, cotesting at age >=30 years old every 5 years","Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.","Cytologic testing every 3 years","NE"
"2014-01-16271","2014","Ryabov 2014 Public Health","16000","Monthly visits from community health workers (CHW's) providing well-structured educational message, self management
plan VERSUS no monthly visits from CHW's IN Specific disease- type-2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Mexico.","24999158","Specific disease- type-2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Mexico.","Monthly visits from community health workers (CHW's) providing well-structured educational message, self management
plan","Cost-effectiveness of Community Health Workers in controlling diabetes epidemic on the U.S.-Mexico border.","no monthly visits from CHW's","NE"
"2012-01-10293","2012","Salinas-Escudero 2012 Salud Publica Mex","11000","Surfactant rescue treatment with bovine surfactant (BS) therapy VERSUS None IN Premature infants with respiratory distress syndrom (RDS) in Mexico","22965446","Premature infants with respiratory distress syndrom (RDS) in Mexico","Surfactant rescue treatment with bovine surfactant (BS) therapy","Economic evaluation of the use of exogenous pulmonary surfactants in preterm newborns in a Mexican population.","None","NE"
"2012-01-08871","2012","D?az de Le?n-Casta?eda 2012 Clinicoecon Outcomes Res","130","Glibenclamide VERSUS Metaformin IN Adult outpatients with type 2 diabetes attending a public primary care clinic in Mexico City","22427724","Adult outpatients with type 2 diabetes attending a public primary care clinic in Mexico City","Glibenclamide","Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City.","Metaformin","NE"
"2012-01-08871","2012","D?az de Le?n-Casta?eda 2012 Clinicoecon Outcomes Res","750","Glibenclamide VERSUS Acarbose IN Adult outpatients with type 2 diabetes attending a public primary care clinic in Mexico City","22427724","Adult outpatients with type 2 diabetes attending a public primary care clinic in Mexico City","Glibenclamide","Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City.","Acarbose","NE"
"2012-01-08662","2012","Salinas-Escudero 2012 Salud Publica Mex","21000","Prophylaxis with palivizumab during 6 months of respiratory syncytial virus season (RSV) season VERSUS None IN Patients less than 29 weeks of gestational age in Mexico","22286828","Patients less than 29 weeks of gestational age in Mexico","Prophylaxis with palivizumab during 6 months of respiratory syncytial virus season (RSV) season","Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.","None","NE"
"2012-01-08662","2012","Salinas-Escudero 2012 Salud Publica Mex","24000","Prophylaxis with palivizumab during 6 months of respiratory syncytial virus season (RSV) season VERSUS None IN Preterm newborn patients less than 29-32 weeks of gestational age in Mexico","22286828","Preterm newborn patients less than 29-32 weeks of gestational age in Mexico","Prophylaxis with palivizumab during 6 months of respiratory syncytial virus season (RSV) season","Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.","None","NE"
"2012-01-08292","2012","Carlos                           2012 J Med Econ","47000","Pregabalin (150mg twice daily) VERSUS Generic gabapentin (600 three-times daily) IN Adult patients with painful diabetic peripheral neuropathy suffering from moderate-to-severe pain in Mexico","22082033","Adult patients with painful diabetic peripheral neuropathy suffering from moderate-to-severe pain in Mexico","Pregabalin (150mg twice daily)","Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico.","Generic gabapentin (600 three-times daily)","NE"
"2012-01-08292","2012","Carlos                           2012 J Med Econ","9300","Duloxetine as first-line treatment (60mg once daily) VERSUS Generic gabapentin (600mg three-times daily) IN Adult patients with painful diabetic peripheral neuropathy suffering from moderate-to-severe pain in Mexico","22082033","Adult patients with painful diabetic peripheral neuropathy suffering from moderate-to-severe pain in Mexico","Duloxetine as first-line treatment (60mg once daily)","Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico.","Generic gabapentin (600mg three-times daily)","NE"
"2012-01-08292","2012","Carlos                           2012 J Med Econ","Cost-Saving","Duloxetine as first-line treatment (60mg once daily) VERSUS Branded gabapentin (150mg twice daily) IN Adult patients with painful diabetic peripheral neuropathy suffering from moderate-to-severe pain in Mexico","22082033","Adult patients with painful diabetic peripheral neuropathy suffering from moderate-to-severe pain in Mexico","Duloxetine as first-line treatment (60mg once daily)","Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico.","Branded gabapentin (150mg twice daily)","SE"
"2012-01-08292","2012","Carlos                           2012 J Med Econ","Cost-Saving","Duloxetine as first-line treatment (60mg once daily) VERSUS Pregabalin (150mg twice daily) IN Adult patients with painful diabetic peripheral neuropathy suffering from moderate-to-severe pain in Mexico","22082033","Adult patients with painful diabetic peripheral neuropathy suffering from moderate-to-severe pain in Mexico","Duloxetine as first-line treatment (60mg once daily)","Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico.","Pregabalin (150mg twice daily)","SE"
"2012-01-08292","2012","Carlos                           2012 J Med Econ","Cost-Saving","Pregabalin (150mg twice daily) VERSUS Branded gabapentin (150mg twice daily) IN Adult patients with painful diabetic peripheral neuropathy suffering from moderate-to-severe pain in Mexico","22082033","Adult patients with painful diabetic peripheral neuropathy suffering from moderate-to-severe pain in Mexico","Pregabalin (150mg twice daily)","Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico.","Branded gabapentin (150mg twice daily)","SE"
"2016-01-19911","2016","Dabanovic 2016 Vojnosanit Pregl","670","oral treatment with dutasteride in the dosage regimen of 0.5 mg/day VERSUS oral treatment with finasteride in the dosage regimen of 5 mg/day IN Specific disease- benign prostatic hyperplasia; Age- 41 to 64 years, >=65 years; Gender- Male; Country- Montenegro.","26964381","Specific disease- benign prostatic hyperplasia; Age- 41 to 64 years, >=65 years; Gender- Male; Country- Montenegro.","oral treatment with dutasteride in the dosage regimen of 0.5 mg/day","Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia--The Markov model based on data from Montenegro.","oral treatment with finasteride in the dosage regimen of 5 mg/day","NE"
"2006-01-12900","2006","Jankovic 2006 Exp Clin Cardiol","220","Low molecular weight heparin enoxaparin VERSUS Unfractionated heparin IN Patients aged 60-70 years with acute deep venous thrombosis (inpatients)","18651046","Patients aged 60-70 years with acute deep venous thrombosis (inpatients)","Low molecular weight heparin enoxaparin","Cost and utility of a low-molecular-weight heparin and unfractionated heparin for treatment of deep venous thrombosis in a Balkan country: A model analysis.","Unfractionated heparin","NE"
"2006-01-12900","2006","Jankovic 2006 Exp Clin Cardiol","95","Low molecular weight heparin enoxaparin VERSUS Unfractionated heparin IN Patients aged 60-70 years with acute deep venous thrombosis (outpatients)","18651046","Patients aged 60-70 years with acute deep venous thrombosis (outpatients)","Low molecular weight heparin enoxaparin","Cost and utility of a low-molecular-weight heparin and unfractionated heparin for treatment of deep venous thrombosis in a Balkan country: A model analysis.","Unfractionated heparin","NE"
"2013-01-14297","2013","Masterton 2013 J Med Econ","12000","Micafungin (100mg/day) VERSUS Standard/Usual Care- fluconazole 400mg/day IN Specific disease- Systemic candida infection; Age- 41 to 64 years; Gender- Both; Country- United Kingdom; Other- Intensive care non-neutropenic patients with diabetes.","24003830","Specific disease- Systemic candida infection; Age- 41 to 64 years; Gender- Both; Country- United Kingdom; Other- Intensive care non-neutropenic patients with diabetes.","Micafungin (100mg/day)","De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.","Standard/Usual Care- fluconazole 400mg/day","NE"
"2013-01-14297","2013","Masterton 2013 J Med Econ","210000","Micafungin (100mg/day) VERSUS Standard/Usual Care- fluconazole 400mg/day IN Specific disease- Systemic candida infection; Age- 41 to 64 years; Gender- Both; Country- United Kingdom; Other- Intensive care non-neutropenic patients with advanced cancer.","24003830","Specific disease- Systemic candida infection; Age- 41 to 64 years; Gender- Both; Country- United Kingdom; Other- Intensive care non-neutropenic patients with advanced cancer.","Micafungin (100mg/day)","De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.","Standard/Usual Care- fluconazole 400mg/day","NE"
"2013-01-14297","2013","Masterton 2013 J Med Econ","44000","Micafungin (100mg/day) VERSUS Standard/Usual Care- fluconazole 400mg/day IN Specific disease- Systemic candida infection; Age- 41 to 64 years; Gender- Both; Country- United Kingdom; Other- Intensive care non-neutropenic patients.","24003830","Specific disease- Systemic candida infection; Age- 41 to 64 years; Gender- Both; Country- United Kingdom; Other- Intensive care non-neutropenic patients.","Micafungin (100mg/day)","De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.","Standard/Usual Care- fluconazole 400mg/day","NE"
"2013-01-14297","2013","Masterton 2013 J Med Econ","45000","Micafungin (100mg/day) VERSUS Standard/Usual Care- fluconazole 400mg/day IN Specific disease- Systemic candida infection; Age- 41 to 64 years; Gender- Both; Country- United Kingdom; Other- Intensive care non-neutropenic patients with cancer.","24003830","Specific disease- Systemic candida infection; Age- 41 to 64 years; Gender- Both; Country- United Kingdom; Other- Intensive care non-neutropenic patients with cancer.","Micafungin (100mg/day)","De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.","Standard/Usual Care- fluconazole 400mg/day","NE"
"2013-01-11577","2013","Carrion 2013 J Hepatol","Cost-Saving","Multidisciplinary support programme VERSUS Standard/Usual Care IN Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Spain.","23811030","Specific disease- Hepatitis C; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Spain.","Multidisciplinary support programme","A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.","Standard/Usual Care","SE"
"2013-01-11099","2013","Alba 2013 Expert Rev Pharmacoecon Outcomes Res","28000","Nanoparticle albumin-bound paclitaxel administered every 3 weeks VERSUS polyethylated castor oil-based standard paclitaxel administered every 3 weeks IN Specific disease- breast cancer; Age- Adult; Gender- Female; Country- Spain; Other- failed first-line antitumor treatment.","23534988","Specific disease- breast cancer; Age- Adult; Gender- Female; Country- Spain; Other- failed first-line antitumor treatment.","Nanoparticle albumin-bound paclitaxel administered every 3 weeks","Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel  in monotherapy in pretreated metastatic breast cancer in Spain.","polyethylated castor oil-based standard paclitaxel administered every 3 weeks","NE"
"2011-01-07622","2011","Carles 2011 BMC Cancer","16000","Biennial mammography screening from age 45-69 years VERSUS Biennial mammography screening from age 50-69 years IN Women aged 40-79 years in Spain","21605383","Women aged 40-79 years in Spain","Biennial mammography screening from age 45-69 years","Cost-effectiveness of early detection of breast cancer in Catalonia (Spain).","Biennial mammography screening from age 50-69 years","NE"
"2011-01-07622","2011","Carles 2011 BMC Cancer","20000","Biennial mammography screening from age 45-74 years VERSUS Biennial mammography screening from age 45-69 years IN Women aged 40-79 years in Spain","21605383","Women aged 40-79 years in Spain","Biennial mammography screening from age 45-74 years","Cost-effectiveness of early detection of breast cancer in Catalonia (Spain).","Biennial mammography screening from age 45-69 years","NE"
"2011-01-07622","2011","Carles 2011 BMC Cancer","26000","Annual mammography screening from age 45-69 years VERSUS Biennial mammography screening from age 45-74 years IN Women aged 40-79 years in Spain","21605383","Women aged 40-79 years in Spain","Annual mammography screening from age 45-69 years","Cost-effectiveness of early detection of breast cancer in Catalonia (Spain).","Biennial mammography screening from age 45-74 years","NE"
"2011-01-07622","2011","Carles 2011 BMC Cancer","40000","Annual mammography screening from age 40-69 years VERSUS Annual mammography screening from age 45-69 years IN Women aged 40-79 years in Spain","21605383","Women aged 40-79 years in Spain","Annual mammography screening from age 40-69 years","Cost-effectiveness of early detection of breast cancer in Catalonia (Spain).","Annual mammography screening from age 45-69 years","NE"
"2011-01-07622","2011","Carles 2011 BMC Cancer","43000","Annual mammography screening from age 40-74 years VERSUS Annual mammography screening from age 40-69 years IN Women aged 40-79 years in Spain","21605383","Women aged 40-79 years in Spain","Annual mammography screening from age 40-74 years","Cost-effectiveness of early detection of breast cancer in Catalonia (Spain).","Annual mammography screening from age 40-69 years","NE"
"2011-01-07622","2011","Carles 2011 BMC Cancer","7200","Biennial mammography screening from age 50-69 years VERSUS None IN Women aged 40-79 years in Spain","21605383","Women aged 40-79 years in Spain","Biennial mammography screening from age 50-69 years","Cost-effectiveness of early detection of breast cancer in Catalonia (Spain).","None","NE"
"2009-01-04849","2009","Vera-Llonch 2009 Eur J Health Econ","40000","Pregabalin (300-600 mg/day) VERSUS Venlafaxine extended release (XR) (75-225 mg/day) IN Generalized anxiety disorder patients","19506926","Generalized anxiety disorder patients","Pregabalin (300-600 mg/day)","Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.","Venlafaxine extended release (XR) (75-225 mg/day)","NE"
"2008-01-04670","2008","Vera-Llonch 2008 J Rheumatol","57000","Abatacept plus oral disease modifying antirheumatic drugs VERSUS Oral disease modifying antirheumatic drugs IN US women aged 55-64 years old with moderate to severely active rheumatoid arthritis and inadequate response to anti-TNF (tumor necrosis factor) drugs; lifetime horizon","18634164","US women aged 55-64 years old with moderate to severely active rheumatoid arthritis and inadequate response to anti-TNF (tumor necrosis factor) drugs; lifetime horizon","Abatacept plus oral disease modifying antirheumatic drugs","Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.","Oral disease modifying antirheumatic drugs","NE"
"2008-01-04670","2008","Vera-Llonch 2008 J Rheumatol","63000","Abatacept plus oral disease modifying antirheumatic drugs VERSUS Oral disease modifying antirheumatic drugs IN US women aged 55-64 years old with moderate to severely active rheumatoid arthritis and inadequate response to anti-TNF (tumor necrosis factor) drugs; 10-year horizon","18634164","US women aged 55-64 years old with moderate to severely active rheumatoid arthritis and inadequate response to anti-TNF (tumor necrosis factor) drugs; 10-year horizon","Abatacept plus oral disease modifying antirheumatic drugs","Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.","Oral disease modifying antirheumatic drugs","NE"
"2008-01-03107","2008","Vera-Llonch 2008 Epilepsia","66000","Pregabalin as add-on therapy (average daily dose of 300 mg/day) VERSUS Standard therapy IN Patients with partial seizures (simple partial, complex partial, with or without secondary generalized tonic-clonic) not adequately controlled on at least one antiepileptic drug","17822431","Patients with partial seizures (simple partial, complex partial, with or without secondary generalized tonic-clonic) not adequately controlled on at least one antiepileptic drug","Pregabalin as add-on therapy (average daily dose of 300 mg/day)","Cost-effectiveness of Add-on Therapy with Pregabalin in Patients with Refractory Partial Epilepsy.","Standard therapy","NE"
"2006-01-02289","2006","Tarride 2006 Clin Ther","Cost-Saving","VERSUS  IN Patients with neuropathic pain associated with peripheral neuropathy and postherpetic neuralgia","17213013","Patients with neuropathic pain associated with peripheral neuropathy and postherpetic neuralgia"," ","Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective."," ","SE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","19000","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Morocco.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Morocco.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","8600","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Morocco.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Morocco.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","9100","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Morocco.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Morocco.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2009-01-05429","2009","Lansingh 2009 Arch Ophthalmol","5","Cataract surgery VERSUS Do-nothing strategy IN Patient underwent cataract surgery in devoloping countries(Nepal, MSICS: manual small-incision cataract surgery)","19752429","Patient underwent cataract surgery in devoloping countries(Nepal, MSICS: manual small-incision cataract surgery)","Cataract surgery","Use of Global Visual Acuity Data in a time trade-off approach to calculate the cost utility of cataract surgery.","Do-nothing strategy","NE"
"2018-01-28611","2018","Sluiter 2018 Eur Addict Res","16000","OPRM1 screening to guide alcohol use disorder treatment allocation VERSUS No OPRM1 screening, random assignment of naltrexone or acamprosate IN Specific disease- Alcohol use disorder; Age- Adult; Gender- Both; Country- Netherlands.","30384381","Specific disease- Alcohol use disorder; Age- Adult; Gender- Both; Country- Netherlands.","OPRM1 screening to guide alcohol use disorder treatment allocation","Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach.","No OPRM1 screening, random assignment of naltrexone or acamprosate","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","11000","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Dutch Antilles.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Dutch Antilles.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","11000","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Poland.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Poland.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","11000","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Dutch Antilles.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Dutch Antilles.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","12000","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Suriname.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Suriname.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","12000","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Poland.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Poland.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","140000","Hepatitis C Virus Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Turkey.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Turkey.","Hepatitis C Virus Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","22000","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Poland.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Poland.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","35000","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Dutch Antilles.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Dutch Antilles.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","5500","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Pakistan.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Pakistan.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","5600","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Pakistan.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Pakistan.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","5700","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Soviet Union.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Soviet Union.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","5700","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Vietnam.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Vietnam.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","5800","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","5800","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Soviet Union.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Soviet Union.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","5900","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Syria.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Syria.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6000","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Syria.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Syria.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6100","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Vietnam.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Vietnam.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6200","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6300","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Vietnam.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Vietnam.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6600","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Yugoslavia.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Yugoslavia.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6600","Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Suriname.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Suriname.","Both Hepatitis B and Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6700","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","6700","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Suriname.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Suriname.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","7200","Hepatitis B Screening;  VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Yugoslavia.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Yugoslavia.","Hepatitis B Screening;","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","7200","Hepatitis B Virus Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Turkey.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Turkey.","Hepatitis B Virus Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","7300","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Soviet Union.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Soviet Union.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28306","2018","de Boer 2018 BMC Med","Cost-Saving","Zoster vaccine live (live-attenuated vaccine) VERSUS Standard/Usual Care- No Vaccination  IN Healthy; Age- >=65 years; Gender- Both; Country- Netherlands.","30518427","Healthy; Age- >=65 years; Gender- Both; Country- Netherlands.","Zoster vaccine live (live-attenuated vaccine)","Cost-effectiveness of vaccination of immunocompetent older adults against herpes  zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.","Standard/Usual Care- No Vaccination","SE"
"2018-01-28306","2018","de Boer 2018 BMC Med","Cost-Saving","Zoster vaccine live (live-attenuated vaccine) VERSUS Standard/Usual Care- No vaccine IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Netherlands.","30518427","Healthy; Age- 41 to 64 years; Gender- Both; Country- Netherlands.","Zoster vaccine live (live-attenuated vaccine)","Cost-effectiveness of vaccination of immunocompetent older adults against herpes  zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.","Standard/Usual Care- No vaccine","SE"
"2018-01-28188","2018","Finch 2018 Pharmacoeconomics","38000","Doxycycline + prednisolone VERSUS Placebo IN Specific disease- Chronic obstructive pulmonary disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Netherlands; Other- Mild-to-severe COPD.","30565022","Specific disease- Chronic obstructive pulmonary disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Netherlands; Other- Mild-to-severe COPD.","Doxycycline + prednisolone","Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.","Placebo","NE"
"2018-01-27880","2018","Thorrington 2018 PLoS One","11000","PPV23 vaccination at age 65 VERSUS Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants IN Healthy; Age- >=65 years; Gender- Both; Country- Netherlands.","29425249","Healthy; Age- >=65 years; Gender- Both; Country- Netherlands.","PPV23 vaccination at age 65","Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.","Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants","NE"
"2018-01-27880","2018","Thorrington 2018 PLoS One","11000","PPV23 vaccination at ages 60, 65, and 70 VERSUS Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Netherlands.","29425249","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Netherlands.","PPV23 vaccination at ages 60, 65, and 70","Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.","Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants","NE"
"2018-01-27880","2018","Thorrington 2018 PLoS One","17000","PPV23 vaccination at age 60 VERSUS Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Netherlands.","29425249","Healthy; Age- 41 to 64 years; Gender- Both; Country- Netherlands.","PPV23 vaccination at age 60","Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.","Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants","NE"
"2018-01-27880","2018","Thorrington 2018 PLoS One","26000","PCV13 vaccination in infants + PPV23 vaccination at ages 60, 65, and 70 VERSUS Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants IN Healthy; Age- 0 to 18 years, 41 to 64 years, >=65 years; Gender- Both; Country- Netherlands.","29425249","Healthy; Age- 0 to 18 years, 41 to 64 years, >=65 years; Gender- Both; Country- Netherlands.","PCV13 vaccination in infants + PPV23 vaccination at ages 60, 65, and 70","Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.","Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants","NE"
"2018-01-27880","2018","Thorrington 2018 PLoS One","27000","PCV13 vaccination in infants (90% reduction in serotype 19A) VERSUS Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Netherlands.","29425249","Healthy; Age- 0 to 18 years; Gender- Both; Country- Netherlands.","PCV13 vaccination in infants (90% reduction in serotype 19A)","Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.","Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants","NE"
"2018-01-27880","2018","Thorrington 2018 PLoS One","41000","PCV13 at 70 years old VERSUS Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants IN Healthy; Age- >=65 years; Gender- Both; Country- Netherlands.","29425249","Healthy; Age- >=65 years; Gender- Both; Country- Netherlands.","PCV13 at 70 years old","Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.","Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants","NE"
"2018-01-27880","2018","Thorrington 2018 PLoS One","51000","PCV13 vaccination at age 65 VERSUS Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants IN Healthy; Age- >=65 years; Gender- Both; Country- Netherlands.","29425249","Healthy; Age- >=65 years; Gender- Both; Country- Netherlands.","PCV13 vaccination at age 65","Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.","Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants","NE"
"2018-01-27880","2018","Thorrington 2018 PLoS One","7200","PPV23 vaccination at age 70 VERSUS Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants IN Healthy; Age- >=65 years; Gender- Both; Country- Netherlands.","29425249","Healthy; Age- >=65 years; Gender- Both; Country- Netherlands.","PPV23 vaccination at age 70","Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.","Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants","NE"
"2018-01-27880","2018","Thorrington 2018 PLoS One","77000","PCV13 vaccination at age 60 VERSUS Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Netherlands.","29425249","Healthy; Age- 41 to 64 years; Gender- Both; Country- Netherlands.","PCV13 vaccination at age 60","Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.","Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants","NE"
"2018-01-27880","2018","Thorrington 2018 PLoS One","95000","PCV13 vaccination (40% reduction in serotype 19A) in infants VERSUS Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Netherlands.","29425249","Healthy; Age- 0 to 18 years; Gender- Both; Country- Netherlands.","PCV13 vaccination (40% reduction in serotype 19A) in infants","Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.","Standard/Usual Care- 10-valent pneumococcal conjugated vaccine (PCV10) vaccination in infants","NE"
"2018-01-27642","2018","Hartman 2018 Respirology","28000","Endobronchial valve treatment VERSUS Standard/Usual Care- Standard of care IN Specific disease- Severe emphysema; Age- Adult; Gender- Both; Country- Netherlands.","29575395","Specific disease- Severe emphysema; Age- Adult; Gender- Both; Country- Netherlands.","Endobronchial valve treatment","Cost-effectiveness of endobronchial valve treatment in patients with severe emphysema compared to standard medical care.","Standard/Usual Care- Standard of care","NE"
"2018-01-27642","2018","Hartman 2018 Respirology","30000","Endobronchial valve treatment VERSUS Standard/Usual Care- Standard of care IN Specific disease- Severe emphysema; Age- Adult; Gender- Both; Country- Netherlands.","29575395","Specific disease- Severe emphysema; Age- Adult; Gender- Both; Country- Netherlands.","Endobronchial valve treatment","Cost-effectiveness of endobronchial valve treatment in patients with severe emphysema compared to standard medical care.","Standard/Usual Care- Standard of care","NE"
"2018-01-27642","2018","Hartman 2018 Respirology","48000","Endobronchial valve treatment VERSUS Standard/Usual Care- Standard of care IN Specific disease- Severe emphysema; Age- Adult; Gender- Both; Country- Netherlands.","29575395","Specific disease- Severe emphysema; Age- Adult; Gender- Both; Country- Netherlands.","Endobronchial valve treatment","Cost-effectiveness of endobronchial valve treatment in patients with severe emphysema compared to standard medical care.","Standard/Usual Care- Standard of care","NE"
"2018-01-27642","2018","Hartman 2018 Respirology","50000","Endobronchial valve treatment VERSUS Standard/Usual Care- Standard of care IN Specific disease- Severe emphysema; Age- Adult; Gender- Both; Country- Netherlands.","29575395","Specific disease- Severe emphysema; Age- Adult; Gender- Both; Country- Netherlands.","Endobronchial valve treatment","Cost-effectiveness of endobronchial valve treatment in patients with severe emphysema compared to standard medical care.","Standard/Usual Care- Standard of care","NE"
"2018-01-27540","2018","Westendorp 2018 Neurology"," ","Preventive antibiotic therapy with ceftriaxone VERSUS Standard/Usual Care- Standard stroke unit care without preventive antimicrobial therapy IN Specific disease- Acute stroke; Age- Adult; Gender- Both; Country- Netherlands.","29626176","Specific disease- Acute stroke; Age- Adult; Gender- Both; Country- Netherlands.","Preventive antibiotic therapy with ceftriaxone","Preventive Antibiotics in Stroke Study (PASS): A cost-effectiveness study.","Standard/Usual Care- Standard stroke unit care without preventive antimicrobial therapy","SE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","110000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","110000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","120000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","120000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","130000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","130000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","130000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","130000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","140000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- New Zealand; Other- Maori population; smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- New Zealand; Other- Maori population; smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","140000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Maori population (total population): smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Maori population (total population): smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","140000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","150000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","150000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","160000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","170000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","190000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","190000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","190000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","200000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","200000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","210000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","210000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- New Zealand; Other- Smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years, >=65 years; Gender- Female; Country- New Zealand; Other- Smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","220000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","220000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","220000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- New Zealand; Other- All populations; smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- New Zealand; Other- All populations; smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","230000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","240000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- >=65 years; Gender- Male; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","240000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- New Zealand; Other- Non-Maori population; smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- New Zealand; Other- Non-Maori population; smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","240000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","240000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","240000","Low-dose computed tomography screening programme for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- New Zealand; Other- smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- New Zealand; Other- smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening programme for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","260000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","260000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","260000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","270000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Non-Maori population (total population); smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","300000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Non-Maori population (total population): smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","30268467","Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Non-Maori population (total population): smoking history of at least 30 pack years, or (if a former smoker) having quit within last 15 years.","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28859","2018","Jaine 2018 Lung Cancer","300000","Low-dose computed tomography screening for lung cancer VERSUS No screening IN Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","30268467","Healthy; Age- 41 to 64 years; Gender- Male; Country- New Zealand; Other- Non-Maori population; current smokers (smoking history of at least 30 pack years).","Low-dose computed tomography screening for lung cancer","Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.","No screening","NE"
"2018-01-28715","2018","Cobiac 2018 Inj Prev","8300","Alcohol excise taxes VERSUS None IN Healthy; Age- Adult; Gender- Both; Country- New Zealand.","30337354","Healthy; Age- Adult; Gender- Both; Country- New Zealand.","Alcohol excise taxes","Cost-effectiveness of raising alcohol excise taxes to reduce the injury burden of road traffic crashes.","None","NE"
"2018-01-28715","2018","Cobiac 2018 Inj Prev","Cost-Saving","Alcohol excise taxes  VERSUS None IN Healthy; Age- Adult; Gender- Both; Country- New Zealand.","30337354","Healthy; Age- Adult; Gender- Both; Country- New Zealand.","Alcohol excise taxes","Cost-effectiveness of raising alcohol excise taxes to reduce the injury burden of road traffic crashes.","None","SE"
"2017-01-23744","2017","Teng 2017 BMC Infect Dis","42000","Fecal antigen based screening VERSUS None IN Specific disease- H. pylori infection; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- New Zealand; Other- Non-Maori.","28219322","Specific disease- H. pylori infection; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- New Zealand; Other- Non-Maori.","Fecal antigen based screening","A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity.","None","NE"
"2017-01-23470","2017","Leung 2017 Tob Induc Dis","2600","Fit2Quit + Quitline - ""Six-month home and community-based exercise programme delivered by Green Prescription (GRx) services, delivered in 10 contacts (face-to-face and telephone support sessions) over six months"" VERSUS Standard/Usual Care- Quitline IN Specific disease- Smoking; Age- 19 to 40 years; Gender- Female; Country- New Zealand; Other- Insufficiently-active 40-year-old female cigarette smokers.","28360828","Specific disease- Smoking; Age- 19 to 40 years; Gender- Female; Country- New Zealand; Other- Insufficiently-active 40-year-old female cigarette smokers.","Fit2Quit + Quitline - ""Six-month home and community-based exercise programme delivered by Green Prescription (GRx) services, delivered in 10 contacts (face-to-face and telephone support sessions) over six months""","Economic evaluation of an exercise-counselling intervention to enhance smoking cessation outcomes: The Fit2Quit trial.","Standard/Usual Care- Quitline","NE"
"2017-01-23470","2017","Leung 2017 Tob Induc Dis","3900","Fit2Quit + Quitline - ""Six-month home and community-based exercise programme delivered by Green Prescription (GRx) services, delivered in 10 contacts (face-to-face and telephone support sessions) over six months"" VERSUS Standard/Usual Care- Quitline IN Specific disease- Smoking; Age- 19 to 40 years; Gender- Male; Country- New Zealand; Other- Insufficiently-active 40-year-old male cigarette smokers.","28360828","Specific disease- Smoking; Age- 19 to 40 years; Gender- Male; Country- New Zealand; Other- Insufficiently-active 40-year-old male cigarette smokers.","Fit2Quit + Quitline - ""Six-month home and community-based exercise programme delivered by Green Prescription (GRx) services, delivered in 10 contacts (face-to-face and telephone support sessions) over six months""","Economic evaluation of an exercise-counselling intervention to enhance smoking cessation outcomes: The Fit2Quit trial.","Standard/Usual Care- Quitline","NE"
"2016-01-22730","2016","Heard 2016 J Tissue Viability","41000","Negative pressure wound therapy (NPWT) prophylactically used following surgery VERSUS Standard/Usual Care IN Healthy; Age- Adult; Gender- Female; Country- Australia; Other- Obese women undergoing elective caesarean section.","27320010","Healthy; Age- Adult; Gender- Female; Country- Australia; Other- Obese women undergoing elective caesarean section.","Negative pressure wound therapy (NPWT) prophylactically used following surgery","Cost-effectiveness analysis alongside a pilot study of prophylactic negative pressure wound therapy.","Standard/Usual Care","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","100000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease-  Breast Cancer; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor positive (ER+/PR+).","27504960","Specific disease-  Breast Cancer; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor positive (ER+/PR+).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","100000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease- Breast Cancer; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor negative (ER+/PR-).","27504960","Specific disease- Breast Cancer; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor negative (ER+/PR-).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","110000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor negative and progesterone receptor negative (ER-/PR-).","27504960","Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor negative and progesterone receptor negative (ER-/PR-).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","110000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease-  Breast Cancer; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor negative (ER+/PR-).","27504960","Specific disease-  Breast Cancer; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor negative (ER+/PR-).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","110000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease- Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor negative (ER+/PR-).","27504960","Specific disease- Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor negative (ER+/PR-).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","120000","12 month trastuzumab regimen VERSUS chemotherapy alone (treatment with an anthracycline) IN Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor negative and progesterone receptor positive (ER-/PR+).","27504960","Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor negative and progesterone receptor positive (ER-/PR+).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","140000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor positive (ER+/PR+).","27504960","Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor positive (ER+/PR+).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","140000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease-  Breast Cancer; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor positive (ER+/PR+).","27504960","Specific disease-  Breast Cancer; Age- 41 to 64 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor positive (ER+/PR+).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","150000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease- Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand.","27504960","Specific disease- Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand.","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","180000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor negative (ER+/PR-).","27504960","Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor negative (ER+/PR-).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","210000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease- Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor negative and progesterone receptor negative (ER-/PR-).","27504960","Specific disease- Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor negative and progesterone receptor negative (ER-/PR-).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","230000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor negative and progesterone receptor positive (ER-/PR+).","27504960","Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor negative and progesterone receptor positive (ER-/PR+).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","240000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease- Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor positive (ER+/PR+).","27504960","Specific disease- Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor positive (ER+/PR+).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","280000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand.","27504960","Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand.","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","350000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor negative (ER+/PR-).","27504960","Specific disease-  Breast Cancer; Age- >=65 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor positive and progesterone receptor negative (ER+/PR-).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2016-01-22384","2016","Leung 2016 PLoS Med","48000","12 month trastuzumab regimen VERSUS Chemotherapy alone (treatment with an anthracycline) IN Specific disease- Breast Cancer; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor negative and progesterone receptor negative (ER-/PR-).","27504960","Specific disease- Breast Cancer; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- New Zealand; Other- Estrogen receptor negative and progesterone receptor negative (ER-/PR-).","12 month trastuzumab regimen","Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.","Chemotherapy alone (treatment with an anthracycline)","NE"
"2018-01-25593","2018","Li                               2018 Lancet Glob Health","220","Tranexamic acid in addition to usual care for treatment of postpartum hemorrhage VERSUS Standard/Usual Care- Usual care for treatment of postpartum hemorrhage IN Specific disease- Post-partum hemorrhage; Age- Adult; Gender- Female; Country- Nigeria.","29389542","Specific disease- Post-partum hemorrhage; Age- Adult; Gender- Female; Country- Nigeria.","Tranexamic acid in addition to usual care for treatment of postpartum hemorrhage","Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial.","Standard/Usual Care- Usual care for treatment of postpartum hemorrhage","NE"
"2018-01-25593","2018","Li                               2018 Lancet Glob Health","87","Tranexamic acid in addition to usual care for treatment of postpartum hemorrhage VERSUS Standard/Usual Care- Usual care for treatment of postpartum hemorrhage IN Specific disease- Post-partum hemorrhage; Age- Adult; Gender- Female; Country- Pakistan.","29389542","Specific disease- Post-partum hemorrhage; Age- Adult; Gender- Female; Country- Pakistan.","Tranexamic acid in addition to usual care for treatment of postpartum hemorrhage","Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial.","Standard/Usual Care- Usual care for treatment of postpartum hemorrhage","NE"
"2016-01-22616","2016","Udeh 2016 BMC Cancer","1600","Fixed -dose combination of dutasteride and tamsulosin VERSUS Dutasteride monotherapy IN Specific disease- Benign prostatic hyperplasia; Age- 41 to 64 years, >=65 years, Adult; Gender- Male; Country- Nigeria; Other- International Prostate Symptom Score =12, prostate volume =30 cm(3), prostate-specific antigen 1.5-10 ng/ml, and maximum urinary flow rate (Q(max)) >5 and =15.","27388750","Specific disease- Benign prostatic hyperplasia; Age- 41 to 64 years, >=65 years, Adult; Gender- Male; Country- Nigeria; Other- International Prostate Symptom Score =12, prostate volume =30 cm(3), prostate-specific antigen 1.5-10 ng/ml, and maximum urinary flow rate (Q(max)) >5 and =15.","Fixed -dose combination of dutasteride and tamsulosin","A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.","Dutasteride monotherapy","NE"
"2013-01-10971","2013","Schneider 2013 PLoS One","12000","Lopinavir + Ritonavir (LPV/r) + Raltegravir as second line therapy VERSUS Standard/Usual care IN Specific disease- HIV; Age- Adult; Gender- Both; Country- South Africa; Other- N(t)RTI and NNRTI experienced with treatment failure.","23457450","Specific disease- HIV; Age- Adult; Gender- Both; Country- South Africa; Other- N(t)RTI and NNRTI experienced with treatment failure.","Lopinavir + Ritonavir (LPV/r) + Raltegravir as second line therapy","The potential cost and benefits of raltegravir in simplified second-line therapy  among HIV infected patients in Nigeria and South Africa.","Standard/Usual care","NE"
"2013-01-10971","2013","Schneider 2013 PLoS One","18000","Lopinavir + Ritonavir (LPV/r) + Raltegravir as second line therapy VERSUS Standard/Usual care IN Specific disease- HIV; Age- Adult; Gender- Both; Country- Nigeria; Other- N(t)RTI and NNRTI experienced with treatment failure.","23457450","Specific disease- HIV; Age- Adult; Gender- Both; Country- Nigeria; Other- N(t)RTI and NNRTI experienced with treatment failure.","Lopinavir + Ritonavir (LPV/r) + Raltegravir as second line therapy","The potential cost and benefits of raltegravir in simplified second-line therapy  among HIV infected patients in Nigeria and South Africa.","Standard/Usual care","NE"
"2013-01-10798","2013","Ekwunife 2013 Cost Eff Resour Alloc","14000","Calcium channel blocker (CCB) VERSUS None IN Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- High cardiovascular risk.","23343250","Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- High cardiovascular risk.","Calcium channel blocker (CCB)","Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis.","None","NE"
"2013-01-10798","2013","Ekwunife 2013 Cost Eff Resour Alloc","1500","Thiazide diuretic VERSUS None IN Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- Medium cardiovascular risk.","23343250","Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- Medium cardiovascular risk.","Thiazide diuretic","Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis.","None","NE"
"2013-01-10798","2013","Ekwunife 2013 Cost Eff Resour Alloc","1600","Thiazide diuretic VERSUS None IN Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- High cardiovascular risk.","23343250","Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- High cardiovascular risk.","Thiazide diuretic","Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis.","None","NE"
"2013-01-10798","2013","Ekwunife 2013 Cost Eff Resour Alloc","17000","Angiotensin converting enzyme inhibitor (ACEI) VERSUS None IN Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- Low cardiovascular risk.","23343250","Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- Low cardiovascular risk.","Angiotensin converting enzyme inhibitor (ACEI)","Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis.","None","NE"
"2013-01-10798","2013","Ekwunife 2013 Cost Eff Resour Alloc","17000","Calcium channel blocker (CCB) VERSUS None IN Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- Medium cardiovascular risk.","23343250","Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- Medium cardiovascular risk.","Calcium channel blocker (CCB)","Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis.","None","NE"
"2013-01-10798","2013","Ekwunife 2013 Cost Eff Resour Alloc","3100","Thiazide diuretic VERSUS None IN Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- Low cardiovascular risk.","23343250","Specific disease- Hypertension; Age- Adult; Gender- Both; Country- Nigeria; Other- Low cardiovascular risk.","Thiazide diuretic","Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis.","None","NE"
"2018-01-27020","2018","Aas 2018 J Clin Child Adolesc Psychol","Cost-Saving","Trauma-focused cognitive behavioral therapy VERSUS Standard/Usual Care- Treatment regularly provided in mental health clinics IN Specific disease- Post-traumatic stress; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Norway.","29877724","Specific disease- Post-traumatic stress; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Norway.","Trauma-focused cognitive behavioral therapy","Cost-Effectiveness Analysis of Trauma-Focused Cognitive Behavioral Therapy: A Randomized Control Trial among Norwegian Youth.","Standard/Usual Care- Treatment regularly provided in mental health clinics","SE"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Dimethyl fumarate (Tecifidera) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Dimethyl fumarate (Tecifidera)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Fingolimod (Gilenya) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Fingolimod (Gilenya)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Glatiramer acetate 20 mg (Copaxone) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Glatiramer acetate 20 mg (Copaxone)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Interferon beta 1a 22 ug (Rebif) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Interferon beta 1a 22 ug (Rebif)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Interferon beta 1a 30 ug (Avonex) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Interferon beta 1a 30 ug (Avonex)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Interferon beta 1a 44 ug (Rebif) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Interferon beta 1a 44 ug (Rebif)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Interferon beta 1b (Betaferon) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Interferon beta 1b (Betaferon)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Interferon beta-1b (extavia) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Interferon beta-1b (extavia)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Natalizumab (Tysabri) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Natalizumab (Tysabri)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Peg-interferon beta 1a (Plegridy) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Peg-interferon beta 1a (Plegridy)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-26123","2018","Hamidi 2018 J Clin Med Res","Dominated","Teriflunomide (Aubagio) VERSUS Alemtuzumab (lemtrada) IN Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","29317954","Specific disease- Relapse remitting multiple sclerosis; Age- Adult; Gender- Both; Country- Norway.","Teriflunomide (Aubagio)","A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.","Alemtuzumab (lemtrada)","NW"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","1.1e+007","HPV test (5-year), age 25 years VERSUS HPV test (7-year), age 25 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","HPV test (5-year), age 25 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (7-year), age 25 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","110000","2-times HPV test (ages 30 and 45) VERSUS HPV test (20-year) IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","2-times HPV test (ages 30 and 45)","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (20-year)","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","12000","Vaccination only with 2/4vHPV VERSUS None IN Healthy; Age- Unknown; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- Unknown; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","Vaccination only with 2/4vHPV","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","None","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","130000","HPV test (20-year) at age 28 VERSUS 2-times HPV test (ages 30 and 45)  IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","HPV test (20-year) at age 28","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","2-times HPV test (ages 30 and 45)","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","140000","1 time HPV test, age 35 years VERSUS 1 time HPV test, age 40 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","1 time HPV test, age 35 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","1 time HPV test, age 40 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","15000","1-time HPV test (age 40)  VERSUS Vaccination with 2/4vHPV vaccine, no screening IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","1-time HPV test (age 40)","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","Vaccination with 2/4vHPV vaccine, no screening","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","1e+008","HPV test (5-year), age 25 years VERSUS HPV test (7-year), age 25 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","HPV test (5-year), age 25 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (7-year), age 25 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","2.7e+007","HPV test (7-year), age 25 years VERSUS HPV test (10-year), age 25 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","HPV test (7-year), age 25 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (10-year), age 25 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","210000","HPV test (15-year), age 28 years VERSUS HPV test (20-year), age 28 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","HPV test (15-year), age 28 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (20-year), age 28 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","240000","HPV test (20-year), age 31 years VERSUS 1 time HPV test, age 35 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","HPV test (20-year), age 31 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","1 time HPV test, age 35 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","29000","1-time HPV test, age 40 years VERSUS 9vHPV vaccination only IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","1-time HPV test, age 40 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","9vHPV vaccination only","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","320000","HPV test (15-year), age 25 years  VERSUS HPV test (15-year), age 28 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","HPV test (15-year), age 25 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (15-year), age 28 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","36000","1 time HPV test (age 35) VERSUS 1 time HPV test (age 40) IN Healthy; Age- 19 to 40 years, Unknown; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years, Unknown; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","1 time HPV test (age 35)","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","1 time HPV test (age 40)","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","3e+006","HPV test (10-year), age 25 years VERSUS HPV test (15-year), age 25 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","HPV test (10-year), age 25 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (15-year), age 25 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","4.6e+006","HPV test (7-year), age 25 years VERSUS HPV test (10-year), age 25 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","HPV test (7-year), age 25 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (10-year), age 25 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","480000","HPV test (20-year), age 28 years VERSUS HPV test (20-year), age 31 years IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","29335156","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","HPV test (20-year), age 28 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (20-year), age 31 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","5.1e+007","HPV test (3-year), age 25 years VERSUS HPV test (5-year), age 25 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","HPV test (3-year), age 25 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (5-year), age 25 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","580000","HPV test (10-year), age 25 years VERSUS HPV test (15-year), age 25 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","HPV test (10-year), age 25 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (15-year), age 25 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","62000","1 time HPV test (age 30) VERSUS 1 time HPV test (age 35) IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","1 time HPV test (age 30)","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","1 time HPV test (age 35)","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","640000","HPV test (20-year), age 25 years VERSUS HPV test (20-year), age 28 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","HPV test (20-year), age 25 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (20-year), age 28 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","76000","HPV test (20-year) at age 31 VERSUS 1 time HPV test (age 30) IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Women vaccinated against human papillomavirus infections with 2/4vHPV.","HPV test (20-year) at age 31","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","1 time HPV test (age 30)","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","890000","HPV test (15-year), age 25 years VERSUS HPV test (20-year), age 25 years IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","29335156","Healthy; Age- 19 to 40 years; Gender- Female; Country- Norway; Other- Vaccinated with 9vHPV.","HPV test (15-year), age 25 years","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","HPV test (20-year), age 25 years","NE"
"2018-01-25657","2018","Pedersen 2018 Eur J Cancer","9500","9vHPV vaccine only VERSUS None IN Healthy; Age- Unknown; Gender- Female; Country- Norway.","29335156","Healthy; Age- Unknown; Gender- Female; Country- Norway.","9vHPV vaccine only","Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.","None","NE"
"2018-01-25586","2018","Wisloff 2018 Pharmacoeconomics","180000","Paritaprevir/ritonavir, 12 weeks + ombitasvir, 12 weeks + dasabuvir, 12 weeks + ribavirin, 12 weeks VERSUS Paritaprevir/ritonavir, 12 weeks + ombitasvir, 12 weeks + dasabuvir, 12 weeks IN Specific disease- Hepatitis C, genotype 1; Age- Adult; Gender- Both; Country- Norway.","29396744","Specific disease- Hepatitis C, genotype 1; Age- Adult; Gender- Both; Country- Norway.","Paritaprevir/ritonavir, 12 weeks + ombitasvir, 12 weeks + dasabuvir, 12 weeks + ribavirin, 12 weeks","Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.","Paritaprevir/ritonavir, 12 weeks + ombitasvir, 12 weeks + dasabuvir, 12 weeks","NE"
"2018-01-25586","2018","Wisloff 2018 Pharmacoeconomics","32000","Paritaprevir/ritonavir, 12 weeks + ombitasvir, 12 weeks + dasabuvir, 12 weeks VERSUS Standard/Usual Care- Pegylated interferon-alpha-2a and ribavirin, 48 weeks IN Specific disease- Hepatitis C, genotype 1; Age- Adult; Gender- Both; Country- Norway.","29396744","Specific disease- Hepatitis C, genotype 1; Age- Adult; Gender- Both; Country- Norway.","Paritaprevir/ritonavir, 12 weeks + ombitasvir, 12 weeks + dasabuvir, 12 weeks","Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.","Standard/Usual Care- Pegylated interferon-alpha-2a and ribavirin, 48 weeks","NE"
"2018-01-25586","2018","Wisloff 2018 Pharmacoeconomics","4.9e+006","Sofosbuvir, 12 weeks + ledipasvir, 12 weeks VERSUS Paritaprevir/ritonavir, 12 weeks + ombitasvir, 12 weeks + dasabuvir, 12 weeks + ribavirin, 12 weeks IN Specific disease- Hepatitis C, genotype 1; Age- Adult; Gender- Both; Country- Norway.","29396744","Specific disease- Hepatitis C, genotype 1; Age- Adult; Gender- Both; Country- Norway.","Sofosbuvir, 12 weeks + ledipasvir, 12 weeks","Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.","Paritaprevir/ritonavir, 12 weeks + ombitasvir, 12 weeks + dasabuvir, 12 weeks + ribavirin, 12 weeks","NE"
"2018-01-25586","2018","Wisloff 2018 Pharmacoeconomics","67000","Sofosbuvir, 12 weeks + ribavirin, 12 weeks VERSUS Standard/Usual Care- Pegylated interferon-alpha-2a and ribavirin, 24 weeks IN Specific disease- Hepatitis C, genotype 2; Age- Adult; Gender- Both; Country- Norway.","29396744","Specific disease- Hepatitis C, genotype 2; Age- Adult; Gender- Both; Country- Norway.","Sofosbuvir, 12 weeks + ribavirin, 12 weeks","Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.","Standard/Usual Care- Pegylated interferon-alpha-2a and ribavirin, 24 weeks","NE"
"2018-01-25586","2018","Wisloff 2018 Pharmacoeconomics","7.7e+006","Daclatasvir, 12 weeks + sofosbuvir, 12 weeks VERSUS Sofosbuvir, 12 weeks + pegylated interferon-alpha-2a and ribavirin, 12 weeks IN Specific disease- Hepatitis C, genotype 3; Age- Adult; Gender- Both; Country- Norway.","29396744","Specific disease- Hepatitis C, genotype 3; Age- Adult; Gender- Both; Country- Norway.","Daclatasvir, 12 weeks + sofosbuvir, 12 weeks","Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.","Sofosbuvir, 12 weeks + pegylated interferon-alpha-2a and ribavirin, 12 weeks","NE"
"2017-01-24846","2017","Pike 2017 BMJ Open","350000","Trametinib VERSUS Standard/Usual Care- Dacarbazine IN Specific disease- Malignant melanoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Norway.","28827234","Specific disease- Malignant melanoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Norway.","Trametinib","Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.","Standard/Usual Care- Dacarbazine","NE"
"2017-01-24846","2017","Pike 2017 BMJ Open","370000","Dabrafenib+trametinib VERSUS Standard/Usual Care- Dacarbazine IN Specific disease- Malignant melanoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Norway.","28827234","Specific disease- Malignant melanoma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Norway.","Dabrafenib+trametinib","Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.","Standard/Usual Care- Dacarbazine","NE"
"2017-01-24840","2017","Lindemark 2017 Crit Care","1300","Patient group: Medical patients admitted in Intensive Care Unit VERSUS Rejected from Intensive care unit IN Healthy; Age- Adult; Gender- Both; Country- Norway.","28830479","Healthy; Age- Adult; Gender- Both; Country- Norway.","Patient group: Medical patients admitted in Intensive Care Unit","Costs and expected gain in lifetime health from intensive care versus general ward care of 30,712 individual patients: a distribution-weighted cost-effectiveness analysis.","Rejected from Intensive care unit","NE"
"2017-01-24840","2017","Lindemark 2017 Crit Care","1400","All patient group: Patients admitted in Intensive Care Unit VERSUS Rejected from Intensive Care Unit IN Healthy; Age- Adult; Gender- Both; Country- Norway.","28830479","Healthy; Age- Adult; Gender- Both; Country- Norway.","All patient group: Patients admitted in Intensive Care Unit","Costs and expected gain in lifetime health from intensive care versus general ward care of 30,712 individual patients: a distribution-weighted cost-effectiveness analysis.","Rejected from Intensive Care Unit","NE"
"2017-01-24840","2017","Lindemark 2017 Crit Care","1500","Patient group: Acute surgery patients admitted in Intensive Care Unit.  VERSUS Rejected from Intensive Care Unit IN Healthy; Age- Adult; Gender- Both; Country- Norway.","28830479","Healthy; Age- Adult; Gender- Both; Country- Norway.","Patient group: Acute surgery patients admitted in Intensive Care Unit.","Costs and expected gain in lifetime health from intensive care versus general ward care of 30,712 individual patients: a distribution-weighted cost-effectiveness analysis.","Rejected from Intensive Care Unit","NE"
"2017-01-24840","2017","Lindemark 2017 Crit Care","1800","Patient group: Planned surgery patients admitted in Intensive Care Unit. VERSUS Rejected from Intensive Care Unit IN Healthy; Age- Adult; Gender- Both; Country- Norway.","28830479","Healthy; Age- Adult; Gender- Both; Country- Norway.","Patient group: Planned surgery patients admitted in Intensive Care Unit.","Costs and expected gain in lifetime health from intensive care versus general ward care of 30,712 individual patients: a distribution-weighted cost-effectiveness analysis.","Rejected from Intensive Care Unit","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","110000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab VERSUS Ezetimibe IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians at higher risk for a cardiovascular disease event due to history of myocardial infarction (secondary prevention), statin intolerant.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians at higher risk for a cardiovascular disease event due to history of myocardial infarction (secondary prevention), statin intolerant.","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Ezetimibe","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","110000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Evolocumab VERSUS Ezetimibe IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), diabetics.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), diabetics.","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Evolocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Ezetimibe","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","12000","Ezetimibe VERSUS Standard/Usual Care IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention),statin intolerant.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention),statin intolerant.","Ezetimibe","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Standard/Usual Care","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","120000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Evolocumab VERSUS Ezetimibe IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), heterozygous familial hypercholesterolaemia (HeFH).","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), heterozygous familial hypercholesterolaemia (HeFH).","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Evolocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Ezetimibe","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","130000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab VERSUS Ezetimibe IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), diabetics.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), diabetics.","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Ezetimibe","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","14000","Ezetimibe VERSUS Standard/Usual Care IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), miscellaneous high risk.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), miscellaneous high risk.","Ezetimibe","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Standard/Usual Care","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","140000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab VERSUS Ezetimibe IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), heterozygous familial hypercholesterolaemia (HeFH).","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), heterozygous familial hypercholesterolaemia (HeFH).","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Ezetimibe","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","150000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Evolocumab VERSUS Ezetimibe IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians at higher risk for a cardiovascular disease event due to history of myocardial infarction (secondary prevention), miscellaneous high risk.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians at higher risk for a cardiovascular disease event due to history of myocardial infarction (secondary prevention), miscellaneous high risk.","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Evolocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Ezetimibe","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","160000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Evolocumab VERSUS Ezetimibe IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention),statin intolerant.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention),statin intolerant.","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Evolocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Ezetimibe","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","180000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab VERSUS Ezetimibe IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians at higher risk for a cardiovascular disease event due to history of myocardial infarction (secondary prevention), miscellaneous high risk.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians at higher risk for a cardiovascular disease event due to history of myocardial infarction (secondary prevention), miscellaneous high risk.","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Ezetimibe","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","190000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab VERSUS Ezetimibe IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention),statin intolerant.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention),statin intolerant.","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Ezetimibe","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","250000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Evolocumab VERSUS Standard/Usual Care IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), miscellaneous high risk.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), miscellaneous high risk.","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Evolocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Standard/Usual Care","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","2800","Ezetimibe VERSUS Standard/Usual Care IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), heterozygous familial hypercholesterolaemia (HeFH).","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), heterozygous familial hypercholesterolaemia (HeFH).","Ezetimibe","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Standard/Usual Care","NE"
"2017-01-23297","2017","Korman 2017 Eur Heart J Cardiovasc Pharmacother","290000","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab VERSUS Standard/Usual Care IN Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), miscellaneous high risk.","28444187","Specific disease- Cardiovascular disease; Age- >=65 years; Gender- Both; Country- Norway; Other- Norwegians with no history of myocardial infarction (primary prevention), miscellaneous high risk.","Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor: Alirocumab","Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.","Standard/Usual Care","NE"
"2014-01-16146","2014","Lutgens 2014 Gastrointest Endosc","Cost-Saving","Colonoscopic surveillance stragetry based on British Society of Gastroenterology VERSUS Colonoscopic surveillance stragetry based on American Gastroenterological Association (AGA) IN Specific disease- Inflammatory bowel disease (IBD); Age- 19 to 40 years; Gender- Male; Country- United States.","25088918","Specific disease- Inflammatory bowel disease (IBD); Age- 19 to 40 years; Gender- Male; Country- United States.","Colonoscopic surveillance stragetry based on British Society of Gastroenterology","A risk-profiling approach for surveillance of inflammatory bowel disease-colorectal carcinoma is more cost-effective: a comparative cost-effectiveness analysis between international guidelines.","Colonoscopic surveillance stragetry based on American Gastroenterological Association (AGA)","SE"
"2014-01-15940","2014","Cocker 2014 PLoS One","Dominated","Absenteeism (not working when feeling ill) over a five-year time horizon VERSUS Presenteeism (working while feeling ill) amongst employed Australians reporting lifetime major depressionover a five-year time horizon IN Specific disease- Major depression; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Australia.","25181469","Specific disease- Major depression; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Australia.","Absenteeism (not working when feeling ill) over a five-year time horizon","Depression in working adults: comparing the costs and health outcomes of working  when ill.","Presenteeism (working while feeling ill) amongst employed Australians reporting lifetime major depressionover a five-year time horizon","NW"
"2014-01-15936","2014","Mewes 2014 J Cancer Surviv","32000","Cognitive behavioral therapy for alleviating treatment-induced menopausal symptoms in breast cancer patients VERSUS Standard/Usual Care- Waiting list control group IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Netherlands.","25179578","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Netherlands.","Cognitive behavioral therapy for alleviating treatment-induced menopausal symptoms in breast cancer patients","Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients.","Standard/Usual Care- Waiting list control group","NE"
"2014-01-15936","2014","Mewes 2014 J Cancer Surviv","40000","Physical exercise to alleviate treatment-induced menopausal symptoms in breast cancer patients VERSUS Standard/Usual Care- Waiting list control group IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Netherlands.","25179578","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Netherlands.","Physical exercise to alleviate treatment-induced menopausal symptoms in breast cancer patients","Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients.","Standard/Usual Care- Waiting list control group","NE"
"2014-01-15115","2014","Gordon 2014 Diabetes Res Clin Pract","Cost-Saving","Telephone linked intervention VERSUS Standard/Usual Care- Not specified IN Specific disease- Type 2 Diabetes; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Australia.","24503043","Specific disease- Type 2 Diabetes; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Australia.","Telephone linked intervention","A cost-effectiveness analysis of a telephone-linked care intervention for individuals with Type 2 diabetes.","Standard/Usual Care- Not specified","SE"
"2014-01-14208","2014","van der Have 2014 Dig Dis Sci","130000","Hepatitis B Virus Screening (HbSAg, HbCAb), prior to TNF-a therapy. VERSUS No Hepatitis B Virus Screening IN Specific disease- Crohn's Disease; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Netherlands.","23949640","Specific disease- Crohn's Disease; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Netherlands.","Hepatitis B Virus Screening (HbSAg, HbCAb), prior to TNF-a therapy.","Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-alpha inhibitors in Crohn''s disease.","No Hepatitis B Virus Screening","NE"
"2014-01-14208","2014","van der Have 2014 Dig Dis Sci","90000","Extensive Tuberculosis Screening:  initial screening with tuberculin skin test and chest X-ray followed by an IGRA (Quantiferon-TB Gold In-Tube) VERSUS conventional TB screening - including tuberculin skin test and chest X-ray IN Specific disease- Crohn's Disease; Age-; Gender- Both; Country- Netherlands.","23949640","Specific disease- Crohn's Disease; Age-; Gender- Both; Country- Netherlands.","Extensive Tuberculosis Screening:  initial screening with tuberculin skin test and chest X-ray followed by an IGRA (Quantiferon-TB Gold In-Tube)","Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-alpha inhibitors in Crohn''s disease.","conventional TB screening - including tuberculin skin test and chest X-ray","NE"
"2013-01-11298","2013","Turkstra 2013 BMC Cardiovasc Disord","170000","Health coaching (HC) intervention: telephone-based health coaching to prevent coronary heart disease (CHD) VERSUS Standard/Usual Care IN Specific disease- myocardial infarction; Age- Adult; Gender- Both; Country- Australia.","23634982","Specific disease- myocardial infarction; Age- Adult; Gender- Both; Country- Australia.","Health coaching (HC) intervention: telephone-based health coaching to prevent coronary heart disease (CHD)","Cost-effectiveness of a coronary heart disease secondary prevention program in patients with myocardial infarction: results from a randomised controlled trial (ProActive Heart).","Standard/Usual Care","NE"
"2012-01-09579","2012","Connolly 2012 Neth J Med","Cost-Saving","Mesalazine (2g) VERSUS Mesalazine (1g) IN Patients aged over 18 years with extensive ulcerative colitis in Netherlands","22859419","Patients aged over 18 years with extensive ulcerative colitis in Netherlands","Mesalazine (2g)","The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands.","Mesalazine (1g)","SE"
"2012-01-09579","2012","Connolly 2012 Neth J Med","Cost-Saving","Oral mesalazine (4g) + mesalazine enema (1g ) VERSUS Oral mesalazine (4g) + placebo enema IN Patients aged over 18 years with extensive ulcerative colitis in Netherlands","22859419","Patients aged over 18 years with extensive ulcerative colitis in Netherlands","Oral mesalazine (4g) + mesalazine enema (1g )","The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands.","Oral mesalazine (4g) + placebo enema","SE"
"1997-01-01928","1997","Salkeld 1997 Health Policy","1.4e+007","Video + self help VERSUS Routine care IN Australian GP patients with >= 1 modifiable CVD risk factors, female","10169297","Australian GP patients with >= 1 modifiable CVD risk factors, female","Video + self help","The cost-effectiveness of a cardiovascular risk reduction program in general practice.","Routine care","NE"
"1997-01-01928","1997","Salkeld 1997 Health Policy","190000","Video + self help VERSUS Routine care IN Australian GP patients with >= 1 modifiable CVD risk factors, male","10169297","Australian GP patients with >= 1 modifiable CVD risk factors, male","Video + self help","The cost-effectiveness of a cardiovascular risk reduction program in general practice.","Routine care","NE"
"1997-01-01928","1997","Salkeld 1997 Health Policy","37000","Video VERSUS Routine care IN Australian GP patients with high risk of CVD (DBP>95 or TC>6.5), male","10169297","Australian GP patients with high risk of CVD (DBP>95 or TC>6.5), male","Video","The cost-effectiveness of a cardiovascular risk reduction program in general practice.","Routine care","NE"
"1997-01-01928","1997","Salkeld 1997 Health Policy","Dominated","Video + self help VERSUS Video IN Australian GP patients with high risk of CVD (DBP>95 or TC>6.5), female","10169297","Australian GP patients with high risk of CVD (DBP>95 or TC>6.5), female","Video + self help","The cost-effectiveness of a cardiovascular risk reduction program in general practice.","Video","NW"
"1997-01-01928","1997","Salkeld 1997 Health Policy","Dominated","Video + self help VERSUS Video IN Australian GP patients with high risk of CVD (DBP>95 or TC>6.5), male","10169297","Australian GP patients with high risk of CVD (DBP>95 or TC>6.5), male","Video + self help","The cost-effectiveness of a cardiovascular risk reduction program in general practice.","Video","NW"
"1997-01-01928","1997","Salkeld 1997 Health Policy","Dominated","Video VERSUS Routine care IN Australian GP patients with >= 1 modifiable CVD risk factors, female","10169297","Australian GP patients with >= 1 modifiable CVD risk factors, female","Video","The cost-effectiveness of a cardiovascular risk reduction program in general practice.","Routine care","NW"
"1997-01-01928","1997","Salkeld 1997 Health Policy","Dominated","Video VERSUS Routine care IN Australian GP patients with >= 1 modifiable CVD risk factors, male","10169297","Australian GP patients with >= 1 modifiable CVD risk factors, male","Video","The cost-effectiveness of a cardiovascular risk reduction program in general practice.","Routine care","NW"
"1997-01-01928","1997","Salkeld 1997 Health Policy","Dominated","Video VERSUS Routine care IN Australian GP patients with high risk of CVD (DBP>95 or TC>6.5), female","10169297","Australian GP patients with high risk of CVD (DBP>95 or TC>6.5), female","Video","The cost-effectiveness of a cardiovascular risk reduction program in general practice.","Routine care","NW"
"2018-01-26719","2018","Mennini 2018 Reprod Biol Endocrinol","19000","Recombinant follicle-stimulating hormone + recombinant luteinising hormone VERSUS Highly purified human Menopausal Gonadotropin IN Specific disease- Infertility; Age- Adult; Gender- Female; Country- Italy.","30021630","Specific disease- Infertility; Age- Adult; Gender- Female; Country- Italy.","Recombinant follicle-stimulating hormone + recombinant luteinising hormone","Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with  recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF.","Highly purified human Menopausal Gonadotropin","NE"
"2018-01-26719","2018","Mennini 2018 Reprod Biol Endocrinol","7600","Recombinant follicle-stimulating hormone + recombinant luteinising hormone VERSUS Highly purified human Menopausal Gonadotropin IN Specific disease- Infertility; Age- Adult; Gender- Female; Country- Italy.","30021630","Specific disease- Infertility; Age- Adult; Gender- Female; Country- Italy.","Recombinant follicle-stimulating hormone + recombinant luteinising hormone","Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with  recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF.","Highly purified human Menopausal Gonadotropin","NE"
"2018-01-26145","2018","Lim 2018 Anesthesiology","38000","Intra Operative Cell Salvage high risk only for Obstetric Hemorrhage VERSUS No Intra Operative Cell Salvage IN Specific disease- Obstetric Hemorrhage; Age- 19 to 40 years; Gender- Female; Country- United States of America (USA); Other- Primiparous; scheduled cesarean delivery.","29194062","Specific disease- Obstetric Hemorrhage; Age- 19 to 40 years; Gender- Female; Country- United States of America (USA); Other- Primiparous; scheduled cesarean delivery.","Intra Operative Cell Salvage high risk only for Obstetric Hemorrhage","Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage.","No Intra Operative Cell Salvage","NE"
"2018-01-26145","2018","Lim 2018 Anesthesiology","450000","Intra Operative Cell Salvage all VERSUS No Intra Operative Cell Salvage IN Specific disease- Obstetric Hemorrhage; Age- 19 to 40 years; Gender- Female; Country- United States of America (USA); Other- Primiparous; scheduled cesarean delivery.","29194062","Specific disease- Obstetric Hemorrhage; Age- 19 to 40 years; Gender- Female; Country- United States of America (USA); Other- Primiparous; scheduled cesarean delivery.","Intra Operative Cell Salvage all","Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage.","No Intra Operative Cell Salvage","NE"
"2017-01-23433","2017","Kim 2017 J Natl Cancer Inst","140000","HPV test (every 10 years), starting at age 30 VERSUS HPV test (every 10 years), starting at age 35 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","HPV test (every 10 years), starting at age 30","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","HPV test (every 10 years), starting at age 35","NE"
"2017-01-23433","2017","Kim 2017 J Natl Cancer Inst","150000","HPV test (every 5 years), starting at age 25 VERSUS HPV test (every 5 years), starting at age 30 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-2 or HPV-4.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-2 or HPV-4.","HPV test (every 5 years), starting at age 25","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","HPV test (every 5 years), starting at age 30","NE"
"2017-01-23433","2017","Kim 2017 J Natl Cancer Inst","2.4e+007","HPV test (every 5 years), starting at age 25 VERSUS HPV test (every 10 years), starting at age 25 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","HPV test (every 5 years), starting at age 25","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","HPV test (every 10 years), starting at age 25","NE"
"2017-01-23433","2017","Kim 2017 J Natl Cancer Inst","20000","HPV test (1 time), age 40 VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","27754955","Healthy; Age- 19 to 40 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","HPV test (1 time), age 40","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","None","NE"
"2017-01-23433","2017","Kim 2017 J Natl Cancer Inst","23000","Cytology (every 5 years), starting at age 35 VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-2 or HPV-4.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-2 or HPV-4.","Cytology (every 5 years), starting at age 35","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","None","NE"
"2017-01-23433","2017","Kim 2017 J Natl Cancer Inst","3.1e+008","HPV test (every 3 years), starting at age 25 VERSUS HPV test (every 5 years), starting at age 25 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","HPV test (every 3 years), starting at age 25","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","HPV test (every 5 years), starting at age 25","NE"
"2017-01-23433","2017","Kim 2017 J Natl Cancer Inst","38000","Cytology (every 5 years) starting age 30 VERSUS Cytology (every 5 years) starting age 35 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-2 or HPV-4.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-2 or HPV-4.","Cytology (every 5 years) starting age 30","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","Cytology (every 5 years) starting age 35","NE"
"2017-01-23433","2017","Kim 2017 J Natl Cancer Inst","44000","HPV test (every 10 years), starting at age 35 VERSUS HPV test (1 time), age 40 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","HPV test (every 10 years), starting at age 35","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","HPV test (1 time), age 40","NE"
"2017-01-23433","2017","Kim 2017 J Natl Cancer Inst","450000","HPV test (every 10 years), starting at age 25 VERSUS HPV test (every 10 years), starting at age 30 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-9.","HPV test (every 10 years), starting at age 25","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","HPV test (every 10 years), starting at age 30","NE"
"2017-01-23433","2017","Kim 2017 J Natl Cancer Inst","58000","HPV test (every 5 years), starting at age 35 VERSUS Cytology (every 5 years), starting at age 30 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-2 or HPV-4.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States of America (USA); Other- Vaccinated with HPV-2 or HPV-4.","HPV test (every 5 years), starting at age 35","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","Cytology (every 5 years), starting at age 30","NE"
"2017-01-23399","2017","Havrilesky 2017 Gynecol Oncol","14000","Risk-Reducing Salpingo-Oophorectomy (RRSO) + Hysterectomy VERSUS Standard/Usual Care- Risk-Reducing Salpingo-Oophorectomy (RRSO) IN Specific disease- Breast or Ovarian Cancer; Age- 19 to 40 years; Gender- Female; Country- United States; Other- BRCA1 mutation carriers.","28390820","Specific disease- Breast or Ovarian Cancer; Age- 19 to 40 years; Gender- Female; Country- United States; Other- BRCA1 mutation carriers.","Risk-Reducing Salpingo-Oophorectomy (RRSO) + Hysterectomy","Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.","Standard/Usual Care- Risk-Reducing Salpingo-Oophorectomy (RRSO)","SE"
"2017-01-23107","2017","Tsiachristas 2017 J Med Screen","11000","Nurse navigator VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","28530515","Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","Nurse navigator","Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).","None","SW"
"2017-01-23107","2017","Tsiachristas 2017 J Med Screen","11000","Requested self-sampler VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","28530515","Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","Requested self-sampler","Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).","None","NE"
"2017-01-23107","2017","Tsiachristas 2017 J Med Screen","15000","Choice of requested self-sampler or nurse navigator VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","28530515","Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","Choice of requested self-sampler or nurse navigator","Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).","None","NE"
"2017-01-23107","2017","Tsiachristas 2017 J Med Screen","16000","Timed appointment VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","28530515","Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","Timed appointment","Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).","None","NE"
"2017-01-23107","2017","Tsiachristas 2017 J Med Screen","19000","unrequested self-sampler VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","28530515","Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","unrequested self-sampler","Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).","None","NE"
"2017-01-23107","2017","Tsiachristas 2017 J Med Screen","21000","Internet booking VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","28530515","Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","Internet booking","Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).","None","NE"
"2017-01-23107","2017","Tsiachristas 2017 J Med Screen","4900","Pre-leaflet cervical cancer screening intervention VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","28530515","Healthy; Age- 19 to 40 years; Gender- Female; Country- United Kingdom; Other- all women registered in general practices from three Greater Manchester (England) Primary Care Trusts and Grampian (Scotland), who were about to receive their initial cervical cancer screening invitation (aged 25 in Manchester and 20 in Grampian).","Pre-leaflet cervical cancer screening intervention","Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).","None","SW"
"2017-01-21914","2017","Kim 2017 J Natl Cancer Inst","1.5e+006","Cotest (1-time), age 40 VERSUS HPV (1-time), age 40 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Vaccinated with HPV-9.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Vaccinated with HPV-9.","Cotest (1-time), age 40","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","HPV (1-time), age 40","NE"
"2017-01-21914","2017","Kim 2017 J Natl Cancer Inst","1.8e+007","HPV test (3-year), age 25 VERSUS HPV test (5-year), age 25 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Vaccinated with HPV-2 or HPV-4.","27754955","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States; Other- Vaccinated with HPV-2 or HPV-4.","HPV test (3-year), age 25","Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.","HPV test (5-year), age 25","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","8000","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Pakistan.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Pakistan.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2017-01-25841","2017","David 2017 Pak J Pharm Sci","1500","Pegylated interferon a-2a and ribavirin VERSUS Standard/Usual Care- Interferon a-2a and ribavirin IN Specific disease- Hepatits C; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Pakistan.","29175794","Specific disease- Hepatits C; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Pakistan.","Pegylated interferon a-2a and ribavirin","Cost effectiveness evaluation of hepatitis C therapy in Lahore.","Standard/Usual Care- Interferon a-2a and ribavirin","NE"
"2016-01-20552","2016","Field 2016 Thorax","14000","Once-only lung cancer screening using low-dose Computed Tomography CT VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- A 5-year lung cancer risk of =5%.","26645413","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- A 5-year lung cancer risk of =5%.","Once-only lung cancer screening using low-dose Computed Tomography CT","UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening.","Standard/Usual Care","NE"
"2014-01-16411","2014","Parmar 2014 J Gastrointest Surg","Dominated","Early elective cholecystectomy VERSUS observation IN Specific disease- mild biliary disease; Age- >=65 years; Gender- Not Specified; Country- United States.","24919433","Specific disease- mild biliary disease; Age- >=65 years; Gender- Not Specified; Country- United States.","Early elective cholecystectomy","Cost-effectiveness of elective laparoscopic cholecystectomy versus observation in older patients presenting with mild biliary disease.","observation","NW"
"2012-01-08531","2012","Manca 2012 Value Health","25000","First-line combination therapy of fluorouracil plus irinotecan VERSUS First-line fluorouracil until treatment failure followed by single agent irinotecan IN UK patients diagnosed with colorectal cancer","22264968","UK patients diagnosed with colorectal cancer","First-line combination therapy of fluorouracil plus irinotecan","The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS).","First-line fluorouracil until treatment failure followed by single agent irinotecan","NE"
"2012-01-08531","2012","Manca 2012 Value Health","25000","First-line modification of de Gramont regimen (MdG) regimen until treatment failure followed by doublet therapy with MdG and irinotecan (IrMdG regimen) VERSUS First-line fluorouracil until treatment failure followed by single agent irinotecan IN UK patients diagnosed with colorectal cancer","22264968","UK patients diagnosed with colorectal cancer","First-line modification of de Gramont regimen (MdG) regimen until treatment failure followed by doublet therapy with MdG and irinotecan (IrMdG regimen)","The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS).","First-line fluorouracil until treatment failure followed by single agent irinotecan","NE"
"2012-01-08531","2012","Manca 2012 Value Health","49000","First-line modification of de Gramont regimen (MdG) regimen until treatment failure followed by doublet therapy with MdG and oxaliplatin (OxMdG regimen) VERSUS First-line fluorouracil until treatment failure followed by single agent irinotecan IN UK patients diagnosed with colorectal cancer","22264968","UK patients diagnosed with colorectal cancer","First-line modification of de Gramont regimen (MdG) regimen until treatment failure followed by doublet therapy with MdG and oxaliplatin (OxMdG regimen)","The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS).","First-line fluorouracil until treatment failure followed by single agent irinotecan","NE"
"2012-01-08531","2012","Manca 2012 Value Health","97000","First-line doublet therapy with modification of de Gramont regimen (MdG) and oxaliplatin (OxMdG) VERSUS First-line fluorouracil until treatment failure followed by single agent irinotecan IN UK patients diagnosed with colorectal cancer","22264968","UK patients diagnosed with colorectal cancer","First-line doublet therapy with modification of de Gramont regimen (MdG) and oxaliplatin (OxMdG)","The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS).","First-line fluorouracil until treatment failure followed by single agent irinotecan","NE"
"2018-01-27419","2018","Nuijten 2018 J Med Econ","6800","OPTIFAST weight loss program VERSUS None IN Specific disease- Class I and II obesity (BMI = 30-39.9 kg/m2); Age- 19 to 40 years; Gender- Both; Country- United States; Other- Without type 2 diabetes mellitus.","29678127","Specific disease- Class I and II obesity (BMI = 30-39.9 kg/m2); Age- 19 to 40 years; Gender- Both; Country- United States; Other- Without type 2 diabetes mellitus.","OPTIFAST weight loss program","A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.","None","NE"
"2018-01-26133","2018","Caceda 2018 J Comp Eff Res","17000","Carbetocin VERSUS Standard/Usual Care- Oxytocin IN Healthy; Age- Adult; Gender- Female; Country- Peru; Other- Risk for postpartum hemorrhage.","29264934","Healthy; Age- Adult; Gender- Female; Country- Peru; Other- Risk for postpartum hemorrhage.","Carbetocin","Pharmacoeconomic study comparing carbetocin with oxytocin for the prevention of hemorrhage following cesarean delivery in Lima, Peru.","Standard/Usual Care- Oxytocin","NE"
"2017-01-23671","2017","Ahmed 2017 Hepatology","39000","Pre-liver transplant treatment with all-oral direct acting antiviral therapy (Ledipasvir/sofosbuvir) VERSUS Post-liver transplant  treatment with all-oral direct acting antiviral therapy (Ledipasvir/sofosbuvir) IN Specific disease- Hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United States of America (USA); Other- Genotype 1 waitlisted for liver transplant with decompensated cirrhosis (DCC) and MELD score > = 15.","28257591","Specific disease- Hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United States of America (USA); Other- Genotype 1 waitlisted for liver transplant with decompensated cirrhosis (DCC) and MELD score > = 15.","Pre-liver transplant treatment with all-oral direct acting antiviral therapy (Ledipasvir/sofosbuvir)","Treatment of Patients Waitlisted for Liver Transplant with an All-Oral DAAs is a  Cost-Effective Treatment Strategy in the United States.","Post-liver transplant  treatment with all-oral direct acting antiviral therapy (Ledipasvir/sofosbuvir)","NE"
"2017-01-23671","2017","Ahmed 2017 Hepatology","79000","Pre-liver transplant treatment with all-oral direct acting antiviral therapy (Ledipasvir/sofosbuvir) VERSUS Post-liver transplant treatment with all-oral direct acting antiviral therapy (Ledipasvir/sofosbuvir) IN Specific disease- Hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United States of America (USA); Other- Genotype 1 patients waitlisted for liver transplant with hepatocellular carcinoma (HCC) .","28257591","Specific disease- Hepatitis C; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United States of America (USA); Other- Genotype 1 patients waitlisted for liver transplant with hepatocellular carcinoma (HCC) .","Pre-liver transplant treatment with all-oral direct acting antiviral therapy (Ledipasvir/sofosbuvir)","Treatment of Patients Waitlisted for Liver Transplant with an All-Oral DAAs is a  Cost-Effective Treatment Strategy in the United States.","Post-liver transplant treatment with all-oral direct acting antiviral therapy (Ledipasvir/sofosbuvir)","NE"
"2014-01-16188","2014","Caresano 2014 Adv Ther","Cost-Saving","Asenapine VERSUS Olanzapine (OLA) strategy IN Specific disease- Bipolar I disorder; Age- Unknown; Gender- Not Specified; Country- Italy; Other- experiencing mixed episodes.","25055791","Specific disease- Bipolar I disorder; Age- Unknown; Gender- Not Specified; Country- Italy; Other- experiencing mixed episodes.","Asenapine","Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context.","Olanzapine (OLA) strategy","SE"
"2013-01-14601","2013","Gomez 2013 BMC Public Health","2100","13-valent pneumococcal conjugate vaccine VERSUS 7-valent pneumococcal conjugate vaccine IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru; Other- Newborn cohort in Peru (2007).","24171921","Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru; Other- Newborn cohort in Peru (2007).","13-valent pneumococcal conjugate vaccine","Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.","7-valent pneumococcal conjugate vaccine","NE"
"2013-01-14601","2013","Gomez 2013 BMC Public Health","5300","10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) VERSUS No vaccination IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru; Other- Newborn cohort in Peru (2007).","24171921","Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru; Other- Newborn cohort in Peru (2007).","10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV)","Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.","No vaccination","NE"
"2013-01-14601","2013","Gomez 2013 BMC Public Health","6200","13-valent pneumococcal conjugate vaccine VERSUS No vaccination IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru; Other- Newborn cohort in Peru (2007).","24171921","Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru; Other- Newborn cohort in Peru (2007).","13-valent pneumococcal conjugate vaccine","Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.","No vaccination","NE"
"2013-01-14601","2013","Gomez 2013 BMC Public Health","7000","7-valent pneumococcal conjugate vaccine VERSUS No vaccination IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru; Other- Newborn cohort in Peru (2007).","24171921","Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru; Other- Newborn cohort in Peru (2007).","7-valent pneumococcal conjugate vaccine","Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.","No vaccination","NE"
"2013-01-14601","2013","Gomez 2013 BMC Public Health","Cost-Saving","10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) VERSUS 7-valent pneumococcal conjugate vaccine IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru; Other- Newborn cohort in Peru (2007).","24171921","Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru; Other- Newborn cohort in Peru (2007).","10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV)","Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.","7-valent pneumococcal conjugate vaccine","SE"
"2013-01-11427","2013","Beard 2013 Eur J Health Econ","11000","Febuxostat 80 mg or 120 mg alone VERSUS allopurinol alone IN Specific disease- Gout; Age- Adult; Gender- Both; Country- United Kingdom.","23719971","Specific disease- Gout; Age- Adult; Gender- Both; Country- United Kingdom.","Febuxostat 80 mg or 120 mg alone","Cost-effectiveness of febuxostat in chronic gout.","allopurinol alone","NE"
"2013-01-11427","2013","Beard 2013 Eur J Health Econ","5400","Allopurinol alone VERSUS Placebo IN Specific disease- Gout; Age- Adult; Gender- Both; Country- United Kingdom.","23719971","Specific disease- Gout; Age- Adult; Gender- Both; Country- United Kingdom.","Allopurinol alone","Cost-effectiveness of febuxostat in chronic gout.","Placebo","NE"
"2013-01-11427","2013","Beard 2013 Eur J Health Econ","6400","First line use of allopurinol 300 mg QD, followed by a switch to febuxostat 80 or 120 mg VERSUS allopurinol alone IN Specific disease- Gout; Age- Adult; Gender- Both; Country- United Kingdom.","23719971","Specific disease- Gout; Age- Adult; Gender- Both; Country- United Kingdom.","First line use of allopurinol 300 mg QD, followed by a switch to febuxostat 80 or 120 mg","Cost-effectiveness of febuxostat in chronic gout.","allopurinol alone","NE"
"2015-01-17758","2015","Haasis 2015 PLoS One","1400","Pneumococcal Conjugate Vaccines 13 VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- infants (universal coverage).","26131961","Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- infants (universal coverage).","Pneumococcal Conjugate Vaccines 13","Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.","None","NE"
"2015-01-17758","2015","Haasis 2015 PLoS One","1700","Pneumococcal Conjugate Vaccines 10 VERSUS Standard/Usual Care IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- infants (universal coverage).","26131961","Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- infants (universal coverage).","Pneumococcal Conjugate Vaccines 10","Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.","Standard/Usual Care","NE"
"2015-01-17758","2015","Haasis 2015 PLoS One","2200","Pneumococcal Conjugate Vaccines 13 VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).","26131961","Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).","Pneumococcal Conjugate Vaccines 13","Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.","None","NE"
"2015-01-17758","2015","Haasis 2015 PLoS One","2900","Pneumococcal Conjugate Vaccines 10 VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).","26131961","Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).","Pneumococcal Conjugate Vaccines 10","Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.","None","NE"
"2015-01-17758","2015","Haasis 2015 PLoS One","400","Pneumococcal Conjugate Vaccines 13 VERSUS Pneumococcal Conjugate Vaccines 10 IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (universal coverage).","26131961","Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (universal coverage).","Pneumococcal Conjugate Vaccines 13","Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.","Pneumococcal Conjugate Vaccines 10","NE"
"2015-01-17758","2015","Haasis 2015 PLoS One","610","Pneumococcal Conjugate Vaccines 13 VERSUS Pneumococcal Conjugate Vaccines 10 IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).","26131961","Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).","Pneumococcal Conjugate Vaccines 13","Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.","Pneumococcal Conjugate Vaccines 10","NE"
"2015-01-17555","2015","Guerrero 2015 BMC Public Health","Cost-Saving","Visual inspection with acetic acid (VIA) VERSUS Pap smear at 8 % coverage for women aged 35-55 years old at 5-year intervals IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Philippines.","26223975","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Philippines.","Visual inspection with acetic acid (VIA)","A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.","Pap smear at 8 % coverage for women aged 35-55 years old at 5-year intervals","SE"
"2018-01-27450","2018","Holko 2018 Pharmacoeconomics","18000","Adalimumab or vedolizumab (2nd line, after failure with infliximab) VERSUS Standard/Usual Care- Second-line adalimumab after failure of therapy with infliximab in the first line IN Specific disease- Crohn's Disease (moderate to severe); Age- Adult; Gender- Both; Country- Poland; Other- Not adequately treated with standard treatments.","29667146","Specific disease- Crohn's Disease (moderate to severe); Age- Adult; Gender- Both; Country- Poland; Other- Not adequately treated with standard treatments.","Adalimumab or vedolizumab (2nd line, after failure with infliximab)","Cost-Effectiveness Analysis of Crohn''s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-alpha Antagonist.","Standard/Usual Care- Second-line adalimumab after failure of therapy with infliximab in the first line","NE"
"2018-01-27450","2018","Holko 2018 Pharmacoeconomics","22000","Adalimumab or ustekinumab (2nd line, after failure with infliximab) VERSUS Standard/Usual Care- Second-line adalimumab after failure of therapy with infliximab in the first line IN Specific disease- Crohn's Disease (moderate to severe); Age- Adult; Gender- Both; Country- Poland; Other- Not adequately treated with standard treatments.","29667146","Specific disease- Crohn's Disease (moderate to severe); Age- Adult; Gender- Both; Country- Poland; Other- Not adequately treated with standard treatments.","Adalimumab or ustekinumab (2nd line, after failure with infliximab)","Cost-Effectiveness Analysis of Crohn''s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-alpha Antagonist.","Standard/Usual Care- Second-line adalimumab after failure of therapy with infliximab in the first line","NE"
"2018-01-27450","2018","Holko 2018 Pharmacoeconomics","Cost-Saving","Adalimumab or vedolizumab (2nd line, after failure with infliximab) VERSUS Standard/Usual Care- Adalimumab or ustekinumab in the second line after failure of therapy with infliximab, and each of the second-line treatments after another one in the third line IN Specific disease- Crohn's Disease (moderate to severe); Age- Adult; Gender- Both; Country- Poland; Other- Not adequately treated with standard treatments.","29667146","Specific disease- Crohn's Disease (moderate to severe); Age- Adult; Gender- Both; Country- Poland; Other- Not adequately treated with standard treatments.","Adalimumab or vedolizumab (2nd line, after failure with infliximab)","Cost-Effectiveness Analysis of Crohn''s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-alpha Antagonist.","Standard/Usual Care- Adalimumab or ustekinumab in the second line after failure of therapy with infliximab, and each of the second-line treatments after another one in the third line","SE"
"2018-01-25570","2018","Pelczarska 2018 Atherosclerosis","1200","Universal screening of 6-year olds, based on genetic diagnosis VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Poland.","29407882","Healthy; Age- 0 to 18 years; Gender- Both; Country- Poland.","Universal screening of 6-year olds, based on genetic diagnosis","The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.","None","NE"
"2018-01-25570","2018","Pelczarska 2018 Atherosclerosis","130","Opportunistic screening of people after first onset of acute coronary syndrome or stroke, age limit VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Poland.","29407882","Healthy; Age- 41 to 64 years; Gender- Both; Country- Poland.","Opportunistic screening of people after first onset of acute coronary syndrome or stroke, age limit","The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.","None","NE"
"2018-01-25570","2018","Pelczarska 2018 Atherosclerosis","1300","Opportunistic screening of people after first onset of acute coronary syndrome or stroke, any age VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Poland.","29407882","Healthy; Age- >=65 years; Gender- Both; Country- Poland.","Opportunistic screening of people after first onset of acute coronary syndrome or stroke, any age","The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.","None","NE"
"2018-01-25570","2018","Pelczarska 2018 Atherosclerosis","5700","Opportunistic screening of people after the first onset of acute coronary syndrome VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Poland.","29407882","Healthy; Age- >=65 years; Gender- Both; Country- Poland.","Opportunistic screening of people after the first onset of acute coronary syndrome","The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.","None","NE"
"2018-01-25570","2018","Pelczarska 2018 Atherosclerosis","610","Universal screening of people getting first job using clinical diagnosis only VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Both; Country- Poland.","29407882","Healthy; Age- 19 to 40 years; Gender- Both; Country- Poland.","Universal screening of people getting first job using clinical diagnosis only","The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.","None","NE"
"2018-01-25570","2018","Pelczarska 2018 Atherosclerosis","900","Opportunistic screening of people after the first onset of acute coronary syndrome (ACS-G-55/65) VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Poland.","29407882","Healthy; Age- 41 to 64 years; Gender- Both; Country- Poland.","Opportunistic screening of people after the first onset of acute coronary syndrome (ACS-G-55/65)","The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.","None","NE"
"2018-01-25570","2018","Pelczarska 2018 Atherosclerosis","910","Universal screening of people getting first job using clinical diagnosis and genetic diagnosis VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Both; Country- Poland.","29407882","Healthy; Age- 19 to 40 years; Gender- Both; Country- Poland.","Universal screening of people getting first job using clinical diagnosis and genetic diagnosis","The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.","None","NE"
"2016-01-22406","2016","Stawowczyk 2016 PLoS One","99000","Golimumab+standard care VERSUS Standard/Usual Care IN Specific disease- Ulcerative colitis(UC); Age- Adult; Gender- Both; Country- Poland.","27494322","Specific disease- Ulcerative colitis(UC); Age- Adult; Gender- Both; Country- Poland.","Golimumab+standard care","Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and  Standard Care Alone for Ulcerative Colitis in Poland.","Standard/Usual Care","NE"
"2016-01-22394","2016","Stawowczyk 2016 Eur J Clin Pharmacol","84000","Adalimumab + standard care VERSUS Standard/Usual Care IN Specific disease- Ulcerative Colitis; Age- Adult; Gender- Both; Country- Poland.","27497991","Specific disease- Ulcerative Colitis; Age- Adult; Gender- Both; Country- Poland.","Adalimumab + standard care","Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.","Standard/Usual Care","NE"
"2015-01-18575","2015","Snarski 2015 Acta Diabetol","60000","Autologous hematopoietic stem cell transplantation VERSUS Standard/Usual Care- Standard insulin therapy (daily dose of 0.69IU/kg) IN Specific disease- Type 1 diabetes; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Poland.","25744552","Specific disease- Type 1 diabetes; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Poland.","Autologous hematopoietic stem cell transplantation","An economic analysis of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of new onset type 1 diabetes.","Standard/Usual Care- Standard insulin therapy (daily dose of 0.69IU/kg)","NE"
"2015-01-18049","2015","Kawalec 2015 Kardiol Pol","Cost-Saving","Single-pill combinations (spcs) of indapamide and amlodipine VERSUS free combination therapy (FC) IN Specific disease- arterial hypertension; Age- Adult; Gender- Both; Country- Poland; Other- under hypertensive treatment.","25987296","Specific disease- arterial hypertension; Age- Adult; Gender- Both; Country- Poland; Other- under hypertensive treatment.","Single-pill combinations (spcs) of indapamide and amlodipine","Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting.","free combination therapy (FC)","SE"
"2014-01-16553","2014","Paweska 2014 Kardiol Pol","8900","Ticagrelor (180 mg/daily dose) VERSUS Clopidogrel (75 mg/daily dose) IN Specific disease- Acute coronary syndrome; Age- 41 to 64 years, >=65 years; Gender- Not Specified; Country- Poland; Other- with or without ST-segment elevation (STEMI and NSTEMI) or unstable angina (UA).","24846362","Specific disease- Acute coronary syndrome; Age- 41 to 64 years, >=65 years; Gender- Not Specified; Country- Poland; Other- with or without ST-segment elevation (STEMI and NSTEMI) or unstable angina (UA).","Ticagrelor (180 mg/daily dose)","Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.","Clopidogrel (75 mg/daily dose)","NE"
"2013-01-14765","2013","Kawalec 2013 Postepy Dermatol Alergol","24000","Ruconest VERSUS Placebo IN Specific disease- Angioedema; Age-; Gender- Both; Country- Poland.","24278067","Specific disease- Angioedema; Age-; Gender- Both; Country- Poland.","Ruconest","Cost-utility analysis of Ruconest((R)) (conestat alfa) compared to Berinert((R))  P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema.","Placebo","NE"
"2013-01-14765","2013","Kawalec 2013 Postepy Dermatol Alergol","43000","Berinert VERSUS Placebo IN Specific disease- Angioedema; Age-; Gender- Both; Country- Poland.","24278067","Specific disease- Angioedema; Age-; Gender- Both; Country- Poland.","Berinert","Cost-utility analysis of Ruconest((R)) (conestat alfa) compared to Berinert((R))  P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema.","Placebo","NE"
"2013-01-11752","2013","Sovic 2013 Kardiol Pol","20000","Comprehensive cardiovascular disease (CVD) primary prevention programme co-ordinated by specially trained nurses VERSUS Standard/Usual Care IN Specific disease- high-risk cardiovascular patients; Age- 41 to 64 years; Gender- Female; Country- Poland; Other- smokers.","23907903","Specific disease- high-risk cardiovascular patients; Age- 41 to 64 years; Gender- Female; Country- Poland; Other- smokers.","Comprehensive cardiovascular disease (CVD) primary prevention programme co-ordinated by specially trained nurses","Cost-effectiveness of a cardiovascular disease primary prevention programme in a  primary health care setting. Results of the Polish part of the EUROACTION project.","Standard/Usual Care","NE"
"2013-01-11752","2013","Sovic 2013 Kardiol Pol","30000","Comprehensive cardiovascular disease (CVD) primary prevention programme co-ordinated by specially trained nurses VERSUS Standard/Usual Care IN Specific disease- high-risk cardiovascular patients; Age- 41 to 64 years; Gender- Female; Country- Poland; Other- non-smokers.","23907903","Specific disease- high-risk cardiovascular patients; Age- 41 to 64 years; Gender- Female; Country- Poland; Other- non-smokers.","Comprehensive cardiovascular disease (CVD) primary prevention programme co-ordinated by specially trained nurses","Cost-effectiveness of a cardiovascular disease primary prevention programme in a  primary health care setting. Results of the Polish part of the EUROACTION project.","Standard/Usual Care","NE"
"2013-01-11752","2013","Sovic 2013 Kardiol Pol","4600","Comprehensive cardiovascular disease (CVD) primary prevention programme co-ordinated by specially trained nurses VERSUS Standard/Usual Care IN Specific disease- high-risk cardiovascular patients; Age- 41 to 64 years; Gender- Male; Country- Poland; Other- smokers.","23907903","Specific disease- high-risk cardiovascular patients; Age- 41 to 64 years; Gender- Male; Country- Poland; Other- smokers.","Comprehensive cardiovascular disease (CVD) primary prevention programme co-ordinated by specially trained nurses","Cost-effectiveness of a cardiovascular disease primary prevention programme in a  primary health care setting. Results of the Polish part of the EUROACTION project.","Standard/Usual Care","NE"
"2013-01-11752","2013","Sovic 2013 Kardiol Pol","7200","Comprehensive cardiovascular disease (CVD) primary prevention programme co-ordinated by specially trained nurses VERSUS Standard/Usual Care IN Specific disease- high-risk cardiovascular patients; Age- 41 to 64 years; Gender- Male; Country- Poland; Other- non-smokers.","23907903","Specific disease- high-risk cardiovascular patients; Age- 41 to 64 years; Gender- Male; Country- Poland; Other- non-smokers.","Comprehensive cardiovascular disease (CVD) primary prevention programme co-ordinated by specially trained nurses","Cost-effectiveness of a cardiovascular disease primary prevention programme in a  primary health care setting. Results of the Polish part of the EUROACTION project.","Standard/Usual Care","NE"
"2013-01-11688","2013","Schuetz                          2013 PLoS One","17000","A Standardized Vascular Disease Health Check, Italy VERSUS Standard/Usual Care IN Healthy; Age- Adult; Gender- Both; Country- Italy.","23869204","Healthy; Age- Adult; Gender- Both; Country- Italy.","A Standardized Vascular Disease Health Check, Italy","A standardized vascular disease health check in europe: a cost-effectiveness analysis.","Standard/Usual Care","NE"
"2013-01-11688","2013","Schuetz                          2013 PLoS One","180","A Standardized Vascular Disease Health Check, Germany VERSUS Standard/Usual Care IN Healthy; Age- Adult; Gender- Both; Country- Germany.","23869204","Healthy; Age- Adult; Gender- Both; Country- Germany.","A Standardized Vascular Disease Health Check, Germany","A standardized vascular disease health check in europe: a cost-effectiveness analysis.","Standard/Usual Care","NE"
"2013-01-11688","2013","Schuetz                          2013 PLoS One","18000","A Standardized Vascular Disease Health Check, Denmark VERSUS Placebo IN Healthy; Age- Adult; Gender- Both; Country- Denmark.","23869204","Healthy; Age- Adult; Gender- Both; Country- Denmark.","A Standardized Vascular Disease Health Check, Denmark","A standardized vascular disease health check in europe: a cost-effectiveness analysis.","Placebo","NE"
"2013-01-11688","2013","Schuetz                          2013 PLoS One","23000","A Standardized Vascular Disease Health Check, France VERSUS Standard/Usual Care IN Healthy; Age- Adult; Gender- Both; Country- France.","23869204","Healthy; Age- Adult; Gender- Both; Country- France.","A Standardized Vascular Disease Health Check, France","A standardized vascular disease health check in europe: a cost-effectiveness analysis.","Standard/Usual Care","NE"
"2013-01-11688","2013","Schuetz                          2013 PLoS One","3800","A Standardized Vascular Disease Health Check, United Kingdom VERSUS Standard/Usual Care IN Healthy; Age- Adult; Gender- Both; Country- United Kingdom.","23869204","Healthy; Age- Adult; Gender- Both; Country- United Kingdom.","A Standardized Vascular Disease Health Check, United Kingdom","A standardized vascular disease health check in europe: a cost-effectiveness analysis.","Standard/Usual Care","NE"
"2013-01-11688","2013","Schuetz                          2013 PLoS One","Cost-Saving","A Standardized Vascular Disease Health Check, Poland VERSUS Placebo IN Healthy; Age- Adult; Gender- Both; Country- Poland.","23869204","Healthy; Age- Adult; Gender- Both; Country- Poland.","A Standardized Vascular Disease Health Check, Poland","A standardized vascular disease health check in europe: a cost-effectiveness analysis.","Placebo","SE"
"2012-01-09962","2012","Grzesiowski 2012 Hum Vaccin Immunother","380","Pneumococcal vaccination program with pneumococcal polysaccharide vaccine covering 23 serotypes (PPV23) VERSUS None IN Individuals aged 65 and over at high risk of developing pneumococcal infections in Poland","23095867","Individuals aged 65 and over at high risk of developing pneumococcal infections in Poland","Pneumococcal vaccination program with pneumococcal polysaccharide vaccine covering 23 serotypes (PPV23)","Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.","None","NE"
"2012-01-09962","2012","Grzesiowski 2012 Hum Vaccin Immunother","910","Pneumococcal vaccination program with pneumococcal polysaccharide vaccine covering 23 serotypes (PPV23) VERSUS None IN Individuals aged 65 and over in Poland","23095867","Individuals aged 65 and over in Poland","Pneumococcal vaccination program with pneumococcal polysaccharide vaccine covering 23 serotypes (PPV23)","Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.","None","NE"
"2012-01-09916","2012","Morawski 2012 J Med Econ","27000","Pancreatic enzyme replacement therapy (PERT) with pancreatin minimicrospheres [MMS] VERSUS None IN Polish patients with pancreatic exocrine insufficiency due to chronic pancreatitis with stool fat excretion below 10g/day","23043594","Polish patients with pancreatic exocrine insufficiency due to chronic pancreatitis with stool fat excretion below 10g/day","Pancreatic enzyme replacement therapy (PERT) with pancreatin minimicrospheres [MMS]","Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis.","None","NE"
"2012-01-09916","2012","Morawski 2012 J Med Econ","9800","Pancreatic enzyme replacement therapy (PERT) with pancreatin minimicrospheres [MMS] VERSUS None IN Polish patients with pancreatic exocrine insufficiency due to chronic pancreatitis","23043594","Polish patients with pancreatic exocrine insufficiency due to chronic pancreatitis","Pancreatic enzyme replacement therapy (PERT) with pancreatin minimicrospheres [MMS]","Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis.","None","NE"
"2018-01-25856","2018","Areia 2018 United European Gastroenterol J","170000","Pepsinogens screening every two years VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- Patients with an intermediate gastric cancer risk.","29511549","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- Patients with an intermediate gastric cancer risk.","Pepsinogens screening every two years","Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk.","None","NE"
"2018-01-25856","2018","Areia 2018 United European Gastroenterol J","18000","Endoscopy combined with colonoscopy every 10 years VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- Patients with an intermediate gastric cancer risk.","29511549","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- Patients with an intermediate gastric cancer risk.","Endoscopy combined with colonoscopy every 10 years","Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk.","None","NE"
"2018-01-25856","2018","Areia 2018 United European Gastroenterol J","36000","Endoscopy combined with colonoscopy every five years VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- Patients with an intermediate gastric cancer risk.","29511549","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- Patients with an intermediate gastric cancer risk.","Endoscopy combined with colonoscopy every five years","Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk.","None","NE"
"2018-01-25856","2018","Areia 2018 United European Gastroenterol J","82000","Stand-alone endoscopic screening every five years VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- Patients with an intermediate gastric cancer risk.","29511549","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- Patients with an intermediate gastric cancer risk.","Stand-alone endoscopic screening every five years","Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk.","None","NE"
"2018-01-25589","2018","Stollenwerk 2018 Pharmacoeconomics","2100","Etecalcetide VERSUS Cinacalcet IN Specific disease- Secondary hyperparathyroidism; Age- Adult; Gender- Both; Country- Italy, Spain, Portugal, Switzerland, Czech Republic; Other- Hemodialysis patients.","29392552","Specific disease- Secondary hyperparathyroidism; Age- Adult; Gender- Both; Country- Italy, Spain, Portugal, Switzerland, Czech Republic; Other- Hemodialysis patients.","Etecalcetide","A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.","Cinacalcet","NE"
"2017-01-24562","2017","Miguel 2017 Value Health","55000","Pembrolizumab VERSUS Standard/Usual Care- Ipilimumab (3 mg/kg every 3 weeks, with a maximum of four cycles) IN Specific disease- Advanced Melanoma; Age- Adult; Gender- Both; Country- Portugal; Other- Patients who were in first line treatment (65.8% were treatment-naÃ¯ve)but also patients in second line (34.2% had received one previous treatment, mainly BRAF or/and MEK inhibitors)..","28964438","Specific disease- Advanced Melanoma; Age- Adult; Gender- Both; Country- Portugal; Other- Patients who were in first line treatment (65.8% were treatment-naÃ¯ve)but also patients in second line (34.2% had received one previous treatment, mainly BRAF or/and MEK inhibitors)..","Pembrolizumab","Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.","Standard/Usual Care- Ipilimumab (3 mg/kg every 3 weeks, with a maximum of four cycles)","NE"
"2017-01-23503","2017","Paquete 2017 Appl Health Econ Health Policy","21000","Obinutuzumab and chlorambucil (GClb) VERSUS Rituximab and chlorambucil (RClb) IN Specific disease- Chronic Lymphocytic Leukaemia (CLL); Age- Adult; Gender- Both; Country- Portugal; Other- Previously Untreated Chronic Lymphocytic Leukaemia.","28342061","Specific disease- Chronic Lymphocytic Leukaemia (CLL); Age- Adult; Gender- Both; Country- Portugal; Other- Previously Untreated Chronic Lymphocytic Leukaemia.","Obinutuzumab and chlorambucil (GClb)","Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.","Rituximab and chlorambucil (RClb)","NE"
"2017-01-23503","2017","Paquete 2017 Appl Health Econ Health Policy","24000","Obinutuzumab and chlorambucil (GClb) VERSUS Chlorambucil IN Specific disease- Chronic Lymphocytic Leukaemia; Age- Adult; Gender- Both; Country- Portugal; Other- Patients with CD20-positive previously untreated Chronic Lymphocytic Leukaemia.","28342061","Specific disease- Chronic Lymphocytic Leukaemia; Age- Adult; Gender- Both; Country- Portugal; Other- Patients with CD20-positive previously untreated Chronic Lymphocytic Leukaemia.","Obinutuzumab and chlorambucil (GClb)","Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.","Chlorambucil","NE"
"2017-01-23503","2017","Paquete 2017 Appl Health Econ Health Policy","30000","Rituximab and chlorambucil (RClb) VERSUS Chlorambucil (Clb) IN Specific disease- Chronic Lymphocytic Leukaemia (CLL); Age- Adult; Gender- Both; Country- Portugal; Other- Patients with CD20-positive previously untreated Chronic Lymphocytic Leukaemia.","28342061","Specific disease- Chronic Lymphocytic Leukaemia (CLL); Age- Adult; Gender- Both; Country- Portugal; Other- Patients with CD20-positive previously untreated Chronic Lymphocytic Leukaemia.","Rituximab and chlorambucil (RClb)","Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.","Chlorambucil (Clb)","NE"
"2016-01-19980","2016","Silva Miguel 2016 Rev Port Cardiol","Cost-Saving","treatment with Dabigatran VERSUS treatment with Rivaroxaban IN Specific disease- atrial fibrillation (AF); Age-; Gender- Both; Country- .","26928016","Specific disease- atrial fibrillation (AF); Age-; Gender- Both; Country- .","treatment with Dabigatran","Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation.","treatment with Rivaroxaban","SE"
"2016-01-19567","2016","Einarson 2016 J Med Econ","19000","Paliperidone palmitate long acting injectable (PP-LAI) VERSUS haloperidol  long acting injectable (HAL-LAI) IN Specific disease- Chronic Schizophrenia; Age- Unknown; Gender- Both; Country- Portugal.","27124697","Specific disease- Chronic Schizophrenia; Age- Unknown; Gender- Both; Country- Portugal.","Paliperidone palmitate long acting injectable (PP-LAI)","Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.","haloperidol  long acting injectable (HAL-LAI)","NE"
"2016-01-19567","2016","Einarson 2016 J Med Econ","20000","Paliperidone palmitate long acting injectable (PP-LAI) VERSUS oral-olanzapine (OLZ) IN Specific disease- Chronic Schizophrenia; Age- Unknown; Gender- Both; Country- Portugal.","27124697","Specific disease- Chronic Schizophrenia; Age- Unknown; Gender- Both; Country- Portugal.","Paliperidone palmitate long acting injectable (PP-LAI)","Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.","oral-olanzapine (OLZ)","NE"
"2016-01-19567","2016","Einarson 2016 J Med Econ","Cost-Saving","Paliperidone palmitate long acting injectable (PP-LAI) VERSUS risperidone microspheres long acting injectable (RIS-LAI) IN Specific disease- Chronic Schizophrenia; Age- Unknown; Gender- Both; Country- Portugal.","27124697","Specific disease- Chronic Schizophrenia; Age- Unknown; Gender- Both; Country- Portugal.","Paliperidone palmitate long acting injectable (PP-LAI)","Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.","risperidone microspheres long acting injectable (RIS-LAI)","SE"
"2015-01-18648","2015","Esteves 2015 Neurosurgery","13000","5-aminolevulinic acid (5-ALA) fluorescence-guided neuro-surgery VERSUS White-light surgery IN Specific disease- High-grade gliomas; Age- Adult; Gender- Both; Country- Portugal; Other- Newly diagnosed high-grade (grade III/IV) giloma eligible for surgical resection and adjuvant therapy.","25714513","Specific disease- High-grade gliomas; Age- Adult; Gender- Both; Country- Portugal; Other- Newly diagnosed high-grade (grade III/IV) giloma eligible for surgical resection and adjuvant therapy.","5-aminolevulinic acid (5-ALA) fluorescence-guided neuro-surgery","A pilot cost-effectiveness analysis of treatments in newly diagnosed high-grade gliomas: the example of 5-aminolevulinic Acid compared with white-light surgery.","White-light surgery","NE"
"2015-01-18474","2015","Laires 2015 J Med Econ","24000","Atorvastatin 10 mg or 20 mg + Ezetimibe 10 mg VERSUS Rosuvastatin 10 mg or 20 mg IN Specific disease- Coronary heart disease and/or diabetes; Age- Adult; Gender- Both; Country- Portugal.","25788039","Specific disease- Coronary heart disease and/or diabetes; Age- Adult; Gender- Both; Country- Portugal.","Atorvastatin 10 mg or 20 mg + Ezetimibe 10 mg","Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.","Rosuvastatin 10 mg or 20 mg","NE"
"2014-01-16777","2014","Viriato 2014 J Med Econ","13000","Metformin + vildagliptin VERSUS metformin + sulphonylurea IN Specific disease- diabetes type 2; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal.","24708176","Specific disease- diabetes type 2; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal.","Metformin + vildagliptin","Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.","metformin + sulphonylurea","NE"
"2014-01-16003","2014","Areia 2014 Helicobacter","26000","Endoscopic Surveillance every 3 years/3-yearly VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal.","25164596","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal.","Endoscopic Surveillance every 3 years/3-yearly","Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions.","None","NE"
"2014-01-16003","2014","Areia 2014 Helicobacter","Dominated","Endoscopic Surveillance every 10 years/10-yearly VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal.","25164596","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal.","Endoscopic Surveillance every 10 years/10-yearly","Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions.","None","NW"
"2014-01-16003","2014","Areia 2014 Helicobacter","Dominated","Endoscopic Surveillance every 5 years/5-yearly VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal.","25164596","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Portugal.","Endoscopic Surveillance every 5 years/5-yearly","Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions.","None","NW"
"2014-01-15927","2014","Morais 2014 Rev Port Cardiol","6100","Rivaroxaban VERSUS Treating non-valvular atrial fibrillation patients for stroke prevention with warfarin IN Specific disease- Atrial fibrillation; Age- >=65 years; Gender- Not Specified; Country- Portugal.","25241380","Specific disease- Atrial fibrillation; Age- >=65 years; Gender- Not Specified; Country- Portugal.","Rivaroxaban","Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting.","Treating non-valvular atrial fibrillation patients for stroke prevention with warfarin","NE"
"2014-01-15554","2014","Santos 2014 Acta Med Port","Cost-Saving","Rivaroxaban VERSUS Standard/Usual Care- Enoxaparin/warfarin IN Specific disease- Deep Vein thrombolism; Age- 41 to 64 years; Gender- Not Specified; Country- Portugal.","25409218","Specific disease- Deep Vein thrombolism; Age- 41 to 64 years; Gender- Not Specified; Country- Portugal.","Rivaroxaban","Economic analysis of rivaroxaban for the treatment and long-term prevention of venous thromboembolism in Portugal.","Standard/Usual Care- Enoxaparin/warfarin","SE"
"2014-01-15554","2014","Santos 2014 Acta Med Port","Cost-Saving","Rivaroxaban VERSUS Standard/Usual Care- Enoxaparin/warfarin IN Specific disease- Pulmonary embolism (PE); Age- 41 to 64 years; Gender- Not Specified; Country- Portugal.","25409218","Specific disease- Pulmonary embolism (PE); Age- 41 to 64 years; Gender- Not Specified; Country- Portugal.","Rivaroxaban","Economic analysis of rivaroxaban for the treatment and long-term prevention of venous thromboembolism in Portugal.","Standard/Usual Care- Enoxaparin/warfarin","SE"
"2014-01-15282","2014","Gouveia 2014 Rev Port Cardiol","8400","Ticagrelor VERSUS Clopidogrel (loading dose, 75 mg daily thereafter) IN Specific disease- Acute coronary syndrome with or without ST-segment elevation; Age- Adult; Gender- Both; Country- Portugal.","25528973","Specific disease- Acute coronary syndrome with or without ST-segment elevation; Age- Adult; Gender- Both; Country- Portugal.","Ticagrelor","Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes.","Clopidogrel (loading dose, 75 mg daily thereafter)","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","38000","One-Time HIV screening VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Men who have sex with men.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Men who have sex with men.","One-Time HIV screening","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","38000","One-Time HIV screening, with secondary transmission VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","One-Time HIV screening, with secondary transmission","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","38000","One-Time HIV screening, without secondary transmission VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","One-Time HIV screening, without secondary transmission","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","39000","One-Time HIV screening VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Injection drug users.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Injection drug users.","One-Time HIV screening","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","43000","HIV screening every 3 years, with secondary transmission VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","HIV screening every 3 years, with secondary transmission","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","43000","HIV screening every 3 years, without secondary transmission VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","HIV screening every 3 years, without secondary transmission","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","45000","Annual HIV screening, with secondary transmission VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","Annual HIV screening, with secondary transmission","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","45000","Annual HIV screening, without accounting for secondary transmission VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- national population.","Annual HIV screening, without accounting for secondary transmission","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","45000","HIV screening Every Three Years VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Injection drug users.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Injection drug users.","HIV screening Every Three Years","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","45000","HIV screening Every Three Years VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Men who have sex with men.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Men who have sex with men.","HIV screening Every Three Years","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","46000","Annual HIV screening VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Men who have sex with men.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Men who have sex with men.","Annual HIV screening","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-14931","2013","Yazdanpanah 2013 PLoS One","47000","Annual HIV screening VERSUS Current practice of targeted and on-demand HIV screening IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Injection drug users.","24367639","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal; Other- High Risk Groups- Injection drug users.","Annual HIV screening","Routine HIV screening in Portugal: clinical impact and cost-effectiveness.","Current practice of targeted and on-demand HIV screening","NE"
"2013-01-11761","2013","Mendonca 2013 Eur J Health Econ","120000","Lung transplant VERSUS Waiting list IN Specific disease- Idiopathic pulmonary fibrosis, chronic pulmonary obstructive disease, and cystic fibrosis; Age- Unknown; Gender- Both; Country- Portugal.","23913127","Specific disease- Idiopathic pulmonary fibrosis, chronic pulmonary obstructive disease, and cystic fibrosis; Age- Unknown; Gender- Both; Country- Portugal.","Lung transplant","Cost-effectiveness of lung transplantation and its evolution: the Portuguese case.","Waiting list","NE"
"2013-01-11721","2013","Silva Miguel 2013 Rev Port Cardiol","12000","Dabigatran VERSUS combination of warfarin, aspirin and no treatment IN Specific disease- non-valvular atrial fibrillation; Age- >=65 years; Gender- Both; Country- Portugal.","23890991","Specific disease- non-valvular atrial fibrillation; Age- >=65 years; Gender- Both; Country- Portugal.","Dabigatran","Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation.","combination of warfarin, aspirin and no treatment","NE"
"2013-01-11721","2013","Silva Miguel 2013 Rev Port Cardiol","13000","Dabigatran VERSUS combination of warfarin, aspirin and no treatment IN Specific disease- non-valvular atrial fibrillation; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal.","23890991","Specific disease- non-valvular atrial fibrillation; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Portugal.","Dabigatran","Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation.","combination of warfarin, aspirin and no treatment","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","16000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with sustained-release (SR) morphine IN Individuals with chronic, nonmalignant pain in Denmark","21957828","Individuals with chronic, nonmalignant pain in Denmark","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with sustained-release (SR) morphine","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","17000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with sustained-release (SR) morphine IN Individuals with chronic, malignant pain in Germany","21957828","Individuals with chronic, malignant pain in Germany","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with sustained-release (SR) morphine","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","17000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with sustained-release (SR) morphine IN Individuals with chronic, nonmalignant pain in Germany","21957828","Individuals with chronic, nonmalignant pain in Germany","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with sustained-release (SR) morphine","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","1800","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with bid hydromorphone IN Individuals with chronic, nonmalignant pain in Denmark","21957828","Individuals with chronic, nonmalignant pain in Denmark","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with bid hydromorphone","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","18000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with extended-release (ER) oxycodone IN Individuals with chronic, malignant pain in Italy","21957828","Individuals with chronic, malignant pain in Italy","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with extended-release (ER) oxycodone","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","18000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with sustained-release (SR) morphine IN Individuals with chronic, nonmalignant pain in Italy","21957828","Individuals with chronic, nonmalignant pain in Italy","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with sustained-release (SR) morphine","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","2000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with extended-release (ER) oxycodone IN Individuals with chronic, nonmalignant pain in Germany","21957828","Individuals with chronic, nonmalignant pain in Germany","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with extended-release (ER) oxycodone","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","21000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with sustained-release (SR) morphine IN Individuals with chronic, malignant pain in Slovakia","21957828","Individuals with chronic, malignant pain in Slovakia","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with sustained-release (SR) morphine","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","23000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with sustained-release (SR) morphine IN Individuals with chronic, malignant pain in Denmark","21957828","Individuals with chronic, malignant pain in Denmark","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with sustained-release (SR) morphine","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","2400","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with extended-release (ER) oxycodone IN Individuals with chronic, malignant pain in Denmark","21957828","Individuals with chronic, malignant pain in Denmark","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with extended-release (ER) oxycodone","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","3100","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with extended-release (ER) oxycodone IN Individuals with chronic, nonmalignant pain in Denmark","21957828","Individuals with chronic, nonmalignant pain in Denmark","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with extended-release (ER) oxycodone","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","37000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with sustained-release (SR) morphine IN Individuals with chronic, malignant pain in Portugal","21957828","Individuals with chronic, malignant pain in Portugal","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with sustained-release (SR) morphine","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","9400","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with extended-release (ER) oxycodone IN Individuals with chronic, nonmalignant pain in Slovakia","21957828","Individuals with chronic, nonmalignant pain in Slovakia","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with extended-release (ER) oxycodone","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","Cost-Saving","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with bid (twice daily) hydromorphone IN Individuals with chronic, nonmalignant pain in Germany","21957828","Individuals with chronic, nonmalignant pain in Germany","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with bid (twice daily) hydromorphone","SE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","Cost-Saving","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with bid hydromorphone IN Individuals with chronic, malignant pain in Denmark","21957828","Individuals with chronic, malignant pain in Denmark","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with bid hydromorphone","SE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","Cost-Saving","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with bid hydromorphone IN Individuals with chronic, malignant pain in Germany","21957828","Individuals with chronic, malignant pain in Germany","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with bid hydromorphone","SE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","Cost-Saving","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with bid hydromorphone IN Individuals with chronic, malignant pain in Slovakia","21957828","Individuals with chronic, malignant pain in Slovakia","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with bid hydromorphone","SE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","Cost-Saving","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with bid hydromorphone IN Individuals with chronic, nonmalignant pain in Slovakia","21957828","Individuals with chronic, nonmalignant pain in Slovakia","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with bid hydromorphone","SE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","Cost-Saving","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with extended-release (ER) oxycodone IN Individuals with chronic, malignant pain in Germany","21957828","Individuals with chronic, malignant pain in Germany","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with extended-release (ER) oxycodone","SE"
"2011-01-07800","2011","Wilson 2011 Eur J Cardiovasc Prev Rehabil","7900","Varenicline plus counselling VERSUS Placebo plus counselling IN Smokers aged 35 years or older with stable cardiovascular disease in Spain: healthcare perspective","21840967","Smokers aged 35 years or older with stable cardiovascular disease in Spain: healthcare perspective","Varenicline plus counselling","An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.","Placebo plus counselling","NE"
"2017-01-25818","2017","Ortiz 2017 PLoS One","2100","Female and Male 11Â±15 years vaccination scenario:80%F/60%M VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United States of America (USA).","29190725","Healthy; Age- 0 to 18 years; Gender- Both; Country- United States of America (USA).","Female and Male 11Â±15 years vaccination scenario:80%F/60%M","Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico.","None","NE"
"2017-01-25818","2017","Ortiz 2017 PLoS One","3700","Female and Male 11Â±15 years vaccination scenario:50%F/40%M VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United States of America (USA).","29190725","Healthy; Age- 0 to 18 years; Gender- Both; Country- United States of America (USA).","Female and Male 11Â±15 years vaccination scenario:50%F/40%M","Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico.","None","NE"
"2017-01-25818","2017","Ortiz 2017 PLoS One","4900","Female and Male 11-15 years vaccination scenario: 34% F/13% M VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United States of America (USA).","29190725","Healthy; Age- 0 to 18 years; Gender- Both; Country- United States of America (USA).","Female and Male 11-15 years vaccination scenario: 34% F/13% M","Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico.","None","NE"
"2017-01-24667","2017","Martes-Martinez 2017 P R Health Sci J","160000","Pharmacogenetic-guided dosing of warfarin VERSUS Standard/Usual Care- Standard care IN Specific disease- Thromboembolic event; Age- Unknown; Gender- Both; Country- United States of America (USA); Other- Puerto Rican population, VKORC1 BB.","28915306","Specific disease- Thromboembolic event; Age- Unknown; Gender- Both; Country- United States of America (USA); Other- Puerto Rican population, VKORC1 BB.","Pharmacogenetic-guided dosing of warfarin","Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.","Standard/Usual Care- Standard care","NE"
"2018-01-28911","2018","Kim 2018 Pharmacoeconomics"," ","Quadrivalent Influenza Vaccines VERSUS Trivalent Influenza Vaccines IN Healthy; Age- 0 to 18 years; Gender- Both; Country- South Korea.","30251078","Healthy; Age- 0 to 18 years; Gender- Both; Country- South Korea.","Quadrivalent Influenza Vaccines","Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.","Trivalent Influenza Vaccines","NE"
"2018-01-28911","2018","Kim 2018 Pharmacoeconomics","Cost-Saving","Quadrivalent Influenza Vaccine VERSUS Trivalent Influenza Vaccine IN Healthy; Age- >=65 years; Gender- Both; Country- South Korea.","30251078","Healthy; Age- >=65 years; Gender- Both; Country- South Korea.","Quadrivalent Influenza Vaccine","Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.","Trivalent Influenza Vaccine","SE"
"2018-01-28911","2018","Kim 2018 Pharmacoeconomics","Cost-Saving","Quadrivalent Influenza Vaccine VERSUS Trivalent Influenza Vaccine IN Healthy; Age- 0 to 18 years; Gender- Both; Country- South Korea.","30251078","Healthy; Age- 0 to 18 years; Gender- Both; Country- South Korea.","Quadrivalent Influenza Vaccine","Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.","Trivalent Influenza Vaccine","SE"
"2018-01-28651","2018","Kim 2018 Hepatology","25000","Magnetic Resonance Imaging surveillance for hepatocellular carcinoma, 3% incidence VERSUS Ultrasonography surveillance for hepatocellular carcinoma IN Specific disease- Cirrhosis; Age- 41 to 64 years; Gender- Both; Country- South Korea.","30365164","Specific disease- Cirrhosis; Age- 41 to 64 years; Gender- Both; Country- South Korea.","Magnetic Resonance Imaging surveillance for hepatocellular carcinoma, 3% incidence","Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis.","Ultrasonography surveillance for hepatocellular carcinoma","NE"
"2018-01-28622","2018","Ho 2018 PLoS One","13000","Systematic examination for age-related macular degeneration VERSUS Systematic photography screening for age-related macular degeneration IN Healthy; Age- 19 to 40 years; Gender- Both; Country- South Korea.","30379971","Healthy; Age- 19 to 40 years; Gender- Both; Country- South Korea.","Systematic examination for age-related macular degeneration","The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea.","Systematic photography screening for age-related macular degeneration","NE"
"2018-01-28622","2018","Ho 2018 PLoS One","3000","Systematic photography screening for age-related macular degeneration VERSUS Opportunistic treatment for age-related macular degeneration IN Healthy; Age- 19 to 40 years; Gender- Both; Country- South Korea.","30379971","Healthy; Age- 19 to 40 years; Gender- Both; Country- South Korea.","Systematic photography screening for age-related macular degeneration","The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea.","Opportunistic treatment for age-related macular degeneration","NE"
"2018-01-28622","2018","Ho 2018 PLoS One","3400","Opportunistic treatment for age-related macular degeneration VERSUS No screening for age-related macular degeneration IN Healthy; Age- 19 to 40 years; Gender- Both; Country- South Korea.","30379971","Healthy; Age- 19 to 40 years; Gender- Both; Country- South Korea.","Opportunistic treatment for age-related macular degeneration","The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea.","No screening for age-related macular degeneration","NE"
"2018-01-28622","2018","Ho 2018 PLoS One","Dominated","Opportunistic examination for age-related macular degeneration VERSUS Systematic photography for age-related macular degeneration IN Healthy; Age- 19 to 40 years; Gender- Both; Country- South Korea.","30379971","Healthy; Age- 19 to 40 years; Gender- Both; Country- South Korea.","Opportunistic examination for age-related macular degeneration","The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea.","Systematic photography for age-related macular degeneration","NW"
"2018-01-26878","2018","Choi 2018 Hum Vaccin Immunother","1500","13-valent pneumococcal conjugate vaccine VERSUS Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccine IN Healthy; Age- >=65 years; Gender- Both; Country- South Korea; Other- Total population.","29953307","Healthy; Age- >=65 years; Gender- Both; Country- South Korea; Other- Total population.","13-valent pneumococcal conjugate vaccine","Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.","Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccine","NE"
"2018-01-26878","2018","Choi 2018 Hum Vaccin Immunother","1800","13-valent pneumococcal conjugate vaccine VERSUS Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccine IN Healthy; Age- >=65 years; Gender- Both; Country- South Korea; Other- Moderate & high-risk patients with one or more conditions.","29953307","Healthy; Age- >=65 years; Gender- Both; Country- South Korea; Other- Moderate & high-risk patients with one or more conditions.","13-valent pneumococcal conjugate vaccine","Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.","Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccine","NE"
"2018-01-26878","2018","Choi 2018 Hum Vaccin Immunother","3500","13-valent pneumococcal conjugate vaccine + 23-valent pneumococcal polysaccharide vaccine VERSUS Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccine monotherapy IN Healthy; Age- >=65 years; Gender- Both; Country- South Korea; Other- Total population (all risk groups).","29953307","Healthy; Age- >=65 years; Gender- Both; Country- South Korea; Other- Total population (all risk groups).","13-valent pneumococcal conjugate vaccine + 23-valent pneumococcal polysaccharide vaccine","Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.","Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccine monotherapy","NE"
"2018-01-26878","2018","Choi 2018 Hum Vaccin Immunother","3600","13-valent pneumococcal conjugate vaccine + 23-valent pneumococcal polysaccharide vaccine VERSUS Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccine IN Healthy; Age- >=65 years; Gender- Both; Country- South Korea; Other- Moderate & high-risk patients with one or more conditions.","29953307","Healthy; Age- >=65 years; Gender- Both; Country- South Korea; Other- Moderate & high-risk patients with one or more conditions.","13-valent pneumococcal conjugate vaccine + 23-valent pneumococcal polysaccharide vaccine","Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.","Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccine","NE"
"2018-01-26878","2018","Choi 2018 Hum Vaccin Immunother","3800","13-valent pneumococcal conjugate vaccine + 23-valent pneumococcal polysaccharide vaccine VERSUS Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccine IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Korea; Other- Moderate & high-risk patients with one or more conditions.","29953307","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Korea; Other- Moderate & high-risk patients with one or more conditions.","13-valent pneumococcal conjugate vaccine + 23-valent pneumococcal polysaccharide vaccine","Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.","Standard/Usual Care- 23-valent pneumococcal polysaccharide vaccine","NE"
"2018-01-26878","2018","Choi 2018 Hum Vaccin Immunother","7000","13-valent pneumococcal conjugate vaccine + 23-valent pneumococcal polysaccharide vaccine VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Korea; Other- Moderate & high-risk patients with one or more conditions.","29953307","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Korea; Other- Moderate & high-risk patients with one or more conditions.","13-valent pneumococcal conjugate vaccine + 23-valent pneumococcal polysaccharide vaccine","Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.","None","NE"
"2018-01-26789","2018","Kim 2018 Liver Int","7600","Hepatitis C screening VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29998565","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Hepatitis C screening","Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.","Standard/Usual Care","NE"
"2018-01-26789","2018","Kim 2018 Liver Int","7900","Hepatitis C screening VERSUS Standard/Usual Care IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29998565","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Hepatitis C screening","Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.","Standard/Usual Care","NE"
"2018-01-26789","2018","Kim 2018 Liver Int","7900","Hepatitis C screening VERSUS Standard/Usual Care IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Korea.","29998565","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Korea.","Hepatitis C screening","Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.","Standard/Usual Care","NE"
"2018-01-26789","2018","Kim 2018 Liver Int","8200","Hepatitis C screening VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29998565","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Hepatitis C screening","Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.","Standard/Usual Care","NE"
"2018-01-26648","2018","Lee 2018 Eur Heart J Cardiovasc Imaging","56000","Myocardial single photon emission computed tomography (SPECT) VERSUS Coronary computed tomography angiography (CCTA) IN Specific disease- Intermediate-risk chest pain; Age- Adult; Gender- Both; Country- South Korea.","30052964","Specific disease- Intermediate-risk chest pain; Age- Adult; Gender- Both; Country- South Korea.","Myocardial single photon emission computed tomography (SPECT)","Coronary computed tomography angiography vs. myocardial single photon emission computed tomography in patients with intermediate risk chest pain: a randomized clinical trial for cost-effectiveness comparison based on real-world cost.","Coronary computed tomography angiography (CCTA)","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","100000","Chronic kidney disease screen starting at age 40 VERSUS Chronic kidney disease screen starting at age 50 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen starting at age 40","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","Chronic kidney disease screen starting at age 50","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","190000","Chronic kidney disease screen starting at age 30 VERSUS Standard/Usual Care- Chronic kidney disease screen starting at age 40 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen starting at age 30","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","Standard/Usual Care- Chronic kidney disease screen starting at age 40","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","40000","Chronic kidney disease screen only  VERSUS None IN Specific disease- Diabetes; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Specific disease- Diabetes; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen only","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","None","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","43000","Chronic kidney disease screen  VERSUS None IN Specific disease- Hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Specific disease- Hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","None","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","450000","Chronic kidney disease screen starting at age 20 VERSUS Chronic kidney disease screen starting at age 30 IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen starting at age 20","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","Chronic kidney disease screen starting at age 30","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","55000","Chronic kidney disease screen, concession age at 60 VERSUS Chronic kidney disease screen, concession age at 70 IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen, concession age at 60","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","Chronic kidney disease screen, concession age at 70","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","62000","Chronic kidney disease screen, concession age at 70 VERSUS Chronic kidney disease screen, concession age at 80 IN Healthy; Age- >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen, concession age at 70","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","Chronic kidney disease screen, concession age at 80","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","65000","Chronic kidney disease screen starting at age 50 VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen starting at age 50","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","None","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","68000","Chronic kidney disease screen with Dipstick VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen with Dipstick","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","None","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","69000","Chronic kidney disease screen every 3 years VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen every 3 years","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","None","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","69000","Chronic kidney disease screen with estimated glomerular filtration rate VERSUS  Chronic kidney disease screen with Dipstick IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen with estimated glomerular filtration rate","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","Chronic kidney disease screen with Dipstick","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","70000","Chronic kidney disease screen, current screening strategy VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen, current screening strategy","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","None","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","70000","Chronic kidney disease screen, no concession age VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen, no concession age","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","None","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","75000","Chronic kidney disease screen every 2 years VERSUS  Chronic kidney disease screen every 3 years IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen every 2 years","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","Chronic kidney disease screen every 3 years","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","80000","Chronic kidney disease screen every 1 year VERSUS Standard/Usual Care-  Chronic kidney disease screen every 2 years IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen every 1 year","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","Standard/Usual Care-  Chronic kidney disease screen every 2 years","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","80000","Chronic kidney disease screen, concession age at 80 VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen, concession age at 80","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","None","NE"
"2017-01-25795","2017","Go 2017 Nephrology (Carlton)","91000","Chronic kidney disease screen with Dipstick and estimated glomerular filtration rate VERSUS  Chronic kidney disease screen with  estimated glomerular filtration rate IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","29206319","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea.","Chronic kidney disease screen with Dipstick and estimated glomerular filtration rate","Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea.","Chronic kidney disease screen with  estimated glomerular filtration rate","NE"
"2017-01-25170","2017","Moon 2017 Medicine (Baltimore)","40000","Deep brain stimulation VERSUS Standard/Usual Care- Treatment as usual IN Specific disease- Treatment-resistant obsessive compulsive disorder; Age- 19 to 40 years; Gender- Both; Country- South Korea.","28682894","Specific disease- Treatment-resistant obsessive compulsive disorder; Age- 19 to 40 years; Gender- Both; Country- South Korea.","Deep brain stimulation","The cost-effectiveness of deep brain stimulation for patients with treatment-resistant obsessive-compulsive disorder.","Standard/Usual Care- Treatment as usual","NE"
"2017-01-24353","2017","Jeong 2017 Brain Behav","Cost-Saving","<= 6 -hr onset to recanalization  VERSUS No recanalization  IN Specific disease- Acute ischemic stroke; Age- Adult; Gender- Both; Country- South Korea.","29075576","Specific disease- Acute ischemic stroke; Age- Adult; Gender- Both; Country- South Korea.","<= 6 -hr onset to recanalization","Cost benefits of rapid recanalization using intraarterial thrombectomy.","No recanalization","SE"
"2017-01-24353","2017","Jeong 2017 Brain Behav","Cost-Saving","<= 6 hr recanalization VERSUS > 6 hr recanalization IN Specific disease- Acute ischemic stroke; Age- Adult; Gender- Both; Country- South Korea.","29075576","Specific disease- Acute ischemic stroke; Age- Adult; Gender- Both; Country- South Korea.","<= 6 hr recanalization","Cost benefits of rapid recanalization using intraarterial thrombectomy.","> 6 hr recanalization","SE"
"2017-01-24353","2017","Jeong 2017 Brain Behav","Cost-Saving","> 6 -hr onset to recanalization  VERSUS No recanalization IN Specific disease- Acute ischemic stroke; Age- Adult; Gender- Both; Country- South Korea.","29075576","Specific disease- Acute ischemic stroke; Age- Adult; Gender- Both; Country- South Korea.","> 6 -hr onset to recanalization","Cost benefits of rapid recanalization using intraarterial thrombectomy.","No recanalization","SE"
"2016-01-21852","2016","Park 2016 Clin Ther","13000","Etanercept sequence VERSUS Leflunomide followed by etanercept IN Specific disease- Rheumatoid arthritis; Age- Adult; Gender- Both; Country- South Korea.","27771177","Specific disease- Rheumatoid arthritis; Age- Adult; Gender- Both; Country- South Korea.","Etanercept sequence","Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea.","Leflunomide followed by etanercept","NE"
"2016-01-21852","2016","Park 2016 Clin Ther","8600","Etanercept sequence VERSUS Leflunomide sequence IN Specific disease- Rheumatoid arthritis; Age- Adult; Gender- Both; Country- South Korea.","27771177","Specific disease- Rheumatoid arthritis; Age- Adult; Gender- Both; Country- South Korea.","Etanercept sequence","Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea.","Leflunomide sequence","NE"
"2016-01-20739","2016","Lee 2016 Gynecol Oncol","14000","Treatment with an MRI-based triage strategy where all patients underwent pelvic MRI, and the primary treatment modality was recommended according to these results. Low-risk groups underwent primary radical surgery followed by tailored adjuvant therapy based on final pathology, and high-risk patients underwent primary chemoradiation. VERSUS Treatment with priimary surgery (radical hyterectomy and pelvic lymphadenectomy). Patients with at least one high risk factor received postoperative chemoradiation, patients with at least 2 mor more intermediate risk factors received adjuvent radiotherapy. IN Specific disease- Stage IB Cervical Cancer; Age- Adult; Gender- Female; Country- South Korea; Other- Diagnosed and clinically staged by a gyneocologic oncologist using patient history, a physical examination, and a cervical biopsy..","26548733","Specific disease- Stage IB Cervical Cancer; Age- Adult; Gender- Female; Country- South Korea; Other- Diagnosed and clinically staged by a gyneocologic oncologist using patient history, a physical examination, and a cervical biopsy..","Treatment with an MRI-based triage strategy where all patients underwent pelvic MRI, and the primary treatment modality was recommended according to these results. Low-risk groups underwent primary radical surgery followed by tailored adjuvant therapy based on final pathology, and high-risk patients underwent primary chemoradiation.","Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis  from Korean, Canadian and U.S. perspectives.","Treatment with priimary surgery (radical hyterectomy and pelvic lymphadenectomy). Patients with at least one high risk factor received postoperative chemoradiation, patients with at least 2 mor more intermediate risk factors received adjuvent radiotherapy.","NE"
"2016-01-20739","2016","Lee 2016 Gynecol Oncol","150000","Treatment with concurrent chemoradiation with whole pelvic external-beam radiation. VERSUS Treatment with primary surgery (radical hyterectomy and pelvic lymphadenectomy). Patients with at least one high risk factor received postoperative chemoradiation, patients with at least 2 more intermediate risk factors received adjuvent radiotherapy. IN Specific disease- Stage IB Cervical Cancer; Age- Adult; Gender- Female; Country- South Korea; Other- Diagnosed and clinically staged by a gyneocologic oncologist using patient history, a physical examination, and a cervical biopsy..","26548733","Specific disease- Stage IB Cervical Cancer; Age- Adult; Gender- Female; Country- South Korea; Other- Diagnosed and clinically staged by a gyneocologic oncologist using patient history, a physical examination, and a cervical biopsy..","Treatment with concurrent chemoradiation with whole pelvic external-beam radiation.","Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis  from Korean, Canadian and U.S. perspectives.","Treatment with primary surgery (radical hyterectomy and pelvic lymphadenectomy). Patients with at least one high risk factor received postoperative chemoradiation, patients with at least 2 more intermediate risk factors received adjuvent radiotherapy.","NE"
"2016-01-20561","2016","Choi 2016 Expert Rev Pharmacoecon Outcomes Res","Cost-Saving","Vortioxetine VERSUS Venlafaxine XR - extended release IN Specific disease- Major Depressive Disorder (MDD); Age- Adult; Gender- Both; Country- South Korea.","26641142","Specific disease- Major Depressive Disorder (MDD); Age- Adult; Gender- Both; Country- South Korea.","Vortioxetine","Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.","Venlafaxine XR - extended release","SE"
"2016-01-20561","2016","Choi 2016 Expert Rev Pharmacoecon Outcomes Res","Cost-Saving","Vortioxetine VERSUS Venlafaxine XR - extended release IN Specific disease- Major Depressive Disorder; Age- Adult; Gender- Both; Country- South Korea.","26641142","Specific disease- Major Depressive Disorder; Age- Adult; Gender- Both; Country- South Korea.","Vortioxetine","Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.","Venlafaxine XR - extended release","SE"
"2015-01-19070","2015","Yu 2015 J Alzheimers Dis","28000","Opportunistic Screening for Dementia VERSUS None IN Healthy; Age- >=65 years; Gender- Not Specified; Country- South Korea.","25208621","Healthy; Age- >=65 years; Gender- Not Specified; Country- South Korea.","Opportunistic Screening for Dementia","Cost-effectiveness of nationwide opportunistic screening program for dementia in  South Korea.","None","NE"
"2015-01-19070","2015","Yu 2015 J Alzheimers Dis","31000","Opportunistic Screening for Dementia VERSUS None IN Healthy; Age- >=65 years; Gender- Not Specified; Country- South Korea.","25208621","Healthy; Age- >=65 years; Gender- Not Specified; Country- South Korea.","Opportunistic Screening for Dementia","Cost-effectiveness of nationwide opportunistic screening program for dementia in  South Korea.","None","NE"
"2015-01-19070","2015","Yu 2015 J Alzheimers Dis","34000","Opportunistic Screening for Dementia VERSUS None IN Healthy; Age- >=65 years; Gender- Not Specified; Country- South Korea.","25208621","Healthy; Age- >=65 years; Gender- Not Specified; Country- South Korea.","Opportunistic Screening for Dementia","Cost-effectiveness of nationwide opportunistic screening program for dementia in  South Korea.","None","NE"
"2015-01-19070","2015","Yu 2015 J Alzheimers Dis","41000","Opportunistic Screening for Dementia VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- South Korea.","25208621","Healthy; Age- >=65 years; Gender- Both; Country- South Korea.","Opportunistic Screening for Dementia","Cost-effectiveness of nationwide opportunistic screening program for dementia in  South Korea.","None","NE"
"2015-01-18069","2015","Lee 2015 J Cardiovasc Comput Tomogr","Cost-Saving","Coronary ct angiography VERSUS single photon emission CT IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea; Other- suspected coronary artery disease.","25977116","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- South Korea; Other- suspected coronary artery disease.","Coronary ct angiography","Cost-effectiveness of coronary CT angiography in patients with chest pain: Comparison with myocardial single photon emission tomography.","single photon emission CT","SE"
"2015-01-17508","2015","Lee 2015 Clin Ther","13000","First-line tofacitinib, an oral Janus kinase inhibitor, treatment before the standard of care VERSUS Standard/Usual Care IN Specific disease- Rheumatoid Arthritis; Age- Adult; Gender- Both; Country- South Korea; Other- Rheumatoid arthritis patients with inadequate response to conventional disease-modifying antirheumatic drugs..","26243076","Specific disease- Rheumatoid Arthritis; Age- Adult; Gender- Both; Country- South Korea; Other- Rheumatoid arthritis patients with inadequate response to conventional disease-modifying antirheumatic drugs..","First-line tofacitinib, an oral Janus kinase inhibitor, treatment before the standard of care","Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.","Standard/Usual Care","NE"
"2014-01-15985","2014","Lee 2014 Clin Ther","Cost-Saving","Tolvaptan VERSUS Placebo IN Specific disease- Euvolemic or hypervolemic hyponatremia; Age- Unknown; Gender- Not Specified; Country- South Korea; Other- serum sodium level <135 mEq/L.","25151571","Specific disease- Euvolemic or hypervolemic hyponatremia; Age- Unknown; Gender- Not Specified; Country- South Korea; Other- serum sodium level <135 mEq/L.","Tolvaptan","Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia.","Placebo","SE"
"2014-01-15798","2014","Lim 2014 Cost Eff Resour Alloc","24000","Ferric carboxymaltose VERSUS Placebo IN Specific disease- Chronic heart failure with Iron-deficiency anemia (IDA); Age- Unknown; Gender- Not Specified; Country- Korea.","25278814","Specific disease- Chronic heart failure with Iron-deficiency anemia (IDA); Age- Unknown; Gender- Not Specified; Country- Korea.","Ferric carboxymaltose","Cost-utility of ferric carboxymaltose (Ferinject(R)) for iron-deficiency anemia patients with chronic heart failure in South Korea.","Placebo","NE"
"2014-01-15712","2014","Han 2014 Asian Pac J Cancer Prev","51000","Human papillomavirus (HPV) vaccination VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Female; Country- South Korea.","25339055","Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Female; Country- South Korea.","Human papillomavirus (HPV) vaccination","Cost-effectiveness analysis of HPV vaccination: comparing the general population  with socially vulnerable individuals.","None","NE"
"2014-01-15712","2014","Han 2014 Asian Pac J Cancer Prev","9300","Human papillomavirus (HPV) vaccine VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Female; Country- South Korea; Other- Socially Vulnerable: adolescents from broken families and low-income families.","25339055","Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Female; Country- South Korea; Other- Socially Vulnerable: adolescents from broken families and low-income families.","Human papillomavirus (HPV) vaccine","Cost-effectiveness analysis of HPV vaccination: comparing the general population  with socially vulnerable individuals.","None","NE"
"2009-01-05354","2009","Sava 2009 J Clin Psychol","2000","Cognitive Therapy: Maximum of 20 individual 50-min therapy sessions or a maximum of 20 individual 20-min pharmacotherapy sessions, over the 14 weeks allowed for treatment VERSUS No treatment IN Patients diagnosed with major depressive disorder within the Romanian healthcare system.","19051275","Patients diagnosed with major depressive disorder within the Romanian healthcare system.","Cognitive Therapy: Maximum of 20 individual 50-min therapy sessions or a maximum of 20 individual 20-min pharmacotherapy sessions, over the 14 weeks allowed for treatment","Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.","No treatment","NE"
"2009-01-05354","2009","Sava 2009 J Clin Psychol","2200","Rational Emotive Behavioral Therapy: maximum of 20 individual 50-min therapy sessions or a maximum of 20 individual 20-min pharmacotherapy sessions, over the 14 weeks allowed for treatment VERSUS No treatment IN Patients diagnosed with major depressive disorder within the Romanian healthcare system.","19051275","Patients diagnosed with major depressive disorder within the Romanian healthcare system.","Rational Emotive Behavioral Therapy: maximum of 20 individual 50-min therapy sessions or a maximum of 20 individual 20-min pharmacotherapy sessions, over the 14 weeks allowed for treatment","Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.","No treatment","NE"
"2009-01-05354","2009","Sava 2009 J Clin Psychol","2800","Fluoxetine (Prozac) Therapy: Initial 50-min meeting with the psychiatrist, subsequent sessions 20 min. once per week. Initial dose of 10 mg/day was increased to 20 mg/d during Week 1 and to 40 mg/d by Weeks 2 to 12. The maximum dosage allowed was 60 to 80 mg/d (M550.1, SD54.5). During Weeks 12 to 14, dosage was reduced again to 20 mg/d for 53% of participants whose depression improved VERSUS No treatment IN Patients diagnosed with major depressive disorder within the Romanian healthcare system.","19051275","Patients diagnosed with major depressive disorder within the Romanian healthcare system.","Fluoxetine (Prozac) Therapy: Initial 50-min meeting with the psychiatrist, subsequent sessions 20 min. once per week. Initial dose of 10 mg/day was increased to 20 mg/d during Week 1 and to 40 mg/d by Weeks 2 to 12. The maximum dosage allowed was 60 to 80 mg/d (M550.1, SD54.5). During Weeks 12 to 14, dosage was reduced again to 20 mg/d for 53% of participants whose depression improved","Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.","No treatment","NE"
"2013-01-11443","2013","Coffin 2013 J Med Econ","110","Distribution of naloxone for lay overdose reversal VERSUS None IN Healthy; Age- Adult; Gender- Both; Country- Russia; Other- Heroin users.","23730942","Healthy; Age- Adult; Gender- Both; Country- Russia; Other- Heroin users.","Distribution of naloxone for lay overdose reversal","Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities.","None","NE"
"2012-01-10107","2012","Winetsky 2012 PLoS Med","100","Sputum polymerase chain reaction (PCR) screening VERSUS Combined mass miniature radiography (MMR) and symptom screening IN Prisoners in Tajikistan","23209384","Prisoners in Tajikistan","Sputum polymerase chain reaction (PCR) screening","Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis.","Combined mass miniature radiography (MMR) and symptom screening","NE"
"2012-01-10107","2012","Winetsky 2012 PLoS Med","1800","Sputum polymerase chain reaction (PCR) screening VERSUS Mass miniature radiography (MMR) with sputum PCR detection of multidrug resistant-tuberculosis (MDR-TB) IN Prisoners in Russia","23209384","Prisoners in Russia","Sputum polymerase chain reaction (PCR) screening","Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis.","Mass miniature radiography (MMR) with sputum PCR detection of multidrug resistant-tuberculosis (MDR-TB)","NE"
"2012-01-10107","2012","Winetsky 2012 PLoS Med","640","Sputum polymerase chain reaction (PCR) screening VERSUS Mass miniature radiography (MMR) with sputum PCR detection of multidrug resistant-tuberculosis (MDR-TB) IN Prisoners in Russia and Eastern Europe","23209384","Prisoners in Russia and Eastern Europe","Sputum polymerase chain reaction (PCR) screening","Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis.","Mass miniature radiography (MMR) with sputum PCR detection of multidrug resistant-tuberculosis (MDR-TB)","NE"
"2012-01-10107","2012","Winetsky 2012 PLoS Med","Cost-Saving","Combined mass miniature radiography (MMR) and symptom screening VERSUS Standard of care (mass miniature radiography (MMR) screening) IN Prisoners in Tajikistan","23209384","Prisoners in Tajikistan","Combined mass miniature radiography (MMR) and symptom screening","Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis.","Standard of care (mass miniature radiography (MMR) screening)","SE"
"2012-01-10107","2012","Winetsky 2012 PLoS Med","Cost-Saving","Mass miniature radiography (MMR) with sputum polymerase chain reaction (PCR) detection of multidrug resistant-tuberculosis (MDR-TB) VERSUS Standard of care (mass miniature radiography (MMR) screening) IN Prisoners in Russia","23209384","Prisoners in Russia","Mass miniature radiography (MMR) with sputum polymerase chain reaction (PCR) detection of multidrug resistant-tuberculosis (MDR-TB)","Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis.","Standard of care (mass miniature radiography (MMR) screening)","SE"
"2012-01-10107","2012","Winetsky 2012 PLoS Med","Cost-Saving","Mass miniature radiography (MMR) with sputum polymerase chain reaction (PCR) detection of multidrug resistant-tuberculosis (MDR-TB) VERSUS Standard of care (mass miniature radiography (MMR) screening) IN Prisoners in Russia and Eastern Europe","23209384","Prisoners in Russia and Eastern Europe","Mass miniature radiography (MMR) with sputum polymerase chain reaction (PCR) detection of multidrug resistant-tuberculosis (MDR-TB)","Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis.","Standard of care (mass miniature radiography (MMR) screening)","SE"
"2009-01-05343","2009","Tole 2009 Int J STD AIDS","16000","Once-per-lifetime screening VERSUS No screening IN Index cases only (aged 15-49 individuals)","19103893","Index cases only (aged 15-49 individuals)","Once-per-lifetime screening","Cost-effectiveness of voluntary HIV screening in Russia.","No screening","NE"
"2009-01-05343","2009","Tole 2009 Int J STD AIDS","31000","Screening every 5 years VERSUS Once-per-lifetime Screening IN Index cases only (aged 15-49 individuals)","19103893","Index cases only (aged 15-49 individuals)","Screening every 5 years","Cost-effectiveness of voluntary HIV screening in Russia.","Once-per-lifetime Screening","NE"
"2009-01-05343","2009","Tole 2009 Int J STD AIDS","8400","Once-per-lifetime Screening VERSUS No screening IN Index cases only (aged 15-49 individuals) and their sexual partners","19103893","Index cases only (aged 15-49 individuals) and their sexual partners","Once-per-lifetime Screening","Cost-effectiveness of voluntary HIV screening in Russia.","No screening","NE"
"2009-01-05343","2009","Tole 2009 Int J STD AIDS","9000","Screening every 5 years VERSUS Once-per-lifetime Screening IN Index cases only (aged 15-49 individuals) and their sexual partners","19103893","Index cases only (aged 15-49 individuals) and their sexual partners","Screening every 5 years","Cost-effectiveness of voluntary HIV screening in Russia.","Once-per-lifetime Screening","NE"
"2006-01-02369","2006","Long 2006 AIDS","2000","VERSUS  IN Adult population aged 15-49 in St. Petersburg","17086061","Adult population aged 15-49 in St. Petersburg"," ","Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia."," ","NE"
"2006-01-02369","2006","Long 2006 AIDS","2400","VERSUS  IN Adult population aged 15-49 in St. Petersburg","17086061","Adult population aged 15-49 in St. Petersburg"," ","Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia."," ","NE"
"2006-01-02369","2006","Long 2006 AIDS","2500","VERSUS  IN Adult population aged 15-49 in St. Petersburg","17086061","Adult population aged 15-49 in St. Petersburg"," ","Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia."," ","NE"
"2006-01-02369","2006","Long 2006 AIDS","3400","VERSUS  IN Adult population aged 15-49 in St. Petersburg","17086061","Adult population aged 15-49 in St. Petersburg"," ","Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia."," ","NE"
"2016-01-21572","2016","Silverstein 2016 World J Surg","5200","Laparoscopic Cholecystectomy VERSUS Standard/Usual Care- Open Cholecystectomy IN Specific disease- Gallstone Disease; Age- Adult; Gender- Both; Country- Rwanda.","27905020","Specific disease- Gallstone Disease; Age- Adult; Gender- Both; Country- Rwanda.","Laparoscopic Cholecystectomy","Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital.","Standard/Usual Care- Open Cholecystectomy","NE"
"2005-01-01457","2005","Maclean 2005 J Acquir Immune Defic Syndr","110","Breast feeding (6 months) plus Nevirapine VERSUS Breast feeding (6 months) IN HIV infected mothers (to protect against transmission to child via breastfeeding)","15793368","HIV infected mothers (to protect against transmission to child via breastfeeding)","Breast feeding (6 months) plus Nevirapine","Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding.","Breast feeding (6 months)","NE"
"2005-01-01457","2005","Maclean 2005 J Acquir Immune Defic Syndr","120","Breast feeding (6 months) plus combination antiretroviral therapy VERSUS Breast feeding (6 months) IN HIV infected mothers (to protect against transmission to child via breastfeeding)","15793368","HIV infected mothers (to protect against transmission to child via breastfeeding)","Breast feeding (6 months) plus combination antiretroviral therapy","Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding.","Breast feeding (6 months)","NE"
"2005-01-01457","2005","Maclean 2005 J Acquir Immune Defic Syndr","430","Breast feeding (6 months) plus combination antiretroviral therapy VERSUS Breast feeding (6 months) IN HIV infected mothers (to protect against transmission to child via breastfeeding) with CD4 count >= 200 cells/mL","15793368","HIV infected mothers (to protect against transmission to child via breastfeeding) with CD4 count >= 200 cells/mL","Breast feeding (6 months) plus combination antiretroviral therapy","Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding.","Breast feeding (6 months)","NE"
"2005-01-01457","2005","Maclean 2005 J Acquir Immune Defic Syndr","Dominated","Breast feeding (12 months) VERSUS Breast feeding (6 months) IN HIV infected mothers (to protect against transmission to child via breastfeeding)","15793368","HIV infected mothers (to protect against transmission to child via breastfeeding)","Breast feeding (12 months)","Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding.","Breast feeding (6 months)","NW"
"2005-01-01457","2005","Maclean 2005 J Acquir Immune Defic Syndr","Dominated","Fomula feeding (12 months) VERSUS Breast feeding (6 months) IN HIV infected mothers (to protect against transmission to child via breastfeeding)","15793368","HIV infected mothers (to protect against transmission to child via breastfeeding)","Fomula feeding (12 months)","Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding.","Breast feeding (6 months)","NW"
"2017-01-25773","2017","Alsaqa'aby 2017 Ann Saudi Med","360000","Interferon b1a (Avonex 30 mcg) VERSUS Interferon B1a (Rebif 44 mcg) IN Specific disease- Multiple sclerosis; Age- Adult; Gender- Both; Country- Saudi Arabia; Other- Relapsing-remitting subtype.","29229891","Specific disease- Multiple sclerosis; Age- Adult; Gender- Both; Country- Saudi Arabia; Other- Relapsing-remitting subtype.","Interferon b1a (Avonex 30 mcg)","Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.","Interferon B1a (Rebif 44 mcg)","NE"
"2017-01-25773","2017","Alsaqa'aby 2017 Ann Saudi Med","370000","Fingolimod VERSUS Interferon b1a (Rebif 44 mcg) IN Specific disease- Multiple sclerosis; Age- Adult; Gender- Both; Country- Saudi Arabia; Other- Relapsing-remitting subtype.","29229891","Specific disease- Multiple sclerosis; Age- Adult; Gender- Both; Country- Saudi Arabia; Other- Relapsing-remitting subtype.","Fingolimod","Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.","Interferon b1a (Rebif 44 mcg)","NE"
"2017-01-25773","2017","Alsaqa'aby 2017 Ann Saudi Med","560000","Dimethyl Fumarate (DMF) VERSUS Interferon B1a (Rebif 44 mcg) IN Specific disease- Multiple sclerosis; Age- Adult; Gender- Both; Country- Saudi Arabia; Other- Relapsing-remitting subtype.","29229891","Specific disease- Multiple sclerosis; Age- Adult; Gender- Both; Country- Saudi Arabia; Other- Relapsing-remitting subtype.","Dimethyl Fumarate (DMF)","Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.","Interferon B1a (Rebif 44 mcg)","NE"
"2017-01-25773","2017","Alsaqa'aby 2017 Ann Saudi Med","Dominated","Teriflunomide VERSUS Interferon B1a (Rebif 44 mcg) IN Specific disease- Multiple sclerosis; Age- Adult; Gender- Both; Country- Saudi Arabia; Other- Relapsing-remitting subtype.","29229891","Specific disease- Multiple sclerosis; Age- Adult; Gender- Both; Country- Saudi Arabia; Other- Relapsing-remitting subtype.","Teriflunomide","Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.","Interferon B1a (Rebif 44 mcg)","NW"
"2018-01-27361","2018","Lalic 2018 Diabetes Ther","11000","Insulin degludec VERSUS Insulin glargine U100 IN Specific disease- Type 2 diabetes mellitus ; Age- Adult; Gender- Both; Country- Serbia; Other- Using basal-bolus therapy .","29700772","Specific disease- Type 2 diabetes mellitus ; Age- Adult; Gender- Both; Country- Serbia; Other- Using basal-bolus therapy .","Insulin degludec","Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia.","Insulin glargine U100","NE"
"2018-01-27361","2018","Lalic 2018 Diabetes Ther","4000","Insulin degludec VERSUS Insulin glargine U100 IN Specific disease- Type 1 diabetes mellitus ; Age- Adult; Gender- Both; Country- Serbia; Other- Using basal bolus therapy.","29700772","Specific disease- Type 1 diabetes mellitus ; Age- Adult; Gender- Both; Country- Serbia; Other- Using basal bolus therapy.","Insulin degludec","Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia.","Insulin glargine U100","NE"
"2018-01-27361","2018","Lalic 2018 Diabetes Ther","5300","Insulin degludec VERSUS Insulin glargine U100 IN Specific disease- Type 2 diabetes mellitus; Age- Adult; Gender- Both; Country- Serbia; Other- Using basal oral therapy .","29700772","Specific disease- Type 2 diabetes mellitus; Age- Adult; Gender- Both; Country- Serbia; Other- Using basal oral therapy .","Insulin degludec","Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia.","Insulin glargine U100","NE"
"2013-01-14695","2013","Mihajlovic 2013 Clin Ther","120000","Everolimus VERSUS best supportive care IN Specific disease- MetastaticRenalCellCarcinoma; Age- Adult; Gender- Both; Country- Serbia.","24238790","Specific disease- MetastaticRenalCellCarcinoma; Age- Adult; Gender- Both; Country- Serbia.","Everolimus","Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.","best supportive care","NE"
"2009-01-05518","2009","Jankovic 2009 Vojnosanit Pregl","240000","Symptom management alone in combination with subcutaneous glatiramer acetate VERSUS Symptomatic management therapy IN Patients diagnosed with relapsing remitting multiple sclerosis, (MS); Serbian perspective.","19678581","Patients diagnosed with relapsing remitting multiple sclerosis, (MS); Serbian perspective.","Symptom management alone in combination with subcutaneous glatiramer acetate","Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.","Symptomatic management therapy","NE"
"2009-01-05518","2009","Jankovic 2009 Vojnosanit Pregl","530000","Symptom management alone in combination with Subcutaneous interferon Ã-1ab (beta 1-b) VERSUS Symptomatic management therapy IN Patients diagnosed with relapsing remitting multiple sclerosis, (MS); Serbian perspective.","19678581","Patients diagnosed with relapsing remitting multiple sclerosis, (MS); Serbian perspective.","Symptom management alone in combination with Subcutaneous interferon Ã-1ab (beta 1-b)","Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.","Symptomatic management therapy","NE"
"2009-01-05518","2009","Jankovic 2009 Vojnosanit Pregl","590000","Symptom management alone in combination with intramuscular interferon Ã-1a  (beta 1-a) VERSUS Symptomatic management therapy IN Patients diagnosed with relapsing remitting multiple sclerosis, (MS); Serbian perspective.","19678581","Patients diagnosed with relapsing remitting multiple sclerosis, (MS); Serbian perspective.","Symptom management alone in combination with intramuscular interferon Ã-1a  (beta 1-a)","Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.","Symptomatic management therapy","NE"
"2009-01-05518","2009","Jankovic 2009 Vojnosanit Pregl","590000","Symptom management alone in combination with Subcutaneous interferon Ã-1a  (beta 1-a) VERSUS Symptomatic management therapy IN Patients diagnosed with relapsing remitting multiple sclerosis, (MS); Serbian perspective.","19678581","Patients diagnosed with relapsing remitting multiple sclerosis, (MS); Serbian perspective.","Symptom management alone in combination with Subcutaneous interferon Ã-1a  (beta 1-a)","Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.","Symptomatic management therapy","NE"
"2009-01-05398","2009","Perovic 2009 Vojnosanit Pregl","57000","Dialysis VERSUS No treatment IN Serbian patients diagnosed with Chronic renal insufficiency (CRI), diabetes, hypertension, or autosomal dominant polycystic kidney disease (ADPKD).  (diagnoses that are associated with compromised kidney function).","19780419","Serbian patients diagnosed with Chronic renal insufficiency (CRI), diabetes, hypertension, or autosomal dominant polycystic kidney disease (ADPKD).  (diagnoses that are associated with compromised kidney function).","Dialysis","Renal transplantation vs hemodialysis: cost-effectiveness analysis.","No treatment","NE"
"2009-01-05398","2009","Perovic 2009 Vojnosanit Pregl","Cost-Saving","Kidney Transplantation VERSUS Dialysis IN Serbian patients diagnosed with Chronic renal insufficiency (CRI), diabetes, hypertension, or autosomal dominant polycystic kidney disease (ADPKD).  (diagnoses that are associated with compromised kidney function).","19780419","Serbian patients diagnosed with Chronic renal insufficiency (CRI), diabetes, hypertension, or autosomal dominant polycystic kidney disease (ADPKD).  (diagnoses that are associated with compromised kidney function).","Kidney Transplantation","Renal transplantation vs hemodialysis: cost-effectiveness analysis.","Dialysis","SE"
"2018-01-28219","2018","Lin 2018 Int J Rheum Dis","13000","Adherence-enhancing program VERSUS None IN Specific disease- Gout; Age- Adult; Gender- Both; Country- Singapore.","30556300","Specific disease- Gout; Age- Adult; Gender- Both; Country- Singapore.","Adherence-enhancing program","Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data.","None","NE"
"2018-01-27618","2018","Tan 2018 BMC Cancer","100000","Afatinib as first-line treatment VERSUS Pemetrexed-cisplatin chemotherapy as first-line treatment IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Singapore; Other- Locally advanced or metastatic epidermal growth factor receptor mutation positive non-small-cell lung cancer.","29587666","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Singapore; Other- Locally advanced or metastatic epidermal growth factor receptor mutation positive non-small-cell lung cancer.","Afatinib as first-line treatment","Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer''s perspective.","Pemetrexed-cisplatin chemotherapy as first-line treatment","NE"
"2018-01-27026","2018","Teng 2018 Cardiovasc Ther","21000","Biodegradable polymer drug-eluting stent, at 1st year VERSUS Standard/Usual Care- Durable polymer drug-eluting stent, at 1st year IN Specific disease- Coronary artery disease; Age- 41 to 64 years; Gender- Both; Country- Singapore; Other- Undergoing Percutaneous coronary intervention (.","29873191","Specific disease- Coronary artery disease; Age- 41 to 64 years; Gender- Both; Country- Singapore; Other- Undergoing Percutaneous coronary intervention (.","Biodegradable polymer drug-eluting stent, at 1st year","Cost-effectiveness analysis of biodegradable polymer versus durable polymer drug-eluting stents incorporating real-world evidence.","Standard/Usual Care- Durable polymer drug-eluting stent, at 1st year","NE"
"2018-01-27026","2018","Teng 2018 Cardiovasc Ther","4200","Biodegradable polymer drug-eluting stent, 5 years VERSUS Standard/Usual Care- Durable polymer drug-eluting stent, 5 years IN Specific disease- Coronary artery disease; Age- 41 to 64 years; Gender- Both; Country- Singapore; Other- Undergoing Percutaneous coronary intervention (.","29873191","Specific disease- Coronary artery disease; Age- 41 to 64 years; Gender- Both; Country- Singapore; Other- Undergoing Percutaneous coronary intervention (.","Biodegradable polymer drug-eluting stent, 5 years","Cost-effectiveness analysis of biodegradable polymer versus durable polymer drug-eluting stents incorporating real-world evidence.","Standard/Usual Care- Durable polymer drug-eluting stent, 5 years","NE"
"2018-01-25856","2018","Areia 2018 United European Gastroenterol J","130000","Stand-alone endoscopic screening every five years VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Singapore; Other- Patients with an intermediate gastric cancer risk.","29511549","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Singapore; Other- Patients with an intermediate gastric cancer risk.","Stand-alone endoscopic screening every five years","Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk.","None","NE"
"2017-01-25815","2017","Saxena 2017 Geriatr Gerontol Int","25000","Primary Care Dementia Clinic VERSUS Memory clinic IN Specific disease- Dementia; Age- >=65 years; Gender- Both; Country- Singapore.","29193721","Specific disease- Dementia; Age- >=65 years; Gender- Both; Country- Singapore.","Primary Care Dementia Clinic","Evaluation of an integrated primary care-led dementia shared care program in Singapore: An effectiveness and cost-effectiveness study.","Memory clinic","NE"
"2017-01-25788","2017","Botteman 2017 Singapore Med J","Cost-Saving","Exclusive use of partially hydrolysed 100% whey-based (PHF-W) VERSUS Standard/Usual Care- Standard cowâs milk formula (CMF) IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Singapore; Other- Healthy, non-exclusively breastfed, high-risk infants (i.e. those with a parent or sibling with an allergic disease history) of atopic dermatitis.","29214323","Healthy; Age- 0 to 18 years; Gender- Both; Country- Singapore; Other- Healthy, non-exclusively breastfed, high-risk infants (i.e. those with a parent or sibling with an allergic disease history) of atopic dermatitis.","Exclusive use of partially hydrolysed 100% whey-based (PHF-W)","Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk infants not exclusively breastfed in Singapore.","Standard/Usual Care- Standard cowâs milk formula (CMF)","SE"
"2017-01-25733","2017","Kuie 2017 BJOG","780","Nonavalent vaccination VERSUS Bivalent vaccination IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Singapore.","29266694","Healthy; Age- 0 to 18 years; Gender- Female; Country- Singapore.","Nonavalent vaccination","The Clinical and Economic Impact of School-based Nonavalent Human Papillomavirus  Vaccine on Females in Singapore: A Transmission Dynamic Mathematical Model Analysis.","Bivalent vaccination","NE"
"2017-01-25733","2017","Kuie 2017 BJOG","8300","Nonavalent HPV vaccination VERSUS Quadrivalent vaccination IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Singapore.","29266694","Healthy; Age- 0 to 18 years; Gender- Female; Country- Singapore.","Nonavalent HPV vaccination","The Clinical and Economic Impact of School-based Nonavalent Human Papillomavirus  Vaccine on Females in Singapore: A Transmission Dynamic Mathematical Model Analysis.","Quadrivalent vaccination","NE"
"2017-01-25450","2017","Wang 2017 Clin Ther","Cost-Saving","Antibiotics with therapeutic filgrastim VERSUS Standard/Usual Care- Antibiotic treatment alone IN Specific disease- Febrile neutropenia; Age- Adult; Gender- Both; Country- Singapore; Other- Adult cancer patients hospitalized with solid tumors or lymphomas .","28554533","Specific disease- Febrile neutropenia; Age- Adult; Gender- Both; Country- Singapore; Other- Adult cancer patients hospitalized with solid tumors or lymphomas .","Antibiotics with therapeutic filgrastim","Therapeutic Use of Filgrastim for Established Febrile Neutropenia Is Cost Effective Among Patients With Solid Tumors and Lymphomas.","Standard/Usual Care- Antibiotic treatment alone","SE"
"2017-01-24818","2017","Nguyen 2017 J Med Genet","99000","Algorithm driven Maturity onset diabetes of the young testing VERSUS No genetic testing IN Specific disease- Type 2 Diabetes; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Singapore.","28835481","Specific disease- Type 2 Diabetes; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Singapore.","Algorithm driven Maturity onset diabetes of the young testing","Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore.","No genetic testing","NE"
"2017-01-24574","2017","Liang 2017 J Med Econ","55000","Sacubitril/Valsartan VERSUS Enalapril 10 mg IN Specific disease- Heart failure and reduced ejection fraction; Age- >=65 years; Gender- Both; Country- United States of America (USA).","28959905","Specific disease- Heart failure and reduced ejection fraction; Age- >=65 years; Gender- Both; Country- United States of America (USA).","Sacubitril/Valsartan","Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.","Enalapril 10 mg","NE"
"2017-01-24511","2017","Saing 2017 ANZ J Surg","32000","Contrast enhanced magnetic resonance imaging (CE MRI) VERSUS Standard/Usual Care- Contrast enhanced computed tomography (CE CT) IN Specific disease- Colorectal cancer; Age- Adult; Gender- Both; Country- Singapore; Other- Patients with a suspicion of liver metastasis.","28982209","Specific disease- Colorectal cancer; Age- Adult; Gender- Both; Country- Singapore; Other- Patients with a suspicion of liver metastasis.","Contrast enhanced magnetic resonance imaging (CE MRI)","Cost-effective imaging for resectability of liver lesions in colorectal cancer: an economic decision model.","Standard/Usual Care- Contrast enhanced computed tomography (CE CT)","NE"
"2017-01-24505","2017","Tay 2017 Singapore Med J","9800","AS04-Human papillomavirus (HPV)-16/18v in addition to screening VERSUS Standard/Usual Care- Screening alone  IN Specific disease- Cervical cancer; Age- 0 to 18 years; Gender- Female; Country- Singapore.","28983579","Specific disease- Cervical cancer; Age- 0 to 18 years; Gender- Female; Country- Singapore.","AS04-Human papillomavirus (HPV)-16/18v in addition to screening","Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.","Standard/Usual Care- Screening alone","NE"
"2017-01-24505","2017","Tay 2017 Singapore Med J","Cost-Saving","AS04-human papillomavirus-16/18v VERSUS Screening alone IN Specific disease- Cervical cancer; Age- 0 to 18 years; Gender- Female; Country- Singapore.","28983579","Specific disease- Cervical cancer; Age- 0 to 18 years; Gender- Female; Country- Singapore.","AS04-human papillomavirus-16/18v","Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.","Screening alone","SE"
"2016-01-22505","2016","Wu 2016 Asia Pac J Clin Oncol","37000","Surveillance strategy esophagogastroduodenoscopy screening every two years VERSUS None IN Specific disease- gastric cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Singapore; Other- precancerous lesions.","27452189","Specific disease- gastric cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Singapore; Other- precancerous lesions.","Surveillance strategy esophagogastroduodenoscopy screening every two years","Determining the cost-effectiveness of endoscopic surveillance for gastric cancer  in patients with precancerous lesions.","None","NE"
"2016-01-22505","2016","Wu 2016 Asia Pac J Clin Oncol","580000","Annual screening strategy/ esophagogastroduodenoscopy screening every  year VERSUS surveillance strategy esophagogastroduodenoscopy screening every two years IN Specific disease- gastric cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Singapore.","27452189","Specific disease- gastric cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Singapore.","Annual screening strategy/ esophagogastroduodenoscopy screening every  year","Determining the cost-effectiveness of endoscopic surveillance for gastric cancer  in patients with precancerous lesions.","surveillance strategy esophagogastroduodenoscopy screening every two years","NE"
"2016-01-21973","2016","Nguyen 2016 Ophthalmology","Cost-Saving","Singapore Integrated Diabetic Retinopathy Program (SiDRP) VERSUS Standard/Usual Care- Family Physician model IN Specific disease- Diabetic Retinopathy; Age- 41 to 64 years; Gender- Both; Country- Singapore; Other- Type 2 Diabetes previously not screened for Diabetes Retinopathy.","27726962","Specific disease- Diabetic Retinopathy; Age- 41 to 64 years; Gender- Both; Country- Singapore; Other- Type 2 Diabetes previously not screened for Diabetes Retinopathy.","Singapore Integrated Diabetic Retinopathy Program (SiDRP)","Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore.","Standard/Usual Care- Family Physician model","SE"
"2015-01-20724","2015","Dong 2015 Pharmacogenomics","Dominated","No Urate-lowering therapy and treatment of acute flares only VERSUS HLA-B*5801 genetic testing-guided Urate-lowering therapy treatment: probenecid for test positive, allopurinol for test negative IN Specific disease- Gout; Age- Adult; Gender- Both; Country- Singapore.","26554739","Specific disease- Gout; Age- Adult; Gender- Both; Country- Singapore.","No Urate-lowering therapy and treatment of acute flares only","Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.","HLA-B*5801 genetic testing-guided Urate-lowering therapy treatment: probenecid for test positive, allopurinol for test negative","NW"
"2015-01-20697","2015","Yang 2015 Nephrology (Carlton)","120000","Automated peritoneal dialysis VERSUS Continuous ambulatory peritoneal dialysis IN Specific disease- End-stage renal disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Singapore.","26566750","Specific disease- End-stage renal disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Singapore.","Automated peritoneal dialysis","Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.","Continuous ambulatory peritoneal dialysis","NE"
"2015-01-20697","2015","Yang 2015 Nephrology (Carlton)","74000","Haemodialysis VERSUS Continuous ambulatory peritoneal dialysis IN Specific disease- End-stage renal disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Singapore.","26566750","Specific disease- End-stage renal disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Singapore.","Haemodialysis","Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.","Continuous ambulatory peritoneal dialysis","NE"
"2015-01-18917","2015","Ang 2015 Br J Ophthalmol","3100","TST (tuberculin skin test) only VERSUS TST Positive + IGRA (Interferon-Y release assay) IN Specific disease- Intraocular inflammation suggestive of tuberculous uveitis; Age- Unknown; Gender- Both; Country- Singapore.","25573149","Specific disease- Intraocular inflammation suggestive of tuberculous uveitis; Age- Unknown; Gender- Both; Country- Singapore.","TST (tuberculin skin test) only","Cost-effectiveness of alternative strategies for interferon-gamma release assays  and tuberculin skin test in tuberculous uveitis.","TST Positive + IGRA (Interferon-Y release assay)","NE"
"2015-01-18917","2015","Ang 2015 Br J Ophthalmol","9700","Dual test strategy VERSUS IGRA (Interferon-Y release assay) only IN Specific disease- Intraocular inflammation suggestive of tuberculous uveitis; Age- Unknown; Gender- Both; Country- Singapore.","25573149","Specific disease- Intraocular inflammation suggestive of tuberculous uveitis; Age- Unknown; Gender- Both; Country- Singapore.","Dual test strategy","Cost-effectiveness of alternative strategies for interferon-gamma release assays  and tuberculin skin test in tuberculous uveitis.","IGRA (Interferon-Y release assay) only","NE"
"2015-01-18917","2015","Ang 2015 Br J Ophthalmol","Dominated","IGRA (Interferon-Y release assay) only VERSUS TST (tuberculin skin test) only IN Specific disease- Intraocular inflammation suggestive of tuberculous uveitis; Age- Unknown; Gender- Both; Country- Singapore.","25573149","Specific disease- Intraocular inflammation suggestive of tuberculous uveitis; Age- Unknown; Gender- Both; Country- Singapore.","IGRA (Interferon-Y release assay) only","Cost-effectiveness of alternative strategies for interferon-gamma release assays  and tuberculin skin test in tuberculous uveitis.","TST (tuberculin skin test) only","NW"
"2015-01-18335","2015","Lin 2015 Cardiovasc Drugs Ther","38000","Statin treatment VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Singapore.","25860556","Healthy; Age- >=65 years; Gender- Both; Country- Singapore.","Statin treatment","Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.","None","NE"
"2015-01-17406","2015","Khoo 2015 CNS Drugs","310000","Agomelatine VERSUS Mirtazapine IN Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","26293743","Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","Agomelatine","Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.","Mirtazapine","NE"
"2015-01-17406","2015","Khoo 2015 CNS Drugs","730000","Venlafaxine VERSUS Mirtazapine IN Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","26293743","Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","Venlafaxine","Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.","Mirtazapine","NE"
"2015-01-17406","2015","Khoo 2015 CNS Drugs","Dominated","Duloxetine VERSUS Mirtazapine IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","26293743","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","Duloxetine","Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.","Mirtazapine","NW"
"2015-01-17406","2015","Khoo 2015 CNS Drugs","Dominated","Escitalopram VERSUS Mirtazapine IN Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","26293743","Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","Escitalopram","Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.","Mirtazapine","NW"
"2015-01-17406","2015","Khoo 2015 CNS Drugs","Dominated","Fluoxetine VERSUS Mirtazapine IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","26293743","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","Fluoxetine","Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.","Mirtazapine","NW"
"2015-01-17406","2015","Khoo 2015 CNS Drugs","Dominated","Fluvoxamine VERSUS Mirtazapine IN Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","26293743","Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","Fluvoxamine","Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.","Mirtazapine","NW"
"2015-01-17406","2015","Khoo 2015 CNS Drugs","Dominated","Paroxetine VERSUS Mirtazapine IN Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","26293743","Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","Paroxetine","Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.","Mirtazapine","NW"
"2015-01-17406","2015","Khoo 2015 CNS Drugs","Dominated","Sertraline VERSUS Mirtazapine IN Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","26293743","Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","Sertraline","Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.","Mirtazapine","NW"
"2015-01-17406","2015","Khoo 2015 CNS Drugs","Dominated","Trazodone VERSUS Mirtazapine IN Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","26293743","Specific disease- Major depressive disorder (MDD); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Singapore; Other- Diagnosed with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-III, DSM-III-R, DSM-IV or DSM-IV-TR).","Trazodone","Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.","Mirtazapine","NW"
"2015-01-16852","2015","Lim 2015 Hepatology","120000","Cadaveric Liver Transplantation VERSUS Liver Resection IN Specific disease- Hepatocellular carcinoma; Age- 41 to 64 years; Gender- Both; Country- Singapore.","24638991","Specific disease- Hepatocellular carcinoma; Age- 41 to 64 years; Gender- Both; Country- Singapore.","Cadaveric Liver Transplantation","Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.","Liver Resection","NE"
"2015-01-16852","2015","Lim 2015 Hepatology","130000","Cadaveric Liver Transplantation VERSUS Liver Resection IN Specific disease- Hepatocellular carcinoma; Age- 41 to 64 years; Gender- Both; Country- United States; Other- Early defined by Milan criteria and adequate liver function (defined as Child-Pugh A/B cirrhosis), who have undergone either liver resection or cadaveric liver transplantation.","24638991","Specific disease- Hepatocellular carcinoma; Age- 41 to 64 years; Gender- Both; Country- United States; Other- Early defined by Milan criteria and adequate liver function (defined as Child-Pugh A/B cirrhosis), who have undergone either liver resection or cadaveric liver transplantation.","Cadaveric Liver Transplantation","Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.","Liver Resection","NE"
"2015-01-16852","2015","Lim 2015 Hepatology","170000","Cadaveric Liver Transplantation VERSUS Liver Resection IN Specific disease- Hepatocellular carcinoma; Age- 41 to 64 years; Gender- Both; Country- Switzerland; Other- Early defined by Milan criteria and adequate liver function (defined as Child-Pugh A/B cirrhosis), who have undergone either liver resection or cadaveric liver transplantation.","24638991","Specific disease- Hepatocellular carcinoma; Age- 41 to 64 years; Gender- Both; Country- Switzerland; Other- Early defined by Milan criteria and adequate liver function (defined as Child-Pugh A/B cirrhosis), who have undergone either liver resection or cadaveric liver transplantation.","Cadaveric Liver Transplantation","Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.","Liver Resection","NE"
"2014-01-16085","2014","Dan 2014 Antivir Ther","150","Boceprevir co-administration VERSUS Standard/Usual Care IN Specific disease- Chronic HCV Genotype 1 infection; Age- Unknown; Gender- Both; Country- Singapore.","25105844","Specific disease- Chronic HCV Genotype 1 infection; Age- Unknown; Gender- Both; Country- Singapore.","Boceprevir co-administration","Cost-effectiveness of boceprevir co-administration versus pegylated interferon-alpha2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.","Standard/Usual Care","NE"
"2017-01-25716","2017","Psota 2017 Clinicoecon Outcomes Res","10000","Insulin degludec/liraglutide (iDeglira) VERSUS Basal-bolus  therapy IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Slovakia.","29276398","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Slovakia.","Insulin degludec/liraglutide (iDeglira)","Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.","Basal-bolus  therapy","NE"
"2017-01-25682","2017","Tesar 2017 Front Pharmacol","110000","Heberprot-P plus Good Wound Care VERSUS Standard/Usual Care- Good wound care IN Specific disease- Advanced diabetic foot ulcer; Age- Adult; Gender- Both; Country- Slovakia.","29311943","Specific disease- Advanced diabetic foot ulcer; Age- Adult; Gender- Both; Country- Slovakia.","Heberprot-P plus Good Wound Care","Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for  Patients in Slovakia with Advanced Diabetic Foot Ulcer.","Standard/Usual Care- Good wound care","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","10000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with extended-release (ER) oxycodone IN Individuals with chronic, malignant pain in Slovakia","21957828","Individuals with chronic, malignant pain in Slovakia","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with extended-release (ER) oxycodone","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","11000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with sustained-release (SR) morphine IN Individuals with chronic, nonmalignant pain in Slovakia","21957828","Individuals with chronic, nonmalignant pain in Slovakia","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with sustained-release (SR) morphine","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","13000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with sustained-release (SR) morphine IN Individuals with chronic, nonmalignant pain in Portugal","21957828","Individuals with chronic, nonmalignant pain in Portugal","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with sustained-release (SR) morphine","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","15000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with extended-release (ER) oxycodone IN Individuals with chronic, nonmalignant pain in Italy","21957828","Individuals with chronic, nonmalignant pain in Italy","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with extended-release (ER) oxycodone","NE"
"2011-01-07866","2011","Hauber 2011 J Opioid Manag","15000","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic) VERSUS Treatment with sustained-release (SR) morphine IN Individuals with chronic, malignant pain in Italy","21957828","Individuals with chronic, malignant pain in Italy","Treatment with osmotic extended-release oral delivery system (OROS) hydropmorphone (a long-acting opioid analgesic)","Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.","Treatment with sustained-release (SR) morphine","NE"
"2018-01-26277","2018","Mihajlovic 2018 Ticks Tick Borne Dis","53000","Anti-tick vaccine VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; ; Country- Netherlands.","30197268","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; ; Country- Netherlands.","Anti-tick vaccine","Cost-effectiveness of a potential anti-tick vaccine with combined protection against Lyme borreliosis and tick-borne encephalitis in Slovenia.","None","NE"
"2014-01-15347","2014","Janzic 2014 Pharmacoeconomics","22000","Apixaban VERSUS Standard/Usual Care- Standard adjusted-dose (target INR of 2-3) warfarin treatment IN Specific disease- Nonvalvular atrial fibrillatrion; Age- >=65 years; Gender- Both; Country- Slovenia; Other- Nondisabled, increased risk for stroke, started on anticoagulation treatment.","25512096","Specific disease- Nonvalvular atrial fibrillatrion; Age- >=65 years; Gender- Both; Country- Slovenia; Other- Nondisabled, increased risk for stroke, started on anticoagulation treatment.","Apixaban","Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.","Standard/Usual Care- Standard adjusted-dose (target INR of 2-3) warfarin treatment","NE"
"2014-01-15347","2014","Janzic 2014 Pharmacoeconomics","24000","Dabigatran VERSUS Standard/Usual Care- Standard adjusted-dose (target INR of 2-3) warfarin treatment IN Specific disease- Nonvalvular atrial fibrillatrion; Age- >=65 years; Gender- Both; Country- Slovenia; Other- Nondisabled, increased risk for stroke, started on anticoagulation treatment.","25512096","Specific disease- Nonvalvular atrial fibrillatrion; Age- >=65 years; Gender- Both; Country- Slovenia; Other- Nondisabled, increased risk for stroke, started on anticoagulation treatment.","Dabigatran","Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.","Standard/Usual Care- Standard adjusted-dose (target INR of 2-3) warfarin treatment","NE"
"2014-01-15347","2014","Janzic 2014 Pharmacoeconomics","27000","High-dose Edoxaban [60 mg] VERSUS Standard/Usual Care- Standard adjusted-dose (target INR of 2-3) warfarin treatment IN Specific disease- Nonvalvular atrial fibrillatrion; Age- >=65 years; Gender- Both; Country- Slovenia; Other- Nondisabled, increased risk for stroke, started on anticoagulation treatment.","25512096","Specific disease- Nonvalvular atrial fibrillatrion; Age- >=65 years; Gender- Both; Country- Slovenia; Other- Nondisabled, increased risk for stroke, started on anticoagulation treatment.","High-dose Edoxaban [60 mg]","Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.","Standard/Usual Care- Standard adjusted-dose (target INR of 2-3) warfarin treatment","NE"
"2014-01-15347","2014","Janzic 2014 Pharmacoeconomics","7500","Warfarin, genotype-guided dosing VERSUS Standard/Usual Care- Standard adjusted-dose (target INR of 2-3) warfarin treatment IN Specific disease- Nonvalvular atrial fibrillatrion; Age- >=65 years; Gender- Not Specified; Country- Slovenia; Other- Nondisabled, increased risk for stroke, started on anticoagulation treatment.","25512096","Specific disease- Nonvalvular atrial fibrillatrion; Age- >=65 years; Gender- Not Specified; Country- Slovenia; Other- Nondisabled, increased risk for stroke, started on anticoagulation treatment.","Warfarin, genotype-guided dosing","Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.","Standard/Usual Care- Standard adjusted-dose (target INR of 2-3) warfarin treatment","NE"
"2014-01-15347","2014","Janzic 2014 Pharmacoeconomics","94000","Rivaroxaban VERSUS Standard/Usual Care- Standard adjusted-dose (target INR of 2-3) warfarin treatment IN Specific disease- Nonvalvular atrial fibrillatrion; Age- >=65 years; Gender- Both; Country- Slovenia; Other- Nondisabled, increased risk for stroke, started on anticoagulation treatment.","25512096","Specific disease- Nonvalvular atrial fibrillatrion; Age- >=65 years; Gender- Both; Country- Slovenia; Other- Nondisabled, increased risk for stroke, started on anticoagulation treatment.","Rivaroxaban","Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.","Standard/Usual Care- Standard adjusted-dose (target INR of 2-3) warfarin treatment","NE"
"2013-01-10836","2013","Naversnik 2013 Telemed J E Health","2200","'Improvehealth.eu' e-health service to support depression care and reported positive outcomes consisting of a web based information and communication technology system and online- and phone-based care management performed by trained psychologists VERSUS Standard/Usual care- physician visits and antidepressant treatment IN Specific disease- Depression; Age- Adult; Gender- Both; Country- Slovenia.","23374036","Specific disease- Depression; Age- Adult; Gender- Both; Country- Slovenia.","'Improvehealth.eu' e-health service to support depression care and reported positive outcomes consisting of a web based information and communication technology system and online- and phone-based care management performed by trained psychologists","Cost-effectiveness of a novel e-health depression service.","Standard/Usual care- physician visits and antidepressant treatment","NE"
"2012-01-09616","2012","Smit 2012 Vaccine","24000","Tick-borne encephalitis vaccination (FSME-Immun) VERSUS None IN Adults aged 18-80 years with of without tick-borne encephalitis vaccination in Slovenia: healthcare perspective","22885012","Adults aged 18-80 years with of without tick-borne encephalitis vaccination in Slovenia: healthcare perspective","Tick-borne encephalitis vaccination (FSME-Immun)","Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults.","None","NE"
"2012-01-09616","2012","Smit 2012 Vaccine","31000","Tick-borne encephalitis vaccination (Encepur) VERSUS None IN Adults aged 18-80 years with of without tick-borne encephalitis vaccination in Slovenia: healthcare perspective","22885012","Adults aged 18-80 years with of without tick-borne encephalitis vaccination in Slovenia: healthcare perspective","Tick-borne encephalitis vaccination (Encepur)","Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults.","None","NE"
"2012-01-09616","2012","Smit 2012 Vaccine","Cost-Saving","Tick-borne encephalitis vaccination (Encepur) VERSUS None IN Adults aged 18-80 years with of without tick-borne encephalitis vaccination in Slovenia: societal perspective","22885012","Adults aged 18-80 years with of without tick-borne encephalitis vaccination in Slovenia: societal perspective","Tick-borne encephalitis vaccination (Encepur)","Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults.","None","SE"
"2012-01-09616","2012","Smit 2012 Vaccine","Cost-Saving","Tick-borne encephalitis vaccination (FSME-Immun) VERSUS None IN Adults aged 18-80 years with of without tick-borne encephalitis vaccination in Slovenia: societal perspective","22885012","Adults aged 18-80 years with of without tick-borne encephalitis vaccination in Slovenia: societal perspective","Tick-borne encephalitis vaccination (FSME-Immun)","Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults.","None","SE"
"2010-01-06577","2010","Obradovic 2010 Eur J Public Health","40000","Human Papillomavirus (HPV) vaccination with current cervical cancer screening program VERSUS Current cervical cancer screening program IN 12-year old girls in Slovenia","20624834","12-year old girls in Slovenia","Human Papillomavirus (HPV) vaccination with current cervical cancer screening program","Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.","Current cervical cancer screening program","NE"
"2008-01-03880","2008","Rojnik 2008 Value Health","69000","Breast cancer screening 3 times a year in women aged 40-80 years VERSUS Breast cancer creening 3 times a year in women aged 40-75 years IN 40- year-old Slovenian women","18380626","40- year-old Slovenian women","Breast cancer screening 3 times a year in women aged 40-80 years","Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia.","Breast cancer creening 3 times a year in women aged 40-75 years","NE"
"2018-01-27452","2018","de Montigny 2018 Sci Rep","14000","Campaign Vaccination VERSUS No vaccination IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","29666455","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","Campaign Vaccination","Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.","No vaccination","NE"
"2018-01-27452","2018","de Montigny 2018 Sci Rep","19000","Clinical-based vacinnation  VERSUS No vaccination IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","29666455","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","Clinical-based vacinnation","Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.","No vaccination","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","1100","Trivalent influenza vaccine, 10% Symptomatic attack rate VERSUS None IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- South Africa; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- South Africa; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Trivalent influenza vaccine, 10% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","None","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","1100","Trivalent influenza vaccine, 5% Symptomatic attack rate VERSUS None IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Vietnam; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Vietnam; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Trivalent influenza vaccine, 5% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","None","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","1600","Quadrivalent influenza vaccine, 5% Symptomatic attack rate VERSUS Trivalent influenza vaccine, 5% Symptomatic attack rate IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Vietnam; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Vietnam; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Quadrivalent influenza vaccine, 5% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","Trivalent influenza vaccine, 5% Symptomatic attack rate","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","1700","Quadrivalent influenza vaccine, 10% Symptomatic attack rate VERSUS Trivalent influenza vaccine, 10% Symptomatic attack rate IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- South Africa; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- South Africa; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Quadrivalent influenza vaccine, 10% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","Trivalent influenza vaccine, 10% Symptomatic attack rate","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","1900","Trivalent influenza vaccine, 5% symptomatic attack rate  VERSUS None IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- South Africa; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- South Africa; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Trivalent influenza vaccine, 5% symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","None","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","4500","Quadrivalent influenza, 5% Symptomatic attack rate VERSUS Trivalent influenza vaccine IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- South Africa; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- South Africa; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Quadrivalent influenza, 5% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","Trivalent influenza vaccine","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","670","Quadrivalent influenza vaccine, 10% Symptomatic attack rate VERSUS Trivalent influenza vaccine, 10% Symptomatic attack rate IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Vietnam; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Vietnam; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Quadrivalent influenza vaccine, 10% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","Trivalent influenza vaccine, 10% Symptomatic attack rate","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","670","Trivalent influenza vaccine, 10% Symptomatic attack rate VERSUS None IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Vietnam; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Vietnam; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Trivalent influenza vaccine, 10% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","None","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","87000","Quadrivalent influenza vaccine, 5% Symptomatic attack rate VERSUS Trivalent influenza vaccine, 5% Symptomatic attack rate IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Australia; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Australia; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Quadrivalent influenza vaccine, 5% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","Trivalent influenza vaccine, 5% Symptomatic attack rate","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","9000","Quadrivalent influenza vaccine, 10% Symptomatic attack rate VERSUS Trivalent influenza vaccine, 10% Symptomatic attack rate IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Australia; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Australia; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Quadrivalent influenza vaccine, 10% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","Trivalent influenza vaccine, 10% Symptomatic attack rate","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","980","Trivalent influenza vaccine, 5% Symptomatic attack rate VERSUS None IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Australia; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Australia; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Trivalent influenza vaccine, 5% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","None","NE"
"2018-01-25608","2018","de Boer 2018 Vaccine","Cost-Saving","Trivalent influenza vaccine, 10% Symptomatic attack rate VERSUS None IN Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Australia; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","29373192","Healthy; Age- 0 to 18 years, >=65 years, Adult; Gender- Both; Country- Australia; Other- HIV-infected individuals prioritized, before elderly aged 65+ years and young children.","Trivalent influenza vaccine, 10% Symptomatic attack rate","The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.","None","SE"
"2016-01-20510","2016","Fraser 2016 Pharmacoeconomics","Cost-Saving","Sofosbuvir + pegylated interferon and ribavirin VERSUS Standard/Usual Care- Pegylated interferon and ribavirin IN Specific disease- Chronic hepatitis C virus genotype 5; Age- Adult; Gender- Both; Country- South Africa; Other- Treatment-naÃ¯ve, HIV-negative patients.","26666639","Specific disease- Chronic hepatitis C virus genotype 5; Age- Adult; Gender- Both; Country- South Africa; Other- Treatment-naÃ¯ve, HIV-negative patients.","Sofosbuvir + pegylated interferon and ribavirin","Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.","Standard/Usual Care- Pegylated interferon and ribavirin","SE"
"2016-01-20510","2016","Fraser 2016 Pharmacoeconomics","Cost-Saving","Sofosbuvir-ledipasvir VERSUS Sofosbuvir + pegylated interferon and ribavirin IN Specific disease- Chronic hepatitis C virus genotype 5; Age- Adult; Gender- Both; Country- South Africa; Other- Treatment-naÃ¯ve, HIV-negative patients.","26666639","Specific disease- Chronic hepatitis C virus genotype 5; Age- Adult; Gender- Both; Country- South Africa; Other- Treatment-naÃ¯ve, HIV-negative patients.","Sofosbuvir-ledipasvir","Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.","Sofosbuvir + pegylated interferon and ribavirin","SE"
"2016-01-20510","2016","Fraser 2016 Pharmacoeconomics","Cost-Saving","Sofosbuvir-ledipasvir VERSUS Standard/Usual Care- Pegylated interferon and ribavirin IN Specific disease- Chronic hepatitis C virus genotype 5; Age- Adult; Gender- Both; Country- South Africa; Other- Treatment-naÃ¯ve, HIV-negative patients.","26666639","Specific disease- Chronic hepatitis C virus genotype 5; Age- Adult; Gender- Both; Country- South Africa; Other- Treatment-naÃ¯ve, HIV-negative patients.","Sofosbuvir-ledipasvir","Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.","Standard/Usual Care- Pegylated interferon and ribavirin","SE"
"2016-01-19356","2016","Ying 2016 Lancet HIV","1800","Home HIV testing and counseling (HTC) every 5 years plus additional antiretroviral therapy (ART) VERSUS None IN Specific disease- HIV; Age- Adult; Gender- Both; Country- South Africa; Other- High viral load, >10,000 copies per mL.","27240790","Specific disease- HIV; Age- Adult; Gender- Both; Country- South Africa; Other- High viral load, >10,000 copies per mL.","Home HIV testing and counseling (HTC) every 5 years plus additional antiretroviral therapy (ART)","Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.","None","NE"
"2016-01-19356","2016","Ying 2016 Lancet HIV","930","Home HIV testing and counseling (HTC) every 5 years with antiretroviral therapy (ART) initiation VERSUS None IN Specific disease- HIV; Age- Adult; Gender- Both; Country- South Africa; Other- CD4 counts of 350 cells per ÂµL or less.","27240790","Specific disease- HIV; Age- Adult; Gender- Both; Country- South Africa; Other- CD4 counts of 350 cells per ÂµL or less.","Home HIV testing and counseling (HTC) every 5 years with antiretroviral therapy (ART) initiation","Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.","None","NE"
"2016-01-19356","2016","Ying 2016 Lancet HIV","970","Home HIV testing and counseling (HTC) every 5 years plus additional antiretroviral therapy (ART) VERSUS None IN Specific disease- HIV; Age- Adult; Gender- Both; Country- South Africa; Other- CD4 counts of 350-500 cells per ÂµL or less.","27240790","Specific disease- HIV; Age- Adult; Gender- Both; Country- South Africa; Other- CD4 counts of 350-500 cells per ÂµL or less.","Home HIV testing and counseling (HTC) every 5 years plus additional antiretroviral therapy (ART)","Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.","None","NE"
"2015-01-20534","2015","Li 2015 BMC Infect Dis","9200","Screening + HPV Vaccination VERSUS Screening IN Healthy; Age- 0 to 18 years; Gender- Female; Country- South Africa.","26652918","Healthy; Age- 0 to 18 years; Gender- Female; Country- South Africa.","Screening + HPV Vaccination","Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.","Screening","NE"
"2014-01-17112","2014","Zulliger 2014 AIDS Behav","1300","Rapid antiretroviral therapy in pregnancy pilot program VERSUS Standard/Usual Care- Standard prevent mother-to-child transmission services (women initiated on ART much later) IN Specific disease- HIV; Age- Adult; Gender- Female; Country- South Africa; Other- Pregnant women.","24122044","Specific disease- HIV; Age- Adult; Gender- Female; Country- South Africa; Other- Pregnant women.","Rapid antiretroviral therapy in pregnancy pilot program","Cost-effectiveness of a package of interventions for expedited antiretroviral therapy initiation during pregnancy in Cape Town, South Africa.","Standard/Usual Care- Standard prevent mother-to-child transmission services (women initiated on ART much later)","NE"
"2014-01-16833","2014","Alistar 2014 BMC Med","450","Antiretroviral therapy (ART) and oral pre-exposure prophylaxis (PrEP) for HIV prevention (scaling access for CD4 counts = 350 cells/ÂµL) VERSUS None IN Healthy; Age- 19/40 years, Gender- both, Country- South Africa","24629217","Healthy; Age- 19/40 years, Gender- both, Country- South Africa","Antiretroviral therapy (ART) and oral pre-exposure prophylaxis (PrEP) for HIV prevention (scaling access for CD4 counts = 350 cells/ÂµL)","Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.","None","NE"
"2014-01-16266","2014","Hulme 2014 J Dent","Dominated","Silicone impression for complete dentures VERSUS alginate impression IN Specific disease- tooth loss; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom.","24995472","Specific disease- tooth loss; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom.","Silicone impression for complete dentures","Cost-effectiveness of silicone and alginate impressions for complete dentures.","alginate impression","NW"
"2013-01-11331","2013","Irlam 2013 Circ Cardiovasc Qual Outcomes","150000","Treat those with CDR 3+, culture CDR negative and treat those with positive culture (treatment with intramuscular penicillin) VERSUS clinical decision rule (CDR) score =2 (CDR 2+) (treatment with intramuscular penicillin) IN Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","23652737","Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","Treat those with CDR 3+, culture CDR negative and treat those with positive culture (treatment with intramuscular penicillin)","Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis.","clinical decision rule (CDR) score =2 (CDR 2+) (treatment with intramuscular penicillin)","NE"
"2013-01-11331","2013","Irlam 2013 Circ Cardiovasc Qual Outcomes","150000","Treat those with positive throat culture (treatment with intramuscular penicillin), culture all VERSUS clinical decision rule (CDR) score =2 (CDR 2+) (treatment with intramuscular penicillin) IN Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","23652737","Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","Treat those with positive throat culture (treatment with intramuscular penicillin), culture all","Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis.","clinical decision rule (CDR) score =2 (CDR 2+) (treatment with intramuscular penicillin)","NE"
"2013-01-11331","2013","Irlam 2013 Circ Cardiovasc Qual Outcomes","170","Clinical decision rule (CDR) score =2 (CDR 2+) (treatment with intramuscular penicillin) VERSUS Treat all (treatment with intramuscular penicillin) IN Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","23652737","Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","Clinical decision rule (CDR) score =2 (CDR 2+) (treatment with intramuscular penicillin)","Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis.","Treat all (treatment with intramuscular penicillin)","NE"
"2013-01-11331","2013","Irlam 2013 Circ Cardiovasc Qual Outcomes","400000","Treat those with CDR 2+, culture CDR negatives and treat those with positive cultures (treatment with intramuscular penicillin) VERSUS Clinical decision rule (CDR) score =2 (CDR 2+)  (treatment with intramuscular penicillin) IN Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","23652737","Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","Treat those with CDR 2+, culture CDR negatives and treat those with positive cultures (treatment with intramuscular penicillin)","Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis.","Clinical decision rule (CDR) score =2 (CDR 2+)  (treatment with intramuscular penicillin)","NE"
"2013-01-11331","2013","Irlam 2013 Circ Cardiovasc Qual Outcomes","Dominated","Clinical decision rule (CDR) score =3 (CDR 3+) (treatment with intramuscular penicillin) VERSUS clinical decision rule (CDR) score =2 (CDR 2+) (treatment with intramuscular penicillin) IN Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","23652737","Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","Clinical decision rule (CDR) score =3 (CDR 3+) (treatment with intramuscular penicillin)","Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis.","clinical decision rule (CDR) score =2 (CDR 2+) (treatment with intramuscular penicillin)","NW"
"2013-01-11331","2013","Irlam 2013 Circ Cardiovasc Qual Outcomes","Dominated","Observation only (treat none) VERSUS Clinical decision rule (CDR) score =2 (CDR 2+) (treatment with intramuscular penicillin) IN Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","23652737","Specific disease- Pharyngitis; Age- 0 to 18 years; Gender- Both; Country- South Africa.","Observation only (treat none)","Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis.","Clinical decision rule (CDR) score =2 (CDR 2+) (treatment with intramuscular penicillin)","NW"
"2013-01-11215","2013","Long 2013 J Gen Intern Med","10000","Oral pre-exposure prophylaxis (PrEP) with 50% utilization VERSUS Standard/Usual care- HIV testing and treatment IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","23588668","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","Oral pre-exposure prophylaxis (PrEP) with 50% utilization","Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness  analysis.","Standard/Usual care- HIV testing and treatment","NE"
"2013-01-11215","2013","Long 2013 J Gen Intern Med","11000","Combination portfolio includes all five programs: screening with annual frequency, ART (75% utilization), male circumcision (75% coverage) within 5 years, microbicide (50% utilization) and PrEP (50% utilization) VERSUS Screening with annual frequency and ART with 75% utilization IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","23588668","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","Combination portfolio includes all five programs: screening with annual frequency, ART (75% utilization), male circumcision (75% coverage) within 5 years, microbicide (50% utilization) and PrEP (50% utilization)","Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness  analysis.","Screening with annual frequency and ART with 75% utilization","NE"
"2013-01-11215","2013","Long 2013 J Gen Intern Med","1200","Screening with annual frequency and antiretroviral therapy (ART) with 75% utilization VERSUS Circumcision IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","23588668","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","Screening with annual frequency and antiretroviral therapy (ART) with 75% utilization","Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness  analysis.","Circumcision","NE"
"2013-01-11215","2013","Long 2013 J Gen Intern Med","1300","Antiretroviral therapy (ART) (CD4 < 350 cells/mm3) with 75% utilization VERSUS Standard/Usual care- HIV testing and treatment IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","23588668","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","Antiretroviral therapy (ART) (CD4 < 350 cells/mm3) with 75% utilization","Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness  analysis.","Standard/Usual care- HIV testing and treatment","NE"
"2013-01-11215","2013","Long 2013 J Gen Intern Med","170","HIV screening with annual frequency VERSUS Standard/Usual care- HIV testing and treatment IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","23588668","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","HIV screening with annual frequency","Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness  analysis.","Standard/Usual care- HIV testing and treatment","NE"
"2013-01-11215","2013","Long 2013 J Gen Intern Med","610","Microbicide with regular use by 50% of uninfected women VERSUS Standard/Usual care IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","23588668","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","Microbicide with regular use by 50% of uninfected women","Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness  analysis.","Standard/Usual care","NE"
"2013-01-11215","2013","Long 2013 J Gen Intern Med","6600","Circumcision, microbicide, and oral pre-exposure prophylaxis VERSUS Standard/Usual care- HIV testing and treatment IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","23588668","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","Circumcision, microbicide, and oral pre-exposure prophylaxis","Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness  analysis.","Standard/Usual care- HIV testing and treatment","NE"
"2013-01-11215","2013","Long 2013 J Gen Intern Med","Cost-Saving","Male circumcision with 75% coverage within 5 years VERSUS Standard/Usual care- HIV screening and treatment by ART IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","23588668","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- South Africa.","Male circumcision with 75% coverage within 5 years","Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness  analysis.","Standard/Usual care- HIV screening and treatment by ART","SE"
"2013-01-11132","2013","Bergh 2013 S Afr Med J","12000","Dabigatran VERSUS warfarin IN Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- South Africa.","23547700","Specific disease- atrial fibrillation; Age- Adult; Gender- Both; Country- South Africa.","Dabigatran","Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.","warfarin","NE"
"2013-01-10977","2013","Estill 2013 AIDS","10000","Point-of-care viral load tests of ART with detection limits between 1000 and 10000 copies/ml VERSUS Clinical monitoring of ART IN Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years, Adult; Gender- Both; Country- Saharan Africa.","23462219","Specific disease- HIV; Age- 19 to 40 years, 41 to 64 years, >=65 years, Adult; Gender- Both; Country- Saharan Africa.","Point-of-care viral load tests of ART with detection limits between 1000 and 10000 copies/ml","Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.","Clinical monitoring of ART","NE"
"2010-01-06486","2010","Athan 2010 AIDS","100","Low cost CD4 T-cell counting VERSUS WHO staging only IN HIV-infected individuals in the Republic of South Africa and Cote d'Ivoire considering initiating antiretroviral therapy in resource limited settings","20543661","HIV-infected individuals in the Republic of South Africa and Cote d'Ivoire considering initiating antiretroviral therapy in resource limited settings","Low cost CD4 T-cell counting","Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings.","WHO staging only","NE"
"2010-01-06486","2010","Athan 2010 AIDS","1100","Annual routine t CD4 T-cell counting VERSUS WHO staging only IN HIV-infected individuals in the Republic of South Africa and Cote d'Ivoire considering initiating antiretroviral therapy in resource limited settings","20543661","HIV-infected individuals in the Republic of South Africa and Cote d'Ivoire considering initiating antiretroviral therapy in resource limited settings","Annual routine t CD4 T-cell counting","Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings.","WHO staging only","NE"
"2009-01-05500","2009","Sinanovic 2009 Vaccine","1300","Vaccination of 12-year-old girls followed by screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30 VERSUS Screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30 IN Women screened for cervical cancer from societal perspective","19698807","Women screened for cervical cancer from societal perspective","Vaccination of 12-year-old girls followed by screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30","The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.","Screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30","NE"
"2009-01-05500","2009","Sinanovic 2009 Vaccine","1800","Vaccination of 12-year-old girls followed by screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30 VERSUS Screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30 IN Women screened for cervical cancer from health care perspective","19698807","Women screened for cervical cancer from health care perspective","Vaccination of 12-year-old girls followed by screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30","The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.","Screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30","NE"
"2009-01-04282","2009","Vijayaraghavan 2009 Gynecol Oncol","1200","HPV DNA testing followed by colposcopy for all HPV-positive women VERSUS Conventional cytology IN Women aged 30 in South Africa","19081611","Women aged 30 in South Africa","HPV DNA testing followed by colposcopy for all HPV-positive women","Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.","Conventional cytology","NE"
"2009-01-04282","2009","Vijayaraghavan 2009 Gynecol Oncol","1500","HPV DNA testing followed by cytology for HPV-positive women VERSUS Conventional cytology IN Women aged 30 in South Africa","19081611","Women aged 30 in South Africa","HPV DNA testing followed by cytology for HPV-positive women","Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.","Conventional cytology","NE"
"2009-01-04282","2009","Vijayaraghavan 2009 Gynecol Oncol","1500","Simultaneous HPV DNA testing abd conventional cytology co-screening VERSUS Conventional cytology IN Women aged 30 in South Africa","19081611","Women aged 30 in South Africa","Simultaneous HPV DNA testing abd conventional cytology co-screening","Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.","Conventional cytology","NE"
"2009-01-04282","2009","Vijayaraghavan 2009 Gynecol Oncol","2500","Conventional cytology followed by HPV for equivocal cytology results VERSUS No screening IN Women aged 30 in South Africa","19081611","Women aged 30 in South Africa","Conventional cytology followed by HPV for equivocal cytology results","Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.","No screening","NE"
"2009-01-04282","2009","Vijayaraghavan 2009 Gynecol Oncol","2800","HPV DNA testing followed by colposcopy for all HPV-positive women VERSUS No screening IN Women aged 30 in South Africa","19081611","Women aged 30 in South Africa","HPV DNA testing followed by colposcopy for all HPV-positive women","Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.","No screening","NE"
"2009-01-04282","2009","Vijayaraghavan 2009 Gynecol Oncol","2900","Simultaneous HPV DNA testing and conventional cytology co-screening VERSUS Conventional cytology IN Women aged 30 in South Africa","19081611","Women aged 30 in South Africa","Simultaneous HPV DNA testing and conventional cytology co-screening","Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.","Conventional cytology","NE"
"2009-01-04282","2009","Vijayaraghavan 2009 Gynecol Oncol","3400","HPV DNA testing followed by cytology for HPV-positive women VERSUS No screening IN Women aged 30 in South Africa","19081611","Women aged 30 in South Africa","HPV DNA testing followed by cytology for HPV-positive women","Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.","No screening","NE"
"2009-01-04282","2009","Vijayaraghavan 2009 Gynecol Oncol","7800","Conventional cytology VERSUS No screening IN Women aged 30 in South Africa","19081611","Women aged 30 in South Africa","Conventional cytology","Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.","No screening","NE"
"2009-01-04282","2009","Vijayaraghavan 2009 Gynecol Oncol","Cost-Saving","Conventional cytology followed by HPV triage for equivocal cytology results VERSUS Conventional cytology IN Women aged 30 in South Africa","19081611","Women aged 30 in South Africa","Conventional cytology followed by HPV triage for equivocal cytology results","Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.","Conventional cytology","SE"
"2008-01-04732","2008","Rosen 2008 J Acquir Immune Defic Syndr","11000","Tenofovir disoproxil fumarate VERSUS Stavudine (d4T) IN Patients who experienced d4T-(stavudine) and TDF (tenofovir disoproxil fumarate) related events over the 2 years after antiretroviral therapy initiation in South Africa","18545151","Patients who experienced d4T-(stavudine) and TDF (tenofovir disoproxil fumarate) related events over the 2 years after antiretroviral therapy initiation in South Africa","Tenofovir disoproxil fumarate","Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.","Stavudine (d4T)","NE"
"2008-01-04618","2008","Cleary 2008 AIDS","1200","First-line anti-retroviral therapy VERSUS No anti-retroviral therapy IN HIV positive South Africans","18664951","HIV positive South Africans","First-line anti-retroviral therapy","Assessing efficiency and costs of scaling up HIV treatment.","No anti-retroviral therapy","NE"
"2008-01-04618","2008","Cleary 2008 AIDS","2200","First and second-line anti-retroviral therapy VERSUS First-line anti-retroviral therapy IN HIV positive South Africans","18664951","HIV positive South Africans","First and second-line anti-retroviral therapy","Assessing efficiency and costs of scaling up HIV treatment.","First-line anti-retroviral therapy","NE"
"2007-01-03215","2007","Vijayaraghavan 2007 J Acquir Immune Defic Syndr","5100","treat CD4 counts <=350 cells/mm3 or viral loads >100,000 copies/mL, and monitor CD4 cell counts and viral load every 3 months VERSUS Treat CD4 counts <=200 cells/mm3 or patients with AIDS, and monitor CD4 cell counts every 6 months IN HIV-positive adults in South Africa.","17621241","HIV-positive adults in South Africa.","treat CD4 counts <=350 cells/mm3 or viral loads >100,000 copies/mL, and monitor CD4 cell counts and viral load every 3 months","Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.","Treat CD4 counts <=200 cells/mm3 or patients with AIDS, and monitor CD4 cell counts every 6 months","NE"
"2006-01-02774","2006","Badri 2006 Antivir Ther","1500","VERSUS  IN South African population based on Cape Town AIDS Cohort Study","16518961","South African population based on Cape Town AIDS Cohort Study"," ","When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study."," ","NE"
"2006-01-02774","2006","Badri 2006 Antivir Ther","72","VERSUS  IN South African population based on Cape Town AIDS Cohort Study","16518961","South African population based on Cape Town AIDS Cohort Study"," ","When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study."," ","NE"
"2006-01-02774","2006","Badri 2006 Antivir Ther","820","VERSUS  IN South African population based on Cape Town AIDS Cohort Study","16518961","South African population based on Cape Town AIDS Cohort Study"," ","When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study."," ","NE"
"2018-01-28729","2018","Salavert 2018 Adv Ther","11000","Bezlotoxumab + Oral antibiotic therapy VERSUS Standard/Usual Care- Oral antibiotic therapy (metronidazole, vancomycin or fidaxomicin) IN Specific disease- Clostridium Difficile Infection ; Age- Adult; Gender- Both; Country- Spain; Other- Immunocompromised.","30328061","Specific disease- Clostridium Difficile Infection ; Age- Adult; Gender- Both; Country- Spain; Other- Immunocompromised.","Bezlotoxumab + Oral antibiotic therapy","Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.","Standard/Usual Care- Oral antibiotic therapy (metronidazole, vancomycin or fidaxomicin)","NE"
"2018-01-28729","2018","Salavert 2018 Adv Ther","15000","Bezlotoxumab + Oral antibiotic therapy VERSUS Standard/Usual Care- Oral antibiotic therapy (metronidazole, vancomycin or fidaxomicin) IN Specific disease- Clostridium difficile Infection; Age- >=65 years; Gender- Both; Country- Spain.","30328061","Specific disease- Clostridium difficile Infection; Age- >=65 years; Gender- Both; Country- Spain.","Bezlotoxumab + Oral antibiotic therapy","Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.","Standard/Usual Care- Oral antibiotic therapy (metronidazole, vancomycin or fidaxomicin)","NE"
"2018-01-28729","2018","Salavert 2018 Adv Ther","20000","Bezlotoxumab + Oral antibiotic therapy VERSUS Standard/Usual Care- Oral antibiotic therapy (metronidazole, vancomycin or fidaxomicin) IN Specific disease- Clostridium difficile Infection; Age- Adult; Gender- Both; Country- Spain; Other- Severe.","30328061","Specific disease- Clostridium difficile Infection; Age- Adult; Gender- Both; Country- Spain; Other- Severe.","Bezlotoxumab + Oral antibiotic therapy","Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.","Standard/Usual Care- Oral antibiotic therapy (metronidazole, vancomycin or fidaxomicin)","NE"
"2018-01-28729","2018","Salavert 2018 Adv Ther","5100","Bezlotoxumab + Oral antibiotic therapy VERSUS Standard/Usual Care- Oral antibiotic therapy (metronidazole, vancomycin or fidaxomicin) IN Specific disease- Clostridium difficile Infection; Age- >=65 years; Gender- Both; Country- Spain; Other- At least 1 episode of CDI in previous 6 months.","30328061","Specific disease- Clostridium difficile Infection; Age- >=65 years; Gender- Both; Country- Spain; Other- At least 1 episode of CDI in previous 6 months.","Bezlotoxumab + Oral antibiotic therapy","Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.","Standard/Usual Care- Oral antibiotic therapy (metronidazole, vancomycin or fidaxomicin)","NE"
"2018-01-28729","2018","Salavert 2018 Adv Ther","8600","Bezlotoxumab + Oral antibiotic therapy VERSUS Standard/Usual Care- Oral antibiotic therapy (metronidazole, vancomycin or fidaxomicin) IN Specific disease- Clostridium difficile Infection; Age- Adult; Gender- Both; Country- Spain; Other- Had at least 1 episode of CDI in previous 6 months.","30328061","Specific disease- Clostridium difficile Infection; Age- Adult; Gender- Both; Country- Spain; Other- Had at least 1 episode of CDI in previous 6 months.","Bezlotoxumab + Oral antibiotic therapy","Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.","Standard/Usual Care- Oral antibiotic therapy (metronidazole, vancomycin or fidaxomicin)","NE"
"2018-01-28594","2018","Kasaie 2018 PLoS One","34000","Early Antiretroviral Treatment + Improved Testing VERSUS Delayed Antiretroviral Treatment (CD4<350) IN Specific disease- HIV; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain.","30395635","Specific disease- HIV; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain.","Early Antiretroviral Treatment + Improved Testing","Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain.","Delayed Antiretroviral Treatment (CD4<350)","NE"
"2018-01-28594","2018","Kasaie 2018 PLoS One","34000","Early Antiretroviral Treatment VERSUS Delayed Antiretroviral Treatment (CD4<350) IN Specific disease- HIV; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain.","30395635","Specific disease- HIV; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain.","Early Antiretroviral Treatment","Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain.","Delayed Antiretroviral Treatment (CD4<350)","NE"
"2018-01-28460","2018","Driessen 2018 Respir Res","Cost-Saving","Umeclidinium bromide/vilanterol VERSUS Tiotropium/olodaterol 5/5 mcg  IN Specific disease- Chronic obstructive pulmonary disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smoking history =10 pack-years.","30458866","Specific disease- Chronic obstructive pulmonary disease; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smoking history =10 pack-years.","Umeclidinium bromide/vilanterol","Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.","Tiotropium/olodaterol 5/5 mcg","SE"
"2018-01-28391","2018","Buti 2018 PLoS One","10000","Hepatitis C virus screening and treatment of the general adult population VERSUS Hepatitis C virus screening of individuals in high-risk groups (the currently recommended strategy) IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain.","30485377","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain.","Hepatitis C virus screening and treatment of the general adult population","Healthcare value of implementing hepatitis C screening in the adult general population in Spain.","Hepatitis C virus screening of individuals in high-risk groups (the currently recommended strategy)","NE"
"2018-01-28391","2018","Buti 2018 PLoS One","8600","Hepatitis C virus screening and treatment of the general adult population VERSUS Hepatitis C virus screening of adults with the highest prevalence of HCV antibodies (anti-HCV) plus high-risk groups IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain.","30485377","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain.","Hepatitis C virus screening and treatment of the general adult population","Healthcare value of implementing hepatitis C screening in the adult general population in Spain.","Hepatitis C virus screening of adults with the highest prevalence of HCV antibodies (anti-HCV) plus high-risk groups","NE"
"2018-01-27745","2018","Trapero-Bertran 2018 Addiction","Cost-Saving","Alternative scenario (proactive telephone calls + current provision),  VERSUS Current provision (brief physician advice + self-help material + tobacco duty + smoking ban) IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smokers.","29532966","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smokers.","Alternative scenario (proactive telephone calls + current provision),","Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.","Current provision (brief physician advice + self-help material + tobacco duty + smoking ban)","SE"
"2018-01-27745","2018","Trapero-Bertran 2018 Addiction","Cost-Saving","Bupropion + current provision,  VERSUS Current provision (brief physician advice + self-help material + tobacco duty + smoking ban) IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smokers.","29532966","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smokers.","Bupropion + current provision,","Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.","Current provision (brief physician advice + self-help material + tobacco duty + smoking ban)","SE"
"2018-01-27745","2018","Trapero-Bertran 2018 Addiction","Cost-Saving","Current provision for smoking cessation  VERSUS Tobacco duty + smoking ban (baseline) IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smokers.","29532966","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smokers.","Current provision for smoking cessation","Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.","Tobacco duty + smoking ban (baseline)","SE"
"2018-01-27745","2018","Trapero-Bertran 2018 Addiction","Cost-Saving","Prescription nicotine replacement therapy + current provision VERSUS Current provision (brief physician advice + self-help material + tobacco duty + smoking ban) IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smokers.","29532966","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smokers.","Prescription nicotine replacement therapy + current provision","Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.","Current provision (brief physician advice + self-help material + tobacco duty + smoking ban)","SE"
"2018-01-27745","2018","Trapero-Bertran 2018 Addiction","Cost-Saving","Varenicline + current provision,  VERSUS Current provision (brief physician advice + self-help material + tobacco duty + smoking ban) IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smokers.","29532966","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Smokers.","Varenicline + current provision,","Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.","Current provision (brief physician advice + self-help material + tobacco duty + smoking ban)","SE"
"2018-01-27552","2018","Lopez-Villegas 2018 J Telemed Telecare","Cost-Saving","Telemonitoring of users with pacemakers VERSUS Standard/Usual Care- Conventional follow-up in hospital IN Healthy; Age- Adult; Gender- Both; Country- Spain; Other- With internet-based transmission pacemakers.","29621908","Healthy; Age- Adult; Gender- Both; Country- Spain; Other- With internet-based transmission pacemakers.","Telemonitoring of users with pacemakers","Cost-utility analysis on telemonitoring of users with pacemakers: The PONIENTE study.","Standard/Usual Care- Conventional follow-up in hospital","SE"
"2018-01-26817","2018","Garcia-Lorenzo 2018 Neurosurgery","12000","Stereoelectroencephalography VERSUS Standard/Usual Care- Antiepileptic drugs IN Specific disease- Epilepsy; Age- Adult; Gender- Both; Country- Spain; Other- Medically refractory epilepsy considered for surgery.","29982799","Specific disease- Epilepsy; Age- Adult; Gender- Both; Country- Spain; Other- Medically refractory epilepsy considered for surgery.","Stereoelectroencephalography","Stereoelectroencephalography for Refractory Epileptic Patients Considered for Surgery: Systematic Review, Meta-Analysis, and Economic Evaluation.","Standard/Usual Care- Antiepileptic drugs","NE"
"2018-01-26785","2018","Tremblay 2018 Epilepsy Behav","19000","Perampanel VERSUS Standard/Usual Care- Antiepileptic drug maintenance therapy IN Specific disease- Epilepsy; Age- Adult; Gender- Both; Country- Spain.","30001911","Specific disease- Epilepsy; Age- Adult; Gender- Both; Country- Spain.","Perampanel","Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective.","Standard/Usual Care- Antiepileptic drug maintenance therapy","NE"
"2018-01-26785","2018","Tremblay 2018 Epilepsy Behav","Cost-Saving","Perampanel VERSUS Standard/Usual Care- Antiepileptic drug maintenance therapy IN Specific disease- Epilepsy; Age- Adult; Gender- Both; Country- Spain.","30001911","Specific disease- Epilepsy; Age- Adult; Gender- Both; Country- Spain.","Perampanel","Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective.","Standard/Usual Care- Antiepileptic drug maintenance therapy","SE"
"2018-01-26527","2018","Ielpo 2018 Ann Surg","4300","Laparoscopic transabdominal preperitoneal (TAPP) repair VERSUS Open Lichtenstein repair  IN Specific disease- Bilateral inguinal hernia; Age- Adult; Gender- Both; Country- Spain.","30095476","Specific disease- Bilateral inguinal hernia; Age- Adult; Gender- Both; Country- Spain.","Laparoscopic transabdominal preperitoneal (TAPP) repair","Cost-effectiveness of Randomized Study of Laparoscopic Versus Open Bilateral Inguinal Hernia Repair.","Open Lichtenstein repair","NE"
"2018-01-26475","2018","Schur 2018 PLoS One","4600","Everolimus-eluting stent VERSUS Bare metal stent IN Specific disease- ST-elevation myocardial infarction; Age- Adult; Gender- Both; Country- Spain.","30114230","Specific disease- ST-elevation myocardial infarction; Age- Adult; Gender- Both; Country- Spain.","Everolimus-eluting stent","Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial.","Bare metal stent","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","170000","Biosimilar-infliximab (bsIFX) and Vedolizumab VERSUS Biosimilar-infliximab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","Biosimilar-infliximab (bsIFX) and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","170000","Vedolizumab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","180000","Biosimilar-infliximab and Adalimumab and Vedolizumab  VERSUS Biosimilar-infliximab and Adalimumab IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","Biosimilar-infliximab and Adalimumab and Vedolizumab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Biosimilar-infliximab and Adalimumab","NE"
"2018-01-25855","2018","Baji 2018 United European Gastroenterol J","64000","Biosimilar-infliximab VERSUS Standard/Usual Care IN Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","29511561","Specific disease- Crohn's Disease; Age- Adult; Gender- Both; Country- Spain.","Biosimilar-infliximab","Cost-effectiveness of biological treatment sequences for fistulising Crohn''s disease across Europe.","Standard/Usual Care","NE"
"2018-01-25659","2018","Gaultney 2018 Pharmacogenomics","Cost-Saving","Risk-stratified treatment: FISH+ISS+SKY92: stratified using any biomarker VERSUS Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly IN Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Newly diagnosed, transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","29334316","Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Newly diagnosed, transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","Risk-stratified treatment: FISH+ISS+SKY92: stratified using any biomarker","Potential therapeutic and economic value of risk-stratified treatment as initial  treatment of multiple myeloma in Europe.","Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly","SE"
"2018-01-25659","2018","Gaultney 2018 Pharmacogenomics","Cost-Saving","Risk-stratified treatment: Florescent in situ hybridization+International staging system VERSUS Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly IN Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Newly diagnosed,transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","29334316","Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Newly diagnosed,transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","Risk-stratified treatment: Florescent in situ hybridization+International staging system","Potential therapeutic and economic value of risk-stratified treatment as initial  treatment of multiple myeloma in Europe.","Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly","SE"
"2018-01-25659","2018","Gaultney 2018 Pharmacogenomics","Cost-Saving","Risk-stratified treatment: SKY92 molecular test VERSUS Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly IN Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Spain; Other- Newly diagnosed, transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","29334316","Specific disease- Multiple myeloma; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Spain; Other- Newly diagnosed, transplant-eligible patients, with Durie-Salmon stage II-III and WHO performance status 0-2, or WHO 3 when caused by MM.","Risk-stratified treatment: SKY92 molecular test","Potential therapeutic and economic value of risk-stratified treatment as initial  treatment of multiple myeloma in Europe.","Standard/Usual Care- Uniform treatment (UT) comprised of treating all patients similarly","SE"
"2017-01-25820","2017","Sanchez-Santos 2017 Expert Rev Pharmacoecon Outcomes Res","120","Surgery VERSUS Conservative management IN Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- Spain; Other- No diabetes-Super obese.","29188745","Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- Spain; Other- No diabetes-Super obese.","Surgery","Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis.","Conservative management","NE"
"2017-01-25820","2017","Sanchez-Santos 2017 Expert Rev Pharmacoecon Outcomes Res","2400","Surgery VERSUS Conservative management IN Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Spain; Other- No diabetes-Severely obese.","29188745","Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Spain; Other- No diabetes-Severely obese.","Surgery","Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis.","Conservative management","NE"
"2017-01-25820","2017","Sanchez-Santos 2017 Expert Rev Pharmacoecon Outcomes Res","3100","Surgery VERSUS Conservative management IN Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- Spain; Other- No diabetes-Severely obese.","29188745","Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- Spain; Other- No diabetes-Severely obese.","Surgery","Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis.","Conservative management","NE"
"2017-01-25820","2017","Sanchez-Santos 2017 Expert Rev Pharmacoecon Outcomes Res","3400","Surgery VERSUS Conservative management IN Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Spain; Other- No diabetes-Moderately obese.","29188745","Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Spain; Other- No diabetes-Moderately obese.","Surgery","Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis.","Conservative management","NE"
"2017-01-25820","2017","Sanchez-Santos 2017 Expert Rev Pharmacoecon Outcomes Res","390","Surgery VERSUS Conservative management IN Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Spain; Other- No diabetes-Morbidly obese.","29188745","Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Spain; Other- No diabetes-Morbidly obese.","Surgery","Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis.","Conservative management","NE"
"2017-01-25820","2017","Sanchez-Santos 2017 Expert Rev Pharmacoecon Outcomes Res","4000","Surgery VERSUS Conservative management IN Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- Spain; Other- No diabetes-Moderately obese.","29188745","Specific disease- Obesity; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- Spain; Other- No diabetes-Moderately obese.","Surgery","Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis.","Conservative management","NE"
"2017-01-25264","2017","Turnes 2017 Gastroenterol Hepatol","2800","Post Direct-Acting Antivirals (DAA) strategy VERSUS Pre Direct-Acting Antivirals (DAA) strategy IN Specific disease- Chronic hepatitis C Virus Infection; Age- Adult; Gender- Both; Country- Spain.","28645446","Specific disease- Chronic hepatitis C Virus Infection; Age- Adult; Gender- Both; Country- Spain.","Post Direct-Acting Antivirals (DAA) strategy","Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain.","Pre Direct-Acting Antivirals (DAA) strategy","NE"
"2017-01-25252","2017","Mezquita-Raya 2017 Expert Rev Pharmacoecon Outcomes Res","13000","Insulin degludec with basal-bolus therapy VERSUS Insulin glargine with basal-bolus therapy IN Specific disease- Type 1 and type 2 diabetes mellitus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Type 2 diabetes.","28649881","Specific disease- Type 1 and type 2 diabetes mellitus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Type 2 diabetes.","Insulin degludec with basal-bolus therapy","Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.","Insulin glargine with basal-bolus therapy","NE"
"2017-01-25252","2017","Mezquita-Raya 2017 Expert Rev Pharmacoecon Outcomes Res","61","Insulin degludec with basal-bolus therapy VERSUS Insulin glargine with basal-bolus therapy IN Specific disease- Diabetes mellitus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Type 1 diabetes.","28649881","Specific disease- Diabetes mellitus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Type 1 diabetes.","Insulin degludec with basal-bolus therapy","Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.","Insulin glargine with basal-bolus therapy","NE"
"2017-01-25252","2017","Mezquita-Raya 2017 Expert Rev Pharmacoecon Outcomes Res","Cost-Saving","Insulin degludec with basal-oral therapy VERSUS Insulin glargine with basal-oral therapy IN Specific disease- Diabetes mellitus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Type 2 diabetes.","28649881","Specific disease- Diabetes mellitus; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Type 2 diabetes.","Insulin degludec with basal-oral therapy","Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.","Insulin glargine with basal-oral therapy","SE"
"2017-01-24959","2017","Perez-Martin 2017 Laryngoscope","12000","Simultaneous bilateral cochlear implantation  VERSUS Unilateral cochlear implantation (UCI) IN Specific disease- Bilateral sensorineural severe to profound hearing loss; Age- 0 to 18 years; Gender- Both; Country- Spain; Other- Not been implanted previously.","28776715","Specific disease- Bilateral sensorineural severe to profound hearing loss; Age- 0 to 18 years; Gender- Both; Country- Spain; Other- Not been implanted previously.","Simultaneous bilateral cochlear implantation","Cost-effectiveness of pediatric bilateral cochlear implantation in Spain.","Unilateral cochlear implantation (UCI)","NE"
"2017-01-24790","2017","Moreno Guillen 2017 Farm Hosp","Cost-Saving","Dolutegravir with abacavir and lamivudine (DTG/ABC/3TC) VERSUS Darunavir/r (DRV/r) with Emtricitabine/Tenofovir (FTC/TDF) or Abacavir/Lamivudine (ABC/3TC) IN Specific disease- Human Immunodeficiency Virus (HIV); Age- Adult; Gender- Both; Country- Spain.","28847249","Specific disease- Human Immunodeficiency Virus (HIV); Age- Adult; Gender- Both; Country- Spain.","Dolutegravir with abacavir and lamivudine (DTG/ABC/3TC)","Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.","Darunavir/r (DRV/r) with Emtricitabine/Tenofovir (FTC/TDF) or Abacavir/Lamivudine (ABC/3TC)","SE"
"2017-01-24790","2017","Moreno Guillen 2017 Farm Hosp","Cost-Saving","Dolutegravir with abacavir and lamivudine (DTG/ABC/3TC) VERSUS Emtricitabine/ Tenofovir/Efavirenz (FTC/TDF/EFV) IN Specific disease- Human Immunodeficiency Virus (HIV); Age- Adult; Gender- Both; Country- Spain.","28847249","Specific disease- Human Immunodeficiency Virus (HIV); Age- Adult; Gender- Both; Country- Spain.","Dolutegravir with abacavir and lamivudine (DTG/ABC/3TC)","Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.","Emtricitabine/ Tenofovir/Efavirenz (FTC/TDF/EFV)","SE"
"2017-01-24790","2017","Moreno Guillen 2017 Farm Hosp","Cost-Saving","Dolutegravir with abacavir and lamivudine (DTG/ABC/3TC) VERSUS Raltegravir (RAL) with Emtricitabine/Tenofovir (FTC/TDF) or Abacavir/Lamivudine (ABC/3TC) IN Specific disease- Human Immunodeficiency Virus (HIV); Age- Adult; Gender- Both; Country- Spain.","28847249","Specific disease- Human Immunodeficiency Virus (HIV); Age- Adult; Gender- Both; Country- Spain.","Dolutegravir with abacavir and lamivudine (DTG/ABC/3TC)","Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.","Raltegravir (RAL) with Emtricitabine/Tenofovir (FTC/TDF) or Abacavir/Lamivudine (ABC/3TC)","SE"
"2017-01-24699","2017","Filipovic-Pierucci 2017 EuroIntervention","Cost-Saving","Drug coated stent VERSUS Bare metal stent IN Healthy; Age- Adult; Gender- Both; Country- Spain; Other- High risk of bleeding.","28891471","Healthy; Age- Adult; Gender- Both; Country- Spain; Other- High risk of bleeding.","Drug coated stent","Polymer-Free Drug-Coated Coronary Stents Are Cost-Effective in Patients at High Bleeding Risk: Economic Evaluation of the LEADERS FREE Trial.","Bare metal stent","SE"
"2017-01-24699","2017","Filipovic-Pierucci 2017 EuroIntervention","Cost-Saving","Drug coated stent VERSUS Bare metal stent IN Healthy; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- High risk of bleeding.","28891471","Healthy; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- High risk of bleeding.","Drug coated stent","Polymer-Free Drug-Coated Coronary Stents Are Cost-Effective in Patients at High Bleeding Risk: Economic Evaluation of the LEADERS FREE Trial.","Bare metal stent","SE"
"2017-01-24420","2017","Sanchez-Luna 2017 BMC Infect Dis","13000","Palivizumab VERSUS No Prophylaxis IN Specific disease- Respiratory Syncytial Virus infection prophylaxis; Age- 0 to 18 years; Gender- Both; Country- Spain; Other- 2 major risk factors and 2 minor risk factors.","29041909","Specific disease- Respiratory Syncytial Virus infection prophylaxis; Age- 0 to 18 years; Gender- Both; Country- Spain; Other- 2 major risk factors and 2 minor risk factors.","Palivizumab","Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.","No Prophylaxis","NE"
"2017-01-24420","2017","Sanchez-Luna 2017 BMC Infect Dis","16000","Palivizumab VERSUS No Prophylaxis IN Specific disease- Respiratory Syncytial Virus infection prophylaxis; Age- 0 to 18 years; Gender- Both; Country- Spain; Other- 2 major factors and 1 minor factor.","29041909","Specific disease- Respiratory Syncytial Virus infection prophylaxis; Age- 0 to 18 years; Gender- Both; Country- Spain; Other- 2 major factors and 1 minor factor.","Palivizumab","Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.","No Prophylaxis","NE"
"2017-01-24420","2017","Sanchez-Luna 2017 BMC Infect Dis","16000","Palivizumab VERSUS No Prophylaxis IN Specific disease- Respiratory Syncytial Virus infection prophylaxis; Age- 0 to 18 years; Gender- Both; Country- Spain; Other- 2 major factors.","29041909","Specific disease- Respiratory Syncytial Virus infection prophylaxis; Age- 0 to 18 years; Gender- Both; Country- Spain; Other- 2 major factors.","Palivizumab","Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.","No Prophylaxis","NE"
"2017-01-24420","2017","Sanchez-Luna 2017 BMC Infect Dis","23000","Palivizumab VERSUS Non-prophylaxis IN Specific disease- Respiratory Syncytial Virus (RSV) infection; Age- 0 to 18 years; Gender- Both; Country- Spain.","29041909","Specific disease- Respiratory Syncytial Virus (RSV) infection; Age- 0 to 18 years; Gender- Both; Country- Spain.","Palivizumab","Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.","Non-prophylaxis","NE"
"2017-01-24155","2017","Esteban 2017 Rev Esp Enferm Dig","15000","Endoscopic treatment based on radiofrequency ablation plus endoscopic mucosal resection (RFA-EMR) VERSUS Standard/Usual Care- Endoscopic surveillance IN Specific disease- Dysplastic Barrett's esophagus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Barrett's esophagus with low-grade dysplasia.","29168641","Specific disease- Dysplastic Barrett's esophagus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Barrett's esophagus with low-grade dysplasia.","Endoscopic treatment based on radiofrequency ablation plus endoscopic mucosal resection (RFA-EMR)","Economic evaluation of endoscopic radiofrequency ablation for the treatment of dysplastic Barrett''s esophagus in Spain.","Standard/Usual Care- Endoscopic surveillance","NE"
"2017-01-24155","2017","Esteban 2017 Rev Esp Enferm Dig","Cost-Saving","Endoscopic treatment based on radiofrequency ablation plus endoscopic mucosal resection (RFA-EMR) VERSUS Standard/Usual Care- Esophagectomy IN Specific disease- Dysplastic Barrett's esophagus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Barrett's esophagus with high-grade dysplasia (HGD).","29168641","Specific disease- Dysplastic Barrett's esophagus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Barrett's esophagus with high-grade dysplasia (HGD).","Endoscopic treatment based on radiofrequency ablation plus endoscopic mucosal resection (RFA-EMR)","Economic evaluation of endoscopic radiofrequency ablation for the treatment of dysplastic Barrett''s esophagus in Spain.","Standard/Usual Care- Esophagectomy","SE"
"2017-01-23951","2017","Rivera 2017 J Med Econ","27000","Panitumumab + oxaliplatin, 5-fluorouracil, and leucovorin (mFOLFOX6) VERSUS Bevacizumab + oxaliplatin, 5-fluorouracil, and leucovorin (mFOLFOX6) IN Specific disease- Colorectal cancer; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Patients with wild-type RAS metastatic colorectal cancer who had not received prior chemotherapy, anti-epidermal growth factor receptor therapy, or bevacizumab therapy.","28107090","Specific disease- Colorectal cancer; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Spain; Other- Patients with wild-type RAS metastatic colorectal cancer who had not received prior chemotherapy, anti-epidermal growth factor receptor therapy, or bevacizumab therapy.","Panitumumab + oxaliplatin, 5-fluorouracil, and leucovorin (mFOLFOX6)","Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line  treatment of patients with wild-type RAS metastatic colorectal cancer.","Bevacizumab + oxaliplatin, 5-fluorouracil, and leucovorin (mFOLFOX6)","NE"
"2018-01-27502","2018","Kim 2018 Spine (Phila Pa 1976)","8600","Cervical disc replacement VERSUS Standard/Usual Care- Anterior cervical discectomy and fusion IN Specific disease- Cervical disc degeneration; Age- 19 to 40 years; Gender- Both; Country- Swaziland; Other- Acute disc herniation with associated myelopathy or radiculopathy.","29642136","Specific disease- Cervical disc degeneration; Age- 19 to 40 years; Gender- Both; Country- Swaziland; Other- Acute disc herniation with associated myelopathy or radiculopathy.","Cervical disc replacement","The Seven-Year Cost-Effectiveness of Anterior Cervical Discectomy and Fusion Versus Cervical Disc Arthroplasty: A Markov Analysis.","Standard/Usual Care- Anterior cervical discectomy and fusion","NE"
"2018-01-28684","2018","Bilir 2018 Eur Endocrinol","36000","Flash monitoring VERSUS Standard/Usual Care- Self-monitored blood glucose IN Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Sweden; Other- Well-controlled Type 1 diabetes (HbA1c =7.5% [58 mmol/mol]) using multiple daily injection insulin therapy or continuous subcutaneous insulin infusion and testing glucose levels at least 10 times/week.","30349598","Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Sweden; Other- Well-controlled Type 1 diabetes (HbA1c =7.5% [58 mmol/mol]) using multiple daily injection insulin therapy or continuous subcutaneous insulin infusion and testing glucose levels at least 10 times/week.","Flash monitoring","Cost-effectiveness Analysis of a Flash Glucose Monitoring System for Patients with Type 1 Diabetes Receiving Intensive Insulin Treatment in Sweden.","Standard/Usual Care- Self-monitored blood glucose","NE"
"2018-01-28683","2018","Bilir 2018 Eur Endocrinol","37000","Flash monitoring VERSUS Standard/Usual Care- Self-monitoring of blood glucose IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Sweden; Other- HbA1c 7.5â12% (58â108 mmol/mol); Using multiple daily injection therapy or continuous subcutaneous insulin infusion for at least 6 months.","30349599","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Sweden; Other- HbA1c 7.5â12% (58â108 mmol/mol); Using multiple daily injection therapy or continuous subcutaneous insulin infusion for at least 6 months.","Flash monitoring","The Cost-effectiveness of a Flash Glucose Monitoring System for Management of Patients with Type 2 Diabetes Receiving Intensive Insulin Treatment in Sweden.","Standard/Usual Care- Self-monitoring of blood glucose","NE"
"2018-01-28662","2018","Djerf 2018 Br J Surg","49000","Revascularization + best medical therapy (as-treated analysis) VERSUS Best medical therapy alone IN Specific disease- Intermittent claudication; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","30357819","Specific disease- Intermittent claudication; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","Revascularization + best medical therapy (as-treated analysis)","Cost-effectiveness of revascularization in patients with intermittent claudication.","Best medical therapy alone","NE"
"2018-01-28662","2018","Djerf 2018 Br J Surg","50000","Revascularization + best medical therapy (intention-to-treat analysis) VERSUS Best medical therapy alone IN Specific disease- Intermittent claudication; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","30357819","Specific disease- Intermittent claudication; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","Revascularization + best medical therapy (intention-to-treat analysis)","Cost-effectiveness of revascularization in patients with intermittent claudication.","Best medical therapy alone","NE"
"2018-01-28609","2018","Shedrawy 2018 Vaccine","12000","Structured vaccination program for tick-born encephalitis VERSUS Out-of-pocket vaccination for tick-born encephalitis vaccine starting at age 40 (53% of cohort vaccinated on own expenses with no booster doses) IN Healthy; Age- 19 to 40 years; Gender- Both; Country- Sweden.","30385058","Healthy; Age- 19 to 40 years; Gender- Both; Country- Sweden.","Structured vaccination program for tick-born encephalitis","Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis.","Out-of-pocket vaccination for tick-born encephalitis vaccine starting at age 40 (53% of cohort vaccinated on own expenses with no booster doses)","NE"
"2018-01-28609","2018","Shedrawy 2018 Vaccine","19000","Structured vaccination program for tick-born encephalitis VERSUS Out-of-pocket vaccination for tick-born encephalitis vaccine starting at age 50 (53% of cohort vaccinated on own expenses with no booster doses) IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Sweden.","30385058","Healthy; Age- 41 to 64 years; Gender- Both; Country- Sweden.","Structured vaccination program for tick-born encephalitis","Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis.","Out-of-pocket vaccination for tick-born encephalitis vaccine starting at age 50 (53% of cohort vaccinated on own expenses with no booster doses)","NE"
"2018-01-28609","2018","Shedrawy 2018 Vaccine","3300","Structured vaccination program for tick-born encephalitis  VERSUS Out-of-pocket vaccination for tick-born encephalitis vaccine starting at age 3 (53% of cohort vaccinated on own expenses with no booster doses) IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Sweden.","30385058","Healthy; Age- 0 to 18 years; Gender- Both; Country- Sweden.","Structured vaccination program for tick-born encephalitis","Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis.","Out-of-pocket vaccination for tick-born encephalitis vaccine starting at age 3 (53% of cohort vaccinated on own expenses with no booster doses)","NE"
"2018-01-27534","2018","Hansson 2018 Bone Joint J","13000","Osseointegrated prostheses VERSUS Standard/Usual Care- Conventional care with socket-suspended prosthesis IN Specific disease- Unilateral transfemoral amputation ; Age- Adult; Gender- Both; Country- Sweden.","29629586","Specific disease- Unilateral transfemoral amputation ; Age- Adult; Gender- Both; Country- Sweden.","Osseointegrated prostheses","Patients with unilateral transfemoral amputation treated with a percutaneous osseointegrated prosthesis.","Standard/Usual Care- Conventional care with socket-suspended prosthesis","NE"
"2018-01-27511","2018","Hogberg 2018 Eur J Vasc Endovasc Surg","6700","Screening Strategy for Asymptomatic Carotid Stenosis VERSUS Standard/Usual Care- No Screening Strategy IN Healthy; Age- >=65 years; Gender- Male; Country- Sweden.","29636252","Healthy; Age- >=65 years; Gender- Male; Country- Sweden.","Screening Strategy for Asymptomatic Carotid Stenosis","Clinical Effect and Cost-Effectiveness of Screening for Asymptomatic Carotid Stenosis: A Markov Model.","Standard/Usual Care- No Screening Strategy","NE"
"2018-01-27373","2018","Westin 2018 Knee Surg Sports Traumatol Arthrosc","66000","Surgical treatment of acute Achilles tendon rupture VERSUS Non-surgical treatment: brace for 8 weeks with three heel pads IN Specific disease- Acute Achilles tendon rupture; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","29696317","Specific disease- Acute Achilles tendon rupture; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","Surgical treatment of acute Achilles tendon rupture","Cost-effectiveness analysis of surgical versus non-surgical management of acute Achilles tendon ruptures.","Non-surgical treatment: brace for 8 weeks with three heel pads","NE"
"2018-01-27149","2018","Ekerstad 2018 J Am Med Dir Assoc","Cost-Saving","Comprehensive Geriatric Assessments in Acute Hospital Care VERSUS Standard/Usual Care- Conventional Acute Medical Care IN Specific disease- Severely Frail; Age- >=65 years; Gender- Both; Country- Sweden; Other- Elderly.","29784592","Specific disease- Severely Frail; Age- >=65 years; Gender- Both; Country- Sweden; Other- Elderly.","Comprehensive Geriatric Assessments in Acute Hospital Care","Short-term Resource Utilization and Cost-Effectiveness of Comprehensive Geriatric Assessment in Acute Hospital Care for Severely Frail Elderly Patients.","Standard/Usual Care- Conventional Acute Medical Care","SE"
"2018-01-26966","2018","Holst 2018 BMJ Open","8900","Internet-mediated cognitive behavioural therapy VERSUS Standard/Usual Care- Treatment as Usual IN Specific disease- Depression; Age- Adult; ; Country- Sweden.","29903785","Specific disease- Depression; Age- Adult; ; Country- Sweden.","Internet-mediated cognitive behavioural therapy","Cost-effectiveness analysis of internet-mediated cognitive behavioural therapy for depression in the primary care setting: results based on a controlled trial.","Standard/Usual Care- Treatment as Usual","SW"
"2018-01-26735","2018","Wolff 2018 Vaccine","47000","Sex-neutral vaccination VERSUS Girls-only HPV vaccination IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Sweden.","30017146","Healthy; Age- 0 to 18 years; Gender- Both; Country- Sweden.","Sex-neutral vaccination","Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.","Girls-only HPV vaccination","NE"
"2018-01-26605","2018","Aronsson 2018 HPB (Oxford)","190000","Total pancreatectomy VERSUS Watchful waiting: symptomatic lesions were investigated and underwent partial pancreatectomy if deemed operable. IN Specific disease- Branch-duct intraductal papillary mucinous neoplasm (BD-IPMN); Age- >=65 years; Gender- Both; Country- Sweden.","30064727","Specific disease- Branch-duct intraductal papillary mucinous neoplasm (BD-IPMN); Age- >=65 years; Gender- Both; Country- Sweden.","Total pancreatectomy","Intraductal papillary mucinous neoplasms of the pancreas - a cost-effectiveness analysis of management strategies for the branch-duct subtype.","Watchful waiting: symptomatic lesions were investigated and underwent partial pancreatectomy if deemed operable.","NE"
"2018-01-26605","2018","Aronsson 2018 HPB (Oxford)","320000","Partial pancreatectomy VERSUS Watchful waiting IN Specific disease- Intraductal papillary mucinous neoplasms of the pancreas; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","30064727","Specific disease- Intraductal papillary mucinous neoplasms of the pancreas; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","Partial pancreatectomy","Intraductal papillary mucinous neoplasms of the pancreas - a cost-effectiveness analysis of management strategies for the branch-duct subtype.","Watchful waiting","NE"
"2018-01-26605","2018","Aronsson 2018 HPB (Oxford)","37000","Initial surveillance VERSUS Watchful waiting: symptomatic lesions (BDIPMN/high-risk BD-IPMN/cancer) were investigated and underwent partial pancreatectomy if deemed operable IN Specific disease- Branch-duct intraductal papillary mucinous neoplasm (BD-IPMN); Age- >=65 years; Gender- Both; Country- Sweden.","30064727","Specific disease- Branch-duct intraductal papillary mucinous neoplasm (BD-IPMN); Age- >=65 years; Gender- Both; Country- Sweden.","Initial surveillance","Intraductal papillary mucinous neoplasms of the pancreas - a cost-effectiveness analysis of management strategies for the branch-duct subtype.","Watchful waiting: symptomatic lesions (BDIPMN/high-risk BD-IPMN/cancer) were investigated and underwent partial pancreatectomy if deemed operable","NE"
"2018-01-26459","2018","Asper 2018 J Affect Disord","Cost-Saving","Post-partum depression screening VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- Sweden; Other- New fathers.","30121448","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- Sweden; Other- New fathers.","Post-partum depression screening","Screening fathers for postpartum depression can be cost-effective: An example from Sweden.","None","SE"
"2018-01-25567","2018","Ericsson 2018 PLoS One","3900","Liraglutide 1.8mg added to basal insulin VERSUS Lixisenatide 20 micro-g added to basal insulin IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Sweden; Other- Patients with inadequate glycemic control after at least 3 months basal insulin treatment.","29408938","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- Sweden; Other- Patients with inadequate glycemic control after at least 3 months basal insulin treatment.","Liraglutide 1.8mg added to basal insulin","Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.","Lixisenatide 20 micro-g added to basal insulin","NE"
"2017-01-25968","2017","Sabale 2017 Pharmacoecon Open","40000","Fulverstrant  VERSUS Standard/Usual Care- Generic aromatase inhibitor letrozole 2.5mg IN Specific disease- Advanced or metastic breast cancer; Age- Adult; Gender- Female; Country- Sweden; Other- Postmenopausal women with estrogen receptor-positive locally advanced or metastic breast cancer, whose disease progressed or relapsed while on/after previous endocrine therapies.","29441507","Specific disease- Advanced or metastic breast cancer; Age- Adult; Gender- Female; Country- Sweden; Other- Postmenopausal women with estrogen receptor-positive locally advanced or metastic breast cancer, whose disease progressed or relapsed while on/after previous endocrine therapies.","Fulverstrant","Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden.","Standard/Usual Care- Generic aromatase inhibitor letrozole 2.5mg","NE"
"2017-01-25968","2017","Sabale 2017 Pharmacoecon Open","40000","Fulverstrant VERSUS Standard/Usual Care- Generic aromatase inhibitor anastrozole 1mg IN Specific disease- Advanced or metastic breast cancer; Age- Adult; Gender- Female; Country- Sweden; Other- Postmenopausal women with estrogen receptor-positive locally advanced or metastic breast cancer, whose disease progressed or relapsed while on/after previous endocrine therapies.","29441507","Specific disease- Advanced or metastic breast cancer; Age- Adult; Gender- Female; Country- Sweden; Other- Postmenopausal women with estrogen receptor-positive locally advanced or metastic breast cancer, whose disease progressed or relapsed while on/after previous endocrine therapies.","Fulverstrant","Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden.","Standard/Usual Care- Generic aromatase inhibitor anastrozole 1mg","NE"
"2017-01-25968","2017","Sabale 2017 Pharmacoecon Open","58000","Fulverstrant VERSUS Standard/Usual Care- Exemestane 25mg IN Specific disease- Advanced or metastic breast cancer; Age- Adult; Gender- Female; Country- Sweden; Other- Postmenopausal women with estrogen receptor-positive locally advanced or metastic breast cancer, whose disease progressed or relapsed while on/after previous endocrine therapies.","29441507","Specific disease- Advanced or metastic breast cancer; Age- Adult; Gender- Female; Country- Sweden; Other- Postmenopausal women with estrogen receptor-positive locally advanced or metastic breast cancer, whose disease progressed or relapsed while on/after previous endocrine therapies.","Fulverstrant","Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden.","Standard/Usual Care- Exemestane 25mg","NE"
"2017-01-25811","2017","Jonsson 2017 Osteoporos Int","22000","Combined strategies VERSUS Current clinical management IN Specific disease- Osteoporosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","29196775","Specific disease- Osteoporosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","Combined strategies","A health economic simulation model for the clinical management of osteoporosis.","Current clinical management","NE"
"2017-01-25811","2017","Jonsson 2017 Osteoporos Int","23000","Patients who discontinue treatment switch to next line of treatment VERSUS Current clinical management IN Specific disease- Osteoporosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","29196775","Specific disease- Osteoporosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","Patients who discontinue treatment switch to next line of treatment","A health economic simulation model for the clinical management of osteoporosis.","Current clinical management","NE"
"2017-01-25811","2017","Jonsson 2017 Osteoporos Int","33000","Patients who sustained a hip or vertebral fracture started treatment VERSUS Current clinical management IN Specific disease- Osteoporosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Sweden; Other- Sustained a hip or vertebral fracture.","29196775","Specific disease- Osteoporosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Sweden; Other- Sustained a hip or vertebral fracture.","Patients who sustained a hip or vertebral fracture started treatment","A health economic simulation model for the clinical management of osteoporosis.","Current clinical management","NE"
"2017-01-25811","2017","Jonsson 2017 Osteoporos Int","36000","Bone mineral density measurement and treatment VERSUS Current clinical management IN Specific disease- Osteoporosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Sweden; Other- 15% 10-year fracture risk.","29196775","Specific disease- Osteoporosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Sweden; Other- 15% 10-year fracture risk.","Bone mineral density measurement and treatment","A health economic simulation model for the clinical management of osteoporosis.","Current clinical management","NE"
"2017-01-25811","2017","Jonsson 2017 Osteoporos Int","Cost-Saving","Current clinical management; increasing persistence by 50% VERSUS Current clinical management IN Specific disease- Osteoporosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","29196775","Specific disease- Osteoporosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Sweden.","Current clinical management; increasing persistence by 50%","A health economic simulation model for the clinical management of osteoporosis.","Current clinical management","SE"
"2017-01-25775","2017","Bjermer 2017 Respir Res","Cost-Saving","Indacaterol/glycopyrronium VERSUS Salmeterol/fluticasone IN Specific disease- Chronic obstructive pulmonary disease (COPD); Age- 19 to 40 years; Gender- Both; Country- Sweden.","29228950","Specific disease- Chronic obstructive pulmonary disease (COPD); Age- 19 to 40 years; Gender- Both; Country- Sweden.","Indacaterol/glycopyrronium","Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.","Salmeterol/fluticasone","SE"
"2017-01-25437","2017","Aronsson 2017 Br J Surg","2500","Colonoscopy, every 10 years VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","28561259","Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","Colonoscopy, every 10 years","Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer.","None","NE"
"2017-01-25437","2017","Aronsson 2017 Br J Surg","3100","Faecal immunochemical test, every 2 years VERSUS None IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","28561259","Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","Faecal immunochemical test, every 2 years","Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer.","None","NE"
"2017-01-25437","2017","Aronsson 2017 Br J Surg","31000","Colonoscopy, every 10 years VERSUS Standard/Usual Care- Colonoscopy once IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","28561259","Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","Colonoscopy, every 10 years","Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer.","Standard/Usual Care- Colonoscopy once","NE"
"2017-01-25437","2017","Aronsson 2017 Br J Surg","5600","Colonoscopy, every 10 years VERSUS Faecal immunochemical test (FIT) twice IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","28561259","Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","Colonoscopy, every 10 years","Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer.","Faecal immunochemical test (FIT) twice","NE"
"2017-01-25437","2017","Aronsson 2017 Br J Surg","7200","Faecal immunochemical test, every 2 years VERSUS Faecal immunochemical test (FIT) twice IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","28561259","Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","Faecal immunochemical test, every 2 years","Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer.","Faecal immunochemical test (FIT) twice","NE"
"2017-01-25437","2017","Aronsson 2017 Br J Surg","94000","Faecal immunochemical test, every 2 years VERSUS Standard/Usual Care- Colonoscopy once IN Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","28561259","Healthy; Age- 41 to 64 years; Gender- Female; Country- Sweden.","Faecal immunochemical test, every 2 years","Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer.","Standard/Usual Care- Colonoscopy once","NE"
"2017-01-24589","2017","Finnes 2017 J Occup Environ Med","690000","Acceptance and Commitment Therapy (ACT) and a Workplace Dialogue Intervention (WDI) VERSUS Acceptance and Commitment Therapy (ACT) IN Healthy; Age- Adult; Gender- Both; Country- Sweden; Other- Working age, reside in Stockholm county, have a current employment status of at least 50%, and have been on sickness absence (full- or part-time) for the past 1 to 12 months due to an anxiety disorder, depression, reaction to severe stress or adjustment disorder..","28953070","Healthy; Age- Adult; Gender- Both; Country- Sweden; Other- Working age, reside in Stockholm county, have a current employment status of at least 50%, and have been on sickness absence (full- or part-time) for the past 1 to 12 months due to an anxiety disorder, depression, reaction to severe stress or adjustment disorder..","Acceptance and Commitment Therapy (ACT) and a Workplace Dialogue Intervention (WDI)","Cost-Effectiveness of Acceptance and Commitment Therapy and a Workplace Intervention for Employees on Sickness Absence due to Mental Disorders.","Acceptance and Commitment Therapy (ACT)","NE"
"2017-01-24589","2017","Finnes 2017 J Occup Environ Med","93000","Acceptance and Commitment Therapy (ACT) VERSUS None IN Healthy; Age- Adult; Gender- Both; Country- Sweden; Other- Working age, reside in Stockholm county, have a current employment status of at least 50%, and have been on sickness absence (full- or part-time) for the past 1 to 12 months due to an anxiety disorder, depression, reaction to severe stress or adjustment disorder..","28953070","Healthy; Age- Adult; Gender- Both; Country- Sweden; Other- Working age, reside in Stockholm county, have a current employment status of at least 50%, and have been on sickness absence (full- or part-time) for the past 1 to 12 months due to an anxiety disorder, depression, reaction to severe stress or adjustment disorder..","Acceptance and Commitment Therapy (ACT)","Cost-Effectiveness of Acceptance and Commitment Therapy and a Workplace Intervention for Employees on Sickness Absence due to Mental Disorders.","None","NE"
"2017-01-24589","2017","Finnes 2017 J Occup Environ Med","Dominated","Treatment as usual (TAU) VERSUS Acceptance and Commitment Therapy (ACT) and a Workplace Dialogue Intervention (WDI) IN Healthy; Age- Adult; Gender- Both; Country- Sweden; Other- Working age, reside in Stockholm county, have a current employment status of at least 50%, and have been on sickness absence (full- or part-time) for the past 1 to 12 months due to an anxiety disorder, depression, reaction to severe stress or adjustment disorder..","28953070","Healthy; Age- Adult; Gender- Both; Country- Sweden; Other- Working age, reside in Stockholm county, have a current employment status of at least 50%, and have been on sickness absence (full- or part-time) for the past 1 to 12 months due to an anxiety disorder, depression, reaction to severe stress or adjustment disorder..","Treatment as usual (TAU)","Cost-Effectiveness of Acceptance and Commitment Therapy and a Workplace Intervention for Employees on Sickness Absence due to Mental Disorders.","Acceptance and Commitment Therapy (ACT) and a Workplace Dialogue Intervention (WDI)","NW"
"2017-01-24589","2017","Finnes 2017 J Occup Environ Med","Dominated","Treatment as usual (TAU) VERSUS Acceptance and Commitment Therapy (ACT) IN Specific disease- Common mental health disorder; Age- Adult; Gender- Both; Country- Sweden; Other- Working age, reside in Stockholm county, have a current employment status of at least 50%, and have been on sickness absence (full- or part-time) for the past 1 to 12 months due to an anxiety disorder, depression, reaction to severe stress or adjustment disorder..","28953070","Specific disease- Common mental health disorder; Age- Adult; Gender- Both; Country- Sweden; Other- Working age, reside in Stockholm county, have a current employment status of at least 50%, and have been on sickness absence (full- or part-time) for the past 1 to 12 months due to an anxiety disorder, depression, reaction to severe stress or adjustment disorder..","Treatment as usual (TAU)","Cost-Effectiveness of Acceptance and Commitment Therapy and a Workplace Intervention for Employees on Sickness Absence due to Mental Disorders.","Acceptance and Commitment Therapy (ACT)","NW"
"2017-01-24589","2017","Finnes 2017 J Occup Environ Med","Dominated","Workplace Dialogue Intervention (WDI) VERSUS Standard/Usual Care- Treatment as usual (TAU) IN Healthy; Age- Adult; Gender- Both; Country- Sweden; Other- Working age, reside in Stockholm county, have a current employment status of at least 50%, and have been on sickness absence (full- or part-time) for the past 1 to 12 months due to an anxiety disorder, depression, reaction to severe stress or adjustment disorder..","28953070","Healthy; Age- Adult; Gender- Both; Country- Sweden; Other- Working age, reside in Stockholm county, have a current employment status of at least 50%, and have been on sickness absence (full- or part-time) for the past 1 to 12 months due to an anxiety disorder, depression, reaction to severe stress or adjustment disorder..","Workplace Dialogue Intervention (WDI)","Cost-Effectiveness of Acceptance and Commitment Therapy and a Workplace Intervention for Employees on Sickness Absence due to Mental Disorders.","Standard/Usual Care- Treatment as usual (TAU)","NW"
"2017-01-24221","2017","Henry 2017 J Med Econ","Cost-Saving","Prophylaxis with Recombinant FVIII (rFVIIIFc) VERSUS Standard/Usual Care- Prophylaxis with recombinant factor VIII (rFVIII) IN Specific disease- Hemophilia A; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Sweden; Other- Patients with severe hemophila A who are treated with rFVIIIFc are considered for this study..","29139314","Specific disease- Hemophilia A; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Sweden; Other- Patients with severe hemophila A who are treated with rFVIIIFc are considered for this study..","Prophylaxis with Recombinant FVIII (rFVIIIFc)","Cost-utility analysis of life-long prophylaxis with recombinant factor VIII Fc vs. recombinant factor VIII for the management of severe haemophilia A in Sweden.","Standard/Usual Care- Prophylaxis with recombinant factor VIII (rFVIII)","SE"
"2017-01-24074","2017","Landstedt-Hallin 2017 Curr Med Res Opin","Cost-Saving","Insulin degludec (IDeg) VERSUS Other basal insulins IN Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Sweden; Other- Previously switched from other basal insulins treatment.","28035840","Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Sweden; Other- Previously switched from other basal insulins treatment.","Insulin degludec (IDeg)","Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.","Other basal insulins","SE"
"2017-01-24025","2017","Ericsson 2017 Appl Health Econ Health Policy","12000","Insulin degludec plus liraglutide (IDegLira) VERSUS NPH (neutral protamine Hagedorn) insulin IN Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-Smoker.","28063135","Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-Smoker.","Insulin degludec plus liraglutide (IDegLira)","Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.","NPH (neutral protamine Hagedorn) insulin","NE"
"2017-01-24025","2017","Ericsson 2017 Appl Health Econ Health Policy","4700","Insulin degludec plus liraglutide (IDegLira) VERSUS Insulin glargine IN Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-smoker.","28063135","Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-smoker.","Insulin degludec plus liraglutide (IDegLira)","Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.","Insulin glargine","NE"
"2017-01-24025","2017","Ericsson 2017 Appl Health Econ Health Policy","9900","Insulin degludec plus liraglutide (IDegLira)  VERSUS Liraglutide 1.2 mg added to NPH insulin IN Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-smoker.","28063135","Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-smoker.","Insulin degludec plus liraglutide (IDegLira)","Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.","Liraglutide 1.2 mg added to NPH insulin","NE"
"2017-01-24025","2017","Ericsson 2017 Appl Health Econ Health Policy","Cost-Saving","Insulin degludec plus liraglutide (IDegLira)  VERSUS Insulin aspart added to insulin glargine IN Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-smoker.","28063135","Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-smoker.","Insulin degludec plus liraglutide (IDegLira)","Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.","Insulin aspart added to insulin glargine","SE"
"2017-01-24025","2017","Ericsson 2017 Appl Health Econ Health Policy","Cost-Saving","Insulin degludec plus liraglutide (IDegLira)  VERSUS Insulin aspart added to NPH (neutral protamine Hagedorn) insulin IN Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-smoker.","28063135","Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-smoker.","Insulin degludec plus liraglutide (IDegLira)","Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.","Insulin aspart added to NPH (neutral protamine Hagedorn) insulin","SE"
"2017-01-24025","2017","Ericsson 2017 Appl Health Econ Health Policy","Cost-Saving","Insulin degludec plus liraglutide (IDegLira)  VERSUS Liraglutide 1.2 mg added to insulin glargine IN Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-Smoker.","28063135","Specific disease- Type 2 Diabetes; Age- Adult; Gender- Male; Country- Sweden; Other- Non-Smoker.","Insulin degludec plus liraglutide (IDegLira)","Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.","Liraglutide 1.2 mg added to insulin glargine","SE"
"2017-01-23508","2017","Aronsson 2017 Europace","11000","Handheld-electrocardiography to detect atrial fibrillation VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","28340009","Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","Handheld-electrocardiography to detect atrial fibrillation","Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis.","None"," "
"2017-01-23508","2017","Aronsson 2017 Europace","18000","Handheld-electrocardiography to detect atrial fibrillation VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","28340009","Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","Handheld-electrocardiography to detect atrial fibrillation","Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis.","None"," "
"2017-01-23508","2017","Aronsson 2017 Europace","19000","Handheld-electrocardiography to detect atrial fibrillation VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","28340009","Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","Handheld-electrocardiography to detect atrial fibrillation","Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis.","None"," "
"2017-01-23508","2017","Aronsson 2017 Europace","23000","Handheld-electrocardiography to detect atrial fibrillation VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","28340009","Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","Handheld-electrocardiography to detect atrial fibrillation","Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis.","None"," "
"2017-01-23508","2017","Aronsson 2017 Europace","28000","Handheld-electrocardiography to detect atrial fibrillation VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","28340009","Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","Handheld-electrocardiography to detect atrial fibrillation","Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis.","None"," "
"2017-01-23508","2017","Aronsson 2017 Europace","5600","Handheld-electrocardiography to detect atrial fibrillation VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","28340009","Healthy; Age- >=65 years; Gender- Both; Country- Sweden.","Handheld-electrocardiography to detect atrial fibrillation","Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis.","None"," "
"2017-01-23434","2017","Steen Carlsson 2017 Int J Stroke","Cost-Saving","Thrombectomy after thrombolysis VERSUS Standard/Usual Care- Thrombolysis alone IN Specific disease- Stroke; Age- Adult; Gender- Both; Country- Sweden; Other- Acute ischaemic stroke.","28375069","Specific disease- Stroke; Age- Adult; Gender- Both; Country- Sweden; Other- Acute ischaemic stroke.","Thrombectomy after thrombolysis","Long-term cost-effectiveness of thrombectomy for acute ischaemic stroke in real life: An analysis based on data from the Swedish Stroke Register (Riksstroke).","Standard/Usual Care- Thrombolysis alone","SE"
"2018-01-28292","2018","Hirschmann 2018 Oral Oncol","110000","Nivolumab VERSUS Standard/Usual Care- Investigatorâs choice/ standard therapy IN Specific disease- Head and Neck Cancer; Age- Adult; Gender- Both; Country- Switzerland.","30527224","Specific disease- Head and Neck Cancer; Age- Adult; Gender- Both; Country- Switzerland.","Nivolumab","Cost-effectiveness of nivolumab in the treatment of head and neck cancer.","Standard/Usual Care- Investigatorâs choice/ standard therapy","NE"
"2018-01-26496","2018","Panje 2018 Radiother Oncol","42000","Local therapy VERSUS Standard/Usual Care- Maintenance Chemotherapy (MC) alone IN Specific disease- Oligometastatic Non-squamous Non-Small Cell Lung Cancer (NSCLC); Age- Adult; Gender- Both; Country- Switzerland.","30104008","Specific disease- Oligometastatic Non-squamous Non-Small Cell Lung Cancer (NSCLC); Age- Adult; Gender- Both; Country- Switzerland.","Local therapy","A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).","Standard/Usual Care- Maintenance Chemotherapy (MC) alone","NE"
"2017-01-25822","2017","Ademi 2017 Swiss Med Wkly","44000","Sacubitril/valsartan and standard care VERSUS Angiotensin-converting enzyme inhibitors (ACEIs) and standard care IN Specific disease- Heart failure with reduced ejection fraction; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Switzerland.","29185253","Specific disease- Heart failure with reduced ejection fraction; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Switzerland.","Sacubitril/valsartan and standard care","Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.","Angiotensin-converting enzyme inhibitors (ACEIs) and standard care","NE"
"2017-01-24063","2017","Aichmair 2017 Eur Spine J","370000","Surgery VERSUS Standard/Usual Care- Conservative treatment IN Specific disease- Lumbar Spinal Stenosis (LSS); Age- 41 to 64 years, >=65 years; Gender- Both; Country- Switzerland; Other- Patients with the diagnosis of LSS, with a minimum age of 50 years, neurogenic claudication, available magnetic resonance and/or computed tomography imaging studies, and an absence of vertebral fractures, spine infection, scoliosis, or clinically relevant peripheral artery occlusive disease.","28040872","Specific disease- Lumbar Spinal Stenosis (LSS); Age- 41 to 64 years, >=65 years; Gender- Both; Country- Switzerland; Other- Patients with the diagnosis of LSS, with a minimum age of 50 years, neurogenic claudication, available magnetic resonance and/or computed tomography imaging studies, and an absence of vertebral fractures, spine infection, scoliosis, or clinically relevant peripheral artery occlusive disease.","Surgery","Cost-effectiveness of conservative versus surgical treatment strategies of lumbar spinal stenosis in the Swiss setting: analysis of the prospective multicenter Lumbar Stenosis Outcome Study (LSOS).","Standard/Usual Care- Conservative treatment","SW"
"2017-01-23911","2017","Hunt 2017 Diabetes Obes Metab","14000","Liraglutide VERSUS lixisenatide 20 ug IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Type 2 diabetes failing to achieve glycaemic control on meformin monotherapy.","28124820","Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Type 2 diabetes failing to achieve glycaemic control on meformin monotherapy.","Liraglutide","Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.","lixisenatide 20 ug","NE"
"2017-01-23725","2017","von Dach 2017 Clin Microbiol Infect","620000","Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment VERSUS Linezolid (600 mg twice daily) IN Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Infections associated with deep-seated foci.","28232163","Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Infections associated with deep-seated foci.","Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment","Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus  infection: a healthcare system perspective.","Linezolid (600 mg twice daily)","SW"
"2017-01-23725","2017","von Dach 2017 Clin Microbiol Infect","Cost-Saving","Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment VERSUS Linezolid (600 mg twice daily) IN Specific disease- Methicillin-resistant staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland.","28232163","Specific disease- Methicillin-resistant staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland.","Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment","Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus  infection: a healthcare system perspective.","Linezolid (600 mg twice daily)","SE"
"2017-01-23725","2017","von Dach 2017 Clin Microbiol Infect","Cost-Saving","Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment VERSUS Linezolid (600 mg twice daily) IN Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Non-severe infections.","28232163","Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Non-severe infections.","Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment","Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus  infection: a healthcare system perspective.","Linezolid (600 mg twice daily)","SE"
"2017-01-23725","2017","von Dach 2017 Clin Microbiol Infect","Cost-Saving","Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment VERSUS Linezolid (600 mg twice daily) IN Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Severe MRSA infection.","28232163","Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Severe MRSA infection.","Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment","Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus  infection: a healthcare system perspective.","Linezolid (600 mg twice daily)","SE"
"2017-01-23213","2017","Blank 2017 Hum Vaccin Immunother","35000","Herpes zoster vaccination with 15% vaccine coverage rate VERSUS None IN Healthy; Age- >=65 years; Gender- Both; Country- Switzerland.","28481678","Healthy; Age- >=65 years; Gender- Both; Country- Switzerland.","Herpes zoster vaccination with 15% vaccine coverage rate","Herpes zoster vaccine: A health economic evaluation for Switzerland.","None","NE"
"2016-01-21863","2016","Matter-Walstra 2016 J Thorac Oncol","150000","Nivolumab for patients with  programmed death-ligand 1 test with cutoff of 10% positive tumor cells VERSUS Standard/Usual Care- Docetaxel for all patients IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Switzerland; Other- Advanced nonsquamous non-small cell lung cancer.","27311996","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Switzerland; Other- Advanced nonsquamous non-small cell lung cancer.","Nivolumab for patients with  programmed death-ligand 1 test with cutoff of 10% positive tumor cells","A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.","Standard/Usual Care- Docetaxel for all patients","NE"
"2016-01-21863","2016","Matter-Walstra 2016 J Thorac Oncol","150000","Nivolumab for patients with programmed death-ligand 1 test with cutoff of 1% positive tumor cells VERSUS Standard/Usual Care- Docetaxel for all patients IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Switzerland; Other- Advanced nonsquamous non-small cell lung cancer.","27311996","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Switzerland; Other- Advanced nonsquamous non-small cell lung cancer.","Nivolumab for patients with programmed death-ligand 1 test with cutoff of 1% positive tumor cells","A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.","Standard/Usual Care- Docetaxel for all patients","NE"
"2016-01-21863","2016","Matter-Walstra 2016 J Thorac Oncol","210000","Nivolumab for all patients VERSUS Standard/Usual Care- Docetaxel for all patients IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Switzerland; Other- Advanced nonsquamous non-small cell lung cancer.","27311996","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Switzerland; Other- Advanced nonsquamous non-small cell lung cancer.","Nivolumab for all patients","A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.","Standard/Usual Care- Docetaxel for all patients","NE"
"2016-01-21863","2016","Matter-Walstra 2016 J Thorac Oncol","44000","Nivolumab for patients with programmed death-ligand 1 test with cutoff of 10% positive tumor cells VERSUS Standard/Usual Care- Nivolumab for all patients IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Switzerland; Other- Advanced nonsquamous non-small cell lung cancer.","27311996","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Switzerland; Other- Advanced nonsquamous non-small cell lung cancer.","Nivolumab for patients with programmed death-ligand 1 test with cutoff of 10% positive tumor cells","A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.","Standard/Usual Care- Nivolumab for all patients","NE"
"2016-01-21863","2016","Matter-Walstra 2016 J Thorac Oncol","73000","Nivolumab for patients with programmed death-ligand 1 test with cutoff of 1% positive tumor cells VERSUS Standard/Usual Care- Nivolumab for all patients IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Switzerland; Other- Advanced nonsquamous non-small cell lung cancer.","27311996","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- Switzerland; Other- Advanced nonsquamous non-small cell lung cancer.","Nivolumab for patients with programmed death-ligand 1 test with cutoff of 1% positive tumor cells","A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.","Standard/Usual Care- Nivolumab for all patients","NE"
"2016-01-21537","2016","Ademi 2016 Swiss Med Wkly","78000","Primarily Surgical treatment VERSUS Primarily Conservative treatment IN Specific disease- Acute and Subacute Radiculopathies due to intervertebral disc herniation; Age- Adult; Gender- Both; Country- Switzerland.","27922167","Specific disease- Acute and Subacute Radiculopathies due to intervertebral disc herniation; Age- Adult; Gender- Both; Country- Switzerland.","Primarily Surgical treatment","Cost-effectiveness of primarily surgical versus primarily conservative treatment  of acute and subacute radiculopathies due to intervertebral disc herniation from  the Swiss perspective.","Primarily Conservative treatment","NE"
"2016-01-20355","2016","Adedokun 2016 Adv Ther","Cost-Saving","Ranibizumab VERSUS Standard/Usual Care- Aflibercept IN Specific disease- Macular edema; Age- Adult; Gender- Both; Country- United Kingdom; Other- Secondary to branch retinal vein occlusion.","26747252","Specific disease- Macular edema; Age- Adult; Gender- Both; Country- United Kingdom; Other- Secondary to branch retinal vein occlusion.","Ranibizumab","Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary  to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.","Standard/Usual Care- Aflibercept","SE"
"2015-01-18075","2015","Pfeil 2015 PLoS One","100000","Sofosbuvir + ribavirin (24 weeks) VERSUS None IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4 treatment-naÃ¯ve interferon ineligiblle genotype 1.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4 treatment-naÃ¯ve interferon ineligiblle genotype 1.","Sofosbuvir + ribavirin (24 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","None"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","110000","Sofosbuvir + ribavirin (24 weeks) VERSUS Standard/Usual Care- pegylated interferon 2a/2b + ribavirin (24 weeks) IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon eligiblle genotype 3.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon eligiblle genotype 3.","Sofosbuvir + ribavirin (24 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","Standard/Usual Care- pegylated interferon 2a/2b + ribavirin (24 weeks)"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","12000","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks) VERSUS Standard/Usual Care- telaprevir + pegylated interferon 2a + ribavirin for 24/48 weeks IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon eligible genotype 1.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon eligible genotype 1.","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","Standard/Usual Care- telaprevir + pegylated interferon 2a + ribavirin for 24/48 weeks"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","12000","Sofosbuvir + ribavirin (12 weeks) VERSUS None IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon ineligiblle genotype 2.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon ineligiblle genotype 2.","Sofosbuvir + ribavirin (12 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","None"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","15000","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks) VERSUS Standard/Usual Care- boceprevir + pegylated interferon 2a + ribavirin for 28/48 weeks IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon eligible genotype 1.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon eligible genotype 1.","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","Standard/Usual Care- boceprevir + pegylated interferon 2a + ribavirin for 28/48 weeks"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","19000","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks) VERSUS Standard/Usual Care- pegylated interferon 2a/2b + ribavirin (48 weeks) IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-experienced interferon eligiblle genotype 3.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-experienced interferon eligiblle genotype 3.","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","Standard/Usual Care- pegylated interferon 2a/2b + ribavirin (48 weeks)"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","23000","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks) VERSUS Standard/Usual Care- pegylated interferon 2a/2b + ribavirin for 48 weeks IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon eligible genotype 1.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon eligible genotype 1.","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","Standard/Usual Care- pegylated interferon 2a/2b + ribavirin for 48 weeks"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","40000","Sofosbuvir + ribavirin (24 weeks) VERSUS None IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon ineligiblle genotype 3.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon ineligiblle genotype 3.","Sofosbuvir + ribavirin (24 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","None"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","42000","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks) VERSUS Standard/Usual Care- pegylated interferon 2a/2b + ribavirin (48 weeks) IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-experienced interferon ineligiblle genotype 4.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-experienced interferon ineligiblle genotype 4.","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","Standard/Usual Care- pegylated interferon 2a/2b + ribavirin (48 weeks)"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","45000","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks) VERSUS Standard/Usual Care- pegylated interferon 2a/2b + ribavirin (24 weeks) IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon eligiblle genotype 3.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-naÃ¯ve interferon eligiblle genotype 3.","Sofosbuvir + pegylated interferon 2a + ribavirin (12 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","Standard/Usual Care- pegylated interferon 2a/2b + ribavirin (24 weeks)"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","53000","Sofosbuvir + ribavirin (24 weeks) VERSUS None IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-experienced interferon ineligiblle genotype 3.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-experienced interferon ineligiblle genotype 3.","Sofosbuvir + ribavirin (24 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","None"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","87000","Sofosbuvir + ribavirin (24 weeks) VERSUS Standard/Usual Care- pegylated interferon 2a/2b + ribavirin (48 weeks) IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-experienced interferon eligiblle genotype 3.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4, treatment-experienced interferon eligiblle genotype 3.","Sofosbuvir + ribavirin (24 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","Standard/Usual Care- pegylated interferon 2a/2b + ribavirin (48 weeks)"," "
"2015-01-18075","2015","Pfeil 2015 PLoS One","89000","Sofosbuvir + ribavirin (12 weeks) VERSUS Standard/Usual Care- pegylated interferon 2a/2b + ribavirin for 24 weeks IN Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4 treatment-naÃ¯ve interferon eligiblle genotype 2.","25974722","Specific disease- Chronic Hepatitis C; Age- Adult; Gender- Both; Country- Switzerland; Other- non-HIV-infected patients diagnosed with CHC genotypes 1-4 treatment-naÃ¯ve interferon eligiblle genotype 2.","Sofosbuvir + ribavirin (12 weeks)","Cost-effectiveness analysis of sofosbuvir compared to current standard treatment  in Swiss patients with chronic hepatitis C.","Standard/Usual Care- pegylated interferon 2a/2b + ribavirin for 24 weeks"," "
"2015-01-17889","2015","Poncet 2015 PLoS One","9300","Screening strategy, using a systemic electricardiographic LQT detection at hospital admission to reduce sudden cardiac arrest VERSUS Standard/Usual Care- Abstention strategy, no routine ECG screening IN Specific disease- Mental illness; Age- Adult; Gender- Both; Country- Switzerland; Other- Patients admitted to the public Psychiatric Hospital of Geneva.","26070071","Specific disease- Mental illness; Age- Adult; Gender- Both; Country- Switzerland; Other- Patients admitted to the public Psychiatric Hospital of Geneva.","Screening strategy, using a systemic electricardiographic LQT detection at hospital admission to reduce sudden cardiac arrest","Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis.","Standard/Usual Care- Abstention strategy, no routine ECG screening","NE"
"2015-01-17324","2015","Matter-Walstra 2015 Br J Dermatol","420000","Trametinib plus dabrafenib VERSUS Vemurafenib monotherapy IN Specific disease- Metastatic BRAF V600-mutated melanoma; Age- Adult; Gender- Both; Country- Switzerland; Other- Metastatic BRAF V600-mutated melanoma.","26332527","Specific disease- Metastatic BRAF V600-mutated melanoma; Age- Adult; Gender- Both; Country- Switzerland; Other- Metastatic BRAF V600-mutated melanoma.","Trametinib plus dabrafenib","A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting.","Vemurafenib monotherapy","NE"
"2012-01-09049","2012","Nilsson                          2012 Eur J Health Econ","7000","Dronederone (400 mg twice daily) plus standard of care VERSUS Sotalol plus standard of care IN Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Canada","22552487","Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Canada","Dronederone (400 mg twice daily) plus standard of care","Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.","Sotalol plus standard of care","NE"
"2012-01-09049","2012","Nilsson                          2012 Eur J Health Econ","7300","Dronederone (400 mg twice daily) plus standard of care VERSUS Flecainide plus standard of care IN Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Sweden","22552487","Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Sweden","Dronederone (400 mg twice daily) plus standard of care","Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.","Flecainide plus standard of care","NE"
"2012-01-09049","2012","Nilsson                          2012 Eur J Health Econ","8100","Dronederone (400 mg twice daily) plus standard of care VERSUS Amiodarone plus standard of care IN Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Canada","22552487","Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Canada","Dronederone (400 mg twice daily) plus standard of care","Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.","Amiodarone plus standard of care","NE"
"2012-01-09049","2012","Nilsson                          2012 Eur J Health Econ","8600","Dronederone (400 mg twice daily) plus standard of care VERSUS Amiodarone plus standard of care IN Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Switzerland","22552487","Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Switzerland","Dronederone (400 mg twice daily) plus standard of care","Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.","Amiodarone plus standard of care","NE"
"2012-01-09049","2012","Nilsson                          2012 Eur J Health Econ","8900","Dronederone (400 mg twice daily) plus standard of care VERSUS Flecainide plus standard of care IN Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Italy","22552487","Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Italy","Dronederone (400 mg twice daily) plus standard of care","Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.","Flecainide plus standard of care","NE"
"2012-01-09049","2012","Nilsson                          2012 Eur J Health Econ","9400","Dronederone (400 mg twice daily) plus standard of care VERSUS Flecainide plus standard of care IN Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Canada","22552487","Patients with paroxysmal or persistent atrial fibrillation or atrial flutter in Canada","Dronederone (400 mg twice daily) plus standard of care","Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.","Flecainide plus standard of care","NE"
"2012-01-08677","2012","Kessler 2012 Swiss Med Wkly","110000","Annual microalbuminuria screening for chronic kidney disease VERSUS None IN Swiss population without diabetes or hypertension aged over 50 years","22307760","Swiss population without diabetes or hypertension aged over 50 years","Annual microalbuminuria screening for chronic kidney disease","Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.","None","NE"
"2012-01-08677","2012","Kessler 2012 Swiss Med Wkly","24000","Microalbuminuria screening for chronic kidney disease every 2 years VERSUS None IN Swiss population with diabetes aged over 50 years","22307760","Swiss population with diabetes aged over 50 years","Microalbuminuria screening for chronic kidney disease every 2 years","Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.","None","NE"
"2012-01-08677","2012","Kessler 2012 Swiss Med Wkly","29000","Microalbuminuria screening for chronic kidney disease every 2 years VERSUS None IN Swiss population with hypertension aged over 50 years","22307760","Swiss population with hypertension aged over 50 years","Microalbuminuria screening for chronic kidney disease every 2 years","Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.","None","NE"
"2012-01-08677","2012","Kessler 2012 Swiss Med Wkly","32000","Annual microalbuminuria screening for chronic kidney disease VERSUS None IN Swiss population with diabetes aged over 50 years","22307760","Swiss population with diabetes aged over 50 years","Annual microalbuminuria screening for chronic kidney disease","Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.","None","NE"
"2012-01-08677","2012","Kessler 2012 Swiss Med Wkly","44000","Annual microalbuminuria screening for chronic kidney disease VERSUS None IN Swiss population with hypertension aged over 50 years","22307760","Swiss population with hypertension aged over 50 years","Annual microalbuminuria screening for chronic kidney disease","Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.","None","NE"
"2012-01-08677","2012","Kessler 2012 Swiss Med Wkly","71000","Microalbuminuria screening for chronic kidney disease every 2 years VERSUS None IN Swiss population aged over 50 years","22307760","Swiss population aged over 50 years","Microalbuminuria screening for chronic kidney disease every 2 years","Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.","None","NE"
"2012-01-08677","2012","Kessler 2012 Swiss Med Wkly","74000","Microalbuminuria screening for chronic kidney disease every 2 years VERSUS None IN Swiss population without diabetes or hypertension aged over 50 years","22307760","Swiss population without diabetes or hypertension aged over 50 years","Microalbuminuria screening for chronic kidney disease every 2 years","Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.","None","NE"
"2012-01-08677","2012","Kessler 2012 Swiss Med Wkly","96000","Annual microalbuminuria screening for chronic kidney disease VERSUS None IN Swiss population aged over 50 years","22307760","Swiss population aged over 50 years","Annual microalbuminuria screening for chronic kidney disease","Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.","None","NE"
"2012-01-08546","2012","Iannazzo 2012 Appl Health Econ Health Policy","100000","Cinacalet plus standard treatment (vitamin D sterols and phosphate binders) VERSUS Standard treatment- vitamin D sterols and phosphate binders IN Patients with chronic kidney disease on dialysis with secondary hyperparathyroidism in Italy","22268372","Patients with chronic kidney disease on dialysis with secondary hyperparathyroidism in Italy","Cinacalet plus standard treatment (vitamin D sterols and phosphate binders)","A Cost-Utility Analysis of Cinacalcet in Secondary Hyperparathyroidism in Five European Countries.","Standard treatment- vitamin D sterols and phosphate binders","NE"
"2012-01-08546","2012","Iannazzo 2012 Appl Health Econ Health Policy","120000","Cinacalet plus standard treatment (vitamin D sterols and phosphate binders) VERSUS Standard treatment- vitamin D sterols and phosphate binders IN Patients with chronic kidney disease on dialysis with secondary hyperparathyroidism in Czech Republic","22268372","Patients with chronic kidney disease on dialysis with secondary hyperparathyroidism in Czech Republic","Cinacalet plus standard treatment (vitamin D sterols and phosphate binders)","A Cost-Utility Analysis of Cinacalcet in Secondary Hyperparathyroidism in Five European Countries.","Standard treatment- vitamin D sterols and phosphate binders","NE"
"2012-01-08546","2012","Iannazzo 2012 Appl Health Econ Health Policy","180000","Cinacalet plus standard treatment (vitamin D sterols and phosphate binders) VERSUS Standard treatment- vitamin D sterols and phosphate binders IN Patients with chronic kidney disease on dialysis with secondary hyperparathyroidism in Switzerland","22268372","Patients with chronic kidney disease on dialysis with secondary hyperparathyroidism in Switzerland","Cinacalet plus standard treatment (vitamin D sterols and phosphate binders)","A Cost-Utility Analysis of Cinacalcet in Secondary Hyperparathyroidism in Five European Countries.","Standard treatment- vitamin D sterols and phosphate binders","NE"
"2012-01-08546","2012","Iannazzo 2012 Appl Health Econ Health Policy","88000","Cinacalet plus standard treatment (vitamin D sterols and phosphate binders) VERSUS Standard treatment- vitamin D sterols and phosphate binders IN Patients with chronic kidney disease on dialysis with secondary hyperparathyroidism in Spain","22268372","Patients with chronic kidney disease on dialysis with secondary hyperparathyroidism in Spain","Cinacalet plus standard treatment (vitamin D sterols and phosphate binders)","A Cost-Utility Analysis of Cinacalcet in Secondary Hyperparathyroidism in Five European Countries.","Standard treatment- vitamin D sterols and phosphate binders","NE"
"2012-01-08546","2012","Iannazzo 2012 Appl Health Econ Health Policy","93000","Cinacalet plus standard treatment (vitamin D sterols and phosphate binders) VERSUS Standard treatment- vitamin D sterols and phosphate binders IN Patients with chronic kidney disease on dialysis with secondary hyperparathyroidism in Portugal","22268372","Patients with chronic kidney disease on dialysis with secondary hyperparathyroidism in Portugal","Cinacalet plus standard treatment (vitamin D sterols and phosphate binders)","A Cost-Utility Analysis of Cinacalcet in Secondary Hyperparathyroidism in Five European Countries.","Standard treatment- vitamin D sterols and phosphate binders","NE"
"2012-01-08534","2012","Matter-Walstra 2012 Value Health","160000","Maintenance therapy with pemetrexed plus best supportive care VERSUS Best supportive care IN Patients with stage IIIB or IV advanced non-squamous cell lung cancer in Switzerland","22264973","Patients with stage IIIB or IV advanced non-squamous cell lung cancer in Switzerland","Maintenance therapy with pemetrexed plus best supportive care","Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the swiss health care system.","Best supportive care","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","8100","Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Syria.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Syria.","Hepatitis B Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-27437","2018","Chan 2018 Int J Chron Obstruct Pulmon Dis","150000","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (1 year) VERSUS salmeterol/fluticasone combination+LAMA and LABA (1 year) IN Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29670344","Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (1 year)","Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.","salmeterol/fluticasone combination+LAMA and LABA (1 year)","NE"
"2018-01-27437","2018","Chan 2018 Int J Chron Obstruct Pulmon Dis","16000","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (5 years) VERSUS Tiotropium + LAMA and LABA (5 years) IN Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29670344","Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (5 years)","Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.","Tiotropium + LAMA and LABA (5 years)","NE"
"2018-01-27437","2018","Chan 2018 Int J Chron Obstruct Pulmon Dis","16000","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (lifetime) VERSUS Salmeterol/fluticasone combination+LAMA and LABA (lifetime) IN Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29670344","Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (lifetime)","Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.","Salmeterol/fluticasone combination+LAMA and LABA (lifetime)","NE"
"2018-01-27437","2018","Chan 2018 Int J Chron Obstruct Pulmon Dis","29000","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (3 years) VERSUS Tiotropium + LAMA and LABA (3 years) IN Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29670344","Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (3 years)","Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.","Tiotropium + LAMA and LABA (3 years)","NE"
"2018-01-27437","2018","Chan 2018 Int J Chron Obstruct Pulmon Dis","30000","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (10 years) VERSUS salmeterol/fluticasone combination+LAMA and LABA (10 years) IN Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29670344","Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (10 years)","Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.","salmeterol/fluticasone combination+LAMA and LABA (10 years)","NE"
"2018-01-27437","2018","Chan 2018 Int J Chron Obstruct Pulmon Dis","46000","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (3 years) VERSUS salmeterol/fluticasone combination+LAMA and LABA (3 years) IN Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29670344","Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (3 years)","Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.","salmeterol/fluticasone combination+LAMA and LABA (3 years)","NE"
"2018-01-27437","2018","Chan 2018 Int J Chron Obstruct Pulmon Dis","50000","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (1 year) VERSUS Tiotropium + LAMA and LABA (1 year) IN Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29670344","Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (1 year)","Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.","Tiotropium + LAMA and LABA (1 year)","NE"
"2018-01-27437","2018","Chan 2018 Int J Chron Obstruct Pulmon Dis","6200","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (lifetime) VERSUS Tiotropium + LAMA and LABA (lifetime) IN Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29670344","Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (lifetime)","Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.","Tiotropium + LAMA and LABA (lifetime)","NE"
"2018-01-27437","2018","Chan 2018 Int J Chron Obstruct Pulmon Dis","74000","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (5 years) VERSUS salmeterol/fluticasone combination+LAMA and LABA (5 years) IN Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29670344","Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (5 years)","Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.","salmeterol/fluticasone combination+LAMA and LABA (5 years)","NE"
"2018-01-27437","2018","Chan 2018 Int J Chron Obstruct Pulmon Dis","9700","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (10 years) VERSUS Tiotropium + LAMA and LABA (10 years) IN Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29670344","Specific disease- COPD; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Dual bronchodilator indacaterol/glycopyrronium combine with LAMA and LABA (10 years)","Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.","Tiotropium + LAMA and LABA (10 years)","NE"
"2018-01-27347","2018","Ho 2018 Value Health Reg Issues","95000","Combination therapy (Sorafenib with other treatment) VERSUS Standard/Usual Care- Monotherapy (Sorafenib alone) IN Specific disease- Hepatocellular Carcinoma; Age- Adult; Gender- Both; Country- China.","29704658","Specific disease- Hepatocellular Carcinoma; Age- Adult; Gender- Both; Country- China.","Combination therapy (Sorafenib with other treatment)","Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.","Standard/Usual Care- Monotherapy (Sorafenib alone)","NE"
"2017-01-25708","2017","Tseng 2017 J Chin Med Assoc","120","Microscopic Tympanoplasty (MT) VERSUS Endoscopic Tympanoplasty IN Specific disease- Chronic otitis media; Age- Adult; Gender- Both; Country- Taiwan.","29287705","Specific disease- Chronic otitis media; Age- Adult; Gender- Both; Country- Taiwan.","Microscopic Tympanoplasty (MT)","Cost-effectiveness analysis of endoscopic tympanoplasty versus microscopic tympanoplasty for chronic otitis media in Taiwan.","Endoscopic Tympanoplasty","NE"
"2017-01-25319","2017","Yang 2017 Lung Cancer","21000","Screening for lung cancer with Computed Tomography VERSUS Screening for lung cancer without Computed Tomography IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan; Other- High risk (=> 30 pack-years) smokers.","28625633","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan; Other- High risk (=> 30 pack-years) smokers.","Screening for lung cancer with Computed Tomography","Cost-effectiveness of implementing computed tomography screening for lung cancer  in Taiwan.","Screening for lung cancer without Computed Tomography","NE"
"2017-01-25254","2017","Vilain 2017 Value Health Reg Issues","14000","Edoxaban  VERSUS Standard/Usual Care- Warfarin  IN Specific disease- Atrial fibrillation; Age- Adult; Gender- Both; Country- Taiwan.","28648320","Specific disease- Atrial fibrillation; Age- Adult; Gender- Both; Country- Taiwan.","Edoxaban","Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation  Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.","Standard/Usual Care- Warfarin","NE"
"2017-01-24608","2017","Chang 2017 Clin Transplant","Cost-Saving","Direct ventricular assist device VERSUS Double bridges, extracorporeal membrane oxygenation before ventricular assist device IN Specific disease- Refractory heart failure; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","28944511","Specific disease- Refractory heart failure; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Direct ventricular assist device","Cost-utility analysis of direct VAD versus double bridges to heart transplantation in patients with refractory heart failure.","Double bridges, extracorporeal membrane oxygenation before ventricular assist device","SE"
"2017-01-24551","2017","Leung 2017 Expert Rev Pharmacoecon Outcomes Res","620000","Pertuzumab plus trastuzumab and docetaxel VERSUS Trastuzumab and docetaxel (TD) IN Specific disease- Metastatic breast cancer; Age- Adult; Gender- Female; Country- Taiwan.","28965422","Specific disease- Metastatic breast cancer; Age- Adult; Gender- Female; Country- Taiwan.","Pertuzumab plus trastuzumab and docetaxel","Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.","Trastuzumab and docetaxel (TD)","NE"
"2017-01-24463","2017","Chang 2017 Int J Qual Health Care","15000","Pharmacist-Assisted Warfarin Monitoring (PAWM)  VERSUS Standard/Usual Care- Usual Care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","29025143","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Pharmacist-Assisted Warfarin Monitoring (PAWM)","Cost-effectiveness of the pharmacist-assisted warfarin monitoring program at a Medical Center in Taiwan.","Standard/Usual Care- Usual Care","NE"
"2017-01-24323","2017","Leung 2017 Oncotarget","6900","Proton beam therapy  VERSUS Standard/Usual Care- Stereotactic body radiation therapy IN Specific disease- Hepatocellular carcinoma; Age- Adult; Gender- Both; Country- Taiwan; Other- Inoperable advanced hepatocellular carcinoma.","29088891","Specific disease- Hepatocellular carcinoma; Age- Adult; Gender- Both; Country- Taiwan; Other- Inoperable advanced hepatocellular carcinoma.","Proton beam therapy","Cost-utility of stereotactic radiation therapy versus proton beam therapy for inoperable advanced hepatocellular carcinoma.","Standard/Usual Care- Stereotactic body radiation therapy","NE"
"2017-01-23181","2017","Leung 2017 Oncotarget","6900","proton beam therapy VERSUS stereotactic radiation therapy IN Specific disease- Hepatocellular Carcinoma; Age- Adult; Gender- Both; Country- Taiwan; Other- inoperable advanced hepatocellular carcinoma.","28493847","Specific disease- Hepatocellular Carcinoma; Age- Adult; Gender- Both; Country- Taiwan; Other- inoperable advanced hepatocellular carcinoma.","proton beam therapy","Cost-utility of stereotactic radiation therapy versus proton beam therapy for inoperable advanced hepatocellular carcinoma.","stereotactic radiation therapy","NE"
"2017-01-22200","2017","Chiou 2017 Int J Audiol","3600","Transient evoked otoacoustic emission (TEOAE) hearing screening VERSUS Automatic acoustic brainstem response (aABR) hearing screening IN Specific disease- Congenital hearing loss; Age- 0 to 18 years; Gender- Both; Country- Taiwan.","27598544","Specific disease- Congenital hearing loss; Age- 0 to 18 years; Gender- Both; Country- Taiwan.","Transient evoked otoacoustic emission (TEOAE) hearing screening","Economic evaluation of long-term impacts of universal newborn hearing screening.","Automatic acoustic brainstem response (aABR) hearing screening","NE"
"2017-01-22200","2017","Chiou 2017 Int J Audiol","Cost-Saving","Automatic acoustic brainstem response (aABR) hearing screening VERSUS No screening IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Taiwan.","27598544","Healthy; Age- 0 to 18 years; Gender- Both; Country- Taiwan.","Automatic acoustic brainstem response (aABR) hearing screening","Economic evaluation of long-term impacts of universal newborn hearing screening.","No screening","SE"
"2017-01-22200","2017","Chiou 2017 Int J Audiol","Cost-Saving","Transient evoked otoacoustic emission (TEOAE) hearing screening VERSUS No Screening IN Specific disease- Congenital hearing loss; Age- 0 to 18 years; Gender- Both; Country- Taiwan.","27598544","Specific disease- Congenital hearing loss; Age- 0 to 18 years; Gender- Both; Country- Taiwan.","Transient evoked otoacoustic emission (TEOAE) hearing screening","Economic evaluation of long-term impacts of universal newborn hearing screening.","No Screening","SE"
"2016-01-22710","2016","Chan 2016 Int J Gen Med","Cost-Saving","Amlodipine (5/10 mg), a calcium channel blocker VERSUS Valsartan (80/160 mg), a angiotensin II receptor blocker (ARB) IN Specific disease- Hypertensive; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","27330323","Specific disease- Hypertensive; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Amlodipine (5/10 mg), a calcium channel blocker","Cost-effectiveness of amlodipine compared with valsartan in preventing stroke and myocardial infarction among hypertensive patients in Taiwan.","Valsartan (80/160 mg), a angiotensin II receptor blocker (ARB)","SE"
"2016-01-22150","2016","Yang                             2016 Hum Vaccin Immunother","3500","Quadrivalent influenza vaccine (QIV) VERSUS Standard/Usual Care- Trivalent influenza vaccine (TIV) IN Specific disease- Influenza; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","27624648","Specific disease- Influenza; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Taiwan.","Quadrivalent influenza vaccine (QIV)","Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.","Standard/Usual Care- Trivalent influenza vaccine (TIV)","NE"
"2016-01-21446","2016","Liu 2016 Clin Drug Investig","30000","Dabigatran 110 mg VERSUS Apixaban 5 mg IN Specific disease- Stroke; Age- Adult; Gender- Both; Country- Taiwan; Other- Atrial fibrillation (AF).","27988835","Specific disease- Stroke; Age- Adult; Gender- Both; Country- Taiwan; Other- Atrial fibrillation (AF).","Dabigatran 110 mg","Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.","Apixaban 5 mg","SW"
"2016-01-21446","2016","Liu 2016 Clin Drug Investig","43000","Warfarin VERSUS Apixaban 5 mg IN Specific disease- Stroke; Age- Adult; Gender- Both; Country- Taiwan; Other- Atrial fibrillation (AF).","27988835","Specific disease- Stroke; Age- Adult; Gender- Both; Country- Taiwan; Other- Atrial fibrillation (AF).","Warfarin","Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.","Apixaban 5 mg","SW"
"2016-01-21446","2016","Liu 2016 Clin Drug Investig","45000","Dabigatran 150 mg VERSUS Apixaban 5 mg IN Specific disease- Stroke; Age- Adult; Gender- Both; Country- Taiwan; Other- Atrial fibrillation (AF).","27988835","Specific disease- Stroke; Age- Adult; Gender- Both; Country- Taiwan; Other- Atrial fibrillation (AF).","Dabigatran 150 mg","Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.","Apixaban 5 mg","SW"
"2016-01-21446","2016","Liu 2016 Clin Drug Investig","53000","Rivaroxaban 10 mg VERSUS Apixaban 5 mg IN Specific disease- Stroke; Age- Adult; Gender- Both; Country- Taiwan; Other- Atrial fibrillation (AF).","27988835","Specific disease- Stroke; Age- Adult; Gender- Both; Country- Taiwan; Other- Atrial fibrillation (AF).","Rivaroxaban 10 mg","Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.","Apixaban 5 mg","SW"
"2016-01-20196","2016","Yang 2016 Curr Alzheimer Res","15000","Synthetic intact amyloid Ã peptides 42 VERSUS None IN Specific disease- Alzheimer's disease; Age- >=65 years; Gender- Both; Country- Taiwan; Other- Mild or moderate Alzheimer's disease.","26825097","Specific disease- Alzheimer's disease; Age- >=65 years; Gender- Both; Country- Taiwan; Other- Mild or moderate Alzheimer's disease.","Synthetic intact amyloid Ã peptides 42","Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease.","None","NE"
"2016-01-19760","2016","Leung 2016 Clin Ther","72000","gem-SBRT regimen: 6 months of weekly gemcitabine given at 1000 mg/m2 once a week, 3 of 4 weeks each month, 1 month after stereotactic body radiotherapy (SBRT) VERSUS gem-alone (gemcitabine) at a dose of 1000 mg/m2 intravenously per week for 6 weeks, followed by 1 week rest, after which treatment was consolidated at 1000 mg/m2 weekly for 3 eeks, followed by 1 week rest, for a total of 5 cycles, 4 weeks/cycle. IN Specific disease- Pancreatic cancer; Age-; Gender- Both; Country- .","27033672","Specific disease- Pancreatic cancer; Age-; Gender- Both; Country- .","gem-SBRT regimen: 6 months of weekly gemcitabine given at 1000 mg/m2 once a week, 3 of 4 weeks each month, 1 month after stereotactic body radiotherapy (SBRT)","Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer.","gem-alone (gemcitabine) at a dose of 1000 mg/m2 intravenously per week for 6 weeks, followed by 1 week rest, after which treatment was consolidated at 1000 mg/m2 weekly for 3 eeks, followed by 1 week rest, for a total of 5 cycles, 4 weeks/cycle.","NE"
"2016-01-19760","2016","Leung 2016 Clin Ther","910000","gem-IMRT regimen: gemcitabine 600 mg/m2 intravenously (over 30 to 60 minutes), beginning on the first day of radiation therapy, then weekly therafter during radiation for 5.5 weeks. Radiation dose was 1.8 Gy per daily fraction, 5 days per week, for a total dose of 50.4 Gy administered in 28 fractions over 5.5 weeks, with a required field reduction after 39.6 GY. After completion of intensity-modulated radiotherapy (IMRT), gemcitabine was resumed at a full dosage (as gem-alone) for a total of 5 c VERSUS gem-alone (gemcitabine) at a dose of 1000 mg/m2 intravenously per week for 6 weeks, followed by 1 week rest, after which treatment was consolidated at 1000 mg/m2 weekly for 3 eeks, followed by 1 week rest, for a total of 5 cycles, 4 weeks/cycle. IN Specific disease- Pancreatic cancer; Age-; Gender- Both; Country- .","27033672","Specific disease- Pancreatic cancer; Age-; Gender- Both; Country- .","gem-IMRT regimen: gemcitabine 600 mg/m2 intravenously (over 30 to 60 minutes), beginning on the first day of radiation therapy, then weekly therafter during radiation for 5.5 weeks. Radiation dose was 1.8 Gy per daily fraction, 5 days per week, for a total dose of 50.4 Gy administered in 28 fractions over 5.5 weeks, with a required field reduction after 39.6 GY. After completion of intensity-modulated radiotherapy (IMRT), gemcitabine was resumed at a full dosage (as gem-alone) for a total of 5 c","Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer.","gem-alone (gemcitabine) at a dose of 1000 mg/m2 intravenously per week for 6 weeks, followed by 1 week rest, after which treatment was consolidated at 1000 mg/m2 weekly for 3 eeks, followed by 1 week rest, for a total of 5 cycles, 4 weeks/cycle.","NE"
"2016-01-19516","2016","Lin 2016 Thorac Cancer","41000","Neoadjuvant concurrent chemoradiotherapy VERSUS esophagectomy IN Specific disease- esophageal squamous cell carcinoma; Age- Adult; Gender- Both; Country- Taiwan; Other- locally-advanced stage.","27148413","Specific disease- esophageal squamous cell carcinoma; Age- Adult; Gender- Both; Country- Taiwan; Other- locally-advanced stage.","Neoadjuvant concurrent chemoradiotherapy","Cost-effectiveness of neoadjuvant concurrent chemoradiotherapy versus esophagectomy for locally advanced esophageal squamous cell carcinoma: A population-based matched case-control study.","esophagectomy","NE"
"2016-01-19421","2016","Leung 2016 Radiat Oncol","130000","Continuous sorafenib (400mg) twice daily for 6 week cycles VERSUS Stereotactic body radiation therapy (SBRT) treatment over 2 weeks IN Specific disease- Hepatocellular carcinoma; Age- 41 to 64 years, >=65 years; Gender- Both; Country- ; Other- Patients with inoperable, advanced hepatocellular carcinoma (HCC).","27193904","Specific disease- Hepatocellular carcinoma; Age- 41 to 64 years, >=65 years; Gender- Both; Country- ; Other- Patients with inoperable, advanced hepatocellular carcinoma (HCC).","Continuous sorafenib (400mg) twice daily for 6 week cycles","Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.","Stereotactic body radiation therapy (SBRT) treatment over 2 weeks","NE"
"2015-01-18618","2015","Pan 2015 J Psychiatr Res","270000","Serotonin norepinephrine reuptake inhibitor (SNRI) VERSUS Tricyclic antidepressant (TCA) IN Specific disease- Major depression; Age- Adult; Gender- Both; Country- Taiwan; Other- Without painful physical symptoms.","25727051","Specific disease- Major depression; Age- Adult; Gender- Both; Country- Taiwan; Other- Without painful physical symptoms.","Serotonin norepinephrine reuptake inhibitor (SNRI)","Depression and pain: an appraisal of cost effectiveness and cost utility of antidepressants.","Tricyclic antidepressant (TCA)","NE"
"2015-01-18618","2015","Pan 2015 J Psychiatr Res","360000","Serotonin norepinephrine reuptake inhibitor (SNRI) VERSUS Tricyclic antidepressant (TCA) IN Specific disease- Major depression; Age- Adult; Gender- Both; Country- Taiwan; Other- With painful physical symptoms.","25727051","Specific disease- Major depression; Age- Adult; Gender- Both; Country- Taiwan; Other- With painful physical symptoms.","Serotonin norepinephrine reuptake inhibitor (SNRI)","Depression and pain: an appraisal of cost effectiveness and cost utility of antidepressants.","Tricyclic antidepressant (TCA)","NE"
"2015-01-18618","2015","Pan 2015 J Psychiatr Res","85000","Selective serotonin reuptake inhibitor (SSRI) VERSUS Tricyclic antidepressant (TCA) IN Specific disease- Major depression; Age- Adult; Gender- Both; Country- Taiwan; Other- Without painful physical symptoms.","25727051","Specific disease- Major depression; Age- Adult; Gender- Both; Country- Taiwan; Other- Without painful physical symptoms.","Selective serotonin reuptake inhibitor (SSRI)","Depression and pain: an appraisal of cost effectiveness and cost utility of antidepressants.","Tricyclic antidepressant (TCA)","NE"
"2011-01-08285","2011","Hung 2011 Pharmacoeconomics","Cost-Saving","Lamivudine (100mg/day) prescribed in last month until delivery and all neonates received HBV vaccine at 0, 1 and 6 months after birth; neonates born to mothers with positive serum hepatitis B surface antigen and hepatitis B e antigen received HBIG (200 IU) VERSUS All neonates receive HBV vaccine at 0, 1 and 6 months after birth; neonates born to mothers with positive serum hepatitis B surface antigen and hepatitis B e antigen received HBIG (200 IU) IN Pregnant women carriers of hepatitis B virus (HBV)","22077578","Pregnant women carriers of hepatitis B virus (HBV)","Lamivudine (100mg/day) prescribed in last month until delivery and all neonates received HBV vaccine at 0, 1 and 6 months after birth; neonates born to mothers with positive serum hepatitis B surface antigen and hepatitis B e antigen received HBIG (200 IU)","Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.","All neonates receive HBV vaccine at 0, 1 and 6 months after birth; neonates born to mothers with positive serum hepatitis B surface antigen and hepatitis B e antigen received HBIG (200 IU)","SE"
"2011-01-08128","2011","Itzler                           2011 J Med Econ","2600","Universal vaccination with pentavalent human-bovine reassortant rotavirus vaccine (RV5) against rotavirus gastroenteritis (RGE) VERSUS None IN Children aged 5 years or younger in Taiwan: healthcare perspective","21919673","Children aged 5 years or younger in Taiwan: healthcare perspective","Universal vaccination with pentavalent human-bovine reassortant rotavirus vaccine (RV5) against rotavirus gastroenteritis (RGE)","Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children =5 years of age in Taiwan.","None","NE"
"2011-01-08128","2011","Itzler                           2011 J Med Econ","Cost-Saving","Universal vaccination with pentavalent human-bovine reassortant rotavirus vaccine (RV5) against rotavirus gastroenteritis (RGE) VERSUS None IN Children aged 5 years or younger in Taiwan: societal perspective","21919673","Children aged 5 years or younger in Taiwan: societal perspective","Universal vaccination with pentavalent human-bovine reassortant rotavirus vaccine (RV5) against rotavirus gastroenteritis (RGE)","Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children =5 years of age in Taiwan.","None","SE"
"2011-01-08057","2011","Hsu                              2011 Value Health","Cost-Saving","Adjuvant therapy with capecitabine VERSUS Standard treatment- adjuvant therapy with intravenous bolus 5-fluorouracil (5-FU) and leucovorin (LU) for 6-8 months (either weekly or monthly) IN Patients with resected confirmed stage III colon carcinoma in Taiwan","21839401","Patients with resected confirmed stage III colon carcinoma in Taiwan","Adjuvant therapy with capecitabine","Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.","Standard treatment- adjuvant therapy with intravenous bolus 5-fluorouracil (5-FU) and leucovorin (LU) for 6-8 months (either weekly or monthly)","SE"
"2011-01-08017","2011","Chan 2011 Clin Drug Investig","45000","Cetuximab plus radiotherapy VERSUS Radiotherapy IN Patients with locally advanced squamous cell carcinoma of the head and neck in Taiwan","21744880","Patients with locally advanced squamous cell carcinoma of the head and neck in Taiwan","Cetuximab plus radiotherapy","Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis.","Radiotherapy","NE"
"2010-01-06187","2010","Liu 2010 BMC Health Serv Res","16000","Human papilloma virus vaccination against HPV-16 and HPV-18 VERSUS No vaccination IN Taiwanese girls aged 12+ years old.","20064239","Taiwanese girls aged 12+ years old.","Human papilloma virus vaccination against HPV-16 and HPV-18","Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.","No vaccination","NE"
"2010-01-06111","2010","Shih 2010 J Formos Med Assoc","22000","A two-stage screening, mass screening campaign and subsequent continuing surveillance for hepatocellular carcinoma  (HCC) VERSUS Opportunistic screening alone IN All Taiwanese individuals born before 1984","20123585","All Taiwanese individuals born before 1984","A two-stage screening, mass screening campaign and subsequent continuing surveillance for hepatocellular carcinoma  (HCC)","Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan.","Opportunistic screening alone","NE"
"2009-01-05542","2009","Chou 2009 J Formos Med Assoc","3500","Three weekly intra-articular injection of chemically cross-linked Hylan G-F 20 (Synvisc) VERSUS None IN Patients with mild to moderate OA (osteroarthritis) of the knee in Taiwan","19666354","Patients with mild to moderate OA (osteroarthritis) of the knee in Taiwan","Three weekly intra-articular injection of chemically cross-linked Hylan G-F 20 (Synvisc)","Hylan G-F 20 has better pain relief and cost-effectiveness than sodium hyaluronate in treating early osteoarthritic knees in Taiwan.","None","NE"
"2009-01-05542","2009","Chou 2009 J Formos Med Assoc","6400","Five weekly intra-articular injection of sodium hyaluronate (Artz) VERSUS None IN Patients with mild to moderate OA (osteroarthritis) of the knee in Taiwan","19666354","Patients with mild to moderate OA (osteroarthritis) of the knee in Taiwan","Five weekly intra-articular injection of sodium hyaluronate (Artz)","Hylan G-F 20 has better pain relief and cost-effectiveness than sodium hyaluronate in treating early osteoarthritic knees in Taiwan.","None","NE"
"2009-01-05453","2009","Hung 2009 Vaccine","Cost-Saving","Universal vaccination for all newborns at age 0, 2, and 6 months and  a hepatitis B immunoglobulin (HBIG) injection within 24 h after birth for neonates born to mothers who test positive for either HBsAg or Hepatitis B e Antigen VERSUS No vaccination IN A birth cohort of 300,000 newborns in 1984 in Taiwan. This is from health care payer perspective.","19735755","A birth cohort of 300,000 newborns in 1984 in Taiwan. This is from health care payer perspective.","Universal vaccination for all newborns at age 0, 2, and 6 months and  a hepatitis B immunoglobulin (HBIG) injection within 24 h after birth for neonates born to mothers who test positive for either HBsAg or Hepatitis B e Antigen","Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: An experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.","No vaccination","SE"
"2009-01-05453","2009","Hung 2009 Vaccine","Cost-Saving","Universal vaccination for all newborns at age 0, 2, and 6 months and  a hepatitis B immunoglobulin (HBIG) injection within 24 h after birth for neonates born to mothers who test positive for either HBsAg or Hepatitis B e Antigen VERSUS No vaccination IN A birth cohort of 300,000 newborns in 1984 in Taiwan. This is from societal perspective.","19735755","A birth cohort of 300,000 newborns in 1984 in Taiwan. This is from societal perspective.","Universal vaccination for all newborns at age 0, 2, and 6 months and  a hepatitis B immunoglobulin (HBIG) injection within 24 h after birth for neonates born to mothers who test positive for either HBsAg or Hepatitis B e Antigen","Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: An experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.","No vaccination","SE"
"2009-01-05352","2009","Yen 2009 Acad Radiol","1700","18-Fluoro-2-Deoxyglucose Positron emission tomography (PET scan) of the nasal passages VERSUS Magnetic resonance imaging of the nasal passages IN Southern China and Southeast Asia patients suspected of nasopharyngeal carcinoma. Taiwanese healthcare system.","19064212","Southern China and Southeast Asia patients suspected of nasopharyngeal carcinoma. Taiwanese healthcare system.","18-Fluoro-2-Deoxyglucose Positron emission tomography (PET scan) of the nasal passages","The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma.","Magnetic resonance imaging of the nasal passages","NE"
"2009-01-05352","2009","Yen 2009 Acad Radiol","560","MRI followed by PET scan if MRI results are uncertain VERSUS Magnetic Resonance Imaging (MRI) scan of the nasal passages IN Southern China and Southeast Asia patients suspected of nasopharyngeal carcinoma. Taiwanese healthcare system.","19064212","Southern China and Southeast Asia patients suspected of nasopharyngeal carcinoma. Taiwanese healthcare system.","MRI followed by PET scan if MRI results are uncertain","The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma.","Magnetic Resonance Imaging (MRI) scan of the nasal passages","NE"
"2009-01-05144","2009","Lee 2009 J Clin Neurosci","13000","Gamma knife radiosurgery for treatment of brain tumors VERSUS No treatment IN Taiwanese patients 18 to 80 years old with multiple metastatic brain tumors and a pre-operative Karnofsky performance scale (KPS) score of 50 to 100.","19269828","Taiwanese patients 18 to 80 years old with multiple metastatic brain tumors and a pre-operative Karnofsky performance scale (KPS) score of 50 to 100.","Gamma knife radiosurgery for treatment of brain tumors","Outcomes and cost-effectiveness of gamma knife radiosurgery and whole brain radiotherapy for multiple metastatic brain tumors.","No treatment","NE"
"2009-01-05144","2009","Lee 2009 J Clin Neurosci","21000","Whole brain radiotherapy for treatment of brain tumors VERSUS No treatment IN Taiwanese patients 18 to 80 years old with multiple metastatic brain tumors and a pre-operative Karnofsky performance scale (KPS) score of 50 to 100.","19269828","Taiwanese patients 18 to 80 years old with multiple metastatic brain tumors and a pre-operative Karnofsky performance scale (KPS) score of 50 to 100.","Whole brain radiotherapy for treatment of brain tumors","Outcomes and cost-effectiveness of gamma knife radiosurgery and whole brain radiotherapy for multiple metastatic brain tumors.","No treatment","NE"
"2008-01-04555","2008","Chao 2008 Otol Neurotol","13000","Hearing aid use VERSUS No hearing aid use IN Men with hearing impairment aged between 50-80 years","18725859","Men with hearing impairment aged between 50-80 years","Hearing aid use","Cost-effectiveness of hearing aids in the hearing-impaired elderly: a probabilistic approach.","No hearing aid use","NE"
"2008-01-04555","2008","Chao 2008 Otol Neurotol","18000","Hearing aid use VERSUS No hearing aid use IN Women with hearing impairment aged between 50-80 years","18725859","Women with hearing impairment aged between 50-80 years","Hearing aid use","Cost-effectiveness of hearing aids in the hearing-impaired elderly: a probabilistic approach.","No hearing aid use","NE"
"2008-01-04520","2008","Chen 2008 Nurs Econ","19000","Hospital-based 12-week walking program was designed for residential community older adults VERSUS Usual care IN People aged 65 and over who live in the Shin-I district, Kee-long City, Taiwan and are able to walk independently","18777976","People aged 65 and over who live in the Shin-I district, Kee-long City, Taiwan and are able to walk independently","Hospital-based 12-week walking program was designed for residential community older adults","Health services utilization and cost utility analysis of a walking program for residential community elderly.","Usual care","NE"
"2008-01-04384","2008","Dasbach 2008 Asian Pac J Cancer Prev","16000","Quadrivalent Human Papillomavirus Vaccine + catch up program for 12-24 females VERSUS No vaccination IN 12 year old girls in Taiwan","18990021","12 year old girls in Taiwan","Quadrivalent Human Papillomavirus Vaccine + catch up program for 12-24 females","The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.","No vaccination","NE"
"2008-01-04384","2008","Dasbach 2008 Asian Pac J Cancer Prev","17000","Quadrivalent Human Papillomavirus Vaccine VERSUS No vaccination IN 12 year old girls in Taiwan","18990021","12 year old girls in Taiwan","Quadrivalent Human Papillomavirus Vaccine","The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.","No vaccination","NE"
"2018-01-28374","2018","Kumdee 2018 PLoS One","9200","Oral precancer screening program VERSUS No screening IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand.","30496214","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand.","Oral precancer screening program","Cost-utility analysis of the screening program for early oral cancer detection in Thailand.","No screening","NE"
"2018-01-27274","2018","Pattanaprateep 2018 Value Health Reg Issues","2100","Renin-angiotensin aldosterone system VERSUS Non-renin-angiotensin aldosterone system IN Specific disease- Chronic Kidney Disease; Age- Adult; Gender- Both; Country- Thailand; Other- Non-diabetic.","29730248","Specific disease- Chronic Kidney Disease; Age- Adult; Gender- Both; Country- Thailand; Other- Non-diabetic.","Renin-angiotensin aldosterone system","Cost-Effectiveness Analysis of Renin-Angiotensin Aldosterone System Blockade in Progression of Chronic Kidney Disease.","Non-renin-angiotensin aldosterone system","NE"
"2018-01-27274","2018","Pattanaprateep 2018 Value Health Reg Issues","2400","Renin-angiotensin aldosterone system blockade VERSUS Non-renin-angiotensin aldosterone system blockade IN Specific disease- Chronic Kidney Disease; Age- Adult; Gender- Both; Country- Thailand; Other- Diabetic.","29730248","Specific disease- Chronic Kidney Disease; Age- Adult; Gender- Both; Country- Thailand; Other- Diabetic.","Renin-angiotensin aldosterone system blockade","Cost-Effectiveness Analysis of Renin-Angiotensin Aldosterone System Blockade in Progression of Chronic Kidney Disease.","Non-renin-angiotensin aldosterone system blockade","NE"
"2018-01-27234","2018","Limwattananon 2018 Lung Cancer","210000","Epidermal growth factor receptor test; followed by Afatinib M+/Platin M- VERSUS Epidermal growth factor receptor test; Erlotinib M+/Platin M- IN Specific disease- Non-small cell lung cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Patients with stage IIIB/IV, advanced NSCLC, who previously had neither chemotherapy nor TKIs.","29748023","Specific disease- Non-small cell lung cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Patients with stage IIIB/IV, advanced NSCLC, who previously had neither chemotherapy nor TKIs.","Epidermal growth factor receptor test; followed by Afatinib M+/Platin M-","Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.","Epidermal growth factor receptor test; Erlotinib M+/Platin M-","NE"
"2018-01-27234","2018","Limwattananon 2018 Lung Cancer","49000","Epidermal growth factor receptor test; followed by Erlotinib M+/Platin M- VERSUS No epidermal growth factor receptor test; followed by Platin M+/M- IN Specific disease- Non-small cell lung cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Patients with stage IIIB/IV, advanced NSCLC, who previously had neither chemotherapy nor TKIs.","29748023","Specific disease- Non-small cell lung cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Patients with stage IIIB/IV, advanced NSCLC, who previously had neither chemotherapy nor TKIs.","Epidermal growth factor receptor test; followed by Erlotinib M+/Platin M-","Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.","No epidermal growth factor receptor test; followed by Platin M+/M-","NE"
"2018-01-27234","2018","Limwattananon 2018 Lung Cancer","Dominated","Epidermal growth factor receptor test; followed by Gefitinib M+ / Platin M- VERSUS Standard/Usual Care- Epidermal growth factor receptor test, followed by Erlotinib M+/Platin M- IN Specific disease- Non-small cell lung cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Patients with stage IIIB/IV, advanced NSCLC, who previously had neither chemotherapy nor TKIs.","29748023","Specific disease- Non-small cell lung cancer; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Patients with stage IIIB/IV, advanced NSCLC, who previously had neither chemotherapy nor TKIs.","Epidermal growth factor receptor test; followed by Gefitinib M+ / Platin M-","Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.","Standard/Usual Care- Epidermal growth factor receptor test, followed by Erlotinib M+/Platin M-","NW"
"2018-01-27168","2018","Luangasanatip 2018 J Hosp Infect","490","Hand Hygiene intervention in adult ICU VERSUS None IN Healthy; Age- Adult; Gender- Both; Country- Thailand.","29775628","Healthy; Age- Adult; Gender- Both; Country- Thailand.","Hand Hygiene intervention in adult ICU","Cost-effectiveness of interventions to improve hand hygiene in healthcare workers in middle-income hospital settings: a model-based analysis.","None","NE"
"2018-01-27168","2018","Luangasanatip 2018 J Hosp Infect","690","Hand Hygiene intervention in pediatric ICU VERSUS None IN Healthy; Age- Adult; Gender- Both; Country- Thailand.","29775628","Healthy; Age- Adult; Gender- Both; Country- Thailand.","Hand Hygiene intervention in pediatric ICU","Cost-effectiveness of interventions to improve hand hygiene in healthcare workers in middle-income hospital settings: a model-based analysis.","None","NE"
"2018-01-26927","2018","Krittayaphong 2018 Am J Cardiovasc Drugs","4900","Sacubitril-valsartan VERSUS Enalapril IN Specific disease- Heart failure with reduced ejection fraction; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Left ventricular ejection fraction (LVEF) of <= 40% and New York Heart Association functional class II-IV.","29926351","Specific disease- Heart failure with reduced ejection fraction; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Left ventricular ejection fraction (LVEF) of <= 40% and New York Heart Association functional class II-IV.","Sacubitril-valsartan","Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.","Enalapril","NE"
"2018-01-25914","2018","Rattanavipapong 2018 PLoS One","Cost-Saving","Sofosbuvir and ledipasvir + sofosbuvir, peginterferon alfa, and ribavirin VERSUS Standard/Usual Care- Peginterferon alfa and ribavirin for 24 weeks in chronic hepatitis C viral genotype 3 and 48 weeks for other genotypes IN Specific disease- Chronic Hepatitis C Viral infection; Age- Adult; Gender- Both; Country- Thailand; Other- Treatment-naive.","29466415","Specific disease- Chronic Hepatitis C Viral infection; Age- Adult; Gender- Both; Country- Thailand; Other- Treatment-naive.","Sofosbuvir and ledipasvir + sofosbuvir, peginterferon alfa, and ribavirin","Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.","Standard/Usual Care- Peginterferon alfa and ribavirin for 24 weeks in chronic hepatitis C viral genotype 3 and 48 weeks for other genotypes","SE"
"2017-01-25828","2017","Kantito 2017 J Thromb Thrombolysis","3800","Patient self-testing of international normalized ratio for warfarin management VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Taking warfarin for anticoagulation therapy.","29181693","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Taking warfarin for anticoagulation therapy.","Patient self-testing of international normalized ratio for warfarin management","Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation.","Standard/Usual Care","NE"
"2017-01-25828","2017","Kantito 2017 J Thromb Thrombolysis","3900","Patient self-testing (PST) of international normalized ratio (INR) for warfarin management VERSUS Anticoagulation clinic care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Taking warfarin for anticoagulation therapy.","29181693","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Taking warfarin for anticoagulation therapy.","Patient self-testing (PST) of international normalized ratio (INR) for warfarin management","Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation.","Anticoagulation clinic care","NE"
"2017-01-25793","2017","Kotirum 2017 Front Public Health","36","Haemophilus influenzae Type b (HiB) vaccination VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Thailand.","29209602","Healthy; Age- 0 to 18 years; Gender- Both; Country- Thailand.","Haemophilus influenzae Type b (HiB) vaccination","Economic Evaluation and Budget Impact Analysis of Vaccination against Haemophilus influenzae Type b Infection in Thailand.","None","NE"
"2017-01-25251","2017","Permsuwan                        2017 J Med Econ","1.8e+006","Insulin Detemir (mixed dose) VERSUS Insulin Glargine IN Specific disease- Type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand.","28649943","Specific disease- Type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand.","Insulin Detemir (mixed dose)","Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer''s perspective.","Insulin Glargine","NE"
"2017-01-25251","2017","Permsuwan                        2017 J Med Econ","2.6e+006","Insulin Detemir (double dose) VERSUS Insulin Glargine IN Specific disease- Type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand.","28649943","Specific disease- Type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand.","Insulin Detemir (double dose)","Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer''s perspective.","Insulin Glargine","NE"
"2017-01-25251","2017","Permsuwan                        2017 J Med Econ","Cost-Saving","Insulin Detemir (single dose) VERSUS Insulin Glargine IN Specific disease- Type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand.","28649943","Specific disease- Type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Thailand.","Insulin Detemir (single dose)","Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer''s perspective.","Insulin Glargine","SE"
"2017-01-25009","2017","Rautenberg                       2017 Clinicoecon Outcomes Res","Cost-Saving","Racecadotril plus oral rehydration solution (R+ORS) VERSUS Standard/Usual Care- Oral rehydration solution IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Thailand.","28761363","Healthy; Age- 0 to 18 years; Gender- Both; Country- Thailand.","Racecadotril plus oral rehydration solution (R+ORS)","The cost utility and budget impact of adjuvant racecadotril for acute diarrhea in children in Thailand.","Standard/Usual Care- Oral rehydration solution","SE"
"2016-01-21560","2016","Kitwitee 2016 World Neurosurg","1600","Video-Electroencephalography Monitoring VERSUS None IN Specific disease- Drug-Resistant Focal Epilepsy; Age- 41 to 64 years; Gender- Both; Country- Thailand; Other- A hypothetical cohort was 35-year-old patients with 15 years of focal epilepsy history who were drug resistant for at least 12 months..","27913266","Specific disease- Drug-Resistant Focal Epilepsy; Age- 41 to 64 years; Gender- Both; Country- Thailand; Other- A hypothetical cohort was 35-year-old patients with 15 years of focal epilepsy history who were drug resistant for at least 12 months..","Video-Electroencephalography Monitoring","Cost-Utility of Video-Electroencephalography Monitoring Followed by Surgery in Adults with Drug-Resistant Focal Epilepsy in Thailand.","None","NE"
"2016-01-19988","2016","Luealon 2016 Asian Pac J Cancer Prev","13000","Second line chemotherapy with gemcitabine followed by best supportive care VERSUS Standard/Usual Care- Best supportive care IN Specific disease- Ovarian cancer; Age- 41 to 64 years; Gender- Female; Country- Thailand; Other- Platinum-resistant or refractory epithelial ovarian cancer.","26925683","Specific disease- Ovarian cancer; Age- 41 to 64 years; Gender- Female; Country- Thailand; Other- Platinum-resistant or refractory epithelial ovarian cancer.","Second line chemotherapy with gemcitabine followed by best supportive care","Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.","Standard/Usual Care- Best supportive care","NE"
"2016-01-19988","2016","Luealon 2016 Asian Pac J Cancer Prev","14000","Second line chemotherapy with gemcitabine followed by third line chemotherapy with topotecan followed by best supportive care VERSUS Standard/Usual Care- Best supportive care IN Specific disease- Ovarian cancer; Age- 41 to 64 years; Gender- Female; Country- Thailand; Other- Platinum-resistant or refractory epithelial ovarian cancer..","26925683","Specific disease- Ovarian cancer; Age- 41 to 64 years; Gender- Female; Country- Thailand; Other- Platinum-resistant or refractory epithelial ovarian cancer..","Second line chemotherapy with gemcitabine followed by third line chemotherapy with topotecan followed by best supportive care","Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.","Standard/Usual Care- Best supportive care","NE"
"2016-01-19988","2016","Luealon 2016 Asian Pac J Cancer Prev","14000","Second line chemotherapy with pegylated liposomal doxorubicin (PLD) followed by best supportive care VERSUS Standard/Usual Care- Best supportive care IN Specific disease- Ovarian cancer; Age- 41 to 64 years; Gender- Female; Country- Thailand; Other- Platinum-resistant or refractory epithelial ovarian cancer..","26925683","Specific disease- Ovarian cancer; Age- 41 to 64 years; Gender- Female; Country- Thailand; Other- Platinum-resistant or refractory epithelial ovarian cancer..","Second line chemotherapy with pegylated liposomal doxorubicin (PLD) followed by best supportive care","Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.","Standard/Usual Care- Best supportive care","NE"
"2016-01-19988","2016","Luealon 2016 Asian Pac J Cancer Prev","15000","Second line chemotherapy with pegylated liposomal doxorubicin (PLD) followed by third line chemotherapy with topotecan followed best supportive care VERSUS Standard/Usual Care- Best supportive care IN Specific disease- Ovarian cancer; Age- 41 to 64 years; Gender- Female; Country- Thailand; Other- Platinum-resistant or refractory epithelial ovarian cancer.","26925683","Specific disease- Ovarian cancer; Age- 41 to 64 years; Gender- Female; Country- Thailand; Other- Platinum-resistant or refractory epithelial ovarian cancer.","Second line chemotherapy with pegylated liposomal doxorubicin (PLD) followed by third line chemotherapy with topotecan followed best supportive care","Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.","Standard/Usual Care- Best supportive care","NE"
"2016-01-19921","2016","Permsuwan                        2016 Appl Health Econ Health Policy","7700","Treatment for type II diabetes with Insulin glargine (Iglar) VERSUS Treatment for type II diabetes with Neutral protamine Hagedorn (NPH) Insulin IN Specific disease- Type II diabetes; Age- 41 to 64 years; Gender- Both; Country- Thailand.","26961276","Specific disease- Type II diabetes; Age- 41 to 64 years; Gender- Both; Country- Thailand.","Treatment for type II diabetes with Insulin glargine (Iglar)","Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.","Treatment for type II diabetes with Neutral protamine Hagedorn (NPH) Insulin","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","120000","Sildenafil; if unresponsive, then sildenafil + iloprost VERSUS Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) IN Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","Sildenafil; if unresponsive, then sildenafil + iloprost","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","150000","Sildenafil; if unresponsive, then sildenafil + iloprost VERSUS Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) IN Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","Sildenafil; if unresponsive, then sildenafil + iloprost","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","28000","Sildenafil; if unresponsive, then sildenafil + bosentan VERSUS Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) IN Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","Sildenafil; if unresponsive, then sildenafil + bosentan","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","29000","Sildenafil; if unresponsive, then sildenafil + bosentan VERSUS Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) IN Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","Sildenafil; if unresponsive, then sildenafil + bosentan","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","51000","Sidenafil; if unresponsive, then sidenafil + iloprost VERSUS Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) IN Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","Sidenafil; if unresponsive, then sidenafil + iloprost","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","55000","Sildenafil; if unresponsive, then sildenafil + iloprost VERSUS Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) IN Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","Sildenafil; if unresponsive, then sildenafil + iloprost","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","6500","Beraprost; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) VERSUS Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive) IN Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","Beraprost; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","6800","Beraprost; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) VERSUS Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive) IN Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class II.","Beraprost; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","6800","Beraprost; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) VERSUS Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive) IN Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","Beraprost; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","6800","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) VERSUS Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive) IN Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","7100","Beraprost; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) VERSUS Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive) IN Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","Beraprost; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","76000","Sildenafil; if unreponsive, then sildenafil + bosentan VERSUS Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) IN Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","Sildenafil; if unreponsive, then sildenafil + bosentan","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","8000","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) VERSUS Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive) IN Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 0 to 18 years, 19 to 40 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertension associated with congenital heart disease patients; functional class III.","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive)","NE"
"2015-01-20696","2015","Thongsri 2015 Expert Rev Pharmacoecon Outcomes Res","8000","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) VERSUS Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive) IN Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertensionassociated with congenital heart disease patients; functional class II.","26566873","Specific disease- Pulmonary arterial hypertension; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Thailand; Other- Pulmonary arterial hypertensionassociated with congenital heart disease patients; functional class II.","Sildenafil; if unresponsive, then standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin)","Cost-utility and budget impact analysis of drug treatments in pulmonary arterial  hypertension associated with congenital heart diseases in Thailand.","Standard treatment (anticoagulation therapy, diuretics, oxygen, or digoxin) as initial and sequential (if initial unresponsive)","NE"
"2007-01-03202","2007","Zijlstra 2007 Rheumatology (Oxford)","44000","Spa treatment VERSUS Usual care IN Patients with fibromyalgia aged 18-65","17636181","Patients with fibromyalgia aged 18-65","Spa treatment","Cost-effectiveness of Spa treatment for fibromyalgia: general health improvement is not for free.","Usual care","NE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","7400","Screening for Hepatitis B and Hepatitis C VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Turkey.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Turkey.","Screening for Hepatitis B and Hepatitis C","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2016-01-22727","2016","Akin 2016 PLoS One","31","Increasing the influenza vaccination coverage rate (VCR) for adults with type 2 diabetes to 20% VERSUS Standard/Usual Care- Vaccine coverage rate at 9.1% IN Specific disease- Type II Diabetes; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Turkey.","27322384","Specific disease- Type II Diabetes; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Turkey.","Increasing the influenza vaccination coverage rate (VCR) for adults with type 2 diabetes to 20%","Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in Turkey.","Standard/Usual Care- Vaccine coverage rate at 9.1%","NE"
"2016-01-22371","2016","Yalcin Balcik 2016 Turk J Med Sci","86000","Pemetrexed/cisplatin VERSUS Gemcitabine/cisplatin IN Specific disease- Nonsmall cell lung cancer; Age- Adult; Gender- Both; Country- Turkey.","27511349","Specific disease- Nonsmall cell lung cancer; Age- Adult; Gender- Both; Country- Turkey.","Pemetrexed/cisplatin","Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced  nonsmall cell lung cancer in Turkey.","Gemcitabine/cisplatin","NE"
"2016-01-22035","2016","Pouwels 2016 PLoS One","29000","Respiratory Syncytial Virus (RSV) Vaccination at 2 months and 4 months VERSUS None IN Specific disease- Respiratory Syncytial Virus (RSV); Age- 0 to 18 years; Gender- Both; Country- Turkey.","27689356","Specific disease- Respiratory Syncytial Virus (RSV); Age- 0 to 18 years; Gender- Both; Country- Turkey.","Respiratory Syncytial Virus (RSV) Vaccination at 2 months and 4 months","Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in  Turkey: An Illustration Based on Bursa Data.","None","NE"
"2016-01-22035","2016","Pouwels 2016 PLoS One","34000","Respiratory Syncytial Virus (RSV) Vaccination during third trimester of pregnancy VERSUS None IN Specific disease- Respiratory Syncytial Virus (RSV); Age- 0 to 18 years; Gender- Both; Country- Turkey.","27689356","Specific disease- Respiratory Syncytial Virus (RSV); Age- 0 to 18 years; Gender- Both; Country- Turkey.","Respiratory Syncytial Virus (RSV) Vaccination during third trimester of pregnancy","Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in  Turkey: An Illustration Based on Bursa Data.","None"," "
"2016-01-22035","2016","Pouwels 2016 PLoS One","35000","Respiratory Syncytial Virus (RSV) Vaccination during pregnancy and at 2 months and 4 months VERSUS None IN Specific disease- Respiratory Syncytial Virus (RSV); Age- 0 to 18 years; Gender- Both; Country- Turkey.","27689356","Specific disease- Respiratory Syncytial Virus (RSV); Age- 0 to 18 years; Gender- Both; Country- Turkey.","Respiratory Syncytial Virus (RSV) Vaccination during pregnancy and at 2 months and 4 months","Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in  Turkey: An Illustration Based on Bursa Data.","None"," "
"2013-01-10791","2013","Davies 2013 J Med Econ","10000","Prasugrel VERSUS Clopidogrel IN Specific disease- Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); Age- Adult; Gender- Not Specified; Country- Sweden.","23339464","Specific disease- Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); Age- Adult; Gender- Not Specified; Country- Sweden.","Prasugrel","Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.","Clopidogrel","NE"
"2013-01-10791","2013","Davies 2013 J Med Econ","11000","Prasugrel VERSUS Clopidogrel IN Specific disease- Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); Age- Adult; Gender- Not Specified; Country- Netherlands.","23339464","Specific disease- Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); Age- Adult; Gender- Not Specified; Country- Netherlands.","Prasugrel","Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.","Clopidogrel","NE"
"2013-01-10791","2013","Davies 2013 J Med Econ","11000","Prasugrel VERSUS Clopidogrel IN Specific disease- Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); Age- Adult; Gender- Not Specified; Country- Turkey.","23339464","Specific disease- Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); Age- Adult; Gender- Not Specified; Country- Turkey.","Prasugrel","Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.","Clopidogrel","NE"
"2013-01-10791","2013","Davies 2013 J Med Econ","22000","Prasugrel VERSUS Clopidogrel IN Specific disease- Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); Age- Adult; Gender- Not Specified; Country- Germany.","23339464","Specific disease- Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); Age- Adult; Gender- Not Specified; Country- Germany.","Prasugrel","Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.","Clopidogrel","NE"
"2013-01-10123","2013","Bakir 2013 Vaccine","Cost-Saving","Rotavirus vaccination VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Turkey; Other- 1-year age groups (0-1 year; 1-2 years; 2-3 years; 3-4 years; 4-5 years).","23219433","Healthy; Age- 0 to 18 years; Gender- Both; Country- Turkey; Other- 1-year age groups (0-1 year; 1-2 years; 2-3 years; 3-4 years; 4-5 years).","Rotavirus vaccination","Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model.","None","SE"
"2012-01-10009","2012","Bakir 2012 BMC Health Serv Res","Cost-Saving","10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) VERSUS 13-valent pneumococcal conjugate vaccine (PCV-13) IN Population aged <10 years in Turkey","23137037","Population aged <10 years in Turkey","10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)","Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.","13-valent pneumococcal conjugate vaccine (PCV-13)","SE"
"2012-01-10009","2012","Bakir 2012 BMC Health Serv Res","Cost-Saving","10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) VERSUS 7-valent pneumococcal conjugate vaccine (PCV-13) IN Population aged <10 years in Turkey","23137037","Population aged <10 years in Turkey","10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)","Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.","7-valent pneumococcal conjugate vaccine (PCV-13)","SE"
"2012-01-10009","2012","Bakir 2012 BMC Health Serv Res","Cost-Saving","13-valent pneumococcal conjugate vaccine (PCV-13) VERSUS 7-valent pneumococcal conjugate vaccine (PCV-7) IN Population aged <10 years in Turkey","23137037","Population aged <10 years in Turkey","13-valent pneumococcal conjugate vaccine (PCV-13)","Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.","7-valent pneumococcal conjugate vaccine (PCV-7)","SE"
"2012-01-09512","2012","Toy 2012 Eur J Health Econ","11000","Lamivudine + Tenofovir salvage (patients with resistance to lamivudine therapy are salvaged by add-on adefovir) VERSUS None IN Patients with treatment-naive active chronic hepatitis B, HBeAg positive and no cirrhosis in Turkey","22815098","Patients with treatment-naive active chronic hepatitis B, HBeAg positive and no cirrhosis in Turkey","Lamivudine + Tenofovir salvage (patients with resistance to lamivudine therapy are salvaged by add-on adefovir)","The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.","None","NE"
"2012-01-09512","2012","Toy 2012 Eur J Health Econ","13000","Lamivudine + Tenofovir salvage (patients with resistance to lamivudine therapy are switched to tenofovir) VERSUS None IN Patients with treatment-naive active chronic hepatitis B, HBeAg negative and no cirrhosis in Turkey","22815098","Patients with treatment-naive active chronic hepatitis B, HBeAg negative and no cirrhosis in Turkey","Lamivudine + Tenofovir salvage (patients with resistance to lamivudine therapy are switched to tenofovir)","The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.","None","NE"
"2012-01-09512","2012","Toy 2012 Eur J Health Econ","13000","Patients start therapy with lamivudine, after 24 weeks virologic response on treatment is assessed, continue treatment until resistance or virologic breakthrough occurs, after which patients are switched to tenofovir (if HBV DNA is detectable then switch to tenefovir monotherapy) VERSUS None IN Patients with treatment-naive active chronic hepatitis B, HBeAg negative and no cirrhosis in Turkey","22815098","Patients with treatment-naive active chronic hepatitis B, HBeAg negative and no cirrhosis in Turkey","Patients start therapy with lamivudine, after 24 weeks virologic response on treatment is assessed, continue treatment until resistance or virologic breakthrough occurs, after which patients are switched to tenofovir (if HBV DNA is detectable then switch to tenefovir monotherapy)","The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.","None","NE"
"2012-01-09512","2012","Toy 2012 Eur J Health Econ","13000","Tenofovir monotherapy (300mg for 20 years) VERSUS None IN Patients with treatment-naive active chronic hepatitis B, HBeAg negative and no cirrhosis in Turkey","22815098","Patients with treatment-naive active chronic hepatitis B, HBeAg negative and no cirrhosis in Turkey","Tenofovir monotherapy (300mg for 20 years)","The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.","None","NE"
"2017-01-23776","2017","Lofgren 2017 Br J Surg","Cost-Saving","Herniorrhaphy with low-cost mosquito mesh VERSUS Standard/Usual Care- Commercial mesh IN Specific disease- Inguinal hernia; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- Uganda.","28206682","Specific disease- Inguinal hernia; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Male; Country- Uganda.","Herniorrhaphy with low-cost mosquito mesh","Cost-effectiveness of groin hernia repair from a randomized clinical trial comparing commercial versus low-cost mesh in a low-income country.","Standard/Usual Care- Commercial mesh","SE"
"2017-01-23524","2017","Negoescu 2017 Clin Infect Dis","1400","Adaptive policy optimized for 3*GDP VERSUS Adaptive monitoring at 1*GDP IN Specific disease- HIV/AIDS; Age- Adult; Gender- Both; Country- Uganda; Other- Viral load (VL) monitoring for patients receiving antiretroviral therapy (ART).","28329208","Specific disease- HIV/AIDS; Age- Adult; Gender- Both; Country- Uganda; Other- Viral load (VL) monitoring for patients receiving antiretroviral therapy (ART).","Adaptive policy optimized for 3*GDP","Differentiated HIV Rna Viral Load Monitoring in Resource Limited Settings: An Economic Analysis.","Adaptive monitoring at 1*GDP","NE"
"2017-01-23524","2017","Negoescu 2017 Clin Infect Dis","1600","Fixed 12-month interval monitoring policy VERSUS Monitoring at 1*GDP IN Specific disease- HIV/AIDS; Age- Adult; Gender- Both; Country- Uganda; Other- Viral load (VL) monitoring for patients receiving antiretroviral therapy (ART).","28329208","Specific disease- HIV/AIDS; Age- Adult; Gender- Both; Country- Uganda; Other- Viral load (VL) monitoring for patients receiving antiretroviral therapy (ART).","Fixed 12-month interval monitoring policy","Differentiated HIV Rna Viral Load Monitoring in Resource Limited Settings: An Economic Analysis.","Monitoring at 1*GDP","NE"
"2017-01-23524","2017","Negoescu 2017 Clin Infect Dis","530","The adaptive policy optimized for the Ugandan resource context CET $572 VERSUS Monitoring at fixed intervals of 24 months IN Specific disease- HIV/AIDS; Age- Adult; Gender- Both; Country- Uganda.","28329208","Specific disease- HIV/AIDS; Age- Adult; Gender- Both; Country- Uganda.","The adaptive policy optimized for the Ugandan resource context CET $572","Differentiated HIV Rna Viral Load Monitoring in Resource Limited Settings: An Economic Analysis.","Monitoring at fixed intervals of 24 months","NE"
"2015-01-19012","2015","Revill 2015 AIDS","Dominated","Laboratory and clinical monitoring VERSUS Clinically driven monitoring (no CD4Ã¾, haematology/biochemistry, if needed, for clinical management) IN Specific disease- HIV; Age- 0 to 18 years, Adult; Gender- Both; Country- Uganda; Other- Untreated HIV-infected children/adolescents meeting WHO 2006 criteria for ART initiation.","25396263","Specific disease- HIV; Age- 0 to 18 years, Adult; Gender- Both; Country- Uganda; Other- Untreated HIV-infected children/adolescents meeting WHO 2006 criteria for ART initiation.","Laboratory and clinical monitoring","Opportunities for improving the efficiency of paediatric HIV treatment programmes.","Clinically driven monitoring (no CD4Ã¾, haematology/biochemistry, if needed, for clinical management)","NW"
"2015-01-19012","2015","Revill 2015 AIDS","Dominated","Stop cotrimoxazole VERSUS Continue cotrimoxazole IN Specific disease- HIV; Age- 0 to 18 years, Adult; Gender- Both; Country- Uganda; Other- Untreated HIV-infected children/adolescents meeting WHO 2006 criteria for ART initiation.","25396263","Specific disease- HIV; Age- 0 to 18 years, Adult; Gender- Both; Country- Uganda; Other- Untreated HIV-infected children/adolescents meeting WHO 2006 criteria for ART initiation.","Stop cotrimoxazole","Opportunities for improving the efficiency of paediatric HIV treatment programmes.","Continue cotrimoxazole","NW"
"2014-01-15414","2014","Nichols 2014 J Int AIDS Soc","1800","Increased second line treatment immediately VERSUS Standard/Usual Care- Treat immediately IN Specific disease- Drug-resistant HIV; Age- Unknown; Gender- Not Specified; Country- Uganda.","25491351","Specific disease- Drug-resistant HIV; Age- Unknown; Gender- Not Specified; Country- Uganda.","Increased second line treatment immediately","Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.","Standard/Usual Care- Treat immediately","NE"
"2014-01-15414","2014","Nichols 2014 J Int AIDS Soc","2400","Increased second line treatment at CD4 cell count <500 VERSUS Standard/Usual Care- Treatment at CD4 cell count <500 IN Specific disease- Drug-resistant HIV; Age- Unknown; Gender- Not Specified; Country- Uganda.","25491351","Specific disease- Drug-resistant HIV; Age- Unknown; Gender- Not Specified; Country- Uganda.","Increased second line treatment at CD4 cell count <500","Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.","Standard/Usual Care- Treatment at CD4 cell count <500","NE"
"2014-01-15414","2014","Nichols 2014 J Int AIDS Soc","2700","Increase in second line treatment at CD4 cell count <350 VERSUS Standard/Usual Care- Treatment at CD<350 at base rate IN Specific disease- Drug-resistant HIV; Age- Unknown; Gender- Not Specified; Country- Uganda.","25491351","Specific disease- Drug-resistant HIV; Age- Unknown; Gender- Not Specified; Country- Uganda.","Increase in second line treatment at CD4 cell count <350","Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.","Standard/Usual Care- Treatment at CD<350 at base rate","NE"
"2013-01-10750","2013","Mupere 2013 Int J Tuberc Lung Dis","240","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control VERSUS PCF alone IN Healthy; Age- 19 to 40 years; Gender- Both; Country- Uganda/Kampala.","23317956","Healthy; Age- 19 to 40 years; Gender- Both; Country- Uganda/Kampala.","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control","Effectiveness of active case-finding strategies in tuberculosis control in Kampala, Uganda.","PCF alone","NE"
"2013-01-10750","2013","Mupere 2013 Int J Tuberc Lung Dis","56","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control VERSUS PCF alone IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Uganda/Kampala.","23317956","Healthy; Age- 41 to 64 years; Gender- Both; Country- Uganda/Kampala.","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control","Effectiveness of active case-finding strategies in tuberculosis control in Kampala, Uganda.","PCF alone","NE"
"2013-01-10750","2013","Mupere 2013 Int J Tuberc Lung Dis","60","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control VERSUS PCF alone IN Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Uganda/Kampala.","23317956","Healthy; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Uganda/Kampala.","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control","Effectiveness of active case-finding strategies in tuberculosis control in Kampala, Uganda.","PCF alone","NE"
"2013-01-10750","2013","Mupere 2013 Int J Tuberc Lung Dis","600","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control VERSUS PCF alone IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Uganda/Kampala.","23317956","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Uganda/Kampala.","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control","Effectiveness of active case-finding strategies in tuberculosis control in Kampala, Uganda.","PCF alone","NE"
"2013-01-10750","2013","Mupere 2013 Int J Tuberc Lung Dis","600","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control VERSUS PCF alone IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Uganda/Kampala.","23317956","Healthy; Age- 0 to 18 years; Gender- Both; Country- Uganda/Kampala.","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control","Effectiveness of active case-finding strategies in tuberculosis control in Kampala, Uganda.","PCF alone","NE"
"2013-01-10750","2013","Mupere 2013 Int J Tuberc Lung Dis","65","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control VERSUS PCF alone IN Healthy; Age- 41 to 64 years; Gender- Both; Country- Uganda/Kampala.","23317956","Healthy; Age- 41 to 64 years; Gender- Both; Country- Uganda/Kampala.","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control","Effectiveness of active case-finding strategies in tuberculosis control in Kampala, Uganda.","PCF alone","NE"
"2013-01-10750","2013","Mupere 2013 Int J Tuberc Lung Dis","95","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control VERSUS PCF alone IN Healthy; Age- >=65 years; Gender- Both; Country- Uganda/Kampala.","23317956","Healthy; Age- >=65 years; Gender- Both; Country- Uganda/Kampala.","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control","Effectiveness of active case-finding strategies in tuberculosis control in Kampala, Uganda.","PCF alone","NE"
"2013-01-10750","2013","Mupere 2013 Int J Tuberc Lung Dis","95","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control VERSUS PCF alone IN Healthy; Age- 19 to 40 years; Gender- Both; Country- Uganda/Kampala.","23317956","Healthy; Age- 19 to 40 years; Gender- Both; Country- Uganda/Kampala.","Active case finding (ACF) of symptomatic individuals combined with passive case finding (PCF) strategy in tuberculosis control","Effectiveness of active case-finding strategies in tuberculosis control in Kampala, Uganda.","PCF alone","NE"
"2012-01-09836","2012","Rajasingham 2012 PLoS Med","17","Amphotericin B (1.0 mg/kg/d) for 7 days + fluconazole (1200 mg/d) for 14 days VERSUS Fluconazole (1200 mg/d) for 14 days IN HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa","23055838","HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa","Amphotericin B (1.0 mg/kg/d) for 7 days + fluconazole (1200 mg/d) for 14 days","Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis.","Fluconazole (1200 mg/d) for 14 days","NE"
"2012-01-09836","2012","Rajasingham 2012 PLoS Med","58","Fluconazole + flucytosine (5FC) (100 mg/kg/d) + fluconazole (1200 mg/d) for 14 days VERSUS Fluconazole (1200 mg/d) for 14 days IN HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa","23055838","HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa","Fluconazole + flucytosine (5FC) (100 mg/kg/d) + fluconazole (1200 mg/d) for 14 days","Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis.","Fluconazole (1200 mg/d) for 14 days","NE"
"2012-01-09836","2012","Rajasingham 2012 PLoS Med","75","Amphotericin B (0.7 mg/kg/d) for 14 days + fluconazole (800 mg/d) for 14 days VERSUS Fluconazole (1200 mg/d) for 14 days IN HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa","23055838","HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa","Amphotericin B (0.7 mg/kg/d) for 14 days + fluconazole (800 mg/d) for 14 days","Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis.","Fluconazole (1200 mg/d) for 14 days","NE"
"2014-01-19253","2014","Kim 2014 Cost Eff Resour Alloc","1200","Combined strategy: needle and syringe programmes and opioid substitution therapy VERSUS Needle and syringe programmes (NSP) IN Healthy; Age- 19 to 40 years, Adult; Gender- Both; Country- Ukraine.","25873788","Healthy; Age- 19 to 40 years, Adult; Gender- Both; Country- Ukraine.","Combined strategy: needle and syringe programmes and opioid substitution therapy","Comparing the cost effectiveness of harm reduction strategies: a case study of the Ukraine.","Needle and syringe programmes (NSP)","NE"
"2014-01-15104","2014","Alistar 2014 PLoS One","1100","Methadone maintenace treatment with anti-retroviral treatment VERSUS Methadone maintenace treatment alone IN Specific disease- Injection Drug Users in mixed HIV epidemics; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Ukraine.","24489747","Specific disease- Injection Drug Users in mixed HIV epidemics; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Ukraine.","Methadone maintenace treatment with anti-retroviral treatment","Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.","Methadone maintenace treatment alone","NE"
"2014-01-15104","2014","Alistar 2014 PLoS One","1400","Pre-exposure prophylaxis in addition to methadone and anti-retroviral treatment VERSUS Methadone maintenace treatment alone IN Specific disease- Injection Drug Users in mixed HIV epidemics; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Ukraine.","24489747","Specific disease- Injection Drug Users in mixed HIV epidemics; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Ukraine.","Pre-exposure prophylaxis in addition to methadone and anti-retroviral treatment","Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.","Methadone maintenace treatment alone","NE"
"2014-01-15104","2014","Alistar 2014 PLoS One","570","Methadone treatment VERSUS None IN Specific disease- Injection Drug Users in mixed HIV epidemics; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Ukraine.","24489747","Specific disease- Injection Drug Users in mixed HIV epidemics; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Both; Country- Ukraine.","Methadone treatment","Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.","None","NE"
"2011-01-07443","2011","Alistar 2011 PLoS Med","1300","High Methadone Substitution Therapy, High ART (25% of IDUs on methadone substitution therapy, 80% of all eligible patients on ART) VERSUS High methadone substitution therapy (25% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART) IN Ukraine population of non-injection drug users (IDUs) on methadone substitution therapy and opiates","21390264","Ukraine population of non-injection drug users (IDUs) on methadone substitution therapy and opiates","High Methadone Substitution Therapy, High ART (25% of IDUs on methadone substitution therapy, 80% of all eligible patients on ART)","Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.","High methadone substitution therapy (25% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART)","NE"
"2011-01-07443","2011","Alistar 2011 PLoS Med","2600","High ART (no methadone substitution therapy slots, 80% of all eligible patients on ART) VERSUS High methadone substitution therapy (25% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART) IN Ukraine population of non-injection drug users (IDUs) on methadone substitution therapy and opiates","21390264","Ukraine population of non-injection drug users (IDUs) on methadone substitution therapy and opiates","High ART (no methadone substitution therapy slots, 80% of all eligible patients on ART)","Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.","High methadone substitution therapy (25% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART)","NE"
"2011-01-07443","2011","Alistar 2011 PLoS Med","620","High methadone substitution therapy (25% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART) VERSUS Status quo (no methadone substitution therapy slots, 10% of eligible non-injection drug users (IDUs) on antiretroviral therapy (ART), 2% of eligible IDUs on ART) IN Ukraine population of non-injection drug users (IDUs) on methadone substitution therapy and opiates","21390264","Ukraine population of non-injection drug users (IDUs) on methadone substitution therapy and opiates","High methadone substitution therapy (25% of IDUs on methadone substitution therapy, ART according to status quo except 25% of eligible IDUs on methadone substitution therapy on ART)","Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.","Status quo (no methadone substitution therapy slots, 10% of eligible non-injection drug users (IDUs) on antiretroviral therapy (ART), 2% of eligible IDUs on ART)","NE"
"2018-01-26127","2018","Nuhoho 2018 Curr Med Res Opin","Cost-Saving","Paliperidone palmitate  VERSUS Standard/Usual Care- Oral antipsychotics IN Specific disease- Schizophrenia; Age- Adult; Gender- Both; Country- United Arab Emirates (UAE).","29292670","Specific disease- Schizophrenia; Age- Adult; Gender- Both; Country- United Arab Emirates (UAE).","Paliperidone palmitate","Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates.","Standard/Usual Care- Oral antipsychotics","SE"
"2014-01-17269","2014","Livingston 2014 Lancet Psychiatry","Cost-Saving","START psychological manual-based coping intervention. VERSUS Standard/Usual Care- Treatment as usual: medical, psychological, and social, and is supposed to consist of assessment, diagnosis and information-giving, risk assessment and managementmedical, psychological, and social, and is supposed to consist of assessment, diagnosis and information-giving, risk assessment and management, drug treatment, cognitive-stimulation therapy, practical support, treatment of neuropsychiatric and cognitive symptoms, assessment of capacity to make long-term decisions an IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Arab Emirates.","26361313","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Arab Emirates.","START psychological manual-based coping intervention.","Long-term clinical and cost-effectiveness of psychological intervention for family carers of people with dementia: a single-blind, randomised, controlled trial.","Standard/Usual Care- Treatment as usual: medical, psychological, and social, and is supposed to consist of assessment, diagnosis and information-giving, risk assessment and managementmedical, psychological, and social, and is supposed to consist of assessment, diagnosis and information-giving, risk assessment and management, drug treatment, cognitive-stimulation therapy, practical support, treatment of neuropsychiatric and cognitive symptoms, assessment of capacity to make long-term decisions an","SE"
"2014-01-16298","2014","Treharne 2014 Appl Health Econ Health Policy","Cost-Saving","Peritoneal dialysis (PD) (39% uptake) and in-centre haemodialysis haemodialysis (HD) VERSUS peritoneal dialysis (PD) (22% uptake) IN Specific disease- endstage renal disease (ESRD); Age- Adult; Gender- Both; Country- United Arab Emirates.","25017433","Specific disease- endstage renal disease (ESRD); Age- Adult; Gender- Both; Country- United Arab Emirates.","Peritoneal dialysis (PD) (39% uptake) and in-centre haemodialysis haemodialysis (HD)","Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective.","peritoneal dialysis (PD) (22% uptake)","SE"
"2018-01-28886","2018","Velickovic 2018 PLoS One","Cost-Saving","CardioCel  VERSUS Autologous Patches IN Specific disease- Congenital Heart Defect; Age- Adult; Gender- Both; Country- United Kingdom.","30261033","Specific disease- Congenital Heart Defect; Age- Adult; Gender- Both; Country- United Kingdom.","CardioCel","Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model.","Autologous Patches","SE"
"2018-01-28886","2018","Velickovic 2018 PLoS One","Cost-Saving","CardioCel  VERSUS Synthetic Patches IN Specific disease- Congenital Heart Defect; Age- Adult; Gender- Both; Country- United Kingdom.","30261033","Specific disease- Congenital Heart Defect; Age- Adult; Gender- Both; Country- United Kingdom.","CardioCel","Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model.","Synthetic Patches","SE"
"2018-01-28886","2018","Velickovic 2018 PLoS One","Cost-Saving","CardioCel  VERSUS Xenogenic Patches IN Specific disease- Congenital Heart Defect; Age- Adult; Gender- Both; Country- United Kingdom.","30261033","Specific disease- Congenital Heart Defect; Age- Adult; Gender- Both; Country- United Kingdom.","CardioCel","Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model.","Xenogenic Patches","SE"
"2018-01-28858","2018","Georgieva 2018 Lung Cancer","110000","Pembrolizumab VERSUS Standard/Usual Care- Platinum-doublet chemotherapy IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United Kingdom; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","30268469","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United Kingdom; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","Pembrolizumab","Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small  cell lung cancer.","Standard/Usual Care- Platinum-doublet chemotherapy","NE"
"2018-01-28858","2018","Georgieva 2018 Lung Cancer","110000","Pembrolizumab VERSUS Standard/Usual Care- Platinum-doublet chemotherapy IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United States; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","30268469","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United States; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","Pembrolizumab","Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small  cell lung cancer.","Standard/Usual Care- Platinum-doublet chemotherapy","NE"
"2018-01-28858","2018","Georgieva 2018 Lung Cancer","31000","Pembrolizumab VERSUS Standard/Usual Care- Platinum-doublet chemotherapy IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United States; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","30268469","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United States; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","Pembrolizumab","Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small  cell lung cancer.","Standard/Usual Care- Platinum-doublet chemotherapy","NE"
"2018-01-28858","2018","Georgieva 2018 Lung Cancer","34000","Pembrolizumab VERSUS Standard/Usual Care- Platinum-doublet chemotherapy IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United Kingdom; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","30268469","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United Kingdom; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","Pembrolizumab","Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small  cell lung cancer.","Standard/Usual Care- Platinum-doublet chemotherapy","NE"
"2018-01-28858","2018","Georgieva 2018 Lung Cancer","49000","Pembrolizumab VERSUS Standard/Usual Care- Platinum-doublet chemotherapy IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United States; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","30268469","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United States; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","Pembrolizumab","Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small  cell lung cancer.","Standard/Usual Care- Platinum-doublet chemotherapy","NE"
"2018-01-28858","2018","Georgieva 2018 Lung Cancer","52000","Pembrolizumab VERSUS Standard/Usual Care- Platinum-doublet chemotherapy IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United Kingdom; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","30268469","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United Kingdom; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","Pembrolizumab","Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small  cell lung cancer.","Standard/Usual Care- Platinum-doublet chemotherapy","NE"
"2018-01-28858","2018","Georgieva 2018 Lung Cancer","74000","Pembrolizumab VERSUS Standard/Usual Care- Platinum-doublet chemotherapy IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United States; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","30268469","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United States; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","Pembrolizumab","Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small  cell lung cancer.","Standard/Usual Care- Platinum-doublet chemotherapy","NE"
"2018-01-28858","2018","Georgieva 2018 Lung Cancer","81000","Pembrolizumab VERSUS Standard/Usual Care- Platinum-doublet chemotherapy IN Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United Kingdom; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","30268469","Specific disease- Lung cancer; Age- Adult; Gender- Both; Country- United Kingdom; Other- PD-L1 expression =50%, non-mutated EGFR, and non-translocated ALK.","Pembrolizumab","Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small  cell lung cancer.","Standard/Usual Care- Platinum-doublet chemotherapy","NE"
"2018-01-28813","2018","Giorgakoudi 2018 Vaccine","32000","Maternal immunisation with risk factor-based intrapartum antibiotic prophylaxis VERSUS Standard/Usual Care- Risk factor-based intrapartum antibiotic prophylaxis alone IN Healthy; Age- 0 to 18 years, Adult; Gender- Both; Country- United Kingdom.","30293765","Healthy; Age- 0 to 18 years, Adult; Gender- Both; Country- United Kingdom.","Maternal immunisation with risk factor-based intrapartum antibiotic prophylaxis","Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study.","Standard/Usual Care- Risk factor-based intrapartum antibiotic prophylaxis alone","NE"
"2018-01-28776","2018","Bessey 2018 Orphanet J Rare Dis","Cost-Saving","X-linked adrenoleukodystrophy screening VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United Kingdom.","30309370","Healthy; Age- 0 to 18 years; Gender- Both; Country- United Kingdom.","X-linked adrenoleukodystrophy screening","Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme.","None","SE"
"2018-01-28412","2018","Pollit 2018 Curr Med Res Opin","4000","Endoscopic eradication therapy VERSUS Endoscopic surveillance IN Specific disease- Barrett's esophagus ; Age- Unknown; Gender- Both; Country- United Kingdom; Other- Low-grade or high-grade dysplasia.","30479169","Specific disease- Barrett's esophagus ; Age- Unknown; Gender- Both; Country- United Kingdom; Other- Low-grade or high-grade dysplasia.","Endoscopic eradication therapy","A cost-effectiveness analysis of endoscopic eradication therapy (EET) for management of dysplasia arising in patients with Barrett''s esophagus in the United Kingdom.","Endoscopic surveillance","NE"
"2018-01-28349","2018","Driessen 2018 Respir Med","12000","Umeclidinium bromide + fluticasone propionate/salmeterol  VERSUS Fluticasone propionate/salmeterol alone 250/50 Âµg IN Specific disease- Chronic obstructive pulmonary disease (COPD); Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- Patients with a smoking history of =10 pack-years.","30509701","Specific disease- Chronic obstructive pulmonary disease (COPD); Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- Patients with a smoking history of =10 pack-years.","Umeclidinium bromide + fluticasone propionate/salmeterol","Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective.","Fluticasone propionate/salmeterol alone 250/50 Âµg","NE"
"2018-01-28349","2018","Driessen 2018 Respir Med","6600","Umeclidinium bromide + fluticasone furoate/vilanterol VERSUS Fluticasone furoate/vilanterol alone 100/25 Âµg IN Specific disease- Chronic obstructive pulmonary disease (COPD); Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- Patients with a smoking history of =10 pack-years.","30509701","Specific disease- Chronic obstructive pulmonary disease (COPD); Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- Patients with a smoking history of =10 pack-years.","Umeclidinium bromide + fluticasone furoate/vilanterol","Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective.","Fluticasone furoate/vilanterol alone 100/25 Âµg","NE"
"2018-01-28349","2018","Driessen 2018 Respir Med","9400","Umeclidinium bromide +  inhaled corticosteroid/long-acting Ã2-agonist VERSUS Inhaled corticosteroid/long-acting Ã2-agonist IN Specific disease- Chronic obstructive pulmonary disease (COPD); Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- Patients with a smoking history of =10 pack-years.","30509701","Specific disease- Chronic obstructive pulmonary disease (COPD); Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- Patients with a smoking history of =10 pack-years.","Umeclidinium bromide +  inhaled corticosteroid/long-acting Ã2-agonist","Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective.","Inhaled corticosteroid/long-acting Ã2-agonist","NE"
"2018-01-28293","2018","Hinde 2018 Lung Cancer","14000","Low-dose CT lung cancer screening program VERSUS Symptomatic presentation IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- Ever-smokers.","30527175","Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- Ever-smokers.","Low-dose CT lung cancer screening program","The cost-effectiveness of the Manchester ''lung health checks'', a community-based  lung cancer low-dose CT screening pilot.","Symptomatic presentation","NE"
"2018-01-28184","2018","Pawaskar 2018 Diabetes Obes Metab","Cost-Saving","Sodiumglucose co-transporter-2 (SGLT2) inhibitors (pathway 1)  VERSUS NPH insulin (pathway 2) - a transition from metformin + sitagliptin directly to metformin + sitagliptin + NPH insulin IN Specific disease- Type 2 diabetes ; Age- Adult; Gender- Both; Country- United Kingdom.","30565386","Specific disease- Type 2 diabetes ; Age- Adult; Gender- Both; Country- United Kingdom.","Sodiumglucose co-transporter-2 (SGLT2) inhibitors (pathway 1)","Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.","NPH insulin (pathway 2) - a transition from metformin + sitagliptin directly to metformin + sitagliptin + NPH insulin","SE"
"2018-01-27769","2018","Meng 2018 Eur J Health Econ","25000","Nivolumab VERSUS Ipilimumab IN Specific disease- Advanced melanoma; Age- Adult; Gender- Both; Country- United Kingdom; Other- BRAF mutation-positive patients.","29524005","Specific disease- Advanced melanoma; Age- Adult; Gender- Both; Country- United Kingdom; Other- BRAF mutation-positive patients.","Nivolumab","The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.","Ipilimumab","NE"
"2018-01-27769","2018","Meng 2018 Eur J Health Econ","32000","Ipilimumab VERSUS Dacarbazine IN Specific disease- Advanced Melanoma; Age- Adult; Gender- Both; Country- United Kingdom; Other- BRAF mutation-negative patients.","29524005","Specific disease- Advanced Melanoma; Age- Adult; Gender- Both; Country- United Kingdom; Other- BRAF mutation-negative patients.","Ipilimumab","The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.","Dacarbazine","NE"
"2018-01-27769","2018","Meng 2018 Eur J Health Econ","35000","Nivolumab VERSUS Ipilimumab IN Specific disease- Advanced Melanoma; Age- Adult; Gender- Both; Country- United Kingdom; Other- BRAF mutation-negative patients.","29524005","Specific disease- Advanced Melanoma; Age- Adult; Gender- Both; Country- United Kingdom; Other- BRAF mutation-negative patients.","Nivolumab","The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.","Ipilimumab","NE"
"2018-01-27769","2018","Meng 2018 Eur J Health Econ","Dominated","Dabrafenib VERSUS Ipilimumab IN Specific disease- Advanced Melanoma; Age- Adult; Gender- Both; Country- United Kingdom; Other- BRAF mutation-positive patients.","29524005","Specific disease- Advanced Melanoma; Age- Adult; Gender- Both; Country- United Kingdom; Other- BRAF mutation-positive patients.","Dabrafenib","The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.","Ipilimumab","NW"
"2018-01-27769","2018","Meng 2018 Eur J Health Econ","Dominated","Vemurafenib VERSUS Ipilimumab IN Specific disease- Advanced Melanoma; Age- Adult; Gender- Both; Country- United Kingdom; Other- BRAF mutation-positive patients.","29524005","Specific disease- Advanced Melanoma; Age- Adult; Gender- Both; Country- United Kingdom; Other- BRAF mutation-positive patients.","Vemurafenib","The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.","Ipilimumab","NW"
"2009-01-05760","2009","Shim 2009 Vaccine","33","PEP vaccine administered VERSUS Control, did not receive administration of PEP IN Victtims bitten by suspected rabid animals from two districts in Northwest Tanzania: Serengeti and Ngorongoro.  648 exposures total. (healthcare perspective)","19925948","Victtims bitten by suspected rabid animals from two districts in Northwest Tanzania: Serengeti and Ngorongoro.  648 exposures total. (healthcare perspective)","PEP vaccine administered","Evaluating the cost-effectiveness of rabies post-exposure prophylaxis: a case study in Tanzania.","Control, did not receive administration of PEP","NE"
"2009-01-05760","2009","Shim 2009 Vaccine","39","PEP vaccine administered VERSUS Control, did not receive administration of PEP IN Victtims bitten by suspected rabid animals from two districts in Northwest Tanzania: Serengeti and Ngorongoro.  648 exposures total. (societal perspective)","19925948","Victtims bitten by suspected rabid animals from two districts in Northwest Tanzania: Serengeti and Ngorongoro.  648 exposures total. (societal perspective)","PEP vaccine administered","Evaluating the cost-effectiveness of rabies post-exposure prophylaxis: a case study in Tanzania.","Control, did not receive administration of PEP","NE"
"2018-01-28899","2018","Chen 2018 J Neuroeng Rehabil","12000","Microprocessor-Controlled Prosthetic Knee VERSUS Standard/Usual Care- Non-Microcompressor Controlled  Prosthetic Knees IN Specific disease- Loss of Limb; Age- Adult; Gender- Both; Country- United States; Other- Individuals have lost a leg.","30255802","Specific disease- Loss of Limb; Age- Adult; Gender- Both; Country- United States; Other- Individuals have lost a leg.","Microprocessor-Controlled Prosthetic Knee","Economic benefits of microprocessor controlled prosthetic knees: a modeling study.","Standard/Usual Care- Non-Microcompressor Controlled  Prosthetic Knees","NE"
"2018-01-28888","2018","Roth 2018 J Med Econ","60000","Axicabtagene ciloleucel VERSUS Standard/Usual Care- Salvage Chemotherapy Strategy IN Specific disease- Large B-Cell Lymphoma; Age- Adult; Gender- Both; Country- United States.","30260711","Specific disease- Large B-Cell Lymphoma; Age- Adult; Gender- Both; Country- United States.","Axicabtagene ciloleucel","Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.","Standard/Usual Care- Salvage Chemotherapy Strategy","NE"
"2018-01-28871","2018","Ponnusamy 2018 J Arthroplasty","17000","Total Hip Arthroplasty VERSUS Standard/Usual Care- Nonoperative Management IN Specific disease- Obesity; Age- Adult; Gender- Both; Country- United States; Other- Super obese: >50 bmi.","30266324","Specific disease- Obesity; Age- Adult; Gender- Both; Country- United States; Other- Super obese: >50 bmi.","Total Hip Arthroplasty","Cost-Effectiveness of Total Hip Arthroplasty Versus Nonoperative Management in Normal, Overweight, Obese, Severely Obese, Morbidly Obese, and Super Obese Patients: A Markov Model.","Standard/Usual Care- Nonoperative Management","NE"
"2018-01-28871","2018","Ponnusamy 2018 J Arthroplasty","5600","Total Hip Arthroplasty VERSUS Standard/Usual Care- Nonoperative Management IN Specific disease- Obesity; Age- Adult; Gender- Both; Country- United States; Other- Obese 30-34.9 bmi.","30266324","Specific disease- Obesity; Age- Adult; Gender- Both; Country- United States; Other- Obese 30-34.9 bmi.","Total Hip Arthroplasty","Cost-Effectiveness of Total Hip Arthroplasty Versus Nonoperative Management in Normal, Overweight, Obese, Severely Obese, Morbidly Obese, and Super Obese Patients: A Markov Model.","Standard/Usual Care- Nonoperative Management","NE"
"2018-01-28871","2018","Ponnusamy 2018 J Arthroplasty","5900","Total Hip Arthroplasty VERSUS Standard/Usual Care- Nonoperative Management IN Specific disease- Obesity; Age- Adult; Gender- Both; Country- United States; Other- Overweight 25-29.9 bmi.","30266324","Specific disease- Obesity; Age- Adult; Gender- Both; Country- United States; Other- Overweight 25-29.9 bmi.","Total Hip Arthroplasty","Cost-Effectiveness of Total Hip Arthroplasty Versus Nonoperative Management in Normal, Overweight, Obese, Severely Obese, Morbidly Obese, and Super Obese Patients: A Markov Model.","Standard/Usual Care- Nonoperative Management","NE"
"2018-01-28871","2018","Ponnusamy 2018 J Arthroplasty","6200","Total Hip Arthroplasty VERSUS Standard/Usual Care- Nonoperative Management IN Healthy; Age- Adult; Gender- Both; Country- United States; Other- Normal weight 18.5-24.9 bmi.","30266324","Healthy; Age- Adult; Gender- Both; Country- United States; Other- Normal weight 18.5-24.9 bmi.","Total Hip Arthroplasty","Cost-Effectiveness of Total Hip Arthroplasty Versus Nonoperative Management in Normal, Overweight, Obese, Severely Obese, Morbidly Obese, and Super Obese Patients: A Markov Model.","Standard/Usual Care- Nonoperative Management","NE"
"2018-01-28871","2018","Ponnusamy 2018 J Arthroplasty","7600","Total Hip Arthroplasty VERSUS Standard/Usual Care- Nonoperative Management  IN Specific disease- Obesity; Age- Adult; Gender- Both; Country- United States; Other- Severely obese 35-39.9 bmi.","30266324","Specific disease- Obesity; Age- Adult; Gender- Both; Country- United States; Other- Severely obese 35-39.9 bmi.","Total Hip Arthroplasty","Cost-Effectiveness of Total Hip Arthroplasty Versus Nonoperative Management in Normal, Overweight, Obese, Severely Obese, Morbidly Obese, and Super Obese Patients: A Markov Model.","Standard/Usual Care- Nonoperative Management","NE"
"2018-01-28871","2018","Ponnusamy 2018 J Arthroplasty","8500","Total Hip Arthroplasty VERSUS Standard/Usual Care- Nonoperative Management IN Specific disease- Obesity; Age- Adult; Gender- Both; Country- United States; Other- Morbidly obese 40-49.9 bmi.","30266324","Specific disease- Obesity; Age- Adult; Gender- Both; Country- United States; Other- Morbidly obese 40-49.9 bmi.","Total Hip Arthroplasty","Cost-Effectiveness of Total Hip Arthroplasty Versus Nonoperative Management in Normal, Overweight, Obese, Severely Obese, Morbidly Obese, and Super Obese Patients: A Markov Model.","Standard/Usual Care- Nonoperative Management","NE"
"2018-01-28870","2018","Nguyen 2018 Int J Cardiol","47000","Ranolazine VERSUS None IN Specific disease- Type II Diabetes; Age- Adult; Gender- Both; Country- United States; Other- Chronic Angina.","30266352","Specific disease- Type II Diabetes; Age- Adult; Gender- Both; Country- United States; Other- Chronic Angina.","Ranolazine","Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.","None","NE"
"2018-01-28863","2018","Sharma 2018 Orphanet J Rare Dis","3.8e+006","Combined Lumacaftor and Ivacaftor + usual care VERSUS Standard/Usual Care- Usual Care (treatment with antibiotics, pancreatic enzymes, aminoglycosides (inhaled tobramycin as well as intravenously administered aminoglycosides and DNase) IN Specific disease- Cystic Fibrosis; Age- 0 to 18 years; Gender- Both; Country- United States.","30268148","Specific disease- Cystic Fibrosis; Age- 0 to 18 years; Gender- Both; Country- United States.","Combined Lumacaftor and Ivacaftor + usual care","Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.","Standard/Usual Care- Usual Care (treatment with antibiotics, pancreatic enzymes, aminoglycosides (inhaled tobramycin as well as intravenously administered aminoglycosides and DNase)","NE"
"2018-01-28839","2018","Kazarian 2018 J Bone Joint Surg Am","Cost-Saving","Total knee arthroplasty VERSUS Nonsurgical treatment  IN Specific disease- Knee osteoarthritis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30277995","Specific disease- Knee osteoarthritis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Total knee arthroplasty","Cost-Effectiveness of Surgical and Nonsurgical Treatments for Unicompartmental Knee Arthritis: A Markov Model.","Nonsurgical treatment","SE"
"2018-01-28839","2018","Kazarian 2018 J Bone Joint Surg Am","Cost-Saving","Unicompartmental knee arthroplasty  VERSUS Total knee arthroplasty IN Specific disease- Knee osteoarthritis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30277995","Specific disease- Knee osteoarthritis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Unicompartmental knee arthroplasty","Cost-Effectiveness of Surgical and Nonsurgical Treatments for Unicompartmental Knee Arthritis: A Markov Model.","Total knee arthroplasty","SE"
"2018-01-28839","2018","Kazarian 2018 J Bone Joint Surg Am","Cost-Saving","Unicompartmental knee arthroplasty VERSUS Nonsurgical treatment IN Specific disease- Knee osteoarthritis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30277995","Specific disease- Knee osteoarthritis; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Unicompartmental knee arthroplasty","Cost-Effectiveness of Surgical and Nonsurgical Treatments for Unicompartmental Knee Arthritis: A Markov Model.","Nonsurgical treatment","SE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","110000","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive) VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","160000","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","170000","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","19000","Supplemental Nutrition Assistance Program, (F&V incentive/SSB restriction) VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program, (F&V incentive/SSB restriction)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","210000","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive) VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","24000","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive) VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","27000","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","300000","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","5300","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","560000","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","63000","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive) VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","68000","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","71000","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)  VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","NE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","Cost-Saving","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)  VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","SE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","Cost-Saving","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)  VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","SE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","Cost-Saving","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","SE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","Cost-Saving","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction) VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (F&V incentive/SSB restriction)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","SE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","Cost-Saving","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive) VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (Fruit and vegetable incentive)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","SE"
"2018-01-28838","2018","Mozaffarian                      2018 PLoS Med","Cost-Saving","Supplemental Nutrition Assistance Program (SNAP-plus)  VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","30278053","Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.","Supplemental Nutrition Assistance Program (SNAP-plus)","Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.","None","SE"
"2018-01-28641","2018","Smith 2018 Arthritis Care Res (Hoboken)","Cost-Saving","Prolonged Rivaroxaban Strategy  VERSUS Standard/Usual Care- Standard Warfarin Strategy  IN Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","30369093","Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","Prolonged Rivaroxaban Strategy","Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients.","Standard/Usual Care- Standard Warfarin Strategy","SE"
"2018-01-28641","2018","Smith 2018 Arthritis Care Res (Hoboken)","Cost-Saving","Prolonged Warfarin Strategy  VERSUS Standard/Usual Care- Standard Low Molecular Weight Heparin Strategy  IN Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","30369093","Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","Prolonged Warfarin Strategy","Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients.","Standard/Usual Care- Standard Low Molecular Weight Heparin Strategy","SE"
"2018-01-28641","2018","Smith 2018 Arthritis Care Res (Hoboken)","Cost-Saving","Prolonged Warfarin Strategy  VERSUS Standard/Usual Care- Standard Warfarin Strategy  IN Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","30369093","Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","Prolonged Warfarin Strategy","Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients.","Standard/Usual Care- Standard Warfarin Strategy","SE"
"2018-01-28641","2018","Smith 2018 Arthritis Care Res (Hoboken)","Cost-Saving","Standard Rivaroxaban Strategy  VERSUS Standard/Usual Care- Standard Low Molecular Weight Heparin Strategy  IN Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","30369093","Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","Standard Rivaroxaban Strategy","Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients.","Standard/Usual Care- Standard Low Molecular Weight Heparin Strategy","SE"
"2018-01-28641","2018","Smith 2018 Arthritis Care Res (Hoboken)","Cost-Saving","Standard Rivaroxaban Strategy  VERSUS Standard/Usual Care- Standard Warfarin Strategy  IN Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","30369093","Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","Standard Rivaroxaban Strategy","Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients.","Standard/Usual Care- Standard Warfarin Strategy","SE"
"2018-01-28641","2018","Smith 2018 Arthritis Care Res (Hoboken)","Cost-Saving","Standard Warfarin Strategy  VERSUS Standard/Usual Care- Standard Low Molecular Weight Heparin Strategy  IN Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","30369093","Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","Standard Warfarin Strategy","Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients.","Standard/Usual Care- Standard Low Molecular Weight Heparin Strategy","SE"
"2018-01-28641","2018","Smith 2018 Arthritis Care Res (Hoboken)","Dominated","No Prophylaxis  VERSUS Standard/Usual Care- Standard Aspirin Therapy  IN Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","30369093","Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","No Prophylaxis","Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients.","Standard/Usual Care- Standard Aspirin Therapy","NW"
"2018-01-28641","2018","Smith 2018 Arthritis Care Res (Hoboken)","Dominated","Prolonged Aspirin Strategy  VERSUS Standard/Usual Care- Standard Warfarin Strategy  IN Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","30369093","Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","Prolonged Aspirin Strategy","Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients.","Standard/Usual Care- Standard Warfarin Strategy","NW"
"2018-01-28641","2018","Smith 2018 Arthritis Care Res (Hoboken)","Dominated","Standard Aspirin Strategy  VERSUS Standard/Usual Care- Standard Warfarin Strategy  IN Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","30369093","Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","Standard Aspirin Strategy","Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients.","Standard/Usual Care- Standard Warfarin Strategy","NW"
"2018-01-28641","2018","Smith 2018 Arthritis Care Res (Hoboken)","Dominated","Standard Low Molecular Weight Heparin VERSUS Standard/Usual Care- Standard Warfarin  IN Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","30369093","Specific disease- Total knee arthroplasty; Age- Adult; Gender- Both; Country- United States.","Standard Low Molecular Weight Heparin","Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients.","Standard/Usual Care- Standard Warfarin","NW"
"2018-01-28608","2018","Honing 2018 Gastrointest Endosc","27000","Mobile van ultrathin transnasal endoscopy VERSUS No screening IN Specific disease- Chronic reflux disease; Age- 41 to 64 years; Gender- Male; Country- United States.","30385112","Specific disease- Chronic reflux disease; Age- 41 to 64 years; Gender- Male; Country- United States.","Mobile van ultrathin transnasal endoscopy","Endosheath ultrathin transnasal endoscopy is a cost-effective method for screening for Barrett''s esophagus in patients with GERD symptoms.","No screening","NE"
"2018-01-28608","2018","Honing 2018 Gastrointest Endosc","31000","Unsedated transnasal endoscopy VERSUS No Screening IN Specific disease- Chronic reflux disease ; Age- 41 to 64 years; Gender- Male; Country- United States.","30385112","Specific disease- Chronic reflux disease ; Age- 41 to 64 years; Gender- Male; Country- United States.","Unsedated transnasal endoscopy","Endosheath ultrathin transnasal endoscopy is a cost-effective method for screening for Barrett''s esophagus in patients with GERD symptoms.","No Screening","NE"
"2018-01-28608","2018","Honing 2018 Gastrointest Endosc","50000","Endoscopy screening VERSUS No screening IN Specific disease- Chronic reflux disease; Age- 41 to 64 years; Gender- Male; Country- United States.","30385112","Specific disease- Chronic reflux disease; Age- 41 to 64 years; Gender- Male; Country- United States.","Endoscopy screening","Endosheath ultrathin transnasal endoscopy is a cost-effective method for screening for Barrett''s esophagus in patients with GERD symptoms.","No screening","NE"
"2018-01-28597","2018","Kwan 2018 J Vasc Interv Radiol","58000","Transjugular Intrahepatic Portosystemic Shunt VERSUS Large-Volume Paracentesis IN Specific disease- Refractory Ascites; Age- 41 to 64 years; Gender- Male; Country- United States.","30392803","Specific disease- Refractory Ascites; Age- 41 to 64 years; Gender- Male; Country- United States.","Transjugular Intrahepatic Portosystemic Shunt","Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunt versus Large-Volume Paracentesis in Refractory Ascites: Results of a Markov Model Incorporating Individual Patient-Level Meta-Analysis and Nationally Representative Cost Data.","Large-Volume Paracentesis","NE"
"2018-01-28574","2018","Wan 2018 Med Decis Making","Dominated","Continuous Glucose Monitoring with Continuous Subcutaneous Insulin Infusion  VERSUS Continuous Glucose Monitoring with Multiple Daily Injections IN Specific disease- Type 1 Diabetes; Age- Adult; Gender- Both; Country- United States; Other- High baseline HbA1c.","30403576","Specific disease- Type 1 Diabetes; Age- Adult; Gender- Both; Country- United States; Other- High baseline HbA1c.","Continuous Glucose Monitoring with Continuous Subcutaneous Insulin Infusion","Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial.","Continuous Glucose Monitoring with Multiple Daily Injections","NW"
"2018-01-28574","2018","Wan 2018 Med Decis Making","Dominated","Continuous Glucose Monitoring with Continuous Subcutaneous Insulin Infusion VERSUS Continuous Glucose Monitoring with Multiple Daily Injections  IN Specific disease- Type 1 Diabetes; Age- Adult; Gender- Both; Country- United States.","30403576","Specific disease- Type 1 Diabetes; Age- Adult; Gender- Both; Country- United States.","Continuous Glucose Monitoring with Continuous Subcutaneous Insulin Infusion","Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial.","Continuous Glucose Monitoring with Multiple Daily Injections","NW"
"2018-01-28574","2018","Wan 2018 Med Decis Making","Dominated","Continuous Glucose Monitoring with Continuous Subcutaneous Insulin Infusion VERSUS Continuous Glucose Monitoring with Multiple Daily Injections IN Specific disease- Type 1 Diabetes; Age- Adult; Gender- Both; Country- United States; Other- Low baseline HbA1c.","30403576","Specific disease- Type 1 Diabetes; Age- Adult; Gender- Both; Country- United States; Other- Low baseline HbA1c.","Continuous Glucose Monitoring with Continuous Subcutaneous Insulin Infusion","Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial.","Continuous Glucose Monitoring with Multiple Daily Injections","NW"
"2018-01-28566","2018","Rihn 2018 J Am Acad Orthop Surg","4200","Cervical Injection VERSUS None IN Specific disease- Cervical Radiculopathy; Age- Adult; Gender- Both; Country- United States.","30407977","Specific disease- Cervical Radiculopathy; Age- Adult; Gender- Both; Country- United States.","Cervical Injection","Economic and Outcomes Analysis of Recalcitrant Cervical Radiculopathy: Is Nonsurgical Management or Surgery More Cost-Effective?","None","NE"
"2018-01-28566","2018","Rihn 2018 J Am Acad Orthop Surg","6000","Cervical Injection VERSUS None IN Specific disease- Cervical Radiculopathy; Age- Adult; Gender- Both; Country- United States.","30407977","Specific disease- Cervical Radiculopathy; Age- Adult; Gender- Both; Country- United States.","Cervical Injection","Economic and Outcomes Analysis of Recalcitrant Cervical Radiculopathy: Is Nonsurgical Management or Surgery More Cost-Effective?","None","NE"
"2018-01-28566","2018","Rihn 2018 J Am Acad Orthop Surg","7100","Anterior Cervical Diskectomy and Fusion  VERSUS None IN Specific disease- Cervical Radiculopathy; Age- Adult; Gender- Both; Country- United States.","30407977","Specific disease- Cervical Radiculopathy; Age- Adult; Gender- Both; Country- United States.","Anterior Cervical Diskectomy and Fusion","Economic and Outcomes Analysis of Recalcitrant Cervical Radiculopathy: Is Nonsurgical Management or Surgery More Cost-Effective?","None","NE"
"2017-01-23877","2017","Bardach 2017 BMC Public Health","130000","Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18 VERSUS Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18 (HPV): quadrivalent vaccine against HPV 6, 11, 16,  and 18 IN Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.","28148228","Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.","Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18","Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.","Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18 (HPV): quadrivalent vaccine against HPV 6, 11, 16,  and 18","NE"
"2017-01-23877","2017","Bardach 2017 BMC Public Health","Cost-Saving","Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18 VERSUS None IN Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.","28148228","Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.","Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18","Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.","None","SE"
"2017-01-23877","2017","Bardach 2017 BMC Public Health","Cost-Saving","Human Papillomavirus (HPV): quadrivalent vaccine against HPV 6, 11, 16, and 18 VERSUS None IN Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.","28148228","Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.","Human Papillomavirus (HPV): quadrivalent vaccine against HPV 6, 11, 16, and 18","Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.","None","SE"
"2018-01-28565","2018","Suijkerbuijk 2018 PLoS One","8700","Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Yugoslavia.","30408079","Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from former Yugoslavia.","Hepatitis C Screening","Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.","None","NE"
"2018-01-28466","2018","Zeng                             2018 Bull World Health Organ","1400","Result-based financing to increase use and quality of maternal & child health services VERSUS Input-based financing (increased funding not tied to performance) IN Healthy; Age- 0 to 18 years, Adult; Gender- Both; Country- Zambia.","30455531","Healthy; Age- 0 to 18 years, Adult; Gender- Both; Country- Zambia.","Result-based financing to increase use and quality of maternal & child health services","Cost-effectiveness of results-based financing, Zambia: a cluster randomized trial.","Input-based financing (increased funding not tied to performance)","NE"
"2018-01-28466","2018","Zeng                             2018 Bull World Health Organ","450","Input-based financing to increase use and quality of maternal & child health services VERSUS Control (no additional funding) IN Healthy; Age- Unknown; Gender- Both; Country- Zambia.","30455531","Healthy; Age- Unknown; Gender- Both; Country- Zambia.","Input-based financing to increase use and quality of maternal & child health services","Cost-effectiveness of results-based financing, Zambia: a cluster randomized trial.","Control (no additional funding)","NE"
"2018-01-28466","2018","Zeng                             2018 Bull World Health Organ","870","Result-based financing to increase use and quality of maternal & child health services VERSUS Control (no additional funding) IN Healthy; Age- Unknown; Gender- Both; Country- Zambia.","30455531","Healthy; Age- Unknown; Gender- Both; Country- Zambia.","Result-based financing to increase use and quality of maternal & child health services","Cost-effectiveness of results-based financing, Zambia: a cluster randomized trial.","Control (no additional funding)","NE"
"2014-01-16989","2014","Griffiths 2014 Cost Eff Resour Alloc","300","Cataract surgery VERSUS None IN Specific disease- Cataracts; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Zambia.","24568593","Specific disease- Cataracts; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Zambia.","Cataract surgery","Cost-effectiveness of eye care services in Zambia.","None","NE"
"2014-01-16989","2014","Griffiths 2014 Cost Eff Resour Alloc","430","Refractive error/presbyopia correction corrected with spectacles VERSUS None IN Specific disease- Cataracts; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Zambia.","24568593","Specific disease- Cataracts; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Zambia.","Refractive error/presbyopia correction corrected with spectacles","Cost-effectiveness of eye care services in Zambia.","None","NE"
"2014-01-15156","2014","Ishikawa 2014 PLoS One","Cost-Saving","Anti-retrovirals during pregnancy and breastfeeding, Triple anti-retrovirals till end of breastfeeding VERSUS If CD4<350 , lifelong ART; if CD4>350, Antiretroviral drugs (ARV) prophylaxis (mother and infant) (option A) IN Specific disease- HIV positive; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Zambia.","24604067","Specific disease- HIV positive; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Zambia.","Anti-retrovirals during pregnancy and breastfeeding, Triple anti-retrovirals till end of breastfeeding","Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.","If CD4<350 , lifelong ART; if CD4>350, Antiretroviral drugs (ARV) prophylaxis (mother and infant) (option A)","SE"
"2014-01-15156","2014","Ishikawa 2014 PLoS One","Cost-Saving","Lifelong antiretroviral therapy VERSUS If CD4<350 , lifelong ART; if CD4>350, Antiretroviral drugs (ARV) prophylaxis (mother and infant) (option A) IN Specific disease- HIV; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Zambia; Other- Pregnant.","24604067","Specific disease- HIV; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Zambia; Other- Pregnant.","Lifelong antiretroviral therapy","Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.","If CD4<350 , lifelong ART; if CD4>350, Antiretroviral drugs (ARV) prophylaxis (mother and infant) (option A)","SE"
"2013-01-11086","2013","Nichols 2013 PLoS One","360","Prioritized pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections to most sexually active VERSUS Standard/Usual care IN Healthy; Age- Unknown; Gender- Not Specified; Country- Zambia.","23527217","Healthy; Age- Unknown; Gender- Not Specified; Country- Zambia.","Prioritized pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections to most sexually active","Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study.","Standard/Usual care","NE"
"2013-01-11086","2013","Nichols 2013 PLoS One","Cost-Saving","Prioritized pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections to most sexually active VERSUS Non-prioritized PrEP, PrEP randomly distributed IN Healthy; Age- Unknown; Gender- Not Specified; Country- Zambia.","23527217","Healthy; Age- Unknown; Gender- Not Specified; Country- Zambia.","Prioritized pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections to most sexually active","Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study.","Non-prioritized PrEP, PrEP randomly distributed","SE"
"2008-01-03914","2008","Ryan 2008 AIDS","11","Cotrimoxazole 240 mg daily HIV prophylaxis, starting at age 8 VERSUS No prophylaxis, starting at age 8 IN Children (1-14 y.o.) Zambian children HIV/AIDS positive","18356605","Children (1-14 y.o.) Zambian children HIV/AIDS positive","Cotrimoxazole 240 mg daily HIV prophylaxis, starting at age 8","The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.","No prophylaxis, starting at age 8","NE"
"2008-01-03914","2008","Ryan 2008 AIDS","120","Cotrimoxazole HIV prophylaxis 240 mg Daily VERSUS No prophylaxis IN Children (1-14 y.o.) Zambian children HIV/AIDS positive","18356605","Children (1-14 y.o.) Zambian children HIV/AIDS positive","Cotrimoxazole HIV prophylaxis 240 mg Daily","The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.","No prophylaxis","NE"
"2008-01-03914","2008","Ryan 2008 AIDS","120","Cotrimoxazole HIV prophylaxis 240mg Daily, follow up 19 months VERSUS No prophylaxis, follow up 19 months IN Children (1-14 y.o.) Zambian children HIV/AIDS positive.","18356605","Children (1-14 y.o.) Zambian children HIV/AIDS positive.","Cotrimoxazole HIV prophylaxis 240mg Daily, follow up 19 months","The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.","No prophylaxis, follow up 19 months","NE"
"2008-01-03914","2008","Ryan 2008 AIDS","180","Cotrimoxazole 240 mg daily HIV prophylaxis, starting at age 3 VERSUS No prophylaxis, starting at age 3 IN Children (1-14 y.o.) Zambian children HIV/AIDS positive","18356605","Children (1-14 y.o.) Zambian children HIV/AIDS positive","Cotrimoxazole 240 mg daily HIV prophylaxis, starting at age 3","The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.","No prophylaxis, starting at age 3","NE"
"2008-01-03914","2008","Ryan 2008 AIDS","270","Cotrimoxazole 240 mg daily HIV prophylaxis, including bi-monthly CD4 % monitoring VERSUS No prophylaxis, including bi-monthly CD4 % monitoring IN Children (1-14 y.o.) Zambian children HIV/AIDS positive","18356605","Children (1-14 y.o.) Zambian children HIV/AIDS positive","Cotrimoxazole 240 mg daily HIV prophylaxis, including bi-monthly CD4 % monitoring","The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.","No prophylaxis, including bi-monthly CD4 % monitoring","NE"
"2008-01-03914","2008","Ryan 2008 AIDS","6","Cotrimoxazole 240 mg daily HIV prophylaxis, local basic healthcare VERSUS No prophylaxis, local basic healthcare IN Children (1-14 y.o.) Zambian children HIV/AIDS positive","18356605","Children (1-14 y.o.) Zambian children HIV/AIDS positive","Cotrimoxazole 240 mg daily HIV prophylaxis, local basic healthcare","The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.","No prophylaxis, local basic healthcare","NE"
"2008-01-03914","2008","Ryan 2008 AIDS","Cost-Saving","Cotrimoxazole HIV prophylaxis, starting at age 9 VERSUS No prophylaxis, starting at age 9 IN Children (1-14 y.o.) Zambian children HIV/AIDS positive","18356605","Children (1-14 y.o.) Zambian children HIV/AIDS positive","Cotrimoxazole HIV prophylaxis, starting at age 9","The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.","No prophylaxis, starting at age 9","SE"
"2016-01-22026","2016","Mafirakureva 2016 Transfusion","11000","Individual-Donation Nucleic Acid Testing (ID-NAT) and Serologic Tests VERSUS Serologic Tests IN Specific disease- Hepatitis B Virus (HBV), Hepatits C Virus (HCV), Human Immunodeficiency Virus (HIV); Age- 19 to 40 years; Gender- Both; Country- Zimbabwe; Other- Blood donors.","27696441","Specific disease- Hepatitis B Virus (HBV), Hepatits C Virus (HCV), Human Immunodeficiency Virus (HIV); Age- 19 to 40 years; Gender- Both; Country- Zimbabwe; Other- Blood donors.","Individual-Donation Nucleic Acid Testing (ID-NAT) and Serologic Tests","Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.","Serologic Tests","NE"
"2013-01-10779","2013","Miller 2013 Prev Sci","7","School Support for orphan girls in both boarding and non boarding schools for HIV prevention VERSUS Standard/usual care IN Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Female; Country- Zimbabwe.","23334923","Healthy; Age- 0 to 18 years, 19 to 40 years; Gender- Female; Country- Zimbabwe.","School Support for orphan girls in both boarding and non boarding schools for HIV prevention","Cost-effectiveness of school support for orphan girls to prevent HIV infection in Zimbabwe.","Standard/usual care","NE"
"2012-01-09034","2012","Medina Lara 2012 PLoS One","9100","Laboratory and clinical monitoring treatment of antiretroviral therapy VERSUS Clinically-driven monitoring treatment IN Adults starting antiretroviral therapy in Uganda and Zimbabwe","22545079","Adults starting antiretroviral therapy in Uganda and Zimbabwe","Laboratory and clinical monitoring treatment of antiretroviral therapy","Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.","Clinically-driven monitoring treatment","NE"
